trend
sourc
advers
drug
reaction
report
spontan
report
system
taiwan
chan
shao
ms
pharmaci
linkou
chang
gung
memori
hospit
linkou
taiwan
pharmaci
institut
clinic
pharmaci
pharmaceut
scienc
colleg
medicin
nation
cheng
kung
univers
tainan
taiwan
introduct
analys
advers
drug
reaction
adr
report
clinic
relev
issu
avoid
unintend
outcom
patient
understand
trend
sourc
adr
report
could
help
us
develop
strategi
improv
underreport
adr
research
question
hypothesi
investig
trend
sourc
spontan
adr
report
system
taiwan
studi
design
observ
studi
method
extract
data
spontan
adr
report
system
chang
gung
medic
foundat
cgmf
consist
medic
center
region
hospit
district
hospit
taiwan
classifi
sourc
follow
categori
level
hospit
medic
center
region
hospit
district
hospit
set
inpati
outpati
emerg
room
healthcar
provid
clinician
nurs
pharmacist
calcul
proport
categori
compar
proport
test
consid
p
valu
statist
signific
examin
whether
chang
exist
time
result
identifi
total
adr
report
number
report
increas
studi
period
adr
report
inpati
medic
center
clinician
found
proport
sourc
adr
report
medic
center
outpati
increas
p
respect
howev
region
hospit
inpati
account
decreas
proport
sourc
adr
report
p
respect
signific
chang
proport
adr
report
differ
healthcar
provid
conclus
found
proport
sourc
adr
report
chang
time
especi
decreas
proport
region
hospit
inpati
warrant
investig
identifi
factor
affect
report
rate
overrid
high
prioriti
interact
alert
newli
implement
commerci
computer
provid
order
entri
system
overrid
appropri
advers
drug
event
heba
edre
mari
amato
pharmd
adrian
wong
pharmd
dian
seger
david
bate
md
pharmaci
mcph
univers
boston
pharmaci
practic
mcph
univers
boston
center
patient
safeti
research
practic
divis
gener
intern
medicin
primari
care
brigham
women
hospit
boston
center
patient
safeti
research
practic
divis
gener
intern
medicin
primari
care
brigham
women
hospit
boston
medic
school
boston
introduct
institut
formerli
util
develop
electron
health
record
ehr
clinic
decis
support
cd
incorpor
tier
interact
ddi
alert
includ
highest
sever
ddi
transit
commerci
system
cd
allow
alert
overridden
rais
concern
potenti
seriou
ddi
could
reach
patient
increas
risk
advers
drug
event
ade
research
question
hypothesi
compar
rate
cd
alert
overrid
associ
ade
ehr
studi
design
retrospect
studi
overridden
ddi
alert
inpati
outpati
set
method
alert
assess
highest
sever
ddi
legaci
system
addit
ddi
identifi
clinic
experi
literatur
review
highest
sever
alert
overrid
plu
random
sampl
addit
overrid
n
total
evalu
two
independ
review
overrid
appropri
use
criteria
develop
multidisciplinari
group
overridden
alert
result
medic
administr
chart
review
identifi
potenti
ade
chi
squar
test
use
compar
ade
rate
appropri
overrid
result
total
alert
occur
includ
ddi
alert
seen
provid
overridden
overrid
occur
highest
sever
alert
ddi
overrid
appropri
overal
highest
sever
addit
alert
alert
result
medic
administr
n
ade
identifi
appropri
overrid
n
administ
inappropri
overrid
n
administ
p
conclus
high
prioriti
ddi
alert
overridden
often
inappropri
indic
need
focu
improv
andor
tailor
alert
reduc
alert
fatigu
ade
occur
inappropri
overridden
alert
interact
studi
evalu
effect
multipl
dose
ranitidin
administ
daili
stagger
twice
daili
pharmacokinet
safeti
neratinib
healthi
subject
kiana
keyvanjah
pearl
fang
blair
cook
daniel
diprimeo
jeffrey
pearl
stefan
dyla
daniel
hunt
igor
rubet
alvin
wong
david
martin
biotechnolog
inc
lo
angel
ca
lincoln
ne
usa
inc
princeton
nj
introduct
irrevers
tyrosin
kinas
inhibitor
neratinib
puma
biotechnolog
inc
similar
protein
kinas
inhibitor
pki
weak
base
solubl
agent
increas
gastric
ph
lead
reduc
absorpt
pki
therapi
preval
cancer
patient
evalu
ranitidin
combin
neratinib
known
solubl
absorpt
research
question
hypothesi
evalu
effect
ranitidin
antagonist
given
qd
neratinib
bid
stagger
fashion
pharmacokinet
safeti
neratinib
studi
design
random
crossov
method
forti
healthi
subject
receiv
singl
oral
dose
neratinib
mg
period
combin
multipl
dose
ranitidin
mg
qd
multipl
dose
ranitidin
mg
bid
period
washout
period
pharmacokinet
sampl
perform
hour
follow
neratinib
dose
result
mean
neratinib
exposur
cmax
lower
ranitidin
schedul
versu
neratinib
alon
respect
valu
ngml
neratinib
alon
ngml
neratinib
plu
ranitidin
mg
qd
ngml
neratinib
plu
ranitidin
mg
bid
stagger
geometr
mean
ratio
confid
interv
three
paramet
fell
outsid
equival
rang
neratinib
exposur
greater
stagger
schedul
advers
event
grade
grade
sever
report
patient
respect
conclus
ranitidin
neratinib
significantli
reduc
exposur
neratinib
healthi
subject
stagger
dose
ranitidin
mg
bid
limit
impact
ranitidin
neratinib
exposur
impact
electron
best
practic
alert
prevent
iatrogen
hyperkalemia
christin
hambi
jose
pharmaci
rochest
gener
hospit
rochest
ny
medicin
rochest
gener
hospit
rochest
ny
introduct
potassium
supplement
commonli
order
hospit
patient
howev
care
monitor
need
patient
need
fluctuat
chang
medic
diseas
state
hyperkalemia
report
ten
percent
hospit
patient
may
lead
seriou
advers
effect
cardiac
arrhythmia
mortal
research
question
hypothesi
clinic
decis
support
reduc
rate
iatrogen
hyperkalemia
studi
design
retrospect
method
chart
review
conduct
identifi
patient
receiv
potassium
supplement
serum
potassium
greater
meql
nurs
alert
potassium
valu
remind
notifi
prescrib
confirm
order
alert
deliv
mar
instruct
appear
everi
patient
regardless
potassium
level
week
follow
best
practic
alert
bpa
appear
threshold
reach
requir
respons
nurs
week
result
mean
number
event
potassium
administr
serum
potassium
greater
meql
per
week
baselin
period
mar
instruct
bpa
follow
bpa
deploy
number
event
two
standard
deviat
baselin
result
sustain
throughout
period
record
review
patient
receiv
potassium
despit
serum
potassium
valu
greater
meql
common
reason
diabet
alcohol
ketoacidosi
pediatr
patient
higher
potassium
threshold
hemolyz
sampl
mainten
fluid
patient
eat
five
case
prescrib
continu
potassium
reduc
dose
patient
requir
treatment
hyperkalemia
conclus
use
bpa
result
signific
reduct
administr
potassium
patient
serum
potassium
greater
meql
risk
factor
associ
advers
drug
reaction
among
critic
ill
pediatr
patient
kico
tso
bpharm
mo
ki
wong
bpharm
yin
ting
cheung
bsc
pharm
phd
joyc
pharmd
bcp
celest
ewig
pharmd
school
pharmaci
chines
univers
hong
kong
shatin
new
territori
hong
kong
introduct
critic
ill
pediatr
patient
often
requir
multipl
medic
lead
higher
risk
advers
drug
reaction
adr
incid
natur
potenti
risk
factor
occurr
adr
vulner
popul
well
studi
research
question
hypothesi
characterist
among
critic
ill
pediatr
patient
factor
associ
occurr
adr
studi
design
conduct
retrospect
chart
review
among
patient
age
day
year
old
admit
pediatr
intens
care
high
depend
unit
januari
decemb
method
primari
outcom
occurr
adr
among
patient
admiss
picu
patient
adr
characterist
collect
evalu
causal
clinic
sever
use
naranjo
scale
hartwig
sever
assess
scale
respect
descript
statist
use
determin
incid
natur
adr
multivari
logist
regress
perform
evalu
potenti
risk
factor
result
studi
includ
patient
male
median
age
iqr
identifi
adr
result
incid
major
adr
due
chemotherapeut
agent
opioid
adr
present
elev
alanin
aminotransferas
hypokalemia
bone
marrow
suppress
type
reaction
sever
level
potenti
risk
factor
adr
includ
admiss
glasgow
coma
score
p
serum
urea
upon
admiss
p
use
p
conclus
factor
associ
occurr
adr
includ
low
level
conscious
poor
renal
function
hemodynam
statu
use
multipl
find
may
offer
clinic
guidanc
implement
measur
improv
medic
safeti
within
patient
popul
effect
sulfonylurea
concomit
antimicrobi
hypoglycemia
patient
diabet
mellitu
miyoung
ock
bs
pharm
sera
lee
bs
hyunah
kim
pharmd
pharmaci
sookymyung
women
univers
seoul
korea
republ
south
pharmaci
sookmyung
women
univers
seoul
korea
republ
south
pharmaci
sookmyung
women
univers
seoul
korea
republ
south
introduct
previou
studi
reveal
concurr
use
sulfonylurea
su
antimicrobi
common
could
increas
risk
hypoglycemia
hypoglycemia
associ
interact
ddi
may
caus
import
morbid
increas
healthcar
cost
burden
research
question
hypothesi
certain
antimicrobi
concurr
use
sulfonylurea
could
increas
risk
hypoglycemia
studi
design
conduct
retrospect
cohort
studi
use
nation
health
insur
sampl
cohort
databas
korean
popul
method
type
diabet
patient
began
receiv
su
first
time
without
histori
receiv
prescript
su
diagnosi
hypoglycemia
preced
year
age
year
includ
studi
investig
number
patient
diagnos
hypoglycemia
two
differ
group
patient
treat
su
without
antimicrobi
includ
antimicrobi
prescript
within
first
day
initi
su
order
minim
immort
time
bia
differ
risk
rate
sever
ddi
level
x
c
onlin
major
contraind
sever
level
micromedex
includ
sa
version
use
data
analysi
result
patient
type
diabet
mellitu
identifi
new
su
user
total
patient
met
studi
inclus
criteria
largest
age
group
year
old
patient
male
preval
hypoglycemia
time
group
hypoglycemia
observ
su
antimicrobi
group
su
without
antimicrobi
group
among
patient
use
su
antimicrobi
hypoglycem
episod
commonli
occur
ofloxacin
ciprofloxacin
fluconazol
user
respect
conclus
hypoglycemia
occur
frequent
patient
prescrib
su
antimicrobi
concurr
potenti
drug
interact
quetiapin
critic
ill
patient
korea
sera
lee
bs
pharm
miyoung
ock
bs
hyunah
kim
pharmd
pharmaci
sookmyung
women
univers
seoul
korea
republ
south
pharmaci
sookymyung
women
univers
seoul
korea
republ
south
pharmaci
sookmyung
women
univers
seoul
korea
republ
south
present
korean
societi
critic
care
medicin
annual
congress
asian
critic
care
confer
seoul
korea
april
risk
advers
event
phenazopyridin
use
radiat
cystiti
stephani
shore
pharmd
sara
britnel
pharmd
bcp
jami
brown
pharmd
bcp
bcacp
pharmaci
servic
durham
va
health
care
system
durham
nc
introduct
phenazopyridin
current
lack
robust
safeti
efficaci
data
use
beyond
day
yet
often
use
vari
durat
support
care
cancer
patient
cystiti
research
question
hypothesi
primari
object
studi
compar
incid
composit
advers
drug
reaction
adr
patient
receiv
phenazopyridin
suppli
compar
match
compar
group
secondari
object
compar
incid
individu
adr
ed
visit
hospit
diagnosi
hepatocellular
colorect
cancer
studi
design
retrospect
cohort
studi
method
studi
compar
advers
event
among
cancer
patient
without
phenazopyridin
exposur
includ
patient
receiv
radiat
least
one
chronic
medic
juli
june
phenazopyridin
group
also
receiv
suppli
phenazopyridin
studi
period
patient
match
base
gender
age
year
cancer
diagnosi
palli
cur
treatment
intent
data
collect
occur
baselin
time
presum
exposur
end
studi
period
surveil
purpos
result
total
patient
receiv
phenazopyridin
suppli
studi
period
patient
includ
match
equal
number
patient
compar
group
includ
patient
similar
group
larg
male
diagnosi
prostat
cancer
major
patient
receiv
suppli
phenazopyridin
total
adr
phenazopyridin
group
compar
group
differ
identifi
phenazopyridin
compar
group
secondari
endpoint
conclus
differ
adr
among
patient
receiv
phenazopyridin
day
compar
match
compar
group
overal
incid
advers
event
group
low
effect
electron
lifestyl
intervent
overweight
obes
patient
rachel
frank
pharmd
bcacp
cde
courtney
cantrel
kristina
dogoda
amanda
elchynski
pharmacotherapeut
clinic
research
univers
south
florida
colleg
pharmaci
tampa
fl
fl
introduct
lifestyl
intervent
benefici
effect
eat
behavior
weight
loss
obes
adult
use
weight
reduct
program
shown
efficaci
treat
obes
adult
howev
quantiti
frequenc
remain
unclear
research
question
hypothesi
educ
motiv
materi
deliv
weekli
via
email
improv
knowledg
level
motiv
overweight
obes
patient
improv
abil
lose
weight
studi
design
random
control
trial
method
univers
south
florida
gener
intern
medicin
clinic
patient
age
year
bmi
random
treatment
control
group
particip
exclud
take
warfarin
access
scale
email
account
could
read
english
take
insulin
sulfonylurea
pregnant
intervent
group
receiv
weekli
educ
motiv
email
total
week
control
group
receiv
one
email
start
studi
condens
version
weekli
email
group
complet
determin
knowledg
healthi
lifestyl
chang
level
motiv
bodi
weight
result
particip
enrol
complet
final
survey
intervent
control
group
signific
differ
regard
knowledg
motiv
end
studi
howev
signific
reduct
weight
report
intervent
group
compar
control
group
lb
vs
lb
p
conclus
patient
receiv
weekli
educ
motiv
email
like
report
weight
loss
order
increas
valid
studi
larger
sampl
size
would
need
implement
patient
weight
measur
rather
report
pilot
studi
evalu
potenti
predictor
readmiss
hospit
medicin
patient
henri
okoroik
bs
mathew
thambi
pharmd
bcp
mph
wenchin
li
bs
colleg
pharmaci
univers
illinoi
chicago
chicago
il
introduct
mani
patient
readmit
hospit
shortli
discharg
signific
cost
fifth
medicar
beneficiari
discharg
within
day
cost
medicar
estim
billion
identifi
patient
high
readmiss
risk
import
alloc
resourc
manner
target
research
question
hypothesi
object
pilot
studi
test
survey
predict
readmiss
conjunct
indic
hypothesi
certain
characterist
patient
predict
risk
readmiss
ed
visit
discharg
measur
clinic
set
studi
design
survey
studi
consist
valid
well
investig
develop
survey
instrument
assess
follow
health
literaci
numeraci
medic
adher
toler
method
subject
admit
intern
medicin
univers
illinoi
screen
elig
consent
grant
subject
particip
survey
took
minut
complet
approxim
day
discharg
subject
contact
via
phone
ask
mani
admiss
ed
visit
sinc
discharg
inform
also
record
electron
medic
record
regress
analysi
done
determin
predict
abil
survey
compon
along
indic
includ
lace
cci
cp
result
total
subject
enrol
overal
readmiss
rate
emr
backward
regress
analysi
key
variabl
adjust
variabl
includ
final
regress
gender
medic
insur
cci
score
score
modifi
gener
self
efficaci
scale
score
conclus
base
result
pilot
certain
characterist
potenti
predict
patient
risk
readmiss
need
verifi
larger
appropri
power
studi
evalu
benzodiazepin
use
patient
stress
disord
sarah
g
kessler
pharmd
stephani
coveart
pharmd
bcp
bcpp
depart
pharmaci
memphi
veteran
affair
medic
center
memphi
tn
introduct
stress
disord
ptsd
common
psycholog
consequ
traumat
event
veteran
affair
va
depart
defens
dod
guidelin
recommend
sertralin
paroxetin
fluoxetin
venlafaxin
prefer
agent
treatment
ptsd
use
benzodiazepin
treatment
augment
therapi
recommend
due
low
qualiti
evid
increas
risk
advers
effect
research
question
hypothesi
evalu
preval
benzodiazepin
use
patient
ptsd
vadod
recommend
psychotrop
therapi
studi
design
retrospect
chart
review
method
data
collect
novemb
april
use
medic
record
memphi
veteran
affair
medic
center
patient
includ
diagnosi
ptsd
activ
prescript
benzodiazepin
primari
end
point
number
patient
benzodiazepin
take
vadod
recommend
psychotrop
agent
treatment
ptsd
secondari
endpoint
includ
benzodiazepin
indic
durat
therapi
averag
benzodiazepin
daili
dose
percentag
patient
adequ
titrat
recommend
psychotrop
therapi
defin
maximum
total
daili
dose
result
total
patient
met
studi
inclus
criteria
nearli
half
activ
prescript
clonazepam
patient
patient
underw
chart
review
patient
take
ssri
snri
vadod
recommend
psychotrop
therapi
averag
durat
benzodiazepin
use
year
averag
total
daili
dose
diazepam
equival
milligram
common
indic
anxieti
follow
sleep
conclus
find
suggest
among
patient
receiv
benzodiazepin
concomit
diagnosi
ptsd
roughli
half
vadod
recommend
psychotrop
therapi
evalu
impact
inpati
hyperglycemia
protocol
glycem
control
haley
n
ilcewicz
pharmd
erin
k
hennessey
pharmd
bcp
carmen
b
smith
pharmd
bcp
st
loui
colleg
pharmacymerci
hospit
st
loui
st
loui
mo
introduct
inpati
hyperglycemia
associ
poor
outcom
exist
research
assess
inpati
hyperglycemia
protocol
shown
improv
averag
blood
glucos
level
inconsist
result
regard
rate
hypoglycemia
hyperglycemia
research
question
hypothesi
implement
inpati
hyperglycemia
protocol
associ
improv
glycem
control
studi
design
singl
center
retrospect
cohort
method
patient
care
unit
requir
insulin
administr
glycem
control
includ
inpati
hyperglycemia
protocol
implement
novemb
two
cohort
implement
group
januari
juli
implement
group
januari
juli
compar
primari
outcom
compar
incid
blood
glucos
valu
within
mgdl
period
group
key
secondari
outcom
includ
incid
hypoglycemia
less
mgdl
sever
hyperglycemia
greater
mgdl
total
insulin
use
hospit
length
stay
fisher
exact
perform
categor
data
student
continu
data
use
spss
softwar
result
total
patient
includ
group
group
primari
outcom
significantli
improv
follow
protocol
implement
vs
p
compar
group
group
lower
incid
hypoglycemia
vs
p
sever
hyperglycemia
vs
p
less
total
insulin
use
unitskg
vs
unitskg
p
shorter
length
stay
day
vs
day
p
conclus
implement
inpati
hyperglycemia
protocol
associ
improv
glycem
control
decreas
incid
hypoglycemia
sever
hyperglycemia
less
total
insulin
use
unintent
prescript
persist
medic
discontinu
hospit
discharg
michael
farley
pharmd
bcp
martin
izakov
md
pharmaci
practic
scienc
univers
iowa
iowa
citi
ia
hospitalist
medicin
st
elizabeth
univers
bratislava
slovakia
introduct
medic
discrep
preval
variou
transit
care
medic
chang
hospit
discharg
may
misunderstood
patient
convey
throughout
healthcar
system
unknown
often
medic
intend
stop
discharg
hospit
provid
still
activ
pharmaci
andor
fill
patient
discharg
research
question
hypothesi
quantifi
often
medic
intend
stop
discharg
hospit
provid
still
activ
pharmaci
andor
fill
patient
discharg
studi
design
pilot
retrospect
observ
studi
review
patient
discharg
record
merci
hospit
iowa
citi
patient
outpati
pharmaci
method
discharg
medic
list
evalu
discontinu
substitut
medic
therapi
patient
met
criteria
enrol
patient
pharmaci
call
day
day
post
discharg
determin
prescript
activerefil
result
studi
discontinu
medic
still
activ
sixteen
patient
follow
call
pharmaci
day
hospit
discharg
discharg
prescript
includ
note
pharmacist
discontinu
prior
medic
start
new
prescript
activ
day
compar
includ
instruct
activ
day
medic
discontinu
discharg
hospit
physician
refil
sinc
discharg
conclus
discontinu
medic
often
still
activ
outpati
pharmaci
discharg
prescrib
ad
note
outpati
pharmacist
stop
medic
pseudo
prescript
discontinu
associ
lower
risk
unintent
prescript
persist
day
discharg
discontinu
medic
refil
sinc
discharg
repres
potenti
medic
error
clinic
impact
intraven
calcium
util
hyperkalemia
sahar
torabi
pharmd
eli
deal
pharmd
bcp
christina
anderson
md
william
call
pharmd
bcp
hospit
st
loui
mo
introduct
guidelin
recommend
intraven
iv
calcium
patient
hyperkalemia
ekg
chang
howev
use
patient
without
ekg
chang
less
clearli
defin
research
question
hypothesi
use
iv
calcium
set
hyperkalemia
without
ekg
chang
improv
clinic
outcom
studi
design
retrospect
cohort
studi
method
adult
patient
admit
hospit
juli
june
serum
potassium
meql
ekg
without
acut
chang
includ
patient
receiv
iv
calcium
plu
potassium
lower
agent
compar
receiv
potassium
lower
agent
alon
propens
score
match
perform
use
covari
age
charlson
comorbid
index
intens
care
unit
statu
serum
potassium
level
primari
outcom
inpati
mortal
secondari
outcom
includ
hospit
length
stay
time
hyperkalemia
resolut
hyperkalemia
resolut
hour
mortal
hypercalcemia
hour
subsequ
ekg
chang
result
total
patient
includ
propens
match
sampl
group
inpati
mortal
found
iv
calcium
group
potassium
lower
agent
group
respect
mortal
median
time
hyperkalemia
resolut
hour
hour
respect
patient
hyperkalemia
resolut
hour
incid
hypercalcemia
hour
respect
patient
ekg
subsequ
ekg
chang
found
patient
receiv
iv
calcium
patient
receiv
potassium
lower
agent
alon
conclus
use
iv
calcium
patient
without
ekg
chang
secondari
hyperkalemia
improv
clinic
outcom
limit
cohort
patient
ekg
lower
incid
subsequ
ekg
chang
patient
receiv
iv
calcium
util
enoxaparin
dose
venou
thromboembol
prophylaxi
treatment
emmelin
tran
erin
weeda
univers
south
carolina
charleston
sc
pharmaci
medic
univers
south
carolina
charleston
sc
introduct
routin
monitor
concentr
use
low
molecular
weight
heparin
lmwh
prophylaxi
treatment
venou
thromboembol
vte
gener
unnecessari
due
predict
relationship
addit
major
trial
evalu
lmwh
use
concentr
direct
dose
target
concentr
clinic
valid
research
question
hypothesi
examin
util
monitor
use
enoxaparin
prophylaxi
treatment
vte
studi
design
retrospect
cohort
analysi
method
retrospect
chart
review
includ
patient
least
year
age
older
receiv
least
one
level
regularli
schedul
dose
enoxaparin
vte
prophylaxi
treatment
inpati
februari
februari
medic
univers
south
carolina
patient
exclud
creatinin
clearanc
crcl
could
calcul
use
equat
due
miss
serum
creatinin
weight
height
patient
diagnosi
pregnanc
dose
prescrib
order
primari
outcom
frequenc
enoxaparin
correspond
initi
therapeut
concentr
descript
statist
appli
data
result
studi
examin
patient
uniqu
admiss
total
initi
level
obtain
drawn
appropri
base
renal
function
weight
appropri
enoxaparin
dose
administ
correspond
therapeut
level
dose
supratherapeut
level
dose
subtherapeut
level
conclus
relat
dose
level
unpredict
natur
patient
receiv
enoxaparin
vte
prophylaxi
treatment
studi
need
determin
role
util
level
monitor
enoxaparin
clinic
practic
identifi
medic
inaccuraci
commun
health
center
electron
health
record
pharmacist
led
medic
reconcili
katherin
alfond
student
pharmacist
meissan
benbrahim
student
olivia
iskaro
student
michael
conley
pharmd
univers
boston
health
servic
inc
mattapan
introduct
pharmacist
play
import
role
medic
reconcili
mr
ensur
accuraci
patient
electron
health
record
ehr
accur
medic
list
import
prevent
drug
relat
problem
improv
patient
care
studi
shown
incorrectli
document
medic
common
discrep
ehr
howev
littl
research
conduct
commun
health
center
support
relationship
research
question
hypothesi
studi
aim
investig
accuraci
patient
medic
list
ehr
determin
common
discrep
discov
pharmacist
led
mr
feder
qualifi
health
center
boston
studi
design
retrospect
studi
perform
method
particip
year
older
visit
primari
care
provid
march
april
mr
perform
clinic
pharmacist
pharmaci
student
visit
demograph
medic
discrep
extract
pharmaci
encount
document
ehr
visit
descript
statist
use
analyz
data
result
patient
includ
analysi
least
one
medic
discrep
ehr
medic
discontinu
medic
ad
common
discontinu
class
medic
discontinu
otc
vitaminsmineralsherbalssuppl
commonli
ad
class
medic
addit
conclus
despit
joint
commiss
list
mr
nation
patient
safeti
goal
medic
list
ehr
remain
larg
inaccur
pharmacist
provid
valu
patient
care
appli
clinic
knowledg
conduct
mr
order
reduc
amount
discrep
ehr
therefor
improv
patient
care
addit
medic
expert
pharmacist
educ
provid
import
maintain
updat
medic
list
pharmacist
role
transit
care
set
part
patient
care
manag
team
decreas
klodiana
myftari
kavita
parikh
pharmd
pharmaci
practic
midwestern
univers
downer
grove
il
univers
downer
grove
il
present
annual
meet
pharmaci
qualiti
allianc
baltimor
md
mari
healthcar
util
adher
efficaci
safeti
direct
oral
anticoagul
doac
versu
warfarin
obes
patient
academ
medic
center
primari
care
clinic
christin
kelso
pharmd
depart
pharmaci
hospit
st
loui
mo
introduct
direct
oral
anticoagul
doac
use
obes
patient
concern
due
lack
represent
clinic
trial
sever
organ
recommend
avoid
doac
patient
high
bmi
andor
weight
compar
outcom
doac
warfarin
obes
may
guid
prescrib
treatment
plan
research
question
hypothesi
differ
exist
warfarin
doac
healthcar
util
bleed
event
vte
event
adher
therapi
obes
adult
studi
design
retrospect
chart
review
patient
prescrib
warfarin
doac
primari
care
physician
indic
method
data
obtain
chart
review
renal
function
bmi
weight
insur
clinic
er
visit
hospit
refil
record
medicaid
patient
bleed
event
student
fisher
exact
test
use
evalu
statist
signific
alpha
set
result
two
hundr
patient
prescrib
warfarin
prescrib
doac
percent
warfarin
patient
doac
patient
weigh
notabl
doac
patient
bmi
warfarin
patient
lower
averag
number
er
visit
last
year
compar
apixaban
vs
rivaroxaban
vs
signific
differ
warfarin
doac
found
vte
rate
vs
warfarin
patient
higher
bleed
rate
compar
doac
vs
weight
vs
bmi
howev
differ
statist
signific
averag
medic
possess
ratio
mpr
patient
medicaid
higher
warfarin
vs
conclus
doac
frequent
prescrib
obes
patient
despit
lack
evid
support
use
group
closer
consider
use
frequent
obes
patient
warrant
given
poorer
adher
frequent
er
visit
compar
warfarin
manag
obes
rural
health
famili
medicin
clinic
jennif
clement
pharmd
fccp
bcp
cde
bcacp
presbyterian
colleg
school
pharmaci
clinton
sc
introduct
one
everi
three
adult
us
obes
defin
bodi
mass
index
bmi
evid
support
role
pharmacist
commun
set
obes
manag
limit
evid
member
multidisciplinari
team
howev
public
defin
role
pharmacist
lifestyl
coach
rural
health
famili
medicin
center
obes
manag
research
question
hypothesi
pharmacist
impact
assist
patient
weight
loss
rural
health
famili
medicin
set
studi
design
studi
prospect
cohort
feasibl
trial
conduct
target
sampl
size
patient
method
inclus
criteria
adult
patient
age
year
bmi
enrol
patient
seen
monthli
six
month
individu
visit
last
minut
approxim
minut
lifestyl
modif
primari
outcom
absolut
percentag
chang
weight
baselin
six
month
secondari
outcom
includ
chang
bmi
waist
circumfer
pair
use
statist
analysi
primari
outcom
result
screen
period
total
patient
screen
patient
enrol
studi
agre
inform
consent
among
individu
complet
studi
differ
lb
six
month
secondari
outcom
chang
bmi
inch
statist
signific
greater
chang
outcom
observ
among
individu
complet
six
monthli
visit
conclus
pharmacist
impact
assist
patient
weight
loss
studi
warrant
determin
best
approach
weight
manag
program
word
count
evalu
popul
health
servic
intern
medicin
clinic
joshua
rickard
pharmd
bcp
cde
priya
patel
pharmd
adena
yau
pharmd
clinic
health
profess
colleg
pharmaci
health
scienc
st
john
univers
queen
ny
john
univers
queen
ny
introduct
popul
health
studi
health
outcom
determin
health
aim
improv
health
popul
supplement
public
health
take
broader
rang
factor
consider
impact
health
overal
human
popul
new
opportun
emerg
pharmacist
involv
popul
health
manag
pharmacist
identifi
patient
use
electron
medic
record
tailor
intervent
optim
patient
outcom
one
step
improv
overal
popul
health
develop
implement
patient
focus
treatment
guidelin
high
qualiti
low
cost
research
question
hypothesi
prescrib
accept
popul
recommend
ambulatori
care
clinic
pharmacist
differ
accept
rate
base
provid
type
common
recommend
made
studi
design
retrospect
evalu
studi
clinic
servic
establish
may
method
pharmacist
document
popul
health
intervent
data
intervent
tracker
call
medkeep
data
download
medkeep
may
april
evalu
follow
popul
health
recommend
accept
rate
accept
rate
base
provid
type
andor
month
type
intervent
made
data
manipul
excel
spreadsheet
result
total
recommend
made
pharmacist
recommend
accept
modifi
origin
recommend
recommend
reject
justifi
medic
resid
like
accept
recommend
attend
physician
least
like
common
type
recommend
immun
titrat
medic
addit
therapi
conclus
overal
new
popul
health
recommend
servic
well
receiv
half
recommend
accept
narr
literatur
review
assess
implement
fidel
comprehens
medic
manag
nichola
cox
pharmd
kyle
turner
khoi
le
primari
care
servic
univers
utah
health
salt
lake
citi
ut
pharmacotherapi
univers
utah
colleg
pharmaci
salt
lake
citi
ut
utah
colleg
pharmaci
salt
lake
citi
ut
introduct
univers
utah
health
pharmaci
primari
care
servic
ppc
recent
engag
implement
comprehens
medic
manag
cmm
standard
care
primari
care
clinic
previou
studi
cmm
demonstr
improv
clinic
financi
humanist
outcom
howev
studi
occur
institut
pharmacist
provis
cmm
base
principl
pharmaceut
care
long
standard
practic
pharmacist
nationwid
begin
implement
cmm
littl
known
fidel
assess
practic
site
implement
lead
replic
posit
outcom
one
potenti
fidel
assess
strategi
compar
medic
therapi
problem
mtp
identifi
classifi
pharmacist
mtp
identifi
classifi
previous
publish
research
research
question
hypothesi
mtp
initi
cmm
servic
compar
institut
establish
cmm
program
studi
design
narr
literatur
review
descript
retrospect
studi
method
narr
literatur
review
complet
identifi
publish
studi
evalu
pharmacist
provis
cmm
servic
report
total
mtp
identifi
categori
studi
characterist
mtp
outcom
extract
summar
outcom
includ
institut
year
cmm
practic
total
patient
total
mtp
document
mtp
classif
framework
use
clinic
financi
humanist
outcom
report
outcom
qualit
compar
seven
month
institut
mtp
data
result
seven
studi
includ
narr
summari
comparison
mean
mtp
outcom
seven
studi
compar
institut
data
includ
number
mtp
document
vs
proport
mtp
relat
indic
vs
proport
mtp
relat
effect
vs
proport
mtp
relat
safeti
vs
proport
mtp
relat
adher
vs
conclus
mtp
outcom
recent
implement
cmm
similar
mtp
outcom
institut
establish
cmm
program
increas
access
primari
care
rural
veteran
leverag
clinic
pharmaci
specialist
provid
shawn
mcfarland
pharmd
michael
tran
pharmd
pbm
clinic
pharmaci
practic
offic
depart
veteran
affair
washington
dc
introduct
increas
access
care
rural
veteran
integr
clinic
pharmaci
specialist
cp
provid
opportun
increas
qualiti
care
rural
veteran
would
otherwis
receiv
care
cp
advanc
practic
provid
prescript
author
provid
comprehens
medic
manag
across
spectrum
chronic
diseas
encount
primari
care
research
question
hypothesi
integr
cp
primari
care
increas
access
rural
veteran
studi
design
prospect
qualiti
improv
project
method
cp
hire
octob
octob
grant
improv
access
rural
veteran
cp
evalu
encount
monthli
number
veteran
serv
type
intervent
provid
encount
veteran
serv
collect
via
nation
databas
cp
intervent
track
util
standard
templat
within
va
ehr
call
pharmacist
achiev
result
medic
document
pharmd
tool
allow
cp
effici
document
select
intervent
made
patient
care
encount
result
june
primari
care
cp
serv
total
veteran
rural
account
encount
intervent
document
use
pharmd
tool
top
four
diseas
state
manag
cp
diabet
anticoagul
hypertens
lipid
encount
complet
virtual
includ
via
telephon
clinic
video
telehealth
face
face
visit
compris
total
use
estim
cost
save
rate
convers
physician
visit
cp
visit
visit
initi
result
cost
save
conclus
hire
primari
care
cp
result
underserv
rural
veteran
receiv
care
chronic
diseas
state
overal
overal
cost
save
compar
physician
visit
optim
approach
mobil
applic
use
improv
medic
adher
blood
pressur
patient
hypertens
maria
thurston
pharmd
bcp
ayman
akil
kendra
manigault
pharmd
bcp
bcacp
sweta
patel
pharmd
lydia
newsom
pharmd
kevin
murnan
pharmaci
practic
mercer
univeristi
colleg
pharmaci
atlanta
ga
univeristi
colleg
pharmaci
atlanta
ga
practic
mercer
univers
colleg
pharmaci
atlanta
ga
pharmaci
gradi
health
system
atlanta
ga
pharmaceut
scienc
emori
univers
hospit
atlanta
ga
present
georgia
bio
innov
summit
atlanta
georgia
octob
assess
vitamin
monitor
veteran
type
diabet
metformin
therapi
ashley
higbea
pharmd
haley
runeberg
rick
weideman
carlo
alvarez
pharmd
msc
practic
texa
tech
univers
health
scienc
center
school
pharmaci
dalla
tx
ttuhscvantxhc
dalla
tx
vantxhc
dalla
tx
pharmaci
texa
tech
univers
health
scienc
center
dalla
tx
introduct
metformin
use
link
vitamin
defici
howev
monitor
level
common
practic
sinc
american
diabet
associ
ada
standard
medic
care
diabet
guidelin
includ
new
recommend
period
measur
metformin
treat
patient
complianc
recommend
yet
determin
research
question
hypothesi
ada
guidelin
new
recommend
impact
monitor
veteran
popul
metformin
therapi
studi
design
retrospect
cohort
studi
method
electron
medic
record
veteran
patient
metformin
start
therapi
va
north
texa
health
care
system
vanthc
review
vitamin
monitor
record
compar
versu
patient
patient
metformin
without
regular
condit
medic
could
affect
absorpt
exclud
mcnemar
test
use
primari
outcom
monitor
versu
result
patient
met
inclus
criteria
least
one
vitamin
level
versu
patient
averag
number
vitamin
level
per
patient
document
vitamin
level
sinc
start
metformin
seventeen
patient
newli
diagnos
neuropathi
prescrib
medic
neuropathi
without
vitamin
level
previou
year
low
level
supplement
cyanocobalamin
conclus
vitamin
monitor
increas
releas
ada
standard
medic
care
diabet
guidelin
howev
major
patient
level
symptom
defici
diabet
neuropathi
similar
treatment
differ
patient
prescrib
medic
diabet
neuropathi
without
check
level
studi
larger
sampl
size
need
comprehens
medic
manag
assess
fidel
implement
across
primari
care
clinic
academ
medic
center
kyle
turner
melissa
green
eve
van
wagon
jerilyn
mckeon
golden
berrett
pharmacotherapi
univers
utah
colleg
pharmaci
salt
lake
citi
ut
utah
salt
lake
citi
ut
utah
health
salt
lake
citi
ut
primari
care
servic
univers
utah
health
salt
lake
citi
ut
introduct
comprehens
medic
manag
cmm
standard
care
ensur
patient
medic
indic
effect
safe
abl
taken
patient
intend
univers
utah
health
pharmaci
primari
care
servic
ppc
pharmacist
implement
cmm
primari
care
clinic
provid
clinic
servic
ensur
similar
outcom
publish
literatur
fidel
cmm
model
must
establish
ppc
work
group
overse
cmm
implement
determin
method
assess
implement
fidel
research
question
hypothesi
degre
fidel
clinic
pharmacist
practic
primari
care
implement
comprehens
medic
manag
practic
studi
design
mix
analysi
process
measur
medic
therapi
problem
mtp
identifi
survey
respons
method
two
assess
conduct
investig
fidel
analysi
document
mtp
survey
instrument
understand
implement
cmm
key
element
mtp
categor
document
accord
pharmaci
qualiti
allianc
pqa
mtp
categori
framework
septemb
march
survey
instrument
collect
demograph
frequenc
report
clinic
activ
likert
scale
regard
use
cmm
patient
care
process
result
mtp
identifi
categor
indic
effect
safeti
adher
ppc
pharmacist
complet
survey
demograph
result
includ
time
practic
averag
year
complet
resid
current
board
certif
qualit
assess
cmm
definit
demonstr
pharmacist
understand
comprehens
natur
care
process
pharmacist
report
alway
often
perform
step
patient
care
process
follow
indic
effect
safeti
adher
less
complet
step
precis
order
conclus
implement
cmm
yield
identif
mtp
foundat
fidel
core
principl
refin
implement
need
increas
understand
util
care
process
pharmacist
collabor
increas
antimicrobi
stewardship
treatment
urinari
tract
infect
primari
care
set
keaton
crockett
lindsay
gasch
golden
berrett
utah
health
salt
lake
citi
ut
primari
care
servic
univers
utah
health
salt
lake
citi
ut
introduct
order
preserv
util
avail
antibiot
antimicrobi
stewardship
becom
area
increas
import
focu
publish
literatur
lack
studi
involv
antimicrobi
stewardship
effort
pharmacist
direct
urin
cultur
primari
care
set
research
question
hypothesi
primari
object
studi
determin
effect
pharmacist
intervent
number
inappropri
day
antibiot
avoid
patient
seen
primari
care
provid
urinari
tract
infect
studi
design
pharmaci
resid
qualiti
improv
project
cohort
comparison
cohort
method
period
pharmacist
review
urin
cultur
result
made
recommend
provid
therapi
follow
patient
regard
therapi
plan
primari
outcom
intervent
period
compar
period
clinic
period
immedi
prior
secondari
object
includ
rate
intervent
rate
differ
empir
antibiot
prescrib
averag
antibiot
durat
pharmacist
time
spent
result
intervent
period
inappropri
day
antibiot
avoid
per
cultur
compar
inappropri
day
antibiot
avoid
per
cultur
period
rate
intervent
intervent
period
period
pharmacist
intervent
result
decreas
antibiot
durat
period
provid
never
decreas
durat
modifi
therapi
common
empir
antibiot
prescrib
time
period
nitrofurantoin
follow
sulfamethoxazoletrimethoprim
averag
durat
empir
therapi
day
time
period
averag
time
spent
pharmacist
perform
chart
review
make
intervent
minut
conclus
pharmacist
increas
number
inappropri
day
antibiot
avoid
play
role
antimicrobi
stewardship
primari
care
set
percept
integr
clinic
pharmacist
pcmh
model
pcmh
team
jonathan
hugh
shawn
mcfarland
kristen
lamb
ashley
thoma
justin
gatwood
phd
jacob
hathaway
clinic
saint
thoma
rutherfordsaint
louis
famili
medicin
center
murfreesboro
tn
clinic
pharmaci
practic
offic
depart
veteran
affair
washington
dc
pharmaci
va
tennesse
valley
healthcar
system
nashvil
tn
pharmaci
va
tennesse
valley
healthcar
system
murfreesboro
tn
pharmaci
translat
scienc
univers
tennesse
colleg
pharmaci
nashvil
tn
medicin
va
tennesse
valley
healthcar
system
nashvil
tn
publish
j
healthc
qualiti
dec
impact
pharmacist
pharmacist
transit
care
initi
ashley
thoma
pharmd
bcp
bcacp
shawn
mcfarland
emili
young
pharmd
candac
bryant
jonathan
hugh
care
tvh
murfreesboro
tn
clinic
pharmaci
practic
offic
depart
veteran
affair
washington
dc
nashvil
tn
medic
hopkinsvil
ky
tennesse
valley
healthcar
system
nashvil
tn
introduct
transit
care
remain
one
vulner
time
patient
encount
within
healthcar
system
multipl
research
initi
highlight
valu
includ
pharmacist
discharg
process
prevent
medic
error
readmiss
furthermor
studi
also
shown
benefit
util
pharmacist
outpati
side
aid
transit
prevent
readmiss
howev
studi
date
evalu
benefit
impact
readmiss
rate
implement
initi
leverag
pharmacist
presenc
set
research
question
hypothesi
purpos
initi
assess
impact
readmiss
ambulatori
care
sensit
condit
patient
provid
standard
counsel
prior
discharg
schedul
follow
clinic
pharmacist
within
day
discharg
studi
design
prospect
qualiti
improv
initi
method
patient
admit
primari
secondari
diagnosi
copd
diabet
hypertens
symptomat
heart
failur
enrol
patient
receiv
standard
counsel
discharg
schedul
follow
clinic
pharmaci
specialist
within
day
discharg
primari
object
studi
determin
impact
transit
care
model
composit
readmiss
rate
manual
chart
review
conduct
quantifi
primari
secondari
endpoint
result
octob
june
patient
enrol
caus
readmiss
rate
decreas
heart
copd
diabet
rate
increas
hypertens
index
readmiss
rate
heart
failur
copd
index
readmiss
hypertens
diabet
conclus
coordin
transit
care
initi
posit
impact
composit
readmiss
rate
util
statin
ambulatori
patient
risk
atherosclerot
cardiovascular
diseas
event
nation
studi
john
moorman
pharmd
bcp
jaclyn
boyl
ms
pharmd
leah
bruno
pharmd
sara
dugan
pharmd
bcpp
luka
everli
pharmd
kyle
gustafson
pharmd
bcp
nathan
homan
pharmd
dankesh
joshi
pharmd
cynthia
king
pharmd
bcacp
kevin
king
pharmd
philip
king
pharmd
anthoni
pesc
pharmd
prabodh
sadana
harold
schneider
iii
pharmd
candid
jennif
toth
pharmd
bs
ami
unruh
pharmd
autumn
walkerli
pharmd
pharmaci
practic
northeast
ohio
medic
univers
rootstown
oh
pharmaci
northeast
ohio
medic
univers
rootstown
oh
introduct
american
colleg
cardiolog
american
heart
associ
publish
guidelin
manag
cholesterol
patient
risk
atherosclerot
cardiovascular
diseas
ascvd
event
guidelin
departur
approach
manag
cholesterol
instead
identifi
group
patient
would
benefit
statin
therapi
research
question
hypothesi
impact
cholesterol
guidelin
nation
prescrib
rate
statin
patient
met
criteria
predictor
prescrib
one
agent
studi
design
nation
studi
conduct
use
data
nation
ambulatori
medic
care
survey
method
offic
visit
involv
patient
age
year
met
criteria
statin
therapi
includ
visit
involv
pregnant
patient
exclud
primari
object
compar
prescrib
rate
statin
cholesterol
guidelin
multivari
logist
regress
identifi
variabl
associ
prescrib
statin
result
total
patient
visit
includ
repres
offic
visit
nation
statin
continu
initi
visit
cohort
versu
visit
cohort
odd
ratio
confid
interv
ci
strongest
independ
predictor
prescrib
statin
concomit
antihypertens
therapi
ci
histori
hyperlipidemia
ci
histori
clinic
ascvd
ci
black
race
ci
hispan
ethnic
ci
conclus
prescrib
rate
statin
increas
releas
cholesterol
guidelin
howev
prescrib
rate
much
lower
expect
especi
black
hispan
patient
observ
signifi
opportun
improv
qualiti
care
patient
risk
major
ascvd
event
unit
state
clinic
pharmaci
manag
hyperglycemia
patient
diabet
newli
diagnos
cancer
undergo
treatment
develop
implement
workflow
transit
ambulatori
oncolog
pharmaci
kyann
wiss
pharmd
bcacp
dawn
fuke
samuel
jacobson
yelena
rozenfeld
medic
group
seattl
wa
pharmaci
depart
provid
medic
group
portland
pharmaci
provid
medic
group
portland
medic
group
portland
introduct
glucocorticoid
gc
incorpor
mani
chemotherapi
regimen
hyperglycemia
primari
side
effect
hyperglycemia
independ
associ
neg
outcom
patient
undergo
chemotherapi
gener
medic
care
patient
diabet
cancer
often
fall
primari
care
provid
pcp
howev
studi
defin
transit
patient
oncolog
primari
care
lack
research
question
hypothesi
would
incorpor
primari
care
clinic
pharmaci
specialist
cp
intervent
improv
blood
glucos
manag
patient
diabet
undergo
chemotherapi
gc
studi
design
feasibl
studi
conduct
determin
practic
impact
clinic
pharmaci
specialist
cp
intervent
improv
manag
blood
glucos
level
patient
method
patient
identifi
use
autom
report
collabor
practic
agreement
referr
request
sent
pcp
referr
approv
patient
follow
cp
individu
glycem
goal
met
compar
control
group
patient
start
chemotherapi
year
prior
outcom
assess
includ
chang
diabet
medic
healthcar
util
result
fifteen
patient
enrol
intervent
group
compar
control
group
baselin
characterist
similar
except
intervent
patient
like
male
less
like
dexamethason
mg
per
week
prescrib
telephon
call
oncologist
pcp
decreas
cp
servic
patient
discharg
due
meet
glycem
target
weekli
dose
gc
appear
affect
variat
glycem
control
conclus
effect
workflow
transit
patient
diabet
oncolog
primari
care
team
implement
increas
call
volum
cp
servic
led
decreas
call
oncolog
primari
care
provid
clinic
inertia
amongst
healthcar
provid
diabet
manag
sara
lingow
pharmd
justinn
guyton
pharmd
bcacp
depart
pharmaci
practic
st
loui
colleg
pharmaci
saint
loui
mo
introduct
clinic
inertia
lack
treatment
intensif
patient
therapeut
goal
major
factor
lead
suboptim
patient
care
patient
diabet
one
studi
demonstr
less
clinic
inertia
specialist
manag
diabet
vs
primari
care
provid
limit
literatur
avail
evalu
clinic
inertia
pharmacist
healthcar
provid
diabet
manag
research
question
hypothesi
patient
uncontrol
type
diabet
pharmacist
reduc
rate
clinic
inertia
compar
primari
care
provid
studi
design
retrospect
cohort
studi
method
adult
type
diabet
identifi
period
diabet
care
manag
pharmacist
primari
care
provid
primari
outcom
compar
rate
treatment
intensif
group
four
month
measur
addit
medicin
dose
increas
secondari
outcom
includ
chang
subsequ
number
contact
subgroup
analysi
base
baselin
comorbid
result
patient
pharmacist
group
primari
care
provid
group
elig
final
analysi
baselin
similar
group
higher
percentag
patient
pharmacist
group
obes
comorbid
compar
pharmacist
group
primari
care
provid
group
overal
versu
patient
receiv
treatment
intensif
p
respect
noninsulin
therapi
intensifi
versu
insulin
therapi
intensifi
vs
p
respect
pharmacist
four
patient
contact
primari
care
provid
one
patient
contact
differ
lower
conclus
treatment
intensif
patient
uncontrol
diabet
common
pharmacist
group
thu
reduc
rate
clinic
inertia
compar
primari
care
provid
demonstr
advantag
pharmacist
involv
diabet
care
particularli
regard
intensif
insulin
therapi
evalu
ambulatori
transit
care
pharmacist
servic
high
risk
patient
kelli
kipp
pharmd
bcp
antoinett
coe
pharmd
sarah
aldrich
tami
remington
pharmd
hae
mi
choe
medicin
ann
arbor
mi
clinic
pharmaci
univers
michigan
colleg
pharmaci
ann
arbor
mi
introduct
ambulatori
multidisciplinari
transit
care
program
includ
nurs
navig
phone
call
pharmacist
comprehens
medic
review
cmr
via
telephon
primari
care
provid
pcp
visit
implement
patient
hospit
discharg
research
question
hypothesi
hospit
readmiss
rate
lower
patient
receiv
pharmacist
cmr
identifi
problem
mrp
recommend
resolv
mrp
primari
care
provid
pcp
accept
rate
studi
design
retrospect
cohort
studi
academ
medic
center
method
electron
medic
record
review
septemb
conduct
inclus
criteria
lace
score
upon
discharg
establish
michigan
medicin
pcp
discharg
specif
inpati
servic
discharg
home
primari
outcom
readmiss
rate
compar
cmr
recipi
elig
patient
schedul
secondari
outcom
pharmacist
identifi
mrp
recommend
pcp
accept
rate
descript
statist
analysi
multivari
logist
regress
use
result
total
discharg
elig
receiv
cmr
averag
age
year
sd
women
whitecaucasian
readmit
within
day
cmr
recipi
lower
readmiss
rate
compar
vs
cmr
recipi
lower
odd
compar
without
confid
interv
ci
lace
score
time
higher
odd
compar
score
ci
readmiss
adjust
age
race
averag
mrp
sd
identifi
per
visit
rang
top
mrp
identifi
drug
interact
need
assess
monitor
laboratori
test
need
common
recommend
drug
interact
review
request
provid
review
patient
educ
pcp
accept
pharmacist
recommend
conclus
cmr
reduc
hospit
readmiss
patient
provid
survey
assess
expans
clinic
pharmaci
servic
part
comprehens
primari
care
initi
lisa
beckett
pharmd
abbi
frye
pharmd
yelena
rozenfeld
mph
provid
medic
group
portland
introduct
center
medicar
medicaid
servic
launch
comprehens
primari
care
cpc
initi
promot
innov
primari
care
initi
requir
practic
implement
advanc
care
strategi
includ
comprehens
medic
manag
integr
behavior
health
patient
support
thirteen
primari
care
clinic
provid
medic
region
select
cpc
practic
site
offer
opportun
expand
clinic
pharmaci
servic
order
assess
perceiv
impact
expans
provid
survey
conduct
research
question
hypothesi
primari
care
provid
satisfi
expans
clinic
pharmaci
servic
associ
cpc
initi
studi
design
provid
health
servic
institut
review
board
grant
expedit
studi
approv
mix
survey
creat
distribut
assess
provid
satisfact
method
survey
includ
statement
valu
clinic
pharmaci
rate
scale
question
current
potenti
futur
clinic
pharmaci
servic
provid
cpc
clinic
elig
survey
clinic
leadership
notifi
survey
encourag
survey
complet
clinic
pharmacist
exclud
distribut
collect
process
result
survey
provid
strongli
agre
clinic
pharmacist
improv
qualiti
safeti
valu
effici
patient
care
ask
specif
clinic
pharmaci
servic
major
respond
rank
import
collabor
diseas
manag
high
risk
medic
use
elderli
drug
inform
consult
highli
rank
servic
provid
clinic
higher
panel
ratio
like
want
addit
pharmacist
time
clinic
conclus
survey
result
posit
indic
high
degre
provid
satisfact
expans
clinic
pharmaci
servic
associ
cpc
initi
result
use
inform
expans
clinic
pharmaci
servic
primari
care
develop
valid
measur
assess
progress
success
implement
pharmaci
servic
optim
medic
use
melani
livet
carri
blanchard
pharmd
mari
yannayon
mari
roth
mcclurg
pharmd
todd
sorensen
eshelman
school
pharmaci
chapel
hill
nc
medic
optim
unc
eshelman
school
pharmaci
chapel
hill
nc
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
present
pqa
annual
meet
baltimor
md
may
assess
chronic
diseas
manag
among
patient
diabet
coronari
arteri
diseas
receiv
care
cardiolog
clinic
scott
pearson
courtney
shakowski
joseph
vand
griend
robert
page
ii
pharmd
amber
khanna
garth
wright
joseph
saseen
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
colorado
hospit
aurora
co
health
servic
organ
univers
colorado
health
aurora
co
cardiolog
univers
colorado
anschutz
medic
center
aurora
co
introduct
patient
coronari
arteri
diseas
cad
often
multipl
comorbid
includ
diabet
hypertens
dyslipidemia
unclear
comorbid
adequ
manag
among
patient
establish
cardiolog
clinic
clinic
pharmacist
intervent
could
posit
impact
potenti
gap
though
integr
manag
servic
research
question
hypothesi
well
chronic
diseas
qualiti
measur
achiev
among
cardiolog
clinic
patient
diabet
cad
studi
design
observ
retrospect
method
univers
colorado
health
cardiac
vascular
center
cvc
patient
age
cad
diabet
least
cvc
visit
within
period
includ
primari
outcom
achiev
five
chronic
diseas
qualiti
measur
hemoglobin
blood
pressur
mmhg
antiplatelet
agent
statin
annual
influenza
vaccin
secondari
outcom
includ
addit
measur
care
qualiti
covari
predict
higher
qualiti
measur
achiev
qualiti
measur
assess
use
descript
statist
predictor
qualiti
measur
achiev
investig
logist
regress
use
sa
result
qualiti
measur
achiev
shown
women
less
like
men
achiev
least
four
five
measur
adjust
odd
ratio
confid
interv
ci
patient
two
primari
care
provid
pcp
visit
within
past
year
like
achiev
least
four
measur
compar
patient
less
two
pcp
visit
adjust
ci
appli
optim
measur
patient
achiev
patient
achiev
blood
pressur
mmhg
patient
prescrib
statin
conclus
achiev
chronic
care
qualiti
measur
high
perform
could
improv
especi
among
women
patient
infrequ
pcp
visit
collabor
care
model
vs
standard
care
assess
time
therapeut
rang
patient
hypertens
dave
dixon
eric
parod
evan
sisson
pharmd
benjamin
van
tassel
pramit
nadpara
alan
dow
md
pharmaci
practic
innov
virginia
commonwealth
univers
school
pharmaci
richmond
va
heart
health
system
miramar
beach
fl
pharmaci
virginia
commonwealth
univers
richmond
va
medicin
vcu
health
system
richmond
va
introduct
increas
time
therapeut
rang
ttr
defin
consist
control
systol
blood
pressur
sbp
mmhg
reflect
low
sbp
variabl
associ
reduc
mortal
patient
hypertens
collabor
care
model
ppccm
improv
bp
control
rate
reduc
mean
bp
unknown
ppccm
affect
time
therapeut
rang
research
question
hypothesi
ppccm
increas
ttr
sbp
compar
standard
care
studi
design
subgroup
analysi
retrospect
cohort
studi
method
medic
record
review
free
clinic
use
ppccm
primari
care
practic
link
indig
care
program
manag
academ
medic
center
standard
care
new
patient
present
uncontrol
hypertens
includ
exclus
criteria
consist
egfr
bp
read
pregnanc
patient
match
group
accord
gender
baselin
sbp
histori
cardiovascular
diseas
ttr
determin
proport
clinic
visit
sbp
mmhg
period
mean
compar
use
count
comparison
compar
use
fisher
exact
test
result
match
patient
per
group
identifi
inclus
baselin
characterist
similar
group
except
standard
care
group
slightli
older
ppccm
group
vs
year
ttr
ppccm
group
significantli
higher
standard
care
group
vs
p
total
proport
patient
consist
control
quartil
ttr
ppccm
group
compar
standard
care
group
conclus
find
suggest
ppccm
achiev
higher
ttr
sbp
standard
care
studi
warrant
prospect
evalu
benefit
model
cardiovascular
outcom
pharmacotherapeut
approach
manag
type
diabet
retrospect
studi
clinic
pharmacist
manag
versu
usual
care
feder
qualifi
health
center
emanuela
mooney
rhianna
fink
sarah
billup
joseph
saseen
school
pharmaci
pharmaceut
scienc
univers
colorado
aurora
co
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
present
mountain
state
confer
salt
lake
citi
ut
may
primari
care
provid
perspect
perceiv
barrier
prefer
facilit
regard
hepat
c
viru
screen
primari
care
set
khushbu
tejani
sara
baghikar
md
deval
gor
bpharm
edith
nutescu
pharmd
michel
martin
practic
univers
illinoi
chicago
chicago
il
illinoi
chicago
school
public
health
chicago
il
system
outcom
polici
univers
illinoi
chicago
colleg
pharmaci
chicago
il
system
outcom
polici
center
pharmacoepidemiolog
pharmacoeconom
research
univers
illinoi
chicago
colleg
pharmaci
chicago
il
practic
univers
illinoi
chicago
colleg
pharmacyunivers
illinoi
hospit
health
scienc
system
chicago
il
introduct
percent
patient
unit
state
unawar
hepat
c
viru
hcv
infect
guidelin
recommend
hcv
screen
patient
born
increas
risk
hcv
infect
compar
gener
popul
primari
care
provid
pcp
author
institut
low
hcv
screen
rate
among
patient
born
research
question
hypothesi
pcp
perspect
toward
hcv
screen
perceiv
barrier
prefer
facilit
implement
hcv
screen
process
primari
care
set
studi
design
survey
conduct
method
investig
develop
survey
assess
demograph
confid
comfort
attitud
toward
hcv
screen
test
interpret
treatment
knowledg
perceiv
barrier
facilit
also
assess
survey
item
review
author
physician
institut
face
valid
updat
made
base
feedback
email
address
pcp
obtain
administr
survey
link
email
pcp
three
primari
care
locat
within
academ
medic
center
result
survey
respons
rate
provid
report
patient
born
agre
primari
care
set
appropri
place
conduct
hcv
screen
percent
respond
felt
comfort
refer
patient
hepatolog
clinic
hcv
care
felt
confid
initi
hcv
treatment
lack
time
common
barrier
report
electron
health
record
ehr
prompt
common
facilit
request
aid
hcv
screen
conclus
opportun
exist
improv
hcv
screen
rate
medic
center
pcp
identifi
barrier
time
knowledg
train
yet
perceiv
primari
care
appropri
venu
hcv
screen
direct
includ
implement
train
program
ehr
prompt
increas
hcv
screen
rate
prediabet
pharmacist
opinion
opportun
care
nichola
carri
pharmd
kevin
cowart
pharmd
mph
angela
garcia
pharmd
mph
depart
pharmacotherapeut
clinic
research
univers
south
florida
colleg
pharmaci
tampa
fl
introduct
estim
million
patient
unit
state
prediabet
intervent
prevent
diabet
insuffici
use
expand
diabet
prevent
intervent
pharmacist
involv
care
support
guidelin
feder
agenc
howev
strong
content
regard
prediabet
diabet
prevent
exist
among
clinician
therefor
pharmacist
opinion
must
explor
prior
implement
diabet
prevent
practic
model
research
question
hypothesi
pharmacist
support
american
diabet
associ
ada
recommend
relat
diabet
prevent
studi
design
anonym
survey
electron
distribut
american
colleg
clinic
pharmaci
ambulatori
care
practic
research
network
method
primari
outcom
proport
respond
report
support
three
ada
diabet
prevent
relat
recommend
ie
prediabet
screen
lifestyl
intervent
metformin
univers
south
florida
institut
review
board
determin
studi
exempt
data
collect
analysi
occur
result
total
survey
return
state
gener
ada
guidelin
commonli
support
guidelin
relat
diabet
prevent
respond
support
three
ada
recommend
regard
diabet
prevent
lifestyl
intervent
support
respond
follow
screen
prediabet
metformin
diabet
prevent
nearli
respond
felt
attempt
prevent
type
diabet
import
although
respond
agre
current
practic
structur
conduc
implement
diabet
prevent
method
conclus
outpati
clinic
pharmacist
appear
support
ada
recommend
regard
prediabet
therefor
pharmacist
may
key
partner
implement
diabet
prevent
intervent
andor
partner
center
diseas
control
prevent
recent
initi
rx
nation
diabet
prevent
program
futur
research
explor
implement
diabet
prevent
method
practic
model
improv
adher
control
substanc
agreement
polici
interprofession
approach
insaf
mohammad
pharmd
bcacp
mohamad
elabdallah
ruaa
elteriefi
md
pharmaci
practic
eugen
applebaum
colleg
pharmaci
health
scienc
wayn
state
univers
detroit
mi
intern
medicin
beaumont
hospit
dearborn
dearborn
mi
introduct
overus
control
substanc
creat
public
health
crisi
requir
effort
prevent
misus
abus
divers
death
although
guidelin
recommend
measur
control
substanc
agreement
csa
attenu
risk
adher
practic
remain
inadequ
evalu
furthermor
best
practic
promot
use
adher
csa
undefin
research
question
hypothesi
interprofession
approach
qualiti
improv
qi
impact
adher
csa
polici
intern
medicin
clinic
newli
embed
clinic
pharmacist
studi
design
intervent
studi
util
two
pdsa
cycl
method
percentag
patient
control
substanc
continu
month
recurr
use
month
sign
csa
electron
medic
record
compar
month
prior
week
implement
interprofession
intervent
improv
polici
adher
first
cycl
clinic
pharmacist
identifi
patient
meet
polici
criteria
educ
medic
resid
provid
staff
ensur
csa
discuss
sign
patient
visit
second
cycl
pharmacist
educ
team
optim
also
includ
benzodiazepin
control
substanc
outcom
percentag
sign
csa
medcalc
use
statist
analysi
result
includ
patient
control
substanc
medic
differ
group
prior
qi
initi
elig
patient
sign
csa
five
week
implement
qi
patient
sign
csa
ci
p
versu
proport
increas
week
ci
p
versu
conclus
studi
demonstr
improv
adher
clinic
csa
polici
odd
sign
csa
time
higher
second
pdsa
cycl
demonstr
benefit
approach
clinic
pharmacist
impact
convers
basal
insulin
insulin
glargin
dose
clinic
outcom
marina
mae
emili
ashjian
pharmd
bcp
kelli
kipp
pharmd
vincent
marshal
nada
rida
ami
thompson
pharmd
pharmaci
michigan
medicin
ann
arbor
mi
clinic
pharmaci
univers
michigan
colleg
pharmaci
ann
arbor
mi
clinic
social
administr
scienc
univers
michigan
colleg
pharmaci
ann
arbor
mi
michigan
colleg
pharmaci
ann
arbor
mi
introduct
sever
basal
insulin
recent
come
market
includ
first
insulin
glargin
basaglar
patient
frequent
switch
basaglar
often
due
insur
coverag
current
data
publish
implic
convers
basaglar
dose
glycem
control
research
question
hypothesi
patient
convert
basal
insulin
requir
higher
lower
equival
dose
basaglar
hemoglobin
andor
weight
chang
convers
basaglar
studi
design
retrospect
chart
review
academ
medic
center
patient
prescrib
basaglar
decemb
includ
convert
anoth
basal
insulin
method
primari
outcom
differ
basal
insulin
requir
unitsday
unit
kilogram
kg
day
convers
basaglar
dose
defin
last
dose
patient
take
prior
convers
basaglar
dose
defin
last
dose
basaglar
patient
take
closest
conclus
studi
secondari
outcom
includ
chang
weight
result
patient
convert
lantu
basaglar
mean
basal
insulin
dose
differ
result
signific
patient
basal
dose
basal
dose
differ
weight
base
dose
chang
unitskgday
differ
found
signific
patient
differ
decreas
seen
overal
howev
statist
signific
differ
seen
patient
differ
seen
weight
vs
conclus
patient
requir
higher
dose
basal
insulin
upon
convers
basaglar
clinician
monitor
blood
glucos
close
basal
insulin
transit
impact
educ
appropri
prescrib
patient
copd
roger
iain
pritchard
lauren
donohu
rebecca
falter
pharmaci
practic
bernard
j
dunn
school
pharmaci
shenandoah
univers
winchest
va
pa
j
dunn
school
pharmaci
shenandoah
univers
winchest
va
introduct
current
gold
guidelin
indic
clear
prefer
treatment
muscarin
antagonist
labalama
alon
combin
combin
therapi
inhal
corticosteroid
ic
report
copd
prescrib
practic
correl
global
initi
chronic
obstruct
lung
diseas
gold
guidelin
howev
limit
data
regard
intervent
improv
prescrib
research
question
hypothesi
examin
impact
educ
copd
prescrib
practic
outpati
famili
practic
studi
design
studi
method
patient
chart
review
patient
year
age
older
copd
diagnosi
prescrib
labaic
patient
exclud
diagnosi
asthma
patient
categor
one
four
treatment
group
base
upon
gold
guidelin
prescrib
habit
compar
guidelin
recommend
data
present
provid
showcas
clinic
current
copd
prescrib
practic
practic
compar
current
gold
guidelin
recommend
strategi
improv
concord
guidelin
chart
review
evalu
chang
prescrib
result
prior
intervent
patient
gold
group
b
group
c
prescrib
labaic
without
document
indic
therapi
three
month
analysi
show
decreas
labaic
prescrib
gold
group
b
decreas
gold
group
c
across
gold
group
appropri
prescrib
increas
p
conclus
gold
recommend
updat
standard
care
patient
copd
data
show
lack
align
standard
practic
note
nation
educ
deliv
provid
significantli
improv
appropri
prescrib
rate
patient
copd
though
monitor
warrant
assess
barrier
prescrib
naloxon
primari
care
center
tamara
malm
pharmd
mph
jami
blanck
zuri
erani
jason
duke
md
new
hospit
new
ct
saint
joseph
school
pharmaci
hartford
ct
introduct
opioid
overdos
death
nation
epidem
cdc
recommend
patient
prescrib
morphin
milligram
equival
mme
per
day
chronic
opioid
therapi
naloxon
prescript
despit
recommend
naloxon
prescrib
yale
new
hospit
ynhh
primari
care
center
pcc
inconsist
research
question
hypothesi
primari
care
physician
pcp
discomfort
discuss
prescrib
naloxon
lead
low
rate
naloxon
prescrib
amongst
patient
prescrib
mmeday
opioid
therapi
ynhh
pcc
studi
design
retrospect
review
survey
method
third
parti
insur
claim
databas
util
gener
report
patient
opioid
therapi
march
march
inclus
criteria
year
old
pcp
studi
site
opioid
prescript
fill
specifi
date
rang
exclus
criteria
mme
patient
never
seen
primari
care
studi
site
electron
medic
record
use
collect
total
mmeday
presenc
naloxon
prescript
pcp
given
paper
survey
captur
attitud
regard
naloxon
primari
outcom
rate
barrier
naloxon
prescrib
amongst
pcp
facil
result
patient
met
inclus
exclus
criteria
averag
prescrib
mme
rang
valid
naloxon
prescript
present
patient
pcp
survey
state
prescrib
opioid
prescrib
naloxon
major
pcp
comfort
talk
naloxon
patient
somewhat
comfort
comfort
two
pcp
could
identifi
appropri
rout
naloxon
administr
conclus
pcp
discomfort
prescrib
discuss
naloxon
barrier
increas
rate
qualifi
patient
valid
naloxon
prescript
pcp
valuabl
resourc
increas
patient
naloxon
educ
expand
naloxon
access
effect
clinic
pharmacist
encount
transit
care
clinic
readmiss
priscil
kouamo
panid
borhanjoo
mafuzur
rahman
margaret
rn
madhavi
gavini
downstat
school
public
health
brooklyn
ny
intern
medicin
medic
center
brooklyn
ny
pharmaci
depart
famili
medicin
downstat
medic
center
brooklyn
ny
introduct
hospit
patient
meet
specif
criteria
discharg
refer
transit
care
clinic
nurs
practition
physician
clinic
pharmacist
work
collabor
manag
patient
medic
regimen
team
support
patient
adher
ensur
appropri
care
collabor
provid
clinic
pharmacist
review
medic
appropri
assess
adher
recommend
medic
chang
provid
educ
research
question
hypothesi
effect
clinic
pharmacist
encount
transit
care
clinic
readmiss
rate
compar
readmiss
rate
patient
seen
pharmacist
studi
design
retrospect
studi
method
receiv
irb
approv
retrospect
chart
review
conduct
adult
patient
seen
transit
care
clinic
januari
decemb
result
logist
regress
use
predict
readmiss
reason
presenc
clinic
pharmacist
patient
age
gender
number
comorbid
insur
statu
record
patient
visit
analyz
patient
visit
nurs
practition
physician
pharmacist
includ
pharmacist
patient
readmiss
seen
pharmacist
fisher
exact
test
readmiss
rate
patient
seen
pharmacist
seen
pharmacist
signific
differ
readmiss
base
pharmacist
intervent
test
trend
signific
independ
predictor
readmiss
number
comorbid
adjust
odd
ratio
confid
interv
result
similar
readmiss
reason
differ
reason
exclud
conclus
signific
differ
readmiss
patient
seen
clinic
pharmacist
transit
care
clinic
impact
effort
improv
medic
reconcili
geriatr
patient
intern
medicin
clinic
insaf
mohammad
pharmd
bcacp
rabia
bangash
jeffrey
kane
pharmaci
practic
eugen
applebaum
colleg
pharmaci
health
scienc
wayn
state
univers
detroit
mi
intern
medicin
beaumont
hospit
dearborn
dearborn
mi
introduct
geriatr
patient
complex
medic
regimen
vulner
error
inadequ
medic
reconcili
mr
account
medic
error
error
result
harm
innov
collabor
mr
approach
must
explor
identifi
best
practic
attenu
risk
research
question
hypothesi
impact
mr
qualiti
improv
qi
initi
proport
geriatr
patient
duplic
medic
document
electron
medic
record
emr
medic
list
medic
document
without
dosag
instruct
complet
acut
manag
medic
document
emr
medic
list
studi
design
intervent
studi
util
method
qi
initi
includ
emr
remind
educ
staffprovid
clinic
pharmacist
ensur
mr
complet
everi
patient
visit
review
emr
medic
list
patient
old
medic
outcom
includ
proport
patient
duplic
medic
document
medic
list
differ
dosageinstruct
b
medic
without
dosag
instruct
document
c
complet
acut
manag
medic
remain
list
descript
statist
use
result
includ
patient
mean
age
averag
medic
mean
age
averag
medic
proport
patient
duplic
medic
dosageinstruct
document
decreas
vs
patient
duplic
medic
differ
dosag
medic
decreas
vs
patient
duplic
medic
differ
instruct
medic
decreas
vs
patient
medic
without
dosag
document
decreas
vs
patient
medic
without
instruct
increas
vs
patient
complet
acut
manag
medic
document
decreas
vs
conclus
geriatr
mr
initi
led
reduct
duplic
medic
medic
without
dosag
complet
acut
manag
medic
document
compar
statin
prescrib
rate
elig
hiv
vs
infect
patient
alison
blackman
neha
sheth
pandit
pharmd
aahivp
bcp
kathleen
pincu
pharmd
pharmaci
servic
univers
maryland
medic
center
baltimor
md
pharmaci
practic
scienc
univers
maryland
school
pharmaci
baltimor
md
present
id
week
san
francisco
ca
octob
reliabl
valid
patient
respons
survey
comprehens
medic
manag
carri
blanchard
pharmd
mph
jimmi
xu
pharmd
mari
roth
mcclurg
pharmd
melani
livet
medic
optim
unc
eshelman
school
pharmaci
chapel
hill
nc
eshelman
school
pharmaci
chapel
hill
nc
introduct
measur
patient
respons
extent
patient
engag
accept
intervent
import
precursor
patient
engag
pharmaci
servic
includ
three
compon
relationship
whether
intervent
met
patient
need
patient
satisfact
measur
patient
satisfact
pharmaci
servic
exist
survey
set
measur
patient
respons
comprehens
research
question
hypothesi
purpos
studi
establish
reliabl
valid
patient
respons
survey
comprehens
medic
manag
studi
design
part
cmm
primari
care
studi
network
clinic
pharmacist
use
pilot
survey
method
multiphas
develop
process
use
includ
literatur
search
item
gener
content
valid
pilot
survey
reliabl
test
construct
valid
result
item
questionnair
design
measur
compon
patient
respons
use
likert
scale
develop
content
valid
establish
survey
pilot
respons
rate
reliabl
test
indic
cronbach
alpha
exploratori
factor
analysi
efa
conduct
measur
verifi
sampl
adequaci
analysi
bartlett
test
signific
p
data
appropri
factor
analysi
commun
greater
base
analysi
singl
factor
explain
varianc
second
third
factor
explain
addit
respect
conclus
result
support
reliabl
measur
howev
efa
data
reveal
singl
rather
expect
structur
addit
patient
respons
account
varianc
indic
approxim
varianc
explain
concept
futur
iter
survey
includ
addit
factor
believ
impact
patient
respons
social
determin
health
reduc
risk
nsaid
induc
advers
event
concomit
use
misoprostol
mark
munger
pharmd
depart
pharmacotherapi
intern
medicin
univers
utah
salt
lake
citi
ut
publish
jacc
abstract
low
densiti
lipoprotein
cholesterol
control
patient
ischaem
heart
diseas
elisa
curtolo
final
year
mpharm
francesca
wirth
bpharm
hon
mphil
robert
g
xuereb
md
frcp
fasa
fesc
liberato
camilleri
bed
hon
msc
phd
lanc
andrea
cignarella
mpharm
lilian
azzopardi
bpharm
hon
mphil
phd
mrpharm
ffip
di
scienz
del
farmaco
degli
studi
di
padova
padova
itali
pharmaci
univers
malta
msida
malta
cardiolog
mater
dei
hospit
msida
malta
statist
oper
research
univers
malta
msida
malta
di
medicina
degli
studi
di
padova
padova
itali
introduct
american
guidelin
treatment
blood
cholesterol
reduc
atherosclerot
cardiovascular
diseas
risk
recommend
use
appropri
intens
statin
specif
target
european
guidelin
manag
dyslipidaemia
recommend
target
goal
mmoll
least
rel
reduct
research
question
hypothesi
patient
ischaem
heart
diseas
ihd
reach
target
goal
recommend
european
guidelin
studi
design
retrospect
cohort
studi
method
follow
ethic
approv
patient
coronari
angiographi
perform
decemb
march
diagnos
ihd
refer
percutan
coronari
intervent
pci
coronari
arteri
bypass
graft
cabg
medic
treatment
consecut
identifi
cardiolog
depart
mater
dei
hospit
gener
acut
hospit
patient
previou
pcicabg
exclud
baselin
time
angiogram
month
level
therapi
record
data
analys
ibm
spss
statist
result
data
patient
male
mean
age
year
refer
pci
compil
mean
mmoll
baselin
month
month
month
level
target
patient
baselin
month
month
baselin
patient
simvastatin
chang
statin
record
patient
month
simvastatin
atorvastatin
patient
mean
reduct
baselin
month
statin
chang
significantli
larger
versu
statin
unchang
conclus
mean
significantli
higher
target
timepoint
patient
achiev
target
month
chang
simvastatin
higher
intens
statin
result
significantli
larger
mean
reduct
compar
patient
kept
simvastatin
character
thrombocytopenia
use
low
dose
heparin
anticoagul
protocol
impella
cp
devic
cardiogen
shock
andrea
sikora
newsom
pharmd
bcp
bcccp
ashley
taylor
doctor
seth
garner
pharmd
pharmaci
uga
colleg
pharmaci
augusta
ga
colleg
pharmaci
augusta
ga
introduct
impella
cp
temporari
percutan
left
ventricular
assist
devic
lvad
requir
purg
solut
decreas
risk
devic
thrombosi
data
regard
purg
solut
limit
case
report
one
retrospect
review
patient
use
differ
purg
solut
research
question
hypothesi
platelet
trend
patient
manag
temporari
lvad
devic
low
dose
heparin
purg
solut
studi
design
singl
site
retrospect
review
method
singl
site
retrospect
review
conduct
adult
impella
cp
data
collect
includ
patient
demograph
inform
durat
percutan
lvad
support
compon
concentr
purg
solut
coagul
laboratori
valu
system
anticoagul
advers
event
descript
statist
use
result
total
patient
includ
hour
patient
reduc
platelet
count
hour
patient
reduc
platelet
count
patient
lvad
hour
thrombocytopenia
platelet
count
median
absolut
reduct
platelet
count
iqr
median
percentag
reduct
platelet
count
iqr
six
patient
test
thrombocytopenia
one
test
posit
devic
thrombosi
observ
conclus
patient
reduct
platelet
count
met
criteria
point
score
howev
patient
diagnos
hit
evalu
observ
consist
platelet
reduct
use
lvad
cardiogen
shock
rate
hit
similar
patient
popul
role
desmopressin
blood
conserv
agent
select
patient
undergo
cardiac
surgeri
emili
moos
pharmd
evan
tatum
pharmd
depart
pharmaci
novant
health
forsyth
medic
center
nc
introduct
blood
conserv
strategi
implement
cardiac
surgeri
decreas
potenti
complic
associ
blood
transfus
research
question
hypothesi
object
studi
determin
differ
transfus
requir
factor
viia
use
patient
receiv
desmopressin
ddavp
undergo
cardiac
surgeri
aortic
stenosi
studi
design
retrospect
studi
approv
institut
review
board
method
adult
patient
undergo
cardiac
surgeri
aortic
stenosi
june
august
includ
studi
patient
exclud
uremia
presenc
von
willebrand
diseas
hemophilia
exist
prior
histori
hyponatremia
contraind
hypersensit
ddavp
anticoagul
antiplatelet
therapi
held
appropri
prior
surgeri
treatment
group
receiv
ddavp
mcgkg
intraven
protamin
administr
control
group
receiv
ddavp
random
base
cardiothorac
surgeon
arm
rate
acut
renal
failur
hyponatremia
transfus
requir
recombin
factor
viia
use
evalu
postop
result
total
patient
includ
final
analysi
primari
endpoint
show
less
transfus
requir
hour
surgeri
patient
ddavp
group
patient
control
group
differ
factor
viia
use
rate
renal
failur
hyponatremia
group
conclus
current
bodi
literatur
regard
use
desmopressin
cardiac
surgeri
limit
ddavp
may
role
cardiac
surgeri
patient
aortic
stenosi
addit
research
need
valid
reason
failur
optim
medic
therapi
heart
failur
reduc
eject
fraction
patient
clinic
practic
katelyn
smith
jacquelin
dun
christina
fischer
liliana
fera
msn
taylor
maclean
ms
joshua
lina
matta
pharmd
thoma
gaziano
md
calum
macra
md
benjamin
scirica
akshay
desai
md
innov
program
brigham
women
hospit
boston
innov
program
brigham
women
hospit
bo
present
heart
failur
societi
america
nashvil
tn
septemb
optim
medic
therapi
prescrib
pattern
dispar
identifi
patient
acut
coronari
syndrom
ashley
n
fox
grant
h
skrepnek
phd
jami
l
miller
pharmd
bcp
nichola
c
schwier
pharmd
toni
ripley
pharmd
fccp
bcp
pharmaci
clinic
administr
scienc
univers
oklahoma
hsc
colleg
pharmaci
oklahoma
citi
ok
clinic
administr
scienc
colleg
pharmaci
univers
oklahoma
health
scienc
center
oklahoma
citi
ok
pharmaci
clinic
administr
scienc
univers
oklahoma
colleg
pharmaci
oklahoma
citi
ok
oklahoma
colleg
pharmaci
oklahoma
citi
ok
introduct
cardiovascular
diseas
lead
caus
death
unit
state
oklahoma
rank
within
unit
state
territori
coronari
heart
diseas
chd
death
pharmacotherapi
includ
dual
antiplatelet
therapi
dapt
aspirin
receptor
antagonist
blocker
angiotensin
convert
enzym
inhibitor
angiotensin
receptor
blocker
arb
statin
therapi
reduc
chd
death
regimen
agent
optim
medic
therapi
omt
recommend
guidelin
omt
prescrib
time
may
vari
patient
present
demograph
due
signific
mortal
chd
oklahoma
research
omt
prescrib
warrant
improv
practic
identifi
dispar
research
question
hypothesi
omt
prescrib
academ
medic
center
oklahoma
describ
literatur
studi
design
retrospect
review
academ
medic
center
oklahoma
method
patient
identifi
diagnosi
code
acut
coronari
syndrom
ac
primari
endpoint
percentag
omt
prescrib
secondari
endpoint
includ
identif
factor
patient
receiv
omt
demograph
present
manag
record
medic
obtain
discharg
document
medic
record
screen
contraind
multivari
regress
analysi
conduct
includ
age
sex
race
ac
event
ac
manag
comorbid
priori
alpha
p
variabl
analyz
independ
control
variabl
result
eight
hundr
patient
identifi
patient
exclud
patient
analyz
patient
receiv
omt
group
less
like
receiv
omt
discharg
includ
unstabl
angina
elderli
surgic
manag
conclus
omt
prescrib
academ
medic
center
oklahoma
exceed
report
literatur
howev
omt
prescrib
remain
develop
qualiti
project
improv
prescrib
focu
risk
popul
efficaci
safeti
apixaban
versu
warfarin
preserv
patient
atrial
fibril
extrem
bodi
weight
insight
aristotl
studi
marat
fudim
md
cardiolog
fellowship
duke
univers
lawrencevil
nj
present
american
colleg
cardiolog
orlando
florida
march
bodi
mass
index
influenc
warfarin
dose
requir
retrospect
studi
qatar
eman
alhmoud
bsc
msc
dana
bakdach
moham
abdulgelil
walid
mekkawi
bsc
eyad
almadhoun
msc
clinic
pharmaci
bcp
depart
al
wakra
hamad
medic
corpor
doha
qatar
depart
hamad
gener
hamad
medic
corpor
doha
qatar
gener
hospit
doha
qatar
introduct
percent
qatar
popul
either
overweight
obes
evid
support
effect
bodi
mass
index
bmi
mainten
dose
warfarin
anticoagul
control
contradict
research
question
hypothesi
correl
bmi
weekli
warfarin
dose
requir
maintain
stabl
therapeut
inr
could
individu
bmi
affect
anticoagul
control
reflect
mean
time
therapeut
rang
ttr
incid
thromboembol
andor
bleed
event
studi
design
retrospect
cross
section
studi
method
adult
patient
receiv
stabl
dose
warfarin
defin
therapeut
inr
without
chang
warfarin
dose
least
week
attend
ambulatori
anticoagul
clinic
tertiari
hospit
qatar
one
year
period
includ
relev
data
collect
electron
chart
review
ttr
calcul
use
rosenda
method
bmi
analyz
continu
categor
variabl
six
bmi
categori
correl
warfarin
dose
total
mgkg
weekli
dose
accordingli
result
total
patient
includ
male
bmi
rang
mean
ttr
standard
deviat
weak
posit
correl
demonstr
bmi
weekli
warfarin
mainten
dose
pearson
r
differ
observ
mean
ttr
across
differ
bmi
categori
weak
neg
correl
bmi
weekli
mgkg
warfarin
dose
pearson
r
morbid
sever
obes
patient
requir
lower
dose
compar
normal
bmi
group
respect
thrombot
event
detect
thirteen
incid
minor
bleed
report
insignific
differ
across
bmi
categori
conclus
weak
posit
correl
exist
bmi
total
weekli
warfarin
dose
correl
observ
bmi
anticoagul
control
util
effect
sacubitrilvalsartan
heart
function
clinic
arden
barri
bsc
bsc
pharm
pharmd
acpr
candi
lee
bsc
pharm
gordon
klammer
bsc
pharm
acpr
dale
toew
bsc
pharm
pharmaceut
scienc
univers
british
columbia
vancouv
bc
canada
abbotsford
region
hospit
cancer
centr
abbotsford
bc
canada
introduct
sacubitrilvalsartan
evalu
patient
heart
failur
hf
reduc
eject
fraction
trial
question
extern
valid
due
strict
inclus
criteria
extens
period
util
effect
sacubitrilvalsartan
unknown
research
question
hypothesi
use
sacubitrilvalsartan
practic
compar
trial
studi
design
quantit
retrospectiveprospect
health
record
review
heart
function
clinic
abbotsford
canada
method
hf
patient
age
year
evalu
use
sacubitrilvalsartan
data
collect
juli
includ
age
sex
new
york
heart
associ
nyha
classif
left
ventricular
eject
fraction
lvef
concurr
medic
sacubitrilvalsartan
dosetitr
numbertyp
advers
effect
ratereason
discontinu
primari
outcom
number
patient
met
criteria
analysi
includ
descript
statist
pair
mean
ibm
spss
statist
level
signific
result
patient
includ
mean
age
year
male
nyha
class
ii
tripl
therapi
three
patient
met
criteria
three
patient
meet
criteria
miss
data
primarili
lack
natriuret
peptid
bnp
assess
mean
achiev
dose
mg
twice
daili
achiev
target
dose
mg
twice
daili
signific
improv
mean
lvef
versu
p
nyha
classif
versu
p
initi
sacubitrilvalsartan
achiev
targetmaxim
toler
dose
percent
experienc
advers
effect
commonli
hyperkalemia
hypotens
nine
percent
discontinu
therapi
conclus
sacubitrilvalsartan
well
toler
practic
patient
achiev
target
dose
howev
patient
initi
sacubitrilvalsartan
without
bnp
assess
sacubitrilvalsartan
improv
object
subject
measur
heart
function
though
mani
patient
experienc
advers
effect
often
lead
discontinu
comparison
prevent
cardiovascular
pharmacotherapi
surgic
versu
percutan
coronari
revascular
arden
barri
bsc
bsc
pharm
pharmd
acpr
erica
wang
bsc
pharm
pharmd
acpr
doson
chua
bsc
pharm
pharmd
bcp
aq
cardiolog
glen
pearson
bsc
bscphm
pharmd
fcshp
pharmaceut
scienc
univers
british
columbia
vancouv
bc
canada
st
paul
hospit
vancouv
bc
canada
cardiolog
univers
alberta
edmonton
ab
canada
introduct
data
suggest
patient
undergo
coronari
arteri
bypass
graft
surgeri
cabg
lower
rate
prevent
cardiovascular
pharmacotherapi
use
compar
percutan
coronari
intervent
pci
howev
studi
account
justifi
eg
contraind
research
question
hypothesi
rate
util
prevent
cardiovascular
pharmacotherapi
discharg
cabg
versu
pci
patient
coronari
syndrom
ac
studi
design
quantit
prospect
longitudin
cohort
studi
st
paul
hospit
vancouv
canada
method
consecut
patient
age
year
discharg
cabg
pci
includ
data
collect
use
redcap
databas
includ
demograph
revascular
strategi
prevent
cardiovascular
medic
use
aspirin
inhibitor
enzym
inhibitorsangiotensin
receptor
blocker
aceiarb
statin
includ
adjust
justifi
statist
analys
ibm
spss
statist
includ
test
continu
categor
variabl
respect
signific
level
result
one
hundr
sixti
patient
includ
mean
age
year
male
comorbid
similar
group
percent
present
ac
underw
cabg
ac
patient
underw
cabg
versu
pci
versu
p
patient
discharg
aspirin
cabg
patient
receiv
milligram
versu
p
pci
patient
receiv
inhibitor
primarili
ticagrelor
versu
cabg
patient
primarili
clopidogrel
cabg
patient
receiv
versu
pci
patient
use
aceiarb
higher
pci
versu
cabg
patient
versu
p
statin
use
similar
group
versu
pci
patient
receiv
versu
p
conclus
use
aspirin
high
group
inhibitor
aceiarb
underutil
cabg
patient
even
adjust
contraind
addit
cabg
patient
less
like
receiv
statin
therapi
evalu
patient
instruct
home
blood
pressur
monitor
program
michel
jacob
pharmd
cde
jonathan
chen
bs
pharmaci
studi
school
pharmaci
northeastern
univers
boston
introduct
home
blood
pressur
bp
monitor
recommend
hypertens
diagnosi
confirm
follow
us
intern
guidelin
direct
best
achiev
mix
gener
recommend
check
bp
read
home
twice
daili
check
multipl
read
time
read
sever
day
also
recommend
discard
first
day
first
triplic
read
ambulatori
care
home
bp
monitor
program
patient
instruct
take
home
bp
triplic
time
daili
pm
day
first
read
triplic
discard
averag
overal
home
bp
research
question
hypothesi
differ
overal
home
bp
averag
first
day
read
discard
read
measur
duplic
instead
triplic
studi
design
retrospect
analysi
home
bp
monitor
patient
record
method
use
anova
analysi
comparison
evalu
overal
home
bp
averag
taken
triplic
compar
overal
bp
averag
first
day
discard
read
taken
duplic
result
patient
took
home
bp
read
consecut
pm
time
averag
day
triplic
read
overal
averag
mmhg
discard
first
day
read
overal
averag
mmhg
lower
statist
differ
overal
bp
averag
taken
triplic
compar
taken
duplic
either
averag
first
mmhg
last
mmhg
read
result
statist
differ
conclus
patient
measur
bp
read
twice
daili
home
achiev
similar
result
read
taken
duplic
triplic
unlik
necessari
discard
first
day
read
direct
oral
anticoagul
util
dose
patient
atrial
fibril
arden
barri
bsc
bsc
pharm
pharmd
acpr
priscilla
shum
bsc
pharm
gordon
klammer
bsc
pharm
acpr
dale
toew
bsc
pharm
pharmaceut
scienc
univers
british
columbia
vancouv
bc
canada
abbotsford
region
hospit
cancer
centr
abbotsford
bc
canada
introduct
direct
oral
anticoagul
doac
warfarin
prevent
system
embol
patient
atrial
fibril
nvaf
howev
uptak
practic
variabl
studi
shown
doac
dose
may
inconsist
manufactur
label
research
question
hypothesi
mani
patient
nvaf
discharg
hospit
doac
percentag
receiv
correct
dose
studi
design
quantit
retrospect
health
record
review
abbotsford
region
hospit
abbotsford
canada
method
includ
patient
age
year
nvaf
base
score
data
collect
includ
demograph
comorbid
score
discharg
anticoagul
applic
primari
outcom
percentag
patient
prescrib
doac
apixaban
dabigatran
edoxaban
rivaroxaban
discharg
secondari
outcom
includ
patient
characterist
associ
doac
versu
warfarin
use
percentag
patient
prescrib
correct
doac
dose
statist
analys
microsoft
excel
includ
exact
test
continu
categor
variabl
respect
signific
level
result
one
hundr
twenti
patient
includ
mean
age
year
male
patient
prescrib
doac
patient
prescrib
warfarin
patient
prescrib
anticoagul
signific
differ
patient
characterist
doac
warfarin
group
includ
mean
score
versu
score
versu
common
doac
apixaban
rivaroxaban
prescrib
doac
receiv
correct
dose
respect
receiv
dose
lower
higher
recommend
conclus
patient
nvaf
prescrib
doac
discharg
similar
thromboembol
bleed
risk
compar
prescrib
warfarin
patient
prescrib
doac
approxim
one
receiv
correct
dose
implement
amiodaron
monitor
servic
am
veteran
affair
health
care
system
jisha
jacob
tiffani
tsai
jessina
c
mcgregor
merritt
raitt
harleen
singh
pharmaci
oregon
state
universityoregon
health
scienc
univers
portland
veteran
affair
portland
health
care
system
vaporhc
portland
introduct
appropri
serial
monitor
chronic
amiodaron
use
challeng
clinic
practic
vaporhc
patient
receiv
monitor
evid
suggest
am
improv
adher
monitor
guidelin
identif
advers
effect
research
question
hypothesi
object
evalu
effect
amiodaron
clinic
improv
monitor
studi
design
retrospect
analysi
initi
method
januari
pharmacist
run
clinic
collabor
multidisciplinari
team
establish
ongo
amiodaron
monitor
patient
fill
prescript
amiodaron
identifi
review
patient
activ
follow
outsid
provid
hospic
care
longer
take
amiodaron
exclud
chart
extract
medic
adher
interact
thyroid
function
liver
function
test
everi
six
month
annual
ekg
per
local
cardiolog
prefer
data
collect
includ
demograph
indic
dose
durat
amiodaron
therapi
frequenc
monitor
monitor
paramet
determin
miss
pharmacist
would
place
order
directli
alert
appropri
provid
descript
statist
use
quantifi
number
type
pharmacist
intervent
institut
review
board
approv
project
result
date
patient
review
patient
exclud
forti
percent
patient
overdu
either
lab
ekg
monitor
either
need
refil
expir
prescript
total
intervent
recommend
far
primari
intervent
includ
medic
counsel
lab
order
patient
schedul
ekg
patient
schedul
provid
patient
conclus
find
demonstr
util
pharmacist
within
multidisciplinari
clinic
help
improv
rate
amiodaron
monitor
furthermor
also
highlight
need
establish
monitor
protocol
ensur
time
monitor
toler
african
american
patient
heart
failur
reduc
eject
fraction
clair
carpent
kelsey
fletcher
pharmd
candid
ian
b
holli
zachariah
deyo
school
pharmaci
univers
north
carolina
chapel
hill
nc
north
carolina
hospit
chapel
hill
nc
introduct
trial
show
effect
angiotensin
convert
enzym
inhibit
prevent
hospit
mortal
patient
hfref
howev
african
american
aa
compris
treatment
group
limit
understand
popul
research
question
hypothesi
african
american
exhibit
signific
differ
rel
race
toler
titrat
target
dose
studi
design
retrospect
electron
medic
record
review
method
total
patient
prescript
identifi
use
institut
electron
data
warehous
exclud
patient
due
lack
follow
inabl
afford
medic
patient
refus
initi
death
remain
patient
divid
african
american
race
follow
titrat
target
dose
achiev
titrat
fail
primari
endpoint
achiev
target
dose
secondari
endpoint
pharmacist
impact
achiev
target
dose
analyz
use
chi
squar
test
time
achiev
target
dose
number
clinic
visit
requir
analyz
use
mann
whitney
test
result
includ
patient
achiev
target
dose
signific
differ
percentag
aa
vs
patient
achiev
target
dose
time
achiev
target
dose
day
aa
vs
day
number
clinic
visit
requir
achiev
target
dose
aa
vs
patient
receiv
pharmacist
care
achiev
target
dose
compar
patient
receiv
pharmacist
care
p
conclus
retrospect
review
african
american
differ
significantli
achiev
target
dose
prevent
ensur
clinic
applic
inclus
greater
proport
african
american
futur
clinic
trial
essenti
predict
bleed
thrombosi
complic
patient
continu
flow
left
ventricular
assist
devic
kyle
zacholski
adam
sieg
william
kuan
justin
mccann
pharmd
candid
aaron
cook
aric
schadler
bs
sara
parli
pharmaci
univers
kentucki
healthcar
lexington
ky
pharmaci
servic
univers
kentucki
healthcar
lexington
ky
kentucki
school
pharmaci
lexington
ky
pharmaci
univers
kentucki
healthcar
lexington
ky
pharmaci
univers
kentucki
school
pharmaci
lexington
ky
introduct
left
ventricular
assist
devic
lvad
therapi
proven
reliev
heart
failur
symptom
improv
surviv
associ
complic
bleed
thrombot
event
risk
stratif
tool
util
cardiovascular
diseas
popul
estim
risk
bleed
thrombosi
without
anticoagul
includ
model
unknown
whether
tool
predict
patient
lvad
research
question
hypothesi
studi
object
evalu
predict
valu
risk
model
bleed
thrombot
complic
patient
lvad
studi
design
retrospect
cohort
analysi
method
retrospect
analysi
patient
implant
lvad
juli
june
patient
receiv
lvad
within
studi
period
elig
inclus
primari
endpoint
incid
bleed
thrombosi
event
within
one
year
implant
baselin
risk
model
score
calcul
time
lvad
implant
student
use
measur
baselin
differ
compar
mean
risk
model
score
patient
event
receiv
oper
characterist
roc
curv
analysi
perform
evalu
accuraci
risk
model
predict
event
result
total
patient
underw
lvad
implant
within
studi
time
period
mean
score
statist
significantli
differ
without
event
mean
score
without
bleed
event
respect
p
roc
curv
area
model
highest
conclus
model
model
associ
event
none
model
strong
posit
predict
valu
suggest
better
risk
model
need
predict
bleed
thrombot
event
patient
captopril
versu
dinitr
vasodil
protocol
acut
decompens
heart
failur
patient
transit
sodium
nitroprussid
moham
amar
pharmd
bcp
simon
w
lam
pharmd
fccm
bcp
kathleen
faulkenberg
pharmd
j
bradley
william
pharmd
pharmaci
cleveland
clinic
foundat
cleveland
oh
pharmaci
cleveland
clinic
cleveland
oh
introduct
role
oral
vasodil
transit
manag
acut
decompens
heart
failur
adhf
clearli
defin
studi
compar
use
captopril
vs
dinitr
transit
intraven
vasodil
therapi
acut
decompens
hfref
patient
research
question
hypothesi
time
requir
wean
intraven
vasodil
significantli
affect
oral
vasodil
select
adhf
patient
inpati
oral
vasodil
select
affect
chronic
therapi
prescrib
discharg
studi
design
retrospect
cohort
singl
center
studi
method
retrospect
chart
review
adult
patient
admit
adhf
requir
sodium
nitroprussid
snp
receiv
either
captopril
perform
captopril
patient
match
patient
base
serum
creatinin
scr
ethnic
primari
endpoint
time
snp
discontinu
initi
oral
vasodil
secondari
outcom
includ
icu
hospit
length
stay
lo
vasodil
prescrib
discharg
mortal
rehospit
one
year
post
discharg
result
total
patient
includ
baselin
demograph
serum
chemistri
use
similar
group
time
snp
discontinu
vs
hour
icu
lo
vs
day
hospit
lo
vs
day
similar
captopril
group
fewer
protocol
patient
discharg
vs
despit
similar
kidney
function
time
discharg
scr
vs
numer
less
patient
captopril
protocol
group
deceas
requir
rehospit
within
year
vs
conclus
signific
differ
observ
time
wean
snp
hospit
icu
lo
group
fewer
patient
receiv
protocol
discharg
arb
therapi
vasodil
select
acut
care
may
impact
agent
select
chronic
care
may
implic
mortal
assess
direct
oral
anticoagul
use
initi
treatment
venou
thromboembol
carri
oliph
pharmd
fccp
cardiolog
aacc
brennan
herrmann
anna
jacob
katherin
l
march
pharmd
pharmaci
methodist
univers
hospit
memphi
tn
univers
hospit
memphi
tn
pharamci
methodist
univers
hospit
memphi
tn
clinic
pharmaci
methodist
univers
hospit
memphi
tn
introduct
accord
recent
chest
guidelin
antithrombot
therapi
venou
thromboembol
vte
direct
oral
anticoagul
doac
therapi
recommend
vitamin
k
antagonist
warfarin
initi
therapi
choic
treatment
vte
without
cancer
grade
research
question
hypothesi
guidelin
adher
rate
treatment
newli
diagnos
vte
within
larg
healthcar
system
studi
design
multisit
retrospect
studi
method
retrospect
chart
review
patient
discharg
oral
anticoagul
treatment
newli
diagnos
lower
extrem
deep
venou
thromboembol
dvt
andor
pulmonari
embol
pe
januari
conduct
primari
outcom
treatment
guidelin
adher
doac
use
discharg
secondari
outcom
length
stay
anticoagul
relat
readmiss
appropri
doac
dose
guidelin
adher
base
facil
prescrib
addit
analysi
warfarin
group
perform
identifi
potenti
barrier
prescrib
doac
therapi
comparison
made
use
exact
test
appropri
result
total
patient
includ
receiv
doac
receiv
warfarin
vte
treatment
discharg
length
stay
doac
arm
significantli
shorter
compar
warfarin
day
vs
day
p
appropri
doac
dose
observ
patient
instanc
incorrect
doac
dose
due
dose
rate
anticoagul
relat
readmiss
similar
vs
common
potenti
barrier
prescrib
doac
therapi
state
feder
prescript
insur
prescript
insur
creatinin
clearanc
mlmin
conclus
result
studi
indic
high
guidelin
adher
rate
treatment
acut
vte
patient
access
appear
limit
factor
util
doac
therapi
treatment
vte
evalu
heart
failur
transit
care
via
distanc
health
technolog
ramon
boyd
brittani
florczykowski
kimberli
bischel
caleb
balduff
pharmd
daniel
lewi
pharmaci
cleveland
clinic
cleveland
oh
upmc
pinnacl
health
harrisburg
pa
vascular
institut
cleveland
clinic
cleveland
oh
clinic
cleveland
oh
cleveland
clinic
cleveland
oh
present
american
colleg
clinic
pharmaci
annual
meet
phoenix
az
octob
mono
versu
dual
antiplatelet
therapi
secondari
stroke
prevent
studi
focus
african
american
popul
amir
zaki
pharmd
candid
amn
borghol
pharmd
gabriela
andoni
pharmd
alison
neuliep
pharmd
ahm
zaki
pharmd
bree
bergeron
pharmd
mike
castro
pharmd
pharmaci
xavier
univers
lousiana
new
orlean
la
pharmaci
divis
clinic
administr
scienc
xavier
univers
louisiana
new
orlean
la
introduct
purpos
project
evalu
benefit
efficaci
dual
versu
mono
antiplatelet
therapi
reduc
stroke
recurr
mortal
patient
ischem
stroke
transient
ischem
attack
tia
emphasi
patient
research
question
hypothesi
assess
efficaci
dual
antiplatelet
therapi
versu
monotherapi
reduc
recurr
stroke
mortalityto
compar
incid
bleed
patient
receiv
dual
therapi
versu
monotherapyto
compar
incid
recurr
stroke
mortal
patient
compar
non
patient
studi
design
studi
retrospect
chart
review
cohort
studi
conduct
univers
medic
center
new
orlean
la
studi
includ
patient
admit
umcno
diagnosi
stroke
tia
sinc
method
data
collect
via
retrospect
chart
review
statist
analys
perform
use
spss
version
result
total
stroke
patient
patient
receiv
monotherapi
either
aspirin
clopidogrel
patient
receiv
dual
therapi
includ
two
antiplatelet
medic
major
patient
mono
dual
therapi
group
male
respect
base
outcom
monotherapi
versu
dual
therapi
signific
differ
recurr
stroke
mortal
although
outcom
nt
signific
higher
recurr
stroke
frequenc
within
year
monotherapi
group
versu
dual
group
nearli
signific
higher
bleed
event
associ
dual
therapi
versu
monotherapi
group
conclus
studi
found
signific
differ
use
dual
antiplatelet
therapi
compar
monotherapi
need
studi
evalu
benefit
dual
therapi
ischem
stroke
patient
specif
african
american
popul
associ
west
african
genet
ancestri
blood
pressur
control
among
african
american
treat
hypertens
jackson
heart
studi
jon
van
tassel
mph
diachi
shimbo
rachel
hess
md
rick
kittl
jame
wilson
lynn
jord
man
li
lesli
lang
ethan
lang
paul
muntner
adam
bress
pharmd
pharmaci
univers
utah
salt
lake
citi
ut
med
beh
cardiolog
columbia
univers
new
york
ny
health
system
innov
research
univers
utah
salt
lake
citi
ut
health
equiti
depart
popul
scienc
citi
hope
duart
ca
center
clinic
translat
research
univers
mississippi
medic
center
jackson
ms
human
genet
univers
utah
salt
lake
citi
ut
nephrolog
univers
utah
salt
lake
citi
ut
medicin
divis
biomed
informat
person
medicin
univers
colorado
denver
aurora
co
public
health
univers
alabama
birmingham
birmingham
al
depart
popul
health
scienc
univers
utah
salt
lake
citi
ut
introduct
despit
increas
hypertens
awar
treatment
rate
african
american
significantli
lower
blood
pressur
bp
control
rate
compar
european
american
unclear
racial
differ
antihypertens
medic
respons
pharmacogenet
variant
differ
frequenc
ancestr
group
contribut
dispar
research
question
hypothesi
higher
west
african
ancestri
waa
associ
lower
preval
bp
control
among
jackson
heart
studi
particip
treat
hypertens
studi
design
method
analyz
particip
treat
hypertens
report
take
antihypertens
medic
previou
hour
exam
percent
waa
determin
ancestri
inform
marker
categor
quartil
bp
control
defin
systolicdiastol
bp
mmhg
calcul
adjust
preval
ratio
pr
bp
control
associ
upper
quartil
separ
versu
lowest
quartil
waa
result
mean
age
year
femal
overal
bp
control
rate
adjust
pr
ci
bp
control
compar
quartil
quartil
percentag
waa
among
take
inhibitor
angiotensin
receptor
blocker
monotherapi
adjust
pr
ci
bp
control
compar
quartil
quartil
waa
respect
conclus
among
african
american
treat
hypertens
bp
control
rate
differ
across
quartil
waa
lack
associ
genet
ancestri
bp
control
may
indic
differ
clinic
inertia
social
cultur
environ
factor
futur
studi
examin
bp
control
rate
waa
among
take
ace
arb
monotherapi
risk
assess
prescrib
error
medic
prescript
malta
germani
jeffrey
kupka
rph
germani
pharmd
student
mauric
bpharm
bpharm
hon
lond
phd
maresca
attard
pizzuto
bpharm
hon
msc
clinic
pharmaci
phd
anthoni
bpharm
pharmd
cinc
maccp
mrpharm
depart
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
introduct
error
physician
prescript
may
lead
erron
dispens
pharmacist
risk
assess
error
aris
prescript
malta
germani
undertaken
research
question
hypothesi
assess
risk
prescrib
error
physician
perspect
physician
pharmacist
studi
design
prospect
qualit
quantit
studi
design
method
interview
physician
conduct
describ
medic
use
process
countri
two
questionnair
one
physician
one
pharmacist
develop
valid
expert
profess
ask
assess
root
caus
error
discuss
physician
interview
rank
potenti
prescrib
error
scale
low
score
high
score
probabl
sever
get
overal
risk
prioriti
number
rpn
low
risk
medium
risk
high
risk
result
one
hundr
nineti
one
physician
malta
germani
pharmacist
malta
germani
answer
questionnair
respect
prescrib
error
due
illeg
handwrit
rpn
physician
pharmacist
continu
prescript
longer
durat
necessari
rpn
physician
pharmacist
rate
two
highest
risk
lead
potenti
dispens
error
malta
physician
pharmacist
germani
rate
continu
prescript
highest
risk
score
physician
pharmacist
conclus
countri
uncontrol
durat
medic
seen
one
highest
risk
malta
physician
handwrit
view
main
sourc
prescrib
error
error
issu
germani
prescript
issu
electron
risk
minimis
strategi
address
risk
includ
use
electron
softwar
expand
adolesc
contracept
access
pharmaci
predictor
adolesc
willing
util
pharmacist
prescrib
ashley
meredith
tracey
wilkinson
md
thoma
vielott
carolyn
meagher
mari
ott
md
univers
colleg
pharmaci
indianapoli
univers
school
medicin
indianapoli
adolesc
medicin
indiana
univers
school
medicin
indianapoli
introduct
legisl
multipl
state
allow
pharmacist
prescrib
contracept
expand
access
elimin
provid
visit
restrict
prescrib
adult
data
examin
adolesc
accept
pharmacist
prescrib
research
question
hypothesi
factor
influenc
adolesc
desir
obtain
contracept
pharmacist
prescrib
studi
design
prospect
observ
survey
method
irb
approv
femal
age
recruit
gener
subspecialti
clinic
particip
complet
demograph
behavior
health
survey
includ
item
assess
accept
pharmacist
prescrib
whether
accept
chang
made
awar
counsel
pharmacist
part
protocol
respons
code
ye
either
item
answer
affirm
screen
checklist
potenti
contraind
contracept
per
cdc
medic
elig
criteria
complet
bivari
analysi
multivari
logist
regress
examin
effect
age
race
insur
chronic
ill
presenc
medic
contraind
sexual
experi
perceiv
risk
pregnanc
birth
control
use
accept
result
adolesc
particip
gener
clinic
mean
age
yr
sex
use
hormon
contracept
use
iudimpl
answer
ye
one
question
regard
pharmaci
accept
adolesc
like
respond
ye
older
yr
vs
yr
use
condom
last
sex
characterist
found
statist
signific
logist
regress
conclus
almost
half
adolesc
particip
express
desir
obtain
contracept
pharmacist
result
influenc
presenc
potenti
contraind
sexual
experi
use
birth
control
data
illustr
need
addit
outreach
adolesc
relat
pharmaci
access
emphas
need
rigor
screen
process
pharmacist
consum
knowledg
attitud
practic
kap
pain
manag
comparison
studi
singapor
zhi
wei
lim
bsc
pharm
hon
candid
heng
boon
ong
pharm
hon
boon
ka
chong
msc
comm
pharm
kai
zhen
yap
pharmaci
nation
univers
singapor
singapor
singapor
person
care
store
pte
ltd
singapor
singapor
pharmaci
watson
person
care
store
pte
ltd
singapor
singapor
introduct
recent
reclassif
analges
singapor
increas
consum
option
pain
despit
one
common
indic
limit
studi
assess
consum
knowledg
attitud
practic
kap
pain
manag
possibl
differ
may
exist
age
group
research
question
hypothesi
consum
kap
pain
manag
compar
across
age
group
studi
design
studi
involv
survey
method
survey
target
minimum
custom
watson
person
care
store
major
retail
pharmaci
chain
singapor
conveni
sampl
geograph
quota
employ
recruit
respond
januari
march
across
singapor
five
urban
redevelop
author
plan
region
base
geograph
distribut
popul
resid
pregnant
mother
healthcar
profession
student
watson
employe
speak
respond
exclud
respons
analys
use
friedman
wilcoxon
sign
rank
u
test
applic
result
among
respond
recruit
knowledg
score
product
inform
headach
musculoskelet
pain
low
median
respond
rare
consult
commun
pharmacist
despit
report
greatest
trust
healthcar
profession
reliabl
sourc
inform
among
sourc
p
bonferroni
correct
respond
prefer
rather
see
physician
conveni
key
factor
pain
among
younger
individu
year
old
compar
older
age
group
p
bonferroni
correct
conclus
studi
provid
insight
healthcar
consum
percept
may
use
polici
maker
servic
provid
develop
target
intervent
ensur
safe
effect
pain
condit
differ
age
group
evalu
commun
travel
health
clinic
patient
understand
satisfact
erica
wilkinson
ami
robertson
brent
rohl
jacob
hadley
dean
benton
abbi
winter
kansa
school
pharmaci
dillon
pharmaci
wichita
ks
pharmaci
practic
univers
kansa
school
pharmaci
wichita
ks
pharmaci
hutchinson
ks
east
ave
dillon
pharmaci
hutchinson
ks
pharmaci
wichita
ks
washington
diabet
care
center
seattl
wa
introduct
individu
decid
travel
intern
lot
prepar
commun
pharmacist
well
equip
serv
vital
sourc
travel
health
inform
high
access
comprehens
hour
drug
expertis
make
commun
pharmacist
excel
candid
serv
travel
health
expert
implement
travel
health
clinic
commun
pharmaci
set
allow
patient
obtain
oral
travel
medic
vaccin
suppli
counsel
risk
prevent
strategi
one
visit
research
question
hypothesi
impact
intern
travel
health
consult
patient
understand
studi
design
survey
studi
conduct
dillon
pharmaci
wichita
ks
januari
june
method
adult
intern
travel
plan
within
next
three
month
includ
patient
exclud
studi
pregnant
immunocompromis
primari
outcom
chang
patient
understand
travel
health
inform
baselin
secondari
outcom
evalu
patient
satisfact
well
perceiv
monetari
valu
servic
object
measur
questionnair
use
likert
scale
questionnair
administ
studi
particip
consult
studi
outcom
analyz
use
student
descript
statist
appropri
result
total
twelv
patient
evalu
signific
posit
differ
patient
understand
five
question
assess
patient
knowledg
travel
health
inform
p
accept
rate
vaccin
recommend
accept
rate
oral
medic
recommend
total
product
recommend
mean
perceiv
valu
servic
provid
rang
conclus
travel
health
consult
improv
patient
understand
travel
health
inform
inappropri
continu
stress
ulcer
prophylaxi
follow
discharg
medic
intens
care
unit
mikhaila
rice
bsp
katherin
chin
bryan
mcverri
pamela
l
smithburg
pharmd
ms
bcccp
pittsburgh
school
pharmaci
pittsburgh
pa
presbyterian
pittsburgh
pa
pharmaci
therapeut
univers
pittsburgh
school
pharmaci
pittsburgh
pa
introduct
patient
medic
intens
care
unit
often
micu
requir
stress
ulcer
prophylaxi
howev
medic
may
inappropri
continu
follow
discharg
micu
literatur
highlight
complic
associ
prolong
medic
use
medic
discontinu
transit
care
longer
indic
research
question
hypothesi
purpos
studi
identifi
contribut
factor
inappropri
continu
stress
ulcer
prophylaxi
follow
discharg
micu
studi
design
part
qualiti
improv
project
util
retrospect
cohort
review
consecut
patient
complet
upmc
presbyterian
hospit
method
patient
includ
order
proton
pump
inhibitor
receptor
antagonist
micu
may
august
patient
exclud
admit
micu
fewer
hour
medic
prior
admiss
gastrointestin
bleed
descript
statist
multivari
logist
regress
includ
covari
age
mechan
ventil
statu
micu
length
stay
time
discharg
micu
use
analyz
primari
outcom
therapi
continu
discharg
result
patient
includ
appropri
prescrib
stress
ulcer
prophylaxi
medic
inappropri
continu
follow
discharg
micu
follow
discharg
hospit
one
hour
increas
length
stay
associ
increas
odd
continu
medic
follow
discharg
micu
conclus
stress
ulcer
prophylaxi
typic
initi
appropri
micu
inappropri
continu
upon
discharg
micu
half
patient
demonstr
need
greater
attent
detail
transit
care
process
especi
import
follow
extend
micu
stay
likelihood
inappropri
continu
increas
increas
length
stay
incid
neurobehavior
side
effect
associ
levetiracetam
phenytoin
traumat
brain
injuri
retrospect
cohort
studi
tian
yaw
pharmd
jerika
nguyen
pharmd
holli
anderson
pharmd
depart
pharmaci
oregon
health
scienc
univers
portland
present
northwestern
state
pharmaci
resid
confer
portland
may
valid
medic
regimen
complex
score
tool
critic
ill
surgic
patient
andrea
sikora
newsom
pharmd
bcp
bcccp
tiffani
park
doctor
pharmaci
uga
colleg
pharmaci
augusta
ga
colleg
pharmaci
north
augusta
sc
introduct
justif
critic
care
pharmacist
posit
intens
care
unit
icu
remain
common
challeng
due
limit
object
measur
regard
pharmacist
product
develop
valid
medic
intens
care
unit
icu
popul
measur
medic
regimen
complex
associ
patient
acuiti
icu
length
stay
lo
mortal
research
question
hypothesi
purpos
studi
valid
critic
ill
surgic
patient
explor
relationship
patient
specif
outcom
studi
design
studi
prospect
observ
review
patient
surgic
icu
method
patient
identifi
use
unit
censu
report
august
septemb
patient
year
locat
surgic
icu
includ
patient
exclud
length
stay
less
hour
due
either
death
transfer
activ
transfer
hospic
order
hour
demograph
includ
age
sex
icu
lo
inpati
mortal
differ
score
inpati
mortal
examin
use
pearson
product
moment
use
determin
correl
score
icu
lo
weight
number
medic
order
result
mean
icu
lo
day
inpati
mortal
mean
score
converg
valid
confirm
correl
number
medic
order
p
discrimin
valid
confirm
lack
correl
weight
p
posit
correl
score
icu
lo
observ
p
conclus
correl
icu
lo
mortal
could
confirm
find
indic
may
use
medic
surgic
popul
futur
studi
focu
generaliz
institut
relationship
pharmacist
activ
evalu
continu
rate
antipsychot
delirium
treatment
upon
discharg
intens
care
unit
retrospect
chart
review
deepali
dixit
pharmd
bcp
zahava
picado
raphaela
nisenzon
care
robert
wood
johnson
univers
hospit
new
brunswick
nj
brunswick
nj
brunswick
nj
present
american
societi
health
system
pharmacist
midyear
clinic
meet
orlando
fl
decemb
prevent
chronic
pain
use
continu
infus
ketamin
acut
trauma
relat
pain
cara
coleman
pharmd
ba
paig
garber
molli
droeg
carolyn
philpott
denni
hanseman
vanessa
nomellini
md
christoph
droeg
cincinnati
colleg
pharmaci
cincinnati
oh
cincinnati
medic
center
cincinnati
oh
trauma
univers
cincinnati
depart
surgeri
cincinnati
oh
introduct
chronic
pain
cp
common
develop
trauma
patient
ketamin
may
reduc
need
opioid
therapi
subsequ
transit
cp
given
uniqu
pharmacodynam
activ
pain
signal
research
question
hypothesi
administr
continu
intraven
infus
civi
ketamin
hour
icu
patient
acut
trauma
decreas
incid
cp
develop
studi
design
retrospect
propens
score
match
studi
academ
medic
region
level
trauma
center
method
patient
pair
propens
score
match
base
sex
age
race
injuri
sever
score
trauma
mechan
primari
endpoint
determin
differ
cp
develop
defin
pain
requir
treatment
opioid
month
follow
hospit
discharg
patient
receiv
ketamin
kg
versu
standard
care
soc
secondari
endpoint
analyz
differ
opioid
requir
repres
oral
morphin
equival
ome
within
kg
base
whether
therapi
initi
within
hour
admiss
total
amount
ketamin
receiv
separ
quartil
result
baselin
characterist
similar
group
except
weight
initi
opioid
requir
kg
vs
soc
ome
p
differ
cp
develop
group
kg
vs
soc
opioid
requir
quartil
total
amount
ketamin
administ
differ
hospit
discharg
patient
initi
ketamin
hour
admiss
requir
less
opioid
therapi
expos
earlier
vs
ome
differ
observ
hospit
discharg
conclus
exploratori
analysi
found
differ
develop
cp
civi
ketamin
relationship
time
therapi
initi
amount
ketamin
receiv
opioid
requir
relationship
delay
civi
ketamin
initi
decreas
opioid
requir
warrant
investig
get
code
smart
sepsi
medic
alert
respons
team
multidisciplinari
intervent
improv
sepsi
bundl
perform
associ
decreas
mortal
monica
shah
violet
kramer
victor
arcega
prateek
ghatag
daphn
villanueva
justina
girgi
pharmd
thoma
baker
irb
scott
mathi
monmouth
medic
center
long
branch
nj
medicin
pulmonarycrit
care
monmouth
medic
center
long
branch
nj
medicin
monmouth
medic
center
long
branch
nj
mario
school
pharmaci
rutger
univers
piscataway
nj
educ
monmouth
medic
center
long
branch
nj
introduct
surviv
sepsi
campaign
ssc
publish
guidelin
includ
sepsi
bundl
care
sinc
ssc
first
guidelin
releas
sepsi
mortal
decreas
overal
implement
bundl
element
remain
low
due
mani
barrier
includ
recognit
staf
care
organ
research
question
hypothesi
implement
multipl
intervent
improv
diagnosi
manag
sepsi
ssc
bundl
would
yield
improv
bundl
perform
sepsi
mortal
studi
design
retrospect
review
studi
method
evalu
patient
sepsi
sepsi
care
core
measur
implement
januari
intervent
includ
use
st
john
sepsi
agent
alert
improv
recognit
increas
staff
educ
ongo
chart
review
feedback
engag
rrt
nurs
deliveri
sepsi
bundl
part
code
smart
respons
data
collect
includ
adher
ssc
bundl
element
initi
lactat
level
blood
cultur
time
administr
appropri
antibiot
crystalloid
assess
volum
statu
indic
mortal
among
two
group
evalu
two
group
compar
use
fisher
exact
test
result
signific
improv
seen
compar
group
adher
bundl
element
initi
lactat
vs
p
blood
cultur
vs
p
delay
administr
antibiot
vs
p
inappropri
antibiot
vs
p
administr
crystalloid
fluid
vs
p
focus
exam
vs
p
mortal
lower
compar
group
vs
conclus
multipl
intervent
improv
diagnosi
manag
sepsi
bundl
perform
associ
decreas
sepsi
mortal
evalu
prophylact
heparin
dosag
incid
venou
thromboembol
bleed
thrombocytopenia
critic
ill
patient
receiv
mechan
ventil
paul
reynold
garth
wright
r
brett
mcqueen
ellen
burnham
michael
ho
marc
moss
robert
william
vandivi
tyre
kiser
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
scienc
critic
care
medicin
univers
colorado
school
medicin
aurora
co
cardiolog
univers
colorado
school
medicin
aurora
co
introduct
venou
thromboembol
vte
occur
patient
without
prophylaxi
although
heparin
lower
vte
incid
vte
still
occur
patient
higher
dose
propos
lower
incid
vte
patient
remain
unstudi
research
question
hypothesi
heparin
prophylaxi
dose
unit
tid
lower
incid
new
vte
compar
bid
dose
patient
studi
design
retrospect
cohort
studi
util
healthcar
databas
includ
us
hospit
method
includ
patient
greater
day
without
primari
secondari
admiss
diagnosi
vte
exclus
criteria
switch
heparin
dosag
thrombolyt
orthoped
trauma
death
day
primari
outcom
develop
vte
day
key
secondari
outcom
includ
major
bleed
thrombocytopenia
mortal
primari
analysi
conduct
adjust
unbalanc
covari
conduct
vte
result
total
patient
hospit
match
dose
admiss
diagnos
includ
sepsi
copd
surgeri
vte
day
occur
patient
treat
tid
heparin
vs
bid
heparin
signific
differ
pulmonari
embol
pe
deep
venou
thrombosi
dvt
differ
hospit
mortal
vs
major
bleed
vs
thrombocytopenia
vs
vs
p
signific
vte
includ
sepsi
paralyt
thrombocytopenia
vasopressor
surgeri
p
dvt
pe
diagnosi
increas
length
stay
day
compar
patient
diagnos
vte
respect
p
diagnosi
pe
significantli
increas
mortal
vs
compar
vte
diagnosi
conclus
patient
prophylact
dose
heparin
tid
versu
bid
associ
differ
vte
safeti
sever
modifi
vte
identifi
assess
serum
accumul
inhal
tobramycin
patient
treat
pneumonia
retrospect
analysi
andrew
globk
christoph
droeg
neil
ernst
paig
garber
shaun
keegan
betti
tsuei
jessica
winter
pharmd
madelin
foertsch
pharmd
nicol
harger
pharmd
eric
mueller
medic
center
franklin
tn
cincinnati
medic
center
cincinnati
oh
cincinnati
cincinnati
oh
pharmaci
uc
health
univers
cincinnati
medic
center
cincinnati
oh
introduct
inhal
tobramycin
inht
treatment
pneumonia
vap
consid
altern
intraven
iv
deliveri
thought
minim
risk
serum
accumul
subsequ
nephrotox
littl
data
exist
evalu
incid
risk
factor
accumul
research
question
hypothesi
inht
associ
serum
accumul
critic
ill
mechan
ventil
patient
studi
design
retrospect
safeti
analysi
critic
ill
mechan
ventil
patient
empir
inht
method
adult
icu
patient
receiv
inht
mg
twice
daili
vap
concomit
aminoglycosid
therapi
review
detect
serum
tobramycin
concentr
obtain
third
dose
patient
group
detect
dc
mcgml
undetect
uc
concentr
univari
multivari
logist
regress
perform
factor
associ
detect
concentr
acut
kidney
injuri
aki
result
patient
encount
includ
analysi
dc
uc
differ
group
age
dc
v
uc
year
serum
creatinin
dc
v
uc
mgdl
rate
akiesrd
dc
v
uc
posit
pressur
peep
dc
v
uc
cm
within
hour
inht
age
year
ci
peep
cm
inht
initi
ci
identifi
independ
risk
factor
differ
new
aki
therapi
dc
v
uc
group
conclus
detect
serum
tobramycin
concentr
observ
major
critic
ill
patient
receiv
empir
inht
vap
age
year
peep
cm
inht
initi
identifi
independ
risk
factor
dose
reduct
may
necessari
patient
avoid
potenti
harm
effect
obes
vancomycin
serum
concentr
patient
continu
venoven
hemofiltr
vincent
soriano
kimberli
ackerbau
payal
gurnani
counti
health
hospit
system
chicago
il
medic
center
boston
univers
medic
center
chicago
il
introduct
vancomycin
mainstay
antibiot
treatment
bacteri
infect
critic
ill
obes
use
continu
venoven
hemofiltr
cvvh
significantli
affect
clearanc
attain
goal
trough
concentr
associ
improv
clinic
outcom
optim
dose
regimen
establish
patient
popul
research
question
hypothesi
proport
target
vancomycin
trough
concentr
attain
differ
critic
ill
obes
patient
receiv
cvvh
compar
patient
use
protocol
guid
dose
regimen
studi
design
retrospect
cohort
studi
adult
patient
requir
cvvh
vancomycin
therapi
admit
rush
univers
medic
center
januari
februari
method
patient
includ
year
age
older
receiv
least
hour
vancomycin
therapi
adher
institut
vancomycin
dose
protocol
serum
vancomycin
trough
concentr
drawn
prior
third
fourth
dose
dose
regimen
consist
mgkg
load
dose
use
actual
bodi
weight
follow
mainten
dose
mgkg
everi
hour
primari
outcom
proport
patient
attain
goal
vancomycin
trough
concentr
defin
mcgml
obes
defin
bmi
result
fifteen
patient
includ
analysi
signific
differ
rate
goal
trough
attain
observ
obes
patient
vs
respect
higher
proport
patient
subtherapeut
concentr
vs
median
vancomycin
trough
concentr
obes
patient
mcgml
mcgml
respect
conclus
institut
vancomycin
dose
protocol
achiev
similar
rate
goal
trough
attain
group
given
small
sampl
size
studi
limit
studi
requir
valid
find
explor
potenti
clinic
implic
vasopressin
dose
protocol
may
result
dispar
use
obes
patient
susan
smith
kelli
rumbaugh
susan
hamblin
clinic
administr
pharmaci
univers
georgia
colleg
pharmaci
athen
ga
pharmaceut
servic
vanderbilt
univers
medic
center
nashvil
tn
introduct
due
rise
cost
vasopressin
lack
confirm
mortal
benefit
vasopressin
dose
protocol
implement
guid
appropri
use
decreas
util
cost
research
question
hypothesi
sought
evalu
whether
vasopressin
dose
protocol
affect
vasopressin
util
obes
patient
septic
shock
hypothes
dose
protocol
would
result
earlier
initi
vasopressin
obes
patient
studi
design
retrospect
observ
cohort
studi
conduct
surgic
icu
sicu
trauma
icu
ticu
method
vasopressin
dose
protocol
implement
sicu
august
ticu
februari
sicu
protocol
vasopressin
initi
norepinephrin
mcgmin
hour
ticu
protocol
vasopressin
initi
norepinephrin
mcgmin
hour
adult
bmi
obes
bmi
patient
requir
vasopressin
month
follow
protocol
implement
includ
primari
outcom
time
vasopressin
initi
secondari
outcom
includ
norepinephrin
rate
mcgkgmin
time
vasopressin
initi
vasopressin
norepinephrin
durat
mortal
result
sicu
cohort
includ
obes
patient
ticu
cohort
includ
patient
respect
time
vasopressin
initi
shorter
obes
patient
sicu
vs
obes
h
ticu
vs
h
norepinephrin
rate
time
vasopressin
initi
also
lower
obes
patient
sicu
vs
obes
mcgkgmin
ticu
vs
mcgkgmin
total
durat
vasopressor
incid
hospit
mortal
similar
group
conclus
implement
vasopressin
dose
protocol
result
earlier
initi
vasopressin
obes
patient
unintend
effect
unknown
clinic
signific
futur
research
confirm
find
larger
popul
examin
associ
vasopressor
util
obes
paradox
septic
shock
rifaximin
treatment
septic
shock
target
endotoxemia
jane
lee
stefani
legrand
pharmd
nithya
abraham
pharmd
justin
kinney
pharmd
bcccp
pharmaci
loma
linda
univers
loma
linda
ca
linda
univers
loma
linda
ca
pharmaci
loma
linda
univers
health
loma
linda
ca
introduct
presenc
endotoxin
link
pathogenesi
sepsi
potenti
predictor
mortal
rifaximin
antibiot
normal
use
travel
diarrhea
hepat
encephalopathi
associ
reduct
endotoxemia
especi
patient
cirrhosi
howev
limit
evid
exist
explor
effect
rifaximin
may
septic
patient
research
question
hypothesi
evalu
outcom
septic
shock
patient
receiv
rifaximin
addit
standard
care
soc
studi
design
retrospect
singl
health
system
patient
chart
review
loma
linda
univers
health
admit
method
inclus
criteria
adult
septic
shock
patient
receiv
rifaximin
plu
soc
versu
soc
pregnant
patient
exclud
patient
initi
identifi
screen
result
patient
rifaximin
control
group
respect
primari
outcom
icu
surviv
secondari
outcom
icu
hospit
length
stay
total
durat
vasopressor
therapi
number
vasopressor
lastli
want
compar
outcom
patient
cirrhosi
statist
analys
conduct
spss
version
result
differ
icu
hospit
surviv
rifaximin
group
longer
length
stay
icu
vs
day
p
hospit
vs
day
p
well
longer
durat
vasopressor
therapi
vs
day
p
patient
cirrhosi
rifaximin
arm
improv
icu
surviv
vs
compar
control
longer
icu
stay
vs
day
hospit
stay
vs
durat
vasopressor
vs
conclus
addit
rifaximin
standard
care
septic
shock
demonstr
benefit
either
icu
hospit
surviv
howev
patient
cirrhosi
show
improv
icu
surviv
rifaximin
use
evalu
dexmedetomidin
alcohol
withdraw
syndrom
concomit
benzodiazepin
treatment
length
stay
david
quach
pharmd
mph
megan
musselman
pharmd
ms
bcp
jessica
casey
pharmd
matt
baker
pharmd
bcp
jeremi
john
pharmd
todd
hill
kansa
citi
hospit
north
kansa
citi
mo
health
psychiatri
kansa
citi
mo
introduct
dexmedetomidin
gain
popular
adjunct
therapi
alcohol
withdraw
agit
autonom
hyperreact
previou
studi
identifi
effect
dexmedetomidin
alcohol
withdraw
syndrom
howev
limit
evid
avail
regard
impact
overal
length
stay
research
question
hypothesi
adjunct
dexmedetomidin
therapi
concomit
benzodiazepin
alcohol
withdraw
syndrom
aw
affect
unit
icu
total
hospit
length
stay
studi
design
retrospect
chart
review
method
adult
icu
patient
admit
code
aw
order
benzodiazepin
octob
septemb
evalu
primari
endpoint
studi
icu
total
hospit
length
stay
secondari
endpoint
includ
length
dexmedetomidin
therapi
mortal
delirium
agit
rate
hemodynam
instabl
respiratori
depress
rate
mechan
ventil
statu
result
patient
review
patient
meet
inclus
criteria
icu
length
stay
higher
dexmedetomidin
group
hour
vs
hour
p
total
hospit
length
stay
hour
vs
hour
p
mechan
ventil
rate
significantli
higher
dexmedetomidin
group
compar
benzodiazepin
group
vs
p
dexmedetomidin
group
longer
averag
durat
mechan
ventil
day
vs
day
p
addit
dexmedetomidin
group
significantli
higher
delirium
agit
rate
p
compar
benzodiazepin
group
conclus
adjunct
dexmedetomidin
found
prolong
icu
total
hospit
length
stay
patient
admit
aw
worthi
note
studi
retrospect
review
potenti
limit
patient
characterist
differ
play
unknown
role
patient
sever
two
group
research
need
evalu
clinic
signific
outcom
pertain
safeti
efficaci
dexmedetomidin
adjunct
treatment
patient
popul
evalu
choic
second
therapi
phase
drug
resolut
statu
epilepticu
yasmin
zeid
erin
k
hennessey
pharmd
bcp
matthew
j
korobey
pharmd
loui
colleg
pharmacymerci
hospit
st
loui
st
loui
mo
hospit
st
loui
st
loui
mo
introduct
treatment
algorithm
statu
epilepticu
se
recommend
levetiracetam
valproic
acid
fosphenytoin
second
therapi
phase
treatment
time
clear
evid
one
agent
result
better
outcom
sinc
durat
statu
epilepticu
one
strongest
predictor
morbid
mortal
abil
achiev
resolut
statu
epilepticu
rapidli
imper
research
question
hypothesi
differ
incid
se
resolut
use
levetiracetam
vs
fosphenytoin
second
therapi
phase
agent
studi
design
retrospect
cohort
method
patient
year
old
admit
januari
octob
receiv
one
dose
levetiracetam
fosphenytoin
merci
hospit
st
loui
follow
benzodiazepin
treatment
se
includ
primari
outcom
incid
se
resolut
one
dose
levetiracetam
fosphenytoin
secondari
outcom
includ
mortal
hospit
admiss
hospit
length
stay
lo
readmiss
se
dose
appropri
use
evalu
categor
data
student
use
evalu
continu
data
result
twelv
patient
includ
levetiracetam
group
fosphenytoin
group
incid
se
resolut
similar
group
vs
mortal
admiss
hospit
lo
readmiss
se
differ
group
incid
dose
appropri
significantli
higher
levetiracetam
group
vs
commonli
use
benzodiazepin
lorazepam
similar
averag
dose
group
vs
mg
conclus
se
resolut
associ
choic
second
therapi
phase
agent
larger
prospect
studi
need
better
evalu
differ
patient
outcom
dose
second
therapi
phase
agent
se
institut
optim
ensur
appropri
treatment
evalu
infecti
complic
ppi
h
ra
therapi
patient
jordan
johnson
pharmd
dylan
wilson
pharmd
bcp
depart
pharmaci
counti
gener
hospit
jackson
tn
introduct
stress
ulcer
prophylaxi
sup
commonli
use
follow
cardiovascular
surgic
procedur
proton
pump
inhibitor
ppi
often
favor
receptor
antagonist
due
perceiv
efficaci
benefit
ppi
associ
develop
pneumonia
clostridium
difficil
c
difficil
potenti
decreas
efficaci
clopidogrel
optim
agent
sup
postop
cabg
patient
adequ
studi
research
question
hypothesi
patient
receiv
ppi
sup
increas
risk
pneumonia
c
difficil
compar
patient
receiv
studi
design
retrospect
observ
cohort
studi
patient
method
data
point
obtain
societi
cardiothorac
surgeon
st
databas
patient
retrospect
identifi
includ
age
year
older
underw
cabg
surgeri
one
year
one
year
institut
orderset
chang
use
primarili
ppi
sup
patient
exclud
receiv
ppi
surgeri
underw
valvular
procedur
addit
cabg
primari
outcom
rate
pneumonia
c
difficil
secondari
endpoint
includ
gastrointestin
bleed
myocardi
infarct
stroke
mortal
result
total
patient
screen
patient
includ
eleven
patient
ppi
group
six
patient
group
develop
pneumonia
one
patient
group
diagnos
c
difficil
infect
p
patient
ppi
group
cardiac
arrest
compar
group
statist
signific
differ
rate
stroke
gib
mortal
conclus
use
ppi
sup
compar
increas
risk
pneumonia
c
difficil
infect
patient
midodrin
treatment
septic
shock
possibl
bridg
vasopressor
sharon
jung
vanessa
tran
bs
justin
kinney
pharmd
bcccp
pharmaci
loma
linda
univers
loma
linda
ca
pharmaci
loma
linda
univers
health
loma
linda
ca
introduct
septic
shock
condit
infect
caus
hypotens
poor
tissu
perfus
cellular
metabol
abnorm
higher
mortal
patient
septic
shock
often
prolong
icu
stay
due
persist
hypotens
requir
treatment
iv
vasopressor
midodrin
oral
agonist
caus
increas
blood
pressur
typic
use
orthostat
hypotens
recent
retrospect
studi
identifi
midodrin
could
potenti
wean
vasopressor
sooner
shorten
icu
stay
septic
shock
patient
research
question
hypothesi
evalu
influenc
midodrin
wean
vasopressor
septic
shock
patient
studi
design
retrospect
singl
health
system
patient
chart
review
loma
linda
univers
health
lluh
method
adult
patient
septic
shock
includ
patient
exclud
midodrin
discontinu
vasopressor
primari
outcom
icu
length
stay
lo
hospit
lo
vasopressor
durat
secondari
outcom
icu
hospit
surviv
rate
review
drug
util
midodrin
lluh
statist
analys
conduct
spss
version
result
patient
includ
total
patient
screen
patient
receiv
midodrin
plu
vasopressor
therapi
compar
patient
receiv
vasopressor
therapi
alon
patient
receiv
midodrin
longer
icu
lo
vs
day
p
hospit
lo
vs
day
p
durat
vasopressor
therapi
vs
day
p
differ
icu
surviv
vs
midodrin
group
improv
hospit
surviv
vs
median
initi
max
dose
midodrin
mgday
mgday
respect
conclus
use
midodrin
wean
vasopressor
septic
shock
patient
reduc
icu
lo
hospit
lo
durat
vasopressor
therapi
howev
patient
receiv
midodrin
improv
icu
mortal
percept
pharmacist
regard
cost
contain
strategi
proper
use
vasopressin
septic
shock
drayton
hammond
pharmd
mba
bcp
bcccp
megan
rech
pharmd
ms
bcp
mitchel
daley
john
devlin
kirstin
kooda
pharmd
bcp
ishaq
lat
heather
personett
russel
robert
gretchen
sacha
joanna
stoll
joseph
swanson
seth
bauer
pharmd
fccm
pharmaci
rush
univers
medic
center
chicago
il
pharmaci
loyola
univers
medic
center
maywood
il
austin
tx
univers
boston
pharmaci
servic
mayo
clinic
hospit
rochest
rochest
mn
ryan
lab
chicago
il
clinic
rochest
mn
gener
hospit
boston
clinic
cleveland
oh
pharmaceut
servic
vanderbilt
univers
medic
center
nashvil
tn
pharmaci
univers
tennesse
health
scienc
center
memphi
tn
pharmaci
cleveland
clinic
cleveland
oh
introduct
vasopressin
recommend
adjunct
agent
norepinephrin
patient
septic
shock
cost
vasopressin
continu
rise
may
affect
opinion
institut
initi
research
question
hypothesi
pharmacist
opinion
regard
appropri
vasopressin
use
differ
vasopressin
cost
consid
studi
design
electron
survey
pharmacist
intens
care
unit
emerg
depart
conduct
method
survey
develop
valid
content
construct
valid
email
augustseptemb
use
qualtric
likert
scale
use
question
like
unlik
respons
group
implement
educationin
compar
use
test
menemar
test
use
compar
vasopressin
use
without
cost
consider
stata
use
result
respond
implement
initiativeseduc
regard
vasopressin
rebrand
andor
price
increas
percent
educationin
group
implement
polici
relat
use
indicationsdosag
vasopressin
cost
evid
consid
respond
less
frequent
recommend
vasopressin
initi
combin
norepinephrin
vs
vasopressor
rais
map
preferenti
epinephrin
vs
reduc
norepinephrin
dosag
vs
p
renal
failur
vs
frequent
recommend
vasopressin
stress
dose
steroid
use
vs
p
institut
implement
initi
respond
indic
vasopressin
initi
unitsminut
titrat
effect
vs
fewer
respond
initi
vasopressin
norepinephrin
dosag
mcgminut
vs
conclus
greater
institut
implement
least
one
initiativeeduc
regard
vasopressin
rebrandingpric
increas
vasopressin
cost
consid
pharmacist
recommend
use
less
frequent
multipl
clinic
scenario
grey
area
evalu
bundl
traumat
brain
injuri
admit
level
trauma
intens
care
unit
awak
studi
ruben
villanueva
david
luu
brittani
karfonta
bradley
bohnstedt
pharmaci
clinic
administr
scienc
univers
oklahoma
hsc
colleg
pharmaci
oklahoma
citi
ok
anesthesia
univers
oklahoma
hsc
colleg
medicin
oklahoma
citi
ok
medic
research
foundat
oklahoma
citi
ok
neurosurgeri
univers
oklahoma
hsc
colleg
medicin
oklahoma
citi
ok
introduct
amantadin
robust
data
improv
awakeningcognit
patient
sever
traumat
brain
injuri
tbi
although
sever
pharmacolog
agent
investig
bundl
nsb
includ
amantadin
develop
ou
medic
center
research
question
hypothesi
earli
administr
nsb
increas
rate
improv
glasgow
coma
scale
gc
initi
week
treatment
studi
design
retrospect
chart
review
method
nsb
includ
amantadin
sertralin
gabapentin
trazadon
gener
criteria
use
includ
gc
sed
drip
discontinu
invas
icp
monitor
exclus
criteria
includ
less
three
day
amantadin
gc
day
sedat
stop
die
within
seven
day
admiss
primari
outcom
differ
gc
nsb
control
group
gc
document
day
sed
drip
discontinu
discharg
use
compar
categor
continu
data
respect
result
baselin
signific
differ
mean
age
year
vs
year
nsb
group
lower
mean
ed
vs
p
icu
gc
vs
p
addit
higher
mean
iss
vs
p
control
group
significantli
higher
gc
score
p
comparison
vs
vs
vs
vs
discharg
vs
manova
identifi
signific
interact
nsb
gc
although
time
signific
multipl
regress
identifi
icu
admit
gc
predict
gc
day
discharg
conclus
although
signific
improv
gc
note
dissimilar
group
preclud
firm
conclus
prospect
studi
warrant
determin
optim
time
whether
combin
superior
amantadin
alon
therapeut
drug
monitor
amikacin
augment
renal
clearanc
critic
ill
pediatr
patient
lesli
escobar
pharmd
constanza
rivera
daniela
poblet
roxana
santana
claudio
gonzalez
pediatr
infant
surgeri
univers
chile
santiago
chile
la
cond
santiago
chile
chile
de
chile
santiago
chile
chile
exequiel
gonzalez
cort
santiago
chile
chile
introduct
well
known
critic
ill
pediatr
patient
chang
modifi
pharmacokinet
pk
mainli
distribut
elimin
hydrophil
drug
amikacin
augment
renal
clearanc
arc
slightli
describ
therapeut
drug
monitor
tdm
amikacin
use
one
level
normal
trough
provid
enough
inform
impact
arc
amikacin
plasma
concentr
research
question
hypothesi
observ
arc
impact
amikacin
plasma
concentr
critic
ill
pediatr
patient
differ
time
tdm
studi
design
prospect
jan
descript
pharmacokinet
studi
amikacin
base
peak
propos
post
infus
respect
collect
critic
ill
patient
exequiel
gonzalez
cort
children
hospit
receiv
amikacin
accord
local
antimicrobi
program
neonat
patient
renal
replac
therapi
exclud
method
first
tdm
patient
consid
pk
paramet
lineal
regress
bayesian
analysi
precisepk
softwar
perform
schwartz
formula
use
estim
clearanc
creatinin
clcrea
classifi
patient
arc
group
clcrea
graphpad
prism
use
statist
analysi
median
percentil
use
result
eighti
children
tdm
includ
median
peak
amikacin
concentr
mgl
mgl
respect
percent
patient
arc
signific
higher
clcrea
vs
p
also
obtain
signific
lower
amikacin
plasma
level
compar
patient
arc
cpeak
vs
mgl
vs
mgl
shorter
vs
lower
auc
vs
lh
conclus
arc
frequent
lead
effect
concentr
least
half
day
sampl
could
appropri
trough
level
observ
arc
dose
adjust
patient
fondecyt
physic
compat
variou
medic
balanc
fluid
solut
alyson
g
wilder
pharmd
bcp
jaim
foushe
pharmd
bcp
megan
greer
pharmd
adrienn
wright
pharmd
laura
fox
pharmaci
practic
presbyterian
colleg
school
pharmaci
clinton
sc
colleg
school
pharmaci
clinton
sc
pharmaceut
administr
scienc
presbyterian
colleg
school
pharmaci
clinton
sc
introduct
multipl
intraven
iv
medic
often
requir
critic
ill
patient
limit
venou
access
may
necessit
medic
cathet
lumen
recent
data
suggest
balanc
fluid
solut
associ
decreas
patient
morbid
includ
acut
kidney
injuri
use
resuscit
patient
sepsi
septic
shock
compar
normal
salin
addit
use
agent
crucial
adequ
treatment
septic
patient
compat
data
current
lack
newer
balanc
fluid
solut
mani
iv
medic
minimum
physic
compat
assess
prior
medic
connector
research
question
hypothesi
select
medic
compat
connector
lactat
ringer
studi
design
quantit
vitro
experi
method
studi
medic
includ
acyclovir
ampicillin
aztreonam
cefepim
ceftriaxon
ciprofloxacin
gentamicin
levofloxacin
meropenem
tobramycin
vancomycin
assess
compat
andor
lactat
ringer
studi
solut
test
highest
concentr
util
clinic
practic
physic
compat
check
use
visual
assess
light
dark
background
chang
turbid
assess
use
laboratori
turbidimet
assess
made
time
mix
everi
minut
thereaft
one
hour
simul
contact
time
turbid
differ
ntu
consid
incompat
result
acyclovir
ampicillin
aztreonam
cefepim
ceftriaxon
ciprofloxacin
gentamicin
levofloxacin
meropenem
tobramycin
vancomycin
exhibit
visual
turbidimetr
evid
incompat
combin
studi
period
addit
ampicillin
cefepim
levofloxacin
exhibit
visual
turbidimetr
evid
incompat
combin
lactat
ringer
studi
period
conclus
studi
combin
exhibit
physic
compat
meet
minimum
requir
safe
iv
medic
connector
impact
renal
function
achiev
therapeut
exenatid
concentr
acut
brain
injuri
exploratori
dose
studi
kathryn
morbitz
pharmd
ms
nicol
r
pinelli
pharmd
j
dedrick
jordan
md
luigi
troiani
pa
kelli
dehn
casey
md
emili
durr
denis
rhoney
practic
advanc
clinic
educ
unc
eshelman
school
pharmaci
chapel
hill
nc
eshelman
school
pharmaci
univers
north
carolina
chapel
hill
chapel
hill
nc
neurolog
neurosurgeri
univers
north
carolina
chapel
hill
school
medicin
chapel
hill
nc
north
carolina
school
medicin
chapel
hill
nc
north
carolina
hospit
chapel
hill
nc
school
medicin
chapel
hill
nc
health
system
atlanta
ga
introduct
hyperglycemia
glycem
variabl
gv
associ
poor
outcom
critic
ill
patient
exenatid
predominantli
renal
elimin
approv
improv
glycem
control
type
diabet
mellitu
howev
evid
critic
ill
patient
acut
brain
injuri
abi
limit
particularli
experienc
augment
renal
clearanc
arc
may
impact
abil
achiev
therapeut
exenatid
concentr
cexenatid
research
question
hypothesi
patient
arc
exhibit
subtherapeut
cexenatid
result
reduc
glycem
control
studi
design
prospect
exploratori
dose
studi
method
adult
patient
abi
two
blood
glucos
bg
concentr
includ
intraven
exenatid
infus
administ
within
admiss
continu
cexenatid
obtain
baselin
urin
collect
measur
creatinin
clearanc
mcrcl
perform
daili
arc
defin
capillari
bg
measur
obtain
hourli
infus
primari
endpoint
correl
cexenatid
mcrcl
secondari
endpoint
compar
cexenatid
median
bg
gv
arc
patient
compar
data
present
median
iqr
percentag
primari
endpoint
use
spearman
correl
mcrcl
cexenatid
p
consid
statist
signific
descript
statist
perform
secondari
endpoint
analys
perform
use
result
seven
patient
complet
studi
protocol
age
male
histori
median
mcrcl
four
patient
experienc
arc
median
cexenatid
bg
correl
found
cexenatid
mcrcl
comparison
cexenatid
bg
gv
conclus
continu
infus
dose
protocol
achiev
therapeut
cexenatid
independ
mcrcl
presenc
arc
exploratori
studi
exenatid
infus
use
dose
strategi
may
potenti
option
glycem
control
set
arc
requir
valid
preval
risk
factor
inappropri
dose
pharmacolog
thromboprophylaxi
critic
ill
tia
stitt
pharmd
candid
w
anthoni
hawkin
pharmd
ronald
hall
ii
pharmd
georgia
colleg
pharmaci
albani
ga
clinic
administr
pharmaci
univers
georgia
colleg
pharmaci
albani
ga
tech
health
scienc
center
dalla
tx
introduct
prevent
venou
thromboembol
critic
ill
standard
care
extrem
bodi
weight
associ
bleed
treatment
failur
patient
receiv
pharmacolog
thromboprophylaxi
ptp
consensu
dose
extrem
bodi
weight
lack
evid
divers
due
variabl
anthropometr
stratif
research
question
hypothesi
ptp
commonli
inappropri
dose
overweight
critic
ill
adult
studi
design
analysi
nest
cohort
previou
studi
critic
ill
adult
across
nine
institut
method
patient
receiv
ptp
enoxaparin
enox
unfraction
heparin
ufh
includ
primari
outcom
preval
inappropri
dose
base
bodi
mass
index
bmi
total
bodi
weight
tbw
secondari
outcom
identifi
risk
factor
inappropri
dose
multivari
gener
linear
model
construct
determin
independ
risk
factor
inappropri
dose
ptp
tabl
definit
appropri
dose
result
nest
cohort
includ
patient
inappropri
dose
observ
patient
base
bmi
per
tbw
independ
risk
factor
inappropri
dose
per
bmi
receipt
ufh
ci
bmi
underweight
overweightobes
ci
receiv
ufh
ci
tbw
ci
independ
associ
inappropri
dose
base
tbw
conclus
inappropri
dose
pharmacolog
thromboprophylaxi
occur
frequent
critic
ill
adult
especi
bodi
size
extrem
ufh
use
bivalirudin
versu
heparin
anticoagul
percutan
ventricular
assist
devic
patrick
reed
pharmd
william
cahoon
jr
pharmd
depart
pharmaci
servic
virginia
commonwealth
univers
health
system
richmond
va
introduct
manufactur
impella
percutan
ventricular
assist
devic
vad
recommend
patient
system
anticoagul
heparin
heparin
infus
devic
via
purg
solut
prevent
pump
thrombosi
would
appropri
choic
therapi
patient
thrombocytopenia
minim
report
altern
anticoagul
impella
vad
research
question
hypothesi
evalu
effect
bivalirudin
versu
heparin
patient
impella
vad
studi
design
singl
center
retrospect
medic
chart
review
method
patient
impella
vad
anticoagul
either
bivalirudin
heparin
includ
primari
endpoint
comparison
time
therapeut
aptt
rang
bivalirudin
heparin
group
secondari
endpoint
includ
time
first
therapeut
aptt
number
supratherapeut
subtherapeut
aptt
number
aptt
variat
bleed
complic
thrombosi
complic
addit
inform
collect
character
use
bivalirudin
impella
vad
result
total
patient
bivalirudin
group
heparin
group
met
criteria
inclus
percentag
time
therapeut
aptt
rang
higher
bivalirudin
group
vs
p
differ
identifi
group
time
first
therapeut
aptt
hour
vs
hour
heparin
patient
experienc
significantli
higher
number
subtherapeut
aptt
aptt
variat
differ
found
number
supratherapeut
aptt
group
higher
rate
thrombot
complic
bivalirudin
group
vs
differ
bleed
complic
recogn
conclus
bivalirudin
associ
improv
time
therapeut
aptt
rang
fewer
subtherapeut
aptt
valu
less
variat
previou
aptt
valu
patient
receiv
heparin
howev
bivalirudin
patient
like
experi
thrombot
complic
relat
impella
vad
impact
spontan
awaken
trial
spontan
breath
trial
protocol
implement
amount
durat
sedat
analgesia
critic
ill
lesli
jurado
stephani
price
lisa
hall
zimmerman
marcu
ferguson
kevin
oneil
elizabeth
acquista
depart
new
hanov
region
medic
center
wilmington
nc
hanov
region
medic
center
wilmigton
nc
introduct
daili
spontan
awaken
trial
sat
may
decreas
occurr
oversed
perform
spontan
breath
trial
sbt
sat
lead
extub
quicker
pass
sbt
pair
satsbt
protocol
lead
less
ventil
day
decreas
icu
lo
howev
effect
pair
satsbt
sedat
analgesia
well
defin
research
question
hypothesi
compar
amount
durat
sedat
analgesia
mechan
ventil
patient
underw
separ
versu
concomit
satsbt
studi
design
retrospect
cohort
method
adult
mechan
ventil
patient
sticu
micu
beforeaft
implement
pair
satsbt
protocol
includ
patient
exclud
expir
comfort
measur
profound
neurolog
deficit
data
collect
novemb
decemb
februari
march
result
patient
admit
sticumicu
studi
period
patient
met
inclus
signific
differ
demograph
cohort
averag
daili
dose
propofol
significantli
reduc
cohort
mcgkgmin
per
day
vs
per
day
averag
fentanyl
dose
cohort
mcghr
compar
mcghr
cohort
signific
reduct
durat
propofol
fentanyl
signific
reduct
median
rass
score
cohort
vs
conclus
implement
concomit
satsbt
protocol
decreas
daili
dose
propofol
use
throughout
patient
intub
period
studi
find
reduct
durat
propofol
fentanyl
statist
signific
differ
fentanyl
dose
two
cohort
trend
toward
higher
fentanyl
dose
pair
satsbt
protocol
util
order
decreas
amount
propofol
use
mechan
ventil
patient
incid
icu
delirium
durat
comadelirium
day
associ
mortal
matthew
duprey
mark
van
den
boogaard
rn
han
van
der
hoeven
md
peter
pickker
md
john
devlin
pharmaci
northeastern
univers
boston
univers
medic
center
nijmegen
netherland
univers
school
pharmaci
boston
introduct
delirium
preval
andor
durat
associ
greater
mortal
howev
associ
icu
incid
delirium
mortal
remain
unclear
research
question
hypothesi
measur
associ
incid
icu
delirium
durat
day
coma
andor
delirium
day
icu
admiss
mortal
studi
design
retrospect
evalu
random
delirium
prevent
trial
method
analysi
evalu
adult
delirium
coma
day
measur
mortal
day
delirium
day
posit
icdsc
coma
day
delirium
rass
score
analysi
perform
deliriumcoma
statu
age
score
sepsi
mechan
ventil
use
icu
admiss
type
cumul
haloperidol
delirium
treatment
dose
consid
covari
result
total
patient
mean
age
medic
ventil
sepsi
median
iqr
haloperidol
incid
delirium
durat
median
median
day
delirium
coma
includ
mortal
day
day
neither
incid
delirium
hazard
ratio
hr
durat
delirium
day
associ
mortal
coma
day
deliriumcoma
day
associ
mortal
conclus
icu
incid
delirium
durat
associ
increas
mortal
addit
day
delirium
first
week
icu
admiss
also
associ
mortal
howev
day
coma
week
period
increas
risk
death
type
sourc
pharmaceut
counsel
servic
region
teach
hospit
taiwan
tsai
ms
shao
ms
chen
ms
depart
pharmaci
keelung
chang
gung
memori
hospit
keelung
taiwan
introduct
pharmacist
provid
pharmaceut
counsel
servic
ensur
medic
qualiti
safeti
regular
analyz
counsel
record
could
help
us
realiz
clinic
need
drug
inform
patient
healthcar
provid
research
question
hypothesi
type
sourc
pharmaceut
counsel
hospit
studi
design
retrospect
observ
studi
method
analyz
electron
pharmaceut
counsel
record
region
teach
hospit
taiwan
classifi
record
two
counsel
sourc
includ
patient
healthcar
provid
identifi
type
counsel
question
drug
identif
drug
use
drug
safeti
drug
storag
pregnanc
lactat
drug
reimburs
analyz
trend
counsel
sourc
type
counsel
question
studi
period
analys
report
descript
statist
result
pharmaceut
counsel
record
increas
counsel
patient
decreas
common
type
counsel
question
patient
drug
use
drug
safeti
counsel
question
patient
drug
use
increas
drug
safeti
decreas
among
healthcar
provid
doctor
account
pharmaceut
counsel
common
type
counsel
question
drug
use
drug
identif
counsel
question
healthcar
provid
drug
use
increas
drug
identif
decreas
conclus
pharmacist
play
increas
role
provid
pharmaceut
counsel
servic
hospit
especi
drug
use
find
could
help
develop
strategi
improv
current
use
hospit
inform
system
use
answer
mani
counsel
question
descript
analysi
system
use
contemporari
drug
effect
ryan
rodriguez
kelsey
bridgeman
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
univers
illinoi
chicago
chicago
il
introduct
system
erss
provid
systemat
evalu
qualiti
individu
control
observ
studi
overal
bodi
literatur
includ
ma
pharmacist
conduct
evalu
ma
requir
familiar
erss
determin
level
confid
gener
result
mani
erss
publish
consensu
exist
regard
best
practic
use
research
question
hypothesi
object
describ
varieti
erss
use
ma
drug
therapi
publish
medic
journal
studi
design
analysi
method
top
rank
gener
medic
journal
identifi
pubm
search
identifi
ma
evalu
drug
therapi
journal
method
review
ensur
ma
evalu
drug
therapi
identifi
er
use
rate
individu
studi
overal
bodi
literatur
frequenc
er
use
analyz
use
descript
statist
result
journal
ann
intern
med
bmj
jama
lancet
n
engl
j
med
plo
medicin
articl
identifi
manual
review
exclud
evalu
ma
util
er
commonli
use
cochran
risk
bia
tool
ma
overal
uniqu
erss
includ
system
use
evalu
control
trial
ma
observ
studi
ma
er
use
evalu
bodi
literatur
ma
commonli
use
uniqu
system
grade
methodolog
conclus
among
numer
erss
use
evalu
studi
ma
drug
effect
cochran
risk
bia
tool
frequent
use
erss
evalu
bodi
literatur
infrequ
use
pharmacist
familiar
erss
appropri
evalu
confid
result
gener
ma
base
qualiti
includ
literatur
determin
er
select
candid
pharmaci
resid
nation
survey
resid
program
director
jonathan
cho
pharmd
bcp
colleg
pharmaci
univers
texa
tyler
tyler
tx
introduct
healthcar
treatment
option
continu
evolv
advanc
need
pharmacist
addit
train
american
societi
pharmacist
ashp
envis
pharmacist
work
hospit
complet
year
pharmaci
resid
program
grow
need
resid
train
pharmacist
obtain
resid
becom
competit
research
question
hypothesi
studi
captur
perspect
resid
program
director
rpd
regard
aspect
candid
applic
interview
found
import
select
futur
resid
studi
design
studi
method
electron
survey
distribut
via
pharmaci
rpd
rpd
identifi
via
ashp
pharmaci
resid
directori
remind
complet
survey
sent
everi
two
week
three
time
data
collect
period
data
relat
program
demograph
candid
applic
interview
evalu
collect
rpd
percept
captur
via
likert
scale
disagre
agre
result
total
rpd
complet
survey
rpd
highli
consid
overal
fit
mean
likert
score
letter
recommend
letter
interest
invit
candid
interview
resid
program
focus
acut
care
valu
hospit
pharmaci
work
experi
compar
care
focus
resid
program
vs
ashp
resid
showcas
attend
view
import
consid
candid
onsit
interview
interview
critic
think
abil
verbal
commun
overal
compat
view
highli
import
consid
rank
candid
conclus
studi
highlight
featur
rpd
view
import
consid
resid
applic
result
studi
use
provid
prospect
resid
guidanc
way
better
prepar
resid
applic
interprofession
educ
collabor
practic
resid
pharmaci
resid
program
embed
famili
medicin
resid
program
jodi
lounsberi
pharmd
jenni
jarrett
pharmd
bcp
mmede
minnesota
colleg
pharmaci
depart
pharmaceut
care
health
system
minneapoli
mn
pharmaci
depart
pharmaci
practic
univers
illinoi
chicago
chicago
il
present
societi
teacher
famili
medicin
annual
spring
confer
washington
dc
perceiv
valu
supplement
infecti
diseas
cours
content
social
media
elia
chahin
pharmd
fccp
bcp
rebecca
elyea
pharmd
candid
laura
neubauer
pharmd
candid
catherin
harrington
pharmd
phd
lloyd
l
gregori
school
pharmaci
palm
beach
atlant
univers
west
palm
beach
fl
introduct
use
social
media
platform
educ
tool
innov
way
engag
student
learn
process
howev
limit
studi
analyz
valu
approach
within
pharmaci
educ
research
question
hypothesi
supplement
content
provid
social
media
pharmaci
student
enrol
infecti
diseas
pharmacotherapi
cours
provid
valu
studi
design
singl
center
intervent
prepost
percept
survey
method
pharmaci
student
enrol
infecti
diseas
pharmacotherapi
cours
administ
begin
cours
student
invit
follow
exist
infecti
social
media
profil
instagram
facebook
twitter
idstewardship
week
addit
content
normal
post
account
target
content
post
class
day
compliment
subject
matter
day
administ
end
cours
survey
item
rank
use
likert
scale
data
analyz
wilcoxon
test
use
sa
enterpris
softwar
result
total
student
complet
studi
perceiv
mean
valu
survey
possibl
point
signific
differ
valu
expos
supplement
content
student
age
valu
content
age
year
old
accord
follow
three
survey
domain
new
content
guidelin
link
question
gener
discuss
major
student
report
intent
continu
follow
social
media
profil
studi
conclus
student
perceiv
valu
supplement
educ
content
social
media
chang
cours
semest
indic
campaign
met
origin
expect
result
provid
insight
potenti
use
incorpor
social
media
pharmaci
educ
impact
simul
cardiovascular
pharmacotherapeut
knowledg
retent
larg
classroom
set
angela
bingham
pharmd
bcp
bcnsp
bcccp
jame
holland
pharmd
aq
cardiolog
lisa
charneski
pharmd
bcp
michael
cawley
pharmd
rrt
cpft
fccm
depart
pharmaci
practic
pharmaci
administr
univers
scienc
philadelphia
colleg
pharmaci
philadelphia
pa
introduct
simul
demonstr
improv
achiev
cardiovascular
pharmacotherapeut
learn
goal
outcom
comput
lab
set
evid
suggest
emot
arous
increas
likelihood
memori
enhanc
theoret
use
simul
may
offer
advantag
tradit
didact
case
larg
classroom
set
howev
outcom
compar
method
evalu
research
question
hypothesi
simul
increas
student
pharmacist
cardiovascular
pharmacotherapeut
knowledg
retent
larg
classroom
set
compar
tradit
didact
case
studi
design
singl
center
retrospect
review
method
student
requir
cours
second
profession
year
pharmd
student
complet
case
ischem
stroke
simul
venou
thromboembol
tradit
didact
case
larg
classroom
set
knowledg
retent
ischem
stroke
venou
thromboembol
assess
compar
question
result
util
bloom
taxonomi
methodolog
two
month
instruct
survey
administ
instruct
assess
student
attitud
percept
regard
simul
larg
classroom
set
descript
statist
fisher
exact
test
use
analysi
statist
signific
defin
p
result
percentag
student
correctli
answer
question
two
month
ischem
stroke
simul
venou
thromboembol
tradit
didact
case
larg
classroom
set
vs
respect
p
student
strongli
agre
agre
simul
complet
larg
classroom
set
enhanc
learn
felt
emot
connect
simul
patient
conclus
simul
increas
cardiovascular
pharmacotherapeut
knowledg
retent
larg
classroom
set
compar
tradit
didact
case
larg
classroom
set
unabl
elicit
emot
arous
need
increas
likelihood
memori
enhanc
futur
studi
evalu
cardiovascular
pharmacotherapeut
knowledg
retent
simul
comput
lab
set
experienti
educ
correl
pharmaci
learner
intervent
time
spent
academ
medic
center
johanna
dresser
pharmd
meredith
welti
pharmd
candid
lisa
brennan
ami
loken
sarah
nisli
pharmd
bcp
univers
school
pharmaci
wingat
nc
forest
baptist
health
winston
salem
nc
forest
baptist
health
nc
introduct
previou
studi
demonstr
pharmaci
student
clinic
intervent
provid
institut
cours
singl
rotat
clearli
establish
whether
student
intervent
chang
cours
academ
year
studi
describ
incid
pharmaci
learner
intervent
time
research
question
hypothesi
frequenc
learner
intervent
increas
throughout
academ
year
studi
design
roll
retrospect
review
method
patient
care
intervent
log
student
electron
medic
record
emr
part
routin
practic
intervent
data
collect
monthli
emr
report
student
rotat
complet
within
medic
center
system
studi
period
elig
inclus
primari
endpoint
chang
time
frequenc
intervent
made
per
student
per
rotat
block
main
secondari
endpoint
chang
time
cost
analysi
intervent
per
student
per
rotat
block
result
studi
period
student
elig
inclus
averag
number
intervent
document
per
elig
student
decreas
averag
intervent
per
student
per
block
first
fourth
block
p
averag
document
intervent
document
per
student
per
block
decreas
averag
per
block
first
fourth
block
p
total
intervent
document
studi
period
total
conclus
pharmaci
learner
intervent
result
cost
save
institut
practic
despit
decreas
number
document
intervent
impact
learner
provid
institut
still
evid
addit
longitudin
data
throughout
entireti
academ
year
forthcom
sustain
global
health
improv
project
studi
determin
impact
provid
educ
healthcar
staff
set
michel
holm
pharmd
bcp
holli
burkhartzmey
man
pharmaci
mayo
clinic
rochest
mn
nurs
mayo
clinic
rochest
mn
introduct
global
health
educ
research
thu
far
focus
effect
provid
educ
direct
patient
care
assess
knowledg
gain
howev
need
determin
whether
educ
knowledg
transfer
effect
sustain
research
question
hypothesi
use
structur
educ
tool
associ
increas
medic
knowledg
improv
studi
design
prospect
cohort
studi
conduct
hospit
albert
schweitzer
deschapel
haiti
nurs
invit
particip
educ
train
provid
mayo
clinic
pharmaci
nurs
staff
one
year
method
lectur
focus
specif
nurs
topic
averag
nurs
attend
lectur
major
nurs
receiv
year
nurs
educ
employ
year
prior
educ
studi
quantit
assess
obtain
test
three
point
time
lectur
lectur
month
follow
lectur
use
mcnemar
test
qualit
data
obtain
focu
session
throughout
studi
result
pretest
immedi
posttest
result
statist
signific
show
improv
lectur
p
result
pretest
test
show
improv
lectur
p
qualit
data
result
depict
increas
confid
level
improv
patient
care
activ
conclus
base
qualit
find
ad
valu
provid
nurs
educ
nurs
staff
improv
seen
patient
care
activ
knowledg
gain
recogn
major
lectur
provid
yet
minim
knowledg
gain
depict
test
score
ensur
sustain
provid
educ
educ
studi
need
accomplish
cape
domain
app
student
percept
susan
smith
bs
pharmd
sarah
nisli
pharmd
jamielynn
sebaali
pharmd
lisa
brennan
pharmd
wesley
haltom
pharmd
lisa
mead
pharmd
wingat
univers
school
pharmaci
wingat
nc
introduct
limit
literatur
exist
accomplish
center
advanc
pharmaci
educ
cape
outcom
cape
domain
approach
practic
care
includ
specif
learn
object
within
six
subdomain
advanc
pharmaci
practic
experi
app
focu
student
pharmacist
approach
practic
evalu
accomplish
outcom
import
analyz
curricular
qualiti
assur
student
privat
univers
complet
app
five
distinct
geograph
region
two
concentr
experi
within
region
student
percept
accomplish
cape
outcom
app
correl
region
assign
may
use
school
pharmaci
ensur
high
qualiti
clinic
experi
student
pharmacist
research
question
hypothesi
differ
accomplish
cape
subdomain
app
year
studi
design
survey
research
educ
method
electron
survey
distribut
pharmaci
student
penultim
app
rotat
survey
assess
whether
student
least
opportun
achiev
domain
outcom
affirm
respons
prompt
student
report
percentag
success
accomplish
outcom
descript
inferenti
statist
perform
sa
institut
inc
consid
statist
signific
result
survey
respons
rate
respond
report
median
accomplish
rang
subdomain
signific
differ
subdomain
p
outcom
relat
patient
advocaci
problem
solv
account
lowest
complet
percentag
overal
student
percept
accomplish
among
six
subdomain
differ
accord
region
assign
respect
conclus
student
perceiv
accomplish
outcom
associ
cape
domain
differ
region
assign
impact
student
percept
accomplish
outcom
futur
studi
evalu
achiev
object
relat
patient
advocaci
problem
solv
may
warrant
impact
gener
medicin
elect
cours
student
percept
app
readi
dayna
leseuer
alexa
carlson
pharmd
bcp
stephani
sibicki
pharmd
bcp
mark
douglass
margarita
v
dival
pharmd
med
michael
j
gonyeau
bspharm
pharmd
med
bcp
adam
b
woolley
pharmd
jason
lancast
pharmd
boston
school
pharmaci
boston
univers
boston
univers
depart
pharmaci
practiceboston
medic
center
boston
pharmaci
northeastern
univers
boston
univers
depart
pharmaci
practic
boston
present
american
associ
colleg
pharmaci
annual
meet
nashvil
tn
juli
preceptor
resid
percept
entrust
profession
activ
epa
postgradu
pharmaci
train
sarah
schweiss
pharmd
bcacp
jean
moon
pharmd
jodi
lounsberi
pharmd
ami
pitteng
pharmd
ms
practic
pharmaceut
scienc
univers
minnesota
colleg
pharmaci
duluth
mn
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
minnesota
colleg
pharmaci
depart
pharmaceut
care
health
system
minneapoli
mn
present
pharmaci
educ
confer
american
associ
colleg
pharmaci
boston
juli
percept
pharmaci
faculti
student
regard
use
standard
patient
object
structur
clinic
examin
jonathan
cho
pharmd
bcp
takova
wallac
pharmd
frank
yu
pharmaci
univers
texa
tyler
tyler
tx
clinic
pharmaci
univers
texa
tyler
tyler
tx
univers
texa
tyler
tyler
tx
introduct
demonstr
clinic
compet
commun
skill
necessari
qualiti
pharmacist
one
mean
assess
attribut
doctor
pharmaci
program
object
structur
clinic
examin
osc
osc
requir
student
perform
varieti
clinic
function
interact
simul
patient
mimic
actual
practic
environ
howev
simul
patient
strategi
use
differ
consider
research
question
hypothesi
pharmaci
student
faculti
member
perceiv
standard
patient
sp
benefici
administ
osc
studi
design
studi
method
electron
survey
sent
pharmaci
student
select
faculti
member
particip
osc
spring
semest
data
collect
includ
student
demograph
inform
student
perceiv
level
confid
relat
commun
make
recommend
provid
counsel
patient
faculti
member
percept
relat
interact
use
sp
result
student
twelv
faculti
member
complet
survey
ask
interact
sp
student
either
agre
strongli
agre
sp
portray
patient
realist
student
perceiv
sp
creat
comfort
environ
patient
commun
compar
student
either
agre
strongli
agre
feel
confid
commun
patient
felt
confid
make
recommend
ten
faculti
member
either
agre
strongli
agre
sp
portray
patient
interact
realist
seven
felt
sp
consist
simul
patient
portray
durat
osc
conclus
pharmaci
student
felt
confid
abil
commun
interact
patient
osc
sp
use
student
faculti
member
perceiv
sp
portray
patient
interact
realist
compar
recommend
continu
use
sp
osc
impact
intern
interprofession
experi
percept
relationship
miranda
andru
pharmd
bcp
fccp
emili
powel
taylor
steuber
pharmaci
practic
auburn
famili
medicin
center
huntsvil
al
alabama
medic
center
opelika
al
pharmaci
practic
auburn
univers
harrison
school
pharmaci
huntsvil
al
introduct
accredit
council
pharmaci
educ
acp
place
emphasi
interprofession
educ
accredit
bodi
healthcar
disciplin
intern
medic
mission
trip
offer
uniqu
opportun
interprofession
collabor
underprivileg
area
uniqu
medic
need
limit
resourc
cultiv
educ
opportun
requir
teamwork
ingenu
optim
role
within
interprofession
team
research
question
hypothesi
intern
interprofession
medic
mission
trip
posit
impact
percept
relationship
studi
design
prospect
survey
medic
pharmaci
student
particip
intern
medic
mission
trip
method
anonym
survey
administ
student
complet
intern
medic
mission
trip
dominican
republ
particip
ask
rank
scale
strongli
disagre
strongli
agre
percept
pharmacist
integr
part
medic
mission
trip
level
confid
commun
healthcar
disciplin
whether
believ
interprofession
team
necessari
provid
optim
patient
care
respons
match
chang
percept
analyz
use
wilcoxon
sign
rank
test
instrument
administ
trip
measur
attitud
toward
interprofession
team
result
particip
respond
survey
signific
improv
seen
percept
pharmacist
integr
part
medic
mission
trip
confid
abil
commun
healthcar
disciplin
student
state
would
recommend
experi
agre
interprofession
experi
enhanc
team
work
skill
incorpor
educ
result
demonstr
posit
percept
interprofession
team
question
median
agre
strongli
agre
conclus
intern
interprofession
experi
improv
percept
relationship
experi
increas
student
confid
provid
understand
healthcar
disciplin
cultiv
interest
futur
interprofession
collabor
assess
english
languag
profici
score
academ
perform
curriculum
pharmaci
student
english
second
languag
justin
tenney
maria
paiva
qianwen
wang
pharmaci
chines
univers
hong
kong
shatin
hong
kong
medicin
doha
qatar
chines
univers
hong
kong
shatin
hong
kong
introduct
divers
student
admit
healthcar
educ
program
intern
adopt
english
taught
curriculum
increas
english
profici
test
often
compon
admiss
criteria
also
current
practic
hong
kong
pharmaci
school
research
question
hypothesi
determin
relationship
english
languag
profici
grade
point
averag
gpa
pharmaci
student
english
second
languag
esl
studi
design
student
without
english
first
languag
graduat
bachelor
pharmaci
program
invit
particip
studi
method
compar
pharmaci
student
esl
score
cumul
gpa
graduat
correl
gpa
mathemat
chemistri
nativ
languag
cantones
score
use
point
refer
gaug
degre
correl
result
student
assess
student
particip
studi
male
femal
student
statist
analys
show
strong
correl
esl
score
cumul
graduat
gpa
r
p
though
weaker
mathemat
score
demonstr
correl
cumul
graduat
gpa
well
p
nativ
languag
chemistri
score
correl
graduat
gpa
conclus
first
studi
kind
pharmaci
student
student
chines
nativ
languag
also
first
studi
compar
preadmiss
esl
score
cumul
graduat
gpa
studi
provid
evid
esl
profici
score
correl
academ
perform
evalu
infecti
diseas
healthcar
hashtag
educ
tool
trinh
vu
pharmd
candid
univers
georgia
katherin
lusardi
erin
mccreari
pharmd
kayla
r
stover
pharmd
sarah
wither
christoph
bland
pharmd
bcp
georgia
colleg
pharmaci
athen
ga
arkansa
medic
scienc
littl
rock
ar
wisconsin
hospit
clinic
uw
health
madison
wi
pharmaci
practic
univers
mississippi
school
pharmaci
jackson
ms
servic
greenvil
health
system
greenvil
sc
administr
pharmaci
univers
georgia
colleg
pharmaci
savannah
ga
introduct
social
media
twitter
increasingli
use
educ
platform
allow
healthcar
profession
share
inform
real
time
hashtag
util
social
media
group
messag
post
facilit
search
relat
content
studi
sought
explor
use
healthcar
hashtag
educ
tool
research
question
hypothesi
healthcar
hashtag
idprn
util
infecti
diseas
educ
tool
studi
design
accp
infecti
diseas
practic
research
network
idprn
execut
committe
creat
idprn
distribut
group
educ
content
via
twitter
hashtag
regist
symplur
analyt
tool
gather
data
usag
id
prn
member
encourag
use
idprn
whenev
possibl
post
educ
content
method
symplur
twitter
queri
top
five
use
associ
idprn
august
includ
tweet
retweet
total
impress
data
also
collect
top
five
individu
user
idprn
result
top
five
use
idprn
base
total
number
tweet
retweet
educ
chat
infecti
diseas
confer
content
distribut
publish
articl
personalaward
mention
gener
pharmaci
confer
content
top
five
use
idprn
base
number
impress
educ
chat
infecti
diseas
confer
content
share
publish
articl
gener
pharmaci
confer
content
personalaward
mention
top
five
user
idprn
currentform
id
prn
execut
committe
member
infecti
diseas
pharmaci
organ
conclus
substanti
amount
educ
content
distribut
via
twitter
use
infecti
diseas
healthcar
hashtag
impact
rapid
widespread
distribut
educ
content
requir
investig
healthcar
special
implement
unlimit
form
quizz
larg
cohort
therapeut
cours
sarah
scott
pharmd
stephani
l
sibicki
pharmd
bcgp
bcp
brandon
dionn
pharmd
id
aahivp
northeastern
univers
boston
introduct
form
quizz
shown
help
increas
overal
cours
perform
howev
effect
quizz
exam
score
research
question
hypothesi
perform
form
quizz
predict
exam
score
studi
design
retrospect
cohort
studi
method
student
third
profession
year
therapeut
cours
requir
take
weekli
form
quizz
unlimit
attempt
achiev
masteri
score
number
total
attempt
number
attempt
masteri
percentag
score
quiz
well
percentag
score
exam
cours
obtain
student
learn
manag
system
quiz
score
group
correspond
exam
materi
averag
score
averag
total
attempt
averag
attempt
masteri
proport
quizz
achiev
calcul
group
quizz
evalu
correl
exam
score
spearman
rank
correl
univari
analys
linear
regress
multivari
analysi
perform
use
spss
result
total
student
includ
posit
correl
found
exam
score
averag
quiz
score
rs
p
percentag
quizz
achiev
rs
p
neg
correl
exist
exam
score
averag
number
total
attempt
rs
p
averag
number
attempt
masteri
rs
p
adjust
individu
student
averag
number
total
attempt
higher
quiz
score
b
p
remain
associ
higher
exam
score
conclus
higher
quiz
score
predict
higher
overal
exam
score
regardless
individu
student
number
attempt
student
may
benefit
util
quiz
achiev
rather
achiev
masteri
identif
essenti
knowledg
inpati
gener
medicin
advanc
pharmaci
practic
experi
rebecca
moot
pharmd
msc
bcp
shannon
knutsen
pharmd
michel
claiborn
pharmd
pharmaci
univers
texa
austin
san
antonio
tx
pharmaci
regi
univers
denver
co
present
american
societi
pharmacist
midyear
meet
orlando
florida
decemb
applic
ppcp
via
patient
case
within
pharmacotherapeut
cours
monica
fahmi
pharmd
candid
urvind
silki
kaur
pharmd
candid
richard
silvia
pharmd
robert
dufresn
phd
phd
bcpp
univers
boston
pharmaci
practic
mcph
univers
boston
rhode
island
kingston
ri
introduct
pharmacist
patient
care
process
ppcp
requir
part
acp
pharmd
curriculum
pharmaci
student
need
profici
use
ppcp
provid
optim
patient
care
patient
case
relat
pharmacotherapeut
topic
use
reinforc
cours
materi
ppcp
use
case
educ
ppcp
report
literatur
research
question
hypothesi
ppcp
applic
via
patient
case
relat
pharmacotherapeut
topic
aid
student
ppcp
profici
lectur
materi
reinforc
studi
design
irb
approv
survey
distribut
class
take
pharmacotherapeut
fall
evalu
impact
case
reinforc
ppcp
method
cours
materi
method
two
student
prepar
case
sixteen
topic
share
classmat
student
complet
case
util
ppcp
answer
key
provid
one
week
origin
case
semest
end
survey
distribut
respons
tabul
microsoft
excel
survey
respons
analyz
via
goodman
kruskal
gamma
use
systat
softwar
bonferroni
correct
fourteen
separ
analys
requir
criterion
p
yield
overal
signific
level
p
result
percent
student
complet
case
survey
signific
p
posit
associ
observ
complet
case
util
understand
cours
materi
understand
ppcp
posit
associ
also
observ
use
ppcp
attempt
case
understand
cours
materi
ppcp
student
would
like
use
similar
case
futur
cours
associ
increas
util
understand
cours
materi
ppcp
conclus
student
util
higher
number
case
appropri
like
learn
ppcp
method
understand
cours
materi
learn
activ
improv
student
pharmacist
confid
urinari
incontin
product
emili
peron
pharmd
ms
emili
harmon
bs
laura
morgan
pharmd
med
kaci
power
pharmd
benjamin
van
tassel
pharmd
school
pharmaci
virginia
commonwealth
univers
richmond
va
introduct
urinari
incontin
ui
common
problem
us
popul
particularli
among
older
adult
sinc
mani
ui
product
avail
purchas
pharmacist
uniqu
opportun
counsel
patient
appropri
select
use
product
research
question
hypothesi
hypothes
small
group
activ
learn
experi
would
improv
student
pharmacist
confid
relat
ui
product
studi
design
prepost
survey
assess
student
pharmacist
confid
relat
ui
product
method
student
pharmacist
given
brief
introduct
ui
pathophysiolog
treatment
otc
product
min
follow
patient
case
evalu
small
group
min
complet
case
student
requir
manual
test
absorb
capac
current
avail
ui
product
includ
multipl
brand
pad
liner
diaper
survey
question
administ
immedi
activ
use
likert
scale
pair
result
student
confid
significantli
improv
across
five
survey
question
see
tabl
conclus
learn
activ
significantli
improv
student
pharmacist
confid
work
ui
product
systemat
approach
team
creation
larg
classroom
set
marian
gaviola
meredith
howard
adenik
atanda
w
cheng
yuet
pharmacotherapi
univers
north
texa
system
colleg
pharmaci
fort
worth
tx
univers
north
texa
system
colleg
pharmaci
fort
worth
tx
introduct
learn
tbl
wide
use
pharmaci
educ
evid
multipl
benefit
unfortun
limit
data
exist
support
optim
method
team
creation
lead
random
team
member
need
determin
best
method
team
creation
tbl
within
pharmaci
educ
research
question
hypothesi
implement
evalu
systemat
approach
team
creation
compar
effect
team
dynam
versu
team
creat
random
select
studi
design
student
percept
survey
curricular
innov
relat
team
creation
peer
evalu
method
two
concurr
requir
cours
use
evalu
compar
team
creation
catm
team
maker
versu
random
select
among
pharmaci
student
systemat
team
creation
within
one
cours
catm
incorpor
variabl
prefer
relat
avail
leadership
style
pharmaci
organ
involv
creat
team
match
survey
assess
student
percept
team
creation
peer
evalu
well
prefer
percept
surround
characterist
effect
team
addit
survey
end
semest
compar
team
effect
catm
versu
random
creation
result
student
enrol
cours
complet
match
survey
survey
result
reveal
student
prefer
increas
classroom
skill
heterogen
student
perceiv
better
team
effect
group
decreas
task
relationship
process
conflict
along
increas
task
attract
interperson
cohes
compar
random
alloc
signific
differ
individu
examin
perform
two
cours
mean
score
vs
conclus
systemat
approach
team
creation
improv
team
dynam
signific
effect
individu
examin
use
catm
provid
breadth
inform
may
help
faculti
effect
manag
teamwork
within
larg
classroom
set
design
evalu
third
year
didact
advanc
cardiovascular
pharmacotherapi
elect
focus
app
prepared
caitlin
gibson
pharmd
meredith
howard
pharmd
depart
pharmacotherapi
univers
north
texa
system
colleg
pharmaci
fort
worth
tx
introduct
didact
curriculum
student
often
lack
exposur
practic
numer
activ
encount
advanc
pharmaci
practic
experi
app
rotat
may
limit
student
prepared
app
research
question
hypothesi
clinic
elect
cours
compris
activ
frequent
encount
app
year
improv
student
percept
app
readi
studi
design
qualit
analysi
pharmaci
student
method
pharmaci
student
enrol
advanc
cardiovascular
pharmacotherapi
elect
complet
activ
includ
journal
club
drug
monograph
topic
discuss
oral
case
present
simul
lab
clinic
controversi
present
student
complet
activ
individu
team
receiv
feedback
two
cours
director
manner
consist
app
feedback
student
percept
assess
via
formal
survey
well
midpoint
stop
start
continu
survey
address
impact
cours
perceiv
readi
app
rotat
result
twelv
student
enrol
cours
eight
student
complet
complet
compar
evalu
student
report
increas
confid
analyz
patient
data
creat
individu
care
plan
analyz
biomed
literatur
deliv
present
p
student
identifi
journal
club
topic
discuss
monograph
valuabl
cours
activ
respons
student
report
feel
prepar
rotat
conclus
integr
app
activ
didact
elect
improv
readi
rotat
addit
survey
sent
student
complet
four
app
rotat
determin
cours
impact
survey
also
distribut
student
enrol
futur
iter
cours
increas
sampl
size
assess
impact
cours
percept
app
readi
across
multipl
cohort
addit
control
group
student
enrol
elect
survey
futur
iter
implement
clinic
capston
cours
improv
confid
global
pharmd
candid
paul
reynold
pharmd
joseph
saseen
pharmd
jennif
trujillo
pharmd
scott
mueller
pharmd
sunni
linnebur
pharmd
lyne
sanut
mli
shaun
gleason
pharmd
mg
depart
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
clinic
capston
cours
may
improv
across
healthcar
educ
effect
implement
clinic
capston
cours
intern
practic
pharmacist
pursu
pharmd
describ
research
question
hypothesi
implement
clinic
capston
cours
improv
student
confid
key
area
relat
clinic
pharmaci
practic
studi
design
educ
studi
survey
baselin
midpoint
cours
complet
rubric
base
assess
util
track
compet
regard
differ
abo
method
clinic
capston
incorpor
live
case
discuss
standard
patient
interview
case
scenario
group
activ
primari
outcom
improv
student
confid
critic
think
learn
medicin
ebm
clinic
prepared
advanc
pharmaci
practic
experi
app
student
survey
likert
scale
highest
conduct
baselin
midpoint
cours
complet
assess
primari
outcom
secondari
outcom
includ
achiev
select
abil
base
outcom
abo
assess
use
rubric
wilcoxon
test
use
assess
primari
outcom
descript
statist
secondari
outcom
result
cours
enrol
student
mean
practic
experi
year
sever
geograph
region
compar
baselin
midpoint
survey
mean
likert
score
increas
vs
learn
vs
ebm
vs
clinic
vs
vs
prepared
app
vs
p
comparison
student
achiev
compet
advanc
patient
assess
basic
healthcar
ethic
basic
ebm
basic
advanc
commun
conclus
implement
clinic
capston
cours
effect
improv
perceiv
student
confid
learn
ebm
perceiv
prepared
app
student
success
met
key
abo
relat
pharmaci
practic
result
cours
develop
pharmaci
resid
research
resourc
within
critic
care
prn
adrian
wong
pharmd
mph
zachari
smith
melissa
bastin
joshua
demott
pharmd
kendal
gross
brittani
bissel
pharmd
mojdeh
heavner
pharmd
bcp
molli
droeg
benjamin
hohlfeld
univers
boston
ford
hospit
detroit
mi
pharmaci
servic
univers
kentucki
healthcar
lexington
ky
pharmaci
rush
univers
medic
center
chicago
il
california
san
francisco
san
francisco
san
francisco
ca
maryland
school
pharmaci
baltimor
md
cincinnati
medic
center
cincinnati
oh
clinic
cleveland
oh
introduct
research
project
often
requir
pharmaci
resid
train
resourc
conduct
investig
may
lack
studi
found
approxim
resid
program
director
rpd
low
confid
resid
abil
perform
statist
analys
charg
creat
critic
care
prn
research
committe
identifi
resourc
resid
rpd
might
find
help
conduct
research
project
research
question
hypothesi
determin
area
improv
conduct
resid
research
identifi
optim
format
distribut
type
resourc
studi
design
anonym
voluntari
survey
electron
sent
decemb
resid
rpd
member
critic
care
prn
method
survey
compris
question
includ
respond
demograph
resid
comfort
research
begin
year
decemb
use
potenti
resourc
rank
scale
highest
critic
care
prn
could
help
creat
statist
analysi
complet
use
r
r
core
team
vienna
austria
result
total
survey
respons
complet
survey
rpd
account
respons
critic
care
resid
second
common
median
chang
resid
comfort
perform
research
increas
iqr
statist
analysi
guid
use
resourc
overal
median
iqr
resid
rate
use
propos
resourc
higher
compar
rpd
resourc
statist
signific
p
differ
prefer
potenti
resourc
type
institut
institut
bed
size
conclus
propos
resourc
appear
great
valu
resid
rpd
base
result
statist
analysi
guid
develop
evalu
guid
complet
next
cohort
pharmaci
resid
educ
intervent
pharmaci
nurs
student
affect
attitud
knowledg
regard
gender
individu
mimi
mukherje
goldsmith
ann
lak
ms
pharmaci
depart
pharmaci
practic
mcph
univers
worcest
pharmaci
depart
pharmaceut
scienc
mcph
univers
manchest
nh
nurs
mcph
univers
manchest
nh
introduct
gender
individu
greater
dissatisfact
healthcar
due
discrimin
low
cultur
compet
among
healthcar
profession
pharmaci
nurs
curricula
design
limit
time
lesbian
gay
bisexu
transgend
queer
lgbtq
health
research
question
hypothesi
educ
ipe
gender
individu
posit
effect
student
knowledg
attitud
secondarili
interact
improv
student
collabor
skill
studi
design
pair
survey
method
final
year
pharmaci
nurs
student
attend
lectur
case
discuss
topic
includ
lgbtq
health
dispar
environ
small
group
student
discuss
case
share
thought
larger
group
student
survey
program
use
item
attitud
toward
lgbt
patient
scale
atlp
intern
collabor
compet
attain
survey
icca
use
likert
scale
rang
strongli
disagre
strongli
agre
data
analyz
use
wilcoxon
analysi
via
graph
pad
prism
result
one
hundr
six
student
nurs
pharmaci
particip
major
age
caucasian
cisgend
women
heterosexu
program
student
felt
prepar
talk
lgbtq
patient
mean
sd
sd
student
felt
comfort
known
someon
care
lgbtq
patient
mean
sd
sd
student
less
strongli
disagre
lgbtq
patient
seek
care
lgbtq
health
clinic
mean
sd
sd
addit
student
felt
better
abl
promot
effect
commun
among
member
team
mean
sd
sd
conclus
ipe
lgbtq
health
improv
student
lgbtq
cultur
compet
recognit
health
need
commun
skill
resid
percept
resili
curriculum
postgradu
year
pharmaci
resid
program
sarah
schweiss
pharmd
stephani
swanson
practic
pharmaceut
scienc
univers
minnesota
colleg
pharmaci
duluth
mn
minnesota
minneapoli
mn
present
best
practic
medic
educ
confer
univers
minnesota
minneapoli
mn
may
assess
student
confid
interprofession
commun
primari
care
advanc
pharmaci
practic
experi
app
allison
helmer
pharmd
katelin
lisenbi
pharmd
sean
smithgal
pharmd
bcacp
dana
carrol
pharmd
bcp
cde
e
kelli
hester
pharmd
bcp
pharmaci
practic
auburn
univers
harrison
school
pharmaci
mobil
al
pharmaci
practic
auburn
univers
harrison
school
pharmaci
tuscaloosa
al
pharmaci
practic
auburn
univers
harrison
school
pharmaci
auburn
al
introduct
pharmacist
must
provid
recommend
healthcar
worker
clear
concis
profession
manner
demonstr
expertis
acp
standard
indic
student
must
engag
becom
compet
effect
interprofession
commun
questionnair
indic
student
often
uncomfort
interact
healthcar
profession
address
problem
literatur
indic
pharmaci
student
use
sbar
commun
techniqu
simul
set
improv
interprofession
commun
studi
evalu
techniqu
app
research
question
hypothesi
student
confid
interprofession
commun
improv
throughout
primari
care
app
studi
design
retrospect
analysi
evalu
student
confid
commun
provid
app
via
commun
rubric
inspir
sbar
techniqu
method
rubric
creat
student
interprofession
commun
background
inform
assess
recommend
nonverb
commun
rate
includ
confid
moder
confid
highli
confid
student
rubric
respons
app
five
faculti
preceptor
may
april
includ
student
complet
rubric
least
prefer
begin
end
app
addit
likert
scale
app
survey
assess
student
commun
comfort
perceiv
benefit
preceptor
teach
method
includ
rubric
primari
object
assess
chang
student
confid
interprofession
commun
abil
data
analyz
use
descript
statist
wilcoxon
linear
regress
result
student
complet
app
survey
complet
initi
rubric
complet
final
rubric
student
report
confid
interprofession
commun
follow
app
part
due
rubric
student
confid
rubric
compon
improv
throughout
app
independ
rotat
block
year
signific
improv
commun
background
inform
highli
confid
chang
p
assess
highli
confid
chang
p
conclus
student
confid
interprofession
commun
improv
primari
care
app
use
commun
rubric
assess
advanc
pharmaci
practic
experi
app
readi
skill
third
year
pharmaci
student
ereni
guirgui
mariett
sourial
jay
jackson
harm
maarsingh
pharmaci
palm
beach
atlant
univers
lake
worth
fl
l
gregori
school
pharmaci
palm
beach
atlant
univers
west
palm
beach
fl
pharmaci
palm
beach
atlant
univers
west
palm
beach
fl
pharmaceut
scienc
lloyd
l
gregori
school
pharmaci
palm
beach
atlant
univers
west
palm
beach
fl
introduct
accredit
council
pharmaci
educ
requir
pharmaci
school
determin
student
knowledg
skill
attitud
succeed
app
major
develop
skill
base
compet
app
readi
assess
cours
case
studi
pharmacotherapi
iv
offer
final
didact
semest
prior
app
cours
part
seri
focus
pharmacist
patient
care
process
research
question
hypothesi
assess
student
app
readi
perceiv
abil
perform
select
compet
prior
complet
app
readi
assess
ara
within
cours
studi
design
studi
pre
post
survey
perform
assess
method
eight
app
readi
compet
defin
school
ara
includ
osc
administ
cours
assess
masteri
compet
student
perceiv
abil
perform
app
readi
compet
assess
use
pre
post
survey
primari
endpoint
success
pass
rate
upon
first
attempt
ara
secondari
endpoint
student
perceiv
abil
perform
app
readi
compet
upon
complet
cours
result
upon
complet
cours
averag
pass
rate
first
attempt
across
ara
student
complet
survey
respect
start
cours
student
strongli
agre
compet
perform
compet
ara
perform
ara
receiv
grade
student
strongli
agre
compet
perform
ara
survey
importantli
number
student
strongli
agre
survey
increas
fold
conclus
end
didact
portion
curriculum
student
gregori
school
pharmaci
demonstr
app
readi
skill
preliminari
evalu
addit
transgend
patient
care
doctor
pharmaci
curriculum
cheyenn
newsom
pharmd
li
wei
chen
bs
pharmacotherapi
colleg
pharmaci
pharmaceut
scienc
washington
state
univers
spokan
wa
pharmaci
pharmaceut
scienc
washington
state
univers
spokan
wa
introduct
number
transgend
gender
divers
patient
seek
care
unit
state
increas
mani
pharmacotherapi
part
gender
transit
current
literatur
instruct
method
patient
popul
social
medic
consider
lack
research
question
hypothesi
pharmaci
student
confid
abil
provid
cultur
medic
compet
care
individu
transgend
chang
three
hour
instruct
method
content
student
find
effect
learn
studi
design
intervent
survey
studi
method
cours
materi
encompass
cultur
empathet
medic
consider
peopl
transgend
ad
cours
doctor
pharmaci
curriculum
materi
includ
video
handout
jeopardi
game
view
discuss
stori
patient
transgend
student
gender
ident
explor
exercis
panel
peopl
identifi
transgend
patient
case
onlin
survey
conduct
assess
student
confid
intervent
student
also
ask
rate
help
compon
instruct
chang
confid
provid
compet
care
individu
transgend
u
test
perform
calcul
statist
signific
chang
student
confid
result
student
confid
provid
compet
care
patient
transgend
increas
significantli
follow
intervent
median
confid
level
among
student
increas
p
student
rate
video
jeopardi
game
patient
panel
help
compon
instruct
conclus
inclus
materi
transgend
pharmaci
care
show
improv
student
perceiv
confid
care
transgend
patient
panel
discuss
report
help
compon
could
consid
incorpor
pharmaci
school
curricula
use
entrust
profession
activ
epa
navig
evalu
pharmacist
skill
acceler
pharmaci
curriculum
brandon
nuzial
pharmd
bcacp
daniel
small
pharmd
paulin
low
pharmd
school
pharmaci
pacif
univers
oregon
hillsboro
introduct
american
associ
colleg
pharmaci
aacp
recommend
util
epa
ensur
student
upon
graduat
epa
core
activ
task
new
graduat
abl
complet
independ
therefor
guid
clinic
skill
need
curricular
coverag
addit
aacp
recommend
support
task
help
school
identifi
ensur
student
achiev
epa
pacif
univers
school
pharmaci
acceler
pharmd
program
clinic
skill
cover
mostli
longitudin
cours
research
question
hypothesi
epa
appropri
cover
assess
modifi
block
pharmd
curriculum
studi
design
descript
qualit
research
method
follow
simpl
map
curricula
epa
support
task
tier
system
creat
serv
baselin
assess
epa
coverag
futur
assess
curricular
chang
skill
defin
tier
teach
curricula
assess
mileston
assess
program
progress
tier
teach
classroom
skill
demonstr
necessari
progress
tier
necessari
teach
student
like
expos
experienti
educ
tier
use
priorit
curricular
aspect
need
urgent
attent
result
tier
task
repres
support
task
critic
skill
requir
immedi
attent
attent
action
support
task
tier
need
immedi
attent
attent
attent
support
task
identifi
tier
requir
immedi
attent
need
action
conclus
creat
tier
system
determin
placement
degre
assess
epa
task
effici
methodolog
ensur
pharmaci
curricula
optim
prepar
student
upon
graduat
address
gap
educ
pharmaci
practic
antimicrobi
stewardship
qualit
studi
among
pharmacist
middl
east
ziad
nasr
bsc
pharm
pharmd
bcp
kerri
wilbur
bsc
pharm
acpr
pharmd
mscph
alya
higazi
bsc
pharm
pharmaci
depart
clinic
pharmaci
practic
qatar
univers
doha
qatar
pharmaceut
scienc
univers
british
columbia
vancouv
bc
canada
introduct
antimicrobi
resist
public
health
issu
focu
antimicrobi
stewardship
am
team
within
healthcar
institut
am
comprehens
taught
medic
pharmaci
curricula
littl
known
relev
pharmacist
train
meet
am
need
middl
east
region
research
question
hypothesi
gap
exist
pharmaci
educ
actual
clinic
practic
regard
am
train
qatar
pharmacist
percept
am
role
hospit
environ
studi
design
qualit
studi
design
adopt
method
three
focu
group
discuss
total
pharmaci
alumni
current
practic
pharmacist
conduct
qatar
univers
topic
guid
develop
studi
investig
discuss
transcrib
verbatim
code
data
discuss
potenti
theme
identifi
data
code
analysi
support
nvivo
softwar
result
analyz
use
framework
analysi
result
two
major
theme
relat
gap
infecti
diseas
id
educ
actual
practic
regard
am
train
identifi
throughout
discuss
associ
recommend
made
improv
id
modul
content
deliveri
id
knowledg
skill
applic
two
major
theme
emerg
regard
pharmacist
percept
am
role
hospit
environ
impact
pharmacist
intervent
decis
make
antimicrobi
steward
continu
profession
develop
program
conclus
student
basic
knowledg
skill
relat
id
howev
gap
exist
am
educ
actual
need
clinic
practic
mainli
relat
perceiv
defici
id
cours
content
challeng
inform
retent
lack
relev
experienti
train
opportun
alumni
also
reiter
pharmacist
import
role
am
team
member
need
align
continu
educ
health
profession
realiti
practic
effect
exercis
sleep
perceiv
stress
among
pharmaci
student
abigayl
campbel
bs
psycholog
pharmd
candid
sarah
j
barn
pharmd
candid
g
blair
sarback
pharmd
nanci
taylor
rph
presbyterian
colleg
school
pharmaci
clinton
sc
introduct
stress
pharmaci
student
exercis
shown
reduc
stress
therefor
would
seem
appli
lessen
stress
pharmaci
student
sleep
also
shown
decreas
stress
improv
cognit
perform
knowledg
studi
specif
found
correl
among
exercis
sleep
stress
pharmaci
student
research
question
hypothesi
evalu
associ
sleep
exercis
perceiv
stress
pharmaci
school
student
studi
design
observ
electron
survey
method
first
second
third
year
pharmaci
student
presbyterian
colleg
school
pharmaci
receiv
electron
survey
evalu
amount
time
spent
exercis
type
exercis
perform
amount
sleep
perceiv
stress
scale
perceiv
stress
scale
use
assess
particip
percept
stress
previou
month
particip
score
total
group
base
particip
exercis
sleep
sex
race
graduat
class
age
result
survey
respons
rate
elig
pharmaci
student
first
year
student
second
year
student
third
year
student
found
mean
perceiv
stress
scale
score
higher
pharmaci
student
compar
gener
unit
state
popul
associ
perceiv
stress
either
age
race
sex
year
pharmaci
school
exercis
per
day
exercis
per
week
exercis
howev
slept
least
seven
hour
night
versu
slept
six
less
significantli
lower
perceiv
stress
scale
score
p
conclus
pharmaci
student
sleep
least
seven
hour
per
night
lower
stress
level
compar
get
less
sleep
student
pharmacist
confid
commun
skill
healthcar
practition
seminar
cours
kimberli
barefield
carolin
champion
brent
rollin
r
ph
pharmaci
philadelphia
colleg
osteopath
medicin
georgia
campu
suwane
ga
pharmaci
philadelphia
colleg
osteopath
georgia
campu
suwane
ga
introduct
compet
pharmaci
practic
requir
profici
commun
pharmacotherapi
inform
literatur
recommend
healthcar
profession
given
limit
research
skill
taught
seminar
cours
third
year
curriculum
design
strengthen
skill
abil
evalu
research
question
hypothesi
impact
seminar
cours
student
confid
commun
drug
literatur
evalu
skill
studi
design
prospect
pre
post
cohort
survey
design
method
student
inform
studi
intent
particip
voluntari
affect
cours
grade
student
receiv
survey
semest
begin
end
survey
assess
confid
variou
specif
commun
literatur
evalu
use
strongli
agre
scale
addit
demograph
inform
student
previou
experi
current
internship
experi
collect
descript
statist
pair
student
use
assess
research
question
comparison
base
student
demograph
result
possibl
student
respons
rate
complet
pre
post
survey
remain
student
either
particip
fill
one
two
survey
overal
student
slightli
agre
confid
commun
literatur
evalu
skill
evalu
commun
drug
interact
least
confid
area
significantli
confid
four
measur
area
comparison
statist
signific
differ
measur
demograph
gender
age
previou
degre
intern
experi
cours
grade
conclus
seminar
cours
result
posit
chang
student
percept
confid
commun
healthcar
profession
abil
evalu
drug
literatur
impact
naloxon
train
healthcar
student
comfort
level
abil
adequ
counsel
patient
bystand
naloxon
administr
sara
kjerengtroen
bs
crystal
kuzyk
catherin
derington
shaun
gleason
pharmd
dana
hammer
phd
megan
thompson
school
pharmaci
pharmaceut
scienc
univers
colorado
aurora
co
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
experienti
servic
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
sinc
number
death
unit
state
increas
current
standard
naloxon
train
healthcar
student
howev
implement
increas
naloxon
access
student
inevit
provid
patient
educ
combat
opioid
epidem
research
question
hypothesi
naloxon
train
healthcar
student
impact
abil
understand
comfort
level
counsel
patient
bystand
naloxon
administr
studi
design
anonym
survey
method
interprofession
healthcar
student
univers
colorado
invit
attend
naloxon
train
led
pharmaci
student
earli
train
element
includ
naloxon
naloxon
formul
administr
respond
opioid
overdos
patient
counsel
student
complet
assess
student
comfort
level
train
abil
counsel
bystand
naloxon
administr
naloxon
profil
bystand
naloxon
administr
use
likert
scale
respons
dichotom
agre
disagre
primari
endpoint
proport
student
felt
adequ
train
secondari
endpoint
includ
understand
naloxon
comfort
level
counsel
patient
naloxon
descript
statist
conduct
survey
respons
result
student
attend
train
complet
respect
student
affirm
answer
adequ
train
counsel
patient
naloxon
administr
increas
student
understand
naloxon
increas
student
comfort
level
counsel
patient
naloxon
administr
improv
conclus
studi
demonstr
naloxon
train
session
consider
improv
healthcar
student
abil
understand
comfort
level
counsel
patient
bystand
naloxon
administr
profession
school
consid
includ
standard
naloxon
train
student
util
medicin
garden
activ
achiev
cape
domain
juli
kalabalik
pharmd
bcp
bcccp
malgorzata
slugocki
pharm
ays
elif
ozden
pharm
bcacp
cde
anna
dushenkov
bs
pharm
pharmd
maria
leibfri
bs
pharmd
lillian
rozakli
ligia
westrich
phd
pharmaci
practic
fdu
school
pharmaci
health
scienc
florham
park
nj
dickinson
univers
school
pharmaci
health
scienc
florham
park
nj
practic
fairleigh
dickinson
univers
school
pharmaci
health
scienc
florham
park
nj
introduct
educ
patient
natur
product
paramount
accp
white
paper
natur
product
medicin
garden
activ
develop
address
cape
domain
identifi
curricular
gap
first
profession
year
student
opt
creat
medicin
plant
handout
plant
assign
speci
educ
peer
faculti
patient
local
transit
hous
program
research
question
hypothesi
determin
use
medicin
garden
activ
achiev
cape
domain
studi
design
prospect
observ
cohort
studi
method
student
particip
activ
divid
group
group
assign
one
medicin
plant
creat
handout
one
patient
one
healthcar
profession
faculti
evalu
handout
present
use
rubric
map
element
activ
specif
outcom
object
within
cape
domain
smog
readabl
test
use
estim
handout
read
level
student
answer
one
percept
question
cultur
awar
survey
data
analyz
use
descript
statist
result
base
rubric
student
met
cape
object
patient
handout
demonstr
observ
decreas
read
grade
level
compar
healthcar
profession
handout
student
demonstr
profession
commun
clearli
statist
signific
differ
agreement
rate
mean
detect
activ
compar
activ
vs
percept
question
conclus
medicin
garden
activ
facilit
student
achiev
aforement
outcom
object
cape
domain
futur
deliveri
activ
focu
improv
student
attain
cape
object
incorpor
audienc
assess
enhanc
student
knowledg
medicin
plant
medicin
garden
activ
juli
kalabalik
pharmd
bcp
bcccp
maria
leibfri
bs
pharmd
malgorzata
slugocki
pharm
ays
elif
ozden
pharm
bcacp
cde
anna
dushenkov
bs
pharm
pharmd
lillian
rozakli
ligia
westrich
phd
pharmaci
practic
fdu
school
pharmaci
health
scienc
florham
park
nj
practic
fairleigh
dickinson
univers
school
pharmaci
health
scienc
florham
park
nj
dickinson
univers
school
pharmaci
health
scienc
florham
park
nj
introduct
role
pharmacist
educ
patient
natur
product
recogn
accp
white
paper
natur
product
appendix
acp
standard
learn
integr
pharmaci
educ
enhanc
didact
curriculum
medicin
garden
activ
develop
provid
student
opportun
increas
knowledg
gain
integr
pharmacotherapi
cours
first
profession
year
research
question
hypothesi
determin
use
medicin
garden
activ
increas
student
knowledg
medicin
plant
studi
design
prospect
cohort
studi
method
student
particip
activ
divid
group
group
assign
one
medicin
plant
creat
healthcar
profession
handout
present
faculti
peer
student
answer
question
present
respons
analyz
use
exact
mcnemar
test
descript
statist
result
student
complet
pre
post
test
percentag
student
answer
least
question
correctli
increas
pre
vs
post
p
statist
signific
increas
test
mean
activ
compar
activ
vs
p
percentag
correct
respons
increas
numer
question
statist
signific
four
question
show
minim
decreas
correct
respons
conclus
knowledg
gain
medicin
garden
activ
evid
base
signific
improv
mean
test
score
due
success
program
activ
expand
includ
entir
first
year
student
cohort
descript
assess
pilot
interprofession
drug
compat
simul
elizabeth
covington
jill
hightow
msn
greg
gorman
school
pharmaci
samford
univers
birmingham
al
moffett
school
nurs
samford
univers
birmingham
al
introduct
interprofession
educationcollabor
ipec
core
compon
pharmaci
curricula
import
assess
efficaci
simul
design
increas
ipec
compet
interprofession
simul
pharmaci
nurs
student
design
explor
drug
compat
use
actual
iv
tube
pump
research
question
hypothesi
evalu
effect
interprofession
drug
compat
simul
student
growth
ipec
compet
studi
design
student
complet
anonym
electron
event
survey
via
qualtric
method
pharmaci
nurs
student
invit
particip
voluntari
simul
prior
particip
ident
immedi
follow
survey
establish
likert
scale
survey
base
ipec
compet
student
work
togeth
accomplish
simul
event
analyz
drug
compat
two
commonli
medic
vancomycin
piperacillintazobactam
varieti
differ
concentr
differ
iv
tube
length
iv
medic
prepar
pharmaci
student
iv
pump
prime
program
nurs
student
student
collabor
collect
analyz
sampl
use
ph
turbid
high
perform
liquid
chromatographi
hplc
visual
inspect
descript
statist
perform
survey
data
result
five
student
particip
event
survey
respons
rate
student
versu
survey
data
suggest
improv
compet
interprofession
interact
valu
domain
averag
interact
domain
score
compar
score
averag
valu
domain
score
compar
score
survey
question
largest
chang
relat
engag
health
profession
problem
solv
construct
manag
disagr
conclus
pilot
ipe
simul
event
show
improv
ipec
domain
interact
valu
warrant
evalu
larger
scale
examin
job
avail
requir
qualif
critic
care
pharmaci
posit
kevin
vanmaldeghem
bachelor
scienc
nanci
doctor
pharmaci
univers
tennesse
health
scienc
center
nashvil
tn
clinic
pharmaci
translat
scienc
univers
tennesse
health
scienc
center
colleg
pharmaci
nashvil
tn
introduct
often
impli
clinic
pharmaci
specialist
form
advanc
train
requir
pharmacist
wish
critic
care
pharmaci
specialist
opportun
knowledg
complet
critic
care
pursu
board
certif
critic
care
pharmaci
bcccp
research
question
hypothesi
identifi
qualif
employ
look
critic
care
pharmaci
specialist
examin
job
post
studi
design
descript
retrospect
evalu
method
locat
job
job
search
engin
inde
use
search
took
place
januari
search
phrase
critic
care
pharmacist
use
job
includ
full
time
posit
take
place
exclus
critic
care
set
icu
ccu
etc
job
exclud
part
time
posit
specifi
critic
care
specialist
result
total
result
return
met
inclus
criteria
requir
doctor
pharmaci
degre
requir
complet
pharmaci
resid
equival
experi
year
practic
six
prefer
complet
resid
equival
experi
year
practic
requir
complet
resid
equival
experi
board
certif
requir
posit
anoth
singular
posit
requir
board
certif
within
year
hire
howev
job
prefer
board
certif
conclus
experi
major
requir
came
job
post
critic
care
pharmaci
posit
complet
resid
minimum
job
post
board
certif
may
appeal
employ
minimum
requir
point
critic
care
pharmaci
job
train
pharmaci
student
use
medic
interpret
prospect
random
control
trial
cole
smith
doctor
pharmaci
school
pharmaci
west
virginia
univers
morgantown
wv
introduct
littl
known
well
pharmaci
school
prepar
student
util
medic
interpret
care
patient
limit
english
profici
lep
research
question
hypothesi
instruct
session
interpret
util
improv
compet
confid
pharmaci
student
use
profession
medic
interpret
studi
design
random
prospect
blind
control
trial
student
randomli
divid
fashion
either
test
group
receiv
didact
instruct
lesson
util
medic
interpret
control
group
receiv
train
method
student
underw
medic
reconcili
simul
involv
lep
patient
util
interpret
student
complet
confid
level
survey
use
likert
scale
formal
evalu
compet
use
faculti
observ
rate
scale
for
valid
interpret
util
score
tool
confid
level
survey
complet
twice
test
group
didact
train
control
group
primari
outcom
differ
mean
total
for
score
group
use
assum
equal
varianc
secondari
outcom
descript
statist
use
analyz
differ
student
confid
level
test
group
complet
didact
train
session
well
compar
control
group
result
control
group
averag
for
score
compar
test
group
overal
median
confid
survey
control
group
train
test
group
train
test
group
conclus
studi
suggest
one
hour
interpret
train
session
improv
student
confid
abil
util
interpret
care
lep
patient
incorpor
learn
introductori
pharmaci
practic
experi
jonathan
cho
pharmd
bcp
fadi
alkhateeb
bspharm
mba
phd
faacp
lane
brunner
phd
rph
colleg
pharmaci
univers
texa
tyler
tyler
tx
introduct
introductori
pharmaci
practic
experi
ipp
essenti
learn
experi
doctor
pharmaci
curriculum
variou
approach
optim
pharmaci
student
learn
ipp
employ
chang
pedagog
strategi
use
learn
tbl
vast
knowledg
first
studi
incorpor
formal
activ
pharmaci
experienti
educ
research
question
hypothesi
perspect
pharmaci
student
regard
use
tbl
pedagogi
ipp
studi
design
studi
method
electron
survey
distribut
via
third
year
pharmaci
student
enrol
ipp
spring
data
relat
student
demograph
inform
level
confid
perform
duti
percept
tbl
collect
asid
demograph
inform
respons
format
via
likert
scale
strongli
disagreenot
confid
strongli
agreeextrem
confid
result
total
pharmaci
student
complet
survey
provid
respons
rate
greater
pharmaci
student
either
agre
strongli
agre
tbl
activ
better
prepar
work
collabor
team
mean
likert
score
prepar
commun
effect
reinforc
individu
learn
allow
understand
thought
process
addit
pharmaci
student
either
agre
strongli
agre
ipp
better
prepar
advanc
pharmaci
practic
experi
prefer
ipp
base
ipp
believ
tbl
continu
incorpor
experienti
experi
conclus
pharmaci
student
perceiv
formal
tbl
pedagogi
benefici
experienti
learn
experi
prefer
ipp
base
ipp
differ
pedagog
method
learn
consid
set
outsid
didact
pharmaci
curriculum
medic
student
resid
percept
ambulatori
pharmaci
one
year
interprofession
collabor
adult
medicin
even
clinic
ami
yanicak
pharmd
mph
karen
white
pharmaci
practic
univers
washington
charlott
nc
pharmaci
practic
univers
washington
seattl
wa
introduct
medic
student
resid
interact
pharmaci
student
pharmacist
part
interprofession
educ
requir
colleg
medicin
unknown
interact
clinic
ambulatori
care
pharmacist
impact
percept
pharmacist
research
question
hypothesi
end
weekli
clinic
experi
medic
student
work
clinic
pharmacist
would
greater
confid
ambulatori
care
pharmacist
abil
assign
pharmacist
respons
studi
design
intervent
studi
method
item
survey
develop
demograph
question
likert
scale
question
one
question
given
medic
student
resid
preceptor
begin
august
end
may
medic
student
even
clinic
data
collect
analyz
descript
result
complet
respond
previous
work
pharmacist
vari
set
begin
even
clinic
pharmacist
consult
servic
experi
respond
averag
averag
understand
servic
pharmacist
provid
ambulatori
care
state
pharmacist
respons
diagnosi
likert
scale
end
even
clinic
experi
respond
felt
pharmacist
respons
diagnosi
felt
pharmacist
respons
medic
counsel
like
consult
pharmacist
patient
clinic
conclus
result
indic
mani
medic
student
resid
prior
exposur
work
pharmacist
understand
pharmacist
role
contribut
patient
care
even
clinic
experi
may
chang
perspect
regard
ambulatori
care
pharmaci
research
need
done
determin
specif
area
chang
perspect
pedagog
util
student
pharmacogenom
test
result
counsel
ami
liu
bs
jose
tinajero
sam
oh
phd
tejal
desai
b
joseph
guglielmo
su
guo
alan
wu
esteban
burchard
md
pharmaci
univers
california
san
francisco
san
francisco
ca
univers
california
san
francisco
san
francisco
ca
therapeut
scienc
univers
california
san
francisco
san
francisco
ca
medicin
univers
california
san
francisco
san
francisco
ca
introduct
low
presenc
educ
profession
school
curricula
may
impact
accept
precis
medicin
clinic
practic
previou
studi
shown
posit
effect
integr
person
pharmacogenet
test
educ
futur
healthcar
provid
howev
util
singl
interact
classroom
session
remain
determin
research
question
hypothesi
profession
student
knowledg
attitud
appli
pharmacogenom
chang
person
anonym
popul
result
reveal
classroom
session
studi
design
ucsf
school
pharmaci
doctor
pharmd
student
complet
onlin
survey
pharmacogenet
result
reveal
day
requir
pharmacogenom
cours
method
research
electron
data
captur
softwar
anonym
baselin
survey
assess
student
knowledg
attitud
pharmacogenom
use
likert
scale
subject
consent
dtc
pharmacogenet
test
enrol
applic
program
interfac
api
result
report
receiv
person
result
revel
anonym
popul
frequenc
classroom
reveal
day
student
particip
clinic
counsel
exercis
center
around
common
allel
variant
enzym
eg
cytochrom
survey
survey
result
compar
use
wilcoxon
test
test
consid
statist
signific
result
found
statist
signific
improv
student
knowledg
likert
point
attitud
likert
point
pharmacogenom
follow
dtc
pharmacogenet
test
api
result
report
clinic
counsel
exercis
conclus
find
highlight
appli
pharmacogenom
educ
led
measur
chang
pharmd
student
knowledg
pharmacogenom
modest
effect
student
attitud
toward
pharmacogenom
singl
interact
reveal
day
support
previou
find
pharmacogenom
cours
futur
studi
investig
persist
effect
novel
interprofession
educ
includ
commun
pharmaci
clinic
emerg
room
mari
beth
oconnel
stephani
gilkey
ms
ami
derecyzk
ms
joseph
fava
constanc
burk
ms
practic
depart
wayn
state
univers
eugen
applebaum
colleg
pharmaci
health
scienc
detroit
mi
assist
program
univers
flint
mi
assist
program
univers
detroit
merci
colleg
health
profess
detroit
mi
introduct
interprofession
educ
ipe
care
ipc
import
rare
integr
commun
pharmaci
site
import
transit
care
research
question
hypothesi
ipe
pharmaci
pharmd
physician
assist
pa
student
team
increas
ipc
attitud
skill
studi
design
survey
skill
assess
method
twenti
pharmd
pa
student
team
practic
commun
pharmaci
day
clinic
emerg
room
day
structur
ipc
curriculum
team
occur
daili
outcom
anonym
complet
valid
attitud
toward
healthcar
team
survey
team
observ
structur
clinic
encount
tosc
modifi
assess
tool
observ
train
descript
perform
spss
signific
irb
exempt
result
ipc
attitud
posit
program
mean
high
scale
signific
chang
student
felt
ipc
effici
pharmd
pa
student
overal
similar
view
differ
includ
pharmd
student
becam
posit
physician
legal
respons
team
chang
vs
pa
patient
better
prepar
discharg
chang
vs
pa
student
felt
ipe
ipc
increas
patient
healthcar
commun
skill
understand
patient
problem
intervent
futur
ipc
skill
decreas
error
student
felt
ipe
worthwhil
continu
student
perform
prepost
tosc
mean
standard
deviat
high
scale
team
significantli
increas
commun
vs
collabor
vs
role
respons
vs
care
vs
conflict
manag
vs
team
function
vs
conclus
ipeipc
includ
commun
pharmaci
improv
pharmd
pa
student
skill
felt
improv
healthcar
qualiti
safeti
ipc
attitud
posit
tosc
captur
ipc
skill
develop
impact
elect
appli
improvis
cours
student
pharmacist
patient
commun
skill
ann
graff
ladisa
pharmd
bcp
sarah
ray
pharmd
bcp
fapha
depart
pharmaci
practic
concordia
univers
wisconsin
school
pharmaci
mequon
wi
introduct
excel
commun
skill
essenti
clinic
pharmaci
practic
appli
improvis
ai
offer
innov
strategi
strengthen
student
commun
skill
studi
report
ai
use
medic
educ
requir
pharmaci
student
cours
convers
littl
data
elect
cours
pharmaci
student
use
ai
activ
learn
workshop
format
enhanc
commun
skill
research
question
hypothesi
student
complet
ai
cours
demonstr
perceiv
superior
commun
simul
patient
encount
spe
compar
student
complet
ai
cours
studi
design
student
commun
skill
spe
evalu
via
rubric
fashion
student
complet
commun
skill
percept
survey
ai
cours
student
rate
percept
compar
student
complet
ai
cours
method
student
particip
spe
appli
patient
care
cours
requir
skill
commun
use
student
commun
skill
encount
evalu
investig
use
intern
valid
rubric
student
abil
listen
well
use
empathet
respons
display
confid
spontan
evalu
encount
student
ask
complet
likert
scale
survey
assess
percept
commun
skill
encount
result
eight
student
complet
ai
cours
student
complet
ai
cours
evalu
spe
statist
differ
ai
cours
student
perform
listeningrespond
spontaneityconfid
respect
student
percept
skill
ai
group
group
statist
signific
overal
commun
score
conclus
student
complet
ai
cours
demonstr
perceiv
superior
commun
spe
compar
student
complet
ai
cours
small
number
student
intervent
group
hinder
abil
detect
signific
differ
global
health
learn
outcom
compet
among
pharmaci
student
david
steeb
pharmd
mph
monica
l
miller
pharmd
ellen
schellhas
jodi
malhotra
stuart
hain
eshelman
school
pharmaci
chapel
hill
nc
pharmaci
practic
purdu
univers
colleg
pharmaci
west
lafayett
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
aurora
co
practic
univers
mississippi
school
pharmaci
jackson
ms
introduct
two
third
us
schoolscolleg
pharmaci
offer
intern
app
limit
data
regard
impact
experi
studi
purpos
assess
learn
outcom
global
health
compet
student
pharmacist
particip
intern
app
research
question
hypothesi
intern
app
rotat
student
larger
level
growth
regard
global
health
particip
intern
app
rotat
studi
design
design
use
retrospect
questionnair
method
fourth
year
student
pharmacist
particip
intern
app
match
peer
complet
intern
app
base
age
rotat
schedul
cohort
took
retrospect
questionnair
assess
abil
meet
thirteen
basic
global
health
compet
defin
consortium
univers
global
health
use
likert
scale
intern
app
cohort
answer
addit
question
regard
knowledg
skill
attitud
gain
enhanc
intern
rotat
survey
data
within
cohort
analyz
spss
use
wilcoxon
sign
rank
test
u
test
differ
cohort
data
code
categor
theme
result
among
student
complet
intern
app
score
thirteen
basic
global
health
compet
statement
significantli
increas
p
largest
posit
growth
chang
intern
app
cohort
app
cohort
describ
major
public
health
effort
reduc
dispar
global
health
vs
p
role
major
entiti
influenc
global
health
vs
p
major
theme
code
regard
knowledg
skill
attitud
gain
limit
resourc
util
commun
cultur
appreci
respect
conclus
intern
app
rotat
strengthen
basic
global
health
compet
provid
opportun
impact
learn
increas
odd
match
implement
resid
advis
program
leigh
gravatt
krista
l
donoho
benjamin
van
tassel
abigal
matulewicz
lauren
pamulapati
lauren
calda
emili
peron
pharmd
pharmacotherapi
outcom
scienc
virginia
commonwealth
univers
school
pharmaci
richmond
va
commonwealth
univers
richmond
va
pharmaci
virginia
commonwealth
univers
richmond
va
pharmacotherapi
outcom
scienc
vcu
school
pharmaci
richmond
va
pharmacotherapi
outcom
scienc
virginia
commonweatlh
univers
school
pharmaci
richmond
va
introduct
american
colleg
clinic
pharmaci
accp
advoc
postgradu
year
resid
requir
pharmacist
particip
direct
patient
care
activ
current
number
resid
applic
exce
number
resid
slot
resid
advis
program
rap
develop
initi
fall
virginia
commonwealth
univers
vcu
school
pharmaci
sop
fourth
year
pharmaci
student
voluntarili
enrol
program
includ
faculti
mentorship
podcast
seri
explain
resid
andor
fellowship
applic
process
mock
video
interview
phase
ii
match
assist
research
question
hypothesi
enrol
rap
vcu
increas
odd
student
achiev
resid
fellowship
studi
design
retrospect
analysi
resid
match
rate
fellowship
placement
among
fourth
year
student
vcu
method
student
particip
nation
pharmaci
match
vcu
retrospect
divid
two
student
enrol
rap
versu
match
rate
fellowship
placement
compar
two
group
descript
statist
use
compar
two
group
result
total
student
particip
rap
match
process
versu
student
particip
match
alon
match
percentag
significantli
higher
student
particip
rap
versu
student
versu
p
student
significantli
higher
odd
match
resid
place
fellowship
enrol
program
ci
conclus
student
vcu
sop
success
obtain
resid
fellowship
particip
rap
evalu
knowledg
warfarin
manag
famili
medicin
resid
clinic
ami
robertson
raghuv
vedala
jessica
kieffer
jeena
georg
kari
nilsen
pharmaci
practic
univers
kansa
school
pharmaci
wichita
ks
famili
medicin
resid
program
wichita
ks
famili
commun
medicin
univers
kansa
school
medicin
wichita
ks
introduct
warfarin
manag
challeng
due
narrow
therapeut
window
resid
train
clinic
present
addit
challeng
warfarin
therapi
manag
limit
data
regard
knowledg
manag
warfarin
resid
train
facil
appropri
warfarin
manag
necessari
minim
advers
effect
therefor
essenti
ensur
resid
physician
understand
appli
principl
warfarin
manag
clinic
practic
research
question
hypothesi
impact
educ
resid
physician
knowledg
comfort
regard
warfarin
manag
studi
design
qualiti
improv
studi
conduct
famili
medicin
resid
clinic
method
particip
resid
physician
given
baselin
questionnair
regard
gener
accept
guidelin
best
practic
manag
warfarin
therapi
resid
comfort
level
treat
patient
warfarin
also
assess
use
seven
question
likert
scale
follow
resid
given
didact
lectur
resid
complet
questionnair
immedi
follow
lectur
one
month
lectur
assess
knowledg
retain
chang
comfort
level
primari
outcom
differ
knowledg
score
questionnair
secondari
outcom
includ
differ
comfort
level
score
retent
knowledg
descript
analysi
exact
sign
test
use
assess
studi
aim
appropri
result
thirteen
potenti
resid
attend
didact
session
five
seventeen
question
assess
resid
knowledg
signific
posit
differ
number
correct
respons
analysi
reveal
signific
chang
knowledg
result
didact
session
p
sustain
one
month
signific
chang
level
p
sustain
one
month
conclus
resid
knowledg
warfarin
manag
significantli
improv
educ
util
examsoft
examin
administr
platform
pharmaci
student
perspect
sam
harirforoosh
pharmd
phd
depart
pharmaceut
scienc
east
tennesse
state
univers
johnson
citi
tn
introduct
pharmacokinet
hour
cours
offer
student
five
examin
test
consist
question
administ
class
although
instructor
school
implement
examsoft
test
take
use
pharmacokinet
exam
research
question
hypothesi
object
studi
evalu
student
prefer
use
two
platform
examsoft
administr
exam
studi
design
exploratori
survey
method
student
view
examin
softwar
usag
evalu
three
question
includ
anonym
summ
survey
conduct
academ
affair
offic
likert
scale
disagre
agre
util
semest
end
survey
local
institut
review
board
consid
current
project
human
subject
research
result
class
student
respons
found
question
question
show
respons
rate
vast
major
respond
agre
strongli
agre
pharmacokinet
exam
administ
seem
like
good
idea
question
similar
respons
observ
ask
whether
would
recommend
usag
futur
pharmacokinet
exam
question
addit
respond
agre
strongli
agre
prefer
use
compar
examsoft
examin
question
conclus
result
studi
show
pharmaci
student
prefer
examsoft
usag
gener
howev
due
low
respons
rate
research
may
warrant
confirm
result
pharmaci
without
border
global
classroom
lindsey
edward
pharmd
candid
li
yang
jefferi
cain
rongsheng
zhao
frank
romanelli
pharmd
melodi
ryan
pharmd
mph
fccp
bcp
kentucki
colleg
pharmaci
lexington
ky
pharmaci
peke
univers
third
hospit
beij
china
pharmaci
practic
scienc
univers
kentucki
colleg
pharmaci
lexington
ky
introduct
elect
global
classroom
cours
develop
implement
focus
expos
student
principl
healthcar
american
chines
cultur
well
challeng
student
appli
concept
across
differ
cultur
system
cours
compris
six
live
lectur
lectur
us
student
pair
chines
student
instant
messag
applic
use
pair
commun
facilit
group
work
live
session
conclus
cours
pair
execut
present
research
question
hypothesi
particip
cours
result
higher
global
citizenship
scale
gc
score
studi
design
pretestposttest
studi
method
student
complet
gc
begin
conclus
cours
scale
rang
strongli
disagre
strongli
agre
assess
global
citizenship
principl
social
respons
global
compet
global
civic
engag
student
pair
use
compar
observ
mean
differ
calcul
p
valu
result
student
complet
survey
nine
complet
survey
allow
nine
set
pair
data
gc
yield
mean
gc
mean
mean
differ
statist
signific
averag
increas
p
conclus
studi
found
statist
signific
increas
gc
score
complet
cours
due
lack
return
survey
sampl
size
small
nine
student
limit
studi
rapidli
grow
chang
technolog
world
peopl
across
globe
connect
ever
therefor
find
way
improv
global
citizenship
cultur
compet
paramount
implement
global
classroom
seek
foster
principl
student
career
prepar
collabor
two
pharmaci
school
result
joint
career
fair
fahraj
ahm
pharmd
candid
lydia
girgi
pharmd
lilliana
gonzal
pharmd
danh
nguyen
pharmd
sabrina
haj
pharmd
jennif
suarez
pharmd
randi
martin
pharmd
krystal
edward
pharmd
fccp
pharmaci
texa
tech
univers
health
scienc
center
dalla
tx
pharmaci
univers
north
texa
health
scienc
center
fort
worth
tx
introduct
career
prepar
event
valu
student
institut
alik
mani
exampl
success
jointli
organ
career
event
among
school
collabor
pharmaci
school
fairli
common
particularli
experienti
educ
assess
despit
exist
partnership
literatur
scarc
come
collabor
career
event
host
pharmaci
school
research
question
hypothesi
differ
percept
among
student
vendor
faculti
career
event
collabor
two
school
studi
design
four
survey
develop
administ
qualtric
joint
career
fair
survey
util
question
method
career
fair
consist
twelv
workshop
interact
session
along
career
expo
student
school
receiv
faculti
vendor
receiv
one
primari
object
evalu
student
fair
percept
secondari
object
evalu
faculti
member
vendor
percept
irb
approv
research
descript
statist
along
wilcoxon
fisher
exact
test
use
statist
analysi
appropri
use
stata
softwar
result
student
found
benefici
interact
school
unt
student
found
collabor
school
benefici
compar
ttu
student
p
time
vendor
rate
collabor
event
posit
survey
support
continu
event
faculti
member
report
collabor
two
school
enhanc
workshop
review
room
mock
interview
varieti
vendor
overal
qualiti
event
faculti
agre
ttu
unt
continu
offer
event
conclus
although
percept
student
vari
gener
consensu
among
student
found
benefici
interact
student
school
faculti
vendor
overwhelmingli
favor
conduct
futur
develop
evalu
gener
medicin
elect
cours
alexa
carlson
pharmd
bcp
margarita
v
dival
pharmd
med
mark
douglass
michael
j
gonyeau
bspharm
pharmd
med
bcp
jason
lancast
pharmd
stephani
sibicki
pharmd
bcp
adam
b
woolley
pharmd
univers
school
pharmaci
boston
pharmaci
northeastern
univers
boston
univers
depart
pharmaci
practiceboston
medic
center
boston
univers
boston
univers
depart
pharmaci
practic
boston
present
american
meet
amercian
assoc
colleg
pharmaci
nashvil
tn
juli
impact
clinic
pharmaci
program
pharmaci
resid
nicol
coglianes
jenni
jarrett
pharmd
bcp
mmede
pharmaci
univers
illinoi
chicago
chicago
il
pharmaci
depart
pharmaci
practic
univers
illinoi
chicago
chicago
il
introduct
program
innov
learn
opportun
within
pharmaci
resid
assist
resid
foster
critic
think
skill
commun
skill
clinic
autonomi
object
studi
determin
educ
profession
impact
univers
illinoi
chicago
uic
program
pharmaci
resid
alumni
research
question
hypothesi
uic
program
high
educ
valu
pharmaci
resid
across
multipl
therapeut
knowledg
area
support
resid
particip
across
multipl
specialti
variou
type
health
profession
studi
design
prospect
survey
design
method
prospect
survey
conduct
march
april
among
resid
alumni
particip
uic
pharmaci
resid
program
primari
object
evalu
educ
impact
program
includ
valu
program
pharmacotherapeut
knowledg
profession
skill
secondari
outcom
includ
profession
impact
program
pharmaci
resid
career
trajectori
interprofession
outcom
quantit
result
analyz
use
descript
statist
result
pharmaci
resid
alumni
respond
electron
survey
program
respons
rate
overal
alumni
report
high
satisfact
posit
percept
program
highli
valuabl
compon
resid
program
pharmaci
resid
report
particip
varieti
clinic
practic
activ
across
mani
specialti
id
critic
care
emerg
medicin
gener
medicin
lastli
program
highli
interprofession
experi
allow
interact
varieti
health
care
provid
physician
nurs
pharmacist
advanc
practic
provid
conclus
uic
program
provid
overal
posit
experi
pharmaci
resid
expos
varieti
pharmacotherapeut
knowledg
area
also
strengthen
clinic
skill
furthermor
uic
program
report
highli
interprofession
experi
impact
skill
laboratori
bonu
assign
jeanna
sewel
pharmd
bcacp
kristi
kelley
pharmd
fccp
bcp
cde
pamela
stamm
pharmd
bcp
bcacp
cde
pharmaci
practic
auburn
univers
harrison
school
pharmaci
auburn
al
univers
harrison
school
pharmaci
birmingham
al
introduct
student
appear
put
less
effort
prepar
skill
laboratori
therefor
bonu
assign
implement
improv
student
prepar
research
question
hypothesi
determin
student
percept
benefit
impact
bonu
assign
student
perform
third
profession
year
skill
laboratori
cours
studi
design
investig
conduct
retrospect
analysi
impact
bonu
assign
offer
prepar
three
laboratori
activ
idaho
plate
method
ipm
educ
algorithm
base
insulin
adjust
immun
recommend
util
vaccin
schedul
third
profession
year
skill
laboratori
cours
method
activ
avail
student
complet
lectur
prior
laboratori
activ
impact
assess
compar
relev
examin
question
object
structur
clinic
examin
osc
item
score
bonu
assign
complet
student
ask
perceiv
help
bonu
activ
prepar
lab
exam
osc
item
score
evalu
use
descript
statist
use
assess
student
survey
respons
result
respect
complet
ipm
complet
insulin
complet
immun
complet
vs
averag
score
relev
insulin
ipm
exam
item
relev
ipm
immun
osc
item
statist
differ
student
evalu
complet
show
ipm
insulin
immun
student
perceiv
bonu
activ
help
help
prepar
lab
conclus
bonu
assign
provid
opportun
practic
skill
gain
confid
subject
area
allow
student
prepar
particip
laboratori
activ
activ
appear
improv
assess
score
illustr
appropri
bonu
activ
rather
requir
prepar
correl
intern
extern
characterist
depress
symptom
pharmaci
resid
resid
year
evan
william
pharmd
mba
marissa
ross
pharmd
candid
samahn
soleimanian
pharmd
candid
vasudha
gupta
pharmd
colleg
pharmaci
roseman
univers
health
scienc
henderson
nv
introduct
recent
publish
data
indic
pharmaci
resid
experi
high
level
depress
symptom
symptom
correl
specif
factor
data
present
specif
correl
depress
symptom
highlight
chang
resid
year
research
question
hypothesi
factor
correl
depress
symptom
pharmaci
resid
chang
resid
year
studi
design
studi
conduct
method
nationwid
onlin
survey
pharmaci
resid
gather
demograph
data
assess
rate
depress
symptom
use
patient
health
questionnair
time
point
throughout
resid
year
factor
within
resid
extern
factor
correl
score
greater
indic
high
likelihood
depress
use
logist
regress
control
concomit
diagnosi
treatment
depress
result
survey
sent
program
nation
yield
respons
averag
time
point
juli
signific
correl
depress
symptom
work
outsid
resid
director
support
novemb
exercis
relationship
adequ
sleep
higher
incom
level
protect
depress
symptom
p
directorpreceptor
support
hour
work
effect
teach
method
program
organ
stress
level
relat
resid
strongli
correl
depress
symptom
p
factor
persist
march
ad
likelihood
made
major
medic
error
p
incom
level
longer
protect
june
director
support
made
major
medic
error
resid
relat
factor
associ
depress
symptom
conclus
exercis
sleep
close
person
relationship
protect
depress
symptom
throughout
resid
factor
includ
hour
work
effect
teach
method
program
organ
stress
level
associ
depress
symptom
novemb
march
larg
resolv
june
director
support
signific
intern
correl
throughout
resid
year
student
percept
simul
electron
medic
record
use
valu
within
introductori
experienti
pharmaci
cours
olga
hila
pharmd
mph
tina
caliendo
pharmd
clinic
health
profess
st
john
univers
queen
ny
introduct
first
profession
year
student
doctor
pharmaci
program
st
john
univers
requir
success
complet
introductori
experienti
pharmaci
cours
simul
activ
util
within
cours
introduc
student
variou
area
pharmaci
practic
patient
care
experi
number
cours
activ
recent
incorpor
use
simul
electron
medic
record
emr
determin
valu
program
student
learn
research
question
hypothesi
simul
emr
valuabl
learn
tool
pharmaci
student
studi
design
qualit
descript
studi
method
survey
develop
email
pharmaci
student
enrol
simul
introductori
experienti
pharmaci
cours
complet
survey
voluntari
inform
collect
done
anonym
result
total
student
complet
survey
overal
student
respond
strongli
agre
agre
simul
emr
import
realist
valuabl
learn
tool
introduc
student
prepar
subsequ
experienti
cours
effect
learn
pharmacist
role
transit
care
activ
continu
use
current
cours
incorpor
cours
futur
addit
student
respond
strongli
agre
agre
simul
emr
help
develop
skill
need
provid
patient
care
defin
pharmacist
patient
care
process
also
increas
confid
profession
abil
conclus
incorpor
simul
emr
introductori
experienti
pharmaci
cours
allow
effect
applic
pharmaci
principl
practic
patient
care
activ
among
pharmaci
student
effect
learn
activ
hiv
exam
score
ays
elif
ozden
pharm
bcacp
cde
aahivp
malgorzata
slugocki
pharm
fairleigh
dickinson
univers
school
pharmaci
health
scienc
florham
park
nj
introduct
acp
standard
recommend
integr
activ
learn
pharmaci
curricula
activ
learn
exercis
learn
pbl
activ
enhanc
student
critic
think
skill
skill
vital
pharmacist
work
direct
patient
care
research
question
hypothesi
determin
effect
pbl
activ
hiv
exam
score
studi
design
retrospect
cohort
analysi
method
second
profession
year
student
control
group
learn
topic
hiv
tradit
lectur
method
studi
group
student
learn
hiv
lectur
pbl
activ
group
taught
faculti
student
knowledg
assess
multipl
choic
exam
question
question
remain
cohort
studi
control
group
exam
result
compar
determin
pbl
activ
made
signific
impact
number
correct
answer
test
proport
fisher
exact
test
use
statist
signific
defin
p
result
question
includ
analysi
exam
taker
cohort
respect
statist
signific
differ
number
correct
answer
two
cohort
found
question
question
question
question
question
question
conclus
pbl
activ
modest
impact
student
exam
perform
limit
studi
pbl
activ
grade
therefor
could
affect
student
engag
retent
content
pbl
activ
futur
pbl
activ
grade
order
increas
student
particip
use
object
statement
pharmacotherapi
journal
richard
ogletre
jr
chad
burch
paig
davi
madison
ms
pharmaci
univers
mississippi
jackson
ms
introduct
intern
committe
medic
journal
editor
icmj
guidanc
submiss
origin
research
recommend
use
structur
abstract
direct
author
state
specif
purpos
research
object
hypothesi
test
studi
observ
definit
object
statement
goal
orient
howev
research
public
list
object
often
describ
process
research
rather
aim
research
question
hypothesi
proport
object
statement
includ
abstract
major
pharmacotherapi
journal
studi
design
retrospect
observ
studi
use
previous
publish
articl
method
journal
pharmacotherapi
annal
pharmacotherapi
select
use
project
request
structur
abstract
origin
research
submiss
author
instruct
review
see
except
expect
affect
articl
includ
target
articl
publish
januari
june
abstract
studi
review
object
given
two
review
character
terminolog
use
assess
articl
numer
valu
assign
verb
use
verb
valu
verb
assign
verb
deem
indetermin
valu
zero
one
object
verb
use
score
ad
score
greater
zero
necessari
classifi
articl
verb
use
util
vassarstat
result
report
proport
wilson
interv
result
articl
assess
object
statement
wilson
interv
conclus
sampl
object
statement
use
less
half
time
would
like
challeng
author
editor
review
pay
closer
attent
import
aspect
research
paper
evalu
commun
pharmacist
background
train
percept
attitud
toward
physic
assess
skill
sowndramalingam
sankaralingam
mbb
hanna
moham
bsc
yaw
owusu
pharmd
ahm
awaisu
bpharm
nadir
kheir
pharmaci
qatar
univers
doha
qatar
medic
health
scienc
univers
auckland
auckland
new
zealand
introduct
pharmacist
increasingli
involv
direct
patient
care
therefor
physic
assess
skill
becom
essenti
evalu
patient
monitor
respons
therapi
teach
skill
incorpor
curricula
sever
us
pharmaci
school
commun
pharmacist
practic
qatar
come
differ
geograph
region
vari
educ
background
research
question
hypothesi
unknown
whether
commun
pharmacist
receiv
train
physic
assess
skill
pharmaci
educ
furthermor
skill
attitud
toward
perform
skill
willing
learn
continu
profession
develop
cpd
program
unknown
studi
design
survey
conduct
among
randomli
select
sampl
commun
pharmacist
qatar
method
question
assess
pharmacist
background
train
percept
attitud
willing
learn
differ
physic
examin
skill
use
face
content
valid
pilot
conduct
expert
teach
physic
assess
skill
questionnair
develop
process
data
analyz
use
spss
version
descript
inferenti
statist
analys
appli
result
respond
receiv
train
assess
vital
sign
perceiv
compet
pharmacist
indic
perform
musculoskelet
assess
current
practic
major
respond
will
learn
physic
assess
skill
cpd
examin
ear
nose
throat
assess
drug
allergi
top
skill
will
learn
furthermor
signific
associ
formal
train
physic
assess
skill
pharmacist
perceiv
compet
perform
util
skill
practic
p
conclus
commun
pharmacist
practic
qatar
report
train
physic
assess
skill
show
willing
learn
addit
skill
guid
develop
profession
develop
session
train
practic
pharmacist
capac
conduct
multicent
emerg
pharmaci
research
unit
state
asad
e
patanwala
pharmd
kyle
weant
pharmd
bcp
fccp
nicol
acquisto
practic
scienc
univers
arizona
colleg
pharmaci
tucson
az
pharmaci
medic
univers
south
carolina
charleston
sc
pharmaci
univers
rochest
medic
center
rochest
ny
introduct
mani
singl
center
research
project
publish
field
emerg
medicin
em
pharmaci
practic
howev
multicent
research
project
rel
rare
capac
em
pharmacist
particip
project
previous
investig
research
question
hypothesi
determin
capac
nation
em
pharmaci
network
conduct
multicent
research
studi
design
nation
survey
conduct
unit
state
method
survey
develop
use
iter
process
establish
face
content
valid
question
develop
revis
survey
consid
appropri
investig
ten
em
pharmacist
geograph
divers
locat
unit
state
pilot
test
survey
refin
member
accp
em
practic
research
network
student
resid
invit
complet
survey
use
research
electron
data
captur
onlin
consent
obtain
prior
survey
complet
survey
consist
question
expect
take
less
minut
complet
data
descript
evalu
result
total
potenti
elig
particip
survey
complet
survey
respons
rate
particip
postgradu
resid
em
pharmaci
least
one
prior
public
receiv
prior
research
grant
fund
overal
will
particip
multicent
research
without
fund
will
particip
without
receiv
authorship
term
studi
function
could
particip
retrospect
acquisit
data
could
particip
observ
studi
involv
patient
consent
procedur
conclus
substanti
number
em
pharmacist
will
particip
multicent
research
number
particip
decreas
without
provis
authorship
studi
involv
patient
consent
aspirin
platelet
reactiv
test
guid
therapi
patient
traumat
intracrani
hemorrhag
darla
eastman
pharmd
bcp
nicol
draker
pharmd
carlo
pelaez
md
sarah
spilman
kelli
tang
richard
sidwel
md
univers
colleg
pharmaci
health
scienc
de
moin
ia
servic
trauma
servic
unitypoint
health
de
moin
ia
moin
univers
de
moin
ia
introduct
treatment
patient
present
traumat
intracrani
hemorrhag
tich
may
complic
patient
take
antiplatelet
medic
includ
aspirin
may
requir
emerg
revers
platelet
order
make
transfus
decis
care
team
need
determin
patient
take
antiplatelet
medic
prior
admiss
patient
therapeut
medic
research
question
hypothesi
hypothes
aspirin
platelet
reactiv
test
prt
result
could
use
quickli
ascertain
patient
take
aspirin
prior
admiss
result
could
safe
guid
aspirin
revers
patient
therapeut
medic
studi
design
retrospect
studi
patient
sustain
blunt
tich
receiv
prt
known
suspect
aspirin
use
june
decemb
level
trauma
center
method
differ
assess
test
result
patient
met
studi
inclus
criteria
patient
determin
take
aspirin
prior
admiss
prt
result
avail
approxim
hour
iqr
arriv
patient
take
aspirin
home
medic
found
aspirin
patient
spare
platelet
transfus
seven
percent
patient
clinic
signific
progress
head
bleed
differ
inhibit
transfus
statu
full
medic
reconcili
pharmacist
occur
averag
hour
irq
patient
arriv
howev
patient
home
medic
never
reconcil
conclus
appropri
test
result
suggest
platelet
reactiv
test
safe
guid
care
decis
supplement
medic
reconcili
effort
initi
hour
trauma
versu
antibiot
prophylaxi
therapi
type
iii
open
fractur
suhair
shawar
pharmd
bcp
ohio
state
wexner
medic
center
coumbu
oh
introduct
type
iii
long
bone
open
fractur
associ
infect
rate
without
antibiot
coverag
optim
antibiot
regimen
open
fractur
prophylaxi
remain
unclear
literatur
limit
compar
safeti
efficaci
differ
antibiot
regimen
research
question
hypothesi
use
type
iii
open
fractur
associ
less
ae
compar
antibiot
regimen
studi
design
singl
center
retrospect
cohort
studi
method
patient
includ
admit
hour
januari
decemb
receiv
either
tobramycin
mgkg
plu
cefazolin
clindamycin
singl
agent
open
fractur
prophylaxi
primari
outcom
rate
composit
advers
event
ae
includ
nephrotox
surgic
site
infect
ssi
hospit
readmiss
surgic
intervent
due
infect
within
day
injuri
secondari
outcom
includ
rate
ssi
within
day
injuri
student
u
test
use
continu
variabl
fischer
exact
test
use
categor
variabl
signific
consid
statist
signific
result
patient
includ
studi
patient
tobramycin
group
patient
experienc
least
one
ae
compar
patient
group
overal
composit
ae
score
event
event
tobramycin
group
compar
event
group
day
ssi
occur
patient
tobramycin
group
vs
group
conclus
differ
composit
ae
compar
tobramycin
group
howev
ssi
within
day
significantli
higher
tobramycin
group
phenobarbit
vs
benzodiazepin
alcohol
withdraw
treatment
evalu
three
institut
protocol
emerg
depart
amelia
nelson
joy
keho
kevin
kaucher
acut
care
pharmaci
denver
health
medic
center
denver
co
health
medic
center
denver
co
introduct
recent
drug
shortag
involv
iv
benzodiazepin
left
institut
scrambl
incorpor
altern
agent
treatment
protocol
alcohol
withdraw
object
studi
describ
effect
safeti
institut
protocol
three
time
period
util
benzodiazepin
barbitur
acut
treatment
alcohol
withdraw
emerg
depart
research
question
hypothesi
incorpor
phenobarbit
treatment
protocol
alcohol
withdraw
effect
safe
ed
studi
design
retrospect
cohort
method
adult
patient
present
ed
requir
treatment
acut
alcohol
withdraw
april
januari
review
studi
inclus
patient
includ
year
older
receiv
least
one
dose
treatment
accord
document
symptom
sever
score
depend
avail
iv
benzodiazepin
barbitur
separ
protocol
develop
account
product
avail
patient
treat
accord
specif
protocol
implement
separ
time
period
includ
iv
diazepam
alon
iv
lorazepam
iv
phenobarbit
iv
phenobarbit
alon
primari
outcom
rate
icu
admiss
secondari
outcom
includ
rate
mechan
ventil
rate
hospit
length
hospit
stay
length
icu
stay
primari
admiss
diagnosi
total
dose
benzodiazepin
total
dose
phenobarbit
sew
score
rate
return
within
day
result
patient
encount
includ
overal
baselin
characterist
equal
across
group
except
age
differ
rate
icu
admiss
ed
group
l
patient
rate
mechan
ventil
differ
across
group
l
patient
total
benzodiazepin
use
decreas
phenobarbit
treat
patient
l
mg
conclus
incorpor
phenobarbit
alcohol
withdraw
treatment
protocol
safe
effect
patient
satisfact
pain
manag
patient
emerg
depart
amina
alkhalaf
pharmd
candid
raneem
bukhari
pharmd
candid
elham
alshehri
pharmd
candid
arwa
alkhalaf
hussain
bakhsh
clinic
pharmaci
colleg
pharmaci
king
abdulaziz
univers
jeddah
saudi
arabia
educ
graduat
studi
king
abdul
aziz
univers
jeddah
saudi
arabia
introduct
pain
saudi
arabia
report
emerg
depart
ed
pain
manag
area
opioid
minim
limit
specif
popul
previou
studi
field
pain
manag
base
measur
overlook
patient
satisfact
upon
discharg
saudi
arabia
patient
satisfact
ed
studi
studi
aim
assess
patient
satisfact
pain
manag
receiv
ed
discharg
research
question
hypothesi
base
previou
studi
hypothes
patient
undertr
ed
saudi
arabia
studi
design
studi
follow
prospect
design
method
studi
conduct
two
month
tertiari
academ
hospit
saudi
arabia
modifi
questionnair
conduct
phone
call
use
primari
outcom
question
often
pain
well
control
ed
adult
patient
complain
pain
receiv
analges
ed
within
one
week
use
multivari
analysi
correl
design
identifi
predictor
patient
satisfact
result
studi
includ
patient
mean
age
year
receiv
receiv
opioid
thought
enough
analges
mean
initi
pain
score
discharg
multivari
regress
result
show
ed
diagnosi
coeffici
p
chronic
analges
use
coeffici
p
type
analges
receiv
coeffici
p
initi
pain
score
coeffici
p
pain
score
discharg
coeffici
p
percept
enough
analges
given
coeffici
p
staff
help
coeffici
p
significantli
associ
patient
satisfact
except
type
analges
model
conclus
patient
satisfact
predictor
document
despit
minim
opioid
use
explor
factor
impact
propofol
requir
procedur
sedat
emerg
depart
maegan
well
chara
calhoun
pharmd
jeffrey
caporossi
ryan
barn
kyle
weant
pharmd
bcp
pharmaci
medic
univers
south
carolina
charleston
sc
emerg
medicin
medic
univers
south
carolina
charleston
sc
introduct
propofol
commonli
util
emerg
depart
ed
procedur
sedat
impact
age
dose
requir
investig
patient
specif
factor
may
affect
propofol
dose
requir
procedur
sedat
well
understood
research
question
hypothesi
studi
object
determin
effect
patient
substanc
use
histori
total
propofol
dose
requir
procedur
sedat
ed
studi
design
retrospect
cohort
studi
method
retrospect
cohort
studi
conduct
level
academ
medic
center
ed
patient
year
age
receiv
propofol
procedur
sedat
januari
august
includ
patient
group
base
document
histori
substanc
use
time
present
alcohol
use
disord
illicit
drug
use
disord
document
substanc
use
disord
total
propofol
dose
requir
procedur
sedat
opioid
requir
advers
event
compar
group
result
total
procedur
sedat
includ
analysi
signific
differ
demograph
procedur
procedur
opioid
requir
found
amongst
group
patient
histori
substanc
use
disord
includ
alcohol
illicit
drug
n
significantli
higher
total
propofol
requir
patient
without
substanc
use
disord
p
addit
patient
substanc
use
disord
requir
repeat
dose
procedur
without
use
disord
p
signific
differ
found
incid
advers
effect
respiratori
suppress
amongst
group
conclus
patient
histori
alcohol
illicit
drug
use
disord
may
requir
higher
total
dose
propofol
procedur
sedat
investig
necessari
better
isol
specif
factor
contribut
need
higher
dose
efficaci
ketamin
initi
control
acut
agit
emerg
depart
pilot
studi
justin
lin
yelena
figuerado
adrienn
kercsak
pharmd
jonathan
lee
valeri
norton
harmind
sikand
pharmd
fccp
pharmaci
scripp
merci
san
diego
san
diego
ca
pharmaci
scripp
merci
hospit
san
diego
ca
merci
san
diego
san
diego
ca
introduct
clinician
often
encount
agit
patient
pose
danger
staff
current
treatment
option
includ
benzodiazepin
antipsychot
ketamin
agent
rapidli
induc
dissoci
result
analgesia
amnesia
maintain
cardiovascular
stabil
spontan
respir
airway
reflex
ketamin
util
agit
previou
studi
demonstr
quicker
time
sedat
compar
agent
howev
prospect
random
studi
compar
ketamin
agent
initi
manag
acut
agit
emerg
depart
ed
research
question
hypothesi
determin
efficaci
safeti
ketamin
compar
parenter
haloperidol
plu
lorazepam
initi
control
acut
agit
studi
design
prospect
random
real
world
standard
care
pilot
studi
method
patient
activ
diagnosi
comb
agit
includ
random
via
computer
random
number
gener
either
treatment
arm
patient
known
contraind
studi
medic
exclud
patient
receiv
ketamin
mgkg
im
maximum
mg
mgkg
iv
haloperidollorazepam
haloperidol
mg
im
iv
lorazepam
mg
im
iv
primari
outcom
sedat
within
minut
defin
richmond
agit
sedat
scale
rass
score
secondari
outcom
includ
sedat
within
minut
time
sedat
safeti
result
analyz
use
fisher
exact
test
test
result
significantli
patient
receiv
ketamin
compar
haloperidollorazepam
sedat
within
median
time
sedat
patient
receiv
ketamin
compar
haloperidollorazepam
respect
patient
receiv
ketamin
experienc
nonsignific
transient
tachycardia
hypertens
conclus
patient
comb
agit
ketamin
significantli
effect
p
haloperidollorazepam
initi
control
acut
agit
associ
signific
advers
effect
opioid
overdos
educ
naloxon
distribut
emerg
depart
healthcar
profession
percept
heather
blue
kelsey
melgaard
laura
carpent
lei
zhang
nichola
van
deelen
pharmaci
practic
pharmaceut
scienc
univers
minnesota
colleg
pharmaci
duluth
mn
minnesota
colleg
pharmaci
duluth
mn
translat
scienc
institut
univers
minnesota
minneapoli
mn
luke
hosptial
duluth
mn
present
minnesota
societi
pharmacist
annual
meet
st
cloud
mn
april
implement
evalu
prospect
discharg
prescript
review
process
academ
medic
center
emerg
depart
emili
griffin
pharmd
ms
andrew
north
pharmd
mba
bcp
bcccp
elizabeth
rozycki
pharmd
trisha
jordan
pharmd
jennif
rodi
pharmd
bcp
marjori
neideck
phd
meng
rn
ohio
state
univers
wexner
medic
center
columbu
oh
pharmaci
ohio
state
univers
wexner
medic
center
columbu
oh
pharmaci
ohio
state
univers
columbu
oh
ohio
sate
colleg
pharmaci
columbu
oh
introduct
intern
retrospect
review
target
emerg
depart
ed
discharg
prescript
demonstr
potenti
intervent
rate
high
rate
miss
opportun
need
identifi
process
target
review
discharg
prescript
ed
aim
project
develop
notif
system
target
discharg
prescript
review
well
associ
ed
pharmacist
workflow
evalu
intervent
rate
achiev
target
discharg
prescript
review
research
question
hypothesi
prospect
target
discharg
prescript
review
pharmacist
increas
appropri
prescrib
addit
intervent
type
common
medic
class
highest
risk
studi
design
prospect
implement
qualiti
improv
pilot
project
februari
may
method
discharg
prescript
met
inclus
criteria
filter
work
queue
ed
pharmacist
ed
pharmacist
review
prescript
recommend
independ
made
necessari
adjust
accord
institut
pharmacist
privileg
intervent
review
categor
assess
rate
intervent
type
problem
identifi
result
data
collect
period
discharg
prescript
review
total
prescript
identifi
least
one
medic
relat
problem
mrp
prescript
requir
intervent
result
intervent
rate
pharmacist
common
mrp
chang
dosefrequ
durationrefil
medic
highest
number
intervent
made
anticoagul
conclus
use
target
discharg
prescript
review
criteria
pharmacist
abl
effect
impact
appropri
prescrib
ed
implement
multidisciplinari
outpati
pulmonari
embol
protocol
emerg
depart
laura
martin
pharmd
andrew
tyrrel
pharmd
provid
st
peter
hospit
olympia
wa
introduct
studi
shown
outpati
manag
patient
pulmonari
embol
pe
emerg
depart
ed
safe
studi
guidelin
support
practic
provid
uptak
variabl
valid
tool
proven
reliabl
identifi
patient
elig
outpati
manag
ed
pharmacist
help
evalu
patient
elig
outpati
manag
fill
prescript
provid
discharg
educ
studi
shown
ed
pharmacist
provid
discharg
educ
reduc
readmiss
rate
hypothesi
implement
multidisciplinari
outpati
pe
protocol
increas
number
pe
patient
discharg
er
across
two
emerg
depart
washington
state
studi
design
retrospect
chart
review
conduct
includ
six
month
period
time
pre
analysi
patient
primari
diagnosi
pulmonari
embol
review
see
met
criteria
outpati
manag
discharg
admit
data
collect
help
elucid
narr
behind
adult
pe
patient
method
protocol
implement
involv
ed
pharmacist
streamlin
outpati
manag
low
risk
pe
patient
ed
patient
determin
low
risk
modifi
hestia
criteria
andor
simplifi
pesi
criteria
along
physician
discret
elig
patient
provid
initi
dose
medic
counsel
outpati
prescript
fill
abl
patient
follow
complet
rn
ensur
smooth
transit
care
primari
outcom
compar
number
pulmonari
embol
patient
admit
discharg
pre
post
protocol
result
pulmonari
embol
patient
discharg
ed
increas
follow
protocol
implement
conclus
implement
multidisciplinari
protocol
led
increas
outpati
manag
patient
pulmonari
embol
ed
comparison
three
differ
prothrombin
complex
concentr
regimen
emerg
warfarin
revers
pccwar
studi
scott
dietrich
shaun
row
pharmd
bcp
bcccp
fnc
patrick
blankenship
craig
cocchio
pharmd
amanda
harmon
steven
nerenberg
colorado
health
north
region
fort
collin
co
clinic
pharmaci
univers
tennesse
health
scienc
center
colleg
pharmaci
knoxvil
tn
memori
hospit
maryvil
tn
mario
school
pharmaci
rutger
state
univers
new
jersey
piscataway
nj
joseph
hospit
safeti
harbor
fl
pharmaci
practic
administr
ernest
mario
school
pharmaci
rutger
state
univers
new
jersey
piscataway
nj
introduct
prothrombin
complex
concentr
pcc
agent
choic
emerg
warfarin
revers
controversi
remain
surround
optim
pcc
dose
specif
pcc
product
activ
pcc
apcc
regimen
shown
similar
inr
revers
outcom
emerg
warfarin
revers
directli
compar
research
question
hypothesi
evalu
effect
three
differ
pcc
dose
regimen
revers
warfarin
apcc
studi
design
irb
approv
multicent
retrospect
cohort
analysi
method
patient
admit
januari
decemb
consid
inclus
receiv
warfarin
revers
regimen
interest
patient
without
follow
inr
within
hour
treatment
pretreat
inr
less
requir
massiv
transfus
receiv
plasma
prior
pcc
treat
acut
warfarin
ingest
exclud
result
total
patient
includ
analysi
apcc
higher
proport
receiv
abl
achiev
inr
less
vs
vs
howev
differ
group
regard
absolut
vs
vs
percent
chang
inr
vs
vs
three
thrombot
event
document
within
day
pcc
treatment
howev
differ
proport
event
group
vs
vs
conclus
higher
proport
patient
receiv
achiev
inr
less
howev
type
treatment
affect
absolut
percent
chang
inr
evalu
glycem
control
endotool
glucos
manag
system
insulin
infus
therapi
lauren
igneri
pharmd
bcp
bcccp
alan
schorr
faaim
patricia
gilbert
msn
katherin
krol
bsn
brandon
kim
pharmd
jessica
elli
suzett
cunicelli
benjamin
solomon
depart
cooper
univers
health
care
camden
nj
mari
medic
center
langhorn
pa
publish
crit
care
med
supplement
associ
distress
qualiti
life
muslim
type
diabet
zheng
kang
lum
bsc
pharm
hon
joyc
lee
pharmd
bcp
univers
singapor
singapor
singapor
pharmaci
faculti
scienc
nation
univers
singapor
singapor
singapor
introduct
glycem
dysregul
patient
type
diabet
associ
high
burden
psychosoci
distress
impair
qualiti
life
fast
religi
activ
carri
ramadan
shown
caus
dysregul
glucos
metabol
object
studi
examin
associ
distress
qualiti
life
muslim
fast
ramadan
research
question
hypothesi
distress
patient
fast
ramadan
decreas
qualiti
life
impact
specif
domain
life
studi
design
studi
conduct
singapor
method
muslim
baselin
egfr
mlmin
includ
recurr
hypoglycemia
receiv
activ
corticosteroid
therapi
exclud
distress
qualiti
life
measur
problem
area
diabet
paid
audit
qualiti
life
addqol
respect
questionnair
administ
within
one
month
prior
ramadan
associ
paid
addqol
specif
domain
establish
use
pearson
product
moment
coeffici
test
result
total
individu
analyz
mean
age
year
major
femal
mean
paid
score
individu
highli
distress
ie
paid
score
mean
averag
weight
impact
awi
addqol
paid
found
moder
associ
addqol
significantli
associ
qualiti
life
domain
except
friend
sex
eat
drink
conclus
distress
associ
poor
qualiti
life
muslim
fast
ramadan
healthcar
profession
provid
closer
follow
care
support
anticip
ramadan
impact
profession
continu
glucos
monitor
clinic
pharmacist
ambulatori
care
set
christi
schumach
pharmd
bcp
bcacp
cde
elizabeth
van
dril
pharmd
bcp
depart
pharmaci
practic
midwestern
univers
chicago
colleg
pharmaci
downer
grove
il
introduct
use
continu
glucos
monitor
cgm
manag
diabet
mellitu
dm
continu
grow
despit
cgm
serv
opportun
clinic
pharmacist
improv
care
receiv
reimburs
manag
patient
dm
limit
literatur
describ
involv
technolog
research
question
hypothesi
valu
clinic
profession
continu
glucos
monitor
pcgm
ambulatori
care
set
studi
design
retrospect
intervent
chart
review
method
patient
profession
cgm
place
hour
data
interpret
clinic
pharmacist
includ
analysi
primari
object
determin
pcgm
improv
measur
glycem
control
includ
percentag
time
target
glycem
rang
chang
estim
averag
interstiti
glucos
chang
hemoglobin
baselin
secondari
object
evalu
revenu
gener
measur
reimburs
rate
current
procedur
terminolog
cpt
code
util
clinic
pharmacist
servic
relat
pcgm
use
clinic
data
extract
subject
electron
medic
record
reimburs
data
provid
center
bill
depart
result
subject
receiv
pcgm
includ
analysi
subject
mean
baselin
respect
differ
subject
mean
percentag
time
target
glycem
rang
mean
estim
averag
interstiti
glucos
baselin
subject
met
clinic
pharmacist
total
visit
period
unanticip
visit
mean
payment
amount
cpt
code
receiv
conclus
clinic
pcgm
demonstr
improv
measur
glycem
control
howev
provid
opportun
optim
antihyperglycem
therapi
result
reimburs
clinic
pharmaci
servic
evalu
blood
glucos
manag
care
patient
experienc
hyperglycemia
broderick
olson
pharmd
mba
megan
bond
pharmd
bcp
laura
mudd
pharmd
bcccp
joshua
gaborcik
pharmd
bcp
depart
pharmaci
ohio
state
univers
wexner
medic
center
columbu
oh
introduct
certain
medic
exacerb
hyperglycemia
even
patient
without
diabet
one
class
medic
known
caus
hyperglycemia
glucocorticoid
onset
glucocorticoid
induc
hyperglycemia
seen
two
consecut
day
receiv
equival
total
daili
dose
prednison
pharmacokinet
profil
insulin
nph
make
drug
choic
treat
steroid
induc
hyperglycemia
mani
case
research
question
hypothesi
hyperglycemia
manag
patient
inpati
gener
medicin
servic
studi
design
retrospect
chart
review
method
retrospect
medic
use
evalu
mue
conduct
larg
academ
medic
center
patient
without
diabet
receiv
equival
total
daili
dose
prednison
experienc
minimum
one
blood
glucos
read
within
hour
receiv
initi
steroid
admit
gener
medicin
servic
januari
june
includ
evalu
result
fifti
patient
includ
mue
steroid
prescrib
follow
condit
respiratori
autoimmun
inflammatori
neurolog
hepat
hour
period
common
steroid
use
intraven
methylprednisolon
oral
prednison
median
high
blood
glucos
remain
mgdl
throughout
hour
median
low
remain
mgdl
major
patient
receiv
insulin
hyperglycemia
insulin
order
insulin
aspart
use
often
poct
order
patient
conclus
use
steroid
lead
hyperglycemia
patient
without
diabet
mue
qualiti
improv
opportun
exist
order
improv
care
patient
experienc
hyperglycemia
includ
time
recognit
steroid
induc
hyperglycemia
recommend
obtain
routin
poct
provid
continu
insulin
educ
provid
metformin
prescrib
pattern
previous
inelig
adult
use
egfr
rebecca
falter
pharmd
roshani
patel
pharmd
candid
bernard
j
dunn
school
pharmaci
shenandoah
univers
winchest
va
introduct
though
metformin
gold
standard
therapi
type
diabet
mellitu
nation
prescrib
rate
low
rang
metformin
label
updat
establish
appropri
therapi
use
estim
glomerular
filtrat
rate
egfr
instead
serum
creatinin
scr
past
studi
note
use
scr
restrict
metformin
use
data
lack
see
prescrib
pattern
metformin
util
chang
sinc
label
updat
research
question
hypothesi
examin
impact
metformin
recent
label
updat
prescrib
pattern
metformin
outpati
intern
medicin
practic
studi
design
retrospect
cohort
studi
method
patient
includ
chart
review
least
year
old
diagnos
histori
metformin
use
discontinu
due
scr
restrict
patient
sever
renal
dysfunct
document
metformin
intoler
contraind
exclud
result
total
patient
chart
review
averag
age
male
caucasian
met
inclus
criteria
restart
metformin
label
updat
exclud
accept
scr
continu
metformin
despit
exceed
scr
restrict
note
review
elig
continu
metformin
base
egfr
rather
scr
conclus
util
egfr
increas
total
number
patient
elig
metformin
older
popul
though
metformin
reiniti
includ
patient
opportun
pharmacist
intervent
improv
metformin
util
data
come
forward
prior
suggest
appropri
egfr
monitor
scr
may
explain
notabl
number
patient
continu
metformin
increas
patient
divers
would
improv
extern
valid
result
move
forward
metformin
factor
affect
prescrib
pattern
patient
type
ii
diabet
abdulrhman
althaqafi
pharmd
intern
ahm
alghamdi
bpharm
maryam
alghamdi
pharmd
marwan
allihaibi
bpharm
eman
alzhrani
pharmd
afnan
almahmoudi
pharmd
intern
majid
ali
bpharm
msc
clinic
pharmaci
pgcert
pgdip
colleg
pharmaci
umm
univers
makkah
saudi
arabia
introduct
lifestyl
manag
metformin
prefer
initi
monotherapi
treat
type
ii
diabet
proven
efficaci
favor
profil
initi
treatment
metformin
achiev
target
metformin
toler
therapi
may
offer
open
choic
may
depend
sever
factor
research
question
hypothesi
factor
consid
physician
prescrib
therapi
metformin
studi
design
quantit
survey
method
conduct
survey
sampl
prescrib
makkah
jeddah
citi
questionnair
design
pilot
includ
question
focus
select
therapi
reason
addit
altern
metformin
physician
invit
conveni
sampl
basi
particip
result
physician
contact
complet
questionnair
approxim
often
prescrib
metformin
first
line
mainli
inexpens
complianc
guidelin
major
select
inhibitor
sulfonylurea
stop
metformin
due
side
effect
favor
metformin
fail
reach
target
physician
prefer
ad
sulfonylurea
prefer
inhibitor
prefer
consid
select
therapi
renal
function
comorbid
patient
weight
major
said
choic
affect
hospit
formulari
advertis
pharmaceut
compani
statist
analysi
use
spss
signific
differ
found
prescrib
altern
metformin
addit
metformin
govern
privat
sector
practition
privat
sector
practition
favor
conclus
sulfonylurea
inhibitor
consid
common
choic
metformin
set
howev
number
patient
suffer
hypoglycem
episod
due
sulfonylurea
remain
open
explor
less
favor
physician
despit
increas
evid
avail
favor
extern
valid
comparison
two
day
readmiss
predict
model
patient
diabet
ahmad
alam
pharmd
asad
e
patanwala
pharmd
bcp
fccp
fashp
ali
aldayyen
pharmd
maryam
fazel
pharmd
bcp
bcacp
cde
univers
arizona
colleg
pharmaci
depart
pharmaci
practic
scienc
tucson
az
introduct
hospit
score
diabet
earli
readmiss
risk
indic
derri
design
predict
readmiss
medic
diabet
patient
respect
model
develop
valid
differ
us
hospit
extern
valid
institut
research
question
hypothesi
hospit
score
andor
derri
predict
model
effect
predict
readmiss
risk
diabet
patient
institut
studi
design
retrospect
cohort
studi
method
chart
adult
diabet
patient
admit
banner
univers
medic
center
tucsonsouth
b
umct
januari
septemb
review
patient
hospit
readmiss
randomli
select
compar
control
patient
without
readmiss
test
use
assess
discrimin
two
model
test
use
assess
calibr
result
two
hundr
twenti
patient
screen
patient
includ
hospit
score
ci
good
calibr
p
derri
model
ci
good
calibr
p
statist
signific
differ
two
model
term
discrimin
p
derri
model
predictor
compon
show
associ
readmiss
employ
statu
discharg
within
day
admiss
admiss
hematocrit
diagnosi
anemia
insulin
use
hospit
score
import
predictor
number
admiss
past
year
length
hospit
stay
hemoglobin
discharg
sodium
discharg
conclus
extern
popul
hospit
score
derri
show
good
perform
predict
readmiss
diabet
patient
moder
high
discrimin
power
good
calibr
trend
toward
signific
favor
derri
predict
model
medic
relat
problem
diabet
patient
ramadan
majid
ali
bpharm
msc
clinic
pharmaci
pgcert
pgdip
amjad
albishi
pharmd
intern
amjad
madkhali
pharmd
intern
layal
baun
pharmd
intern
razan
alhazmi
pharmd
intern
elaf
doman
pharmd
intern
anwar
alhazmi
pharmd
intern
abdulrhman
althaqafi
pharmd
intern
hamid
alawi
pharmd
intern
mohammad
alotaibi
pharmd
intern
wale
almalki
pharmd
intern
wale
alluqmani
pharmd
intern
fahad
althobiani
pharmd
intern
colleg
pharmaci
umm
univers
makkah
saudi
arabia
introduct
ramadan
month
islam
calendar
healthi
muslim
adult
oblig
fast
dawn
till
dusk
everyday
detriment
effect
health
patient
patient
consid
unfit
fast
doctor
exempt
fast
howev
mani
diabet
patient
insist
fast
ramadan
make
chang
medic
schedul
without
advic
issu
patient
yet
explor
address
research
question
hypothesi
issu
diabet
patient
face
fast
ramadan
studi
design
mix
method
qualit
follow
quantit
method
conduct
two
phase
phase
involv
interview
patient
attend
diabet
center
makkah
citi
interview
guid
consist
question
explor
issu
ramadan
prepar
pilot
interview
patient
consent
transcrib
verbatim
themat
analys
later
result
phase
util
prepar
structur
questionnair
object
captur
data
wider
popul
questionnair
pilot
appropri
chang
made
patient
select
conveni
sampl
basi
phase
result
twenti
interview
conduct
phase
rang
minut
main
theme
identifi
code
medic
chang
ramadan
diabet
lifestyl
issu
futur
consider
fast
healthcar
issu
patient
complet
questionnair
phase
ii
half
particip
chang
way
take
without
advic
suffer
problem
agre
chang
eat
habit
ramadan
affect
diabet
control
conclus
problem
found
among
diabet
patient
observ
fast
ramadan
especi
fast
made
chang
medic
schedul
without
healthcar
provid
advic
chang
dietari
habit
could
also
contribut
factor
impact
collabor
pharmaceut
care
servic
among
patient
diabet
qatar
petroleum
healthcar
center
multipl
time
seri
studi
ahm
awaisu
bpharm
rana
ahm
saleh
sara
hamdi
abdulrhim
bsc
pharm
nadir
kheir
moham
abdelazim
hussain
ahm
hussein
babik
pharmaci
qatar
univers
doha
qatar
medic
health
scienc
univers
auckland
auckland
new
zealand
petroleum
healthcar
center
doha
qatar
drug
control
ministri
public
health
doha
qatar
publish
qatar
foundat
annual
research
confer
proceed
associ
qualiti
life
glycem
lipid
control
diabet
patient
yazan
edre
pharmd
jalal
abdulsalam
pharmd
rayan
allbaan
pharmd
eyad
bukhari
pharmd
yousuf
kutbi
pharmd
majid
ali
bpharm
msc
clinic
pharmaci
pgcert
pgdip
univers
makkah
saudi
arabia
pharmaci
umm
univers
makkah
saudi
arabia
introduct
alongsid
glycem
control
optimum
lipid
control
also
import
diabet
patient
reduc
risk
cardiovascular
mortal
associ
qualiti
life
patient
littl
known
associ
research
question
hypothesi
associ
qualiti
life
glycem
lipid
control
diabet
patient
studi
design
quantit
studi
method
diabet
patient
attend
two
diabet
center
makkah
citi
approach
conveni
sampl
basi
valid
questionnair
assess
diabet
relat
qualiti
life
dqol
administ
questionnair
consist
question
score
neg
valenc
higher
score
indict
low
qualiti
life
vice
versa
recent
cholesterol
level
patient
complet
questionnair
retriev
comput
system
center
result
one
hundr
patient
complet
questionnair
cholesterol
level
avail
comput
system
male
age
year
mean
cholesterol
level
found
mgdl
respect
mean
dqol
score
found
spss
use
inferenti
statist
analysi
weak
posit
correl
found
dqol
weak
neg
correl
found
dqol
cholesterol
conclus
although
glycem
control
found
gener
poor
among
patient
lipid
control
within
target
rang
good
qualiti
life
howev
associ
found
qualiti
life
glycem
lipid
control
larger
sampl
size
may
provid
reliabl
find
data
collect
analysi
underway
effect
intervent
includ
health
coach
medic
adher
bp
control
rural
primari
care
wu
doyl
cum
pharmd
fcp
fccp
quefeng
li
jacquelin
halladay
md
katrina
donahu
md
crystal
cene
md
alan
l
hinderlit
hayden
bosworth
cassandra
miller
beverli
garcia
jim
tillman
darren
dewalt
md
nurs
univers
north
carolina
chapel
hill
chapel
hill
nc
famili
medicin
east
carolina
univers
brodi
school
medicin
greenvil
nc
biostatist
univers
north
carolina
chapel
hill
chapel
hill
nc
medicin
univers
north
carolina
chapel
hill
chapel
hill
nc
cardiolog
school
medicin
univers
north
carolina
chapel
hill
nc
medicin
duke
univers
durham
nc
present
american
heart
associ
council
hypertens
annual
meet
rural
diabet
care
telehealth
achiev
compar
outcom
care
shivajirao
patil
md
mph
doyl
cum
pharmd
fcp
fccp
alyssa
adam
mph
lisa
rodebaugh
bsn
denni
russo
phd
jill
jen
ms
jessica
sisnero
ms
ann
mari
nye
pharmd
depart
famili
medicin
east
carolina
univers
brodi
school
medicin
greenvil
nc
present
america
diabet
associ
annual
scientif
session
june
refin
valid
clinic
pharmaci
prioriti
score
focu
clinic
pharmaci
servic
famili
medicin
joseph
vand
griend
joseph
saseen
heather
anderson
health
servic
organ
univers
colorado
health
aurora
co
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
clinic
pharmaci
univers
colorado
denver
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
clinic
pharmaci
prioriti
score
includ
demograph
clinic
characterist
score
increas
patient
like
problem
mrp
howev
differenti
well
among
highli
complex
patient
research
question
hypothesi
hypothes
refin
valid
tool
would
differenti
presenc
mrp
among
complex
patient
studi
design
expert
consensu
valid
reliabl
assess
use
retrospect
cohort
method
expert
panel
clinic
pharmacist
famili
medicin
resid
program
idaho
utah
colorado
use
method
identifi
element
believ
import
predict
mrp
retrospect
cohort
adult
patient
age
year
broad
equal
distribut
element
identifi
second
expert
panel
clinic
pharmacist
develop
consensu
presenc
import
mrp
cohort
logist
regress
estim
associ
count
element
mrp
sensit
posit
predict
valu
ppv
use
inform
potenti
number
identifi
patient
like
mrp
result
element
identifi
incorpor
refin
score
addit
element
risk
mrp
doubl
odd
confid
base
balanc
sensit
ppv
total
element
chosen
appropri
identifi
patient
like
mrp
patient
element
mrp
among
patient
mrp
element
conclus
refin
score
contain
addit
element
compar
origin
score
total
element
differenti
patient
without
mrp
research
evalu
contribut
element
import
healthcar
outcom
need
gene
fit
perspect
pharmacogenom
use
famili
medicin
practic
sara
weinstein
patricia
klatt
pharmd
sejla
jukic
melissa
mcgivney
sophia
cothrel
megan
baumgartn
pharmd
joni
carrol
st
margaret
pittsburgh
pa
pittsburgh
school
pharmaci
pittsburgh
pa
present
societi
teacher
famili
medicin
stfm
washington
dc
may
associ
health
literaci
medic
literaci
dyad
rural
underserv
popul
takova
wallac
pharmd
bcacp
gabriela
orsak
ms
clinic
pharmaci
univers
texa
tyler
tyler
tx
univers
texa
health
scienc
center
northeast
tyler
tx
introduct
health
literaci
children
span
continuum
time
often
reflect
parent
caregiv
level
health
literaci
project
aim
address
health
medic
literaci
child
parent
thu
address
two
popul
assess
correl
dyad
research
question
hypothesi
posit
correl
parent
child
health
literaci
statu
parent
health
literaci
directli
associ
medic
literaci
children
studi
design
prospect
correl
analysi
conduct
util
survey
tool
within
independ
school
district
method
within
select
school
district
potenti
child
particip
identifi
primari
caregiv
complet
dyad
child
parent
children
complet
health
medic
literaci
assess
administ
train
investig
health
literaci
assess
includ
rapid
estim
adult
literaci
form
rapid
estim
adolesc
literaci
form
adult
children
respect
medic
literaci
assess
use
medic
literaci
engli
medlitrxs
tool
result
total
dyad
assess
averag
age
parent
children
year
respect
averag
score
sd
averag
medlitrx
score
sd
child
age
relationship
medic
literaci
score
parent
p
howev
parent
insur
statu
significantli
relat
medic
literaci
control
number
comorbid
b
p
partial
specif
among
parent
medic
literaci
score
higher
insur
hand
parent
insur
statu
effect
child
medic
literaci
score
p
conclus
correl
health
literaci
dyad
difficult
reveal
howev
limit
parent
insur
statu
shown
relat
lower
medic
literaci
determin
vaccin
hesit
low
incom
urban
popul
joseph
martin
kathleen
pincu
pharmd
bcp
leila
islam
maryland
school
pharmaci
baltimor
md
pharmaci
practic
scienc
univers
maryland
school
pharmaci
baltimor
md
commonwealth
univers
school
medicin
richmond
va
introduct
vaccin
provid
public
health
benefit
adult
vaccin
rate
remain
low
pharmacist
play
crucial
role
improv
adult
vaccin
rate
varieti
clinic
set
world
health
organ
develop
survey
question
evalu
determin
vaccin
hesit
variou
popul
research
question
hypothesi
domain
contribut
vaccin
hesit
urban
set
studi
design
descript
prospect
survey
studi
design
method
question
appendic
report
sage
work
group
vaccin
hesit
adapt
survey
deliveri
administ
adult
patient
seen
famili
medicin
practic
respons
evalu
use
descript
analysi
character
local
determin
vaccin
hesit
result
particip
mainli
femal
age
medic
assist
medicar
particip
complet
survey
third
particip
report
delay
declin
vaccin
due
advers
reaction
report
belief
better
way
prevent
diseas
vaccin
major
respond
indic
trust
pharmaceut
compani
provid
safe
effect
vaccin
one
respond
experienc
advocaci
vaccin
religi
commun
respons
government
influenc
divid
respond
report
trust
doctor
inform
vaccin
conclus
studi
provid
insight
motiv
determin
vaccin
hesit
urban
insur
patient
popul
influenc
religion
govern
view
pharmaceut
compani
contribut
substanti
vaccin
hesit
popul
fear
advers
effect
belief
altern
strategi
prevent
diseas
may
contribut
vaccin
hesit
target
educ
toward
contributor
vaccin
hesit
may
help
pharmacist
improv
adult
vaccin
rate
assess
famili
medicin
resid
physician
medic
knowledg
improv
requir
pharmacotherapi
rotat
ila
harri
pharmd
bcp
fccp
ann
philbrick
pharmd
bcp
michael
miner
famili
medicin
commun
health
univers
minnesota
medic
school
minneapoli
mn
pharmaceut
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
famili
medicin
commun
health
univers
minnesota
medic
school
minneapoli
mn
introduct
minim
literatur
exist
regard
effect
educ
famili
medicin
physician
resid
clinic
pharmacist
uniqu
requir
pharmacotherapi
rotat
precept
clinic
pharmacist
complet
famili
medicin
physician
resid
second
year
resid
famili
medicin
resid
program
evalu
knowledg
outcom
rotat
research
question
hypothesi
famili
medicin
physician
resid
medic
knowledg
confid
improv
overal
specif
content
area
complet
requir
pharmacotherapi
rotat
studi
design
observ
singl
group
prepost
studi
method
begin
end
pharmacotherapi
rotat
resid
complet
test
medic
knowledg
confid
knowledg
skill
primari
object
studi
determin
famili
medicin
resid
medic
knowledg
gener
specif
content
area
improv
baselin
end
rotat
data
analyz
use
spss
v
differ
explor
use
correl
mean
result
septemb
may
resid
complet
pharmacotherapi
rotat
overal
mean
score
pharmacotherapi
knowledg
improv
significantli
baselin
end
vs
p
score
specif
content
area
also
improv
significantli
diabet
p
pulmonari
p
smoke
cessat
p
anticoagul
p
prevent
medicin
p
pharmacokinet
p
prescrib
practic
p
addit
resid
confid
medic
knowledg
also
improv
significantli
baselin
end
p
conclus
requir
pharmacotherapi
rotat
famili
medicin
physician
resid
second
year
significantli
improv
medic
knowledg
confid
shown
studi
import
addit
exist
literatur
efficaci
safeti
direct
act
antivir
daa
urban
clinic
set
delina
meskel
ba
olga
klibanov
chri
gillett
tagbo
j
ekwonu
univers
school
pharmaci
wingat
nc
famili
physician
charlott
nc
introduct
develop
novel
direct
act
antivir
daa
led
sustain
virolog
respons
rate
patient
hepat
c
viru
hcv
larg
control
clinic
trial
research
question
hypothesi
goal
evalu
safeti
efficaci
daa
urban
clinic
set
compar
result
report
larg
clinic
trial
studi
design
retrospect
cohort
studi
method
patient
initi
daa
march
januari
retrospect
evalu
primari
endpoint
proport
patient
achiev
descript
statist
use
analyz
result
bivari
associ
patient
achiev
treatment
success
demograph
clinic
variabl
conduct
use
fisher
exact
test
independ
sampl
alpha
valu
result
among
patient
hcv
initi
daa
male
african
american
genotyp
cirrhosi
hiv
ledipasvirsofosbuvir
ldvsof
elbasvirgrazoprevir
elbgra
sofosbuvirvelpatasvir
sofvel
ombitasvirparitaprevirritonavir
dasabuvir
obvptvr
dsv
util
patient
respect
patient
initi
therapi
lost
result
yet
avail
patient
patient
complet
therapi
result
avail
achiev
fail
treatment
signific
associ
treatment
failur
cirrhosi
statu
race
bivari
associ
found
none
patient
report
advers
event
relat
daa
therapi
laboratori
abnorm
note
conclus
find
small
urban
clinic
cohort
indic
administr
daa
lead
excel
rate
albeit
rate
seen
larg
control
clinic
trial
safeti
efficaci
year
switch
tenofovir
disoproxil
fumar
tenofovir
alafenamid
chronic
hbv
patient
risk
factor
tdf
use
edward
gane
seto
harri
janssen
phd
florin
caruntu
hyung
joon
kim
dzhamal
abdurakhmanov
shuhei
nishiguchi
ho
bae
shuyuan
mo
suri
vithika
anuj
gaggar
john
flaherti
eunyoung
lee
kao
maurizia
brunetto
calvin
pan
maria
buti
medicin
univers
auckland
auckland
new
zealand
univers
hong
kong
hong
kong
hong
kong
gastroenterolog
toronto
centr
liver
diseas
toronto
gener
hospit
toronto
canada
davila
univers
medicin
pharmaci
bucuresti
romania
univers
colleg
medicin
seoul
korea
republ
south
univers
moscow
russian
feder
hyogo
colleg
medicin
hyogo
prefectur
japan
pacif
liver
center
lo
angel
ca
scienc
foster
citi
ca
scienc
foster
citi
ca
taiwan
univers
hospit
taipei
taiwan
ospedaliero
universitaria
pisana
roma
itali
langon
medic
center
newyork
ny
universitario
vall
hebron
barcelona
spain
present
intern
liver
congress
pari
franc
april
publish
journal
hepatolog
use
immunosuppress
prevent
antibodi
therapi
inflammatori
bowel
diseas
payal
kakadiya
pharmd
bcp
teresa
potter
pharmd
bcp
mph
depart
pharmaci
vcu
health
richmond
va
introduct
therapi
monoclon
antibodi
play
import
role
maintain
remiss
patient
inflammatori
bowel
diseas
ibd
infliximab
ifx
chimer
increas
incid
antibodi
develop
wherea
adalimumab
ada
fulli
human
decreas
risk
antibodi
studi
shown
reduct
antibodi
format
use
concurr
immunosuppress
methotrex
azathioprin
howev
current
guidelin
recommend
standard
use
immunosuppress
prevent
antibodi
format
research
question
hypothesi
object
investig
determin
concurr
immunosuppress
associ
decreas
drug
antibodi
format
compar
develop
antibodi
ifx
ada
studi
design
retrospect
observ
cohort
studi
perform
patient
popul
includ
patient
follow
vcu
health
ambulatori
care
center
gastroenterolog
clinic
januari
decemb
method
inclus
criteria
age
year
diagnosi
crohn
diseas
ulcer
coliti
receiv
ifx
ada
report
serum
drug
level
antibodi
level
primari
outcom
evalu
effect
concurr
immunosuppress
prevent
format
drug
antibodi
determin
incid
drug
antibodi
ifx
compar
ada
result
ada
group
patient
experienc
respons
develop
antibodi
patient
immunosuppress
develop
antibodi
ifx
group
respons
patient
develop
antibodi
nine
patient
immunosuppress
therapi
detect
antibodi
conclus
addit
immunosuppress
therapi
show
statist
signific
prevent
format
antibodi
either
infliximab
adalimumab
group
potenti
inappropri
prescrib
hospit
older
adult
high
cost
healthcar
user
monica
sanh
justin
lee
bscphm
ann
holbrook
md
pharmd
peter
macdonald
dphil
pharmaci
north
york
gener
hospit
north
york
canada
medicin
divis
geriatr
medicin
mcmaster
univers
hamilton
canada
medicin
divis
clinic
pharmacolog
toxicolog
mcmaster
univers
hamilton
canada
mathemat
statist
mcmaster
univers
hamilton
canada
introduct
high
cost
healthcar
user
hcu
small
proport
popul
use
disproportion
amount
healthcar
resourc
medic
import
contributor
hcu
cost
unclear
extent
poor
qualiti
includ
potenti
inappropri
prescrib
pip
may
contribut
hcu
advers
outcom
cost
pip
includ
potenti
inappropri
medic
pim
potenti
prescrib
omiss
ppo
stoppstart
criteria
valid
tool
assess
pip
older
adult
research
question
hypothesi
preval
type
pip
older
adult
hcu
studi
design
retrospect
case
seri
method
conduct
chart
review
older
adult
hcu
admit
gener
intern
medicin
two
academ
hospit
hamilton
canada
fiscal
year
hcu
defin
patient
least
emerg
depart
visit
hospit
past
year
home
medic
taken
prior
admiss
review
appli
stoppstart
criteria
plu
four
addit
pim
criteria
home
discharg
medic
reconcil
determin
proport
pip
address
hospit
discharg
regress
use
character
relationship
pip
futur
healthcar
util
result
hcu
identifi
randomli
select
review
least
one
pip
frequent
therapeut
class
implic
anticoagulantsantiplatelet
ace
inhibitor
benzodiazepin
opioid
ppo
signific
predictor
ed
visit
next
year
p
hospit
pip
pim
signific
predictor
ed
visit
hospit
pip
resolv
hospit
discharg
conclus
older
adult
hcu
optim
appropri
medic
hospit
admiss
opportun
address
pip
hospit
frequent
miss
trial
intervent
optim
medic
hcu
need
see
clinic
outcom
improv
resid
percept
use
telemedicin
commun
nurs
home
hannah
akerberg
pharmd
anticip
adrian
wong
pharmd
maureen
reynold
monica
aspinal
megan
pellett
richard
boyc
colleen
culley
gabriel
dziuba
steven
handler
md
phd
john
kellum
subashan
perera
sandra
pharmd
ms
fccm
pharmaci
univers
pittsburgh
pittsburgh
pa
pittsburgh
pittsburgh
pa
pittsburgh
pa
pharmaci
therapeut
univers
pittsburgh
school
pharmaci
pittsburgh
pa
introduct
telemedicin
grow
area
healthcar
shown
improv
patient
outcom
limit
inform
exist
role
telemedicin
nurs
home
nh
despit
potenti
reduc
advers
drug
event
ade
limit
interact
nh
resid
current
exist
pharmacist
therefor
evalu
commun
prefer
necessari
effect
therefor
perform
survey
determin
nh
resid
percept
toward
use
telemedicin
commun
pharmacist
research
question
hypothesi
resid
prefer
commun
pharmacist
nh
via
telemedicin
increas
exposur
telemedicin
studi
design
survey
administ
resid
admit
nh
within
health
system
conjunct
telemedicin
intervent
intervent
focus
resid
receiv
medic
includ
educ
symptom
method
resid
survey
period
expos
telemedicin
defin
case
primari
outcom
resid
prefer
commun
pharmacist
telemedicin
either
resid
includ
preserv
cognit
function
evidenc
brief
interview
mental
statu
confus
assess
method
test
use
test
differ
commun
prefer
perform
use
r
version
result
total
resid
case
control
met
inclus
criteria
prefer
commun
lower
case
control
vs
p
prefer
telemedicin
either
method
higher
resid
exposur
pharmacist
nh
increas
p
made
possibl
use
telemedicin
conclus
resid
prefer
interact
consult
pharmacist
increas
telemedicin
throughout
studi
futur
studi
need
determin
impact
pharmacist
telemedicin
patient
outcom
decreas
rate
ade
util
potenti
inappropri
medic
nurs
home
resid
duygu
handan
peskircioglu
bs
pharm
beyza
torun
bs
pharm
phd
student
oznur
ozkan
bs
pharm
phd
student
mesut
sancar
prof
betul
okuyan
assoc
prof
clinic
pharmaci
depart
marmara
faculti
pharmaci
istanbul
turkey
introduct
aim
studi
evalu
potenti
inappropri
medic
util
nurs
home
research
question
hypothesi
potienti
inappropri
medic
util
accord
norwegian
gener
home
criteria
nurs
home
istanbul
studi
design
studi
conduct
nurs
home
locat
istanbul
turkey
nurs
home
resid
year
use
least
one
medic
regularli
includ
studi
method
demograph
characterist
medic
histori
patient
retrospect
collect
potenti
inappropri
medic
use
patient
evalu
use
norwegian
gener
home
criteria
result
among
total
individu
male
femal
mean
age
calcul
mean
particip
educ
year
detect
mean
particip
comorbid
mean
total
criteria
score
calcul
differ
gender
mean
total
criteria
score
femal
versu
men
p
total
criteria
score
found
statist
correl
age
p
howev
statist
signific
correl
total
criteria
score
number
comorbid
p
conclus
conclus
nurs
home
resid
util
least
one
potenti
inappropri
medic
usag
potenti
inappropri
medic
gener
high
involv
clinic
pharmacist
healthcar
team
would
essenti
nurs
home
clinic
pharmacist
would
perform
medic
review
detect
potenti
inappropri
medic
nurs
home
resid
potenti
inappropri
prescrib
peopl
dementia
australian
studi
tesfahun
esheti
msc
tuan
nguyen
phd
mariann
gillam
phd
lisa
kalisch
ellett
phd
school
pharmaci
medic
scienc
univers
south
australia
adelaid
australia
introduct
intern
studi
shown
preval
potenti
inappropri
prescrib
pip
peopl
dementia
pip
associ
advers
outcom
limit
australian
studi
topic
research
question
hypothesi
assess
preval
pip
among
peopl
dispens
medicin
dementia
compar
peopl
never
dispens
medicin
dementia
studi
design
retrospect
cohort
studi
conduct
use
australian
pharmaceut
benefit
scheme
sampl
pharmaci
claim
method
peopl
dementia
defin
dispens
medicin
dementia
cholinesteras
inhibitor
memantin
risperidon
behaviour
psycholog
symptom
dementia
august
decemb
age
year
aliv
end
age
match
comparison
cohort
peopl
never
dispens
medicin
dementia
identifi
pip
defin
use
screen
tool
older
person
prescript
stopp
criteria
pip
preval
determin
januari
decemb
result
peopl
dispens
medicin
dementia
comparison
never
dispens
medicin
dementia
includ
femal
median
age
year
pip
preval
amongst
peopl
dementia
compar
amongst
comparison
group
p
preval
stopp
criteria
peopl
dementia
use
anticholinerg
proton
pump
inhibitor
week
use
benzodiazepin
week
adjust
age
gender
comorbid
number
prescrib
peopl
dementia
like
expos
pip
comparison
adjust
ci
p
conclus
potenti
inappropri
prescrib
common
peopl
dispens
medicin
dementia
comparison
result
highlight
need
effect
intervent
optimis
prescrib
peopl
dementia
potenti
inappropri
prescrib
initi
medicin
australian
studi
tesfahun
esheti
msc
tuan
nguyen
phd
mariann
gillam
phd
lisa
kalisch
ellett
phd
school
pharmaci
medic
scienc
univers
south
australia
adelaid
australia
introduct
potenti
inappropri
prescrib
pip
one
core
issu
qualiti
use
medicin
associ
numer
neg
health
outcom
despit
broader
concept
pip
previou
studi
assess
pip
medicin
focus
limit
class
medicin
research
question
hypothesi
improv
qualiti
use
medicin
versu
medicin
measur
preval
pip
studi
design
retrospect
cohort
studi
conduct
use
australian
pharmaceut
benefit
scheme
sampl
pharmaci
claim
method
peopl
first
claim
dispens
medicin
cholinesteras
inhibitor
chei
memantin
januari
decemb
age
year
aliv
end
includ
index
date
defin
date
first
suppli
medicin
pip
identifi
use
screen
tool
older
person
prescript
stopp
criteria
pip
preval
compar
period
prior
medicin
mcnemar
test
use
test
differ
preval
pip
two
time
period
result
total
patient
includ
studi
femal
median
age
year
overal
pip
preval
period
prior
initi
chei
memantin
compar
period
post
initi
p
median
number
stopp
criteria
interquartil
rang
prior
initi
medicin
increas
conclus
potenti
inappropri
prescrib
common
peopl
dispens
medicin
dementia
signific
increas
preval
initi
medicin
compar
prior
preval
predictor
high
anticholinerg
burden
older
adult
popul
studi
lee
kwanghe
jun
young
mi
ah
sunghe
hwang
jee
eun
chung
pharmaci
research
institut
pharmaceut
scienc
seoul
nation
univers
seoul
korea
republ
south
pharmaci
hanyang
univers
korea
republ
south
introduct
despit
untoward
advers
effect
medic
anticholinerg
properti
prescrib
widespread
among
older
adult
howev
limit
studi
estim
anticholinerg
burden
among
older
adult
aim
measur
anticholinerg
burden
identifi
predict
factor
high
anticholinerg
burden
older
adult
cohort
research
question
hypothesi
high
anticholinerg
burden
older
adult
associ
demograph
diseas
healthcar
util
pattern
studi
design
analysi
method
studi
age
patient
sampl
nation
health
insur
claim
data
use
modifi
anticholinerg
drug
scale
ad
includ
anticholinerg
drug
omit
origin
list
avail
korea
daili
dosag
use
measur
dose
standard
anticholinerg
burden
high
anticholinerg
burden
defin
averag
daili
dose
standard
ad
score
maximum
ad
score
concurr
chronic
medic
predictor
high
anticholinerg
burden
identifi
use
multivari
logist
regress
result
total
patient
includ
analysi
averag
age
year
male
patient
compris
charson
comorbid
index
cci
score
averag
polypharmaci
chronic
medic
excess
polypharmaci
chronic
medic
observ
respect
high
anticholinerg
burden
observ
patient
strongli
associ
age
year
femal
cci
score
polypharmaci
depress
urinari
incontin
overact
bladder
parkinson
diseas
schizophrenia
frequenc
healthcar
visit
major
drug
contribut
anticholinerg
burden
ranitidin
chlorpheniramin
dimenhydrin
solifenacin
conclus
studi
show
one
five
korean
older
adult
expos
high
anticholinerg
burden
patient
polypharmaci
high
specif
diseas
depress
urinari
incontin
parkinson
diseas
schizophrenia
frequent
healthcar
visit
high
risk
longitudin
chang
anticholinerg
sed
antipsychot
medic
use
diagnos
dementia
ah
phd
euna
han
kwanghe
jun
master
sunghe
hwang
phd
lee
pharmaci
yeungnam
univers
gyeongsangbuk
korea
republ
south
pharmaci
yonsei
univers
incheon
korea
republ
south
pharmaci
research
institut
pharmaceut
scienc
seoul
nation
univers
seoul
korea
republ
south
pharmaci
hanyang
univers
korea
republ
south
introduct
guidelin
recommend
use
drug
anticholinerg
sed
properti
antipsychot
especi
peopl
alzheim
diseas
ad
limit
research
evalu
chang
use
medic
follow
dementia
diagnosi
aim
assess
longitudin
chang
anticholinerg
sed
antipsychot
medic
use
diagnosi
dementia
comparison
patient
research
question
hypothesi
util
pattern
specif
medic
may
chang
diagnosi
dementia
studi
design
longitudin
cohort
studi
method
patient
without
prescript
n
case
control
korea
nation
health
insur
servic
senior
cohort
databas
includ
analysi
propens
score
match
yearli
dose
adjust
cumul
anticholinerg
cognit
burden
score
acb
sed
load
daili
dose
ddd
antipsychot
calcul
multivari
regress
perform
result
yearli
cumul
acb
sed
load
ddd
antipsychot
higher
dementia
patient
control
diagnosi
dementia
use
acb
sed
load
increas
steadili
use
antipsychot
minim
patient
observ
period
patient
dementia
use
medic
categori
peak
index
year
elev
significantli
higher
compar
patient
dementia
onset
acb
approxim
unit
sed
load
unit
decreas
use
antipsychot
unit
steadili
increas
compar
patient
conclus
use
anticholinerg
sed
higher
dementia
patient
patient
show
peak
diagnosi
dementia
decreas
thereaft
howev
use
antipsychot
continu
rise
diagnosi
dementia
antipsychot
use
effect
qtc
interv
elderli
patient
delirium
cyril
manuel
collant
aaron
pinkhasov
melissa
fazzari
sum
lam
pharmaci
nyu
winthrop
hospit
mineola
ny
behavior
scienc
nyu
winthrop
hospit
mineola
ny
biostatist
nyu
winthrop
hospit
mineola
ny
pharmaci
health
scienc
st
john
univers
queen
ny
introduct
delirium
character
inattent
disorgan
think
alter
level
conscious
may
complic
hospit
cours
delirium
caus
harm
patient
other
low
dose
antipsychot
often
use
acut
set
antipsychot
known
increas
mortal
elderli
patient
psychosi
specif
link
qtc
prolong
sudden
cardiac
death
delirium
cardiac
outcom
associ
advanc
age
research
question
hypothesi
chang
qtc
interv
associ
antipsychot
use
deliri
elderli
patient
studi
design
retrospect
cohort
chart
review
teach
hospit
method
subject
place
constant
observ
may
octob
screen
via
databas
behavior
health
depart
includ
patient
year
older
receiv
antipsychot
delirium
manag
subject
exclud
insuffici
document
ekg
pacemak
qtc
interv
prior
day
compar
use
pair
incid
sudden
cardiac
death
hospit
stay
record
result
patient
screen
met
studi
criteria
overal
elev
qtc
interv
baselin
msec
p
increas
qtc
interv
seen
group
haloperidol
n
msec
p
quetiapin
n
msec
p
risperidon
n
msec
incid
sudden
cardiac
death
conclus
haloperidol
delirium
hospit
elderli
patient
associ
statist
signific
increas
qtc
interv
baselin
howev
antipsychot
use
lead
sudden
cardiac
death
deliri
elderli
patient
hospit
stay
acut
care
set
evalu
potenti
inappropri
medic
patient
bundl
payment
episod
skill
nurs
facil
pooja
kirpekar
frank
damico
emili
kryger
pharmd
heather
sake
pharmd
st
margaret
pittsburgh
pa
biostatist
upmc
st
margaret
pittsburgh
pa
pittsburgh
pa
medic
educ
upmc
st
margaret
pittsburgh
pa
introduct
medicar
healthcar
reimburs
model
seek
provid
coordin
care
use
healthcar
team
howev
role
clinic
pharmacist
team
clearli
defin
current
literatur
research
question
hypothesi
preval
potenti
inappropri
medic
prescrib
transit
hospit
skill
nurs
facil
patient
bundl
payment
episod
studi
design
retrospect
chart
review
method
patient
discharg
hospit
part
larger
one
snf
geriatr
train
pharmacist
part
care
team
review
patient
enrol
comprehens
care
joint
replac
cjr
bundl
payment
care
improv
bpci
reimburs
model
studi
period
medic
appropri
index
mai
valid
tool
measur
potenti
inappropri
medic
prescrib
time
snf
admiss
primari
outcom
determin
preval
inappropri
medic
prescrib
secondari
outcom
descript
analyz
inappropri
prescrib
describ
popul
altern
payment
model
result
patient
identifi
bundl
payment
episod
studi
period
april
april
patient
met
inclus
criteria
patient
femal
averag
age
patient
year
old
mean
charlson
index
score
patient
averag
medic
order
admiss
percent
patient
patient
ci
instanc
potenti
inappropri
medic
prescrib
mean
mai
score
three
conclus
bundl
payment
patient
popul
complex
due
age
condit
polypharmaci
mai
detect
potenti
inappropri
medic
prescrib
care
geriatr
patient
bundl
payment
episod
illustr
pharmacist
may
role
identifi
inappropri
prescrib
associ
pharmacist
workload
perform
pharmaceut
care
taiwan
shao
ms
chan
chen
edward
lai
pharmaci
keelung
chang
gung
memori
hospit
keelung
taiwan
pharmaci
linkou
chang
gung
memori
hospit
linkou
taiwan
pharmaci
institut
clinic
pharmaci
pharmaceut
scienc
colleg
medicin
nation
cheng
kung
univers
tainan
taiwan
introduct
pharmacist
ensur
qualiti
safeti
medic
use
howev
dispens
overload
top
burden
pharmacist
associ
work
outcom
better
understand
impact
dispens
workload
pharmacist
perform
requir
evid
object
measur
drug
dispens
prescript
review
research
question
hypothesi
hypothes
higher
pharmacist
workload
may
lead
poorer
pharmaceut
care
studi
design
observ
studi
method
analyz
report
prescript
suggest
dispens
error
electron
report
system
er
chang
gung
medic
foundat
cgmf
hospit
largest
health
system
consist
hospit
taiwan
calcul
pharmacist
dispens
workload
pdw
number
prescript
divid
number
pharmacist
work
day
use
prescript
suggest
rate
psr
dispens
error
rate
der
outcom
indic
perform
pharmacist
review
dispens
work
respect
specif
psr
number
prescript
suggest
divid
number
pharmacist
work
day
der
number
dispens
error
divid
number
pharmacist
work
day
determin
influenc
pdw
psr
der
gener
mix
effect
model
result
includ
total
monthli
number
pharmacist
sd
contribut
monthli
sd
pharmacist
work
day
mean
number
sd
prescript
mean
pdw
sd
prescript
month
significantli
impact
pdw
psr
coeffici
p
der
coeffici
p
conclus
dispens
workload
neg
influenc
prescript
suggest
pharmacist
significantli
relat
dispens
error
find
implic
higher
workload
may
interfer
pharmacist
profess
ensur
qualiti
medic
use
administr
time
error
inpati
taiwan
studi
chen
shao
ms
chang
pharmaci
keelung
chang
gung
memori
hospit
keelung
taiwan
pharmaci
linkou
chang
gung
memori
hospit
taoyuan
taiwan
introduct
administr
time
error
common
medic
error
relat
studi
still
lack
taiwan
studi
focus
rate
administr
time
error
parenter
drug
find
could
serv
hospit
polici
refer
regard
improv
drug
administr
research
question
hypothesi
rate
administr
time
error
parenter
drug
inpati
set
taiwan
studi
design
retrospect
observ
studi
method
studi
use
medic
administr
system
bcma
record
parenter
drug
inpati
set
medic
center
region
hospit
taiwan
defin
time
error
administr
drug
patient
earlier
later
minut
regular
use
case
later
minut
immedi
use
case
follow
doctor
order
also
analyz
rate
time
error
differ
time
workshift
subgroup
analys
includ
rate
time
error
differ
hospit
level
result
analyz
total
record
bcma
mean
rate
administr
time
error
found
highest
rate
time
error
occur
even
shift
pm
follow
night
shift
morn
shift
pm
subgroup
analys
found
overal
rate
administr
time
error
similar
vs
medic
center
region
hospit
higher
night
shift
region
hospit
vs
conclus
administr
time
error
parenter
drug
inpati
set
common
attent
must
drawn
higher
rate
time
error
noon
shift
futur
studi
evalu
root
caus
administr
time
error
impact
patient
care
warrant
moder
intervent
effect
collabor
care
model
type
diabet
zheng
kang
lum
bsc
pharm
hon
jeffrey
jia
yeong
tan
mbchb
dip
famili
med
dip
joyc
lee
pharmd
bcp
univers
singapor
singapor
singapor
hong
famili
medicin
clinic
singapor
singapor
pharmaci
faculti
scienc
nation
univers
singapor
singapor
singapor
introduct
implement
collabor
care
model
manag
type
diabet
mellitu
recommend
intern
guidelin
literatur
report
promis
yet
vari
outcom
type
healthcar
deliveri
model
question
actual
benefit
collabor
care
model
remain
inadequ
address
studi
adopt
moder
analysi
identifi
characterist
individu
benefit
collabor
care
model
term
chang
distress
level
research
question
hypothesi
characterist
individu
type
diabet
found
improv
distress
manag
collabor
care
model
studi
design
moder
analysi
conduct
accord
macarthur
framework
pincu
et
al
methodolog
criteria
random
control
trial
involv
individu
type
diabet
method
individu
age
year
mmolmol
take
five
chronic
medic
random
collabor
care
usual
care
baselin
sociodemograph
characterist
medic
medic
histori
obtain
electron
databas
qualiti
life
assess
use
audit
qualiti
life
addqol
distress
use
problem
area
diabet
paid
medic
adher
self
report
particip
techniqu
approach
use
probe
interact
result
moder
intervent
effect
chang
includ
qualiti
life
measur
averag
weight
impact
addqol
use
oral
hypoglycaem
agent
oha
baselin
medic
adher
chang
distress
baselin
number
use
oha
found
moder
intervent
effect
conclus
studi
novel
applic
moder
analysi
incorpor
effect
techniqu
identifi
benefici
characterist
vital
advoc
individualis
care
yield
signific
posit
outcom
evalu
program
hospit
readmiss
alan
j
zillich
hannah
davi
wendi
lantaff
jaclyn
myer
susan
perkin
mu
heather
jayn
margi
e
snyder
pharmd
pharmaci
practic
purdu
univers
colleg
pharmaci
indianapoli
pharmaci
indiana
univers
lafayett
biostatist
indiana
univers
school
medicin
indianapoli
pharmci
practic
purdu
univers
colleg
pharmaci
indianapoli
introduct
transit
care
set
vulner
period
patient
effect
program
transit
care
hospit
home
need
improv
patient
outcom
research
question
hypothesi
effect
bedsid
medic
deliveri
program
prior
discharg
ie
hospit
readmiss
studi
design
retrospect
observ
cohort
studi
period
medium
size
suburban
method
intervent
cohort
defin
hospit
patient
elig
opt
program
elig
criteria
includ
patientsdischarg
home
gener
medicalsurg
intens
care
unit
prescrib
one
new
regularli
schedul
oral
medic
control
cohort
defin
hospit
patient
elig
program
receiv
administr
data
collect
includ
healthcar
util
eg
inpati
outpati
emerg
depart
visit
prior
admiss
healthcar
util
discharg
primari
outcom
defin
multivari
logist
regress
model
examin
likelihood
readmiss
intervent
control
group
covari
model
includ
age
gender
race
healthcar
util
month
prior
admiss
readmiss
risk
score
result
data
collect
intervent
control
patient
group
similar
respect
age
gender
race
condit
previou
healthcar
util
readmiss
risk
higher
intervent
compar
control
group
vs
p
proport
patient
readmit
within
day
intervent
group
control
group
multivari
model
patient
intervent
group
less
like
within
discharg
patient
control
group
although
differ
statist
signific
ci
conclus
program
significantli
reduc
readmiss
use
diagnost
util
andor
procedur
code
algorithm
administr
databas
discrimin
elect
percutan
coronari
intervent
catherin
g
derington
lauren
j
heath
david
p
kao
thoma
delat
phd
pharmaci
kaiser
permanent
colorado
aurora
co
clinic
pharmaci
kaiser
permanent
colorado
aurora
co
medicin
univers
colorado
school
medicin
aurora
co
introduct
elect
percutan
coronari
intervent
pci
difficult
discrimin
pci
administr
data
limit
abil
track
patient
outcom
ensur
appropri
medic
manag
perform
research
patient
undergo
elect
pci
research
question
hypothesi
algorithm
use
diagnost
util
andor
procedur
code
discrimin
elect
pci
studi
design
valid
studi
method
administr
healthcar
util
databas
kaiser
permanent
colorado
integr
healthcar
deliveri
system
queri
across
month
identifi
patient
bill
pci
random
sampl
case
manual
two
train
clinic
pharmacist
review
kappa
coeffici
use
clinic
criteria
review
classifi
case
valid
pci
elect
case
test
nine
algorithm
contain
diagnost
util
andor
procedur
code
perform
statist
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
confid
interv
ci
use
wilson
score
method
calcul
algorithm
result
pci
case
could
valid
result
final
sampl
case
repres
uniqu
patient
elect
case
algorithm
exclud
case
acut
myocardi
infarct
ami
diagnosi
code
within
day
prior
pci
numer
highest
perform
statist
overal
sensit
specif
ppv
npv
ci
ci
ci
ci
respect
conclus
elect
pci
best
discrimin
administr
data
exclud
case
ami
diagnosi
code
within
day
prior
pci
sensit
specif
npv
high
algorithm
refin
ppv
algorithm
need
test
research
set
evalu
anemia
commun
serv
shoulder
shoulder
global
santo
domingo
ecuador
kevin
mercer
randal
knoebel
david
mannino
wayn
sanderson
phd
melodi
ryan
pharmd
pharmaci
john
hopkin
hospit
baltimor
md
pharmaci
univers
chicago
medicin
chicago
il
prevent
medicin
environment
health
univers
kentucki
colleg
public
health
lexington
ky
epidemiolog
univers
kentucki
colleg
public
health
lexington
ks
pharmaci
practic
scienc
univers
kentucki
colleg
pharmaci
lexington
ky
introduct
shoulder
shoulder
global
stsg
recogn
anemia
caus
morbid
among
patient
santo
domingo
ecuador
littl
done
assess
target
risk
factor
serv
foundat
futur
pharmacotherapeut
intervent
studi
sought
identifi
risk
factor
anemia
popul
research
question
hypothesi
factor
associ
anemia
santo
domingo
ecuador
studi
design
retrospect
cohort
studi
method
studi
declar
exempt
institut
review
board
data
obtain
exist
patient
record
januari
august
includ
hemoglobinhematocrit
age
sex
pregnanc
statu
present
commun
test
compar
mean
examin
risk
factor
associ
anemia
logist
regress
odd
ratio
use
evalu
factor
associ
anemia
statist
analys
perform
stata
result
uniqu
subject
anem
children
five
femal
pregnant
subject
distribut
throughout
seven
commun
present
indigen
commun
present
commun
plan
de
vivienda
ci
lo
naranjo
ci
el
bua
ci
risk
factor
anemia
compar
age
five
year
age
group
protect
anemia
neither
femal
sex
ci
pregnanc
ci
significantli
associ
anemia
conclus
risk
factor
anemia
popul
previous
determin
studi
risk
factor
age
group
year
present
select
commun
limit
studi
retrospect
design
addit
research
evalu
effect
stsg
health
intervent
anemia
discrimin
dose
frequenc
unstructur
prescript
sig
within
electron
health
record
data
catherin
g
derington
pharmd
jordan
b
king
pharmd
ms
depart
pharmaci
kaiser
permanent
colorado
aurora
co
introduct
clinic
care
reli
clearli
commun
patient
take
medic
includ
dose
rout
frequenc
durat
howev
outcom
research
challeng
research
medic
use
prescript
administr
direct
signatura
ie
sig
store
unstructur
string
within
electron
health
record
ehr
consequ
estim
patient
dose
frequenc
difficult
method
extract
data
need
research
question
hypothesi
develop
text
process
techniqu
discrimin
daili
dose
frequenc
within
ehr
data
studi
design
retrospect
valid
studi
method
lisinopril
use
case
studi
develop
algorithm
fashion
sig
contain
ehr
month
januari
kaiser
permanent
colorado
step
includ
standard
text
eg
capit
spell
pars
sig
identifi
frequenc
iter
modif
base
identif
error
valid
sig
data
februari
primari
outcom
posit
predict
valu
ppv
algorithm
calcul
divid
number
prescript
assign
correct
frequenc
true
posit
total
number
result
algorithm
result
lisinopril
prescript
dispens
februari
distinct
uniqu
sig
sig
repres
dose
frequenc
remaind
dose
frequenc
eg
three
time
daili
ppv
sig
misclassifi
algorithm
qualit
sig
commonli
misclassifi
algorithm
due
spell
error
word
choic
eg
supper
instead
even
conclus
even
simpl
oral
medic
prescript
sig
complex
hundr
way
describ
dose
frequenc
algorithm
high
ppv
develop
refin
analyz
compon
prescript
sig
extract
variabl
interest
risk
factor
vitamin
defici
sickl
cell
diseas
jin
han
pharmd
xu
zhang
santosh
saraf
michel
gowhari
robert
moloki
joharah
hassan
shivi
jain
taimur
abbasi
roberto
machado
victor
gordeuk
pharmaci
practic
colleg
pharmaci
univers
illinoi
chicago
chicago
il
hematologyoncolog
depart
medicin
univers
illinoi
chicago
chicago
il
pulmonari
critic
care
sleep
occup
medicin
indiana
univers
indianapoli
introduct
vitamin
defici
vdd
defin
level
ngml
preval
among
patient
sickl
cell
diseas
scd
link
acutechron
pain
bone
fractur
patient
popul
limit
literatur
studi
risk
factor
associ
develop
vdd
scd
research
question
hypothesi
investig
risk
factor
vdd
scd
studi
design
studi
risk
factor
associ
vdd
scd
patient
method
examin
clinic
genom
paramet
associ
vdd
adult
scd
compar
level
scd
gener
popul
nation
health
nutrit
examin
survey
nhane
analyz
express
gene
involv
vitamin
metabol
result
level
independ
associ
older
age
coeffici
ci
p
vitamin
supplement
coeffici
ci
p
adult
scd
patient
level
greater
scd
patient
year
age
compar
gener
popul
age
rang
season
variat
level
scd
patient
lowest
level
month
least
daylight
novemb
januari
lower
level
associ
increas
express
cytochrom
decreas
express
vitamin
bind
protein
dbp
two
gene
involv
vitamin
metabol
pathway
scd
weekli
oral
ergocalciferol
supplement
significantli
improv
level
median
vs
ngml
p
conclus
found
vdd
associ
younger
age
adult
patient
scd
emphas
import
supplement
vitamin
age
group
year
old
lack
sun
exposur
differenti
gene
express
dbp
also
may
contribut
vdd
patient
popul
interim
report
andexanet
revers
anticoagul
factor
acut
major
bleed
stuart
j
connolli
md
mark
crowther
md
msc
truman
j
mill
md
john
w
eikelboom
c
michael
gibson
andrew
demchuk
patrick
yue
michel
bronson
genmin
lu
pamela
b
conley
peter
verhamm
md
jeannot
schmidt
saskia
middeldorp
alexand
cohen
md
jan
pierr
albaladejo
jose
shelli
goodman
janet
leed
deborah
siegal
elena
zotova
brandi
meek
juliet
nakamya
john
curnutt
md
w
richey
neuman
md
univers
hamilton
canada
dell
medic
school
stroke
institut
austin
tx
medic
school
boston
school
medicin
univers
calgari
calgari
nt
canada
pharmaceut
inc
south
san
francisco
ca
leuven
leuven
belgium
hospitali
universitair
de
franc
medic
center
amsterdam
netherland
st
thoma
hospit
king
colleg
london
london
unit
kingdom
hospit
carl
gustav
caru
dresden
dresden
germani
univers
hospit
grenobl
franc
universitario
la
paz
madrid
spain
present
american
colleg
cardiolog
acc
annual
scientif
session
expo
march
orlando
florida
apixaban
pharmacodynam
octogenarian
patient
atrial
fibril
ran
nissan
galia
spectr
avit
hershkovitz
hefziba
green
shai
shimoni
sigal
nakav
tzipora
shohat
alon
grossman
shmuel
fuch
hospit
rabin
medic
center
petah
tikva
israel
rivka
geriatr
rehabilit
center
petah
tikva
israel
harof
medic
center
zrifin
israel
introduct
pauciti
data
apixaban
level
among
octogenarian
atrial
fibril
nvaf
research
question
hypothesi
hypothes
octogenarian
may
higher
drug
level
apixaban
specifi
manufactur
therefor
sought
assess
apixaban
trough
peak
drug
level
among
real
world
octogenarian
receiv
variou
apixaban
dosag
nvaf
compar
data
level
found
patient
younger
old
studi
design
cross
section
prospect
studi
patient
treat
apixaban
nvaf
method
apixaban
level
compar
among
octogenarian
treat
mg
bid
twice
daili
octogenarian
appropri
reduc
dose
mg
bid
octogenarian
inappropri
reduc
dose
younger
patient
age
year
trough
peak
level
measur
chromogen
assay
calibr
apixaban
least
day
complet
adher
result
signific
proport
cohort
trough
peak
level
especi
octogenarian
bid
dose
trough
peak
signific
differ
found
trough
peak
geometr
mean
gm
level
among
group
apart
peak
gm
level
mg
octogenarian
group
two
mg
bid
octogenarian
group
frequenc
apixaban
peak
level
within
upper
quartil
significantli
higher
mg
octogenarian
group
compar
group
measur
wherea
trough
level
compar
group
conclus
high
peak
apixaban
steadi
state
level
highli
preval
octogenarian
receiv
appropri
dosag
mg
bid
nvaf
stroke
prevent
age
strongli
affect
apixaban
level
evalu
safeti
intraven
ketorolac
patient
admit
sickl
cell
diseas
crisi
rachel
crawford
giulia
barlow
allison
kupsh
katherin
rector
pharmd
jamielynn
sebaali
justin
arnal
pharmd
padmaja
veeramreddi
ifeyinwa
osunkwo
md
pharmaci
carolina
medic
center
charlott
nc
pharmaci
carolina
medic
center
charlott
nc
eshelman
school
pharmaci
carolina
medic
center
charlott
nc
univers
school
pharmaci
wingat
nc
cancer
institut
pharmaci
depart
carolina
healthcar
system
charlott
nc
cell
clinic
levin
cancer
institut
charlott
nc
cancer
institut
charlott
nc
introduct
treatment
sickl
cell
diseas
scd
crise
voc
complex
poorli
defin
due
multifactori
pathophysiolog
scd
pain
scd
treatment
team
carolina
medic
center
util
iv
ketorolac
adjunct
opioid
subset
patient
knowledg
publish
data
examin
safeti
iv
ketorolac
adult
scd
patient
admit
treatment
voc
research
question
hypothesi
iv
ketorolac
safe
use
adult
admit
voc
measur
incid
aki
studi
design
singl
center
retrospect
chart
review
method
scd
patient
admit
voc
juli
identifi
categor
three
group
base
upon
receipt
schedul
iv
ketorolac
need
prn
dose
schedul
oral
nsaid
prn
dose
control
group
patient
receiv
nsaid
receiv
prn
nsaid
dose
secondari
object
includ
incid
bleed
length
stay
result
total
patient
includ
studi
differ
detect
incid
aki
studi
group
patient
schedul
iv
ketorolac
group
better
baselin
renal
function
compar
group
differ
bleed
event
length
stay
concurr
use
medic
increas
risk
bleed
detect
patient
receiv
schedul
oral
nsaid
prn
dose
like
receiv
nephrotox
medic
addit
differ
found
conclus
use
iv
ketorolac
appear
increas
incid
aki
patient
scd
voc
adequ
renal
function
larger
prospect
match
subject
studi
would
need
elucid
safeti
iv
ketorolac
scd
patient
clinic
consequ
relat
discrep
laboratori
point
care
inr
gregori
robert
b
pharm
madison
shepley
b
domin
parker
jessica
dawson
b
barbara
farrelli
b
pharmaci
flinder
medic
centr
bedford
park
australia
pharmaci
bedford
park
australia
medicin
flinder
medic
centr
bedford
park
australia
home
flinder
medic
centr
bedford
park
australia
introduct
lab
test
intern
normalis
ratio
inr
gold
standard
point
care
poc
inr
facilit
extend
hospit
care
discharg
mark
discord
lab
poc
inr
anecdot
note
chang
laboratori
assay
disrupt
clinic
manag
especi
patient
receiv
mechan
heart
valv
poc
system
use
across
entir
studi
period
research
question
hypothesi
compar
concurr
labpoc
inr
patient
transit
extend
hospit
care
pre
pre
post
post
implement
new
laboratori
assay
studi
design
retrospect
inr
measur
concurr
poc
lab
inr
identifi
method
poclab
differ
inr
pair
compar
across
pre
post
period
use
multivari
regress
analysi
variabl
includ
patient
type
gener
surgeri
gensurg
cardiac
surgeri
cardsurg
medic
med
heart
failur
liver
function
albumin
day
concord
standard
assess
use
intern
guidelin
result
poclab
inr
differ
increas
markedli
post
period
pre
post
p
cardsurg
p
gensurg
p
p
med
group
increas
cardsurg
patient
greater
gensurg
med
p
variabl
impact
poclab
relationship
pre
group
inr
pair
within
allow
maximum
inr
differ
inr
rang
compar
post
group
p
use
local
guidelin
use
poc
instead
lab
inr
would
result
extra
dose
held
pre
period
due
inr
compar
post
period
p
conclus
chang
lab
assay
markedli
impact
poclab
inr
relationship
clear
clinic
disrupt
light
evid
guidelin
alter
accommod
discrep
analysi
direct
oral
anticoagul
prescrib
academ
medic
center
juli
murphi
pharmd
fashp
fccp
bcp
rebecca
wong
rachel
e
raru
pharmd
pharmaci
pharmaceut
scienc
univers
toledo
toledo
oh
toledo
medic
center
toledo
oh
introduct
studi
suggest
implement
direct
oral
anticoagul
doac
protocol
help
increas
appropri
doac
prescrib
howev
studi
address
protocol
includ
anticoagul
transit
doac
ensur
adequ
sampl
size
research
question
hypothesi
implement
anticoagul
transit
polici
increas
preval
appropri
doac
prescrib
studi
design
retrospect
studi
method
adult
patient
admit
care
unit
receiv
least
one
dose
apixaban
rivaroxaban
dabigatran
februari
februari
elig
inclus
primari
outcom
preval
appropri
doac
prescrib
implement
anticoagul
transit
polici
secondari
object
includ
identifi
factor
age
renal
function
doac
prescrib
potenti
contribut
inappropri
doac
prescrib
determin
advers
event
associ
inappropri
doac
prescrib
meet
power
total
subject
need
outcom
statist
signific
result
one
hundr
patient
identifi
inclus
group
group
total
patient
receiv
appropri
prescrib
doac
group
respect
patient
group
younger
median
age
vs
year
higher
estim
creatinin
clearanc
median
vs
mlmin
prescrib
apixaban
commonli
doac
p
differ
doac
indic
atrial
fibril
common
indic
group
inappropri
doac
prescrib
result
advers
event
conclus
implement
anticoagul
transit
polici
significantli
affect
overal
appropri
doac
prescrib
anticoagul
qualiti
anticoagul
clinic
rural
set
compar
standard
care
bryan
zobeck
martin
macdowel
sing
ping
chow
pharmaci
practic
univers
illinoi
colleg
pharmaci
rockford
rockford
il
center
rural
health
profess
univers
illinoi
colleg
pharmaci
rockford
rockford
il
illinoi
chicago
rockford
il
introduct
anticoagul
clinic
describ
sinc
improv
intern
normal
ratio
inr
time
therapeut
rang
ttr
reduc
thromboembol
bleed
event
reduc
cost
model
well
describ
major
medic
center
rare
describ
rural
popul
face
uniqu
health
dispar
research
question
hypothesi
anticoagul
clinic
improv
qualiti
measur
anticoagul
care
ttr
inr
adher
rural
popul
studi
design
retrospect
cohort
patient
serv
hisher
histor
control
anticoagul
clinic
enrol
method
patient
enrol
anticoagul
clinic
month
initi
may
evalu
inclus
criteria
includ
age
least
month
warfarin
enrol
clinic
inr
valu
within
day
held
dose
exclud
analysi
primari
endpoint
inr
ttr
use
rosenda
method
secondari
endpoint
includ
percentag
inr
measur
rang
inr
result
ttr
inr
rang
use
relax
inr
goal
day
inr
appoint
miss
number
inr
miss
day
spss
chicago
ibm
corpor
use
analysi
result
patient
met
inclus
criteria
includ
analysi
anticoagul
clinic
increas
inr
ttr
vs
percentag
inr
goal
rang
vs
compar
usual
care
number
day
inr
miss
reduc
vs
day
p
percentag
inr
miss
day
vs
p
compar
usual
care
percentag
inr
significantli
differ
conclus
establish
anticoagul
clinic
significantli
improv
inr
control
inr
monitor
adher
appropri
thrombophilia
test
patient
acut
care
set
evalu
associ
cost
riddhi
virparia
pharmd
candid
luigi
brunetti
pharmd
mph
bcp
christoph
adam
pharmd
bcp
mario
school
pharmaci
rutger
state
univers
new
jersey
piscataway
nj
pharmaci
practic
administr
ernest
mario
school
pharmaci
rutger
state
univers
new
jersey
piscataway
nj
introduct
thrombophilia
test
rare
recommend
acut
care
set
due
high
likelihood
result
inappropri
perform
test
acut
care
set
associ
inaccur
interpret
increas
econom
burden
retrospect
analysi
appropri
thrombophilia
test
order
patient
acut
care
set
evalu
term
clinic
util
econom
cost
research
question
hypothesi
thrombophilia
test
order
appropri
acut
care
set
studi
design
retrospect
analysi
consecut
adult
inpati
discharg
academ
commun
medic
center
novemb
novemb
receiv
thrombophilia
test
method
patient
stratifi
two
group
appropri
test
inappropri
test
base
data
abstract
directli
electron
health
record
primari
outcom
appropri
test
base
publish
criteria
thrombophilia
test
includ
concurr
anticoagul
use
patient
admit
diagnosi
andor
comorbid
associ
thrombosi
risk
secondari
endpoint
financi
burden
inappropri
thrombophilia
test
base
assay
charg
result
analyt
sampl
includ
patient
thrombophilia
test
patient
test
inappropri
conduct
patient
test
inappropri
due
concurr
anticoagul
use
andor
provok
venou
thromboembol
vte
test
inappropri
due
lack
risk
factor
thrombophilia
patient
appropri
test
test
financi
impact
inappropri
test
estim
excess
charg
amount
conclus
thrombophilia
test
acut
care
set
often
inappropri
consid
patient
characterist
may
influenc
interpret
restrict
use
avoid
unnecessari
risk
cost
warrant
analysi
implement
institut
pcc
protocol
assess
simplif
cost
save
cora
housley
scott
mueller
tyre
kiser
edward
van
matr
pharmd
robert
maclaren
pharmd
dougla
n
fish
paul
reynold
tobi
c
trujillo
pharmd
bcp
aq
cardiolog
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
label
dosag
prothrombin
complex
concentr
pcc
urgent
revers
anticoagul
warfarin
base
weight
inr
previou
studi
use
protocol
demonstr
promis
clinic
econom
result
research
question
hypothesi
aim
studi
evalu
impact
pcc
protocol
cost
time
administr
pharmacist
workload
studi
design
conduct
retrospect
review
patient
receiv
pcc
univers
colorado
hospit
uch
august
august
juli
novemb
implement
fix
dose
method
adult
patient
receiv
pcc
uch
elig
inclus
except
receiv
pcc
organ
transplant
primari
outcom
cost
pcc
per
patient
post
vs
secondari
outcom
includ
time
administr
number
pcc
order
modifi
pharmacist
protocol
adher
result
baselin
characterist
clinic
outcom
similar
patient
receiv
pcc
compar
patient
group
receiv
less
initi
total
total
median
pcc
dose
compar
group
vs
unit
vs
unit
vs
unitskg
respect
p
valu
relat
save
per
patient
base
awp
protocol
result
shorter
time
initi
order
verif
minut
differ
fewer
intervent
pharmacist
dose
modif
vs
p
howev
time
order
administr
similar
two
group
vs
minut
protocol
adher
patient
receiv
protocol
dose
receiv
median
excess
unit
conclus
pcc
protocol
result
reduc
cost
pharmacist
workload
addit
educ
improv
protocol
adher
reduc
cost
melatonin
use
academ
medic
center
factor
impact
provid
document
patient
sleep
qualiti
susan
smith
bs
p
brittani
vickeri
samir
kouzi
ph
kishan
patel
univers
school
pharmaci
wingat
nc
univers
school
pharmaci
hendersonvil
nc
introduct
melatonin
prescrib
insomnia
jet
lag
circadian
rhythm
disord
appear
perceiv
benign
sleep
aid
rel
pharmacolog
agent
howev
american
academi
sleep
medicin
guidelin
recommend
melatonin
treatment
insomnia
adult
due
lack
evid
efficaci
unavail
systemat
data
side
effect
research
question
hypothesi
studi
object
includ
determin
percentag
prescrib
document
impact
melatonin
sleep
qualiti
hospit
patient
examin
factor
may
impact
provid
document
studi
design
retrospect
review
method
electron
medic
record
adult
order
melatonin
period
review
primari
outcom
evalu
provid
document
sleep
impact
melatonin
patient
report
sleep
qualiti
secondari
outcom
includ
evalu
provid
medic
reconcili
admissiondischarg
concomit
insomnia
therapi
descript
inferenti
statist
perform
systat
softwar
inc
denot
signific
result
provid
document
sleep
qualiti
patient
rang
specif
mention
melatonin
impact
sleep
qualiti
avail
patient
patient
receiv
melatonin
prior
admiss
continu
therapi
discharg
patient
discharg
melatonin
greater
sleep
qualiti
document
compar
discharg
without
melatonin
vs
p
patient
concomit
insomnia
medic
provid
document
greater
patient
receiv
combin
therapi
compar
melatonin
monotherapi
p
conclus
document
patient
report
sleep
qualiti
lack
patient
melatonin
continu
upon
discharg
addit
studi
patient
patient
receiv
melatonin
plu
addit
insomnia
medic
increas
sleep
qualiti
document
studi
demonstr
melatonin
wide
use
narrowli
monitor
phase
pilot
studi
evalu
switch
elvitegravircobicistatemtricitabinetenofovir
alafenamid
ecftaf
infect
adult
subject
harbor
nrti
resist
mutat
ignacio
josep
llibr
adriano
lazzarin
giovanni
di
perri
federico
pulido
molina
stefan
esser
ian
mcnichol
lorgeoux
nicola
margot
bs
yongwu
shao
david
piontkowski
jd
moupali
da
richard
haubrich
vih
hospit
universitario
la
paz
madrid
spain
lucha
contra
el
sida
barcelona
spain
ircc
san
raffael
del
mont
tabor
milan
itali
di
malatti
infett
e
tropicali
turin
itali
vih
hospit
universitario
de
octubr
ucm
madrid
spain
infecti
diseas
hospit
univers
pari
pari
franc
essen
essen
germani
medic
affair
gilead
scienc
foster
citi
ca
scienc
montreal
qc
canada
virolog
gilead
scienc
inc
foster
citi
ca
scienc
foster
citi
ca
present
oral
aid
amsterdam
juli
diagnost
excess
order
pilot
intervent
studi
optim
test
acut
care
set
daryush
tabatabai
asl
harmind
sikand
pharmd
fcshp
fashp
eva
sullivan
nanci
md
pharmaci
scripp
merci
hospit
san
diego
ca
diseas
scripp
health
san
diego
ca
introduct
unnecessari
order
laboratori
test
count
hiv
rna
level
hiv
genotyp
result
increas
healthcar
cost
unneed
intervent
patient
anxieti
discomfort
recent
data
evalu
method
reduc
excess
test
outpati
limit
data
inpati
set
research
question
hypothesi
implement
intervent
protocol
improv
util
diagnost
alloc
antimicrobi
stewardship
resourc
acut
care
set
studi
design
two
phase
studi
larg
academ
medic
center
arm
evalu
hiv
diagnost
usag
period
follow
arm
analysi
method
patient
includ
year
old
suspect
document
hiv
infect
count
hiv
rna
level
hiv
genotyp
order
intervent
algorithm
test
creat
base
cdc
dhh
guidelin
approv
pharmaci
therapeut
committe
allow
primari
investig
automat
author
cancel
test
deem
inappropri
clinician
provid
educ
appropri
order
prior
studi
initi
result
tabul
present
descript
statist
financi
data
calcul
base
cost
result
arm
test
order
meet
criteria
appropri
result
financi
burden
test
order
interven
upon
cancel
result
cost
avoid
month
annual
common
cancel
reason
avail
recent
outpati
lab
test
decreas
time
attribut
intervent
audit
feedback
provid
conclus
intervent
reduc
number
unnecessari
test
concomit
cost
save
studi
highlight
import
evalu
appropri
diagnost
test
acut
care
set
assess
singl
tablet
antiretrovir
therapi
adher
relat
pharmaci
select
among
individu
infect
merrion
buckley
pharmdmph
candid
drew
armstrong
pharmd
bcacp
crystal
walker
phd
dnp
pharmaci
univers
tennesse
health
scienc
center
memphi
tn
special
care
clinic
region
one
health
memphi
tn
nurs
univers
tennesse
health
scienc
center
memphi
tn
introduct
combin
antiretrovir
therapi
art
mainstay
treatment
individu
infect
human
immunodefici
viru
hiv
adher
art
critic
patient
contribut
viral
suppress
posit
health
outcom
research
question
hypothesi
pharmaci
select
impact
adher
singl
tablet
art
viral
suppress
among
person
infect
hiv
studi
design
singl
center
retrospect
review
method
singl
tablet
antiretrovir
prescript
prescrib
adult
special
care
clinic
collect
use
electron
health
record
singl
tablet
antiretrovir
prescript
sent
region
one
health
specialti
pharmaci
roh
memphi
tn
nashvil
pharmaci
servic
np
nashvil
tn
analyz
group
random
retrospect
evalu
refil
date
patient
roh
date
np
period
patient
exclud
receiv
least
one
suppli
art
interv
patient
demograph
hiv
viral
load
collect
patient
consid
adher
proport
day
prescript
interv
result
total
patient
roh
patient
np
includ
evalu
adher
patient
evalu
consid
adher
individu
roh
adher
medic
compar
patient
util
np
viral
suppress
hiv
rna
copiesml
observ
adher
patient
patient
conclus
individu
infect
util
roh
like
adher
art
receiv
medic
via
np
patient
adher
also
like
viral
suppress
result
provid
evid
recommend
patient
select
specialti
pharmaci
roh
art
medic
evalu
safeti
toler
abacavirdolutegravirlamivudin
incarcer
popul
marisa
brizzi
pharmd
melissa
badowski
pharmd
mph
thoma
chiampa
pharmd
depart
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
introduct
seem
though
major
clinic
trial
overestim
safeti
toler
antiretrovir
therapi
art
trend
increas
side
effect
laboratori
abnorm
patient
treat
univers
illinoi
uih
hiv
telemedicin
clinic
switch
previou
antiretrovir
therapi
art
abacavirdolutegravirlamivudin
research
question
hypothesi
higher
incid
side
effect
laboratori
abnorm
patient
compar
major
clinic
trial
studi
design
studi
retrospect
analysi
incarcer
patient
receiv
care
hiv
telemedicin
clinic
uih
januari
june
method
adult
patient
switch
previou
art
includ
studi
primari
endpoint
includ
incid
patient
report
side
effect
chang
scr
ast
alt
baselin
secondari
endpoint
evalu
virolog
suppress
baselin
switch
data
collect
baselin
visit
descript
statist
use
baselin
characterist
incid
primari
secondari
outcom
wilcoxon
test
use
evalu
chang
scr
mcnemar
test
use
evalu
virolog
suppress
analys
conduct
graphpad
prism
version
result
switch
previou
art
patient
report
side
effect
common
includ
headach
nausea
rash
fatigu
insomnia
statist
signific
increas
scr
patient
p
median
increas
mgdl
final
visit
proport
patient
virolog
suppress
similar
switch
abacavirdolutegravirlamivudin
vs
conclus
appear
similar
less
side
effect
incarcer
popul
compar
clinic
trial
antiretrovir
therapi
caus
statist
signific
increas
scr
patient
integr
pharmacist
treatment
manag
team
patient
live
human
immunodefici
viru
hepat
c
viru
bernadett
jakeman
vu
pharmd
paulina
deme
larri
pineda
letitia
tomaszewski
bs
md
sarah
perez
karla
thornton
md
pharmaci
depart
pharmaci
practic
administr
scienc
univers
new
mexico
health
scienc
center
albuquerqu
nm
qualiti
manag
coven
health
system
lubbock
tx
medicin
depart
intern
medicin
univers
new
mexico
health
scienc
center
albuquerqu
nm
introduct
hepat
c
viru
hcv
coinfect
rate
amongst
person
live
hiv
plwh
high
hcv
treatment
antivir
daa
plwh
complic
drug
interact
adher
insur
restrict
limit
hcv
provid
address
issu
truman
health
servic
th
hcv
clinic
establish
physicianpharmacist
clinician
phc
collabor
practic
model
initi
clinic
visit
conduct
team
visit
conduct
phc
research
question
hypothesi
util
phc
hcv
treatment
manag
hivhcv
patient
result
high
rate
sustain
virolog
respons
svr
studi
design
retrospect
observ
studi
plwh
seen
th
hcv
clinic
method
chart
review
complet
patient
exclud
start
hcv
treatment
monoinfect
hcv
data
collect
includ
demograph
comorbid
hcv
genotyp
viral
load
prior
hcv
treatment
hiv
regimen
chang
hiv
viral
load
count
number
clinic
visit
result
total
chart
review
exclud
monoinfect
treatment
patient
includ
analysi
averag
age
year
male
white
common
genotyp
total
patient
cirrhosi
hcv
start
hcv
treatment
patient
undetect
hiv
viral
load
hiv
regimen
chang
requir
patient
averag
number
phc
visit
post
treatment
patient
lost
remain
patient
achiev
svr
conclus
hivhcv
coinfect
patient
achiev
high
rate
svr
pharmacist
success
integr
hivhcv
manag
team
allow
larger
number
patient
receiv
hcv
treatment
evalu
altern
dose
regimen
intraven
voriconazol
treatment
invas
aspergillosi
pediatr
immunocompromis
patient
therapeut
drug
monitor
safeti
marlon
barraza
sr
torr
md
romina
valenzuela
paula
catalan
jorg
moral
pharmd
msc
patricio
garcia
sr
servic
hospit
dr
lui
calvo
mackenna
santiago
chile
pediatr
research
unit
universidad
de
chile
santiago
chile
marrow
transplant
servic
hospit
dr
lui
calvo
mackenna
santiago
chile
introduct
high
pharmacokinet
variabl
voriconazol
vcz
import
achiev
adequ
plasma
concentr
pc
pediatr
immunocompromis
invas
aspergillosi
ia
led
need
evalu
current
dosag
regimen
gener
new
recommend
research
question
hypothesi
regimen
three
time
day
tid
associ
better
cp
convent
regimen
bid
studi
design
retrospect
studi
singl
center
cohort
pediatr
immunocompromis
patient
suspect
ai
treat
vcz
method
patient
receiv
vcz
includ
trough
pc
obtain
syslab
system
compar
accord
dosag
regimen
tidbid
age
rang
year
consid
optim
cp
safeti
assess
result
patient
includ
pc
tid
regimen
bid
tid
pc
bid
pc
median
cp
dose
mgkgday
tid
mgl
mgkgday
bid
children
younger
year
old
pc
tid
vs
bid
children
year
old
pc
tid
vs
bid
children
older
year
pc
tid
vs
bid
hepat
renal
toxic
detect
visual
alter
occur
patient
tid
patient
bid
conclus
data
obtain
suggest
tid
regimen
associ
higher
percentag
adequ
cp
children
year
old
compar
convent
regimen
hand
children
older
year
achiev
better
cp
convent
regimen
regim
safe
infecti
pharmacist
particip
diagnost
stewardship
invas
aspergillu
infect
diseas
retrospect
observ
studi
bin
lin
bs
pharm
jie
fang
guoqiang
song
weifang
shao
fei
chen
huoquan
lu
yingzh
wu
xiang
xu
mba
clinic
pharmaci
changx
branch
second
affili
hospit
zhejiang
univers
school
medicin
changx
peopl
hospit
changx
china
pharmaci
ruijin
affili
hospit
shanghai
jiao
tong
univers
shanghai
china
respiratori
medicin
changx
branch
second
affili
hospit
zhejiang
univers
school
medicin
changx
peopl
hospit
changx
china
medic
laboratori
changx
branch
second
affili
hospit
zhejiang
univers
school
medicin
changx
peopl
hospit
changx
china
radiolog
changx
branch
second
affili
hospit
zhejiang
univers
school
medicin
changx
peopl
hospit
changx
china
clinic
pharmaci
changx
branch
second
affili
hospit
zhejiang
univers
school
medicin
changx
peopl
hospit
changx
china
introduct
diagnost
stewardship
refer
appropri
use
laboratori
test
guid
patient
manag
includ
treatment
infecti
pharmacist
involv
diagnost
stewardship
base
bedsid
mdt
shorten
time
diagnosi
treatment
optim
antifung
treatment
research
question
hypothesi
pharmacist
particip
diagnost
stewardship
shorten
time
optim
antifung
treatment
studi
design
retrospect
observ
studi
use
clarifi
import
infecti
pharmacist
diagnost
stewardship
model
method
juli
juli
patient
diagnosi
invas
aspergillu
infect
respiratori
medicin
ward
tertiari
hospit
china
observ
retrospect
perform
multidisciplinari
team
diagnost
stewardship
pharmacist
particip
invas
aspergillu
infect
patient
treat
stewardship
juli
juli
control
group
differ
diagnosi
time
time
dosag
adjust
compar
two
group
result
diagnost
time
ds
group
significantli
shorter
group
p
ds
group
due
particip
pharmacist
pharmacist
formul
antifung
treatment
plan
bedsid
accord
actual
situat
patient
microbiolog
result
clear
time
diagnosi
treatment
ds
group
significantli
shorter
group
p
pharmacist
adjust
drug
dose
voriconazol
patient
ds
group
one
patient
group
request
pharmacist
consult
adjust
dose
p
conclus
infecti
pharmacist
involv
diagnost
stewardship
optim
antifung
treatment
shorten
time
diagnosi
time
save
time
treatment
patient
invas
aspergillosi
experi
procalcitonin
assay
rural
facil
intervent
jennif
cole
pharmd
bcp
bcccp
depart
pharmaci
veteran
health
care
system
ozark
fayettevil
ar
introduct
procalcitonin
pct
gain
util
antimicrobi
stewardship
program
tool
decreas
antibiot
exposur
pauciti
outcom
intervent
specif
smaller
hospit
expert
hypothes
pct
may
lead
intervent
implement
pct
assay
studi
facil
previous
report
detail
includ
educ
monitor
solicit
feedback
interim
result
studi
describ
impact
pct
assay
month
util
research
question
hypothesi
benefit
procalcitonin
seen
random
control
trial
tertiari
medic
center
reproduc
primari
hospit
condit
studi
design
studi
design
evalu
two
period
may
april
versu
may
april
method
antibiot
consumpt
measur
day
therapi
dot
per
patient
day
pd
length
stay
lo
admiss
rate
antimicrobi
purchas
cost
period
also
compar
observ
data
includ
number
assay
order
cost
procur
chi
squar
proport
use
compar
student
test
use
continu
variabl
statist
evalu
r
foundat
statist
comput
version
vienna
austria
result
antibiot
consumpt
margin
decreas
intervent
p
chang
averag
lo
day
day
admiss
rate
cost
save
antibiot
purchas
versu
differ
pct
procur
reach
conclus
implement
pct
assay
facil
demonstr
margin
decreas
antibiot
consumpt
effect
lo
admiss
rate
purchas
cost
implement
vancomycin
auc
monitor
program
peak
pitfal
zahra
kassamali
thu
nguyen
pharmaci
univers
washington
seattl
wa
medicin
valley
medic
center
renton
wa
publish
open
forum
infect
di
suppl
clostridium
difficil
time
protocol
optim
test
stewardship
nikunj
vya
pharmd
shereef
ali
pharmd
bcp
bcccp
cindi
hou
lea
ann
kellum
msn
rn
ccrn
mari
miller
rn
bsn
ann
mari
flori
msn
rn
health
new
jersey
stratford
nj
health
new
jersey
cherri
hill
nj
health
allianc
infecti
diseas
voorhe
nj
introduct
remain
challeng
distinguish
colon
versu
infect
clostridium
difficil
c
diff
associ
diarrhea
institut
despit
effect
antimicrobi
stewardship
effort
c
diff
test
posit
infect
remain
high
identifi
need
c
diff
test
stewardship
optim
research
question
hypothesi
cdiff
test
stewardship
optim
decreas
c
diff
test
effect
posit
neg
predict
valu
studi
design
irb
approv
singl
center
trial
method
irb
approv
studi
nurs
driven
algorithm
clostridium
difficil
timeout
cdt
includ
number
shape
stool
absenc
lax
last
hour
control
studi
group
identifi
nurs
provid
c
diff
educ
studi
group
nurs
util
cdt
algorithm
c
diff
pcr
sent
criteria
met
optim
test
stewardship
primari
object
assess
posit
neg
predict
valu
ppv
npv
associ
cdt
result
patient
cdt
perform
june
patient
test
c
diff
pcr
test
baselin
demograph
similar
group
patient
test
group
compar
control
like
meet
criteria
loos
bmsday
vs
lack
new
start
lax
vs
compar
control
group
fewer
test
order
studi
group
vs
per
similar
posit
test
result
vs
per
led
ppv
npv
conclus
cdt
util
declin
total
number
c
diff
test
order
algorithm
test
stewardship
c
diff
optim
ppv
npv
uncov
antimicrobi
stewardship
geriatr
long
term
care
set
better
kit
chan
rph
bscphm
aidle
craft
mdcm
ccfp
michael
kirzner
md
anh
nguyen
msc
samantha
yau
rph
bscphm
acpr
pharmd
pharmaci
baycrest
health
scienc
toronto
canada
famili
medicin
baycrest
health
scienc
toronto
canada
toronto
toronto
canada
introduct
antimicrobi
stewardship
program
asp
well
establish
studi
acut
care
set
howev
gap
exist
care
long
term
care
set
research
question
hypothesi
assess
physician
pharmacist
understand
antimicrobi
stewardship
evalu
util
current
asp
initi
increas
engag
improv
accept
asp
recommend
studi
design
qualit
studi
method
third
parti
interview
conduct
famili
physician
pharmacist
march
respond
ask
rate
impact
current
asp
initi
prescrib
practic
likert
scale
comment
barrier
accept
recommend
provid
suggest
guid
futur
initi
result
respond
abl
articul
purpos
asp
align
goal
endors
accredit
canada
infecti
diseas
societi
america
newslett
updat
provid
team
highest
impact
practic
score
follow
grand
round
guidelin
antibiogram
asp
recommend
address
parent
oral
antibiot
step
rate
impact
follow
antibiot
select
therapi
durat
renal
dose
adjust
respond
comment
asp
recommend
often
prompt
reassess
antibiot
therapi
howev
accept
modest
barrier
identifi
includ
conflict
recommend
specialist
ie
wound
care
team
geriatr
patient
famili
percept
need
antibiot
presum
infect
conclus
major
clinician
express
asp
initi
posit
impact
prescrib
antimicrobi
use
practic
current
asp
recommend
guid
chart
review
impact
accept
rate
result
limit
document
contribut
delay
commun
studi
requir
effect
guid
asp
initi
care
set
increas
clinician
engag
prolong
exposur
antibiot
staphylococcu
aureu
daptomycin
suscept
rachel
jenson
bs
sarah
bain
benjamin
howden
mbb
phd
fracp
andrew
berti
pharmd
phd
warren
rose
wisconsin
school
pharmaci
madison
wi
australia
mi
pharmaci
univers
madison
wi
introduct
daptomycin
dap
activ
dn
mrsa
heighten
presenc
acquisit
dn
link
mutat
within
mprf
gene
prevent
mprf
mutat
dap
exposur
research
question
hypothesi
sought
determin
dn
possess
mprf
mutat
becom
dap
suscept
presenc
whether
enhanc
suscept
associ
mprf
disrupt
studi
design
dn
mrsa
expos
vitro
variabl
penicillin
bind
protein
pbp
inhibit
profil
via
serial
daili
passag
dap
mic
chang
assess
time
method
includ
mrsa
daptomycin
suscept
dn
strain
deriv
clinic
dap
treatment
suscept
test
perform
dap
nafcillin
cloxacillin
ceftriaxon
cefoxitin
three
dn
strain
select
serial
passag
experi
concentr
daptomycin
suscept
whole
genom
sequenc
membran
fluiditi
membran
surfac
charg
studi
perform
result
increas
nafcillin
cloxacillin
suscept
occur
dn
strain
wherea
less
pronounc
effect
note
ceftriaxon
cefoxitin
suscept
passag
enhanc
dap
suscept
day
note
cloxacillin
effect
decreas
mic
mgl
day
mgl
day
addit
polymorph
mprf
locat
synthas
translocas
domain
mutat
observ
cloxacillin
correspond
reduc
membran
surfac
charg
p
alter
membran
fluiditi
conclus
bind
either
pbp
specif
pronounc
effect
dn
passag
especi
specif
cloxacillin
resensit
dn
strain
dap
addit
mutat
mprf
lead
alter
cell
membran
function
target
dap
activ
evalu
gap
patient
knowledg
urinari
tract
infect
medic
underserv
popul
emi
minejima
pharmd
anni
pharmd
usc
school
pharmaci
lo
angel
ca
present
american
societi
microbiolog
atlanta
ga
june
apoptosi
underli
molecular
mechan
proteasom
inhibitor
kill
schistosoma
mansoni
anh
ta
conor
caffrey
anthoni
odonoghu
nelli
betsaida
steven
wang
brian
suzuki
school
pharmaci
univers
california
san
diego
la
jolla
ca
school
pharmaci
univers
california
san
diego
la
jolla
ca
school
pharmaci
cdipd
univers
california
san
diego
la
jolla
ca
school
biomed
scienc
sanford
burnham
prebi
medic
discoveri
institut
la
jolla
ca
biolog
scienc
univers
california
san
diego
la
jolla
ca
california
san
diego
la
jolla
ca
introduct
schistosomiasi
caus
schistosoma
blood
fluke
chronic
pain
diseas
associ
poverti
develop
world
world
health
organ
rank
diseas
second
neglect
tropic
diseas
term
import
public
health
impact
treatment
control
diseas
reli
one
drug
praziquantel
pzq
pzq
number
pharmacolog
pharmaceut
drawback
relianc
one
drug
case
rais
concern
regard
possibl
emerg
drug
resist
group
investig
schistosom
proteasom
possibl
molecular
target
new
antischistosom
drug
research
question
hypothesi
understand
antischistosom
activ
variou
commerci
avail
proteasom
inhibitor
includ
whether
caspas
activ
activ
studi
design
vitro
test
method
adult
schistosoma
mansoni
worm
incub
bortezomib
carfilzomib
hour
worm
motil
marker
antischistosom
activ
measur
use
wormassay
also
employ
fluorometr
apoptosi
assay
measur
caspas
proteolyt
activ
extract
worm
expos
inhibitor
result
often
sever
decreas
motil
measur
mansoni
presenc
proteasom
inhibitor
correl
well
induct
caspas
activ
bortezomib
particularli
effect
wherea
neither
alter
worm
motil
induc
caspas
activ
conclus
data
demonstr
low
micromolar
concentr
proteasom
inhibitor
antischistosom
similar
mammalian
cell
proteasom
inhibitor
trigger
caspas
activ
proteasom
inhibitor
activ
investig
underli
biolog
andor
chemic
basi
find
iv
antibiot
administr
emerg
depart
ed
patient
discharg
home
zahra
kassamali
beau
chiba
michael
hori
cameron
buck
pharmaci
univers
washington
seattl
wa
medicin
valley
medic
center
renton
wa
introduct
use
iv
antibiot
provid
unnecessarili
invas
drug
administr
greater
risk
vs
oral
administr
iv
administr
delay
ed
discharg
due
prepar
infus
time
research
question
hypothesi
evalu
rate
iv
antibiot
use
ed
identifi
qualiti
improv
opportun
studi
design
retrospect
qualiti
improv
review
conduct
seattl
metropolitan
area
ed
see
patient
annual
patientshour
method
patient
present
ed
receiv
one
follow
iv
antibiot
levofloxacin
ceftriaxon
vancomycin
includ
antibiot
select
among
top
prescrib
institut
evalu
discharg
diagnos
rate
home
antibiot
prescript
data
evalu
descript
statist
result
patient
receiv
iv
antibiot
ed
discharg
without
inpati
admiss
among
discharg
receiv
iv
ceftriaxon
receiv
iv
levofloxacin
receiv
iv
vancomycin
base
upon
antibiot
infus
time
repres
addit
spent
ed
receiv
antibiot
prescript
upon
discharg
infecti
diagnosi
common
urinari
tract
infect
uti
follow
respiratori
tract
infect
skin
soft
tissu
infect
top
discharg
antibiot
prescript
fluoroquinolon
cephalexin
amoxicillin
conclus
administr
iv
antibiot
ed
patient
admit
hospit
contribut
hour
almost
full
day
wait
time
patient
high
util
iv
ceftriaxon
fluoroquinolon
prescript
discharg
correspond
frequent
diagnosi
uti
although
patient
may
present
nauseavomit
major
iv
antibiot
util
unnecessari
repres
opportun
improv
patient
safeti
improv
ed
throughput
time
evalu
advers
consequ
routin
prescrib
adult
patient
antibiot
uncompl
ercp
procedur
brittani
faley
bs
pharmd
candid
whitni
patterson
pharmd
candid
josh
kirchner
pharmd
candid
abigayl
renner
pharmd
candid
brett
heintz
pharmd
aq
iowa
colleg
pharmaci
iowa
citi
ia
citi
veteran
affair
health
care
system
iowa
citi
ia
introduct
endoscop
retrograd
cholangiopancreatographi
ercp
elect
surgeri
treat
issu
gallbladd
pancreat
duct
antimicrobi
prophylaxi
necessari
uncompl
ercp
howev
high
risk
case
guidelin
support
antimicrobi
prophylaxi
limit
hour
antimicrobi
stewardship
program
identifi
recur
area
antibiot
misus
routin
use
antimicrobi
prophylaxi
patient
ercp
particular
fluoroquinolon
recent
receiv
fda
safeti
warn
note
seriou
side
effect
associ
class
research
question
hypothesi
primari
object
evalu
antimicrobi
prophylaxi
guidelin
concord
among
patient
receiv
uncompl
ercp
procedur
secondari
object
evalu
differ
among
guidelin
concord
discord
case
includ
antimicrobi
durat
antibiot
associ
diarrhea
c
difficil
infect
resist
mortal
infect
rate
studi
design
retrospect
cohort
method
ercp
perform
electron
medic
record
chart
review
result
studi
period
case
evalu
met
inclus
criteria
overal
guidelin
concord
rate
mean
durat
antimicrobi
prophylaxi
day
vari
significantli
group
guidelin
concord
case
appear
lower
acuiti
lower
incid
cholecystectomycholecystostomi
lower
albumin
level
repeat
ercp
within
three
month
index
procedur
among
evalu
case
guidelin
concord
case
less
antibiot
associ
diarrhea
trend
toward
lower
cholang
combin
c
difficil
infect
document
resist
cefoxitin
common
agent
prescrib
surgic
prophylaxi
ciprofloxacin
common
agent
prescrib
discharg
cholecystectomi
biliarypancreat
malign
lower
albumin
associ
mortal
upon
multivari
regress
analysi
conclus
guidelin
discord
therapi
common
common
guidelin
discord
group
futur
prospect
studi
need
evalu
impact
guidelin
discord
therapi
advers
consequ
agent
nosocomi
pneumonia
maren
cowley
david
ritchi
pharmd
fccp
nichola
hampton
marin
kollef
md
facp
scott
micek
pharmd
fccp
bcp
hospit
saint
loui
mo
hospit
saint
loui
colleg
pharmaci
saint
loui
mo
hospit
washington
univers
school
medicin
saint
loui
mo
introduct
nosocomi
pneumonia
empir
antimicrobi
agent
shown
effect
method
decreas
antibiot
use
without
compromis
patient
outcom
howev
uncertainti
exist
regard
safeti
agent
nosocomi
pneumonia
research
question
hypothesi
studi
aim
determin
agent
nosocomi
pneumonia
affect
mortal
studi
design
retrospect
cohort
studi
includ
adult
patient
admit
nosocomi
pneumonia
neg
respiratori
cultur
method
defin
discontinu
mrsa
agent
within
four
day
initi
secondari
outcom
includ
hospit
mortal
hospit
icu
length
stay
treatment
failur
occurr
acut
kidney
injuri
result
patient
includ
de
group
nde
group
patient
receiv
day
mrsa
coverag
patient
howev
differ
mortal
nde
vs
de
p
patient
shorter
hospit
de
day
vs
nde
day
p
icu
de
day
vs
nde
day
length
stay
index
date
incid
aki
significantli
higher
patient
de
vs
nde
p
conclus
agent
nosocomi
pneumonia
affect
mortal
associ
shorter
hospit
stay
lower
incid
acut
kidney
injuri
studi
risk
factor
outcom
organ
infect
among
singapor
nurs
home
resid
admit
acut
care
hospit
jian
wei
heng
guo
shin
christoph
cheah
bachelor
scienc
pharmaci
christin
teng
msc
clinic
pharmaci
pharmaci
khoo
teck
puat
hospit
singapor
singapor
pharmaci
nation
univers
singapor
singapor
singapor
introduct
resid
nurs
home
nh
risk
factor
organ
mdro
infect
result
empir
broad
spectrum
antibiot
frequent
prescrib
howev
studi
demonstr
mdro
infect
may
lower
infect
infect
research
question
hypothesi
littl
known
risk
factor
outcom
mdro
infect
singapor
nh
popul
research
aim
determin
uniqu
risk
factor
outcom
mdro
infect
establish
predict
tool
aid
empir
antibiot
select
studi
design
studi
perform
hospit
method
patient
admit
nh
within
march
decemb
includ
patient
mdro
infect
bacteri
infect
compar
without
infect
common
control
group
univari
analys
multipl
logist
regress
conduct
predict
score
develop
signific
risk
factor
assess
receiv
oper
characterist
curv
roc
result
studi
includ
patient
mdro
control
group
respect
logist
regress
show
use
fluoroquinolon
last
day
aor
ci
peptic
ulcer
diseas
aor
ci
histori
mdro
colon
previou
year
aor
ci
uniqu
predictor
mdro
infect
mdro
predict
score
rang
develop
score
suggest
high
mdro
risk
specif
area
curv
roc
ci
caus
mortal
mdro
control
group
respect
p
conclus
use
predict
model
help
practition
identifi
high
risk
patient
truli
requir
broad
spectrum
antibiot
minim
inappropri
use
may
lead
antibiot
resist
unnecessari
side
effect
cost
evalu
impact
report
card
peer
profil
fluoroquinolon
util
across
system
john
allen
pharmd
bcp
bcccp
fccm
depart
pharmacotherapi
translat
research
univers
florida
colleg
pharmaci
orlando
fl
introduct
daili
basi
inpati
clinician
balanc
clear
benefit
antibiot
abx
also
attempt
avoid
potenti
neg
consequ
unnecessari
abx
use
among
potenti
agent
abx
use
reduct
fluoroquinolon
attract
target
due
wide
spectrum
activ
known
advers
event
profil
avail
less
toxic
therapeut
option
januari
began
provid
antibiot
report
card
focus
fluoroquinolon
util
across
system
individu
prescrib
group
specialti
allow
peer
comparison
research
question
hypothesi
implement
report
reduc
overal
fluoroquinolon
among
inpati
prescrib
studi
design
retrospect
observ
analysi
method
studi
period
defin
april
decemb
april
decemb
respect
fluoroquinolon
use
assess
use
number
fluoroquinolon
day
therapi
per
adjust
patient
day
apd
studi
period
addit
overal
percent
fluoroquinolon
use
compar
total
antibiot
use
assess
util
trend
unit
type
specialti
also
evalu
patient
specif
data
evalu
studi
review
system
ethic
board
irb
approv
waiv
base
data
distribut
appropri
statist
analysi
use
analyz
studi
result
adult
inpati
antibiot
use
consid
studi
result
across
hospit
system
fluoroquinolon
apd
reduc
period
facil
rang
p
compar
period
addit
overal
percent
fluoroquinolon
day
therapi
reduc
compar
period
facil
rang
p
differ
note
accord
type
unit
conclus
use
report
card
associ
reduc
fluoroquinolon
use
across
hospit
system
pharmacoeconom
analysi
penicillin
skin
test
scratch
surfac
commun
hospit
kristen
pierc
pharmd
candid
bruce
jone
pharmd
christoph
bland
pharmd
bcp
colleg
pharmaci
savannah
ga
josephscandl
health
system
savannah
ga
ga
administr
pharmaci
univers
georgia
colleg
pharmaci
savannah
ga
introduct
penicillin
allergi
true
allergi
associ
signific
morbid
mortal
clinic
outcom
document
penicillin
skin
test
pst
pharmacoeconom
outcom
well
describ
literatur
studi
evalu
direct
antimicrobi
cost
associ
pst
cohort
patient
test
commun
hospit
research
question
hypothesi
administr
pst
appropri
candid
improv
overal
antimicrobi
cost
direct
stewardship
pharmacist
studi
design
retrospect
analysi
patient
receiv
pst
within
commun
hospit
januari
method
primari
outcom
measur
total
cost
associ
pst
defin
cost
antimicrobi
receiv
pst
includ
cost
test
approxim
cost
therapi
calcul
basi
patient
receiv
pst
antimicrobi
regimen
would
continu
durat
antimicrobi
receiv
pst
secondari
outcom
evalu
includ
cost
top
antimicrobi
chang
pst
result
one
hundr
patient
complet
pst
test
neg
averag
cost
save
patient
per
patient
averag
cost
save
demonstr
patient
receiv
antimicrobi
chang
recommend
pharmacist
neg
pst
top
chang
averag
cost
carbapenem
penicillincephalosporin
save
cephalosporin
pcn
lower
gener
cephalosporin
save
fluoroquinolon
pcncephalosporin
loss
two
patient
initi
carbapenem
contribut
significantli
overal
cost
save
remov
averag
cost
save
overal
chang
group
carbapenem
chang
group
per
patient
respect
conclus
pst
offer
overal
cost
save
within
commun
hospit
direct
stewardship
pharmacist
even
account
high
cost
agent
data
need
determin
optim
pst
patient
pharmacoeconom
perspect
attitud
belief
knowledg
regard
influenza
vaccin
amongst
hospit
healthcar
worker
ian
wee
mpharm
clin
pharm
helen
oh
mbb
mmed
int
med
nichola
lim
bsc
pharm
hon
clair
lim
bsc
pharm
hon
pharmaci
changi
gener
hospit
singapor
singapor
medicin
infecti
diseas
changi
gener
hospit
singapor
singapor
introduct
healthcar
worker
increas
risk
influenza
exposur
world
health
organ
recommend
group
receiv
annual
influenza
vaccin
research
question
hypothesi
studi
attitud
belief
knowledg
regard
influenza
vaccin
amongst
healthcar
worker
acut
care
hospit
studi
design
prospect
voluntari
onlin
survey
method
part
world
immun
week
activ
healthcar
worker
invit
particip
anonym
onlin
survey
respons
survey
collect
studi
period
april
result
total
complet
survey
receiv
nurs
respond
awar
local
guidelin
regard
influenza
vaccin
felt
vaccin
import
protect
patient
familyfriend
mere
elderli
although
respond
felt
unsur
high
risk
catch
influenza
almost
understood
infect
could
respons
spread
viru
slightli
respond
felt
influenza
vaccin
gener
safe
concern
side
effect
respond
convinc
vaccin
effect
confer
adequ
temporari
immun
total
either
unconvinc
unsur
benefit
annual
influenza
vaccin
usual
come
influenza
conclus
signific
proport
healthcar
worker
understood
infect
could
sourc
spread
influenza
viru
patient
familyfriend
well
role
vaccin
prevent
viral
spread
respond
felt
vaccin
safe
recipi
half
doubt
efficaci
absenc
frequent
influenza
infect
almost
one
five
respond
also
uncertain
person
benefit
annual
influenza
vaccin
evalu
vs
sir
identifi
patient
risk
mortal
enterobacteracia
infect
ami
kang
dominiqu
werg
emi
minejima
school
pharmaci
lo
angel
ca
pharmaci
lo
angel
countyunivers
southern
california
medic
center
lo
angel
ca
present
american
societi
microbiolog
microb
atlanta
ga
june
impact
versu
vancomycin
dose
strategi
emili
heil
pharmd
bcp
aq
id
patricia
callahan
pharmd
ana
vega
kimberli
claey
pharmd
maryland
school
pharmaci
baltimor
md
pharmaci
practic
scienc
univers
maryland
school
pharmaci
baltimor
md
introduct
area
curv
auc
minimum
inhibitori
concentr
ratio
ideal
pharmacokineticpharmacodynam
descriptor
vancomycin
van
activ
allow
lower
dose
van
potenti
less
nephrotox
dose
strategi
van
launch
univers
maryland
medic
center
januari
research
question
hypothesi
dose
associ
lower
van
dose
therefor
lower
rate
nephrotox
compar
dose
strategi
studi
design
method
retrospect
review
adult
patient
octobernovemb
novemberdecemb
implement
van
dose
patient
match
patient
age
year
icu
admiss
number
concurr
nephrotox
agent
primari
endpoint
incid
nephrotox
versu
secondari
endpoint
includ
target
attain
number
appropri
drawn
van
level
total
daili
van
dose
categor
variabl
compar
use
fisher
exact
test
categor
compar
use
wilcoxon
test
appropri
result
patient
match
median
age
year
median
one
concurr
nephrotox
agent
group
icu
target
attain
versu
p
six
patient
versu
one
develop
nephrotox
p
averag
total
daili
dose
mgkg
van
similar
group
iqr
versu
iqr
number
level
higher
rang
versu
rang
number
appropri
drawnday
therapi
also
significantli
higher
iqr
versu
iqr
p
conclus
vancomycin
dose
strategi
associ
numer
lower
rate
nephrotox
compar
dose
strategi
resourc
util
similar
oral
vancomycin
plu
intraven
metronidazol
sever
clostridium
difficil
infect
critic
ill
patient
ana
vega
sikemi
ibikunl
md
teri
hopkin
pharmd
emili
heil
pharmd
bcp
aq
surbhi
leekha
mbb
jennif
johnson
phd
abmm
kimberli
claey
pharmd
bcp
pharmaci
practic
scienc
univers
maryland
school
pharmaci
baltimor
md
maryland
school
medicin
baltimor
md
south
texa
veteran
health
care
system
san
antonio
tx
maryland
school
pharmaci
baltimor
md
present
idweek
san
francisco
ca
octob
sustain
virolog
respons
rate
hepat
c
viru
therapi
patient
urban
academ
medic
center
michel
martin
chen
pharmd
nadia
nabulsi
bs
todd
lee
pharmd
practic
univers
illinoi
chicago
colleg
pharmacyunivers
illinoi
hospit
health
scienc
system
chicago
il
illinoi
chicago
colleg
pharmaci
chicago
il
system
outcom
polici
univers
illinoi
chicago
colleg
pharmaci
chicago
il
introduct
antivir
regimen
daa
offer
high
sustain
virolog
respons
svr
rate
hepat
c
viru
hcv
treatment
patient
high
cure
rate
clinic
trial
estim
hcv
patient
unit
state
still
research
question
hypothesi
hcv
svr
rate
among
patient
treat
therapi
urban
academ
medic
center
studi
design
retrospect
cohort
studi
method
investig
review
electron
record
patient
receiv
hcv
treatment
patient
start
regimen
includ
analysi
data
describ
countspercentag
categor
data
meansstandard
deviat
continu
data
primari
endpoint
svr
rate
compar
use
test
sa
softwar
result
patient
fit
inclus
criteria
svr
rate
patient
male
black
mean
age
year
bmi
medicaid
addit
genotyp
cirrhosi
metavir
stage
hepatocellular
carcinoma
hcc
diabet
psychiatr
ill
receiv
exclud
patient
discontinu
treatment
svr
rate
per
protocol
differ
stage
svr
rate
differ
gender
vs
hcc
vs
svr
differ
genotyp
raceethn
age
obes
comorbid
insur
p
conclus
patient
high
svr
rate
compris
larg
proport
divers
hcv
popul
gender
differ
daa
svr
rate
yet
report
literatur
higher
svr
rate
cirrhot
hcc
typic
develop
cirrhosi
low
svr
rate
seen
hcc
patient
result
support
hcv
treatment
prior
progress
cirrhosi
allow
improv
svr
rate
oral
fluoroquinolon
definit
treatment
bacteremia
cancer
patient
justin
tossey
zeinab
el
boghdadli
erica
reed
pharmd
jennif
pharmd
kelci
coe
sherri
william
pharmd
kurt
stevenson
md
lynn
wardlow
pharmd
mba
id
pharmaci
ohio
state
univers
wexner
medic
center
columbu
oh
intern
medicin
divis
infecti
diseas
ohio
state
univers
wexner
medic
center
columbu
oh
pharmaci
advoc
health
care
park
ridg
il
introduct
bloodstream
infect
bsi
signific
caus
morbid
mortal
cancer
patient
occur
neutropen
patient
hematopoiet
stem
cell
transplant
hsct
recipi
increas
rate
bsi
limit
data
exist
whether
cancer
patient
may
safe
transit
oral
po
antibiot
research
question
hypothesi
treatment
outcom
cancer
patient
receiv
fluoroquinolon
fq
transit
compar
iv
therapi
bacteremia
studi
design
retrospect
cohort
studi
method
patient
transit
po
fq
within
five
day
first
posit
blood
cultur
novemb
septemb
includ
group
compar
continu
iv
therapi
primari
outcom
treatment
failur
composit
recurr
readmiss
inpati
mortal
secondari
outcom
assess
includ
length
stay
lo
hospit
lo
advers
event
includ
clostridioid
difficil
infect
complic
eg
thrombosi
primari
outcom
evalu
use
test
confound
factor
eg
pitt
bacteremia
score
account
use
logist
regress
model
categor
variabl
compar
use
fisher
exact
test
continu
data
analyz
use
student
wilcoxon
test
parametr
nonparametr
data
respect
result
iv
group
includ
patient
respect
differ
baselin
characterist
includ
higher
incid
neutropenia
hematolog
malign
hsct
icu
admiss
iv
group
patient
iv
group
experienc
significantli
treatment
failur
vs
p
persist
within
regress
model
aor
ci
signific
decreas
hospit
lo
lo
complic
found
group
conclus
low
rate
treatment
failur
observ
cancer
patient
transit
po
fq
bacteremia
predictor
treatment
failur
follow
fluoroquinolon
cultur
neg
nosocomi
pneumonia
amanda
bulta
amit
beri
eli
deal
pharmd
aaron
hartmann
pharmd
sara
k
richter
pharmd
william
call
pharmd
hospit
st
loui
mo
loui
colleg
pharmaci
st
loui
mo
introduct
recommend
antimicrobi
therapi
set
nosocomi
pneumonia
without
posit
cultur
lack
clinic
patient
often
fluoroquinolon
upon
clinic
improv
although
littl
data
avail
support
practic
research
question
hypothesi
predictor
treatment
failur
follow
respiratori
fluoroquinolon
cultur
neg
nosocomi
pneumonia
studi
design
retrospect
cohort
studi
method
cohort
entri
includ
patient
admit
januari
juli
diagnosi
nosocomi
pneumonia
posit
chest
radiographi
receiv
least
hour
fluoroquinolon
monotherapi
follow
least
hour
appropri
empir
antibiot
treatment
failur
defin
use
composit
death
within
day
discharg
treatment
readmiss
pneumonia
within
day
discharg
univari
multivari
analys
perform
use
cox
proport
hazard
model
empir
antibiot
durat
select
priori
inclus
multivari
analysi
exploratori
predictor
includ
multivari
analysi
base
algorithm
involv
signific
univari
analysi
clinic
applic
result
includ
patient
fail
empir
antibiot
durat
hour
vs
hour
associ
treatment
failur
univari
hr
ci
multivari
analys
hr
ci
activ
cancer
icu
admiss
empir
initi
apach
ii
score
steroid
use
prednison
equival
index
hospit
associ
treatment
failur
univari
analysi
icu
admiss
empir
initi
hr
ci
steroid
use
prednison
equival
hr
ci
associ
treatment
failur
multivari
analysi
conclus
empir
antibiot
durat
influenc
failur
fluoroquinolon
monotherapi
cultur
neg
nosocomi
pneumonia
impact
exploratori
predictor
treatment
failur
assess
studi
effect
bodi
weight
clinic
outcom
obes
patient
treat
cephalosporin
austin
r
morrison
johnathon
loper
kati
e
barber
kayla
r
stover
pharmd
jami
l
wagner
pharmaci
henri
ford
hospit
detroit
mi
pharmaci
baptist
memori
hospit
north
mississippi
oxford
ms
pharmaci
practic
univers
mississippi
school
pharmaci
jackson
ms
introduct
differ
pharmacokineticspharmacodynam
obes
patient
ob
exist
clinic
safeti
efficaci
data
packag
ob
lack
purpos
evalu
clinic
outcom
ob
research
question
hypothesi
obes
impact
clinic
outcom
patient
treat
ceftriaxon
cefepim
studi
design
retrospect
cohort
method
adult
inpati
receiv
ceftriaxon
cro
cefepim
cfp
definit
therapi
includ
patient
lack
sourc
control
polymicrobi
infect
exclud
primari
outcom
clinic
treatment
failur
therapi
chang
clinic
worsen
leukocytosi
fever
readmiss
within
day
ob
vs
patient
nob
secondari
outcom
includ
discharg
disposit
descriptiveinferenti
statist
perform
spss
alpha
statist
signific
result
patient
includ
receiv
cro
median
iqr
age
year
male
median
iqr
weight
kg
ob
kg
nob
charlson
score
similar
vs
common
infect
sourc
includ
urin
ob
vs
nob
sputum
ob
vs
nob
cro
regimen
everi
ob
everi
nob
group
receiv
cfp
everi
clinic
failur
occur
ob
vs
nob
p
cro
ob
vs
nob
cfp
ob
vs
nob
inpati
occur
ob
vs
nob
cro
ob
vs
nob
cfp
ob
vs
nob
common
discharg
disposit
home
rehabilit
within
day
conclus
ob
util
dose
cro
similar
dose
cfp
compar
nob
ob
increas
treatment
failur
mortal
treat
cro
cfp
compar
nob
impact
select
antibiot
suscept
report
antibiot
use
across
seven
hospit
ecolog
studi
steven
smoke
pharmd
bcp
luigi
brunetti
pharmd
mph
bcp
navaneeth
narayanan
pharmd
pamela
giordano
pharmd
loui
alert
karan
raja
pharmd
monica
shah
kristin
sobolewski
jessica
hill
pharmd
bcp
jess
sullivan
pharmd
gargi
patel
bs
joseph
cavanaugh
pharmd
bcp
maria
devivo
pharmd
mpa
bcp
indu
lew
robert
adamson
jersey
citi
medic
center
jersey
citi
nj
pharmaci
practic
administr
rutger
state
univers
new
jersey
piscataway
nj
practic
administr
rutger
state
univers
new
jersey
piscataway
nj
morristown
medic
center
morristown
nj
support
rwjbarnaba
health
west
orang
nj
maass
medic
center
bellevil
nj
monmouth
medic
center
long
branch
nj
saint
barnaba
medic
center
livingston
nj
commun
medic
center
tom
river
nj
practic
fairleigh
dickinson
univers
school
pharmaci
health
scienc
florham
park
nj
pharmaci
rwjbarnaba
health
west
orang
nj
introduct
recent
nation
estim
inpati
antibiot
use
report
antibiot
use
increas
significantli
nation
guidelin
identifi
select
antibiot
suscept
report
decreas
antibiot
use
limit
evid
describ
impact
intervent
overal
antibiot
use
within
health
system
research
question
hypothesi
select
antibiot
suscept
report
reduc
overal
antibiot
use
within
health
system
studi
design
retrospect
ecolog
studi
conduct
seven
hospit
health
system
method
standard
select
antibiot
suscept
report
rule
develop
implement
januari
june
seven
hospit
studi
eight
month
individu
hospit
implement
constitut
studi
period
primari
outcom
rate
antibiot
hospit
infect
broad
mdr
use
secondari
outcom
measur
use
rate
agent
carbapenem
gener
cephalosporin
gener
cephalosporin
fluoroquinolon
narrow
spectrum
penicillin
antibiot
use
data
collect
inpati
intraven
antibiot
day
therapi
per
patient
day
interrupt
time
seri
analysi
segment
regress
use
compar
outcom
use
ibm
spss
result
signific
chang
use
broad
mdr
agent
slope
chang
per
month
ci
slope
chang
carbapenem
use
per
month
ci
slope
chang
fluoroquinolon
use
per
month
ci
signific
chang
use
antibiot
class
detect
conclus
implement
select
antibiot
suscept
report
across
seven
hospit
impact
overal
antibiot
use
studi
determin
long
term
impact
intervent
need
random
trial
evalu
immunogen
high
dose
vs
standard
dose
influenza
vaccin
ibd
patient
antitnf
monotherapi
freddi
caldera
sumona
saha
arnold
wald
ian
grime
luke
hillman
youqi
zhang
pharmd
candid
mark
reichelderf
mari
hayney
pharmd
gastroenterolog
hepatolog
univers
wisconsin
school
medicin
public
health
univers
madison
wi
gastroenterolog
hepatolog
univers
madison
wi
gastroenterolog
hepatolog
school
medicin
public
health
univers
madison
wi
medicin
public
health
univers
madison
wi
pharmaci
univers
madison
wi
pharmaci
school
medicin
public
health
univers
madison
wi
publish
gastroenterol
supp
page
hepat
b
immun
among
health
care
worker
immun
young
children
mari
hayney
pharmd
mph
alicia
ritscher
megan
dnp
mallori
wagner
nicol
kalscheur
msn
daniel
freddi
caldera
pharmaci
school
medicin
public
health
univers
madison
wi
pharmaci
univers
madison
wi
wisconsin
hospit
clinic
univers
madison
wi
wisconsin
hospit
clinic
madison
wi
school
pharmaci
madison
wi
gastroenterolog
hepatolog
univers
wisconsin
school
medicin
public
health
univers
madison
wi
introduct
individu
receiv
primari
hepat
b
vaccin
seri
month
follow
advisori
committe
immun
practic
recommend
vaccin
infant
enter
workforc
import
studi
immun
young
health
care
worker
hcw
immun
children
hepat
b
surfac
antibodi
concentr
wane
time
health
care
personnel
expos
bodi
fluid
increas
risk
infect
research
question
hypothesi
percent
young
hcw
receiv
hepat
b
vaccin
seri
children
unmeasur
miuml
mani
mount
anamnest
respons
follow
booster
hepat
b
dose
demonstr
addit
dose
vaccin
unnecessari
studi
design
singl
center
retrospect
review
method
inform
employe
born
obtain
employe
health
servic
includ
hepat
b
immun
record
age
hire
sex
concentr
date
collect
individu
complet
hepat
b
seri
prior
age
year
three
dose
prior
level
measur
exclud
miuml
interpret
unmeasur
result
year
unmeasur
time
hire
hcw
receiv
document
fourth
dose
hepat
b
vaccin
follow
anoth
day
post
vaccin
total
popul
mount
anamnest
respons
conclus
half
young
hcw
enter
workforc
undetect
remain
protect
infect
popul
requir
second
vaccin
seri
suggest
screen
popul
hcw
time
hire
hepat
b
immun
may
unnecessari
assess
antimicrobi
stewardship
knowledg
complet
train
program
taylor
steuber
pharmd
bcp
spencer
durham
pharmd
bcp
pharmaci
practic
auburn
univers
harrison
school
pharmaci
huntsvil
al
pharmaci
practic
auburn
univers
harrison
school
pharmaci
auburn
al
introduct
antimicrobi
resist
increas
alarm
rate
worldwid
scale
antimicrobi
stewardship
am
defin
coordin
effort
promot
appropri
use
antimicrobi
agent
help
decreas
antimicrobi
resist
howev
healthcar
provid
knowledg
requir
adequ
perform
am
research
question
hypothesi
attend
summit
confer
healthcar
provid
feel
knowledg
am
studi
design
prospect
survey
healthcar
profession
pharmacist
nurs
nurs
practition
physician
particip
summit
am
method
alabama
summit
antimicrobi
stewardship
statewid
continu
educ
confer
involv
four
healthcar
disciplin
anonym
survey
administ
particip
one
week
prior
one
week
summit
ask
am
practic
well
rank
scale
disagre
agre
confid
knowledg
follow
area
relat
am
antimicrobi
agent
regulatori
requir
am
inpati
outpati
facil
am
initi
statewid
am
initi
respons
match
chang
analyz
use
wilcoxon
sign
rank
test
consid
statist
signific
result
total
particip
attend
summit
complet
respect
complet
survey
match
survey
signific
improv
seen
confid
knowledg
area
antimicrobi
agent
regulatori
requir
am
p
inpati
p
outpati
facil
p
am
initi
statewid
am
initi
p
median
respons
question
conclus
alabama
summit
antimicrobi
stewardship
effect
endeavor
program
improv
healthcar
profession
confid
knowledg
area
am
cover
effort
made
continu
provid
am
educ
healthcar
provid
assess
outpati
antibiot
prescrib
guid
antibiot
stewardship
initi
univers
affili
health
clinic
bryant
hammershaimb
doctor
medicin
daniel
chung
doctor
pharmaci
candid
jonathan
tracey
doctor
pharmaci
glenn
dreganski
alyssa
woodwyk
heather
rauch
michael
klepser
pharmd
fccp
michigan
univers
colleg
medicin
kalamazoo
mi
state
univers
colleg
pharmacyspectrum
health
butterworth
hospit
grand
rapid
mi
state
univers
colleg
pharmaci
big
rapid
mi
stryker
md
school
medicin
western
michigan
univers
kalamazoo
mi
michigan
univers
homer
stryker
md
school
medicin
kalamazoo
mi
state
univers
colleg
pharmaci
grand
rapid
mi
introduct
understand
baselin
antibiot
use
first
step
develop
outpati
antimicrobi
stewardship
initi
simpl
standard
method
assess
outpati
antibiot
usag
pattern
wide
accept
histor
research
question
hypothesi
object
studi
establish
baselin
oral
antibiot
use
two
clinic
system
compar
usag
pattern
identifi
opportun
stewardship
initi
studi
design
retrospect
analysi
method
episod
oral
antibiot
use
identifi
januari
juli
two
outpati
clinic
system
patient
prescrib
oral
antibiot
identifi
indic
use
establish
use
link
code
prescrib
therapeut
regimen
ptrdose
x
frequenc
x
durat
calcul
prescript
complianc
guidelin
determin
compar
prescrib
agent
ptr
recommend
antibiot
recommend
therapeut
regimen
rtr
deriv
guidelin
endors
regimen
antibiot
usag
rate
estim
use
binomi
confid
interv
frequenc
proport
use
examin
complianc
prescrib
guidelin
data
clinic
compar
result
total
visit
occur
patient
clinic
system
studi
period
global
rate
antibiot
prescrib
antibiot
per
patient
antibiot
per
visit
clinic
system
respect
analysi
complianc
guidelin
recommend
reveal
antibiot
select
dose
regimen
prescrib
system
respect
conclus
establish
baselin
rate
oral
antibiot
use
clinic
identifi
differ
prescrib
patteren
system
observ
high
rate
per
publish
guidelin
number
indic
effort
improv
complianc
guidelin
first
outpati
stewardship
initi
compar
pharmacodynam
cefepim
organ
madison
salam
pharmd
candid
roger
white
pharmaci
medic
univers
south
carolina
charleston
sc
depart
biomed
scienc
charleston
sc
introduct
inhibitor
combin
develop
treatment
resist
organ
cefepim
frequent
use
treat
seriou
infect
util
mont
carlo
analysi
mca
assess
potenti
role
agent
treatment
infect
research
question
hypothesi
differ
target
attain
cefepim
organ
studi
design
mont
carlo
analysi
mca
method
pharmacokinet
pk
pharmacodynam
pd
mic
data
mic
distribut
esbl
e
coli
collect
literatur
protein
bind
volum
normal
infect
patient
clearanc
crcl
vs
cl
regress
pd
target
repres
stasi
net
bacteri
kill
bacteri
kill
use
two
dosag
regimen
one
base
cefepim
label
label
experiment
regimen
experiment
assess
use
pk
equat
inpati
crcl
distribut
serum
pk
profil
simul
use
profil
mic
free
mic
ft
mic
interv
calcul
target
attain
ta
result
display
kg
patient
result
ta
chang
due
differ
volum
experiment
dosag
regimen
minim
drugsorgan
conclus
target
attain
cefepim
suggest
may
still
appropri
empir
therapi
mani
infect
howev
higher
target
attain
organ
expect
differ
strike
esbl
e
coli
clinic
trial
need
assess
differ
clinic
efficaci
agent
preval
allergi
commun
hospit
karan
raja
pharmd
bcp
ruben
patel
pharmd
bcp
mark
attalla
pharmd
mitesh
patel
pharmd
bcccp
mona
philip
rph
ma
clara
maass
medic
center
bellevil
nj
introduct
allergi
report
patient
depend
evalu
popul
allergi
document
associ
increas
use
second
line
antimicrobi
may
less
effect
toxic
costli
appropri
evalu
drug
allergi
document
associ
reaction
hospit
patient
may
yield
consequenti
immedi
benefit
data
suggest
preval
document
allergi
greater
hospit
patient
compar
periop
outpati
howev
limit
data
exist
describ
preval
commun
hospit
inpati
research
question
hypothesi
preval
report
inpati
allergi
commun
hospit
studi
design
retrospect
electron
medic
record
analysi
method
electron
medic
record
queri
document
allergi
associ
reaction
patient
encount
januari
decemb
primari
outcom
assess
preval
document
allergi
secondari
outcom
evalu
character
quantifi
drug
class
interest
document
reaction
descript
statist
use
analyz
data
result
uniqu
patient
encount
preval
document
allergi
percent
patient
allerg
penicillin
cephalosporin
carbapenem
monobactam
reaction
allergi
document
patient
penicillin
frequent
reaction
document
follow
amoxicillin
commonli
document
reaction
rashhiv
facial
swell
pruritu
patient
document
anaphylact
reaction
conclus
preval
allergi
inpati
facil
match
previous
publish
estim
document
descript
allerg
reaction
inconsist
lack
increas
document
reaction
drug
allergi
present
opportun
improv
patient
safeti
stewardship
endeavor
percept
transit
vancomycin
practic
larg
academ
medic
center
kimberli
claey
pharmd
bcp
teri
hopkin
pharmd
jessica
brown
emili
heil
pharmd
bcp
aq
maryland
school
pharmaci
baltimor
md
south
texa
veteran
health
care
system
san
antonio
tx
epidemiolog
public
health
univers
maryland
school
medicin
baltimor
md
pharmaci
practic
scienc
univers
maryland
school
pharmaci
baltimor
md
introduct
vancomycin
polici
implement
univers
maryland
medic
center
ummc
januari
given
larg
practic
methodolog
chang
sought
understand
pharmacist
percept
practic
implement
research
question
hypothesi
pharmacist
percept
strategi
chang
implement
studi
design
prepost
implement
survey
method
mix
method
survey
sent
pharmacist
complet
train
ummc
one
month
prior
eight
month
practic
comparison
made
use
exact
u
test
result
respons
record
group
clinic
specialist
pharmacist
repres
vs
clinic
pharmacist
vs
resid
vs
prior
implement
respond
auc
ideal
pkpd
paramet
monitor
vancomycin
compar
post
p
dose
primarili
use
implement
vs
p
averag
time
spent
evalu
dose
increas
iqr
min
iqr
min
p
respond
strongli
agre
strategi
allow
work
top
degre
vs
p
increas
patient
safeti
vs
p
main
concern
regard
chang
dose
practic
includ
lack
pharmacist
compet
decreas
vs
p
implement
respond
felt
practic
problem
train
session
well
clinic
decis
support
key
success
satisfact
implement
significantli
increas
post
survey
vs
p
conclus
pharmacist
support
strategi
concern
regard
compet
train
session
practic
problem
integr
clinic
decis
support
improv
implement
multicent
evalu
pathogen
distribut
cultur
posit
patient
admit
skin
skin
structur
infect
us
glenn
tillotson
phd
fidsa
fccp
sue
cammarata
john
murray
vika
gupta
pharmd
micro
llc
durham
nc
affair
melinta
therapeut
inc
lincolnshir
il
dickinson
compani
franklin
lake
nj
present
european
congress
clinic
microbiolog
infecti
diseas
madrid
spain
april
demograph
cultur
posit
patient
admiss
period
skin
skin
structur
infect
us
multicent
evalu
pathogen
distribut
glenn
tillotson
phd
fidsa
fccp
sue
cammarata
john
murray
stephen
kurtz
vika
gupta
pharmd
micro
llc
durham
nc
affair
melinta
therapeut
inc
lincolnshir
il
dickinson
compani
franklin
lake
nj
present
european
congress
clinic
microbiolog
infecti
diseas
madrid
spain
april
clinic
outcom
urinari
tract
infect
uti
caus
klebsiella
pneumonia
carbapenemas
produc
klebsiella
pneumonia
follow
treatment
oral
fosfomycin
faisal
minhaj
bryant
lai
celi
abboud
gauri
g
rao
pharmaci
servic
univers
rochest
medic
center
strong
memori
hospit
rochest
ny
mateo
ca
control
depart
instituto
dant
pazzanes
de
cardiologia
sao
paulo
brazil
school
pharmaci
univers
north
carolina
chapel
hill
nc
introduct
optim
treatment
regimen
resist
mdr
pathogen
like
kpc
produc
organ
well
defin
uti
often
treat
oral
antimicrobi
therapi
howev
resist
mani
class
antibiot
necessit
parenter
agent
research
question
hypothesi
evalu
clinic
outcom
uti
treat
oral
fosfomycin
studi
design
retrospect
cohort
studi
method
descript
analysi
adult
inpati
oral
fosfomycin
pcr
posit
bacteriuria
instituto
dant
pazzanes
de
cardiologia
paulo
brazil
august
may
result
patient
met
inclus
criteria
classifi
uti
patient
outcom
data
avail
analysi
major
patient
femal
median
age
iqr
year
success
clinic
outcom
achiev
patient
fosfomycin
dose
use
median
frequenc
hour
iqr
hour
durat
therapi
prolong
median
durat
day
iqr
day
among
patient
fail
therapi
obes
none
success
outcom
obes
analysi
suscept
profil
infect
pathogen
indic
amikacin
colistin
fosfomycin
antibiot
favor
suscept
profil
effect
treatment
uti
conclus
fosfomycin
demonstr
vitro
kill
activ
urinari
pathogen
clinic
success
util
treat
infect
fosfomycin
dose
frequent
longer
durat
tradit
dose
may
led
success
rate
high
rate
obes
within
treatment
failur
suggest
patient
may
difficult
treat
given
lack
antimicrobi
option
research
need
util
older
antibiot
like
fosfomycin
good
activ
mdr
clinic
experi
telavancin
treatment
elderli
patient
year
result
telavancin
observ
use
registri
tour
jeremi
storm
john
pullman
melinda
laci
heidi
goldstein
bibiana
citi
sd
mt
scienc
liaison
therav
biopharma
us
inc
south
san
francisco
ca
san
francisco
ca
present
european
congress
clinic
microbiolog
infecti
diseas
madrid
spain
april
improv
methodolog
determin
compat
vancomycin
piperacillintazobactam
regan
david
pharmd
brook
clark
pharmd
quyen
ly
pharmd
calli
harri
selah
wood
jill
hightow
msn
elizabeth
covington
greg
gorman
school
pharmaci
samford
univers
birmingham
al
moffett
school
nurs
samford
univers
birmingham
al
introduct
vancomycin
piperacillintazobactam
two
commonli
use
antibiot
hospit
howev
report
compat
data
conflict
base
tradit
simul
studi
address
approach
improv
experiment
design
use
iv
pump
tube
gener
sampl
physic
chemic
compat
develop
research
question
hypothesi
clinic
relev
concentr
vancomycin
piperacillintazobactam
physic
chemic
compat
util
iv
pump
tube
studi
design
medic
prepar
pharmaci
student
iv
pump
prime
oper
nurs
student
sampl
collect
function
variou
post
tube
length
simul
clinic
condit
assay
pharmaci
student
method
iv
fluid
path
pump
configur
two
primari
line
locat
post
pump
three
differ
dose
combin
vancomycin
piperacillintazobacatam
evalu
mgml
mgml
mgml
mgml
mgml
mgml
clinic
relev
flow
rate
ghr
vancomycin
mlhr
piperacillintazobactam
use
post
sampl
collect
medic
flow
differ
tube
length
inch
physic
compat
assess
includ
ph
turbid
odor
visual
inspect
chemic
compat
determin
use
high
perform
liquid
chromatographi
result
vancomycin
mgml
demonstr
physic
chemic
compat
piperacillin
mgml
tube
length
vancomycin
mgml
piperacillintazobactam
mgml
convers
vancomycin
mgml
piperacillintazobactam
mgml
incompat
tube
length
conclus
vancomycin
piperacillintazobactam
demonstr
compat
use
iv
pump
iv
tube
clinic
use
concentr
dose
rate
addit
research
need
determin
maximum
compat
concentr
medic
potenti
assess
impact
varieti
iv
tube
product
physic
chemic
compat
implement
antibiot
intervent
integr
health
care
system
calley
paulson
jillian
handley
thoma
j
dilworth
pharmd
rachael
prusi
pharmd
sara
reeb
pharmd
dan
persel
charl
f
brummitt
riley
meyer
katherin
torr
lee
skrupki
pharmd
pharmaci
aurora
baycar
medic
center
green
bay
wi
pharmaci
aurora
saint
luke
medic
center
milwauke
wi
infecti
diseas
aurora
saint
luke
medic
center
milwauke
wi
medicin
aurora
baycar
medic
center
green
bay
wi
infecti
diseas
aurora
medic
group
green
bay
wi
pharmaci
mayo
clinic
rochest
mn
introduct
antibiot
ato
recommend
action
antimicrobi
stewardship
program
implement
challeng
studi
measur
impact
research
question
hypothesi
implement
ato
improv
antibiot
therapi
action
document
hour
studi
design
studi
perform
two
hospit
within
larg
health
system
method
ato
consist
pharmacist
commun
prescrib
servic
regard
antibiot
plan
complet
electron
medic
record
emr
document
hour
emr
alert
facilit
intervent
complet
pharmacist
physician
receiv
educ
inpati
assign
hospitalist
intensivist
servic
select
unit
receiv
antibiot
hour
includ
patient
id
consult
exclud
primari
outcom
emr
document
antibiot
plan
satisfi
requir
secondari
outcom
includ
measur
antibiot
util
antibiot
therapi
action
hour
result
patient
includ
common
indic
pneumonia
infect
uti
signific
differ
emr
document
antibiot
plan
significantli
improv
phase
vs
p
signific
differ
antibiot
therapi
action
hour
observ
p
see
tabl
median
durat
antibiot
therapi
similar
group
vs
day
approxim
patient
group
receiv
discharg
antibiot
median
durat
therapi
prescrib
reduc
vs
day
tabl
antibiot
therapi
action
hr
conclus
implement
ato
feasibl
associ
improv
antibiot
therapi
action
support
document
durat
therapi
discharg
clinic
experi
telavancin
treatment
obes
patient
bmi
kgm
result
telavancin
observ
use
registri
tour
adnan
siddiqui
paul
santo
suresh
antoni
candic
clay
heidi
goldstein
bibiana
mo
nh
paso
tx
biopharma
us
inc
south
san
francisco
ca
san
francisco
ca
present
european
congress
clinic
microbiolog
infecti
diseas
madrid
spain
april
analysi
appropri
corticosteroid
usag
set
suspect
bacteri
mening
patient
two
commun
hospit
mackenzi
pool
pharmd
candid
brian
fox
pharmd
school
pharmaci
univers
colorado
aurora
co
center
rocki
uchealth
loveland
co
introduct
mening
affect
less
popul
annual
howev
associ
high
rate
mortal
morbid
idsa
publish
guidelin
manag
bacteri
mening
made
recommend
favor
dexamethason
usag
base
clinic
data
research
question
hypothesi
use
dexamethason
prior
first
dose
antibiot
patient
suspect
bacteri
mening
reduc
morbid
mortal
limit
advers
effect
two
commun
hospit
studi
design
retrospect
chart
review
patient
present
commun
hospit
northern
colorado
symptom
bacteri
mening
januari
decemb
method
patient
diagnosi
mening
year
includ
primari
outcom
rate
appropri
dexamethason
use
secondari
outcom
includ
advers
effect
associ
dexamethason
use
appropri
antibiot
select
age
indic
durat
antibiot
use
mortal
differ
receiv
dexamethason
result
total
patient
includ
chart
review
patient
receiv
appropri
dose
dexamethason
appropri
time
major
advers
effect
associ
dexamethason
identifi
two
patient
receiv
appropri
empir
antibiot
therapi
base
age
signific
differ
durat
antibiot
use
moral
seen
patient
receiv
dexamethason
conclus
use
corticosteroid
set
possibl
bacteri
mening
low
risk
advers
side
effect
morbid
mortal
benefit
seen
chart
review
howev
demonstr
dexamethason
use
set
mening
optim
commun
hospit
believ
investig
pharmaci
impact
appropri
patient
select
corticosteroid
use
warrant
direct
act
antivir
treatment
hepat
c
viru
elderli
patient
christin
mauriello
pharmd
derek
peiffer
pharmd
candid
jennif
andr
pharmaci
templ
univers
philadelphia
pa
pharmaci
practic
templ
univers
school
pharmaci
philadelphia
pa
introduct
hepat
c
viru
hcv
preval
viru
caus
hepat
damag
minim
research
done
hcv
treatment
antivir
daa
elderli
popul
includ
mani
babi
boomer
babi
boomer
popul
high
rate
hcv
mani
live
hcv
year
lead
liver
organ
dysfunct
elderli
patient
also
like
medic
possibl
affect
adher
outcom
vital
determin
treatment
outcom
differ
elderli
popul
research
question
hypothesi
pill
burden
comorbid
fibrosi
stage
caus
differ
achiev
sustain
virolog
respons
week
hcv
infect
patient
year
old
studi
design
retrospect
chart
review
method
medic
record
review
use
epic
electron
medic
record
system
data
collect
number
daili
medic
number
pill
taken
daili
number
need
medic
number
need
pill
taken
per
day
inform
collect
presenc
patient
comorbid
includ
diabet
cardiovascular
diseas
cognit
impair
lymphoma
kidney
function
egfr
inform
also
collect
fibrosi
stage
result
chart
patient
review
overal
achiev
averag
pill
per
day
count
achiev
averag
patient
achiev
higher
rate
cognit
impair
diabet
patient
achiev
fibrosi
stage
fibrosur
fibrotest
common
method
assess
fibrosi
stage
conclus
appar
effect
pill
burden
achiev
elderli
popul
seem
cognit
impair
diabet
high
fibrosi
score
may
factor
lead
antibiot
alter
respons
patient
staphylococcu
aureu
bacteremia
sab
cecilia
volk
ba
graham
edwardson
victor
nizet
georg
sakoula
warren
rose
pharmaci
univers
madison
wi
pediatr
school
pharmaci
pharmaceut
scienc
univers
san
diego
la
jolla
ca
introduct
innat
immun
respons
sab
poorli
understood
elev
patient
present
recent
biomark
bacteremia
durat
mortal
suggest
major
role
host
respons
infect
outcom
research
question
hypothesi
hypothes
antibiot
differenti
modul
sab
treatment
studi
design
vitro
analysi
prospect
collect
patient
sampl
method
patient
divers
sourc
sab
evalu
mrsa
mssa
first
hour
patient
treat
either
includ
oxacillin
cefazolin
ceftarolin
glycolipopeptid
includ
vancomycin
daptomycin
vandap
patient
sera
obtain
day
hospit
present
day
quantifi
elisa
compar
two
treatment
group
use
u
result
patient
similar
present
prior
receiv
antibiot
median
vs
pgml
vandap
respect
treat
significantli
higher
day
median
vs
pgml
vandap
day
vs
pgml
vandap
importantli
treatment
result
increas
day
vandap
result
reduct
respect
similar
present
median
pgml
pgml
vandap
group
reduct
day
vs
pgml
day
pgml
vs
pgml
conclus
sinc
inflammasom
activ
essenti
infect
clearanc
increas
note
import
therapeut
implic
even
mrsa
may
benefici
decreas
sab
durat
complic
therapeut
regimen
van
dap
combin
mrsa
suggest
base
result
case
seri
adjunct
fibrinolyt
aid
abscess
drainag
amanda
van
matr
master
scienc
meghan
jeffr
school
pharmaci
pharmaceut
scienc
univers
colorado
aurora
co
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
aurora
co
introduct
fibrinolyt
use
facilit
drainag
intrapleur
effus
howev
littl
known
safeti
efficaci
fibrinolyt
assist
drainag
abscess
research
question
hypothesi
use
intracavitari
alteplas
associ
system
bleed
increas
drain
output
abscess
studi
design
case
seri
method
patient
cohort
identifi
electron
health
record
databas
elig
base
receipt
fibrinolyt
abdomin
abscess
follow
drain
placement
patient
least
year
age
primari
outcom
measur
includ
chang
hemoglobin
drain
output
surgic
intervent
result
abscess
patient
met
inclus
criteria
median
age
year
iqr
abscess
locat
periton
caviti
liver
pancrea
pathogen
cultur
abscess
polymicrobi
patient
receiv
alteplas
abscess
drain
common
dose
mg
dwell
time
hour
rang
hour
median
baselin
drain
output
ml
iqr
median
output
first
alteplas
instil
ml
iqr
consecut
median
drain
output
ml
iqr
follow
second
instil
ml
iqr
third
instil
ml
iqr
fourth
instil
median
decreas
hemoglobin
first
second
third
fourth
alteplas
instil
gdl
iqr
gdl
iqr
gdl
iqr
gdl
respect
one
patient
receiv
two
blood
transfus
six
abscess
requir
surgic
intervent
conclus
use
intracavitari
alteplas
effect
method
stimul
abscess
drainag
without
meaning
decreas
hemoglobin
abscess
drainag
increas
repeat
instil
third
instil
alteplas
evalu
statin
therapi
outcom
streptococc
speci
bacteremia
jaimi
chen
bs
cynthia
bor
michel
gandawidjaja
ami
kang
emi
minejima
pharmaci
univers
southern
california
lo
angel
ca
school
pharmaci
lo
angel
ca
introduct
statin
pleiotrop
effect
includ
effect
prior
studi
found
mortal
benefit
adjunct
statin
therapi
aureu
bloodstream
infect
bsi
howev
outcom
streptococc
bsi
evalu
research
question
hypothesi
patient
streptococc
bsi
treat
statin
therapi
addit
antibiot
therapi
improv
surviv
studi
design
retrospect
cohort
studi
method
adult
hospit
patient
streptococc
bsi
admit
jun
oct
includ
exclus
includ
antibiot
therapi
therapi
start
first
posit
cultur
patient
group
receipt
statin
group
vs
statin
ns
group
compar
demograph
clinic
cours
outcom
medic
chart
review
pertin
data
primari
outcom
mortal
secondari
outcom
includ
icu
admiss
durat
bacteremia
length
hospit
stay
lo
result
patient
met
inclus
criteria
median
age
male
hispan
bsi
group
higher
preval
diabet
vs
ns
p
renal
diseas
vs
ns
chf
vs
ns
group
higher
preval
liver
diseas
vs
ns
viridan
strep
common
pathogen
identifi
clinic
present
similar
group
median
sofa
score
iqr
vs
ns
iqr
mortal
rate
vs
ns
icu
admiss
vs
ns
durat
bacteremia
iqr
vs
ns
iqr
lo
iqr
vs
ns
iqr
also
similar
two
conclus
patient
infect
streptococc
bsi
statin
therapi
affect
sever
clinic
present
outcom
algorithm
antibiot
use
icu
patient
pneumonia
ariel
ferdock
ronald
campbel
pharmd
frank
damico
aaron
picker
pharmd
st
margaret
pittsburgh
pa
pharmaci
upmc
st
margaret
pittsburgh
pa
biostatist
upmc
st
margaret
pittsburgh
pa
introduct
antibiot
use
respiratori
tract
infect
lead
unnecessari
antibiot
exposur
potenti
medic
side
effect
order
procalcitonin
pct
laboratori
test
follow
specif
algorithm
may
decreas
occurr
current
pct
order
patient
pneumonia
howev
within
mani
institut
standard
algorithm
help
guid
physician
regard
antibiot
use
research
question
hypothesi
implement
standard
pct
algorithm
increas
rate
pct
util
studi
design
retrospect
chart
review
method
patient
identifi
monthli
report
use
code
pneumonia
adult
icu
patient
pneumonia
includ
patient
exclud
septic
shock
confirm
fungal
infect
current
tumor
chart
audit
perform
collect
baselin
data
pct
valu
baselin
data
collect
august
januari
pct
algorithm
implement
februari
educ
provid
clinic
pharmacist
data
collect
march
may
primari
outcom
rate
pct
order
rate
pct
algorithm
appli
appropri
descript
statist
use
describ
result
group
august
januari
includ
patient
pct
order
ci
patient
pct
valu
hypothet
appli
algorithm
ci
receiv
appropri
treatment
regard
antibiot
mean
antibiot
durat
day
data
consist
patient
pct
order
ci
patient
patient
pct
order
pct
algorithm
appli
appropri
ci
mean
antibiot
durat
day
conclus
implement
standard
pct
algorithm
pharmacist
guidanc
increas
pct
util
appropri
use
judici
use
antibiot
icu
patient
outcom
inappropri
empir
antibiot
therapi
iet
patient
hospit
skin
skin
structur
infect
receiv
appropri
definit
therapi
adt
multicent
studi
glenn
tillotson
phd
fidsa
fccp
sue
cammarata
stephen
brossett
md
vika
gupta
pharmd
ning
zheng
micro
llc
durham
nc
affair
melinta
therapeut
inc
lincolnshir
il
dickinson
compani
franklin
lake
nj
introduct
acut
bacteri
skin
infect
account
million
infect
annual
us
impact
iet
total
hospit
cost
length
stay
lo
patient
receiv
adt
analyz
research
question
hypothesi
admiss
prescrib
iet
higher
adjust
hospit
cost
lo
prescrib
appropri
therapi
studi
design
use
larg
neg
binomi
regress
model
estim
effect
iet
total
hospit
cost
lo
respect
sssi
acut
care
hospit
bd
insight
research
databas
franklin
lake
nj
method
cost
lo
effect
iet
first
posit
skinwound
cultur
patient
discharg
primari
secondari
code
sssi
iet
defin
therapi
day
prior
final
cultur
result
includ
least
one
antibiot
cover
model
includ
physician
hospit
fix
effect
addit
covari
acut
sever
ill
soi
diagnos
procedur
patient
demograph
prior
exposur
healthcar
result
sssi
admiss
first
cultur
posit
empir
definit
treatment
identifi
estim
cost
lo
effect
iet
proport
rang
averag
margin
cost
lo
significantli
higher
patient
receiv
iet
p
conclus
overal
iet
sssi
receiv
appropri
definit
therapi
associ
significantli
higher
cost
lo
infect
pathogen
impact
cost
significantli
chang
microbiolog
hospit
patient
cultur
posit
commun
acquir
pneumonia
cap
treat
empir
antibiot
therapi
multicent
evalu
glenn
tillotson
phd
fidsa
fccp
sue
cammarata
john
murray
vika
gupta
pharmd
micro
llc
durham
nc
affair
melinta
therapeut
inc
lincolnshir
il
dickinson
compani
franklin
lake
nj
introduct
cap
report
million
patient
us
annual
hospit
empir
antibiot
therapi
research
question
hypothesi
evalu
pathogen
distribut
patient
hospit
cultur
posit
cap
studi
design
retrospect
observ
studi
across
acut
care
facil
bd
insight
research
databas
franklin
lake
nj
method
first
posit
bacteri
respiratori
pathogen
patient
discharg
primari
secondari
code
cap
analyz
gn
gp
atyp
pathogen
includ
collect
within
day
admiss
categor
healthcar
associ
hca
routin
cultur
antigen
serolog
test
perform
appropri
result
admiss
respiratori
pathogen
identifi
within
day
admiss
receiv
empir
antimicrobi
therapi
cultur
posit
admiss
identifi
icu
identifi
hca
p
aeruginosa
mrsa
mssa
pneumonia
h
influenza
top
pathogen
identifi
admiss
see
tabl
polymicrobi
conclus
bacteri
etiolog
patient
admit
cap
chang
pathogen
posit
admiss
due
aureu
addit
origin
cap
taken
account
urinari
tract
infect
treatment
protocol
chang
prescrib
practic
care
facil
veteran
healthcar
system
spencer
durham
pharmd
bcp
addison
ragan
pharmaci
practic
auburn
univers
harrison
school
pharmaci
auburn
al
central
alabama
veteran
health
care
system
montgomeri
al
introduct
antimicrobi
therapi
commonli
prescrib
urinari
tract
infect
uti
care
facil
ltcf
often
unnecessari
incorrectli
prescrib
ltcf
central
alabama
veteran
health
care
system
cavhc
resist
antimicrobi
commonli
use
uti
dramat
increas
institut
ltcf
antibiogram
escherichia
coli
demonstr
percent
eighteen
percent
suscept
trimethoprimsulfamethoxazol
ciprofloxacinlevofloxacin
respect
despit
high
resist
trimethoprimsulfamethoxazol
fluoroquinolon
still
commonli
prescrib
empir
uti
therapi
ltcf
research
question
hypothesi
implement
standard
treatment
protocol
urinari
tract
infect
chang
clinician
prescrib
practic
decreas
use
inappropri
empir
antimicrobi
therapi
treatment
uti
cavhc
ltcf
studi
design
prospect
observ
method
pharmaci
depart
develop
uti
treatment
protocol
input
prescrib
ltcf
protocol
emphas
correct
uti
diagnosi
urinalysi
urin
cultur
mean
decreas
unnecessari
antimicrobi
prescrib
base
ltcf
antibiogram
nitrofurantoin
recommend
empir
agent
patient
cefpodoximeceftriaxon
reserv
patient
renal
dysfunct
system
infect
result
eight
month
data
analyz
patient
includ
ciprofloxacin
prescrib
patient
levofloxacin
prescrib
two
patient
also
pneumonia
trimethoprimsulfamethoxazol
prescrib
patient
use
deem
appropri
two
case
base
patient
specif
factor
patient
receiv
nitrofurantoin
cefpodoxim
ceftriaxon
addit
patient
urinalys
obtain
patient
urin
cultur
obtain
result
preliminari
analysi
indic
treatment
protocol
larg
follow
conclus
implement
uti
treatment
protocol
effect
chang
prescrib
practic
decreas
use
inappropri
antimicrobi
ltcf
treatment
failur
rate
patient
receiv
low
versu
high
oral
bioavail
antibiot
bacteremia
ryan
gumbleton
jennif
ott
pharmd
melani
townsend
pharmd
camilla
rees
md
depart
bill
clinic
bill
mt
bill
clinic
bill
mt
clinic
bill
mt
diseas
bill
clinic
bill
clinic
mt
introduct
bacteremia
gnb
associ
high
rate
morbid
mortal
high
bioavail
antibiot
hba
standard
treatment
gnb
popular
decreas
due
resist
rate
potenti
advers
effect
low
bioavail
antibiot
lba
may
effect
altern
howev
use
controversi
due
potenti
decreas
concentr
infect
site
research
question
hypothesi
lba
hba
definit
treatment
enterobacteriacea
bacteremia
studi
design
retrospect
cohort
studi
method
adult
bacteremia
caus
escherichia
coli
proteu
mirabili
klebsiella
pneumonia
receiv
oral
therapi
definit
treatment
least
day
includ
group
divid
base
oral
bioavail
antibiot
primari
outcom
treatment
failur
defin
hospit
readmiss
due
infect
sourc
bacteria
chang
antibiot
treatment
within
day
despit
adequ
dose
studi
antibiot
secondari
outcom
includ
mortal
therapi
durat
hospit
intens
care
unit
icu
length
stay
lo
primari
outcom
noninferior
test
risk
differ
two
arm
perform
margin
use
test
result
patient
screen
includ
lba
group
hba
group
common
caus
gnb
e
coli
due
urinari
sourc
treatment
failur
risk
differ
observ
ci
exclud
noninferior
margin
differ
found
mortal
antibiot
durat
hospit
lo
icu
lo
stratif
subject
weight
yield
differ
group
conclus
treatment
failur
rate
similar
use
low
versu
high
bioavail
oral
antibiot
definit
therapi
patient
gnb
mortal
rate
therapi
durat
length
stay
similar
group
impact
educ
intervent
antibiot
prescrib
acut
upper
respiratori
tract
infect
ambulatori
care
set
kaitlyn
craddock
suzann
molino
paul
strang
kati
suda
pharmd
thoma
kannampallil
jonathan
radosta
john
hickner
nanci
shapiro
susan
c
bleasdal
alan
gross
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
practic
rosalind
franklin
univers
medicin
scienc
north
chicago
il
illinoi
chicago
colleg
pharmaci
chicago
il
famili
medicin
univers
illinoi
chicago
chicago
il
illinoi
hospit
health
scienc
system
chicago
il
illinoi
hospit
health
scienc
system
chicago
il
infecti
diseas
univers
illinoi
chicago
chicago
il
present
idweek
san
francisco
ca
octob
discoveri
character
novel
mechan
clinic
triazol
antifung
resist
mutat
aspergillu
fumigatu
reductas
gene
jeffrey
rybak
nathan
p
wiederhold
jarrod
r
fortwendel
p
david
roger
pharmd
tennesse
colleg
pharmaci
memphi
tn
test
laboratori
ut
health
scienc
center
san
antonio
san
antonio
tx
clinic
pharmaci
univers
tennesse
memphi
tn
introduct
aspergillu
fumigatu
predomin
pathogen
invas
aspergillosi
diseas
state
associ
infect
annual
triazol
antifung
inhibit
ergosterol
biosynthesi
reli
upon
salvag
therapi
treatment
aspergillosi
howev
triazol
resist
among
clinic
isol
fumigatu
increasingli
encount
worldwid
larg
proport
remain
unexplain
research
question
hypothesi
mutat
fumigatu
reductas
gene
directli
contribut
clinic
triazol
resist
studi
design
analysi
clinic
fumigatu
isol
method
whole
genom
sequenc
perform
clinic
isol
suscept
control
isol
unit
state
mutat
uniqu
resist
isol
identifi
transform
util
introduc
mutant
allel
control
isol
correct
mutat
found
clinic
isol
minimum
inhibitori
concentr
mic
voriconazol
itraconazol
posaconazol
determin
isol
result
whole
genom
sequenc
analysi
reveal
mutat
uniqu
isol
resist
isol
collect
introduct
differ
individu
mutat
encod
amino
acid
substitut
control
isol
result
increas
voriconazol
itraconazol
posaconazol
mic
case
correct
mutat
sequenc
individu
resist
clinic
isol
led
decreas
itraconazol
posaconazol
mic
case
conclus
data
demonstr
first
time
mutat
fumigatu
reductas
gene
common
among
clinic
isol
mutat
directli
contribut
clinic
triazol
resist
research
need
evalu
potenti
therapeut
strategi
pharmacolog
inhibit
overcom
triazol
resist
mediat
novel
resist
mechan
pathogen
type
inappropri
empir
therapi
iet
skin
soft
tissu
infect
among
hospit
patient
us
glenn
tillotson
phd
fidsa
fccp
sue
cammarata
marya
zilerberg
md
john
murray
gang
ye
vika
gupta
pharmd
micro
llc
durham
nc
affair
melinta
therapeut
inc
lincolnshir
il
dreieich
germani
dickinson
compani
franklin
lake
nj
dickinson
co
franklin
lake
nj
present
american
societi
microbiolog
atlanta
georgia
june
microbiolog
skin
skin
structur
infect
among
hospit
patient
us
glenn
tillotson
phd
fidsa
fccp
sue
cammarata
marya
zilerberg
md
john
murray
vika
gupta
pharmd
micro
llc
durham
nc
affair
melinta
therapeut
inc
lincolnshir
il
dreieich
germani
dickinson
compani
franklin
lake
nj
present
american
societi
microbiolog
atlanta
june
evalu
proper
empir
therapi
acut
uncompl
cystiti
outpati
set
face
multidrug
resist
kayla
natali
steven
nerenberg
dorothi
mccoy
pharmd
joseph
univers
medic
center
paterson
nj
pharmaci
st
joseph
univers
medic
center
paterson
nj
present
new
jersey
societi
health
system
pharmacist
annual
meet
long
branch
nj
april
advers
outcom
relat
fluoroquionolon
use
patient
urinari
tract
infect
sing
ping
chow
bs
timothi
murrey
mariann
pop
pharmd
juli
b
gidden
pharmd
kevin
rynn
pharmd
fccp
alyssa
christensen
illinoi
chicago
rockford
il
pharmaci
osf
st
anthoni
medic
center
rockford
il
pharmaci
practic
univers
illinoi
colleg
pharmaci
rockford
il
saint
franci
medic
center
peoria
il
introduct
fda
issu
updat
warn
use
fluoroquinolon
risk
use
flouroquinolon
outweigh
benefit
treat
uncompl
urinari
tract
infect
uti
studi
advers
outcom
associ
fluoroquinolon
assess
patient
receiv
antibiot
uti
research
question
hypothesi
advers
outcom
associ
fluoroquinolon
use
compar
altern
antibiot
treatment
uti
studi
design
multicent
retrospect
studi
method
patient
includ
fluoroquinolon
group
drug
therapi
compris
ciprofloxacin
levofloxacin
patient
includ
altern
antibiot
group
drug
regimen
includ
fluoroquinolon
less
treatment
durat
patient
exclud
pregnant
undergo
urolog
procedur
kidney
transplant
receiv
combin
antibiot
particular
antibiot
exceed
total
length
therapi
primari
outcom
composit
outcom
includ
readmiss
develop
c
difficil
infect
resist
mdr
infect
within
month
secondari
outcom
includ
treatment
failur
emerg
depart
hospit
clinic
length
hospit
stay
mortal
intens
care
unit
admiss
result
patient
screen
patient
exclud
patient
includ
final
analysi
patient
includ
fluoroquinolon
group
patient
altern
group
demograph
data
well
balanc
although
patient
fluoroquinolon
group
histori
esbl
infect
vs
sulfa
allergi
vs
statist
differ
primari
outcom
altern
fluoroquinolon
group
vs
statist
differ
group
regard
secondari
outcom
conclus
although
statist
signific
fluoroquinolon
use
associ
trend
toward
increas
advers
outcom
treatment
uti
use
outcom
academ
transplant
center
molli
henri
john
schoen
laura
puzniak
janet
raddatz
trevor
van
schooneveld
md
scott
j
bergman
pharmd
fccp
fidsa
bcp
pharmaceut
nutrit
care
nebraska
medicin
omaha
ne
co
inc
kenilworth
nj
infecti
diseas
univers
nebraska
medic
center
omaha
ne
introduct
transplant
recipi
high
risk
infect
ceftolozanetazobactam
potent
new
agent
broad
activ
descript
use
immunocompromis
patient
limit
research
question
hypothesi
describ
use
ceftolozanetazobactam
includ
solid
organ
transplant
patient
studi
design
retrospect
cohort
method
adult
patient
receiv
hour
ceftolozanetazobactam
includ
characterist
outcom
describ
includ
subset
solid
organ
transplant
sot
stewardship
program
recommend
ceftolozanetazobactam
patient
histori
current
multidrug
resist
infect
clinic
success
absenc
signssymptom
andor
escal
antibiot
treatment
need
within
hour
complet
ceftolozanetazobactam
therapi
result
patient
receiv
ceftolozanetazobactam
cours
median
day
durat
rang
ceftolozanetazobactam
use
empir
cours
monotherapi
cours
median
dose
rang
everi
hour
dose
adjust
renal
dysfunct
includ
hemodialysi
continu
renal
replac
therapi
icu
treatment
common
indic
pneumonia
bacteremia
uti
frequent
organ
pseudomona
aeruginosa
two
isol
suscept
ceftolozanetazobactam
therapi
switch
infecti
diseas
consult
ceftolozanetazobactam
use
success
cours
mortal
sot
recipi
account
cours
success
mortal
rate
median
time
transplant
ceftolozanetazobactam
year
iqr
conclus
much
ceftolozanetazobactam
use
institut
sot
recipi
rest
critic
ill
patient
despit
complex
patient
clinic
success
seen
major
studi
ceftolozanetazobactam
among
subpopul
warrant
elucid
find
compar
result
treatment
regimen
risk
bloodstream
infect
pulmonari
hypertens
patient
receiv
continu
iv
prostacyclin
jenna
yager
doctor
pharmaci
jamal
jamil
doctor
pharmaci
matthew
casciano
doctor
pharmaci
uchealth
aurora
co
introduct
intraven
iv
prostacyclin
improv
outcom
patient
pulmonari
hypertens
pah
patient
receiv
continu
iv
medic
increas
risk
bloodstream
infect
bsi
prostacyclin
infus
cassett
prepar
patient
absenc
steril
compound
environ
contribut
increas
infect
risk
increas
incid
bsi
previous
seen
patient
research
question
hypothesi
hypothes
incid
bsi
among
iv
treprostinil
recipi
greater
epoprostenol
recipi
greater
rate
infect
studi
design
restrospect
cohort
studi
inpati
univers
colorado
hospit
includ
patient
year
diagnos
pah
receiv
continu
iv
epoprostenol
treprostinil
patient
receiv
prostacyclin
via
nebul
subcutan
infus
previou
admiss
within
day
exclud
method
primari
outcom
incid
bsi
four
cohort
patient
receiv
iv
prostacyclin
epoprostenol
steril
diluent
epoprostenol
diluent
epoprostenol
arginin
sucros
treprostinil
secondari
outcom
includ
bsi
incid
caus
microorgan
length
stay
risk
factor
bsi
result
patient
includ
studi
admit
diagnosi
bsi
trend
toward
increas
incid
bsi
treprostinil
compar
recipi
bsi
due
pathogen
significantli
higher
percentag
bsi
due
pathogen
seen
among
treprostinil
compar
epoprostenol
recipi
conclus
pah
patient
receiv
iv
prostacyclin
increas
risk
infect
pah
inpati
receiv
iv
prostacyclin
admit
bsi
treprostinil
recipi
significantli
like
epoprostenol
recipi
bsi
due
pathogen
may
due
neutral
ph
mix
treprostinil
nafcillin
versu
cefazolin
treatment
staphylococcu
aureu
bacteremia
lesli
wooten
pharmd
maria
guido
pharmd
bcp
brittani
woolf
pharmd
bcp
elizabeth
staci
pharmd
bcp
anthoni
genten
pharmd
bcp
siyun
liao
pharmd
phd
bcp
uc
health
univers
cincinnati
medic
center
cincinnati
oh
introduct
recommend
definit
treatment
staphylococcu
aureu
mssa
bacteremia
clinic
outcom
differ
penicillin
cefazolin
vitrodata
support
type
high
affin
hydrolysi
cefazolin
studi
aim
investig
microbiolog
clearanceof
mssa
bacteremia
treat
nafcillin
compar
cefazolin
research
question
hypothesi
differ
microbiolog
cure
mssa
bacteremia
treat
nafcillin
compar
cefazolin
studi
design
studi
retrospect
singl
health
system
studi
includ
hospit
subject
year
older
mssa
bacteremia
receiv
definit
treatment
nafcillin
cefazolin
method
primari
outcom
time
microbiolog
clearanc
secondari
outcom
includ
factor
contribut
prolong
bacteremia
greater
hour
inpati
mortal
relaps
advers
event
lead
drug
discontinu
result
definit
therapi
cefazolin
occur
subject
differ
median
time
microbiolog
clearanc
cefazolin
compar
nafcillin
vs
hour
p
subject
bacteremia
greater
hour
longer
time
microbiolog
clearanc
treat
nafcillin
vs
hour
presenc
metastat
infect
identifi
risk
factor
contribut
bacteremia
greater
hour
higher
rate
treatment
discontinu
due
advers
drug
reaction
subject
treat
nafcillin
compar
cefazolin
vs
p
conclus
differ
overal
time
microbiolog
clearanc
subject
treat
cefazolin
compar
nafcillin
howev
bacteremia
greater
hour
decreas
time
clearanc
cefazolin
bacteremia
greater
hour
associ
metastat
infect
antimicrobi
choic
cefazolin
use
effect
treatment
mssa
bacteremia
evalu
daptomycin
plu
ceftarolin
outcom
persist
staphylococcu
aureu
bacteremia
truong
pharmd
candid
bs
kathi
choi
pharmd
candid
scott
hall
pharmd
vanthida
huang
pharmd
bsphm
pharmaci
practic
midwestern
univers
colleg
glendal
az
john
c
lincoln
medic
center
phoenix
az
introduct
multipl
vitro
studi
demonstr
ceftarolin
cpt
enhanc
activ
daptomycin
dap
staphylococcu
aureu
mrsa
includ
vancomycin
van
strain
limit
case
report
demonstr
success
clinic
outcom
dapcpt
combin
persist
mrsa
bacteremia
research
question
hypothesi
studi
aim
character
evalu
use
dapcpt
mrsa
bacteremia
outcom
studi
design
observ
case
evalu
patient
receiv
dapcpt
admit
honorhealth
facil
novemb
januari
method
inclus
criteria
includ
patient
least
year
age
receiv
dapcpt
least
hour
clinic
microbiolog
cure
advers
event
suscept
treatment
durat
length
stay
lo
time
bacteri
erad
mortal
evalu
result
total
patient
receiv
dapcpt
therapi
mrsa
bacteremia
averag
lo
day
blood
cultur
show
suscept
dap
van
van
mgl
mic
mgl
van
failur
occur
case
case
associ
mgl
blood
cultur
persist
posit
despit
treatment
averag
day
prior
initi
dapcpt
dap
monotherapi
attempt
follow
van
failur
case
remain
bacterem
averag
day
addit
cpt
averag
time
cultur
clearanc
initi
dapcpt
day
one
patient
show
addit
cpt
day
dap
mgl
monotherapi
result
clearanc
day
median
dapcpt
treatment
durat
case
day
mortal
occur
patient
microbiolog
cure
death
occur
patient
conclus
dapcpt
combin
demonstr
effect
clear
persist
bacteremia
combin
dapcpt
effect
altern
option
patient
fail
monotherapi
high
van
dap
mic
studi
warrant
hepat
c
viru
treatment
overweight
obes
patient
treat
urban
academ
medic
center
darbi
rosenfeld
nadia
nabulsi
bs
todd
lee
pharmd
michel
martin
care
wood
dale
il
system
outcom
polici
univers
illinoi
chicago
colleg
pharmaci
chicago
il
practic
univers
illinoi
chicago
colleg
pharmaci
univers
illinoi
hospit
health
scienc
system
chicago
il
introduct
antivir
daa
regimen
offer
high
sustain
virolog
respons
svr
rate
hepat
c
viru
hcv
treatment
cdc
report
american
overweight
obes
real
world
data
grow
patient
popul
need
research
question
hypothesi
svr
rate
overweightobes
hcv
patient
urban
academ
medic
center
studi
design
retrospect
cohort
studi
method
investig
review
electron
record
patient
start
hcv
treatment
patient
start
regimen
includ
data
describ
countspercentag
categor
data
meansstandard
deviat
continu
data
primari
endpoint
svr
overweightobes
patient
rate
compar
use
fisher
exact
test
sa
softwar
result
patient
overweightobes
start
treatment
patient
male
black
mean
age
year
bmi
popul
genotyp
cirrhot
hepatocellular
carcinoma
hcc
hiv
diabet
psychiatr
ill
treat
svr
rate
popul
exclud
patient
patient
discontinu
treatment
svr
rate
per
protocol
svr
rate
differ
presenc
cirrhosi
vs
p
gender
vs
treatment
histori
vs
histori
hcc
vs
svr
rate
differ
raceethn
comorbid
insur
p
conclus
major
patient
overweight
obes
achiev
high
svr
rate
differ
svr
rate
among
subgroup
similar
report
gener
hcv
popul
svr
rate
higher
patient
higher
cirrhot
patient
util
procalcitonin
guid
antibiot
manag
care
unit
vs
intens
care
unit
set
samantha
jay
pharmd
candid
ashley
hung
pharmd
candid
van
doan
pharmd
candid
stephen
ea
pharmd
candid
allison
chambliss
emi
minejima
school
pharmaci
lo
angel
ca
medic
center
lo
angel
ca
introduct
procalcitonin
pct
inflammatori
biomark
upregul
respons
bacteri
infect
use
guid
antibiot
manag
institut
algorithm
creat
educ
appropri
pct
interpret
provid
email
medic
staff
research
question
hypothesi
object
evalu
pct
algorithm
util
similarli
icu
vs
set
avail
pct
inform
provid
clinic
benefit
studi
design
retrospect
cohort
studi
method
adult
hospit
patient
pct
level
drawn
may
screen
everi
third
patient
randomli
select
evalu
patient
demograph
clinic
cours
clinic
outcom
patient
group
icu
vs
admiss
onset
infect
compar
demograph
pct
level
outcom
primari
outcom
mortal
total
durat
antibiot
therapi
data
store
redcap
databas
softwar
result
patient
evalu
mean
age
year
old
male
icu
onset
infect
common
comorbid
hypertens
diabet
mellitu
obes
common
physician
document
indic
antibiot
therapi
pneumonia
sepsi
initi
pct
level
significantli
higher
icu
group
median
ngml
vs
ngml
patient
get
pct
level
icu
vs
p
icu
patient
receiv
pct
guid
antibiot
manag
total
antibiot
durat
icu
vs
mortal
icu
vs
similar
group
patient
antibiot
durat
significantli
shorter
patient
conclus
adher
pct
algorithm
decis
make
base
pct
level
suboptim
institut
icu
set
addit
antimicrobi
stewardship
intervent
warrant
educ
clinician
interpret
pct
algorithm
mont
carlo
analysi
omadacyclin
tigecyclin
staphylococcu
aureu
maha
assadoon
pharmd
candid
roger
white
phamaci
medic
univers
south
carolina
musc
charleston
sc
depart
biomed
scienc
charleston
sc
introduct
omadacyclin
omd
aminomethylcyclin
develop
skin
skin
structur
infect
tigecyclin
tig
glycylcyclin
use
complic
skin
skin
structur
infect
research
question
hypothesi
differ
target
attain
omd
tig
mrsa
mssa
studi
design
mont
carlo
analysi
mca
method
mic
pk
pd
target
literatur
use
mca
input
protein
bind
omd
tig
clearanc
lhr
omd
tig
volum
healthi
patient
pd
target
stasi
net
bacteri
kill
log
kill
use
dosag
regimen
omd
mg
iv
inf
hr
tig
mg
iv
inf
hr
use
pk
paramet
model
mic
free
f
aucmic
hr
target
attain
ta
calcul
result
patient
result
ta
affect
clearanc
especi
higher
target
dosag
regimen
minim
impact
howev
ta
lowest
lower
dose
higher
target
minim
differ
ta
mrsa
mssa
conclus
omd
ta
stasi
target
howev
ta
use
log
kill
tig
ta
stasi
target
use
log
kill
overal
tig
slightli
higher
ta
omd
howev
omd
like
clinic
efficaci
mrsa
mssa
evalu
empir
vancomycin
therapi
outcom
staphylococcu
aureu
bacteremia
nikki
mai
pharmd
candid
univers
southern
california
school
pharmaci
lo
angel
ca
introduct
previou
studi
found
mortal
benefit
patient
receiv
earli
vancomycin
staphylococcu
aureu
bacteremia
sab
although
benefit
receiv
therapi
vancomycin
empir
unclear
research
question
hypothesi
empir
vancomycin
improv
surviv
sab
studi
design
prospect
observ
cohort
studi
method
adult
patient
monomicrobi
sab
admit
screen
exclus
criteria
includ
receiv
effect
therapi
empir
therapi
vancomycin
start
effect
therapi
sab
onset
medic
chart
review
patient
group
receipt
empir
vancomycin
combin
group
vs
vancomycin
monotherapi
vancomycin
group
compar
demograph
clinic
present
outcom
primari
outcom
day
success
secondari
outcom
includ
mortal
durat
sab
length
stay
result
patient
includ
receiv
combin
therapi
mean
age
male
mrsa
sab
common
empir
combin
group
ceftriaxon
half
patient
intermedi
sourc
risk
combin
vs
vancomycin
combin
group
significantli
endocard
vs
combin
group
wors
clinic
present
higher
pitt
bacteremia
score
vs
icu
admiss
vs
durat
initi
optim
therapi
group
patient
mssa
sab
improv
day
clinic
success
vs
shorter
length
stay
vs
shorter
durat
bacteremia
vs
although
mortal
similar
vs
trend
seen
mrsa
sab
comparison
pn
conclus
empir
combin
therapi
vancomycin
led
significantli
faster
clearanc
sab
earli
clinic
success
compar
vancomycin
alon
mssa
sab
mrsa
sab
pharmacist
clinic
intervent
discharg
counsel
medic
rehabilit
ward
nga
suet
rosanna
ip
bachelor
chun
kwok
angu
chu
mb
bs
hk
mrcp
uk
fhkam
medicin
lai
ming
paulin
chu
mpharm
wai
man
grace
young
master
clinic
justin
wade
tenney
pharmd
bcp
bcgp
pharmaci
tuen
mun
hospit
hong
kong
hong
kong
medicin
geriatr
tuen
mun
hospit
hong
kong
hong
kong
pharmaci
chines
univers
hong
kong
hong
kong
hong
kong
present
fip
world
congress
pharmaci
pharmaceut
scienc
intern
pharmaceut
feder
glasgow
uk
septemb
impact
methadon
polici
chang
oregon
medicaid
popul
tiffani
tsai
pharmd
deanna
moretz
pharmd
luke
middleton
bs
megan
herink
pharmd
colleg
pharmaci
oregon
state
universityoregon
health
scienc
univers
portland
introduct
overus
misus
methadon
lead
respiratori
depress
cardiac
arrest
due
long
variabl
pharmacokinet
delay
onset
action
methadon
associ
prescript
death
oregon
due
safeti
concern
januari
methadon
remov
prefer
drug
list
medicaid
popul
research
question
hypothesi
object
evalu
methadon
util
impact
hospit
emerg
depart
ed
visit
polici
chang
studi
design
retrospect
observ
analysi
method
util
methadon
compar
use
paid
oregon
medicaid
pharmaci
claim
patient
exclud
dual
medicar
part
coverag
loss
medicaid
elig
diagnosi
palli
care
termin
diagnosi
pain
descript
statist
use
report
compar
methadon
util
hospit
ed
visit
result
signific
declin
methadon
util
averag
claim
per
month
member
pmpm
compar
claim
per
month
member
pmpm
overal
methadon
polici
seem
directli
impact
rate
methadon
hospit
ed
visit
pmpm
vs
pmpm
nonetheless
overal
downward
trend
observ
convers
overal
upward
trend
heroin
hospit
visit
conclus
methadon
restrict
oregon
medicaid
ff
popul
effect
limit
use
chronic
pain
minim
impact
hospitalizations
visit
increas
trend
heroin
overdos
concur
nation
trend
insuffici
evid
associ
restrict
prescript
opioid
gabapentin
util
oregon
medicaid
popul
pearc
engeld
pharmd
deanna
moretz
pharmd
luke
middleton
bs
megan
herink
pharmd
colleg
pharmaci
oregon
state
universityoregon
health
scienc
univers
portland
introduct
gabapentin
approv
use
partial
onset
seizur
postherpet
neuralgia
often
use
diagnos
despit
lack
evid
benefit
follow
public
center
diseas
control
cdc
guidelin
opioid
use
chronic
pain
subsequ
restrict
opioid
therapi
gabapentin
may
appeal
altern
research
question
hypothesi
describ
gabapentin
util
oregon
medicaid
program
chang
sinc
cdc
guidelin
studi
design
observ
studi
compar
gabapentin
util
prescrib
pattern
prior
follow
releas
cdc
guidelin
method
patient
paid
gabapentin
claim
includ
cohort
design
comparison
medicar
part
coverag
seizur
diagnosi
exclud
averag
daili
gabapentin
dose
calcul
concurr
opioid
use
describ
diagnos
flag
categor
fda
approv
approv
evid
use
evid
use
indic
found
result
averag
gabapentin
util
increas
prescript
per
member
per
month
januari
decemb
chronic
gabapentin
user
concomit
opioid
use
cohort
decreas
percent
user
averag
gabapentin
dose
less
mgday
use
concomitantli
opioid
gabapentin
dose
averag
mgday
higher
use
chronic
musculoskelet
pain
higher
compar
despit
lack
evid
efficaci
popul
patient
gabapentin
describ
less
day
compar
conclus
modest
increas
gabapentin
use
follow
public
cdc
guidelin
seem
relat
use
indic
signific
safeti
misus
concern
identifi
acut
kidney
injuri
elderli
patient
studi
singl
center
china
kunm
pan
master
yi
wu
chen
zhangzhang
chen
wu
wei
cao
lei
qing
xu
xu
peifang
dai
xiaoyu
li
qianzhou
lv
pharmaci
fudan
univers
zhongshan
hospit
shanghai
china
pharmaci
zhongshan
hospit
affili
fudan
univers
shanghai
china
introduct
acut
kidney
injuri
aki
still
main
seriou
advers
drug
reaction
experienc
patient
receiv
vancomycin
van
treatment
older
peopl
race
black
risk
factor
van
nephrotox
howev
studi
elderli
chines
patient
limit
littl
known
risk
factor
aki
among
chines
individu
research
question
hypothesi
investig
current
situat
elderli
chines
patient
identifi
risk
factor
access
outcom
risk
factor
patient
develop
order
provid
suggest
improv
prevent
treatment
elderli
chines
studi
design
retrospect
studi
method
retrospect
identifi
elderli
receiv
dose
van
therapi
compar
patient
definit
develop
aki
van
therapi
within
day
withdraw
van
result
elderli
inpati
includ
among
exclud
exclud
lack
data
serum
creatinin
scr
among
includ
patient
patient
receiv
tdm
van
therapi
inadequ
tdm
rate
rate
correct
tdm
patient
confirm
incid
multipl
logist
regress
analysi
reveal
hyperuricemia
mechan
ventil
concomit
vasopressor
therapi
independ
risk
factor
addit
serum
albumin
valley
determin
independ
protect
factor
conclus
elderli
chines
patient
treat
van
exist
situat
insuffici
monitor
scr
inadequ
van
tdm
rate
incorrect
monitor
time
recommend
hospit
manag
increas
invest
clinic
pharmacist
strength
profession
manag
patient
concomit
hyperuricemia
mechan
ventil
vasopressor
therapi
paid
attent
higher
serum
albumin
recommend
risk
factor
acut
kidney
injuri
critic
ill
elderli
undergo
surgeri
kunm
pan
master
chen
zhangzhang
chen
jin
wu
wei
qing
xu
xiaoyu
li
qianzhou
lv
pharmaci
fudan
univers
zhongshan
hospit
shanghai
china
pharmaci
zhongshan
hospit
affili
fudan
univers
shanghai
china
introduct
acut
kidney
injuri
aki
main
seriou
advers
drug
reaction
van
aki
common
complic
surgeri
older
patient
higher
risk
aki
howev
studi
special
popul
research
question
hypothesi
investig
incid
risk
factor
critic
ill
elderli
patient
undergo
surgeri
give
suggest
ration
use
van
critic
ill
elderli
patient
periop
period
studi
design
retrospect
cohort
studi
method
investig
inpati
receiv
van
therapi
januari
june
hospit
inclus
criteria
follow
age
year
accept
least
dose
van
therapi
undergo
surgeri
exclus
criteria
ckd
receiv
regular
hemodialysi
renal
transplant
statu
incomplet
medic
record
inform
lack
serum
creatinin
scr
monitor
compar
patient
definit
develop
aki
van
therapi
within
day
withdraw
van
result
patient
includ
incid
multivari
regress
analysi
show
higher
rate
tdm
van
trough
concentr
p
independ
risk
factor
lower
serum
albumin
valley
p
lower
baselin
evalu
glomerular
filtrat
rate
egfr
p
independ
protect
factor
conclus
higher
rate
tdm
van
trough
concentr
independ
risk
factor
lower
serum
albumin
lower
baselin
egfr
p
independ
protect
factor
concomit
nephrotox
drug
may
littl
effect
clinician
attent
treatment
patient
pathophysiolog
analysi
quetiapin
olanzapin
misus
use
fda
advers
event
report
system
victor
encarnacion
pharmd
candid
kirk
evoy
chengwen
teng
pharmd
lindsey
groff
bs
pharmd
huda
razzack
pharmd
obiageri
bpharm
msc
christoph
frei
pharmd
ms
fccp
univers
texa
austin
colleg
pharmaci
univers
texa
health
san
antonio
long
school
medicin
san
antonio
tx
univers
texa
austin
colleg
pharmaci
austin
tx
introduct
second
gener
antipsychot
sga
assum
low
abus
potenti
howev
publish
report
abus
emerg
quetiapin
prescrib
increas
recent
year
us
food
drug
administr
fda
advers
event
report
system
faer
provid
inform
regard
advers
drug
report
adr
research
question
hypothesi
disproportion
rate
adr
quetiapin
versu
anoth
commonli
use
sga
olanzapin
studi
design
analysi
perform
use
data
spontan
adr
report
faer
method
total
volum
adr
relat
quetiapin
olanzapin
qt
ot
identifi
queri
drug
gener
brand
name
adr
drug
qa
oa
quantifi
queri
drug
conjunct
twenti
predefin
adr
descriptor
relat
abusemisusedependenceoverdos
descriptor
identifi
search
strategi
previous
conduct
adr
report
system
studi
proport
report
ratio
prr
qaqt
oaot
calcul
assess
whether
report
adr
two
drug
disproportion
result
adr
repres
total
adr
report
quetiapin
olanzapin
result
prr
prr
qaqt
oaot
three
preval
adr
studi
drug
abus
intent
overdos
overdos
quetiapin
patient
adr
younger
median
vs
year
p
like
experi
fatal
event
vs
p
quetiapin
patient
without
adr
conclus
studi
describ
new
evid
regard
quetiapin
rel
olanzapin
corrobor
recent
evid
quetiapin
abus
rigor
studi
conduct
better
understand
abus
potenti
quetiapin
impact
practic
impact
medic
safeti
educ
fair
health
care
profession
knowledg
adher
establish
process
medic
safeti
merlyn
l
joseph
beth
willi
lerma
rangel
colleg
pharmaci
texa
univers
health
scienc
center
houston
tx
hermann
memori
citi
houston
tx
introduct
voluntari
report
medic
error
memori
hermann
memori
citi
mhmc
demonstr
signific
opportun
improv
key
area
sever
error
high
risk
medic
report
despit
document
second
clinician
check
drug
signifi
need
refin
educ
nurs
independ
doubl
check
process
institut
addit
sever
intraven
iv
pump
program
error
heparin
error
indic
need
reeduc
import
step
pump
program
research
question
hypothesi
medic
safeti
fair
improv
nurs
knowledg
complianc
safe
medic
practic
area
report
medic
error
studi
design
prospect
qualiti
improv
project
method
mhmc
nurs
attend
medic
safeti
fair
complet
includ
survey
match
use
raffl
ticket
number
ensur
anonym
descript
statist
use
nomin
data
wilcoxon
sign
rank
use
compar
pair
survey
ibm
spss
statist
result
nurs
complet
respons
rate
seventi
percent
nurs
healthcar
profession
year
nurs
report
attend
previou
medic
safeti
fair
mani
nurs
work
medicalsurg
unit
critic
care
unit
statist
signific
improv
nurs
knowledg
demonstr
independ
process
heparin
protocol
heparin
process
alari
pump
program
iv
fluid
minim
improv
observ
identifi
iv
medic
trace
vs
conclus
medic
safeti
fair
statist
improv
nurs
knowledg
medic
safeti
topic
test
data
emphas
need
continu
educ
ensur
nurs
follow
safe
medic
practic
especi
medic
effici
journey
util
lean
six
sigma
methodolog
admiss
medic
reconcili
larg
hospit
system
sara
eltaki
pharmd
bcp
natali
zilban
pharmd
mph
amada
alonso
msie
mia
pharmaci
memori
region
hospit
hollywood
fl
healthcar
system
fort
lauderdal
fl
introduct
medic
reconcili
complex
process
ensur
medic
safeti
joint
commiss
recogn
reconcili
nation
patient
safeti
goal
essenti
provid
optim
care
larg
hospit
system
florida
consist
six
facil
vari
size
employ
vari
legaci
methodolog
medic
reconcili
amongst
provid
research
question
hypothesi
util
standard
increas
effici
defin
provid
role
ultim
maxim
number
patient
receiv
robust
medic
reconcili
studi
design
multidisciplinari
team
consist
vari
provid
across
system
includ
pharmaci
nurs
physician
informat
process
improv
pi
personnel
form
defin
implement
new
standard
medic
reconcili
process
method
legaci
propos
process
review
lean
six
sigma
methodolog
includ
analysi
dmaic
defin
measur
analyz
improv
control
process
map
sipoc
supplier
input
process
output
custom
gemba
walk
result
numer
step
identifi
within
workflow
stakehold
involv
improv
streamlin
process
develop
elimin
process
defect
approv
implement
across
system
pilot
conduct
achiev
decreas
time
spent
medic
reconcili
conclus
signific
decreas
resourc
requir
medic
reconcili
achiev
util
lean
six
sigma
methodolog
step
identifi
stakehold
elimin
allow
develop
implement
streamlin
reconcili
process
across
hospit
system
evalu
potenti
advers
drug
event
pade
inpati
taiwan
yime
hua
ms
hsieh
ms
chang
ms
ciou
ms
su
phd
depart
pharmaci
chi
mei
medic
center
tainan
taiwan
introduct
taiwan
physician
usual
resum
ambulatori
drug
inpati
without
assess
medic
drug
prescrib
hospit
potenti
harm
advers
event
result
medic
discrep
may
occur
transit
care
research
question
hypothesi
aim
evalu
pade
identifi
medic
reconcili
servic
inpati
studi
design
studi
method
initi
medic
reconcili
servic
analyz
pade
admit
inpati
patient
pharmacist
assess
resum
ambulatori
medic
prescrib
hospit
identifi
drug
relat
problem
pade
would
record
medic
record
medic
discrep
recogn
document
number
type
pade
differ
ward
specialti
test
use
explor
associ
demograph
patient
without
pade
statist
analysi
carri
sa
test
data
consid
statist
signific
result
evalu
patient
total
prescript
januari
april
patient
identifi
pade
among
pade
other
pade
patient
pade
significantli
older
without
vs
p
patient
pade
frequent
type
duplic
medic
follow
advers
drug
reaction
adr
organ
impair
requir
dose
adjust
among
assess
prescript
intern
medicin
ward
howev
incid
rate
pade
higher
surgeri
specialti
conclus
patient
pade
found
older
might
relat
higher
proport
polypharmaci
comorbid
furthermor
duplic
adr
occur
frequent
hospit
patient
may
impli
us
put
effort
access
accur
medic
histori
identifi
patient
facilit
drug
safeti
assess
hospit
inpati
knowledg
medic
advers
effect
use
medic
knowledg
adher
lace
plu
score
predict
hospit
readmiss
studi
alic
hemenway
pharmd
depart
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
rockford
il
introduct
low
level
patient
knowledg
regard
potenti
advers
effect
medic
note
variou
studi
howev
limit
inform
regard
advers
effect
knowledg
hospit
patient
hospit
patient
receiv
inform
medic
variou
provid
throughout
admiss
may
affect
knowledg
research
question
hypothesi
compar
medic
inform
hospit
patient
less
knowledg
regard
potenti
advers
effect
medic
studi
design
prospect
studi
method
irb
approv
obtain
data
collect
januari
august
patient
randomli
select
includ
least
one
schedul
medic
six
month
prior
admiss
capabl
respond
question
patient
exclud
admit
intens
care
surgic
obstetr
floor
readmit
within
day
prior
admiss
valid
medic
knowledg
score
mk
oral
administ
patient
includ
four
question
medic
name
indic
strength
frequenc
potenti
advers
effect
primari
endpoint
comparison
frequenc
correct
individu
mk
answer
compar
use
descript
statist
test
use
ibm
spss
version
result
patient
includ
analysi
greater
number
patient
could
list
name
one
medic
indic
strength
frequenc
compar
potenti
advers
effect
p
comparison
major
patient
mk
score
score
patient
could
list
advers
effect
mk
score
low
mk
score
conclus
confirm
prior
studi
hospit
patient
seem
specif
lack
knowledg
regard
potenti
advers
effect
medic
impact
pharmaci
team
involv
readmiss
due
medic
relat
event
nicol
pharmd
bcp
monica
morgan
heather
savag
use
safeti
educ
ochsner
medic
center
new
orlean
la
health
system
new
orlean
la
clinic
foundat
new
orlean
la
introduct
pharmaci
team
ideal
posit
take
respons
medic
use
process
throughout
differ
transit
care
shown
pharmacist
obtain
accur
inform
physician
nurs
addit
evid
support
pharmaci
team
involv
reduc
error
medic
use
process
studi
show
pharmaci
team
make
impact
chang
patient
care
readmiss
research
question
hypothesi
pharmaci
team
intervent
reduc
readmiss
due
medic
relat
problem
type
pharmaci
team
intervent
biggest
impact
readmiss
rate
due
medic
relat
problem
studi
design
retrospect
observ
chart
review
method
patient
admit
hospit
medicin
team
decemb
octob
readmit
within
day
includ
primari
outcom
studi
readmiss
due
medic
relat
problem
pharmaci
team
intervent
includ
pharmacist
primari
team
admiss
discharg
medic
reconcili
pharmaci
consult
patient
educ
pharmaceut
care
network
europ
pcne
classif
v
use
identifi
possibl
caus
medic
relat
problem
result
one
hundr
fifti
patient
includ
readmiss
higher
due
medic
relat
problem
pharmaci
team
involv
compar
pharmaci
team
involv
vs
median
time
readmiss
similar
group
fewer
patient
pharmaci
team
intervent
group
readmit
factor
ie
incorrect
dosag
nonadher
etc
common
pharmaci
team
intervent
presenc
pharmacist
primari
team
conclus
pharmaci
team
involv
led
fewer
readmiss
due
medic
relat
problem
pcne
classif
v
use
classif
tool
determin
readmiss
due
medic
relat
problem
intraven
labetalol
hydralazin
use
hospit
ward
patient
valeri
magda
pharmd
candid
tess
calcagno
pharmd
candid
briana
schreckengost
pharmd
candid
courtney
montepara
pharmd
jordan
r
covvey
pharmd
phd
bcp
branden
nemecek
pharmd
bcp
duquesn
univers
school
pharmaci
pittsburgh
pa
introduct
use
intraven
iv
medic
blood
pressur
bp
control
inpati
set
common
gener
lack
evidenc
clinic
guidanc
recommend
research
question
hypothesi
assess
safeti
efficaci
iv
hydralazinelabetalol
care
patient
larg
academ
teach
hospit
studi
design
singl
center
retrospect
chart
review
method
sampl
electron
medic
record
hospit
patient
upmc
merci
receiv
iv
hydralazin
andor
labetalol
retrospect
review
patient
intens
care
unit
emerg
depart
procedur
medic
administr
exclud
vital
systolicdiastol
bp
heart
rate
hr
evalu
admiss
discharg
administr
assess
safetyefficaci
studi
approv
pertin
institut
review
board
result
total
patient
includ
receiv
hydralazin
receiv
labetalol
receiv
either
admiss
patient
labetalol
group
higher
mean
hr
admiss
vs
bpm
p
discharg
vs
bpm
compar
hydralazin
greater
number
iv
labetalol
dose
admiss
administ
compar
iv
hydralazin
vs
dosespati
signific
decreas
systol
bp
mean
differ
md
mmhg
p
diastol
bp
md
mmhg
p
hr
md
bpm
p
occur
admiss
discharg
across
patient
largest
decreas
among
patient
receiv
combin
two
iv
medic
admiss
md
mmhg
mmhg
bpm
respect
p
conclus
use
combin
iv
hydralazin
labetalol
hospit
appear
produc
signific
reduct
bp
although
safeti
associ
reduct
assess
basi
implement
medic
reconcili
improv
medic
safeti
patient
polypharmaci
issu
yenrong
chiu
b
pharmaci
guanl
lin
ms
tawei
wu
ms
depart
pharmaci
taipei
tzu
chi
hospit
new
taipei
citi
taiwan
introduct
medic
practic
taiwan
divid
differ
special
order
provid
profession
medic
servic
patient
suffer
differ
diseas
concomitantli
need
visit
differ
specialti
doctor
clinic
accord
statist
nation
health
insur
administraion
largest
medic
problem
repeat
prescript
consequ
gener
polypharmaci
issu
lead
potenti
risk
medic
safeti
research
question
hypothesi
reduc
occurr
duplic
medic
drug
interact
advers
drug
event
medic
reconcili
studi
design
use
retrospect
analyz
medic
reconcili
content
drug
inform
counter
includ
patient
sourc
consult
need
pharmacist
servic
categori
degre
patient
understand
track
result
track
timeli
medic
reconcili
jan
dec
method
patient
ask
medic
reconcili
support
use
present
medic
system
develop
depart
informat
hospit
pharmacloud
system
develop
govern
medic
list
provid
patient
understand
current
medic
also
search
onlin
medic
literatur
databas
check
interact
precaut
patient
confirm
degre
understand
howev
includ
patient
consult
voluntarili
also
patient
high
risk
polypharmaci
refer
drug
inform
counter
reconcili
result
polypharmaci
case
need
medic
reconcili
support
outpati
total
case
patient
take
medicin
prescrib
two
specialti
doctor
simultan
tool
use
mostli
achiev
medic
reconcili
present
medic
system
medic
discrep
found
reconcili
confirm
doctor
doctor
modifi
prescript
base
pharmacist
recommend
reconcili
almost
patient
could
total
understand
content
educ
pharmacist
conclus
implement
practic
medic
reconcili
pharmacist
patient
medic
safeti
improv
cardiovascular
safeti
revefenacin
nebul
review
random
control
trial
data
jame
donohu
gregori
feldman
sanjay
sethi
chri
barn
srikanth
pendyala
david
bourdet
lauren
yarbrough
school
medicin
chapel
hill
nc
carolina
pharmaceut
research
spartanburg
sc
buffalo
school
medicin
buffalo
ny
biopharma
us
inc
south
san
francisco
ca
introduct
revefenacin
muscarin
receptor
antagonist
clinic
develop
nebul
treatment
chronic
obstruct
pulmonari
diseas
copd
produc
sustain
bronchodil
limit
advers
event
ae
research
question
hypothesi
cardiovascular
cv
diseas
highli
preval
copd
patient
evalu
cv
safeti
data
revefenacin
random
trial
studi
design
daili
nebul
revefenacin
evalu
cv
safeti
patient
moder
sever
copd
ident
phase
trial
studi
studi
phase
safeti
trial
studi
method
independ
clinic
event
committe
cec
perform
blind
review
adjud
major
cv
ae
mace
result
clinic
meaning
chang
ecg
record
observ
incid
prolong
qtcf
interv
msec
similar
placebo
revefenacin
arm
studi
respect
studi
incid
prolong
qtcf
similar
revefenacin
tiotropium
group
slightli
lower
revefenacin
group
cec
adjud
mace
studi
revefenacin
placebo
group
respect
zero
mace
studi
mace
studi
revefenacin
tiotropium
group
respect
consid
relat
revefenacin
atrial
fibril
revefenacin
group
studi
conclus
increas
risk
mace
identifi
clinic
trial
week
revefenacin
year
associ
accept
cv
safeti
thu
may
provid
benefici
nebul
therapi
patient
copd
improv
time
medic
administr
pilot
cartless
autom
dispens
cabinet
model
surgic
icu
nyu
langon
brooklyn
prachi
bhatt
pharmd
bcp
bcccp
elizabeth
dougla
bsn
rn
erwin
wang
md
patricia
md
mph
pharmaci
nyu
langon
hospit
brooklyn
brooklyn
ny
langon
hospit
brooklyn
brooklyn
ny
introduct
nyu
langon
hospit
brooklyn
commit
continu
evalu
improv
medic
process
workflow
pilot
cartless
autom
dispens
cabinet
adc
system
discuss
potenti
solut
provid
easier
bedsid
access
medic
decreas
time
first
dose
administr
time
sensit
diagnos
exampl
sepsi
research
question
hypothesi
impact
time
first
dose
administr
perceiv
workload
implement
adc
surgic
icu
studi
design
singl
center
retrospect
review
qualiti
improv
method
baselin
metric
medic
dose
return
pharmaci
time
medic
administr
time
order
verif
surgic
icu
analyz
use
data
electron
medic
record
addit
nurs
satisfact
survey
conduct
evalu
workload
pilot
cartless
adc
model
implement
metric
evalu
result
overal
time
medic
administr
decreas
averag
minut
minut
order
due
within
one
hour
percentag
order
administ
within
intend
one
hour
increas
signific
improv
percentag
first
dose
broad
spectrum
antibiot
administ
within
one
hour
number
dose
return
pharmaci
decreas
base
bedsid
nurs
survey
decreas
time
spent
acquir
medic
averag
min
per
nurs
per
patient
min
per
nurs
per
patient
conclus
icu
without
onsit
satellit
pharmaci
util
autom
dispens
cabinet
system
improv
sever
aspect
medic
deliveri
administr
process
notabl
time
order
entri
administr
decreas
pilot
pharmacoeconom
analysi
safeti
intervent
prior
author
consult
servic
sherin
jacob
pharmd
bcp
rachel
britt
pharmd
bcp
william
bryan
pharmd
bcp
jonathan
hale
pharmd
bcp
moham
hashem
pharmd
bcp
jami
brown
pharmd
bcp
bcacp
pharmaci
servic
durham
va
health
care
system
durham
nc
introduct
central
formulari
manag
system
design
encourag
safe
effect
afford
medic
use
within
system
implement
prior
author
drug
request
padr
consult
servic
potenti
promot
clinic
sound
safe
medic
therapi
research
question
hypothesi
primari
object
determin
cost
avoid
associ
padr
safeti
intervent
within
veteran
affair
healthcar
system
secondari
object
includ
evalu
direct
cost
save
character
sever
advers
drug
event
ade
avoid
studi
design
retrospect
chart
review
method
padr
approv
due
safeti
intervent
juli
june
includ
cost
avoid
determin
multipli
probabl
ade
occurr
absenc
padr
safeti
intervent
estim
cost
avoid
base
type
intervent
direct
cost
save
calcul
total
cost
request
medic
approv
padr
subtract
cost
recommend
altern
therapi
cost
pharmacist
padr
review
sever
estim
avoid
ade
also
assess
potenti
ade
avoid
review
panel
three
clinic
pharmacist
valid
ade
probabl
score
intervent
type
sever
score
descript
statist
use
analys
result
padr
approv
studi
period
met
inclus
criteria
padr
safeti
intervent
result
total
cost
avoid
mean
direct
cost
save
mean
practic
set
anticoagul
infecti
diseas
result
largest
contribut
cost
avoid
cost
save
respect
ade
avoid
classifi
major
padr
conclus
padr
safeti
intervent
result
substanti
econom
benefit
prevent
major
ade
analysi
justifi
pharmacist
role
central
formulari
manag
system
optim
medic
therapi
intraven
immunoglobulin
dose
protocol
obes
patient
acut
versu
chronic
indic
sung
shin
na
pharmd
candid
mark
rusay
pharmd
mari
bridgeman
pharmd
bcp
leonid
kagan
luigi
brunetti
pharmd
mph
bcp
pharmaci
practic
administr
rutger
state
univers
new
jersey
piscataway
nj
pharmaceut
rutger
state
univers
new
jersey
piscataway
nj
introduct
current
standard
dose
intraven
immunoglobulin
g
ivig
therapeut
obes
patient
ivig
dose
publish
literatur
suggest
use
adjust
bodi
weight
adjbw
ideal
bodi
weight
ibw
howev
dose
select
remain
inconsist
larg
base
institut
protocol
research
question
hypothesi
advers
event
ae
frequenc
relat
dose
strategi
studi
design
multicent
retrospect
review
electron
health
record
method
data
patient
collect
two
acut
care
hospit
differ
dose
strategi
patient
stratifi
four
bodi
mass
index
bmi
categori
underweight
bmi
normal
overweight
obes
hospit
actual
bodi
weight
abw
dose
includ
inpati
treat
acut
condit
hospit
abw
adjbw
ibw
dose
includ
outpati
treat
chronic
condit
infus
inform
avail
hospit
primari
outcom
ae
secondari
outcom
ae
frequenc
obeseoverweight
patient
csl
behr
provid
fund
result
final
dataset
includ
patient
hospit
signific
differ
ae
frequenc
obeseoverweight
patient
normalunderweight
patient
vs
respect
hospit
obeseoverweight
patient
experienc
significantli
ae
normalunderweight
patient
vs
respect
differ
ae
frequenc
obeseoverweight
patient
exceed
packag
maximum
infus
rate
versu
conclus
differ
ae
frequenc
obeseoverweight
popul
hospit
suggest
indic
therapi
may
influenc
ae
frequenc
obeseoverweight
patient
function
greater
ivig
exposur
ie
chronic
versu
acut
therapi
despit
reduc
dose
result
adjbw
dose
ivig
obeseoverweight
patient
hospit
frequenc
ae
greater
popul
acut
kidney
injuri
hospit
adult
patient
receiv
vancomycin
monotherapi
compar
combin
therapi
daniel
davenport
nicol
gonzalez
niki
koirola
adam
md
matthew
witri
pharmd
jame
hoehn
pharmd
bcp
fccp
iowa
famili
practic
center
waterloo
ia
medic
center
waterloo
ia
iowa
colleg
pharmaci
iowa
citi
ia
iowa
colleg
pharmaci
northeast
iowa
famili
practic
center
waterloo
ia
introduct
acut
kidney
injuri
aki
associ
increas
morbid
mortal
previou
studi
suggest
increas
aki
combin
vancomycin
vanpt
administr
research
question
hypothesi
primari
endpoint
frequenc
aki
patient
receiv
vanpt
vs
vancomycin
van
secondari
endpoint
evalu
predictor
aki
patient
receiv
vanpt
studi
design
retrospect
chart
review
method
patient
identifi
two
commun
hospit
admiss
occur
hospit
hospit
inclus
criteria
age
year
minimum
hour
van
use
pretreat
repeat
creatinin
valu
patient
serum
creatinin
scr
mgdl
renal
diseas
receiv
dialysi
critic
ill
exclud
aki
defin
time
mgdl
increas
scr
steadi
state
van
trough
level
record
data
collect
electron
medic
record
abstract
univari
multivari
analys
util
irb
approv
obtain
result
patient
receiv
van
vanpt
aki
observ
patient
respect
patient
receiv
van
older
mean
age
vs
respect
univari
analysi
signific
differ
concomit
nephrotoxin
infect
site
durat
van
use
frequenc
supratherapeut
van
level
two
group
multivari
analysi
reveal
follow
characterist
associ
increas
risk
aki
use
vanpt
increas
risk
interact
term
vanpt
use
plu
supratherapeut
van
level
increas
risk
conclus
vanpt
compar
van
associ
increas
risk
aki
patient
receiv
combin
vanpt
supratherapeut
van
level
especi
high
risk
aki
patient
receiv
vanpt
may
warrant
addit
therapeut
drug
monitor
ensur
appropri
van
dose
implement
criteria
predict
readmiss
within
patient
belinda
mang
pharmd
bcp
kristin
alvarez
pharmd
kristi
vo
pharmd
caremor
fort
worth
tx
depart
parkland
hospit
dalla
tx
introduct
transit
care
unit
tcu
program
design
identifi
patient
improv
access
care
promot
engag
reduc
readmiss
discharg
pharmacist
perform
comprehens
assess
medic
reconcil
discrep
provid
extens
counsel
balanc
valu
servic
limit
resourc
risk
stratif
develop
classifi
patient
readmiss
correl
pharmacist
intervent
research
question
hypothesi
determin
implement
risk
stratif
pharmacist
intervent
impact
readmiss
rate
studi
design
retrospect
descript
studi
method
patient
tcu
program
receiv
pharmacist
intervent
octob
decemb
includ
readmiss
review
primari
diagnosi
contribut
problem
readmiss
set
inpati
observ
educc
descript
statist
use
baselin
characterist
outcom
result
patient
elig
patient
categor
receiv
pharmacist
intervent
follow
overal
inpati
readmiss
within
day
associ
medic
result
readmiss
rate
primarili
driven
group
compar
group
due
noncompli
discern
trend
seen
observ
educc
revisit
revisit
rate
group
respect
despit
revisit
rate
conclus
find
suggest
risk
categor
may
predict
readmiss
observ
readmiss
rate
greater
readmiss
observ
group
control
group
avail
compar
impact
pharmacist
intervent
data
provid
foundat
continu
develop
robust
stratif
process
enhanc
pharmaceut
intervent
aim
achiev
sustain
posit
outcom
estim
renal
function
drug
dose
nation
survey
pharmacist
sean
mcconachi
pharmd
bcp
sheila
wilhelm
pharmd
fccp
joshua
raub
pharmd
claudia
hanni
applebaum
colleg
pharmaci
health
scienc
wayn
state
univers
detroit
mi
pharmaci
practic
wayn
state
univers
eugen
applebaum
colleg
pharmaci
health
scienc
detroit
mi
receiv
hospit
detroit
mi
univers
hospit
detroit
mi
introduct
equat
use
estim
renal
function
inaccur
certain
clinic
context
limit
literatur
guid
pharmacist
situat
research
question
hypothesi
inconsist
estim
renal
function
among
pharmacist
impact
drug
dose
caus
variat
pharmacotherapi
studi
design
nation
electron
survey
distribut
captur
current
renal
function
estim
subsequ
drug
dose
practic
method
survey
email
listserv
four
accp
network
adult
medicin
nephrolog
critic
care
infecti
diseas
survey
includ
pharmacist
demograph
practic
site
inform
clinic
applic
scenario
requir
respond
choos
renal
function
estim
overweight
underweight
elderli
patient
year
four
patient
case
captur
respond
enoxaparin
dose
decis
patient
estim
creatinin
clearanc
crcl
around
mlmin
estim
provid
base
modifi
dose
renal
diseas
mdrd
chronic
kidney
diseas
epidemiolog
equat
result
respons
survey
major
respond
pharmacist
practic
hospit
set
clinic
specialist
equat
chosen
estim
renal
function
commonli
total
adjust
bodi
weight
use
estim
commonli
patient
underweight
overweight
respect
given
elderli
patient
low
serum
creatinin
scr
respond
use
actual
scr
round
scr
round
scr
use
enoxaparin
renal
dose
adjust
differ
base
clinic
indic
respond
chose
aggress
dose
patient
pulmonari
embol
versu
atrial
fibril
respond
whose
practic
site
util
renal
dose
adjust
polici
indic
deviat
polici
conclus
larg
variat
exist
among
clinic
pharmacist
applic
renal
function
estim
equat
may
impact
dose
strategi
patient
care
influenc
vs
intens
continu
renal
replac
therapi
cefepim
antibiot
exposur
critic
ill
patient
soo
min
jang
alex
shaw
bruce
mueller
pharmaci
practic
loma
linda
univers
school
pharmaci
loma
linda
ca
therapeut
herndon
va
clinic
pharmaci
univers
michigan
colleg
pharmaci
ann
arbor
mi
introduct
vanih
atn
trial
compar
li
vs
intens
continu
renal
replac
therapi
crrt
determin
whether
intens
crrt
effluent
rate
affect
patient
outcom
howev
antibiot
dose
treatment
arm
regardless
crrt
effluent
rate
may
result
lower
antibiot
exposur
patient
higher
crrt
drug
clearanc
purpos
studi
determin
probabl
target
attain
pta
hour
therapi
cefepim
evalu
influenc
intens
effluent
rate
cefepim
differ
pharmacodynam
pd
target
research
question
hypothesi
critic
ill
patient
receiv
intens
crrt
attain
lower
pta
compar
patient
receiv
li
crrt
studi
design
mont
carlo
simul
mc
method
previous
publish
pharmacokinet
critic
ill
patient
andor
receiv
crrt
demograph
data
atn
trial
use
perform
mc
virtual
patient
publish
cefepim
dose
regimen
appli
mc
account
prescrib
crrt
dose
deliv
pta
calcul
use
pd
target
free
serum
concentr
minimum
inhibitori
concentr
mgl
ft
mic
ft
ft
mic
first
hour
antibiot
therapi
result
pta
pta
regimen
arm
pta
pta
ft
conclus
regardless
pharmacodynam
target
chosen
differ
pta
high
low
intens
crrt
usual
less
factor
associ
increas
hospit
length
stay
periton
dialysi
patient
present
periton
need
antimicrobi
stewardship
taylor
morrisett
robert
canada
daniel
padgett
pharmd
joanna
hudson
pharmd
bcp
fasn
pharmaci
univers
colorado
hospit
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
medicin
nephrolog
univers
tennesse
memphi
tn
pharmaci
methodist
univers
hospit
memphi
tn
clinic
pharmaci
medicin
nephrolog
univers
tennesse
memphi
tn
introduct
periton
remain
common
complic
periton
dialysi
pd
contribut
significantli
morbid
adher
recommend
expect
resolv
periton
within
five
day
howev
hospit
length
stay
lo
patient
periton
pdap
often
prolong
factor
contribut
increas
lo
vigil
antimicrobi
stewardship
asp
popul
well
describ
research
question
hypothesi
factor
associ
increas
lo
patient
pdap
studi
design
retrospect
cohort
adult
patient
present
pdap
methodist
le
bonheur
healthcar
august
august
method
patient
divid
two
group
base
lo
day
reduc
lo
versu
day
prolong
lo
patient
demograph
adher
recommend
antimicrobi
therapi
appropri
antimicrobi
resolut
periton
day
five
blood
glucos
admiss
intens
care
unit
icu
infecti
diseas
id
consult
chang
dialysi
modal
pathogen
characterist
compar
mortal
readmiss
also
evalu
result
patient
screen
met
inclus
criteria
femal
age
year
reduc
lo
group
prolong
lo
group
factor
associ
increas
lo
admiss
icu
id
consult
remov
pd
cathet
switch
hemodialysi
p
concomit
therapi
number
day
blood
glucos
read
mgdl
opportun
antimicrobi
identifi
patient
reduc
prolong
lo
group
respect
howev
occur
patient
differ
mortal
readmiss
conclus
longer
lo
influenc
acuiti
ill
type
resolut
infect
need
improv
asp
within
pdap
popul
impact
epoetin
alpha
dose
monitor
servic
hospit
chronic
kidney
diseas
ckd
patient
academ
medic
center
sy
samad
pharmd
candid
kimberli
zammit
pharmd
bcp
bcccp
calvin
meaney
pharmd
pharmaci
practic
ub
school
pharmaci
pharmaceut
scienc
buffalo
ny
pharmaci
practic
buffalo
gener
medic
center
buffalo
ny
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
introduct
acut
ill
ckd
patient
erythropoietin
stimul
agent
esa
lead
overus
esa
therapi
inform
evalu
impact
pharmacist
manag
esa
dose
protocol
hospit
patient
esa
util
patient
outcom
research
question
hypothesi
manag
esa
therapi
inpati
admiss
ptd
protocol
result
signific
differ
percent
chang
hemoglobin
discharg
compar
provid
driven
dose
secondarili
ptd
protocol
result
lower
weekli
epoetin
alpha
dose
base
bodi
weight
studi
design
singl
center
retrospect
studi
method
patient
ckd
stage
iv
v
receiv
esa
therapi
prior
hospit
admiss
compar
implement
dose
protocol
data
collect
includ
baselin
demograph
total
esa
dose
number
dose
escal
hemoglobin
chang
blood
transfus
patient
outcom
hypothesi
test
use
appropri
spss
alpha
set
result
total
patient
assess
primari
endpoint
per
group
statist
signific
differ
age
weight
bmi
iron
supplement
bleed
two
group
primari
endpoint
group
statist
signific
versu
p
pharmaci
protocol
group
patient
lower
total
epoetin
alpha
dose
vs
ukgweek
respect
p
fewer
dose
increas
p
patient
ptd
group
receiv
fewer
blood
transfus
vs
p
presenc
bleed
administr
blood
transfus
influenc
primari
endpoint
conclus
epoetin
alpha
protocol
associ
lower
dose
ukgweek
dose
increas
statist
signific
chang
percent
differ
hemoglobin
patient
hospit
cours
contrast
induc
nephropathi
comparison
agent
definit
calvin
meaney
pharmd
bcp
kelli
krieger
kimberli
zammit
pharmd
bcp
bcccp
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
pharmaci
buffalo
gener
medic
center
buffalo
ny
introduct
data
conflict
differenti
nephropathi
risk
iohexol
iodixanol
contrast
agent
previou
trial
includ
specif
popul
variou
definit
nephropathi
cin
difficult
compar
research
question
hypothesi
cumul
incid
cin
iohexol
iodixanol
heterogen
popul
secondarili
differ
definit
cin
influenc
studi
result
studi
design
retrospect
cohort
method
patient
undergo
percutan
coronari
intervent
pci
receiv
intraven
iohexol
iodixanol
renal
function
data
avail
hour
includ
exclus
criteria
dialysi
depend
acut
kidney
injuri
present
cin
defin
creatinin
scr
increas
baselin
within
akin
glomerular
filtrat
rate
egfr
decreas
within
hour
increas
within
hour
increas
mgdl
criteria
multivari
logist
regress
use
compar
cin
iohexol
iodixanol
covari
analysi
use
sa
result
includ
patient
year
old
male
caucasian
receiv
median
contrast
baselin
egfr
cin
occur
iohexol
compar
iodixanol
adjust
heart
failur
diabet
mellitu
baselin
renal
function
concomit
nephrotoxin
differ
cin
iohexol
iodixanol
adjust
odd
ratio
ci
overal
cohort
incid
cin
rang
depend
definit
show
trend
toward
increas
cin
iodixanol
conclus
differ
risk
cin
iohexol
iodixanol
real
world
popul
undergo
pci
confirm
control
prospect
studi
balanc
inclus
definit
cin
critic
interpret
studi
result
comparison
kidney
function
estim
drug
dosag
adjust
sheryl
vondracek
barbara
brenneman
garth
wright
toral
patel
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
pharmaci
pharmaceut
scienc
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
nation
kidney
foundat
recommend
individu
modif
diet
renal
diseas
mdrdind
chronic
kidney
diseas
epidemiolog
collabor
equat
drug
dose
cg
howev
origin
cg
equat
modifi
version
still
use
mani
institut
includ
univers
colorado
hospit
uch
use
weight
serum
creatinin
scr
adjust
research
question
hypothesi
drug
dose
discord
estim
equat
studi
design
prospect
observ
method
singl
point
time
data
collect
adult
patient
creatinin
clearanc
crcl
mlmin
stabl
scr
medic
uch
pharmaci
renal
dose
protocol
primari
outcom
comparison
percent
discord
dose
recommend
use
mcnemar
test
bonferroni
correct
secondari
outcom
comparison
differ
crcl
glomerular
filtrat
rate
gfr
equat
use
wilcoxon
sign
rank
test
bonferroni
correct
predictor
discord
use
logist
regress
result
one
hundr
patient
receiv
protocol
drug
includ
mean
sd
age
year
femal
obes
mean
sd
kidney
function
estim
use
equat
significantli
lower
compar
equat
mlmin
versu
cg
mlmin
mlmin
mdrd
mdrdind
mlmin
p
dose
discord
cg
mdrd
mdrdind
respect
approxim
discord
dose
higher
cg
equat
less
discord
mdrd
equat
p
femal
time
like
p
patient
scr
time
like
p
discord
dose
recommend
conclus
equat
result
significantli
lower
kidney
function
estim
differ
dosag
recommend
approxim
time
versu
equat
evalu
thrombosi
hemodialysi
renal
diseas
esrd
patient
receiv
subcutan
heparin
chelsea
mitchel
benjamin
duhart
ms
carri
oliph
pharmd
fccp
cardiolog
leonett
kemp
joanna
hudson
pharmd
bcp
fasn
univers
hospit
memphi
tn
clinic
pharmaci
univers
tennesse
colleg
pharmaci
memphi
tn
pharmaci
methodist
univers
hospit
memphi
tn
univers
tennesse
colleg
pharmaci
methodist
univers
hospit
memphi
tn
clinic
pharmaci
medicin
nephrolog
univers
tennesse
memphi
tn
introduct
renal
diseas
esrd
patient
requir
hemodialysi
hd
risk
thrombosi
access
site
dialysi
circuit
administr
system
unfraction
heparin
ufh
hd
circuit
routin
prevent
thrombosi
outpati
set
practic
vari
inpati
set
institut
employ
polici
hd
inpati
howev
mani
receiv
subcutan
ufh
venou
thromboembol
vte
prophylaxi
research
question
hypothesi
ufh
given
vte
prophylaxi
associ
less
thrombosi
hd
studi
design
retrospect
cohort
studi
method
esrd
patient
receiv
least
two
hd
treatment
hospit
identifi
patient
newli
initi
hd
admit
clot
dialysi
access
site
receiv
new
access
exclud
patient
categor
base
whether
receiv
ufh
vte
prophylaxi
hospit
percentag
patient
experienc
thrombosi
compar
group
ufh
dose
regimen
intervent
thrombosi
length
stay
lo
dialysi
condit
antiplatelet
use
also
compar
result
total
patient
includ
male
mean
age
year
control
group
ufh
group
mean
ufh
dose
unit
twice
daili
dose
patient
three
time
daili
patient
thrombot
event
hd
occur
control
patient
ufh
patient
howev
differ
statist
signific
equal
frequenc
clot
event
requir
temporari
discontinu
hd
group
higher
rate
administr
thrombolyt
agent
discontinu
hd
observ
ufh
group
differ
lo
among
experienc
clot
event
conclus
receipt
subcutan
ufh
vte
prophylaxi
reduc
occurr
thrombot
event
esrd
patient
hd
pharmacist
role
manag
patient
multipl
sclerosi
jennif
cardon
paul
isikw
lisa
farnett
darren
stam
univers
boston
genzym
cambridg
introduct
limit
contradictori
data
publish
regard
role
pharmacist
manag
patient
multipl
sclerosi
pwm
studi
refer
leverag
relationship
addit
data
describ
lack
relationship
patient
compliancepersist
access
pharmacist
indic
unmet
need
evid
elucid
current
trend
role
pharmacist
manag
pwm
research
question
hypothesi
role
pharmacist
manag
pwm
studi
design
anonym
electron
survey
clinic
pharmacist
method
survey
distribut
via
email
member
american
colleg
clinic
pharmaci
ambulatori
care
adult
medicin
central
nervou
system
cn
practic
research
network
prn
particip
provid
inform
consent
respons
analyz
use
percentag
determin
frequent
respons
distribut
respons
result
respons
mean
cn
prn
per
question
common
practic
site
inpati
hospit
academ
center
veteran
affair
medic
center
train
pharmaci
studentsresid
collabor
practic
agreement
bill
servic
see
pwm
often
patient
referr
appoint
medic
dispens
patient
interact
often
minut
includ
discuss
variou
topic
integr
part
healthcar
team
respond
report
recommend
chang
diseas
modifi
therapi
dmt
provid
rational
switch
dmt
side
effect
cost
access
lack
efficaci
respond
also
report
monitor
patient
comprehens
manag
ms
symptom
fatigu
spastic
movementgait
disord
respond
interact
primarili
neurologist
ms
specialist
advanc
practic
clinician
nurs
conclus
clinic
pharmacist
across
practic
set
extens
involv
manag
pwm
number
dmt
expand
individu
diseas
manag
becom
complex
ms
practic
set
may
offer
expand
role
pharmaci
practic
studi
pharmacist
knowledg
advers
drug
reaction
sodium
valproat
reproduct
women
patient
thanarat
suansana
bsc
pharm
bcpp
bcgp
busba
chindavijak
bsc
pharm
phd
depart
pharmaci
faculti
pharmaci
mahidol
univers
bangkok
thailand
introduct
valproat
poss
teratogen
caution
use
women
epilepsi
research
question
hypothesi
object
studi
evalu
knowledg
hospit
pharmacist
advers
drug
reaction
sodium
valproat
women
epilepsi
studi
design
survey
studi
conduct
method
questionnair
develop
evalu
expert
questionnair
send
directli
hospit
pharmacist
work
univers
hospit
hospit
depart
medic
servic
hospit
bangkok
metropolitan
administr
privat
hospit
coordin
hospit
result
result
reveal
questionnair
could
collect
target
hospit
pharmacist
particip
women
age
year
old
work
experi
year
work
univers
hospit
work
hospit
depart
medic
servic
hospit
bangkok
metropolitan
administr
privat
hospit
respect
major
work
dispens
unit
experi
dispens
sodium
valproat
mean
score
highest
correct
item
ask
use
sodium
valproat
pregnanc
risk
teratogen
least
correct
item
relat
drug
interact
sodium
valproat
oral
contracept
pharmacist
experi
dispens
sodium
valproat
statist
signific
higher
score
respect
conclus
studi
show
hospit
pharmacist
low
moder
knowledg
advers
drug
reaction
sodium
valproat
women
epilepsi
might
affect
appropri
patient
counsel
pharmaceut
care
safeti
toler
valbenazin
particip
tardiv
dyskinesia
jack
chen
gari
remington
md
phd
cynthia
comella
joshua
burk
khodayar
farahmand
scott
siegert
univers
health
scienc
signal
hill
ca
addict
mental
health
toronto
canada
univers
medic
center
chicago
il
bioscienc
inc
san
diego
ca
present
colleg
psychiatr
neurolog
pharmacist
annual
meet
indianapoli
indiana
april
focal
epilepsi
photoparoxysm
respons
ethnic
influenc
ronald
reed
bs
pharm
pharmd
fccp
fae
dorothe
trenit
md
phd
clinic
pharmaci
school
pharmaci
west
virginia
univers
morgantown
wv
neurosurgeri
epilepsi
univers
medic
center
utrecht
utrecht
netherland
present
annual
meet
american
epilepsi
societi
ae
washington
dc
decemb
hemorrhag
analysi
tpa
administr
post
ischem
stroke
shima
shafiyan
pharmd
candid
ahm
zaki
pharmd
amn
borghol
pharmd
pharmaci
xavier
univers
louisiana
new
orlean
la
pharmaci
xavier
univers
lousiana
new
orlean
la
pharmaci
divis
clinic
administr
scienc
xavier
univers
louisiana
new
orlean
la
present
louisiana
societi
pharmacist
annual
confer
new
orlean
la
may
nutrit
obes
attenu
serum
vitamin
respons
cholecalciferol
therapi
critic
ill
patient
whitney
holm
malcolm
earl
pharmd
georg
maish
iii
gayl
minard
martin
croce
roland
dickerson
pharmaci
region
one
health
memphi
tn
clinic
pharmaci
translat
scienc
univers
tennesse
colleg
pharmaci
memphi
tn
surgeri
univers
tennesse
health
scienc
center
memphi
tn
present
american
societi
parenter
enter
nutrit
nutrit
scienc
practic
confer
la
vega
nv
januari
potenti
cost
save
elimin
avoid
parenter
nutrit
use
adult
hospit
patient
academ
medic
center
haley
kavelak
pharmd
bcccp
jame
holland
pharmd
aq
justin
delic
pharmd
cori
angelini
angela
bingham
pharmd
bcp
bcnsp
luke
univers
health
network
bethlehem
pa
pharmaci
practic
pharmaci
administr
univers
philadelphia
colleg
pharmaci
philadelphia
pa
univers
hospit
camden
nj
introduct
parenter
nutrit
pn
potenti
lifesav
therapi
indic
judici
select
candid
challeng
mani
institut
research
question
hypothesi
potenti
annual
cost
save
associ
avoid
pn
adult
hospit
patient
academ
medic
center
studi
design
singl
center
retrospect
analysi
method
adult
hospit
patient
receiv
pn
april
march
includ
pn
appropri
assess
patient
encount
base
guidanc
american
societi
parenter
enter
nutrit
categori
avoid
pn
use
includ
inadequ
enter
nutrit
attempt
short
cours
day
earli
initi
earlier
day
unless
malnourish
function
gastrointestin
gi
tract
prolong
cours
return
gi
function
refus
enter
nutrit
wast
defin
pn
order
compound
administ
avoid
pn
wast
charg
determin
multipli
day
mean
institut
charg
pn
product
complic
assess
avoid
pn
encount
descript
statist
use
analysi
result
patient
encount
floor
medic
icu
trauma
icu
cardiac
icu
mortal
mean
hospit
length
stay
day
mean
durat
pn
per
encount
day
central
pn
patient
encount
avoid
pn
account
avoid
pn
day
common
categor
avoid
pn
includ
short
cours
earli
initi
wast
occur
day
contribut
direct
cost
total
annual
direct
cost
associ
avoid
pn
wast
adult
hospit
patient
avoid
pn
encount
account
complic
metabol
infecti
mechan
conclus
avoid
pn
use
wast
adult
hospit
patient
associ
signific
cost
expenditur
increas
burden
metabol
infecti
mechan
complic
extend
use
doxorubicin
chemotherapi
use
natur
product
arthur
nguyen
bs
karen
seo
max
lee
deepa
rao
univers
hllsboro
introduct
doxorubicin
dox
anticanc
agent
act
inhibit
topoisomeras
format
reactiv
oxygen
speci
mechan
respons
cardiotox
limit
use
subclin
cardiotox
possibl
polyphenol
resveratrol
r
quercetin
q
curcumin
c
free
radic
scaveng
known
chemosensit
combin
natur
product
dox
therapeut
strategi
may
mitig
dox
cardiotox
preserv
potenc
research
question
hypothesi
hypothes
use
r
q
dox
rqd
r
c
dox
rcd
r
q
c
dox
rqcd
ratio
synergist
prostat
ovarian
cell
antagonist
cardiomyocyt
studi
design
quantit
cell
base
assay
assess
potenc
dox
natur
product
evalu
degre
interact
combin
method
cancer
cell
cardiomyocyt
seed
well
plate
allow
attach
hour
treat
individu
combin
um
hour
cell
viabil
assess
use
celltiterblu
fluoresc
concentr
individu
combin
need
kill
cell
valu
calcul
use
graphpad
prism
interact
assess
use
combin
index
ci
analysi
ci
valu
synergist
addit
antagonist
respect
result
cell
line
test
dox
highest
potenc
cancer
cell
rqd
rcd
rqcd
combin
synergist
ci
valu
cardiomyocyt
combin
antagonist
ci
valu
conclus
base
result
approach
potenti
increas
lifetim
dose
limit
dox
patient
protect
cardiomyopathi
one
dox
advers
side
effect
determin
clinic
factor
associ
symptom
burden
breast
cancer
patient
latent
lca
alexandr
chan
pharmd
mph
fccp
fisopp
bcp
bcop
yi
long
toh
bscpharm
hon
depart
pharmaci
nation
univers
singapor
singapor
singapor
introduct
given
vast
heterogen
symptom
experienc
breast
cancer
patient
interest
evalu
whether
possibl
profil
patient
base
symptom
burden
level
research
question
hypothesi
studi
aim
profil
symptom
burden
level
among
breast
cancer
patient
identifi
relev
factor
associ
high
symptom
burden
studi
design
multicent
prospect
cohort
studi
method
breast
cancer
stage
patient
receiv
chemotherapi
recruit
patient
symptom
burden
longitudin
assess
use
european
organ
research
treatment
cancer
qualiti
life
questionnair
six
time
point
cours
chemotherapi
survivorship
latent
class
analysi
lca
util
assign
patient
respect
subclass
optim
number
class
determin
base
bayesian
inform
criterion
valu
multinomi
logist
regress
conduct
determin
clinic
determin
distinguish
variou
subclass
result
total
patient
includ
mean
age
sd
year
receiv
chemotherapi
fatigu
pain
insomnia
preval
symptom
report
patient
three
symptom
profil
patient
classifi
low
symptom
burden
moder
symptom
burden
high
symptom
burden
patient
high
symptom
burden
like
diagnos
stage
iii
cancer
ci
age
year
ci
receipt
higher
level
educ
ci
conclus
find
suggest
lca
feasibl
profil
patient
base
symptom
level
provid
promis
strategi
guid
symptom
manag
intervent
patient
differ
level
symptom
burden
institut
evalu
chemotherapi
monoclon
antibodi
dose
round
polici
laura
roccograndi
bs
cali
cerami
bs
leticia
villela
smith
pharmd
bcop
seton
healthcar
famili
austin
tx
introduct
drug
wast
minim
effect
strategi
reduc
wast
expens
oncolog
medic
current
seton
healthcar
famili
shf
util
dose
round
polici
nearest
vial
size
singl
use
vial
within
chemotherapi
monoclon
antibodi
calcul
dose
prescrib
request
expand
dose
round
percentag
chemotherapi
requir
assess
current
polici
complianc
dose
round
clinic
scenario
research
question
hypothesi
chemotherapi
monoclon
antibodi
dose
round
nearest
vial
size
metastat
patient
compliant
round
polici
studi
design
retrospect
cohort
studi
preform
via
chart
review
method
medic
record
cancer
patient
seen
june
decemb
site
within
shf
review
patient
infus
order
weight
height
indic
vial
select
pharmaci
dose
intervent
document
result
patient
metastat
diseas
diseas
assess
patient
receiv
chemotherapi
monoclon
antibodi
patient
treat
metastat
diseas
chemotherapi
dose
automat
round
dose
round
diseas
patient
dose
round
overal
polici
complianc
per
patient
chemotherapi
dose
round
monoclon
antibodi
patient
treat
metastat
diseas
dose
automat
round
dose
round
diseas
patient
dose
round
overal
polici
complianc
per
patient
monoclon
antibodi
dose
round
indic
anticanc
agent
pharmacist
interven
round
infus
order
conclus
although
academ
medic
center
adopt
dose
round
polici
measur
improv
complianc
polici
warrant
due
review
recommend
maintain
current
cutoff
review
polici
prescrib
pharmacist
use
clinic
oncolog
pathway
increas
treatment
decis
brandon
chang
pharmd
timothi
mok
pharmd
andrea
chan
pharmd
kaiser
permanent
san
diego
ca
introduct
advent
newer
immunolog
chemotherapeut
inevit
bring
greater
financi
burden
healthcar
system
improv
measur
need
overcom
financi
challeng
ensur
agent
use
maintain
highest
qualiti
led
use
clinic
pathway
healthcar
organ
improv
patient
outcom
control
cost
clinic
pathway
often
requir
deep
understand
pharmacolog
therapi
oncolog
train
pharmacist
prime
posit
develop
implement
assess
research
question
hypothesi
recommend
base
clinic
oncolog
pathway
accept
oncologist
reduc
cost
studi
design
retrospect
descript
studi
examin
pilot
implement
clinic
pathway
method
retrospect
descript
studi
examin
pilot
implement
clinic
pathway
oncolog
pharmacist
kaiser
permanent
san
diego
develop
clinic
pathway
evalu
treatment
regimen
new
consult
current
patient
studi
analyz
clinic
pathway
recommend
accept
oncolog
provid
treatment
recommend
analysi
conduct
patient
seen
oncologist
septemb
februari
result
oncolog
pharmacist
made
recommend
multipl
diseas
state
major
breast
lymphoma
lung
recommend
made
accept
indic
physician
recept
clinic
pathway
oncolog
pharmacist
made
multipl
type
recommend
new
therapi
recommend
laboratori
test
mutat
test
discontinu
therapi
support
care
switch
therapi
clinic
trial
recommend
result
estim
conclus
found
physician
recept
clinic
pathway
creat
clinic
pathway
improv
commun
relationship
physician
group
oncolog
pharmacist
provid
recommend
base
clinic
oncolog
pathway
improv
care
reduc
cost
evalu
pharmacist
impact
hematolog
oncolog
chemotherapi
order
hailey
lin
master
vivien
ng
master
elton
yip
bachelor
peter
chan
master
keari
zhou
pharmaci
princess
margaret
hospit
hospit
author
kowloon
hong
kong
depart
princess
margaret
hospit
hospit
author
kowloon
hong
kong
pharmaci
chines
univers
hong
kong
shatin
hong
kong
present
intern
societi
pharmacoeconom
outcom
research
asia
pacif
tokyo
japan
septemb
access
orphan
drug
qualiti
life
rare
diseas
amar
abba
iii
mpharm
jani
vella
b
pharm
msc
clinic
pharmaci
anthoni
bpharm
pharmd
cinc
maccp
pharmaci
univers
malta
msida
malta
pharmaci
univers
malta
msida
malta
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
introduct
rare
diseas
rd
affect
around
million
patient
worldwid
date
local
conduct
studi
healthcar
need
peopl
live
rd
research
question
hypothesi
regul
polici
relat
orphan
drug
od
access
exist
local
intern
qualiti
life
rd
patient
studi
design
retrospect
analysi
cross
section
studi
method
retrospect
analysi
carri
observ
featur
od
polici
rd
patient
local
intern
health
relat
qualiti
life
hrqol
assess
tool
develop
valid
publish
onlin
hrqol
tool
explor
issu
diagnosi
inform
provis
time
diagnosi
use
health
support
servic
gener
qualiti
life
rd
patient
includ
mental
health
issu
differ
patient
group
asia
europ
africa
america
contact
invit
member
particip
result
od
specif
legisl
countri
access
od
depend
price
polici
drug
avail
one
hundr
thirti
respons
given
rd
patient
analys
sixti
percent
respons
gather
malta
ireland
usa
access
issu
hurdl
rd
patient
report
medic
avail
countri
countri
forti
percent
receiv
misdiagnosi
wait
year
receiv
diagnosi
seventi
percent
patient
complain
stress
anxieti
problem
conclus
countri
studi
od
regul
place
differ
countri
price
licens
reimburs
od
impact
access
need
improv
qualiti
life
rd
patient
comparison
approv
indic
regulatori
agenc
matthew
camilleri
bsc
hon
pharmsc
anthoni
bpharm
pharmd
cinc
maccp
nicolett
sammut
bartolo
bpharm
hon
melit
msc
melit
phd
melit
borg
bpharm
hon
msc
agricvetpharm
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
temi
zammit
build
malta
life
scienc
park
san
sgn
malta
medicin
author
san
gwann
malta
introduct
medicin
product
allow
market
follow
approv
autonom
regulatori
agenc
task
evalu
differ
evalu
practic
registr
medicin
product
found
europ
unit
state
america
may
lead
discrep
clinic
guidelin
price
polici
drug
use
research
question
hypothesi
differ
authoris
drug
indic
european
medicin
agenc
ema
us
food
drug
administr
fda
use
new
molecular
entiti
medicin
product
model
studi
design
retrospect
observ
review
studi
method
medicin
product
assess
ema
identifi
use
anatom
therapeut
chemic
atc
code
fda
counterpart
use
activ
ingredi
brand
name
authoris
holder
detail
assess
report
ema
review
fda
initi
product
inform
identifi
drug
obtain
tool
develop
valid
compar
differ
authoris
indic
result
product
market
authoris
agenc
identifi
total
fourteen
product
found
differ
indic
compar
label
summari
product
characterist
smpc
differ
indic
categoris
accord
follow
restrict
diseas
state
patient
characterist
differ
clinic
scenario
sever
condit
combin
previou
therapi
failur
inappropri
altern
therapi
reason
restrict
mainli
attribut
align
conduct
clinic
trial
agenc
found
restrict
indic
conclus
differ
approv
indic
exist
ema
fda
pharmaceut
compani
also
contribut
discrep
base
market
strategi
employ
submiss
applic
regulatori
collabor
agenc
deem
essenti
ensur
harmonis
approach
use
medic
develop
safe
effect
medicin
product
treat
leber
hereditari
optic
neuropathi
lhon
clinic
regulatori
challeng
zuccarelli
marta
master
degre
borg
bpharm
hon
msc
agricvetpharm
jani
vella
b
pharm
msc
clinic
pharmaci
anthoni
inglott
pharmaci
univers
malta
msida
msd
malta
temi
zammit
build
malta
life
scienc
park
san
sgn
malta
medicin
author
san
gwann
malta
pharmaci
univers
malta
msida
malta
introduct
leber
hereditari
optic
neuropathi
lhon
rare
mitochondri
optic
neuropathi
caus
three
mitochondri
dna
point
mutat
eu
raxon
idebenon
approv
medicin
product
mp
treat
lhon
mp
lhon
us
research
question
hypothesi
mp
develop
treat
lhon
clinic
develop
program
cdp
pursu
pharmaceut
compani
develop
mp
treat
lhon
studi
design
review
method
mp
treat
lhon
identifi
mechan
action
site
action
mp
natur
activ
substanc
identifi
prospect
treatment
protocol
suggest
emerg
pattern
primari
endpoint
studi
time
identifi
compar
regulatori
pathway
obtain
licenc
orphan
medicin
product
analys
result
eleven
mp
suitabl
treat
lhon
develop
product
small
molecul
product
consist
advanc
therapi
product
consist
phototherapi
five
mp
modul
agent
inhibitor
apoptosi
consist
gene
therapi
product
consist
therapi
ten
product
act
mitochondri
level
product
act
retin
ganglion
cell
one
product
raxon
market
authoris
eu
product
obtain
orphan
design
comparison
among
cdp
show
differ
primari
endpoint
studi
phase
iii
trial
conclus
need
develop
adequ
cdp
approv
mp
treat
lhon
eu
us
implement
redesign
workflow
model
focus
qualiti
improv
interprofession
care
underserv
clinic
amanda
li
student
pharmacist
kimberli
lui
student
pharmacist
huil
zhang
student
pharmacist
sharon
e
connor
pharmd
school
pharmaci
univers
pittsburgh
pittsburgh
pa
introduct
birmingham
free
clinic
bfc
provid
primari
care
prescript
medic
underserv
popul
pittsburgh
pennsylvania
bfc
medic
complex
patient
may
refer
panther
clinic
interprofession
teach
clinic
clinic
provid
patient
longitudin
care
also
allow
student
gain
clinic
experi
elabor
pharmaci
student
volunt
alongsid
medic
student
guidanc
pharmaci
resid
attend
physician
panther
clinic
consist
workflow
challeng
prevent
pharmaci
resid
contribut
valu
base
vb
activ
affect
patient
care
student
learn
research
question
hypothesi
implement
new
clinic
workflow
model
decreas
amount
time
pharmaci
resid
spend
nvb
activ
increas
time
spent
vb
activ
also
encourag
greater
organ
labor
defin
respons
particip
pharmaci
team
pharmaci
resid
pharmaci
student
volunt
studi
design
total
four
time
motion
studi
conduct
measur
pharmaci
resid
distribut
time
two
conduct
intervent
two
conduct
intervent
method
codebook
develop
categor
vb
nvb
task
categor
distribut
pharmaci
resid
time
determin
time
motion
studi
percentag
time
spent
task
intervent
compar
result
intervent
increas
time
pharmaci
resid
spent
vb
task
decreas
time
spent
nvb
task
conclus
increas
time
spent
vb
activ
result
better
defin
respons
volunt
role
clinic
implement
new
workflow
model
achiev
goal
increas
time
spent
direct
patient
care
activ
decreas
time
spent
nvb
activ
impact
electron
dispens
inventori
manag
system
edim
prescrib
pattern
communic
diseas
rural
hondura
angela
li
pharmd
candid
nicolett
diehl
doreen
foy
sharon
e
connor
lauren
j
jonkman
pharmd
mark
meyer
pittsburgh
school
pharmaci
pittsburgh
pa
pharmaci
univers
pittsburgh
pittsburgh
pa
pittsburgh
medic
center
pittsburgh
pa
introduct
effect
medic
suppli
manag
prevent
medic
continu
access
critic
medicin
antimicrobi
lead
inappropri
prescrib
contribut
antibiot
resist
rural
health
clinic
hondura
implement
electron
dispens
inventori
manag
system
edim
fall
purpos
studi
assess
impact
edim
medic
prescrib
communic
diseas
research
question
hypothesi
implement
edim
impact
prescrib
pattern
antibiot
rural
health
clinic
hondura
studi
design
retrospect
chart
review
method
retrospect
chart
review
conduct
rural
clinic
hondura
edim
chart
patient
seen
march
februari
diagnosi
commun
acquir
pneumonia
cap
acut
otiti
media
aom
upper
respiratori
tract
infect
uri
diarrhea
includ
data
extract
use
standard
data
collect
form
pattern
compar
use
descript
statist
test
result
total
chart
met
inclus
criteria
cap
vs
receiv
antibiot
pn
aom
vs
receiv
antibiot
pn
uri
vs
receiv
antibiot
pn
chang
specif
antibiot
use
diarrhea
vs
receiv
antibiot
pn
prepost
implement
vs
receiv
fluid
either
oral
rehydr
salt
or
intraven
fluid
ivf
conclus
result
show
high
antibiot
use
overal
set
signific
chang
prescrib
aom
cap
uri
implement
edim
howev
signific
increas
use
fluid
either
or
ivf
treatment
diarrhea
edim
next
step
research
determin
medic
avail
impact
prescrib
differ
trend
women
authorship
pharmaci
literatur
rebecca
hoover
pharmd
ademola
pharmd
kalon
ludvigson
pharmd
elain
nguyen
pharmd
mph
pharmaci
practic
administr
scienc
idaho
state
univers
colleg
pharmaci
pocatello
id
pharmaci
practic
administr
scienc
idaho
state
univers
colleg
pharmaci
meridian
id
introduct
previou
studi
conduct
nearli
decad
ago
indic
increas
women
authorship
pharmaci
journal
number
women
pharmaci
profess
increas
unknown
whether
women
contribut
pharmaci
literatur
also
increas
research
question
hypothesi
proport
women
first
author
pharmaci
literatur
increas
past
decad
studi
design
retrospect
bibliometr
analysi
method
web
scienc
use
export
citat
promin
pharmaci
journal
outcom
interest
proport
articl
feminin
name
first
author
feminin
first
author
determin
match
first
name
data
social
secur
administr
genderizeio
trend
test
use
determin
differ
proport
women
first
author
time
consid
statist
signific
data
export
prepar
excel
statist
analysi
perform
spss
result
proport
articl
women
first
author
increas
three
four
pharmaci
journal
evalu
tabl
signific
chang
time
observ
journal
american
pharmacist
associ
journal
also
began
women
authorship
begin
time
period
interest
conclus
continu
increas
women
first
author
pharmaci
literatur
past
decad
tabl
statist
signific
chang
data
repres
shown
interpret
understand
prescript
warn
label
refuge
sy
samad
pharmd
candid
gina
prescott
pharmd
pharmaci
practic
ub
school
pharmaci
pharmaceut
scienc
buffalo
ny
pharmaci
pharmaceut
scienc
univers
buffalo
buffalo
ny
introduct
patient
commonli
misunderstand
prescript
warn
label
pwl
lead
medic
error
advers
event
especi
low
literaci
inform
avail
refuge
interpret
pwl
research
question
hypothesi
refuge
abl
interpret
commonli
use
pwl
studi
design
qualit
interview
method
evalu
conduct
pharmaci
student
locat
english
second
languag
class
part
medic
health
literaci
program
eleven
commonli
use
pwl
refriger
take
food
may
caus
drowsi
ear
take
water
extern
use
shake
well
finish
alcohol
drive
avoid
sunlight
evalu
refuge
provid
pwl
english
ask
pwl
meant
use
interpret
respons
record
incorrect
educ
provid
correct
mean
label
descript
statist
fisher
exact
test
use
analyz
data
result
total
refuge
speak
differ
languag
evalu
major
refuge
spoke
spanish
burmes
arab
nepali
refuge
mainli
unit
state
year
year
ear
pwl
commonli
interpret
correctli
refriger
pwl
least
commonli
interpret
correctli
spanish
burmes
karen
congoles
vietnames
speaker
like
correct
interpret
pwl
compar
overal
group
p
speak
arab
nepali
french
chines
farsi
swahili
less
like
correct
p
conclus
refuge
abl
commun
assist
interpret
howev
group
still
difficulti
understand
pwl
pharmacist
need
awar
pwl
appear
aid
refuge
understand
medic
inform
comparison
faculti
standard
patient
global
score
use
evalu
student
commun
skill
assess
kyli
barn
maqual
graham
karen
harding
pharmaci
practic
administr
univers
missouri
kansa
citi
school
pharmaci
kansa
citi
mo
pharmaci
practic
umkc
kansa
citi
mo
introduct
reliabl
valid
assess
pharmaci
student
clinic
skill
compet
essenti
analyt
score
global
rate
two
commonli
use
score
system
object
structur
clinic
examin
osc
research
question
hypothesi
investig
correl
faculti
standard
patient
sp
global
assess
score
assign
pharmaci
student
multipl
osc
studi
design
retrospect
review
faculti
sp
global
score
conduct
comparison
method
second
third
year
pharmaci
student
complet
osc
cours
final
assess
spring
binari
analyt
checklist
global
assess
tool
five
distinct
section
verbal
express
express
respons
patient
feel
need
degre
focu
logic
coher
profession
use
global
score
assign
train
faculti
evalu
train
sp
independ
use
likert
scale
score
faculti
evalu
sp
evalu
determin
differ
assess
student
perform
use
spearman
rho
result
total
student
case
evalu
median
faculti
global
score
median
sp
global
score
fifti
percent
faculti
sp
global
score
equal
sp
score
higher
sp
score
lower
weak
correl
student
faculti
sp
global
score
second
year
p
third
year
p
combin
second
third
year
student
p
conclus
sp
tend
global
score
student
higher
faculti
member
revis
train
faculti
sp
evalu
warrant
improv
reliabl
valid
assess
tool
futur
studi
need
determin
best
method
assess
global
score
assess
impact
electron
dispens
inventori
manag
system
edim
prescrib
pattern
diseas
rural
health
clinic
hondura
niha
idre
bs
pharmd
candid
eryn
gordon
bs
pharmd
doreen
foy
nicolett
diehl
sharon
e
connor
lauren
jonkman
pharmd
mark
meyer
pittsburgh
school
pharmaci
pittsburgh
pa
pharmaci
univers
pittsburgh
pittsburgh
pa
pittsburgh
medic
center
pittsburgh
pa
introduct
medic
challeng
face
set
includ
inventori
manag
march
electron
dispens
inventori
manag
edim
implement
rural
health
clinic
hondura
littl
known
impact
informat
intervent
medic
suppli
result
prescrib
pattern
research
question
hypothesi
prescrib
pattern
chang
common
diseas
ncd
implement
edim
studi
design
retrospect
chart
review
method
chart
patient
seen
march
februari
diagnosi
asthma
hypertens
diabet
includ
train
data
collector
use
standard
form
includ
diseas
data
abstract
data
summar
use
descript
statist
prescrib
pattern
pool
analyz
use
test
result
asthma
patient
persist
asthma
evalu
patient
prescrib
saba
inhal
corticosteroid
ic
anticholinerg
patient
prescrib
saba
ic
patient
prescrib
anticholinerg
hypertens
patient
evalu
includ
ace
inhibitor
thiazid
calcium
channel
blocker
loop
diuret
arb
edim
medic
includ
ace
inhibitor
calcium
channel
blocker
thiazid
loop
diuret
arb
pn
diabet
patient
evalu
glucos
lower
medic
includ
insulin
biguanid
sulfonylurea
edim
medic
includ
biguanid
sulfonylurea
meglitinid
pn
conclus
launch
edim
patient
persist
asthma
prescrib
ic
prescrib
pattern
ncd
significantli
differ
improv
ic
may
secondari
improv
inventori
manag
medicin
avail
improv
prescrib
may
requir
educ
intervent
relev
clinic
pharmaci
intervent
antoin
dupui
pharmd
phd
guillaum
binson
pharmd
fanni
durand
pharmd
paulin
lazaro
pharmd
pharmaci
depart
univers
hospit
poitier
poitier
franc
introduct
prescript
analysi
core
pharmacist
role
establish
chose
optim
analysi
implement
tool
correspond
collect
relev
clinic
pharmaci
intervent
valid
multidisciplinari
way
base
identif
potenti
iatrogen
situat
pisi
pisi
list
research
question
hypothesi
aim
studi
assess
impact
tool
practic
well
accept
pi
physician
studi
design
prospect
studi
academ
hospit
method
pi
collect
six
month
prescript
softwar
pi
rate
accord
french
societi
clinic
pharmaci
sfpc
guidelin
result
pi
identifi
care
unit
pi
relat
list
pisi
among
pisi
entitl
prescript
booklet
anticoagul
prophylaxi
prescript
level
iii
analges
pi
relat
prescript
contraind
associ
overdos
inappropri
administr
atc
class
frequent
involv
cn
drug
digest
metabol
drug
antineoplas
immunomodulatori
drug
cardiovascular
drug
regard
natur
propos
pi
involv
substitut
exchang
dose
adjust
optim
administr
pi
consult
physician
among
result
treatment
modif
conclus
intervent
concern
pisi
rate
pi
accept
prescrib
demonstr
relev
tool
detail
result
present
physician
care
unit
pi
analyz
detail
discuss
physician
order
improv
tool
current
state
medic
dispos
practic
among
univers
california
san
francisco
health
profess
student
yaser
khoshal
bs
hugo
aguilar
katherin
gruenberg
pharmd
b
joseph
guglielmo
pharmaci
univers
california
san
francisco
san
francisco
ca
pharmaci
univers
california
san
francisco
san
francisco
ca
introduct
medic
thrown
away
flush
water
system
neg
impact
environ
safe
medic
dispos
serv
primari
intervent
prevent
drug
divers
accident
poison
health
profession
traine
educ
patient
proper
medic
dispos
method
howev
student
receiv
train
current
practic
belief
health
profession
traine
issu
unknown
research
question
hypothesi
current
practic
belief
health
profess
student
medic
dispos
studi
design
electron
survey
health
profess
student
univers
california
san
francisco
ucsf
method
regist
student
ucsf
invit
take
anonym
electron
survey
octob
februari
inform
medic
use
dispos
practic
belief
improp
medic
dispos
gather
result
total
student
school
pharmaci
medicin
nurs
dentistri
graduat
divis
complet
survey
respond
state
use
one
medic
regularli
commonli
report
medic
includ
analges
hormon
major
respond
indic
util
medic
dispos
program
safe
dispos
medic
use
pharmaci
polic
station
nation
event
doctor
offic
access
state
primari
barrier
practic
safe
medic
dispos
almost
respond
believ
drug
dispos
program
mitig
pharmaceut
pollut
accident
poison
drug
divers
conclus
studi
quantifi
current
medic
use
dispos
practic
among
ucsf
health
profess
student
result
support
need
inform
access
safe
medic
dispos
program
ucsf
proper
medic
dispos
practic
address
curriculum
health
profess
student
ucsf
trend
opioid
analges
util
studi
taiwan
chen
shao
ms
chan
chen
pharmaci
keelung
chang
gung
memori
hospit
keelung
taiwan
pharmaci
linkou
chang
gung
memori
hospit
linkou
taiwan
introduct
pain
major
public
health
issu
countri
regular
measur
opioid
analges
consumpt
could
improv
qualiti
pain
manag
taiwan
sever
opioid
analges
recent
approv
pain
control
oxycodon
hydromorphon
data
provid
consumpt
opioid
analges
research
question
hypothesi
trend
opioid
analges
consumpt
preval
rate
opioid
analges
cancer
pain
taiwan
studi
design
retrospect
studi
method
conduct
descript
studi
use
chang
gung
research
databas
cgrd
contain
taiwanes
outpati
extract
prescript
data
morphin
fentanyl
meperidin
codein
buprenorphin
oxycodon
hydromorphon
calcul
daili
dose
statist
purpos
per
million
patient
cgrd
per
day
opioid
defin
indic
opioid
analges
prescript
cancer
pain
manag
patient
also
diagnos
diagnos
studi
period
result
includ
million
outpati
cgrd
total
consumpt
opioid
markedli
increas
observ
taiwan
analyz
total
opioid
prescript
patin
classifi
cancer
pain
manag
increas
categori
consumpt
morphin
fentayl
use
meperidin
codein
buprenorphin
decreas
found
consumpt
oxycodon
hydromorphon
quickli
increas
respect
conclus
find
indic
increas
demand
opioid
especi
new
opioid
analges
pain
manag
opioid
analges
still
preval
taiwan
studi
need
evalu
benefit
risk
associ
therapi
comparison
preval
factor
opioid
use
chronic
pain
use
nationwid
health
databas
versu
government
surveil
system
taiwan
lee
ms
huang
cheng
kuo
chen
pharm
pharmaci
wan
fang
hospit
taipei
medic
univers
taipei
taiwan
clinic
pharmaci
school
pharmaci
taipei
medic
univers
taipei
taiwan
hospit
taipei
medic
univers
taipei
taiwan
introduct
prescrib
chronic
opioid
therapi
cot
chronic
pain
cncp
expand
past
two
decad
taiwan
hospit
respons
report
cot
recipi
cncp
nation
bureau
control
drug
nbcd
research
question
hypothesi
primari
question
investig
whether
yearli
preval
cot
cncp
deriv
taiwan
nation
health
insur
research
databas
nhird
sampl
reimburs
system
ident
previou
find
nbcd
secondari
question
determin
risk
factor
receiv
cot
cncp
studi
design
retrospect
cohort
studi
method
yearli
preval
cot
cncp
calcul
use
nhird
cot
recipi
defin
nbcd
adult
cncp
receiv
opioid
consecut
day
intermitt
day
within
three
month
candid
opioid
includ
morphin
fentanyl
meperidin
codein
buprenorphin
potenti
risk
factor
cncp
patient
receiv
cot
identifi
compar
characterist
receiv
adjuv
analges
activ
compar
logist
regress
use
sa
eg
program
result
preval
cop
cncp
nhird
markedli
differ
found
use
nbcd
note
increas
per
one
million
popul
year
period
associ
risk
factor
receiv
cot
back
pain
ci
alcohol
use
disord
ci
previou
use
weaker
opioid
ci
benzodiazepin
ci
conclus
risk
factor
identifi
studi
may
assist
clinic
decis
make
use
cot
nhird
studi
warrant
determin
reason
preval
gap
government
surveil
system
evalu
naloxon
ambulatori
patient
receiv
palli
care
lorin
fisher
pharmd
jame
ray
pharmd
kashel
lockman
pharmd
univers
iowa
colleg
pharmaci
univers
iowa
hospit
clinic
iowa
citi
ia
introduct
cdc
ama
recommend
naloxon
patient
receiv
chronic
opioid
therapi
cot
risk
factor
opioid
overdos
seriou
respiratori
depress
osord
palli
care
patient
exclud
recommend
due
uncertain
prognos
yet
often
receiv
cot
naloxon
popul
remain
controversi
studi
date
describ
risk
factor
osord
among
patient
receiv
palli
care
research
question
hypothesi
object
studi
describ
risk
factor
osord
among
ambulatori
palli
care
patient
determin
frequenc
naloxon
overal
well
pharmaci
servic
avail
versu
unavail
studi
design
retrospect
observ
studi
method
chart
retrospect
review
identifi
patient
seen
palli
care
clinic
prescrib
opioid
march
june
publish
risk
factor
seriou
respiratori
depress
includ
factor
risk
index
overdos
seriou
respiratori
depress
riosord
tool
extract
includ
patient
chart
indic
naloxon
defin
cdc
ama
recommend
criteria
riosord
score
naloxon
prescrib
pharmaci
staf
data
also
extract
result
patient
prescrib
opioid
palli
care
clinic
possibl
indic
naloxon
risk
factor
interest
includ
daili
oral
morphin
equival
mg
concurr
benzodiazepin
prescript
approxim
elig
patient
naloxon
naloxon
frequent
clinic
pharmaci
servic
avail
clinic
vs
p
conclus
naloxon
may
benefici
ambulatori
patient
receiv
palli
care
consist
goal
care
risk
factor
osord
preval
popul
impact
pharmaci
involv
palli
care
clinic
naloxon
explor
determin
clinic
import
risk
factor
opioid
stewardship
clinic
dashboard
delphi
consensu
studi
l
diana
berescu
juli
waldfogel
mark
bicket
nicol
arwood
rosemari
ahm
eid
laura
hatfield
joann
hunsberg
leann
mcnamara
todd
nesbit
pharmd
jacob
smith
pharmd
jacki
tran
pharmd
tricia
vecchion
suzann
nesbit
pharmd
bcp
john
hopkin
hospit
baltimor
md
john
hopkin
hospit
baltimor
md
pharmaci
john
hopkin
hospit
baltimor
md
hopkin
medicin
baltimor
md
introduct
opioid
epidem
continu
result
signific
morbid
mortal
epidem
reach
extend
insid
hospit
opioid
account
second
common
caus
advers
event
hospit
patient
respons
regulatori
agenc
develop
prescrib
guidelin
regul
surround
opioid
prescript
opioid
stewardship
program
may
one
model
hospit
ensur
safe
ration
prescrib
produc
optim
clinic
benefit
mitig
prevent
advers
outcom
mechan
need
identifi
patient
risk
factor
advers
event
recent
literatur
identifi
sever
risk
factor
vari
clinic
import
research
question
hypothesi
object
project
establish
expert
consensu
risk
factor
includ
clinic
dashboard
identifi
patient
risk
advers
event
studi
design
delphi
approach
use
gener
consensu
among
nation
group
expert
method
onlin
delphi
survey
conduct
along
two
teleconfer
meet
initi
two
round
obtain
consensu
advers
event
risk
factor
includ
third
fourth
round
particip
rank
import
risk
factor
given
advers
event
result
seventeen
particip
complet
first
round
complet
second
round
complet
third
round
particip
complet
fourth
round
particip
consist
pharmacist
physician
nurs
practition
overdos
discharg
inpati
respiratori
depress
sedat
confus
uncontrol
pain
constip
withdraw
advers
event
achiev
consensu
includ
dashboard
advers
event
includ
list
risk
factor
rang
four
risk
factor
identifi
conclus
delphi
consensu
approach
yield
list
risk
factor
score
indic
risk
advers
event
may
incorpor
clinic
dashboard
naloxon
prescrib
pattern
within
provid
medic
group
pmg
monica
dougherti
pharmd
amanda
wojtusik
pharmd
bcp
dara
johnson
pharmd
bcpp
kristin
tallman
pharmd
bcp
bcacp
clinic
pharmaci
depart
provid
medic
group
portland
introduct
cdc
publish
guidelin
recommend
clinician
offer
naloxon
patient
increas
risk
overdos
recommend
includ
take
morphin
milligram
equival
mme
per
day
unclear
patient
risk
overdos
prescrib
naloxon
research
question
hypothesi
percentag
high
risk
patient
mme
per
day
prescrib
naloxon
patient
characterist
led
naloxon
prescrib
studi
design
retrospect
review
year
method
patient
includ
provid
medic
group
primari
care
physician
portland
metro
area
opioid
report
tool
use
identifi
patient
mme
per
day
characterist
collect
randomli
select
patient
sampl
group
cohort
includ
patient
prescrib
naloxon
regardless
opioid
dose
characterist
collect
includ
mme
dose
histori
substanc
abus
respiratori
disord
pharmd
involv
patient
care
naloxon
dosag
form
opioid
taper
plan
concurr
benzodiazepin
use
characterist
patient
prescrib
naloxon
compar
prescrib
naloxon
result
patient
prescrib
naloxon
opioid
report
tool
identifi
patient
mme
per
day
naloxon
characterist
collect
patient
averag
age
year
naloxon
group
femal
less
patient
mme
per
day
prescrib
naloxon
characterist
group
prescrib
naloxon
versu
prescrib
naloxon
similar
although
patient
prescrib
naloxon
like
pharmacist
involv
care
compar
prescrib
naloxon
vs
conclus
limit
number
patient
prescrib
naloxon
greater
percent
patient
prescrib
naloxon
pharmacist
involv
care
earli
physic
therapi
intervent
reduc
opioid
burden
manag
chronic
lower
back
pain
victoria
nguyen
pharmd
kimberli
tallian
pharmd
aph
bcpp
fccp
fashp
jason
van
dyke
harmind
sikand
pharmd
fccp
pharmaci
scripp
merci
hospit
san
diego
ca
health
center
san
diego
san
diego
ca
introduct
chronic
lower
back
pain
clbp
defin
pain
persist
month
one
lead
caus
disabl
million
day
work
loss
per
year
opioid
use
manag
chronic
nonmalign
pain
continu
controversi
especi
potenti
toler
addict
per
cdc
guidelin
chronic
pain
nonpharmacolog
nonopioid
pharmacolog
therapi
prefer
research
question
hypothesi
earli
intervent
physic
therapi
pt
reduc
opioid
burden
patient
chronic
lower
back
pain
clbp
studi
design
singl
center
retrospect
chart
review
method
ambulatori
care
patient
year
clbp
month
receiv
pt
visit
treat
either
opiat
first
andor
pt
first
ptf
includ
concomit
use
pharmacolog
agent
also
permit
primari
outcom
measur
determin
impact
earli
pt
opiat
burden
pain
score
descript
statist
use
applic
result
patient
enrol
patient
treat
arm
compar
ptf
arm
diagnos
depress
vs
histori
fall
within
past
month
vs
patient
ptf
arm
requir
addit
opiat
oppos
patient
arm
continu
opiat
therapi
initi
pt
treatment
pt
treatment
initi
signific
reduct
opiat
use
seen
arm
wherea
signific
reduct
use
seen
ptf
arm
conclus
result
studi
suggest
pt
intervent
use
first
concomitantli
modal
manag
clbp
prior
initi
opiat
therapi
develop
pharmaceut
care
model
within
paediatr
oncolog
sephorah
falzon
bsc
hon
pharmsc
melit
mpharm
melit
nathali
galea
doctor
medicin
victor
calvagna
doctor
medicin
louis
grech
bpharm
hon
mphil
phd
lilian
azzopardi
bpharm
hon
mphil
phd
mrpharm
ffip
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
paediatr
mater
dei
hospit
msida
malta
pharmaci
univers
malta
msida
malta
introduct
pharmacist
contribut
improv
health
outcom
qualiti
care
paediatr
oncolog
patient
support
safe
optimum
use
complex
pharmacotherapi
research
question
hypothesi
develop
implement
pharmaceut
care
model
paediatr
adolesc
ward
sir
anthoni
mamo
oncolog
centr
studi
design
section
prospect
studi
method
follow
ethic
approv
pharmacist
investig
attend
ward
round
patient
file
treatment
chart
prescript
review
identifi
pharmaceut
care
issu
pci
pci
identifi
discuss
clinician
outcom
record
pharmaceut
servic
found
lack
develop
result
total
pci
identifi
pharmaceut
care
session
provid
month
includ
counsel
need
parentsleg
guardian
medic
incorrect
dose
monitor
need
indic
drug
drug
treatment
despit
exist
indic
miss
wrong
unclear
instruct
treatment
chart
prescript
side
effect
seamless
care
need
incorrect
dosag
regimen
frequenc
drug
interact
inappropri
rout
administr
inappropri
dosag
form
pharmaceut
servic
provid
support
ward
servic
includ
dosag
calcul
drug
inform
healthcar
profession
guid
clinician
nurs
fill
appropri
pharmaci
relat
form
liaison
pharmaci
section
hospit
check
avail
access
drug
attend
interdisciplinari
meet
liaison
unit
respons
patient
access
treatment
nation
health
scheme
prepar
chemotherapi
flow
sheet
particip
research
studi
conclus
studi
reflect
relev
contribut
pharmacist
ward
level
within
interdisciplinari
healthcar
team
implement
novel
pharmaceut
care
model
focus
pci
patient
specif
need
factor
associ
develop
immunogen
infliximab
children
valentina
shakhnovich
mara
becker
md
ryan
funk
pharmd
pediatr
gastroenterolog
hepatolog
nutrit
children
merci
kansa
citi
kansa
citi
mo
pediatr
divis
rheumatolog
children
merci
kansa
citi
kansa
citi
mo
pharmaci
practic
univers
kansa
kansa
citi
ks
introduct
exposur
infliximab
ifx
develop
antibodi
ada
associ
respons
failur
treatment
pediatr
autoimmun
ill
work
measur
ada
infliximab
pediatr
patient
ifx
identifi
variabl
associ
develop
immunogen
research
question
hypothesi
develop
ada
ifx
associ
ifx
dose
paramet
children
studi
design
studi
pediatr
patient
receiv
ifx
children
merci
kansa
citi
method
serum
antibodi
detect
use
assay
arup
laboratori
commerci
avail
immunoassay
eagl
bioscienc
patient
clinic
laboratori
inform
collect
includ
ifx
dose
paramet
age
weight
gender
laboratori
measur
inflamm
statist
analysi
includ
wilcoxon
test
spearman
rank
correl
test
result
three
patient
test
posit
ada
assay
three
patient
plu
addit
six
patient
test
posit
ada
immunoassay
patient
test
posit
ada
found
ibd
patient
repres
ibd
patient
test
none
children
jia
uveiti
found
posit
ada
posit
immunogen
test
associ
lower
trough
ifx
level
assay
immunoassay
reduc
ada
level
observ
patient
azathioprin
femal
patient
treat
rheumatolog
condit
spearman
correl
analysi
reduc
ada
level
correl
shorter
dose
interv
increas
ifx
dose
elev
trough
ifx
level
p
conclus
develop
ada
ifx
common
among
children
ibd
compar
children
treat
jia
uveiti
reduc
ada
level
associ
higher
frequent
dose
ifx
inhal
nitric
oxid
stewardship
neonat
intens
care
unit
deborah
bondi
pooja
shah
walid
hussain
allison
barlett
randal
knoebel
sherwin
morgan
steve
mosakowski
russel
orr
brandi
parker
msn
jaideep
singh
michael
schreiber
pharmaci
univers
chicago
medicin
comer
children
hospit
chicago
il
pediatr
univers
chicago
chicago
il
pharmaci
univers
chicago
medicin
chicago
il
respiratori
therapi
univers
chicago
medicin
chicago
il
intens
care
unit
univers
chicago
medicin
comer
children
hospit
chicago
il
introduct
inhal
nitric
oxid
ino
potent
pulmonari
vasodil
frequent
use
neonat
manag
pulmonari
hypertens
goal
reduc
unnecessari
use
ino
neonat
intens
care
unit
nicu
implement
multidisciplinari
guidelin
ino
stewardship
research
question
hypothesi
implement
standard
ino
wean
guidelin
ino
stewardship
reduc
util
ino
nicu
studi
design
studi
compar
retrospect
control
group
prospect
cohort
implement
ino
wean
guidelin
stewardship
method
infant
receiv
ino
nicu
studi
timefram
elig
inclus
primari
outcom
durat
ino
per
cours
attempt
ino
discontinu
restart
within
hour
count
cours
result
total
cours
ino
occur
timefram
januari
octob
compar
cours
timefram
novemb
may
median
ino
durat
per
cours
hour
iqr
versu
hour
iqr
group
respect
median
ino
util
per
month
hour
iqr
versu
hour
iqr
respect
stewardship
data
reveal
incid
ino
wean
recommend
per
guidelin
incid
success
wean
attempt
failur
due
lack
complianc
guidelin
failur
due
increas
respiratori
requir
conclus
monthli
per
cours
util
ino
decreas
sinc
initi
ino
wean
guidelin
stewardship
addit
multidisciplinari
educ
need
increas
complianc
use
wean
guidelin
particularli
continu
progress
wean
overnight
develop
analyt
methodolog
evalu
compat
recombin
human
rh
intraven
medic
neonat
nazila
christoph
mcpherson
benita
amsden
kerstin
rumpelmayr
paul
salina
jennif
chadwick
dongdong
wang
wu
mark
turner
develop
formul
develop
shire
lexington
pediatr
washington
univers
st
loui
mo
develop
technic
servic
shire
vienna
austria
develop
shire
lexington
cambridg
translat
medicin
univers
liverpool
liverpool
unit
kingdom
introduct
chemic
compat
data
critic
decis
drug
intraven
iv
biolog
drug
recombin
human
rh
protein
complex
administ
continu
iv
infus
studi
prevent
complic
prematur
research
question
hypothesi
assess
potenti
incompat
analyt
methodolog
develop
evalu
qualiti
commonli
use
medic
preliminari
analysi
compat
caffein
citrat
ampicillin
report
studi
design
mix
sampl
control
prepar
analyz
use
equip
mass
spectrometr
detect
liquid
chromatographi
method
vitro
mix
studi
perform
repres
dose
mix
either
caffein
citrat
ampicillin
simul
potenti
clinic
scenario
method
develop
identifi
quantifi
modif
eg
oxid
concentr
mgml
method
qualifi
linear
specif
recoveri
mgml
concentr
rang
addit
method
assess
specif
feasibl
confirm
weight
hmw
speci
form
result
increas
level
oxid
aggreg
observ
post
mix
caffein
citrat
test
accept
recoveri
mix
drug
product
observ
post
mix
caffein
citrat
method
contrast
reveal
lower
drug
product
recoveri
ampicillin
neither
oxid
hmw
speci
observ
ampicillin
conclus
initi
find
methodolog
test
compat
provid
preliminari
support
caffein
demonstr
potenti
risk
ampicillin
method
relev
detect
potenti
protein
modif
repres
clinic
administr
scenario
merit
project
etoposid
hypersensit
pediatr
patient
winifr
stockton
pharmd
bcpp
theresa
nguyen
pharmd
lishi
zhang
thoma
dowl
pharmd
phd
hospit
orang
counti
orang
ca
california
irvin
ca
state
univers
big
rapid
mi
introduct
etoposid
critic
treat
mani
pediatr
cancer
although
hypersensit
reaction
sever
product
label
describ
etoposid
hypersensit
patient
howev
higher
rate
pediatr
report
hypersensit
data
etoposid
phosphat
newer
product
lack
primari
object
assess
hypersensit
incid
within
four
month
initi
dose
secondari
object
includ
evalu
potenti
risk
factor
initi
hypersensit
strategi
prevent
recurr
research
question
hypothesi
pediatr
patient
experi
less
hypersensit
etoposid
phosphat
etoposid
studi
design
retrospect
cohort
studi
method
pediatr
patient
receiv
initi
etoposid
phosphat
etoposid
dose
august
juli
includ
group
assign
base
upon
initi
formul
administ
primari
outcom
document
initi
hypersensit
medic
record
potenti
risk
factor
evalu
associ
hypersensit
includ
age
allergi
dose
infus
rate
infus
concentr
premed
result
patient
hypersensit
reaction
occur
patient
etoposid
phosphat
group
patient
etoposid
group
among
patient
receiv
etoposid
mean
initi
infus
rate
patient
hypersensit
without
hypersensit
etoposid
phosphat
infus
rate
associ
hypersensit
recurr
hypersensit
occur
patient
receiv
etoposid
desensit
patient
chang
formul
etoposid
phosphat
conclus
etoposid
associ
hypersensit
etoposid
phosphat
pediatr
patient
trend
higher
infus
rate
patient
etoposid
hypersensit
etoposid
phosphat
differ
hypersensit
incid
infus
rate
influenc
indic
mani
patient
etoposid
hypersensit
recurr
may
prevent
chang
etoposid
phosphat
formul
comparison
cefotaxim
versu
ceftazidim
neonat
sepsi
payal
patel
deborah
bondi
palak
bhagat
allison
bartlett
pharmaci
servic
univers
chicago
medicin
chicago
il
il
introduct
empir
manag
suspect
sepsi
neonat
intens
care
unit
nicu
commonli
includ
gentamicin
plu
either
ampicillin
antistaphylococc
agent
cephalosporin
may
ad
patient
critic
ill
poor
renal
function
improv
mening
coverag
prefer
agent
cefotaxim
howev
due
nation
drug
shortag
ceftazidim
recommend
place
infant
less
month
old
research
question
hypothesi
incid
late
onset
sepsi
resist
organ
mdro
increas
use
ceftazidim
compar
cefotaxim
neonat
studi
design
retrospect
cohort
studi
nicu
patient
receiv
least
hour
cefotaxim
ceftazidim
within
time
frame
april
august
determin
institut
shortag
statu
method
subject
includ
base
first
time
receiv
studi
antibiot
subject
exclud
receiv
altern
antibiot
greater
hour
admiss
result
total
subject
includ
final
analysi
cefotaxim
ceftazidim
median
gestat
age
significantli
differ
group
iqr
versu
iqr
week
respect
p
result
show
signific
increas
incid
cultur
posit
sepsi
use
ceftazidim
compar
cefotaxim
cefotaxim
versu
ceftazidim
adjust
mdro
infect
versu
respect
sepsi
versu
respect
necrot
enterocol
versu
respect
adjust
mdro
infect
includ
produc
escherichia
coli
pseudomona
aeruginosa
differ
note
mortal
postmenstru
age
discharg
conclus
research
warrant
assess
effect
drug
shortag
neonat
popul
reliabl
administr
oral
drug
young
patient
adelin
chanat
pharmd
guillaum
binson
karen
waton
karin
beuzit
antoin
dupui
pharmd
depart
univers
hospit
poitier
poitier
franc
depart
univers
hospit
lill
lill
franc
depart
univers
hospit
poitier
poitier
franc
introduct
pediatr
care
unit
oral
medicin
suitabl
young
patient
regard
galen
form
drug
dosag
order
figur
issu
nurs
staff
use
modifi
commerci
avail
medicin
split
crush
andor
dilut
anoth
way
administr
requir
treatment
use
drug
appropri
dosag
capsul
oral
suspensionssolut
research
question
hypothesi
compar
accuraci
dose
drug
administr
oral
via
three
differ
method
nurs
modif
commerci
avail
tablet
ii
capsul
iii
oral
suspens
studi
design
spironolacton
chosen
order
assess
accuraci
three
differ
method
use
administr
mg
dose
method
amount
spironolacton
actual
administr
accord
nurs
practic
pediatr
care
unit
academ
hospit
assess
amount
spironolacton
determin
use
valid
analyt
method
similarli
exact
amount
spironolacton
administ
expect
dose
use
capsul
oral
suspens
determin
result
accuraci
dose
spironolacton
administr
via
nurs
practic
averag
accuraci
administ
dose
use
method
compound
capsul
compound
suspens
respect
conclus
studi
demonstr
oral
dose
actual
administ
young
patient
differ
wide
rang
accord
method
use
nurs
practic
well
pharmaci
compound
capsul
lead
inaccur
dose
administr
like
due
loss
drug
especi
hydrophob
molecul
spironolacton
accord
data
oral
suspens
best
option
administr
effici
accur
drug
commerci
medicin
avail
vancomycin
dose
trough
concentr
pediatr
patient
undergo
extracorpor
membran
oxygen
sook
hee
ph
eun
mi
lee
jae
youn
kim
hyesun
gwak
phd
pharmaci
wonkwang
univers
iksan
korea
republ
south
pharmaci
asan
medic
center
seoul
korea
republ
south
pharmaci
divis
life
pharmaceut
scienc
ewha
woman
univers
seoul
korea
republ
south
introduct
effect
extracorpor
membran
oxygen
ecmo
pharmacokinet
vancomycin
pediatr
patient
studi
studi
small
sampl
size
conflict
result
report
optim
dose
regimen
vancomycin
pediatr
patient
ecmo
establish
research
question
hypothesi
evalu
dose
trough
concentr
vancomycin
pediatr
patient
undergo
ecmo
studi
design
singl
center
retrospect
cohort
studi
use
therapeut
drug
monitor
data
august
may
method
retrospect
medic
record
review
identifi
pediatr
patient
receiv
vancomycin
ecmo
support
vancomycin
trough
concentr
document
patient
receiv
ecmo
less
hour
exclud
primari
endpoint
percentag
trough
concentr
vancomycin
within
target
therapeut
rang
secondari
endpoint
total
daili
dose
vancomycin
use
patient
maintain
target
therapeut
rang
trough
level
factor
influenc
vancomycin
trough
concentr
also
assess
multipl
linear
regress
result
total
trough
concentr
vancomycin
patient
includ
analysi
patient
median
age
week
year
median
weight
kg
kg
trough
concentr
vancomycin
within
target
rang
mgl
case
percentag
vancomycin
trough
concentr
mgl
median
total
daili
dose
use
achiev
therapeut
trough
concentr
mgkgday
estim
glomerular
filtrat
rate
significantli
associ
trough
level
vancomycin
adjust
p
conclus
current
dose
regimen
vancomycin
appropri
maintain
target
trough
concentr
mgl
pediatr
patient
ecmo
care
therapeut
drug
monitor
dose
adjust
vancomycin
requir
effect
safe
treatment
pediatr
patient
receiv
ecmo
evalu
drug
administr
enter
feed
tube
pediatr
patient
high
complex
hospit
claudio
gonzalez
sr
msc
candid
roxana
santana
felip
lago
pharmd
lorena
contrera
isadora
bezar
dr
exequiel
gonzalez
cort
santiago
chile
introduct
drug
administr
enter
feed
tube
eft
common
practic
hospit
patient
increas
risk
medic
error
pediatr
patient
suscept
efficaci
safeti
problem
administr
rout
use
due
wrong
administr
techniqu
lack
adequ
dosag
form
research
question
hypothesi
percentag
error
process
drug
administr
eft
pediatr
patient
high
complex
hospit
studi
design
prospect
descript
quantit
studi
sampl
method
procedur
drug
prepar
drug
administr
eft
observ
systemat
observ
made
adapt
classif
ncc
merp
group
categor
detect
consid
error
occur
process
dose
calcul
crush
dilut
administr
techniqu
result
prepar
administr
process
differ
drug
prescrib
differ
patient
observ
least
one
error
total
error
prepar
administr
total
error
correspond
omiss
tube
flush
error
choic
dosag
form
wrong
fraction
techniqu
omiss
drug
administr
whit
result
drug
monograph
made
administr
recommend
incompat
interact
data
conclus
research
allow
us
evalu
character
error
detect
prepar
administr
drug
eft
eight
ten
process
present
least
one
error
frequent
problem
omiss
tube
flush
implement
drug
administr
eft
guid
reduc
risk
associ
nurs
staff
practic
howev
necessari
carri
futur
studi
evalu
impact
implement
guid
evalu
inhal
pharmacotherapi
use
patient
hospit
asthma
indic
john
harri
pharmd
j
andrew
wood
pharmd
zack
ing
pharmd
candid
wingat
univers
school
pharmaci
wingat
nc
introduct
total
cost
asthma
unit
state
estim
billion
includ
absente
absente
cost
approxim
billion
loss
annual
increment
cost
per
person
associ
asthma
hospit
ann
thorac
soc
one
approach
decreas
cost
associ
absente
hospit
decreas
length
stay
lo
base
find
inhal
pharmacotherapi
review
hospit
patient
chronic
obstruct
pulmonari
diseas
hypothes
miss
schedul
inhal
medic
may
increas
lo
southern
medic
journal
hypothes
miss
inhal
schedul
medic
administr
hospit
patient
asthma
may
increas
lo
research
question
hypothesi
miss
schedul
inhal
pharmacotherapi
correl
increas
lo
hospit
patient
age
year
asthma
studi
design
retrospect
review
method
inhal
pharmacotherapi
includ
inhal
corticosteroid
ic
combin
ic
inform
collect
includ
patient
age
data
time
patient
admiss
discharg
order
start
end
pharmacotherapi
order
formul
number
inhal
dose
per
schedul
administr
number
schedul
miss
dose
wilcoxon
mann
whitney
test
spearman
correl
calcul
use
sa
ts
level
result
lo
hour
patient
miss
administr
mean
mean
differ
significantli
p
spearman
coeffici
age
year
number
miss
administr
percentag
miss
administr
number
schedul
administr
percentag
schedul
administr
lo
p
p
respect
conclus
largest
correl
lo
number
schedul
administr
given
follow
number
administr
miss
percentag
administr
given
neg
correl
lo
emphas
import
administ
major
inhal
pharmacotherapi
unit
length
stay
follow
neuromuscular
blockad
revers
sugammadex
compar
neostigmin
calvin
ice
pharmd
bcsp
bcccp
olivia
carnagi
bs
jessica
parker
ms
kari
vavra
pharmd
nichola
watson
pharmaci
servic
spectrum
health
grand
rapid
mi
state
univers
colleg
pharmaci
grand
rapid
mi
health
grand
rapid
mi
practic
consult
pc
grand
rapid
mi
introduct
sugammadex
demonstr
faster
revers
neuromuscular
blockad
nmb
compar
neostigmin
clinic
trial
howev
remain
pauciti
data
demonstr
faster
revers
impact
amount
time
patient
spend
unit
pacu
periprocedur
area
research
question
hypothesi
pacu
length
stay
differ
patient
receiv
postop
sugammadex
versu
receiv
neostigmin
studi
design
retrospect
clinic
studi
method
adult
receiv
neostigmin
may
sugammadex
novemb
revers
nmb
follow
outpati
surgeri
evalu
patient
exclud
histori
chronic
kidney
diseas
receiv
anesthesia
set
receiv
rocuronium
sampl
size
patient
per
group
deem
necessari
power
detect
chang
primari
endpoint
pacu
length
stay
secondari
endpoint
includ
durat
intub
length
pacu
complic
discharg
timefram
result
studi
timefram
adult
receiv
neostigmin
sugammadex
patient
exclud
total
adult
includ
neostigmin
sugammadex
signific
differ
age
surgeri
type
demograph
variabl
median
pacu
length
stay
neostigmin
minut
percentil
compar
minut
percentil
signific
differ
length
intub
length
time
periprocedur
discharg
patient
receiv
sugammadex
extub
slightli
faster
time
revers
agent
dose
compar
receiv
neostigmin
median
minut
percentil
compar
minut
percentil
conclus
revers
nmb
sugammadex
compar
neostigmin
decreas
length
stay
pacu
periprocedur
area
ketamin
toler
rat
follow
chronic
ketamin
morphin
cocain
administr
samantha
gerb
jame
cook
alexandria
gochenau
pharmd
candid
camil
young
linda
fulton
andrew
gradi
kevin
freeman
compar
research
univers
mississippi
medic
center
jackson
ms
neurobiolog
behavior
research
depart
psychiatri
human
behavior
univers
mississippi
medic
center
jackson
ms
pharmaci
univers
mississippi
jackson
ms
introduct
approxim
everi
american
use
illicit
drug
lead
illicit
anesthet
drug
potenti
complic
anesthet
plan
patient
identifi
histori
illicit
drug
use
anecdot
receiv
higher
dose
anesthet
includ
ketamin
research
question
hypothesi
chronic
administr
ketamin
morphin
cocain
effect
ketamin
abil
produc
anesthesia
studi
design
random
control
trial
male
rat
randomli
alloc
studi
low
dose
ketamin
high
dose
ketamin
salin
studi
low
dose
morphin
high
dose
morphin
low
dose
cocain
high
dose
cocain
salin
method
rat
random
daili
intraperiton
inject
ketamin
mgkg
mgkg
studi
morphin
mgkg
mgkg
studi
cocain
mgkg
mgkg
studi
consecut
day
studi
group
test
follow
day
anesthesia
use
procedur
anesthet
depth
evalu
mgkg
anesthesia
plane
iii
rat
show
loss
right
reflex
target
level
full
effect
result
studi
signific
differ
detect
pretreat
group
curv
x
p
time
administr
last
ketamin
dose
deliv
anesthet
test
recoveri
f
p
studi
curv
statist
signific
pretreat
group
x
p
comparison
curv
detect
signific
differ
salin
high
dose
morphin
group
p
conclus
result
suggest
ketamin
clinic
effect
anesthet
vari
function
histori
use
histori
chronic
opioid
use
may
reduc
ketamin
anesthet
effect
econom
outcom
associ
investig
drug
servic
within
veteran
affair
health
care
system
jami
brown
pharmd
bcp
bcacp
sherin
jacob
pharmd
bcp
frank
tillman
iii
pharmd
candid
sara
britnel
pharmd
bcp
pharmaci
servic
durham
va
health
care
system
durham
nc
introduct
investig
drug
servic
idss
provid
mani
valuabl
servic
investig
institut
includ
investig
product
manag
dispens
document
drug
inform
consult
studi
random
blind
medic
safeti
qualiti
assur
regulatori
complianc
econom
valu
id
often
assess
revenu
gener
howev
drug
cost
avoid
may
also
contribut
research
subject
receiv
treatment
place
medic
would
otherwis
fund
institut
research
question
hypothesi
primari
object
assess
determin
cost
avoid
associ
id
two
year
secondari
object
includ
determin
total
revenu
charg
assess
investig
cost
save
studi
differenti
econom
valu
individu
therapeut
research
area
studi
design
retrospect
record
review
method
studi
protocol
dispens
record
investig
drug
studi
conduct
institut
review
januari
decemb
medic
center
contract
acquisit
cost
use
calcul
cost
avoid
revenu
determin
total
fee
charg
id
investig
cost
save
calcul
total
revenu
collect
due
waiv
fee
descript
statist
use
assess
result
total
uniqu
protocol
dispens
record
studi
period
protocol
contribut
total
cost
avoid
fifteen
protocol
result
total
revenu
eight
protocol
total
waiv
revenu
fee
oncolog
infecti
diseas
cardiovascular
protocol
result
highest
cost
avoid
revenu
mental
health
pain
manag
protocol
associ
highest
total
waiv
fee
conclus
period
id
associ
substanti
econom
valu
institut
cost
avoid
revenu
gener
investig
cost
save
econom
benefit
vari
therapeut
categori
patient
may
will
pay
line
extens
product
result
survey
singapor
yen
ping
lim
mclinpharm
paul
anantharajah
tambyah
md
bee
choon
christin
teng
msc
clinpharm
nation
univers
singapor
singapor
singapor
introduct
line
extens
product
eg
combin
formul
wide
use
prolong
brand
lifecycl
prepar
gener
expens
parent
drug
offer
limit
advantag
eg
conveni
complianc
hear
patient
voic
import
hospit
formulari
manag
committe
make
effect
decis
research
question
hypothesi
patient
may
will
pay
line
extens
product
studi
design
anonym
survey
method
patient
wait
collect
medic
outpati
pharmaci
nation
univers
hospit
singapor
approach
survey
definit
line
extens
product
explain
photograph
common
prepar
shown
result
total
adult
mean
year
old
femal
chines
complet
survey
case
high
school
educ
bachelor
degre
mean
monthli
household
incom
sg
us
receiv
govern
subsidi
medic
still
found
medic
expens
paid
averag
sg
us
monthli
subsidi
mean
chronic
medic
particip
took
least
one
line
extens
product
found
product
expens
patient
will
pay
averag
higher
price
inject
line
extens
product
dermatolog
inhal
ophthalm
oral
line
extens
product
higher
price
versu
parent
product
respect
patient
will
pay
less
higher
price
brand
product
gener
avail
nearli
half
respond
know
line
extens
product
price
differ
report
given
choic
parent
product
conclus
line
extens
product
higher
price
probabl
stock
minim
wastag
patient
seem
reluct
pay
prescrib
pharmacist
enquir
patient
prefer
parent
line
extens
product
econom
impact
substandard
falsifi
antimalari
medic
nigeria
sarah
beargi
bs
daniel
evan
sachiko
ozawa
phd
practic
advanc
clinic
educ
unc
eshelman
school
pharmaci
univers
north
carolina
chapel
hill
nc
matern
child
health
unc
gill
school
global
public
health
univeristi
north
carolina
chapel
hill
nc
introduct
substandard
falsifi
medic
creat
signific
risk
global
health
consequ
countri
nearli
one
five
antimalari
circul
develop
countri
substandard
falsifi
poor
qualiti
antimalari
pose
health
threat
patient
acceler
spread
drug
resist
assess
impact
nigeria
malaria
endem
poor
qualiti
medic
commonplac
research
question
hypothesi
health
econom
impact
substandard
falsifi
antimalari
children
five
nigeria
studi
design
develop
dynam
safari
substandard
falsifi
antimalari
research
impact
model
use
netlogo
captur
impact
antimalari
use
nigeria
method
model
simul
children
background
characterist
malaria
infect
patient
diseas
progress
treatment
outcom
incur
cost
use
scenario
analys
simul
impact
substandard
falsifi
medicin
antimalari
resist
well
possibl
intervent
improv
qualiti
treatment
reduc
educ
parent
antimalari
qualiti
result
estim
poor
qualiti
antimalari
annual
respons
death
among
sought
care
million
cost
nigeria
drug
resist
develop
simul
current
cost
malaria
could
increas
million
furthermor
scenario
analys
demonstr
possibl
intervent
remov
privat
facil
act
avail
treatment
patient
educ
reject
treatment
save
hundr
million
cost
annual
reduc
burden
malaria
nigeria
conclus
result
highlight
signific
health
econom
burden
poor
qualiti
antimalari
nigeria
impact
potenti
intervent
counter
effort
reduc
burden
malaria
prevent
antimalari
develop
resist
policymak
donor
examin
implement
intervent
increas
util
act
reduc
impact
ineffect
harm
antimalari
econom
impact
opioid
epidem
liver
transplant
readmiss
lytani
wilson
md
mph
depart
gener
surgeri
medic
univers
south
carolina
charleston
sc
introduct
opioid
abus
depend
associ
increas
readmiss
major
surgeri
howev
impact
opioid
use
readmiss
liver
transplant
limit
research
question
hypothesi
hypothes
opioid
experienc
liver
transplant
recipi
would
higher
readmiss
rate
opioid
liver
transplant
recipi
studi
design
retrospect
cohort
studi
liver
recipi
transplant
method
data
collect
retrospect
chart
review
patient
divid
opioid
experienc
oe
opioid
cohort
analyz
differ
readmiss
rate
primari
endpoint
readmiss
year
secondari
endpoint
includ
readmiss
number
readmiss
total
readmiss
hospit
day
direct
cost
readmiss
prevent
readmiss
caus
readmiss
dichotom
data
analyz
use
chi
squar
fisher
exact
appropri
continu
data
analyz
use
student
mann
whitney
u
appropri
consid
statist
signific
spss
result
liver
transplant
includ
studi
oe
oe
patient
less
like
work
time
transplant
vs
like
take
benzodiazepin
vs
p
differ
readmiss
rate
hospit
day
prevent
readmiss
caus
differ
statist
although
trend
toward
readmiss
oe
cohort
vs
conclus
opioid
use
associ
readmiss
within
year
transplant
studi
warrant
clarifi
investig
differ
caus
readmiss
racial
region
dispar
outcom
among
veteran
initi
adher
oral
antidiabet
therapi
justin
gatwood
phd
mph
mari
robert
davi
fridtjof
thoma
praveen
potukuchi
adriana
hung
csaba
kovesdi
pharmaci
translat
scienc
univers
tennesse
colleg
pharmaci
nashvil
tn
tennesse
health
scienc
center
memphi
tn
pediatr
univers
tennesse
health
scienc
center
memphi
tn
prevent
medicin
univers
tennesse
health
scienc
center
memphi
tn
tennesse
valley
health
system
nashvil
tn
va
medic
center
memphi
tn
introduct
import
medic
adher
among
patient
diabet
howev
adher
may
guarante
consist
improv
health
outcom
research
question
hypothesi
extent
differ
health
outcom
vari
geographi
race
among
us
veteran
adher
oral
antidiabet
oad
regimen
studi
design
retrospect
cohort
studi
method
analysi
involv
us
veteran
type
diabet
new
oad
therapi
patient
initi
adher
oad
proport
day
cover
identifi
follow
year
incid
risk
macrovascular
microvascular
complic
hospit
death
assess
use
neg
binomi
cox
proport
hazard
model
identifi
geograph
racial
differ
result
nearli
rate
outcom
differ
significantli
white
black
resid
urban
versu
rural
area
differ
region
countri
nearli
highest
rate
either
midwest
western
state
black
rate
death
half
compar
white
ci
versu
ci
p
adjust
surviv
analys
indic
highest
event
hazard
black
retinopathi
hr
ci
rural
resid
neuropathi
hr
ci
compar
northeast
region
higher
adjust
hazard
cardiovascular
event
myocardi
infarct
angina
chronic
kidney
diseas
inpati
admiss
highest
valu
west
hr
ci
south
hr
west
hr
ci
respect
adjust
model
race
region
interact
show
region
differ
among
black
white
conclus
subgroup
unit
state
may
prone
differ
rate
outcom
even
among
exhibit
evid
medic
adher
antimicrobi
therapi
suspect
sepsi
patient
intens
care
unit
tsoi
joyc
pharmd
bcp
pharmaci
chines
univers
hong
kong
shatin
hong
kong
pharmaci
chines
univers
hong
kong
shatin
new
territori
hong
kong
introduct
incid
antimicrobi
resist
increas
intens
care
unit
icu
hong
kong
reduc
length
antimicrobi
therapi
icu
potenti
contain
emerg
resist
procalcitonin
pct
promis
biomark
shorten
use
antimicrobi
agent
research
question
hypothesi
aim
analyz
algorithm
antimicrobi
discontinu
patient
suspect
sepsi
icu
set
hong
kong
studi
design
decis
tree
model
perspect
hong
kong
public
healthcar
provid
method
decis
tree
model
design
simul
outcom
algorithm
versu
standard
care
antimicrobi
therapi
discontinu
icu
patient
suspect
sepsi
model
outcom
includ
direct
medic
cost
loss
qali
loss
model
input
deriv
literatur
sensit
analys
conduct
examin
robust
result
result
analysi
arm
reduc
cost
versu
reduc
qali
loss
vs
compar
standard
care
arm
sensit
show
result
sensit
variat
length
stay
lo
icu
rel
reduct
lo
care
probabilist
sensit
analysi
found
arm
prefer
mont
carlo
simul
conclus
algorithm
antimicrobi
discontinu
icu
patient
suspect
sepsi
highli
subject
lo
icu
suspect
sepsi
rel
reduct
lo
associ
algorithm
versu
regimen
treatment
acut
myeloid
leukemia
taml
aml
chang
mrc
anuraag
kansal
oscar
robert
leipold
robert
j
ryan
arthur
c
louie
karen
c
chung
pharmd
kathleen
villa
ms
bethesda
md
pharmaceut
palo
alto
ca
present
annual
meet
american
societi
hematolog
ash
decemb
atlanta
georgia
usa
annual
confer
hematologyoncolog
pharmaci
associ
hopa
march
evalu
interprofession
navig
servic
high
util
counti
tertiari
teach
health
system
taylor
horyna
rosalinda
jimenez
edd
msn
aprn
linda
mcmurri
dnp
rn
dolor
buscemi
barbara
cherri
dnsc
mba
rn
charl
f
seifert
pharmd
fccp
pharmaci
texa
tech
univers
health
scienc
center
lubbock
tx
nurs
texa
tech
univers
health
scienc
center
lubbock
tx
medicin
depart
texa
tech
univers
health
scienc
center
lubbock
tx
present
seventeenth
annual
texa
tech
research
day
amarillo
tx
june
assess
time
laps
associ
medic
access
manufactur
medic
assist
program
thukim
phan
pharmd
candid
rajeev
subu
bachelor
scienc
catherin
bourg
rebitch
pharmd
bcp
rebecca
stone
pharmd
bcacp
georgia
athen
ga
clinic
administr
pharmaci
univers
georgia
colleg
pharmaci
athen
ga
introduct
manufactur
medic
assist
program
mmap
allow
patient
low
econom
statu
obtain
high
cost
medic
cost
mmap
order
often
associ
signific
delay
result
medic
gap
research
question
hypothesi
long
take
receiv
initi
medic
mmap
differ
mmap
time
requir
compar
medic
type
studi
design
retrospect
studi
method
patient
receiv
mmap
medic
order
merci
health
center
includ
data
extract
electron
medic
record
clinic
pharmaci
softwar
mmap
order
log
data
includ
medic
type
day
receiv
medic
manufactur
day
receipt
patient
pick
descript
statist
anova
analys
conduct
use
spss
result
analysi
includ
mmap
medic
order
mean
time
receiv
medic
manufactur
day
statist
differ
day
medic
type
insulin
vs
inhal
vs
patient
medic
pick
data
avail
subset
medic
order
mean
day
receipt
manufactur
patient
pick
overal
mean
time
order
patient
pick
day
conclus
time
mmap
applic
submiss
patient
medic
pick
clinic
signific
averag
time
receiv
medic
manufactur
exceed
week
averag
patient
pick
time
two
week
like
complic
patient
transit
issu
health
literaci
health
care
priorit
addit
strategi
bridg
medic
gap
associ
mmap
need
treatment
opioid
use
disord
unit
state
melika
fini
pharmd
conni
yan
pharmd
daniel
touchett
pharmd
paul
strang
pharmd
univers
illinoi
chicago
colleg
pharmaci
chicago
il
introduct
medic
assist
treatment
mat
much
effect
psychotherapi
alon
treat
opioid
abus
disord
sever
mat
option
avail
treatment
opioid
use
disord
oud
though
signific
differ
medic
cost
lead
uncertainti
whether
agent
effici
use
scarc
healthcar
resourc
research
question
hypothesi
studi
evalu
mat
buprenorphinenaloxon
buprenorphin
buprenorphin
subderm
implant
naltrexon
clinic
stabl
patient
oud
insur
perspect
studi
design
pharmacoeconom
model
method
markov
model
simul
treatment
mat
patient
transit
among
mutual
exclus
markov
state
continu
treatment
relaps
treatment
stop
treatment
die
transit
state
emerg
visit
hospit
treatment
effect
direct
medic
cost
util
deriv
clinic
trial
observ
trial
public
data
primari
outcom
increment
cost
per
life
year
qali
gain
one
year
threshold
per
qali
gain
determinist
probabilist
sensit
analys
conduct
result
associ
lowest
total
cost
least
qali
compar
treatment
option
qali
qali
qali
compar
next
best
option
increment
ratio
compar
compar
correl
higher
cost
less
effectiv
compar
combin
strategi
outcom
sensit
treatment
relaps
probabl
conclus
analysi
demonstr
third
parti
payer
perspect
option
adult
threshold
per
qali
gain
one
option
problemat
potenti
leav
treatment
option
patient
toler
effect
silymarin
cataract
risk
reduct
patient
chronic
hepat
diseas
retrospect
cohort
studi
lu
bachelor
degre
wang
pharmaci
chang
gung
memori
hospit
linkou
branch
taiwan
pharmaci
colleg
pharmaci
taipei
medic
univers
taipei
taiwan
introduct
silymarin
antioxid
commonli
use
flavonoid
compound
treatment
hepat
diseas
worldwid
due
antioxid
properti
cataract
cloud
len
eye
lead
decreas
vision
pathogenesi
cataract
complex
one
underli
caus
cataract
overproduct
oxid
due
insuffici
clinic
data
regard
silymarin
effect
cataract
risk
therefor
conduct
retrospect
studi
assess
risk
cataract
format
among
chronic
hepat
diseas
chd
patient
treat
silymarin
research
question
hypothesi
silymarin
antioxid
might
prevent
cataract
format
chd
patient
studi
design
retrospect
studi
year
follow
period
medic
record
two
million
subject
provid
taiwan
nation
health
insur
research
databas
method
use
cox
proport
hazard
ratio
hr
compar
risk
cataract
chd
patient
receiv
silymarin
studi
group
receiv
silymarin
comparison
group
hr
adjust
possibl
confound
factor
includ
age
gender
hypertens
diabet
mellitu
hyperlipidemia
chronic
renal
diseas
obes
ocular
trauma
tobacco
use
disord
alcohol
abus
macular
degener
glaucoma
oral
steroid
use
day
result
among
chd
patient
mean
age
studi
group
receiv
silymarin
comparison
group
without
receiv
silymarin
year
old
respect
occurr
rate
cataract
two
group
respect
adjust
possibl
confound
factor
chd
patient
receiv
silymarin
reduct
cataract
risk
adjust
hr
ci
studi
group
compar
comparison
group
conclus
result
demonstr
decreas
risk
cataract
chd
patient
use
silymarin
durat
treatment
factor
associ
persist
asthma
children
cohort
studi
lin
chan
ms
yan
chen
pharmaci
taipei
chang
gung
memori
hospit
cgmf
taipei
taiwan
pharmaci
linkou
chang
gung
memori
hospit
linkou
taiwan
pediatr
taipei
chang
gung
memori
hospit
taipei
taiwan
pharmaci
administr
linkou
chang
gung
memori
hospit
cgmf
taipei
taiwan
introduct
current
guidelin
persist
asthma
call
initi
daili
control
medic
parent
caregiv
children
asthma
concern
durat
therapi
dot
take
research
question
hypothesi
aim
studi
investig
dot
factor
associ
popul
studi
design
conduct
cohort
studi
patient
whose
birth
day
use
taiwan
nation
health
insur
research
databas
method
patient
asthma
diagnosi
ever
receiv
medic
month
includ
first
day
receiv
defin
index
date
studi
endpoint
period
mfp
defin
interv
prescrib
medic
one
year
patient
index
date
older
exclud
last
time
surviv
analysi
cox
regress
conduct
analyz
dot
associ
factor
result
total
case
includ
overal
median
dot
day
median
dot
patient
age
day
respect
log
rank
p
case
age
like
achiev
mfp
case
age
adjust
hr
ahr
ahr
age
case
associ
atop
dermat
ad
allerg
rhiniti
ar
less
like
achiev
mfp
ci
ad
ar
diseas
sever
sex
show
relat
studi
endpoint
conclus
found
half
children
persist
asthma
achiev
mfp
receiv
treatment
least
one
year
elder
children
seem
shorter
durat
treatment
children
associ
ad
ar
need
longer
treatment
antidepress
polypharmaci
privat
insur
patient
depress
trinh
nguyen
pharmd
student
xinyu
liu
phd
almut
winterstein
rph
phd
fisp
depart
pharmaceut
outcom
polici
univers
florida
colleg
pharmaci
gainesvil
fl
introduct
antidepress
polypharmaci
may
increas
clinic
benefit
patient
depress
howev
potenti
contraind
antidepress
polypharmaci
avoid
littl
known
preval
research
question
hypothesi
studi
aim
estim
preval
overal
potenti
contraind
antidepress
polypharmaci
nation
sampl
privat
insur
patient
use
truven
marketscan
commerci
databas
studi
design
preval
estim
six
block
block
includ
patient
age
depress
diagnosi
first
year
continu
insur
coverag
throughout
block
micromedex
lexicomp
clinic
pharmacolog
identifi
five
antidepress
class
potenti
contraind
combin
refil
pattern
method
requir
four
altern
overlap
pharmaci
claim
two
uniqu
antidepress
use
identifi
polypharmaci
time
block
method
preval
overal
antidepress
use
overal
polypharmaci
polypharmaci
potenti
contraind
polypharmaci
calcul
block
multivari
logist
regress
model
examin
effect
block
gender
age
region
psychiatr
comorbid
preval
antidepress
polypharmaci
result
averag
patient
depress
identifi
block
receiv
antidepress
among
includ
antidepress
user
receiv
polypharmaci
signific
polypharmaci
predictor
femal
gender
age
psychiatr
comorbid
combin
occur
antidepress
user
two
ssri
two
sra
commonli
use
likewis
use
potenti
contraind
combin
rare
trazodonevenlafaxin
trazodonefluoxetin
trazodoneparoxetin
common
predictor
combin
similar
overal
polypharmaci
conclus
studi
clarifi
antidepress
treatment
pattern
patient
depress
nationwid
claim
databas
analysi
antidepress
polypharmaci
common
inappropri
combin
use
rare
howev
use
inappropri
combin
certain
patient
group
warrant
investig
examin
effect
effect
receptor
agonist
treatment
patient
type
diabet
mellitu
cohort
studi
taiwan
chen
ms
lin
shao
chan
chen
pharmaci
keelung
chang
gung
memori
hospit
keelung
taiwan
pharmaci
linkou
chang
gung
memori
hospit
linkou
taiwan
introduct
clinic
trial
proven
efficaci
receptor
agonist
ra
regard
glucos
weight
lower
effect
patient
type
diabet
mellitu
howev
evid
regard
effect
ra
remain
uncertain
especi
asia
research
question
hypothesi
investig
effect
ra
bodi
mass
index
bmi
patient
studi
design
retrospect
cohort
studi
method
conduct
studi
may
may
four
hospit
cover
outpati
northern
taiwan
identifi
adult
patient
newli
initi
ra
includ
liraglutid
dulaglutid
select
random
sampl
origin
cohort
perform
medic
chart
review
compar
bmi
baselin
treatment
analysi
studi
use
test
determin
statist
differ
ra
treatment
alpha
level
result
patient
continu
use
ra
month
mean
age
year
femal
receiv
liraglutid
final
analysi
incorpor
data
patient
complet
record
bmi
respect
baselin
mean
bmi
mgdl
respect
ra
treatment
mean
chang
bmi
mgdl
ci
ci
respect
conclus
find
indic
signific
lower
effect
bmi
ra
treatment
patient
higher
level
baselin
result
use
studi
taiwan
discontinu
receptor
agonist
patient
type
diabet
mellitu
taiwan
lin
chen
shao
ms
chan
chen
pharmaci
keelung
chang
gung
memori
hospit
keelung
taiwan
pharmaci
linkou
chang
gung
memori
hospit
linkou
taiwan
introduct
persist
receptor
agonist
ra
import
type
diabet
mellitu
patient
understand
treatment
discontinu
set
crucial
develop
strategi
improv
treatment
outcom
research
question
hypothesi
rate
reason
discontinu
ra
treatment
clinic
practic
taiwan
studi
design
retrospect
cohort
studi
method
analyz
data
four
hospit
cover
outpati
northern
taiwan
may
may
select
random
sampl
half
adult
patient
diagnos
newli
initi
ra
liraglutid
dulaglutid
investig
discontinu
rate
ra
period
review
medic
chart
determin
discontinu
reason
includ
loss
ineffect
side
effect
refus
inject
unspecifi
reason
result
identifi
patient
mean
age
year
femal
receiv
liraglutid
averag
patient
receiv
agent
ra
initi
mean
baselin
mgdl
found
patient
discontinu
ra
period
frequent
specifi
reason
discontinu
loss
follow
side
effect
ineffect
refus
inject
ra
discontinu
unspecifi
reason
conclus
found
high
discontinu
rate
ra
clinic
practic
rais
concern
poor
persist
possibl
treatment
failur
studi
provid
foundat
optim
effect
ra
treatment
patient
view
social
media
educ
use
healthcar
adam
pizzuti
pharmd
candid
karan
patel
pharmdmba
candid
erin
mccreari
pharmd
emili
heil
pharmd
bcp
aq
christoph
bland
pharmd
bcp
bryan
love
pharmd
p
brandon
bookstav
pharmd
fccp
carolina
colleg
pharmaci
usc
campu
columbia
sc
wisconsin
hospit
clinic
uw
health
madison
wi
maryland
school
pharmaci
baltimor
md
administr
pharmaci
univers
georgia
colleg
pharmaci
savannah
ga
clinic
pharmaci
outcom
scienc
univers
south
carolina
colleg
pharmaci
columbia
sc
clinic
pharmaci
outcom
scienc
univers
south
carolina
colleg
pharmaci
columbia
sc
introduct
approxim
american
onlin
say
influenc
inform
social
media
social
media
increas
presenc
resourc
healthcar
practic
curriculum
purpos
research
identifi
percept
regard
use
social
media
educ
tool
healthcar
practition
research
question
hypothesi
opinion
healthcar
practition
social
media
educ
tool
studi
design
cross
section
survey
method
survey
administ
physician
nurs
nurs
practition
physician
assist
pharmacist
healthcar
administr
survey
tool
inquir
respond
useview
social
media
educ
purpos
also
address
social
media
access
allow
workplac
redcap
use
survey
develop
survey
respons
anonym
survey
distribut
via
email
four
hospit
system
affili
health
scienc
school
wisconsin
maryland
georgia
south
carolina
survey
launch
januari
close
may
result
top
three
profession
role
amongst
respond
nurs
n
pharmacist
n
administr
n
facebook
n
pinterest
n
instagram
n
top
three
social
media
platform
use
major
respond
agre
social
media
use
effect
tool
educ
purpos
among
particip
social
media
platform
current
use
educ
purpos
pinterest
linkedin
twitter
commonli
use
platform
educ
purpos
fifti
percent
respond
limit
access
social
media
work
unsur
access
conclus
major
particip
varieti
healthcar
disciplin
view
social
media
effect
sourc
educ
result
studi
could
use
aid
dissemin
effort
inform
healthcar
practition
proton
pump
inhibitor
risk
acut
chronic
kidney
diseas
retrospect
cohort
studi
emili
hart
pharmd
student
terri
dunn
pharmd
steve
feuerstein
ms
david
jacob
pharmd
phd
depart
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
introduct
proton
pump
inhibitor
ppi
class
drug
link
acut
kidney
injuri
aki
chronic
kidney
diseas
ckd
less
known
relationship
within
gener
popul
cohort
research
question
hypothesi
hypothes
ppi
exposur
associ
increas
risk
aki
ckd
studi
design
two
separ
retrospect
cohort
studi
employ
use
data
health
mainten
organ
includ
patient
continu
enrol
least
month
juli
septemb
method
patient
age
year
without
evid
renal
diseas
initi
ppi
therapi
identifi
incid
aki
ckd
defin
use
document
code
glomerular
filtrat
rate
mlmin
initi
ppi
therapi
aki
subject
follow
day
cohort
ckd
subject
requir
least
year
data
cohort
multivari
logist
regress
model
use
adjust
differ
group
sa
version
result
aki
cohort
subject
includ
subject
expos
ppi
incid
rate
aki
higher
ppi
group
among
control
vs
per
p
adjust
model
ppi
exposur
associ
increas
risk
aki
aor
ci
p
ckd
cohort
subject
expos
ppi
within
sampl
subject
incid
rate
ckd
higher
patient
expos
ppi
vs
per
p
adjust
model
ppi
associ
higher
risk
ckd
compar
control
aor
ci
p
conclus
result
suggest
ppi
exposur
associ
increas
risk
develop
aki
ckd
role
antagonist
suscept
mycobacteri
infect
associ
genet
polymorph
crohn
diseas
ahmad
qasem
pharmd
ms
saleh
naser
central
florida
orlando
fl
central
florida
orlando
fl
introduct
tumor
necrosi
factor
alpha
antagonist
wide
use
crohn
diseas
cd
although
may
control
cd
symptom
initi
treatment
respons
vari
among
patient
seem
depend
singl
nucleotid
polymorph
snp
receptor
superfamili
importantli
tuberculosi
infect
strongli
associ
medic
studi
elucid
effect
cd
associ
map
mycobacterium
avium
subspeci
paratuberculosi
possibl
caus
agent
cd
research
question
hypothesi
genet
mutat
influenc
map
infect
suscept
treatment
respons
studi
design
cd
patient
healthi
control
recruit
test
map
infect
genet
mutat
gene
express
treatment
respons
addit
studi
effect
treatment
vitro
method
studi
effect
recombin
inflammatori
cytokin
therapeut
macrophag
infect
map
isol
cd
patient
also
test
preval
map
signific
nine
snp
blood
cd
healthi
subject
result
overal
cd
patient
infect
map
compar
control
ci
p
pegyl
form
increas
map
viabil
nearli
log
reduc
map
surviv
infect
macrophag
log
gene
express
fold
higher
follow
map
tuberculosi
infect
compar
bacteri
strain
p
addit
three
snp
distribut
significantli
among
cd
patient
downregul
correspond
gene
express
induc
suscept
map
infect
conclus
studi
provid
data
safeti
use
cd
predict
toward
treatment
respons
base
patient
pharmacogenom
carrier
statu
minnesota
hmong
first
hmong
genotyp
preval
biomark
risk
sever
cutan
advers
reaction
scar
caus
allopurinol
kerui
peng
bs
youssef
roman
pharmd
kathleen
md
may
lo
robert
straka
pharmd
experiment
clinic
pharmacolog
colleg
pharmaci
univers
minnesota
minneapoli
mn
practic
depart
daniel
k
inouy
colleg
pharmaci
univers
hawaii
honolulu
hi
side
commun
health
servic
st
paul
mn
famili
pharmaci
st
paul
mn
introduct
hmong
uniqu
asian
popul
exhibit
higher
preval
gout
hyperuricemia
compar
allopurinol
commonli
use
manag
gout
associ
sever
cutan
advers
reaction
scar
mortal
rate
cost
averag
inpati
care
per
event
carrier
statu
highli
predict
possibl
develop
scar
sensit
ci
specif
ci
yu
et
al
american
colleg
rheumatolog
guidelin
recommend
genotyp
select
asian
popul
use
allopurinol
given
higher
risk
scar
research
question
hypothesi
preval
carrier
statu
minnesota
hmong
indistinguish
han
chines
korean
studi
design
quantit
cohort
analysi
method
pharmacogenom
participatori
research
studi
carrier
statu
minnesota
hmong
adult
without
histori
gout
allopurinol
use
determin
laboratori
use
singl
specif
primer
ssp
carrier
frequenc
hmong
cohort
compar
publish
frequenc
report
han
chines
cohort
korean
cohort
use
test
signific
result
individu
met
inclus
criteria
genotyp
one
uninterpret
result
preval
posit
minnesota
hmong
lower
han
chines
indistinguish
korean
conclus
first
report
frequenc
minnesota
hmong
indic
notabl
differ
hla
posit
hmong
han
chines
though
hmong
commonli
understood
chines
descent
lower
preval
underscor
risk
gener
genotyp
find
chines
uniqu
asian
popul
studi
current
guidelin
recommend
prospect
genotyp
select
asian
popul
allopurinol
use
remain
valid
impact
genet
mutat
factor
incid
bleed
arab
patient
treat
clopidogrel
qatar
zainab
ali
bsc
pharm
loulia
bader
msc
pharmaci
dania
msc
pharmaci
mariam
ali
bsc
chemistri
salah
arafa
abdulrahman
arabi
shaban
moham
rph
bsc
pharm
hon
pebcanada
nasser
rizk
md
phd
fatima
mraich
moza
alhail
bsc
pharm
hazem
elewa
phd
rph
pharmaci
qatar
univers
doha
qatar
medic
corpor
doha
qatar
scienc
qatar
univers
doha
qatar
introduct
aspirin
clopidogrel
mainstay
dual
antiplatelet
regimen
use
qatar
treat
prevent
thrombot
event
patient
acut
coronari
syndrom
undergo
percutan
coronari
intervent
pci
howev
treatment
may
associ
increas
risk
bleed
studi
shown
gof
mutat
may
result
enhanc
platelet
inhibit
possibl
increas
risk
bleed
complic
although
find
controversi
research
question
hypothesi
preval
arab
extent
genet
factor
affect
bleed
outcom
patient
studi
design
prospect
observ
cohort
studi
method
blood
sampl
collect
patient
undergo
pci
receiv
clopidogrel
cardiolog
specialist
tertiari
hospit
doha
qatar
patient
follow
month
via
phonemed
chart
cerner
timi
bleed
primari
endpoint
genotyp
perform
use
taqman
assay
binari
logist
regress
analysi
use
determin
factor
associ
bleed
use
spss
result
patient
recruit
major
male
mean
age
year
minor
allel
frequenc
eleven
case
bleed
identifi
minim
timi
bleed
major
timi
bleed
incid
bleed
carrier
gof
allel
increas
risk
bleed
vs
ci
p
factor
associ
bleed
stent
diamet
mm
ci
p
conclus
result
studi
show
gof
variant
smaller
stent
diamet
associ
increas
bleed
event
arab
patient
take
clopidogrel
differ
allel
frequenc
hmong
east
asian
popul
key
genet
variant
within
import
pharmacogen
wen
kathleen
md
bharat
thyagarajan
md
phd
jeffrey
r
bishop
pharmd
ms
heather
zierhut
phd
muaj
lo
txia
xiong
kerui
peng
katherin
holzer
koobmeej
lee
robert
straka
pharmd
fccp
experiment
clinic
pharmacolog
colleg
pharmaci
univers
minnesota
minneapoli
mn
side
commun
health
servic
st
paul
mn
laboratori
medicin
patholog
school
medicin
univers
minnesota
minneapoli
mn
genet
cell
biolog
develop
colleg
biolog
scienc
univers
minnesota
minneapoli
mn
introduct
implement
pharmacogenom
pgx
import
pharmacogen
vip
facilit
medic
select
hold
promis
improv
clinic
outcom
import
aspect
nation
institut
health
us
initi
inclus
popul
hmong
peopl
ethnic
group
southeast
asia
live
us
repres
popul
exhibit
specif
health
dispar
without
popul
specif
pgx
result
clinician
may
inappropri
gener
east
asian
pgx
data
hmong
allel
frequenc
differ
may
recogn
research
question
hypothesi
determin
allel
frequenc
hmong
high
prioriti
vip
compar
frequenc
east
asian
popul
studi
design
quantit
cohort
studi
minnesota
wisconsin
hmong
adult
method
saliva
hmong
collect
use
oragen
saliva
collect
kit
analyz
singl
nucleotid
polymorph
snp
uniqu
gene
dypd
tmpt
use
taqman
assay
biomark
hd
platform
fluidigm
inc
within
laboratori
fisher
exact
test
correct
use
compar
frequenc
clinic
pharmcogenet
implement
consortium
cpic
action
variant
hmong
particip
east
asian
popul
genom
aggreg
databas
studi
approv
univers
minnesota
irb
result
statist
signific
differ
allel
frequenc
note
cpic
action
variant
includ
vs
vs
vs
vs
vs
hmong
east
asian
respect
conclus
differ
allel
frequenc
key
snp
influenc
medic
dosag
select
may
translat
differ
mediat
recommend
hmong
rel
east
asian
popul
differ
underscor
import
individu
genet
inform
includ
commun
pgx
research
associ
studi
account
medic
exposur
reveal
signific
locu
cognit
perform
psychot
disord
seena
eum
scot
k
hill
ney
leah
h
rubin
adam
lee
lauren
j
mill
jame
l
reilli
rebekka
lencer
sarah
k
keedi
elena
ivleva
rebecca
shafe
steven
mccarrol
richard
se
keef
godfrey
pearlson
brett
clementz
carol
tamminga
matcheri
keshavan
elliot
gershon
john
sweeney
jeffrey
r
bishop
pharmd
ms
experiment
clinic
pharmacolog
univers
minnesota
minneapoli
mn
psycholog
rosalind
franklin
univers
medicin
scienc
north
chicago
il
psychiatri
behavior
neurosci
univers
chicago
chicago
il
neurolog
john
hopkin
univers
school
medicin
baltimor
md
supercomput
institut
univers
minnesota
minneapoli
mn
psychiatri
behavior
scienc
northwestern
univers
feinberg
school
medicin
chicago
il
psychiatri
psychotherapi
univers
muenster
muenster
germani
psychiatri
univers
texa
southwestern
medic
center
dalla
tx
genet
harvard
medic
school
boston
psychiatri
behavior
scienc
duke
univers
medic
center
durham
nc
psychiatri
neurobiolog
yale
univers
school
medicin
new
ct
psycholog
neurosci
univers
georgia
athen
ga
psychiatri
harvard
medic
school
boston
psychiatri
behavior
neurosci
univers
chicago
chicago
il
psychiatri
behavior
neurosci
univers
cincinnati
cincinnati
oh
experiment
clinic
pharmacolog
colleg
pharmaci
univers
minnesota
minneapoli
mn
introduct
identifi
genet
contributor
cognit
impair
disord
advanc
understand
diseas
pathophysiolog
although
medic
exposur
may
affect
cognit
perform
often
account
genet
studi
research
question
hypothesi
exploratori
associ
studi
gwa
cognit
perform
psychot
disord
control
studi
design
analysi
subset
data
network
intermedi
phenotyp
studi
studi
method
includ
particip
schizophrenia
schizoaffect
psychot
bipolar
control
studi
medic
dose
inform
avail
particip
year
age
clinic
stabl
without
recent
major
medic
chang
brief
assess
cognit
schizophrenia
bac
administ
assess
neurocognit
perform
anticholinerg
burden
quantifi
medic
regimen
use
anticholinerg
drug
scale
bac
composit
score
examin
quantit
trait
phenotyp
use
mix
linear
model
control
genet
ancestri
anticholinerg
burden
perform
hierarch
regress
signific
polymorph
test
improv
model
ad
anticholinerg
inform
influenc
antipsychot
dose
investig
examin
effect
signific
polymorph
within
subgroup
patient
receiv
individu
antipsychot
agent
result
compar
analys
without
medic
exposur
significantli
increas
ad
anticholinerg
burden
genet
model
p
analysi
adjust
anticholinerg
burden
reveal
bac
composit
score
significantli
associ
variant
effect
size
top
variant
remain
consist
examin
find
within
specif
antipsychot
drug
account
dose
conclus
identifi
locu
robustli
associ
cognit
function
previous
report
associ
risk
psychot
disord
includ
medic
exposur
inform
gwa
analysi
may
improv
detect
true
genet
associ
reduc
background
varianc
caus
medic
exposur
character
comparison
gene
express
copaxon
mylan
glatiram
acet
jeffrey
smith
hsu
stephen
hull
peter
lipski
laboratori
morgantown
wv
california
san
diego
school
medicin
la
jolla
ca
canonsburg
pa
biosolut
charlottesvil
va
introduct
glatiram
acet
ga
effect
treatment
patient
multipl
sclerosi
provid
gener
altern
brand
mechan
action
moa
ga
fulli
understood
assess
gene
express
potenti
sensit
mean
understand
moa
therapeut
product
research
question
hypothesi
immun
cell
activ
produc
signific
differ
gene
express
respect
immun
system
gene
studi
design
experiment
studi
aim
character
compar
effect
gene
express
murin
splenocyt
method
splenocyt
isol
femal
balbcj
x
sjlj
hybrid
mice
stimul
control
total
rna
assay
use
illumina
mous
microarray
beadchip
raw
data
normal
assess
differenti
express
gene
deg
use
limma
avail
r
packag
deg
fold
chang
log
ratio
fals
discoveri
p
assess
molecular
pathway
assign
use
search
tool
retriev
interact
genesprotein
visual
integr
discoveri
ingenu
pathway
analysi
ipa
result
gene
express
level
de
probe
confirm
yield
highli
similar
global
gene
express
pattern
level
correl
gene
express
sampl
treat
high
direct
comparison
sampl
yield
deg
p
comparison
level
individu
cytokin
transcript
show
signific
differ
cytokin
gene
analyz
ga
found
significantli
impact
immun
pathway
ipa
canon
gene
ontolog
pathway
analys
conclus
induc
highli
similar
gene
express
profil
deg
induc
compar
may
contribut
therapeut
effect
ga
function
analysi
ovarian
cancer
suscept
gene
morgan
ingerson
pharmd
candid
dougla
pittman
pharmaci
pharmaci
univers
south
carolina
columbia
sc
discoveri
biomed
scienc
univers
south
carolina
columbia
sc
introduct
ovarian
cancer
fifth
lead
caus
cancer
death
among
women
serou
ovarian
cancer
hgsoc
common
also
like
benefit
certain
class
chemotherapi
drug
defect
homolog
recombin
hr
pathway
hgsoc
typic
high
degre
genom
instabl
hr
protein
includ
understand
interplay
pathway
compon
assist
guid
ovarian
cancer
treatment
well
identifi
new
chemotherapi
drug
target
research
question
hypothesi
goal
project
perform
lysin
scan
mutagenesi
determin
lysin
necessari
function
test
whether
affect
interact
studi
design
investig
demonstr
undergo
ubiquitin
modif
regul
protein
function
ubiquitin
commonli
occur
lysin
residu
therefor
lysin
scan
mutagenesi
perform
test
cellular
resist
dna
damag
crosslink
agent
mitomycin
c
mutant
test
interact
known
interact
protein
use
yeast
two
hybrid
system
method
mutant
gene
clone
express
vector
yeast
construct
protein
interact
measur
qualit
cellular
growth
quantit
colorimetr
assay
result
three
amino
acid
locat
near
shown
necessari
confer
cellular
resist
mitomycin
c
protein
interact
data
suggest
three
lysin
arginin
substitut
disrupt
protein
interact
conclus
studi
identifi
three
critic
lysin
residu
necessari
confer
chemotherapi
resist
amino
acid
substitut
appear
affect
interact
known
protein
lysin
like
modifi
order
regul
dna
bind
activ
homolog
recombin
repair
educ
benefit
person
pharmacogenom
test
pharmaci
curriculum
heidi
steiner
bs
marti
larriva
patrick
campbel
david
e
nix
pharmd
dee
quinn
walter
klimecki
dvm
jason
karn
pharmd
practic
scienc
univers
arizona
colleg
pharmaci
tucson
az
arizona
colleg
medicin
tucson
az
univers
arizona
colleg
pharmaci
tucson
az
introduct
pharmacist
like
serv
resourc
interpret
pharmacogenom
pgx
result
futur
pharmaci
student
receiv
train
pgx
often
feel
unprepar
incorpor
pgx
practic
person
genom
educ
test
pget
may
improv
student
knowledg
comfort
attitud
regard
pgx
random
studi
avail
evalu
benefit
pget
research
question
hypothesi
evalu
effect
pget
student
knowledg
comfort
attitud
regard
pgx
follow
credit
core
cours
pgx
studi
design
consent
student
random
receiv
pgx
test
pgx
test
student
complet
survey
design
assess
pgx
knowledg
comfort
pgx
patient
educ
comfort
pgx
clinic
skill
attitud
toward
pgx
method
survey
student
random
pgx
test
test
use
panel
pgx
variant
affect
cardiovascular
neurolog
drug
student
random
pgx
test
provid
pgx
panel
hypothet
patient
instructor
blind
pgx
test
assign
follow
survey
pair
use
compar
prepost
pgx
knowledg
survey
respons
wilcoxon
sign
rank
use
compar
comfort
attitud
prepost
survey
data
result
total
pgx
test
test
student
complet
studi
differ
baselin
characterist
group
among
particip
signific
improv
observ
pgx
knowledg
patient
educ
clinic
skill
attitud
toward
pgx
compar
pgx
test
student
demonstr
significantli
higher
comfort
clinic
skill
includ
educ
healthcar
profession
pgx
commun
drug
therapi
incorpor
pgx
result
conclus
pgx
knowledg
attitud
improv
core
coursework
comfort
clinic
skill
pgx
implement
improv
pget
addit
studi
necessari
confirm
educ
valu
pget
associ
polymorph
advers
event
stratifi
hiv
integras
inhibitor
derek
murrel
wang
david
cluck
pharmd
bcp
jonathan
moorman
md
michel
duffourc
sam
harirforoosh
pharmd
pharmaceut
scienc
east
tennesse
state
univers
johnson
citi
tn
biostatist
epidemiolog
east
tennesse
state
univers
johnson
citi
tn
pharmaci
practic
east
tennesse
state
univers
johnson
citi
tn
intern
medicin
east
tennesse
state
univers
johnson
citi
tn
biomed
scienc
east
tennesse
state
univers
johnson
citi
tn
introduct
interest
precis
medicin
rise
sever
drug
class
examin
includ
hiv
antiretrovir
hiv
integras
inhibitor
commonli
prescrib
efficaci
howev
variabl
advers
event
ae
profil
may
limit
usag
thu
pharmacogenet
evalu
in
may
help
explain
ae
occurr
research
question
hypothesi
exploratori
cohort
subject
receiv
in
investig
relationship
select
singl
nucleotid
polymorph
snp
gene
central
nervou
system
ae
studi
design
singl
center
exploratori
observ
studi
method
hiv
posit
adult
differenti
integras
inhibitor
regardless
backbon
regimen
dolutegravir
male
elvitegravir
male
raltegravir
male
binari
data
collect
ae
occurr
preced
two
week
well
individu
genotyp
three
snp
logist
regress
without
covari
age
bmi
sex
regimen
durat
conduct
plink
determin
associ
statist
signific
confer
p
result
one
associ
fatigu
without
covari
found
dolutegravir
group
associ
found
elvitegravir
group
absenc
ae
prior
covari
adjust
final
abnorm
dream
show
associ
adjust
covari
regimen
comparison
statist
signific
conclus
result
indic
pharmacogenet
may
play
role
predict
ae
profil
regimen
specif
fatigu
abnorm
dream
dolutegravir
raltegravir
respect
identif
patient
outcom
determin
contribut
better
util
medic
especi
first
line
therapi
exploratori
find
provid
support
examin
precis
medicin
hiv
pharmacotherapi
warfarin
pharmacogenomi
hispan
popul
candid
snp
studi
justin
kay
ba
psm
heidi
steiner
jare
wahl
bs
nanci
sweitzer
md
jason
karn
pharmd
practic
scienc
univers
arizona
colleg
pharmaci
tucson
az
practic
scienc
tucson
az
heart
center
tucson
az
introduct
warfarin
remain
one
wide
prescrib
anticoagul
lead
caus
advers
drug
reaction
warfarin
dose
algorithm
enabl
accur
dose
estim
potenti
lead
improv
safeti
efficaci
howev
dose
algorithm
develop
primarili
popul
european
descent
limit
data
avail
regard
singl
nucleotid
polymorph
snp
significantli
influenc
warfarin
dose
hispan
popul
research
question
hypothesi
examin
whether
clinic
factor
snp
previous
shown
influenc
warfarin
stabl
dose
popul
european
hispan
descent
accur
predict
warfarin
stabl
dose
hispan
popul
studi
design
hispan
latino
patient
stabl
warfarin
dose
defin
dose
least
two
clinic
visit
separ
least
two
week
recruit
method
candid
snp
includ
genotyp
clinic
data
collect
use
survey
electron
medic
record
stepwis
linear
regress
perform
determin
variabl
significantli
predict
squar
root
weekli
warfarin
dose
result
total
patient
primarili
mexican
american
ancestri
particip
snp
within
equilibrium
final
stepwis
regress
model
incorpor
six
variabl
explain
variabl
warfarin
weekli
dose
requir
signific
predictor
includ
weight
p
age
p
amiodaron
use
prior
stroke
signific
snp
includ
p
significantli
impact
warfarin
dose
requir
despit
previous
publish
associ
hispan
popul
conclus
find
suggest
clinic
genet
predictor
warfarin
weekli
dose
requir
similar
among
popul
european
descent
hispan
popul
mexican
american
ancestri
result
requir
replic
valid
independ
cohort
similar
ethnic
advanc
understand
influenc
warfarin
dose
variabl
among
differ
raceethn
group
implement
genotyp
guid
voriconazol
prophylaxi
neutropen
cancer
patient
rod
quilitz
wonhe
yanina
pasikhova
rebecca
nelson
kerri
kelli
ana
velez
john
green
howard
mcleod
kevin
hick
pharmd
cancer
center
tampa
fl
pharmaci
h
lee
moffitt
cancer
center
research
institut
tampa
fl
famili
person
medicin
institut
moffitt
cancer
center
tampa
fl
introduct
invas
fungal
infect
major
contributor
morbid
mortal
neutropen
cancer
patient
voriconazol
effect
antifung
prophylact
metabol
polymorph
enzym
approxim
individu
carri
genet
variant
predict
rapid
metabol
risk
voriconazol
concentr
research
question
hypothesi
increas
voriconazol
dose
rapid
metabol
result
higher
percentag
patient
attain
therapeut
concentr
studi
design
implement
qualiti
improv
pilot
util
genotyp
optim
voriconazol
prophylact
dose
adult
neutropen
cancer
patient
method
luminex
xtag
kit
util
genotyp
recommend
follow
avoid
voriconazol
ultrarapid
metabol
voriconazol
mg
twice
daili
bid
rapid
metabol
voriconazol
mg
bid
phenotyp
clinic
decis
support
includ
interrupt
alert
autom
antimicrobi
stewardship
consult
deploy
ehr
therapeut
drug
monitor
perform
discret
medic
team
goal
trough
concentr
mcgml
result
date
patient
undergon
genotyp
ultrarapid
rapid
normal
intermedi
poor
metabol
observ
receiv
prophylact
voriconazol
dose
per
recommend
voriconazol
mg
bid
voriconazol
mg
bid
voriconazol
trough
concentr
compar
rapid
metabol
receiv
voriconazol
mg
bid
achiev
goal
trough
concentr
wherea
rapid
metabol
receiv
voriconazol
mg
bid
achiev
goal
trough
concentr
conclus
implement
genotyp
guid
voriconazol
prophylact
dose
feasibl
increas
voriconazol
dose
mg
bid
rapid
metabol
result
patient
achiev
goal
trough
concentr
futur
analysi
determin
voriconazol
dose
prevent
breakthrough
fungal
infect
pharmacogenet
analysi
gastrointestin
advers
effect
profil
hiv
integras
regimen
derek
murrel
wang
david
cluck
pharmd
bcp
aahivp
jonathan
moorman
md
michel
duffourc
sam
harirforoosh
pharmd
pharmaceut
scienc
east
tennesse
state
univers
johnson
citi
tn
biostatist
epidemiolog
east
tennesse
state
univers
johnson
citi
tn
pharmaci
practic
east
tennesse
state
univers
johnson
citi
tn
intern
medicin
east
tennesse
state
univers
johnson
citi
tn
biomed
scienc
east
tennesse
state
univers
johnson
citi
tn
introduct
hiv
integras
inhibitor
current
util
efficaci
frontlin
therapi
howev
addit
goal
virolog
suppress
advers
event
profil
may
vari
among
subject
often
play
import
role
select
mainten
hiv
antiretrovir
therapi
research
question
hypothesi
sought
identifi
associ
gastrointestin
gi
advers
event
singl
nucleotid
polymorph
snp
exploratori
cohort
patient
receiv
integras
regimen
studi
design
observ
studi
exploratori
natur
singl
center
method
adult
patient
infect
current
maintain
integras
inhibitor
recruit
cohort
compris
dolutegravir
subject
femal
elvitegravir
subject
femal
raltegravir
subject
femal
absenc
occurr
gi
advers
event
nausea
vomit
diarrhea
previou
day
record
via
questionnair
use
blood
sampl
collect
subject
sever
snp
iplex
adm
pgx
panel
genotyp
logist
regress
addit
model
via
plink
util
determin
pharmacogenet
associ
less
consid
signific
result
one
associ
found
nausea
gene
within
dolutegravir
group
dolutegravir
group
also
present
associ
vomit
final
diarrhea
associ
snp
dolutegravir
group
within
elvitegravir
group
statist
signific
associ
detect
conclus
result
suggest
subject
genet
makeup
may
influenc
regimen
toler
specif
concern
dolutegravir
elvitegravir
due
exploratori
natur
studi
studi
need
determin
snp
contribut
likelihood
advers
event
polymorph
warfarin
treatment
patient
mechan
cardiac
valv
sook
hee
ph
kyung
eun
lee
lee
ph
pharm
byung
chul
chang
phd
hyesun
gwak
phd
pharmaci
wonkwang
univers
iksan
korea
republ
south
pharmaci
chungbuk
nation
univers
osong
korea
republ
south
thorac
cardiovascular
surgeri
yonsei
univers
medic
center
seoul
korea
republ
south
pharmaci
divis
life
pharmaceut
scienc
ewha
woman
univers
seoul
korea
republ
south
present
ashp
midyear
clinic
meet
orlando
fl
decemb
influenc
creatinin
clearanc
estim
method
aminoglycosid
ag
gentamicin
tobramycin
dose
obes
adult
patient
larri
bauer
pharmd
depart
pharmaci
univers
washington
seattl
wa
introduct
two
method
estim
creatinin
clearanc
ecrcl
obes
adult
patient
predomin
comput
initi
dose
ag
research
question
hypothesi
compar
initi
dose
comput
use
differ
ecrcl
method
modifi
use
adjust
bodi
weight
abw
initi
dose
versu
final
adjust
dose
attain
target
css
initi
css
comput
dose
final
css
studi
design
observ
patient
criterion
obes
ibw
adult
patient
suscept
infect
antibiot
plu
stabl
scr
concentr
method
initi
dose
comput
use
standard
pharmacokinet
equat
appli
clinic
pharmacokinet
either
use
comput
ecrcl
final
adjust
dose
comput
attain
individu
goal
mgl
peak
mgl
trough
initi
versu
final
adjust
dose
estim
versu
final
adjust
css
compar
precis
bia
use
sheiner
beal
method
j
pharmacokinet
biopharm
aug
result
patient
age
year
percent
ibw
scr
mgdl
initi
dose
comput
use
significantli
smaller
p
anova
comput
use
ns
compar
final
adjust
dose
estim
css
use
significantli
less
trough
p
estim
use
trough
ns
compar
final
adjust
css
dose
css
predict
use
less
precis
bias
compar
comput
use
initi
dose
adjust
attain
target
css
patient
use
versu
patient
use
conclus
use
ecrcl
dose
ag
obes
adult
patient
precis
less
bias
use
like
due
comput
ecrcl
valu
less
patient
smaller
number
patient
requir
subsequ
dosag
adjust
use
evalu
vancomycin
dose
strategi
achiev
target
trough
concentr
obes
popul
kisha
dunkley
pharmd
bcp
amanda
sowel
pharmd
kathryn
dzintar
pharmd
virna
almuet
pharmd
maggi
chan
pharmd
jacki
tran
pharmd
leigh
efird
pharmd
mph
john
hopkin
hospit
baltimor
md
health
richland
columbia
sc
hopkin
medicin
baltimor
md
york
presbyterian
hospit
new
york
ny
introduct
optim
dose
vancomycin
obes
popul
unknown
valu
given
obes
epidem
research
question
hypothesi
differ
target
trough
attain
obes
patient
receiv
standard
dose
mgkg
versu
reduc
dose
mgkg
vancomycin
differ
averag
mgkg
dose
supratherapeut
rate
target
trough
attain
two
obes
versu
morbidli
obes
male
versu
femal
studi
design
retrospect
cohort
studi
obes
adult
receiv
vancomycin
januari
june
method
obes
patient
kg
bmi
receiv
least
four
consecut
dose
intraven
vancomycin
appropri
drawn
trough
concentr
includ
therapeut
serum
vancomycin
trough
defin
result
obes
patient
averag
dose
mgkg
commonli
dose
everi
hour
proport
therapeut
trough
attain
reduc
standard
dose
vs
patient
reduc
dose
lower
trough
vs
less
supratherapeut
trough
vs
morbidli
obes
patient
receiv
lower
dose
obes
mgkg
vs
mgkg
p
higher
trough
vs
p
greater
rate
supratherapeut
trough
vs
p
femal
similar
averag
dose
male
higher
trough
vs
p
supratherapeut
trough
vs
differ
found
attain
therapeut
trough
obes
versu
morbidli
obes
vs
femal
versu
male
vs
conclus
studi
demonstr
reduc
vancomycin
dose
may
provid
safeti
maintain
compar
efficaci
standard
vancomycin
dose
strategi
obes
patient
degre
obes
gender
may
import
factor
consid
dose
vancomycin
pharmacokinet
pk
bictegravir
bic
combin
polyval
cation
contain
pvcc
antacid
supplement
anita
mathia
phd
steve
west
msph
deqe
xiao
phd
elena
chan
pharmd
susan
chuck
pharmd
hal
martin
md
mph
erin
quirk
md
brian
kearney
pharmd
gilead
scienc
foster
citi
ca
introduct
bic
potent
unboost
integras
strand
transfer
inhibitor
insti
hiv
regimen
bicemtricitabinetenofovir
alafenamid
bftaf
bic
high
mean
inhibitori
quotient
iq
wide
therapeut
window
like
insti
bic
suscept
drug
interact
result
decreas
bic
exposur
research
question
hypothesi
bftaf
pvcc
antacidssuppl
coadminist
without
alter
bic
efficaci
studi
design
evalu
bic
pk
pvcc
antacid
supplement
healthi
subject
method
bftaf
coadminist
simultan
fast
fed
condit
maximum
strength
antacid
aluminum
hydroxid
magnesium
hydroxid
simethicon
calcium
carbon
stagger
bftaf
hour
antacid
fast
condit
evalu
bic
exposur
compar
bftaf
administ
alon
fast
geometr
mean
glsm
ratio
calcul
result
bftaf
coadminist
simultan
cation
fast
condit
reduc
bic
exposur
fed
condit
bic
exposur
reduc
antacid
remain
unaffect
calcium
carbon
ferrou
fumar
supplement
bftaf
administ
fast
state
hour
antacid
bic
exposur
reduc
project
concentr
bic
exposur
affect
bftaf
administ
fast
hour
antacid
studi
treatment
well
toler
conclus
dose
condit
test
administ
bftaf
pvcc
antacidssuppl
simultan
food
fast
stagger
provid
bic
exposur
within
bftaf
phase
registr
trial
rang
valu
associ
efficaci
develop
limit
sampl
strategi
toward
isoniazid
therapeut
drug
monitor
korean
patient
tuberculosi
giwon
choi
eun
kyoung
chung
pharmd
phd
su
young
jung
suhyun
lee
eun
sun
kim
jong
sun
park
junghan
song
jaeho
lee
jangik
lee
pharmd
pharmaci
colleg
pharmaci
seoul
nation
univers
seoul
korea
republ
south
pharmaci
colleg
pharmaci
kyung
hee
univers
seoul
korea
republ
south
pulmonari
critic
care
medicin
depart
intern
medicin
seoul
nation
univers
colleg
medicin
seoul
nation
univers
hospit
korea
republ
south
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
nation
univers
hospit
korea
republ
south
introduct
clinic
outcom
isoniazid
best
predict
area
curv
hour
although
littl
evid
avail
support
correl
isoniazid
plasma
isoniazid
concentr
two
hour
post
dose
frequent
use
therapeut
drug
monitor
tdm
research
question
hypothesi
optim
time
point
isoniazid
blood
sampl
estim
consid
genotyp
studi
design
prospect
studi
conduct
korean
tuberculosi
patient
receiv
isoniazid
mg
daili
method
isoniazid
plasma
concentr
measur
liquid
chromatographi
mass
spectrometri
genotyp
determin
snapshot
method
pharmacokinet
paramet
estim
use
method
winnonlin
compar
slow
acetyl
linear
regress
analys
sa
perform
evalu
relationship
isoniazid
plasma
concentr
differ
time
point
two
group
separ
statist
signific
defin
p
result
total
patient
enrol
studi
isoniazid
clf
differ
slow
acetyl
vs
mcg
hml
vs
lh
vs
h
respect
regress
analys
point
accur
estim
group
coeffici
determin
adjust
p
p
slow
acetyl
respect
contrast
relationship
weak
slow
fair
acetyl
p
conclus
estim
isoniazid
accur
reliabl
regardless
genotyp
therefor
monitor
rather
consid
purpos
isoniazid
tdm
tuberculosi
patient
compar
pharmacokinet
evalu
enalapril
administ
use
refer
develop
child
appropri
dosag
formul
muhammad
faisal
pharm
mphil
willi
cawello
stephani
laer
md
clinic
pharmaci
pharmacotherapi
heinrich
hein
univers
duesseldorf
duesseldorf
germani
introduct
compar
pharmacokinet
pk
data
analysi
drug
administ
use
develop
market
author
dosag
formul
spars
import
pediatr
drug
develop
question
evalu
pk
differ
enalapril
administ
treatment
refer
renitec
tablet
administ
ml
water
treatment
b
oral
dispers
odmt
ml
water
treatment
c
child
appropri
odmt
ml
water
use
pk
compart
model
cm
valid
lsmm
paramet
estim
studi
design
phase
clinic
trial
conduct
treatment
enalapril
ie
refer
treatment
administ
healthi
adult
volunt
method
phoenix
winnonlin
softwar
incorpor
model
cm
adequ
predict
serum
enalapril
concentr
except
fewer
lower
concentr
second
incomplet
termin
elimin
phase
although
predict
lower
concentr
result
parametr
reject
paramet
estim
ordinari
weight
iter
reweight
lsmm
compar
simul
valid
analysi
iter
reweight
lsmm
select
iter
accur
precis
pk
paramet
includ
rate
constant
absorpt
ka
elimin
ke
rel
bioavail
vdf
delay
drug
appear
serum
tlag
iter
pk
paramet
log
transform
statist
correl
perform
pair
less
consid
statist
signific
result
comparison
pk
paramet
show
signific
differ
earli
appear
drug
tlag
serum
compar
differ
pk
three
treatment
observ
conclus
compar
refer
odmt
administ
water
absorb
appear
earlier
plasma
differ
absorpt
ka
elimin
ke
rel
bioavail
vdf
drug
two
treatment
observ
differ
onset
rate
absorpt
oral
dispers
retain
versu
may
show
absenc
minut
absorpt
character
variabl
calcul
vancomycin
pharmacokinet
paramet
use
dose
strategi
hospit
patient
ana
vega
christin
nguyen
kimberli
claey
pharmd
emili
heil
pharmd
bcp
aq
id
pharmaci
practic
scienc
univers
maryland
school
pharmaci
baltimor
md
maryland
school
pharmaci
baltimor
md
present
idweek
san
francisco
ca
octob
pharmacokinet
vancomycin
critic
ill
patient
undergo
sustain
low
effici
dialysi
sled
therapi
taylor
rider
pharmd
bcp
kevin
silinski
minde
hite
jonathon
bress
pharmaci
rochest
gener
hospit
rochest
ny
depart
rochest
gener
hospit
rochest
ny
introduct
vancomycin
pharmacokinet
pk
data
critic
ill
patient
receiv
sled
limit
publish
data
util
vancomycin
altern
dialysi
method
intermitt
dialysi
continu
renal
replac
therapi
may
applic
due
sled
hybrid
dialysi
modal
current
drug
refer
lack
recommend
vancomycin
dose
patient
receiv
sled
research
question
hypothesi
purpos
studi
defin
vancomycin
elimin
sled
amount
vancomycin
rebound
four
hour
vancomycin
volum
distribut
vd
auc
also
assess
secondari
outcom
studi
design
prospect
singl
center
pk
studi
critic
ill
patient
method
twenti
critic
ill
patient
oligur
anur
renal
failur
concomitantli
receiv
vancomycin
sled
therapi
includ
surround
one
sled
treatment
serum
vancomycin
blood
sampl
drawn
prior
initi
sled
termin
sled
four
hour
complet
sled
treatment
patient
receiv
vancomycin
dose
peak
level
drawn
one
hour
end
infus
sled
treatment
durat
least
seven
hour
continu
data
report
median
iqr
categor
data
percentag
result
vancomycin
elimin
rate
hour
respect
sled
reduc
vancomycin
serum
concentr
vancomycin
rebound
vancomycin
dose
administ
mg
eighteen
patient
vd
lkg
clearanc
lhr
auc
mcg
conclus
vancomycin
significantli
remov
littl
rebound
four
hour
sled
treatment
base
find
critic
ill
patient
receiv
sled
may
requir
mg
sled
treatment
maintain
vancomycin
serum
concentr
mcgml
therapeut
drug
monitor
recommend
persist
rate
oral
anticoagul
atrial
fibril
obes
patient
rashmi
patel
pharmd
rachel
fluri
pharmd
bcp
nanci
yunker
pharmd
fccp
brian
di
pace
commonwealth
univers
health
pharmaci
depart
virginia
commonwealth
univers
richmond
va
commonwealth
univers
school
pharmaci
richmond
va
commonwealth
univers
depart
biostatist
virginia
commonwealth
univers
depart
biostatist
richmond
va
introduct
direct
oral
anticoagul
doac
altern
warfarin
stroke
prevent
patient
atrial
fibril
nvaf
predict
pharmacokinet
requir
less
frequent
monitor
warfarin
unclear
effect
may
medic
persist
studi
specif
evalu
differ
persist
obes
patient
research
question
hypothesi
purpos
qualiti
improv
project
compar
persist
rate
obes
patient
nvaf
prescrib
doac
versu
warfarin
studi
design
singl
center
retrospect
chart
review
includ
patient
older
newli
diagnos
nvaf
obes
bmi
actual
bodi
weight
prescrib
warfarin
apixaban
rivaroxaban
dabigatran
patient
exclud
least
initi
fill
histori
day
pregnant
cancer
prison
valvular
diseas
revers
caus
af
method
primari
object
assess
persist
rate
patient
prescrib
warfarin
versu
prescrib
doac
defin
presenc
day
gap
medic
fill
histori
secondari
outcom
includ
incid
stroke
major
bleed
mortal
hospit
switch
oral
anticoagul
result
patient
includ
averag
bmi
result
found
persist
rate
rang
p
p
month
group
differ
found
group
month
patient
refil
data
possibl
indic
anticoagul
resolv
experienc
medic
side
effect
lost
follow
conclus
differ
found
incid
stroke
bleed
mortal
group
studi
show
strong
persist
rate
obes
patient
take
warfarin
doac
high
medic
discontinu
rate
extend
stabil
isoproterenol
hydrochlorid
inject
polyvinyl
chlorid
bag
store
amber
ultraviolet
light
block
bag
edward
van
matr
pharmd
ms
clark
lyda
michael
larkin
tabetha
mcalwe
tyre
kiser
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
colorado
hospit
aurora
co
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
isoproterenol
hydrochlorid
hcl
inject
catecholamin
potent
properti
util
primarili
acut
bradyarrhythmia
studi
evalu
stabil
isoproterenol
hcl
polyvinyl
chlorid
bag
greater
day
research
question
hypothesi
purpos
studi
determin
physic
chemic
stabil
isoproterenol
hcl
concentr
sodium
chlorid
store
room
temperatur
refriger
day
amber
ultraviolet
light
block
bag
studi
design
drug
stabil
studi
method
dilut
isoproterenol
hcl
concentr
perform
asept
condit
bag
place
ultraviolet
light
block
bag
store
room
temperatur
refriger
three
sampl
prepar
storag
environ
analyz
day
physic
stabil
perform
visual
examin
ph
assess
baselin
upon
final
degrad
evalu
steril
sampl
assess
chemic
stabil
isoproterenol
hcl
evalu
use
tandem
mass
spectrometri
determin
natur
assay
forc
degrad
evalu
sampl
consid
stabl
less
degrad
initi
concentr
result
isoproterenol
hcl
dilut
sodium
chlorid
inject
store
amber
ultraviolet
light
block
bag
physic
stabl
throughout
studi
precipit
observ
day
bag
less
degrad
room
temperatur
refriger
conclus
isoproterenol
hcl
dilut
sodium
chlorid
inject
stabl
day
room
temperatur
refriger
demonstr
equival
mylan
gener
glatiram
acet
mga
copaxon
cop
peter
lipski
patrick
vallano
jeffrey
smith
walter
owen
daniel
snider
viswanath
bandaru
yunfu
sun
ross
wallingford
stephen
hull
joseph
duncan
joshua
h
lewi
jason
southal
azeem
ansari
hong
li
biosolut
charlottesvil
va
laboratori
morgantown
wv
canonsburg
pa
introduct
cop
glatiram
acet
ga
establish
treatment
patient
multipl
sclerosi
rrm
gener
ga
mga
approv
us
food
drug
administr
fda
research
question
hypothesi
mga
therapeut
equival
substitut
cop
studi
design
demonstr
equival
mga
cop
use
criteria
activ
pharmaceut
ingredi
api
same
previous
establish
fda
method
synthet
process
scheme
mga
compar
publish
reaction
scheme
cop
patent
describ
synthesi
compar
physiochem
properti
analys
includ
amino
acid
composit
molecular
weight
distribut
spectroscop
fingerprint
total
diethylamin
dea
content
rel
proport
amino
acid
termin
amino
acid
sequenc
biolog
activ
product
assess
use
experiment
autoimmun
encephalomyel
eae
mous
model
score
eae
clinic
sign
daili
result
mga
produc
use
fundament
reaction
scheme
cop
shown
equival
physicochem
properti
amino
acid
composit
molecular
weight
distribut
polydispers
index
spectral
fingerprint
mga
found
equival
cop
analys
structur
signatur
demonstr
equival
mga
cop
regard
polymer
depolymer
dea
content
mole
fraction
amino
acid
mga
equival
cop
amino
acid
composit
mga
cop
met
equival
criteria
eae
model
mga
cop
compar
reduc
diseas
sever
rel
control
provid
confirmatori
evid
same
valid
vivo
ms
model
conclus
rigor
comparison
mga
cop
demonstr
equival
physiochem
properti
structur
signatur
polymer
depolymer
equival
biolog
activ
evidenc
compar
effect
eae
collect
data
demonstr
mga
meet
fda
criteria
api
same
character
vancomycin
pharmacokinet
pharmacodynam
obes
septic
shock
patient
ann
masich
shamir
kalaria
jeffrey
gonzal
pharmd
bcp
emili
heil
pharmd
bcp
aq
asha
tata
pharmd
kimberli
claey
pharmd
devang
patel
mathangi
gopalakrishnan
ms
commonwealth
univers
health
system
richmond
va
maryland
school
pharmaci
baltimor
md
maryland
medic
center
baltimor
md
maryland
school
medicin
baltimor
md
introduct
patient
obes
septic
shock
may
alter
vancomycin
pharmacokinet
pk
compar
gener
popul
specif
hydrophil
antimicrobi
ie
vancomycin
may
increas
volum
distribut
vd
decreas
protein
bind
alter
renal
clearanc
chang
may
result
improp
dose
inadequ
concentr
current
lack
publish
literatur
evalu
vancomycin
pk
pharmacodynam
pd
obes
septic
shock
patient
research
question
hypothesi
character
vancomycin
adult
obes
patient
septic
shock
studi
design
prospect
observ
singl
center
studi
method
serum
vancomycin
concentr
level
per
patient
collect
within
first
hour
addit
data
collect
includ
age
weight
gender
sever
ill
creatinin
clearanc
crcl
infecti
sourc
outcom
pk
analysi
conduct
data
avail
use
phoenix
softwar
follow
popul
vancomycin
pk
use
comparison
result
nine
patient
male
enrol
median
iqr
age
year
bmi
crcl
apach
ii
sofa
score
seven
patient
acut
renal
failur
infect
sourc
includ
pneumonia
gastrointestin
skin
soft
tissu
bacteremia
unknown
sourc
patient
receiv
load
dose
median
iqr
initi
dose
median
iqr
pk
paramet
median
iqr
trough
mcgml
median
iqr
auc
clinic
cure
hospit
mortal
conclus
base
result
studi
obes
patient
septic
shock
similar
pk
paramet
compar
gener
pk
popul
impact
proxim
gastric
bypass
surgeri
acetaminophen
absorpt
metabol
chen
bs
taurenc
senn
bs
brant
oelschlag
david
flum
md
danni
shen
john
horn
yvonn
lin
chan
pharmaceut
univers
washington
seattl
wa
medicin
chemistri
univers
washington
seattl
wa
surgeri
univers
washington
seattl
wa
pharmaci
univers
washington
seattl
wa
introduct
bariatr
surgeri
one
effect
medic
intervent
treatment
obes
patient
undergo
gastric
bypass
surgeri
rygb
surgic
alter
stomach
length
small
intestin
research
question
hypothesi
aim
studi
determin
gastric
bypass
surgeri
rygb
affect
absorpt
metabol
acetaminophen
studi
design
twelv
morbidli
obes
receiv
g
acetaminophen
apap
oral
three
separ
pharmacokinet
studi
day
ie
baselin
method
plasma
collect
time
point
hr
sampl
analyz
use
liquid
spectrometri
apap
result
peak
concentr
apap
increas
follow
rygb
peak
concentr
increas
smaller
extent
rang
follow
rygb
wherea
peak
concentr
unchang
contrast
peak
concentr
apap
major
differ
clearanc
volum
distribut
termin
apap
interestingli
ratio
four
metabolit
decreas
conclus
rygb
caus
rapid
increas
rate
absorpt
apap
possibl
decreas
activ
phase
ii
enzym
therapeut
equival
gener
product
versu
refer
product
ivabradin
patient
chronic
heart
failur
crossov
studi
hadeer
eliwa
bachelor
degre
pharmaceut
scienc
pharmaceut
naglaa
bazan
ebtissam
darweesh
md
nagwa
sabri
practic
clinic
pharmaci
departmentfaculti
pharmaceut
scienc
pharmaceut
industri
futur
univers
egypt
egypt
care
medicin
depart
cairo
univers
hospit
egypt
practic
clinic
pharmaci
depart
faculti
pharmaceut
scienc
pharmaceut
industri
futur
univers
egypt
egypt
pharmacyain
sham
univers
cairo
egypt
introduct
gener
substitut
brand
ivabradin
prescript
reduc
drug
expenditur
improv
adher
howev
distrust
gener
medicin
practition
patient
due
doubt
regard
qualiti
fear
counterfeit
compromis
accept
practic
research
question
hypothesi
gener
ivabradin
therapeut
equival
brand
ivabradin
adult
patient
chronic
heart
failur
reduc
eject
fraction
hfref
studi
design
random
crossov
studi
method
egyptian
patient
hfref
treat
brand
ivabradin
procrolan
gener
bradipect
week
primari
outcom
rest
heart
rate
hr
nyha
fc
qualiti
life
qol
use
minnesota
live
heart
failur
mlwhf
ef
secondari
outcom
number
hospit
worsen
hfref
advers
effect
washout
period
allow
ethic
reason
result
week
reduct
hr
compar
two
group
vs
bpm
brand
gener
group
respect
also
increas
ef
compar
two
group
vs
brand
gener
group
respect
improv
nyha
fc
compar
group
brand
group
vs
gener
group
mean
valu
qol
improv
vs
brand
gener
group
respect
similarli
end
week
signific
chang
observ
data
observ
week
regard
hr
ef
qol
nyha
fc
minor
side
effect
mainli
phosphen
compar
number
hospit
observ
group
conclus
studi
reveal
statist
signific
differ
therapeut
effect
safeti
gener
brand
ivabradin
assum
practition
safe
interchang
econom
reason
clinic
pharmacokinet
outcom
versu
vancomycin
therapeut
drug
monitor
approach
pragmat
random
control
trial
fatima
ahm
moham
nader
bs
pharm
msc
phd
moham
saad
pharmd
bcp
hani
abdelaziz
pharmd
adila
shaukat
mbb
cabm
rakesh
parakadavathu
ahm
elzubair
daoud
hazem
elewa
phd
rph
ahm
awaisu
bpharm
pharmaci
qatar
univers
doha
qatar
clinic
pharmacolog
indiana
univers
indianapoli
pharmaci
depart
hospit
hamad
medic
corpor
doha
qatar
medicin
al
wakra
hospit
hamad
medic
corpor
doha
qatar
diseas
depart
hospit
hamad
medic
corportaion
doha
qatar
diseas
depart
hamad
gener
hospit
hamad
medic
corpor
doha
qatar
pharmaci
depart
hospit
hamad
medic
corpor
qatar
pharmaci
practic
section
colleg
pharmaci
qatar
univers
doha
qatar
present
accp
virtual
poster
symposium
best
poster
award
winner
access
safeti
antipsychot
treatment
autism
spectrum
disord
children
adolesc
shaista
sadaf
bpharm
luana
mifsud
buhagiar
bpharm
hon
melit
mpharm
melit
maresca
attard
pizzuto
bpharm
hon
melit
msc
melit
phd
melit
anthoni
bpharm
pharmd
cinc
maccp
mrpharm
depart
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
introduct
fda
approv
risperidon
aripiprazol
treatment
irrit
associ
autism
spectrum
disord
asd
children
adolesc
cultur
econom
differ
countri
like
india
malta
may
affect
prescript
drug
asd
research
question
hypothesi
risperidon
aripiprazol
easili
access
india
malta
safe
prescrib
drug
cohort
asd
screen
tool
influenc
prescrib
behaviour
drug
studi
design
studi
method
avail
price
nation
polici
compar
india
malta
studi
access
risperidon
aripiprazol
safeti
signal
access
european
pharmacovigil
system
assess
use
french
causal
assess
indian
scale
assess
autism
isaa
childhood
autism
rate
scale
car
compar
develop
valid
asd
compar
questionnair
intend
psychiatrist
india
malta
consist
question
result
risperidon
aripiprazol
avail
india
indic
asd
cost
differ
singl
tablet
strength
dosag
form
respect
french
causal
assess
detect
signal
conclud
uncertain
unlik
relationship
signal
drug
dissemin
psychiatrist
india
malta
larger
percentag
psychiatrist
india
agre
screen
tool
posit
influenc
prescrib
behaviour
compar
psychiatrist
malta
conclus
access
drug
patient
affect
high
cost
lower
includ
risperidon
aripiprazol
nation
formulari
indic
asd
safe
prescrib
drug
cohort
continu
monitor
recommend
cultur
econom
differ
significantli
affect
approach
toward
treatment
asd
differ
countri
benzodiazepin
monotherapi
patient
depress
nation
studi
mate
soric
chri
paxo
sara
dugan
pharmd
bcpp
susan
fosnight
jodi
turoski
rph
jessica
emshoff
prabodh
sadana
luka
everli
pharmd
brittani
snyder
bhavin
mistri
shubha
bhat
ami
unruh
pharmd
ismail
safi
pharmd
pharmaci
practic
northeast
ohio
medic
univers
rootstown
oh
clinic
akron
gener
akron
oh
ohio
medic
univers
summa
akron
citi
hospit
rootstown
oh
pharmaci
practic
northeast
ohio
medic
univers
st
vincent
chariti
medic
center
rootstown
oh
hospit
geauga
medic
center
chardon
oh
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
pharmaci
northeast
ohio
medic
univers
rootstown
oh
ohio
medic
univers
rootstown
oh
introduct
benzodiazepin
link
increas
risk
depress
symptom
suicid
attempt
depend
depress
guidelin
discourag
benzodiazepin
monotherapi
limit
use
adjunct
therapi
antidepress
howev
patient
depress
continu
receiv
benzodiazepin
monotherapi
preval
predictor
prescrib
pattern
describ
previous
clinician
character
patient
popul
highest
risk
research
question
hypothesi
percentag
adult
treat
depress
prescrib
benzodiazepin
monotherapi
variabl
predict
usag
pattern
studi
design
nation
analysi
nation
ambulatori
medic
care
survey
method
offic
visit
patient
age
treat
depress
includ
analysi
offic
visit
involv
patient
bipolar
disord
schizoaffect
disord
pregnanc
exclud
primari
endpoint
benzodiazepin
monotherapi
prescrib
rate
defin
initi
continu
benzodiazepin
absenc
antidepress
agent
order
identifi
predictor
use
multivari
logist
regress
model
creat
identifi
variabl
significantli
associ
benzodiazepin
monotherapi
result
total
unweight
visit
elig
inclus
repres
million
weight
visit
benzodiazepin
monotherapi
present
patient
treat
depress
ci
predictor
benzodiazepin
monotherapi
includ
patient
age
ci
compar
patient
age
offic
visit
ci
offic
visit
ci
underli
pulmonari
diseas
ci
concomit
opiat
prescrib
ci
psychiatri
specialist
less
like
prescrib
benzodiazepin
monotherapi
ci
compar
primari
care
provid
conclus
benzodiazepin
monotherapi
util
nearli
patient
treat
depress
older
adult
opiat
user
patient
seen
primari
care
provid
underli
anxieti
epilepsi
pulmonari
disord
highest
risk
gut
microbi
commun
structur
vari
atyp
antipsychot
treatment
resist
starch
bipolar
schizophrenia
cohort
stephani
flower
pharmd
zarina
kraal
kristen
ward
vicki
ellingrod
pharmd
practic
univers
illinoi
chicago
chicago
il
pharmaci
depart
colleg
pharmaci
univers
michigan
ann
arbor
mi
introduct
cardiovascular
diseas
cvd
metabol
abnorm
major
caus
mortal
among
treat
atyp
antipsychot
aap
previou
studi
identifi
shift
gut
microbiota
associ
may
link
aap
metabol
burden
dietari
prebiot
like
resist
starch
rs
may
benefici
obes
diabet
littl
known
abil
modifi
gut
microbiota
individu
perform
clinic
studi
determin
effect
rs
bodi
composit
diet
gut
microbiota
psychiatr
popul
research
question
hypothesi
hypothesi
aap
treatment
resist
starch
result
measur
differ
gut
microbiota
composit
clinic
popul
studi
design
comparison
microbi
commun
structur
stool
collect
aap
treat
particip
method
stool
particip
seriou
mental
ill
subject
sequenc
group
divers
measur
perform
permanova
invers
simposon
divers
index
respect
differenti
abund
organ
detect
use
linear
discrimin
analysi
effect
size
anthropometr
measur
diet
endotheli
function
measur
day
rs
result
recruit
particip
male
age
mean
receiv
aap
studi
signific
separ
microbiota
commun
detect
baselin
user
show
increas
fraction
represent
alistip
femal
exhibit
decreas
divers
compar
femal
respons
rs
vari
among
particip
increas
abund
actinobacteria
phylum
observ
respons
rs
conclus
data
suggest
aap
treatment
associ
specif
represent
gut
microbiota
patient
decreas
speci
rich
femal
patient
cohort
exhibit
variabl
respons
rs
supplement
signific
increas
starch
degrad
aripiprazol
lauroxil
nanocryst
dispers
potenti
initi
regimen
aripiprazol
lauroxil
angela
wehr
david
wall
marji
hard
yangchun
du
peter
weiden
lisa
von
moltk
waltham
network
garden
grove
ca
present
societi
biolog
psychiatri
annual
meet
may
new
york
citi
ny
usa
present
may
effect
parent
psychiatr
stress
child
oud
develop
young
adulthood
christoph
lafratt
bsp
jessica
hu
maureen
reynold
levent
kirisci
pharmaci
univers
pittsburgh
pittsburgh
pa
pittsburgh
pittsburgh
pa
present
univers
pittsburgh
depart
psychiatri
research
day
pittsburgh
pennsylvania
june
suicid
prevent
train
student
pharmacist
nathan
painter
pharmd
cde
faad
grace
kuo
pharmd
mph
kelli
lee
pharmd
ma
bcpp
school
pharmaci
pharmaceut
scienc
univers
california
san
diego
la
jolla
ca
la
jolla
ca
school
pharmaci
pharmaceut
scienc
univers
california
san
diego
la
jolla
ca
introduct
suicid
us
major
prevent
public
health
problem
pharmacist
need
educ
suicid
prevent
strategi
increas
awar
identifi
patient
train
program
student
pharmacist
use
improv
recognit
crisi
warn
sign
suicid
research
question
hypothesi
effect
suicid
prevent
train
particip
gener
percept
attitud
studi
design
longitudin
prospect
survey
use
evalu
suicid
prevent
train
session
provid
student
pharmacist
method
given
particip
suicid
train
program
descript
statist
use
describ
demograph
attitud
nonparametr
wilcoxon
sign
rank
analys
match
pair
use
compar
attitud
train
regress
analys
conduct
assess
factor
associ
attitud
result
survey
respons
complet
student
pharmacist
averag
age
year
rang
male
asian
regard
suicid
prevent
greater
respond
felt
somewhat
extrem
confid
identifi
sign
suicid
listen
without
judgement
provid
resourc
suicid
prevent
decid
whether
medic
intervent
necessari
overal
mean
score
attitud
updat
knowledg
suicid
prevent
train
p
respect
overal
mean
score
attitud
make
appropri
intervent
suicid
prevent
train
p
respect
regress
analys
show
sever
demograph
factor
statist
significantli
associ
attitud
conclus
train
program
help
student
pharmacist
build
confid
sever
area
improv
attitud
suicid
prevent
evalu
metabol
risk
manag
pharmacist
inpati
behavior
health
unit
shedrick
martin
pharmd
kimberli
tallian
pharmd
bcpp
fashp
fccp
fcshp
harmind
sikand
pharmd
fccp
fashp
depart
pharmaci
scripp
merci
hospit
san
diego
ca
introduct
mental
health
patient
prescrib
antipsychot
high
risk
metabol
syndrom
lead
cardiovascular
diseas
death
inconsist
monitor
treatment
metabol
condit
complic
prognosi
research
question
hypothesi
pharmacist
metabol
monitor
lead
increas
identif
metabol
risk
patient
prescrib
antipsychot
studi
design
singl
institut
singl
arm
concurr
intervent
retrospect
analysi
method
patient
novemb
februari
admit
behavior
health
unit
bhu
includ
inclus
criteria
age
prescrib
antipsychot
histori
psychiatr
disord
length
stay
day
exclus
criteria
refus
laboratori
draw
unschedul
antipsychot
patient
evalu
pharmacist
base
presenc
fast
lipid
panel
hemoglobin
within
month
valu
unavail
pharmacist
order
recommend
lab
goal
metabol
laboratori
paramet
defin
triglycerid
hemoglobin
valu
meet
goal
paramet
trigger
pharmacist
notifi
physician
initi
optim
therapi
primari
end
point
number
identifi
intervent
opportun
secondari
endpoint
includ
cm
regulatori
adher
number
intervent
accept
physician
result
total
patient
enrol
met
inclus
criteria
patient
primarili
caucasian
age
year
prescrib
least
one
antipsychot
approxim
opportun
interven
identifi
abnorm
laboratori
measur
includ
triglycerid
hemoglobin
physician
interven
contact
interven
patient
laboratori
measur
goal
approxim
pharmacist
recommend
accept
physician
pharmacist
intervent
led
cm
regulatori
adher
identifi
patient
requir
intervent
decreas
unmanag
patient
conclus
pharmacist
initi
metabol
monitor
effect
identifi
opportun
interven
metabol
abnorm
hospit
set
patient
take
antipsychot
optim
therapi
evalu
risk
vs
benefit
concomit
use
budesonid
nebul
system
corticosteroid
copd
exacerb
joseph
hill
pharmd
candid
jon
p
wietholt
pharmd
virginia
univers
school
pharmaci
morgantown
wv
clinic
pharmaci
west
virginia
univers
school
pharmaci
morgantown
wv
introduct
system
corticosteroid
recommend
treatment
chronic
obstruct
pulmonari
diseas
copd
exacerb
studi
suggest
nebul
budesonid
may
equival
system
corticosteroid
copd
exacerb
date
data
benefit
risk
concomit
nebul
system
corticosteroid
copd
exacerb
exist
research
question
hypothesi
concomit
budesonid
nebul
system
corticosteroid
decreas
length
stay
copd
exacerb
studi
design
retrospect
chart
review
studi
evalu
patient
admit
wvu
medicin
septemb
juli
copd
exacerb
receiv
system
corticosteroid
plu
minu
nebul
budesonid
method
patient
includ
copd
exacerb
classifi
via
andor
code
b
receiv
system
corticosteroid
mg
prednison
equival
per
day
hour
upon
admiss
c
receiv
nebul
budesonid
hour
budesonid
arm
exclus
criteria
includ
asthma
activ
cancer
immunosuppress
system
corticosteroid
within
week
activ
fungal
infect
primari
outcom
compar
length
stay
group
receiv
nebul
budesonid
nt
secondari
outcom
compar
advers
effect
rate
group
http
graphpadcom
use
calcul
statist
data
signific
defin
p
result
patient
chart
review
patient
includ
budesonid
group
group
regard
primari
outcom
length
stay
averag
day
p
budesonid
arm
respect
regard
secondari
outcom
hyperglycem
event
occur
significantli
frequent
budesonid
group
vs
p
number
thrush
diagnos
significantli
differ
vs
p
conclus
give
nebul
budesonid
addit
system
corticosteroid
copd
exacerb
decreas
hospit
length
stay
significantli
increas
risk
hyperglycem
event
chronic
obstruct
pulmonari
diseas
exacerb
studi
jessica
spiteri
bsc
pharm
sci
hon
louis
grech
bpharm
hon
mphil
phd
stephen
montefort
md
phd
ston
frcp
lond
frcp
edin
frcp
gla
facp
fefim
lilian
azzopardi
bpharm
hon
mphil
phd
mrpharm
ffip
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
medicin
mater
dei
hospit
msida
malta
pharmaci
univers
malta
msida
malta
introduct
health
care
resourc
utilis
data
chronic
obstruct
pulmonari
diseas
copd
hospitalis
use
drive
introduct
muscarin
antagonist
lama
local
formulari
research
question
hypothesi
studi
aim
identifi
copd
exacerb
lead
hospitalis
result
cost
studi
design
observ
carri
mater
dei
hospit
hospitalis
defin
admiss
medic
ward
intens
therapi
unit
itu
method
data
collect
proforma
design
valid
includ
data
pertain
patient
demograph
clinic
variabl
use
hospit
resourc
hospit
admiss
screen
flag
copd
exacerb
note
exclus
criteria
includ
presenc
consolid
chest
instanc
diagnosi
discharg
letter
differ
initi
diagnosi
copd
exacerb
clinic
data
obtain
patient
file
whilst
econom
data
obtain
hospit
administr
financ
depart
cost
estim
use
cost
approach
comput
result
total
copd
hospitalis
met
studi
inclus
criteria
lama
therapi
indic
low
number
patient
optimum
therapi
length
hospit
stay
rang
day
median
day
nine
patient
requir
ventil
patient
requir
itu
admiss
length
hospit
stay
show
significantli
posit
correl
number
comorbid
score
respect
pearson
correl
estim
total
cost
copd
hospitalis
amount
conclus
cost
estim
copd
hospitalis
give
opportun
measur
impact
healthcar
resourc
use
health
care
may
use
inform
carri
analysi
widespread
local
lama
use
room
temperatur
stabil
aerosol
character
revefenacin
inhal
solut
novel
muscarin
antagonist
nebul
edmund
moran
phd
vijay
sabesan
ms
jame
wertman
ms
kenley
ngim
phd
therav
biopharma
us
inc
south
san
francisco
ca
introduct
phase
trial
establish
efficaci
safeti
revefenacin
inhal
solut
rev
administ
via
standard
jet
nebul
jn
patient
moder
sever
copd
research
question
hypothesi
studi
evalu
room
temperatur
rt
stabil
aerosol
character
rev
use
standard
jn
studi
design
stabil
studi
conduct
rev
ml
ml
strength
batch
rel
humid
rh
month
rh
condit
month
method
aerosol
character
two
jn
pari
lc
plu
pari
lc
sprint
util
assess
rev
compar
publish
data
similarli
formul
commerci
product
brovana
arformoterol
tartrat
perforomist
formoterol
fumar
indic
use
standard
jn
deliv
dose
dd
fine
particl
fraction
fpf
rev
measur
ml
ml
strength
result
rev
attribut
demonstr
stabil
least
month
rt
storag
condit
store
foil
pouch
least
day
remov
foil
pouch
rev
aerosol
perform
data
dd
fpf
two
jn
test
consist
two
establish
commerci
bronchodil
product
within
nebul
perform
rang
observ
independ
studi
use
pari
lc
sprint
nebul
connect
pari
trek
compressor
breath
simul
vitro
condit
mean
dd
mouthpiec
approxim
label
claim
mean
nebul
time
minut
conclus
rev
demonstr
stabil
rt
least
month
show
aerosol
perform
characterist
demonstr
rev
suitabl
administr
use
standard
jet
nebul
qualiti
assess
youtub
video
guid
respimat
soft
misttm
inhal
techniqu
sarah
eudaley
pharmd
bcp
shelbi
brook
pharmd
candid
hannah
rovin
pharmd
candid
shaunta
chamberlin
pharmd
bcp
clinic
pharmaci
translat
scienc
univers
tennesse
health
scienc
center
colleg
pharmaci
knoxvil
tn
famili
medicin
univers
tennesse
graduat
school
medicin
knoxvil
tn
introduct
respimat
soft
mist
inhal
deliveri
devic
four
inhal
us
market
use
treat
asthmacopd
although
widespread
access
internet
conveni
avail
materi
may
lead
patient
inaccur
inform
therefor
import
assess
qualiti
accuraci
onlin
inform
research
question
hypothesi
assess
qualiti
accuraci
respimat
soft
mist
inhal
youtub
video
studi
design
youtub
queri
may
use
search
term
respimat
inhal
descript
statist
use
data
analysi
method
first
video
return
english
demonstr
instruct
use
evalu
use
publish
valid
rate
scale
assess
technic
qualiti
content
assess
use
inform
provid
manufacturerpackag
insert
result
video
profession
organ
intend
layperson
seventi
percent
adequ
qualiti
video
evalu
includ
step
use
includ
prepar
first
time
use
prime
daili
use
step
prepar
first
time
use
includ
video
record
discard
date
commonli
omit
forti
percent
includ
step
prime
commonli
omit
step
repeat
spray
visibl
includ
step
daili
use
commonli
omit
step
includ
remov
inhal
breath
hold
breath
away
mouthpiec
note
includ
instruct
point
inhal
back
throat
conclus
proper
inhal
techniqu
crucial
patient
achiev
optim
result
inhal
medic
mani
video
wide
avail
demonstr
respimat
inhal
techniqu
omit
key
step
proper
use
therefor
thorough
repetit
patient
educ
provid
addit
reput
vet
sourc
ensur
onlin
consum
gain
accur
inform
associ
comorbid
cancer
use
thrombolysi
acut
pulmonari
embol
kevin
hakamiun
pharmd
candid
hannah
leschorn
pharmd
candid
sofia
butt
pharmd
candid
emmelin
tran
pharmd
erin
weeda
pharmd
bcp
medic
univers
south
carolina
charleston
sc
introduct
approxim
patient
present
venou
thromboembol
cancer
thrombolysi
treatment
option
pulmonari
embol
pe
patient
hypotens
howev
patient
cancer
may
increas
risk
bleed
littl
known
use
thrombolysi
patient
research
question
hypothesi
evalu
relationship
comorbid
cancer
use
thrombolysi
acut
pe
treatment
studi
design
retrospect
cohort
studi
util
administr
data
method
unit
state
nation
inpati
sampl
use
identifi
adult
patient
hospit
acut
pe
identifi
admiss
stratifi
base
presenc
absenc
comorbid
cancer
multivari
logist
regress
perform
determin
associ
comorbid
cancer
odd
receiv
thrombolysi
adjust
covari
associ
comorbid
cancer
odd
mortal
adjust
year
sex
receiv
thrombolysi
also
determin
result
identifi
admiss
acut
pe
comorbid
cancer
total
patient
receiv
thrombolysi
upon
multivari
adjust
comorbid
cancer
associ
decreas
odd
receiv
thrombolysi
adjust
odd
ratio
aor
confid
interv
ci
mortal
occur
patient
receiv
thrombolysi
differ
versu
without
comorbid
cancer
conclus
comorbid
cancer
associ
decreas
odd
receiv
thrombolysi
acut
pe
pe
common
complic
among
patient
cancer
clinic
data
set
use
character
use
thrombolysi
patient
popul
characterist
adult
patient
persist
asthma
frequent
refil
inhal
catherin
rigg
pharmd
bcacp
bruce
bender
glenn
goodrich
courtney
anderson
susan
shetterli
marsha
raebel
permanent
colorado
aurora
co
pediatr
behavior
health
nation
jewish
health
denver
co
health
research
kaiser
permanent
colorado
aurora
co
introduct
overus
associ
increas
asthma
exacerb
identifi
characterist
associ
overus
inform
asthma
manag
research
question
hypothesi
adult
patient
persist
asthma
frequent
refil
inhal
differ
adult
patient
persist
asthma
refil
less
frequent
studi
design
investig
part
pragmat
random
trial
conduct
kaiser
permanent
colorado
integr
care
deliveri
system
provid
medic
care
approxim
patient
metropolitan
area
method
studi
includ
patient
age
persist
asthma
without
copd
compar
patient
overfil
fill
frequent
everi
day
studi
period
overfil
time
continu
data
analyz
use
test
categor
data
analyz
use
test
result
studi
includ
patient
patient
characterist
associ
overfil
includ
younger
age
p
hispan
ethnic
p
current
smoke
p
less
high
school
educ
p
lower
median
incom
p
patient
overfil
lower
ratio
asthma
control
medic
total
asthma
reliev
plu
asthma
control
medic
asthma
medic
ratio
amr
p
less
asthma
defin
fill
corticosteroid
burst
p
p
er
visit
p
asthma
conclus
overfil
higher
among
patient
younger
hispan
smoker
lower
socioeconom
statu
patient
overfil
lower
amr
higher
amr
associ
better
asthma
outcom
patient
overfil
also
corticosteroid
burst
er
util
asthma
taken
togeth
result
suggest
opportun
improv
asthma
control
among
patient
overfil
beta
agonist
assess
spacer
action
plan
usag
asthma
manag
bustamant
hospit
children
amanda
daley
lisa
bromfield
bustamant
hospit
children
kingston
jamaica
pharmaci
univers
technolog
jamaica
kingston
jamaica
introduct
use
spacer
meter
dose
inhal
mdi
written
asthma
action
plan
consid
import
tool
effect
manag
asthma
children
signific
portion
caregiv
ie
particip
inappropri
manag
asthma
exacerb
children
clayton
et
al
research
assess
extent
spacer
preval
asthma
action
plan
usag
asthma
manag
bustamant
hospit
children
bhc
research
question
hypothesi
percentag
asthmat
children
util
spacer
mdi
preval
use
written
asthma
action
plan
bhc
studi
design
prospect
studi
conduct
use
purpos
sampl
method
particip
includ
caregiv
children
asthma
bhc
medic
clinic
physician
inform
consent
obtain
questionnair
interview
use
collect
data
confidenti
room
period
june
august
quantit
qualit
data
analyz
use
spss
version
softwar
result
find
show
spacer
use
least
time
caregiv
alway
use
major
caregiv
demonstr
requir
step
proper
inhal
techniqu
averag
number
caregiv
own
asthma
action
plan
use
low
tool
view
posit
physician
perceiv
use
spacer
asthma
action
plan
import
benefici
manag
asthma
children
conclus
use
spacer
among
caregiv
children
asthma
bhc
medic
clinic
high
howev
complianc
use
low
number
caregiv
own
asthma
action
plan
averag
complianc
use
low
cannabi
product
prefer
indic
among
medic
user
scott
coon
kim
hoffman
javier
ponc
terashima
john
muench
md
denni
mccarti
practic
st
loui
colleg
pharmaci
st
loui
mo
public
health
oregon
health
scienc
univers
portland
psychiatri
univers
hospit
cleveland
medic
center
case
western
reserv
univers
cleveland
oh
famili
medicin
oregon
health
scienc
univers
portland
introduct
cannabi
use
approv
medic
recreat
use
seven
state
district
columbia
oregon
preval
cannabi
use
increas
despit
increas
widespread
cannabi
use
littl
data
exist
help
understand
patient
use
cannabi
factor
guid
product
select
therefor
sought
captur
basic
product
inform
factor
affect
product
select
research
question
hypothesi
patient
use
varieti
cannabi
product
select
influenc
characterist
studi
design
survey
focu
group
method
survey
administ
use
redcap
particip
urban
feder
qualifi
health
center
oregon
follow
consent
particip
work
questionnair
independ
follow
structur
interview
surveyor
descript
statist
calcul
use
excel
result
particip
respons
rate
averag
year
old
caucasian
low
incom
identifi
cisfemal
use
cannabi
daili
cannabi
product
vari
inhal
edibl
concentr
topic
cartridg
drink
rectal
vagin
among
respond
consid
tetrahydrocannabinol
thc
cannabidiol
cbd
content
product
state
product
dose
prefer
chang
base
indic
use
slider
likert
scale
contain
littl
contain
great
deal
particip
prefer
product
higher
cbd
content
median
thc
median
indic
vari
pain
relax
anxieti
recreat
nausea
legal
consequ
use
advers
emot
physic
health
effect
infrequ
conclus
within
sampl
particip
use
varieti
cannabi
product
select
vari
base
content
indic
reason
use
commonli
medic
infrequ
advers
effect
trend
commonli
abus
medic
return
drug
enforc
agenc
day
megan
ritter
pharm
candid
anna
wyatt
pharm
candid
kayc
sheali
pharmd
bcp
bcacp
presbyterian
colleg
school
pharmaci
clinton
sc
introduct
medic
abus
misus
grow
problem
unit
state
recent
deem
nation
epidem
abus
misus
medic
obtain
famili
friend
home
proper
dispos
may
reduc
medic
avail
misus
abus
research
question
hypothesi
studi
sought
look
rate
return
well
trend
return
potenti
abus
medic
studi
design
retrospect
studi
method
school
pharmaci
partner
local
law
enforc
rural
south
carolina
town
host
day
data
collect
return
item
includ
activ
ingredi
estim
quantiti
prescript
fill
date
avail
medic
classifi
therapeut
class
identifi
drug
potenti
abus
accord
nida
classif
descript
statist
use
analyz
data
collect
result
differ
medic
return
potenti
drug
abus
year
return
medic
potenti
drug
abus
return
medic
potenti
abus
drug
opioid
analges
commonli
potenti
abus
medic
return
account
medic
return
respect
commonli
return
medic
benzodiazepin
return
hypnot
medic
increas
studi
period
return
medic
loperamid
dextromethorphan
vari
studi
period
conclus
rate
potenti
abus
medic
return
steadili
rose
period
studi
heighten
awar
increas
opportun
proper
dispos
includ
placement
perman
drug
dispos
locat
may
account
decreas
number
prescript
return
follow
assess
naloxon
stock
statu
georgia
retail
pharmaci
rebecca
stone
pharmd
bcacp
bcp
stella
hur
pharmd
henri
young
clinic
administr
pharmaci
univers
georgia
colleg
pharmaci
athen
ga
pharmaci
univers
georgia
athen
ga
introduct
opioid
epidem
impact
mani
commun
across
nation
rural
commun
especi
hard
hit
naloxon
lifesav
medic
patient
support
network
may
purchas
hand
event
opioid
overdos
howev
less
known
avail
medic
across
differ
commun
research
question
hypothesi
avail
naloxon
georgia
retail
pharmaci
differ
naloxon
avail
georgia
retail
pharmaci
depend
upon
locat
pharmaci
type
studi
design
survey
method
list
georgia
retail
pharmaci
obtain
randomli
select
stratifi
across
nation
center
health
statist
code
metropolitan
vs
nonmetropolitan
type
independ
vs
chain
research
assist
call
pharmaci
assess
stock
statu
naloxon
descript
statist
analys
conduct
use
spss
result
pharmaci
call
particip
one
hundr
one
pharmacist
report
naloxon
current
stock
differ
stock
frequenc
compar
pharmaci
locat
metropolitan
nonmetropolitan
area
vs
independ
pharmaci
less
like
naloxon
stock
compar
chain
pharmaci
vs
conclus
patient
georgia
face
barrier
access
potenti
lifesav
medic
naloxon
major
retail
pharmaci
naloxon
stock
naloxon
avail
vari
geograph
region
howev
vari
pharmaci
type
addit
strategi
need
increas
access
naloxon
effort
combat
opioid
epidem
methadon
use
adher
inpati
protocol
order
approv
process
kristen
nelson
tran
tran
pharmd
bcp
melissa
kocek
rush
univers
medic
center
chicago
il
pharmaci
midwestern
univers
downer
grove
il
univers
medic
center
chicago
il
introduct
methadon
prescrib
permit
acut
withdraw
establish
opioid
replac
therapi
inpati
set
dea
allow
methadon
use
treatment
mainten
acut
withdraw
provid
permit
continu
methadon
unlimit
number
day
patient
activ
enrol
methadon
mainten
program
mmp
hospit
admiss
reason
detoxif
provid
permit
order
methadon
treatment
pain
without
restrict
order
must
includ
indic
use
pain
control
opioid
withdraw
opioid
depend
detoxif
research
question
hypothesi
current
methadon
order
practic
adher
inpati
protocol
approv
indic
initi
continu
mmp
treatment
larg
academ
medic
center
studi
design
retrospect
chart
review
order
place
januari
decemb
methadon
administr
document
electron
medic
record
method
sixti
patient
receiv
least
one
dose
methadon
admit
emerg
depart
inpati
unit
data
collect
complianc
hospit
protocol
acut
withdraw
palliativepain
methadon
indic
dose
durat
provid
verifi
mmp
enrol
dose
psychiatri
approv
methadon
prescript
written
discharg
pharmaci
document
initi
methadon
dose
result
percent
methadon
order
pain
opioid
depend
patient
prior
enrol
mmp
acut
withdraw
prior
mmp
order
inappropri
primarili
occur
weekend
overnight
hour
patient
without
prior
establish
mmp
complianc
hospit
protocol
psychiatri
approv
document
within
maximum
dose
allow
conclus
studi
hospit
methadon
prescrib
demonstr
high
adher
current
methadon
protocol
major
inpati
hospit
polici
improv
address
methadon
order
instruct
weekend
overnight
evalu
brief
alcohol
withdraw
scale
protocol
academ
medic
center
brian
lindner
rachel
kruer
vi
gilmor
sam
young
rn
dariu
rastegar
anika
alvanso
md
edward
chen
timothi
niessen
md
keisha
perrin
bsn
paula
murray
rn
andrew
jarrel
pharmaci
john
hopkin
hospit
baltimor
md
pharmaci
john
hopkin
hospit
balitmor
md
surgeri
john
hopkin
hospit
baltimor
md
chemic
depend
john
hopkin
bayview
medic
center
baltimor
md
pulmonari
critic
care
medicin
john
hopkin
hospit
baltimor
md
gener
intern
medicin
john
hopkin
hospit
baltimor
md
medicin
john
hopkin
hospit
baltimor
md
introduct
standard
care
treatment
alcohol
withdraw
dose
benzodiazepin
use
withdraw
scale
commonli
clinic
institut
withdraw
assess
alcohol
revis
scale
shorter
object
scale
desir
brief
alcohol
withdraw
scale
baw
treatment
protocol
develop
implement
institut
research
question
hypothesi
evalu
use
efficaci
safeti
baw
protocol
among
inpati
john
hopkin
hospit
studi
design
singl
center
retrospect
observ
cohort
studi
august
juli
method
benzodiazepin
use
time
protocol
withdraw
sever
agit
delirium
assess
among
patient
protocol
comparison
conduct
patient
medicin
vs
surgic
servic
intens
care
unit
icu
vs
sever
withdraw
vs
withdraw
final
use
adjunct
treatment
symptom
manag
assess
result
patient
includ
patient
receiv
median
iqr
lorazepam
equival
le
protocol
baw
protocol
hour
patient
receiv
benzodiazepin
baw
protocol
median
iqr
le
given
seventeen
patient
sever
withdraw
day
agit
delirium
minim
median
iqr
day
rass
posit
day
rass
patient
receiv
adjunct
medic
symptom
manag
icu
patient
sever
withdraw
patient
receiv
cumul
benzodiazepin
dose
patient
conclus
patient
baw
protocol
receiv
littl
benzodiazepin
sever
withdraw
agit
delirium
uncommon
find
support
baw
reason
alcohol
withdraw
scale
protocol
use
across
varieti
patient
popul
inpati
manag
individu
activ
intraven
heroin
abus
commun
teach
hospit
dian
rudi
christin
hambi
nagesh
jadhav
pharmaci
rochest
gener
hospit
rochest
ny
medicin
rochest
gener
hospit
rochest
ny
introduct
patient
activ
heroin
abus
often
experi
withdraw
symptom
hospit
may
leav
hospit
medic
advic
ama
object
qualiti
improv
project
determin
medic
util
manag
withdraw
symptom
patient
hospit
research
question
hypothesi
patient
heroin
abus
manag
appropri
medic
studi
design
retrospect
method
analysi
retrospect
chart
review
patient
identifi
report
individu
admit
histori
substanc
abus
januari
juli
patient
select
inclus
least
year
age
activ
use
iv
heroin
time
admiss
admit
treatment
medic
ill
opioid
overdos
exclus
patient
admit
observ
elect
surgeri
psychiatri
servic
treat
buprenorphin
methadon
time
admiss
data
collect
electron
medic
record
analyz
use
descript
statist
result
common
medic
use
opioid
benzodiazepin
drug
less
frequent
medic
hydroxyzin
trazodon
gabapentin
clonidin
methadon
suboxon
mean
length
stay
day
patient
left
ama
ama
rate
statist
differ
depend
medic
use
readmiss
rate
significantli
lower
substanc
abus
counsel
offer
compar
offer
vs
illicit
drug
use
admiss
confirm
patient
conclus
illicit
drug
use
admiss
ama
discharg
readmiss
common
patient
popul
opioid
benzodiazepin
frequent
use
hospit
medic
optim
patient
activ
heroin
abus
data
underscor
need
educ
awar
treatment
option
predictor
hospit
readmiss
patient
opioid
use
disord
administ
opioid
initi
hospit
jessica
moreno
matthew
duprey
sarah
wakeman
md
russel
robert
jare
jacobson
john
devlin
health
system
royal
oak
mi
pharmaci
northeastern
univers
boston
gener
hospit
boston
gener
hosptal
boston
health
scienc
northeastern
univers
boston
univers
school
pharmaci
boston
introduct
patient
opioid
use
disord
oud
increasingli
admit
acut
care
hospit
preval
hospit
readmiss
oud
patient
factor
influenc
hospit
readmiss
unknown
research
question
hypothesi
identifi
incid
characterist
predictor
readmiss
patient
oud
administ
hour
opioid
hospit
studi
design
prospect
cohort
studi
method
retrospect
cohort
studi
evalu
consecut
adult
admit
academ
medic
center
oud
admit
year
period
januari
decemb
administ
opioid
hour
admiss
pertin
admiss
hospit
discharg
variabl
collect
compar
patient
readmit
readmit
within
discharg
includ
multivari
logist
regress
model
p
result
among
adult
year
histori
heroin
use
admiss
opioid
agonist
therapi
oat
use
buprenorphin
methadon
medic
vs
surgic
floor
vs
icu
readmit
within
respect
among
readmit
patient
median
time
first
readmiss
day
buprenorphin
use
vs
use
index
hospit
admiss
independ
associ
reduc
ci
ci
readmiss
prior
heroin
vs
prescript
opioid
use
associ
reduc
readmiss
ci
durat
hospit
stay
associ
greater
ci
ci
readmiss
conclus
among
patient
oud
take
buprenorphin
time
hospit
admiss
hospit
readmiss
reduc
respect
impact
transplant
pharmacist
length
stay
hospit
readmiss
retrospect
cohort
studi
razan
alsheikh
pharmd
kati
johnson
pharmd
bcp
ashle
dauenhauer
pharmd
pradeep
kadambi
md
mba
fasn
arizona
tucson
az
univers
medic
center
tucson
az
florida
jacksonvil
fl
introduct
transplant
pharmacist
recogn
integr
part
transplant
team
mani
govern
profession
organ
littl
known
impact
transplant
pharmaci
servic
outcom
transplant
patient
research
question
hypothesi
transplant
pharmaci
servic
provid
center
accord
center
medicar
medicaid
cm
expect
affect
length
stay
lo
transplant
surgeri
caus
hospit
readmiss
kidney
transplant
patient
studi
design
retrospect
cohort
analysi
method
data
collect
two
phase
phase
pharmacist
transplant
pharmacist
servic
includ
patient
transplant
phase
ii
pharmacist
includ
patient
transplant
year
receiv
kidney
transplant
center
steroid
tacrolimu
mycophenol
mainten
includ
transplant
pharmaci
servic
provid
follow
expect
cm
transplant
center
primari
outcom
lo
transplant
surgeri
caus
hospit
readmiss
secondari
outcom
includ
number
discharg
pharmaci
note
achiev
therapeut
level
tacrolimu
day
unpair
use
continu
variabl
fisher
exact
test
test
use
categor
data
data
analysi
perform
use
spss
ibm
corp
result
two
group
phase
phase
ii
similar
demograph
transplant
characterist
baselin
lo
shorter
rate
hospit
readmiss
lower
phase
ii
howev
nt
reach
statist
signific
respect
signific
differ
number
discharg
pharmaci
note
signific
differ
tacrolimu
level
day
mean
phase
ngml
phase
ii
conclus
trend
shorter
hospit
lo
lower
readmiss
rate
pharmacist
cohort
reach
statist
signific
result
investig
larger
random
cohort
clinic
respons
salvag
bortezomib
therapi
antibodi
mediat
reject
mix
acut
reject
high
immunolog
risk
renal
transplant
popul
hannah
underwood
alicia
lichvar
pharmd
jami
benken
pharmd
zahraa
hajjiri
enrico
benedetti
pharmaci
univers
illinoi
chicago
chicago
il
pharmaci
practic
univers
illinoi
hospit
health
scienc
system
chicago
il
illinoi
hospit
health
scienc
system
chicago
il
surgeri
univers
illinoi
hospit
health
scienc
system
chicago
il
introduct
regimen
treat
antibodi
mediat
reject
amr
mix
acut
reject
mar
due
elimin
donor
specif
antibodi
dsa
agent
use
set
salvag
therapi
tradit
treatment
modal
fail
achiev
desir
clinic
respons
impact
strategi
unknown
research
question
hypothesi
salvag
therapi
high
risk
patient
amr
mar
result
clinic
signific
decreas
serum
creatinin
antibodi
level
studi
design
singl
center
retrospect
cohort
studi
method
high
immunolog
risk
renal
transplant
rtx
recipi
experienc
amr
mar
treat
salvag
bortezomib
regimen
assess
salvag
therapi
introduc
primari
therapi
plasmapheresisivig
deem
ineffect
transplant
team
banff
criteria
util
diagnos
amr
acr
mar
defin
acr
amr
concurr
primari
outcom
incid
patient
achiev
greater
reduct
serum
creatinin
scr
day
initi
result
total
rtx
patient
analyz
follow
median
iqr
day
bortezomib
treatment
major
patient
femal
african
american
rtx
dsa
occur
recipi
posit
flow
time
rtx
major
patient
experienc
greater
reduct
scr
patient
experienc
greater
reduct
immunodomin
dsa
four
patient
experienc
graft
loss
iqr
day
bortezomib
therapi
conclus
introduct
bortezomib
reduct
scr
dsa
major
patient
salvag
bortezomib
therapeut
option
refractori
amr
mar
high
immunolog
risk
popul
part
treatment
regimen
develop
de
novo
donor
specif
antibodi
antithymocyt
globulin
induct
kidney
transplant
oxana
megherea
yohanka
elis
caro
pharmd
candid
nicol
sifonti
pharmd
fccp
adam
diamond
pharmd
univers
school
pharmaci
philadelphia
pa
pharmaci
practic
templ
univers
school
pharmaci
philadelphia
pa
univers
health
system
philadelphia
pa
introduct
advanc
immunosuppress
therapi
consider
improv
incid
one
year
graft
patient
surviv
solid
organ
transplant
howev
develop
de
novo
donor
specif
antibodi
dndsa
associ
antibodi
mediat
reject
wors
graft
outcom
identif
risk
factor
develop
dndsa
may
help
preserv
graft
function
improv
outcom
research
question
hypothesi
determin
clinic
signific
dndsa
kidney
transplant
kt
patient
receiv
ratg
induct
studi
design
retrospect
chart
review
method
patient
receiv
kt
institut
jan
june
sixti
eight
met
inclus
criteria
primari
outcom
incid
dndsa
month
secondari
outcom
includ
dndsa
classif
time
develop
dndsa
incid
graft
patient
surviv
month
result
develop
dndsa
occur
patient
median
time
dndsa
develop
day
b
dr
dq
dp
respect
higher
rate
reject
identifi
develop
dndsa
tabl
multivari
analysi
identifi
independ
predictor
develop
dndsa
tabl
conclus
find
suggest
higher
rate
reject
observ
patient
develop
dndsa
common
type
dsa
develop
hla
dq
antibodi
continu
determin
independ
predictor
develop
dndsa
cohort
evalu
renal
bone
safeti
post
liver
transplant
patient
chronic
kidney
diseas
receiv
tenofovir
alafenamid
hbv
prophylaxi
edward
gane
georg
bibin
stephen
munn
john
flaherti
eunyoung
lee
suri
vithika
hongyuan
wang
anuj
gaggar
medicin
univers
auckland
auckland
new
zealand
auckland
citi
hospit
auckland
new
zealand
zealand
liver
transplant
unit
nzltu
auckland
new
zealand
scienc
foster
citi
ca
scienc
foster
citi
ca
publish
journal
hepatolog
chang
trend
first
transplant
pharmacist
job
barrett
crowther
pharmd
christina
doligalski
nicol
alvey
karen
khalil
erik
henricksen
jame
fleme
health
system
san
antonio
tx
pharmaci
univers
north
carolina
health
chapel
hill
nc
univers
hospit
chicago
il
pharmaci
univers
illinoi
hospit
health
scienc
system
chicago
il
california
san
francisco
san
francisco
ca
pharmaci
servic
medic
univers
south
carolina
charleston
sc
introduct
train
program
transplant
sot
pharmaci
increas
year
sought
evalu
chang
job
market
order
maxim
traine
competit
research
question
hypothesi
job
market
chang
sot
pharmacist
enter
workforc
studi
design
analysi
survey
develop
iter
process
assess
pharmacist
first
job
relat
sot
method
survey
irb
approv
sent
via
email
member
two
transplant
pharmacist
societi
record
via
redcap
analyz
data
use
standard
descript
statist
methodolog
use
microsoft
excel
spss
result
receiv
uniqu
respons
year
first
job
rang
first
job
report
past
year
job
taken
sinc
complet
sot
compar
took
job
recent
job
also
respond
train
vs
sinc
pharmacist
less
like
highest
level
formal
train
vs
posit
taken
pharmacist
train
vs
sinc
posit
taken
differ
earlier
era
follow
way
ambulatori
compon
vs
includ
coverag
cardiothorac
transplant
vs
medic
order
entri
job
respons
vs
job
job
compar
respect
sinc
conclus
present
descript
result
survey
identifi
evolv
trend
sot
pharmacist
job
continu
assess
trend
help
us
identifi
chang
need
educ
curriculum
best
prepar
learner
field
grow
need
lung
transplant
cystic
fibrosi
face
multidrug
resist
organ
ryan
winstead
rickey
evan
pharmd
bcp
georgina
waldman
elizabeth
autri
aric
schadler
lindsey
kay
pharmd
maher
baz
michael
anstead
alexi
shafii
megan
goetz
kentucki
healthcar
lexington
ky
south
carolina
colleg
pharmaci
columbia
sc
california
san
diego
health
san
diego
ca
kentucki
colleg
pharmaci
lexington
ky
ohio
state
univers
wexner
medic
center
columbu
oh
introduct
sinc
largest
studi
resist
organ
mdro
lung
transplant
cystic
fibrosi
cf
patient
innov
advanc
treatment
pseudomona
spp
studi
hadjiliadi
colleagu
show
patient
harbor
pseudomona
wors
surviv
lung
transplant
object
studi
assess
clinic
outcom
set
new
antimicrobi
treatment
option
strategi
research
question
hypothesi
differ
clinic
outcom
cf
patient
histori
mdro
infect
undergo
lung
transplant
despit
treatment
advanc
antimicrobi
therapi
studi
design
retrospect
cohort
studi
conduct
cf
patient
chronic
infect
mdro
receiv
lung
transplant
januari
august
method
patient
less
suscept
cohort
either
chronic
infect
pseudomona
sensit
two
class
polymyxin
plu
one
remain
patient
suscept
pseudomona
pseudomona
remain
control
cohort
primari
outcom
composit
patient
surviv
retransplant
chronic
lung
allograft
dysfunct
clad
acut
reject
month
categor
variabl
analyz
use
test
independ
sampl
util
continu
variabl
result
signific
differ
primari
outcom
vs
differ
patient
surviv
vs
incid
acut
reject
vs
incid
clad
vs
statist
signific
group
patient
underw
retransplant
polymyxin
aminoglycosid
common
novel
treatment
strategi
pneumonia
follow
conclus
signific
differ
two
cohort
analyz
primari
composit
outcom
individu
compon
futur
direct
includ
expand
addit
studi
site
analyz
outcom
base
upon
choic
treatment
tacrolimu
ratio
kidney
transplant
recipi
relationship
outcom
felicia
bartlett
claric
carthon
pharmd
bcp
jennif
hagopian
pharmd
spenser
januari
timothi
horwedel
pharmd
hospit
saint
loui
mo
pharmaci
hospit
saint
loui
mo
introduct
tacrolimu
calcineurin
inhibitor
choic
kidney
transplant
requir
regular
trough
level
monitor
determin
efficaci
safeti
develop
subset
literatur
util
tacrolimu
cd
ratio
surrog
tacrolimu
metabol
low
cd
ratio
correl
higher
metabol
question
remain
whether
cd
ratio
possibl
better
indic
tacrolimu
exposur
therefor
better
predictor
clinic
outcom
research
question
hypothesi
patient
low
cd
ratio
higher
bpar
rate
inferior
graft
function
surviv
compar
high
cd
ratio
studi
design
retrospect
chart
review
method
adult
receiv
kidney
transplant
januari
august
evalu
inclus
patient
includ
receiv
globulin
induct
mainten
regimen
consist
tacrolimu
immedi
releas
mycophenol
prednisoneth
primari
endpoint
evalu
bpar
year
result
kidney
transplant
recipi
met
inclus
criteria
patient
cluster
high
cd
ratio
mean
cd
patient
cluster
low
cd
ratio
mean
cd
averag
age
cluster
year
compar
year
cluster
p
entir
african
american
popul
studi
cluster
statist
signific
differ
time
point
tacrolimu
dose
requir
achiev
therapeut
trough
bpar
year
statist
signific
cluster
cluster
vs
graft
loss
year
year
year
found
statist
signific
rate
cmv
bk
virus
statist
signific
two
group
time
point
conclus
data
unabl
correl
cd
ratio
differ
clinic
outcom
erythropoiesi
stimul
agent
transplant
hemoglobin
respons
advers
event
calvin
meaney
pharmd
bcp
hayoung
ryu
yen
ngo
ashley
pulka
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
counti
medic
center
buffalo
ny
introduct
use
erythropoiesi
stimul
agent
esa
renal
transplant
complic
variabl
hemoglobin
respons
immunomodulatori
effect
unknown
risk
seriou
advers
event
vulner
popul
research
question
hypothesi
hemoglobin
respons
major
esa
relat
advers
event
renal
transplant
recipi
studi
design
retrospect
match
studi
method
case
esa
use
match
control
esa
use
base
age
gender
transplant
date
patient
year
old
least
month
treat
similar
immunosuppress
protocol
hemoglobin
respons
evalu
use
time
within
therapeut
rang
ttr
number
blood
transfus
mortal
hypertens
cardiovascular
thromboembol
event
assess
statist
analysi
appropri
hypothesi
test
complet
sa
result
patient
case
control
follow
month
demograph
age
year
femal
month
baselin
estim
glomerular
filtrat
rate
case
compar
control
p
type
esa
use
epoetin
alfa
darbepoetin
alfa
agent
ttr
assess
hemoglobin
observ
case
within
therapeut
rang
target
secondari
endpoint
shown
tabl
conclus
respons
esa
post
poor
low
time
therapeut
rang
frequent
blood
transfus
seriou
advers
event
occur
esa
use
find
confound
lower
baselin
renal
function
case
therefor
requir
confirm
guidelin
use
esa
post
need
immunolog
outcom
erythropoiesi
stimul
agent
renal
transplant
recipi
calvin
meaney
pharmd
bcp
yen
ngo
hayoung
ryu
ashley
pulka
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
counti
medic
center
buffalo
ny
introduct
erythropoietin
shown
inhibit
allogen
cell
prolifer
stimul
regulatori
cell
differenti
vitro
clinic
effect
immunomodulatori
properti
unknown
renal
transplant
popul
research
question
hypothesi
exogen
administr
recombin
human
erythropoietin
affect
immun
outcom
follow
renal
transplant
studi
design
retrospect
match
studi
method
case
erythropoiesi
stimul
agent
esa
use
match
control
esa
use
base
age
gender
transplant
date
patient
year
old
least
month
treat
similar
immunosuppress
protocol
allograft
function
time
assess
percentag
chang
estim
glomerular
filtrat
rate
egfr
use
nankivel
equat
immunolog
transplant
outcom
includ
acut
reject
allograft
loss
infect
mortal
statist
analysi
includ
appropri
hypothesi
test
logist
regress
use
sa
result
studi
includ
renal
transplant
recipi
follow
month
receiv
esa
patient
year
old
femal
month
baselin
egfr
case
compar
control
p
chang
allograft
function
studi
period
case
compar
control
mean
differ
confid
interv
p
immunolog
outcom
shown
tabl
conclus
allograft
function
declin
rapidli
among
esa
user
control
frequent
acut
reject
graft
failur
esa
use
cautious
transplant
given
poor
outcom
result
may
bias
due
lower
baselin
renal
function
among
esa
user
although
inher
drug
indic
effect
immun
allosensit
kate
berlin
bs
gregori
press
thoma
elli
mari
hayney
pharmd
wisconsin
madison
school
pharmaci
madison
wi
wisconsin
hospit
clinic
madison
wi
wisconsin
madison
madison
wi
pharmaci
school
medicin
public
health
univers
madison
wi
introduct
effort
made
fulli
immun
patient
wait
solid
organ
transplant
protect
diseas
prior
initi
immunosuppress
therapi
blood
transfus
pregnanc
known
allosensit
event
howev
observ
immun
may
confer
risk
allosensit
predispos
individu
research
question
hypothesi
immun
caus
increas
calcul
panel
reactiv
antibodi
cpra
valu
individu
await
solid
organ
transplant
studi
design
singl
center
prospect
studi
method
serial
serum
sampl
obtain
hla
antibodi
analysi
uw
clinic
laboratori
adult
wait
kidney
pancrea
simultan
kidneypancrea
transplant
cpra
measur
includ
individu
receiv
solid
organ
transplant
blood
transfus
time
exclud
immun
histori
gather
wisconsin
immun
registri
wir
electron
medic
record
statist
analys
perform
pair
cpra
valu
chang
cpra
note
increas
point
eg
result
year
individu
receiv
least
one
immun
influenza
hepb
tdap
chang
cpra
note
receiv
immun
fisher
exact
conclus
studi
particip
signific
increas
cpra
valu
follow
immun
suggest
routin
immun
safe
practic
patient
await
organ
transplant
despit
past
theori
increas
risk
allosensit
azathioprin
compar
mycophenol
prevent
reject
kidney
transplant
jennif
hagopian
pharmd
bcp
timothi
horwedel
pharmd
bcp
claric
carthon
pharmd
bcp
hospit
st
loui
mo
introduct
use
mainten
immunosuppress
kidney
transplant
evolv
time
commonli
consist
combin
calcineurin
inhibitor
antimetabolit
corticosteroid
debat
choic
antimetabolit
often
favor
mycophenol
azathioprin
high
risk
patient
yet
azathioprin
offer
benefit
administr
avail
inexpens
gener
formul
kidney
transplant
center
hospit
preferenti
use
azathioprin
patient
gi
intoler
mycophenol
women
child
bear
age
regardless
reject
risk
research
question
hypothesi
research
aim
show
similar
rate
reject
patient
use
azathioprin
aza
mycophenol
mpa
part
immunosuppress
regimen
studi
design
kidney
transplant
recipi
receiv
kidney
transplant
januari
present
evalu
inclus
patient
includ
receiv
globulin
induct
mainten
regimen
consist
tacrolimu
prednison
either
aza
mpa
method
patient
separ
two
group
base
use
aza
mpa
primari
endpoint
evalu
risk
acut
cellular
reject
result
total
kidney
transplant
recipi
includ
analysi
patient
receiv
aza
compar
mpa
treat
patient
aza
treat
patient
averag
year
old
time
transplant
femal
black
rate
pretranspl
diabet
coronari
arteri
diseas
hypertens
differ
group
primari
endpoint
risk
acut
cellular
reject
differ
azathioprin
versu
mycophenol
treat
patient
hr
risk
reject
increas
black
patient
hr
p
decreas
older
recipi
hr
p
conclus
data
support
use
azathioprin
altern
primari
antimetabolit
choic
kidney
transplant
urinari
tract
infect
kidney
transplant
recipi
incid
suscept
pattern
terri
pak
michael
wynd
pharmaci
memori
cancer
center
new
york
ny
pharmaci
practic
administr
rutger
state
univers
new
jersey
piscataway
nj
introduct
urinari
tract
infect
uti
common
bacteri
infect
kidney
transplant
recipi
ktr
within
first
year
occur
ktr
manag
uti
ktr
challeng
due
immunocompromis
statu
possibl
pathogen
exposur
routin
antimicrobi
prophylaxi
research
question
hypothesi
identifi
incid
uti
ktr
within
first
year
transplant
describ
suscept
pattern
observ
studi
design
retrospect
chart
review
method
electron
medic
record
use
identifi
patient
receiv
kidney
transplant
may
april
adult
ktr
develop
uti
within
first
year
includ
data
collect
patient
demograph
laboratori
data
histori
uti
bladder
dysregul
prior
transplant
nativ
kidney
diseas
immunosuppress
induct
mainten
durat
indwel
urinari
cathet
presenc
ureter
stent
date
uti
suscept
pattern
isol
organ
antimicrobi
prophylaxi
empiricdefinit
antimicrobi
treatment
durat
occurr
delay
graft
function
patient
allograft
outcom
data
analyz
descript
statist
result
fifti
patient
receiv
kidney
transplant
design
time
period
three
patient
exclud
pediatr
recipi
patient
insuffici
data
fifteen
adult
ktr
least
one
uti
episod
common
pathogen
isol
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
suscept
amongst
three
common
pathogen
piperacillintazobactam
nitrofurantoin
ciprofloxacin
ampicillin
sulfamethoxazoletrimethoprim
organ
produc
e
coli
enterobacteriacea
conclus
incid
uti
ktr
within
first
year
consist
publish
literatur
local
suscept
pattern
patient
characterist
help
guid
empir
antibiot
select
patient
popul
time
within
therapeut
rang
comparison
three
tacrolimu
formul
renal
transplant
recipi
karen
khalil
patricia
alicia
lichvar
pharmd
ms
enrico
benedetti
shree
patel
pharmaci
univers
illinoi
hospit
health
scienc
system
chicago
il
surgeri
univers
illinoi
hospit
health
scienc
system
chicago
il
pharmaci
univers
illinoi
chicago
chicago
il
present
american
transplant
congress
held
american
societi
transplant
seattl
wa
june
obes
impact
emerg
depart
util
hospit
admiss
adult
urban
renal
transplant
popul
alisha
patel
alicia
lichvar
pharmd
ms
rene
petzel
gimbar
maya
campara
pharmd
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
univers
illinoi
chicago
chicago
il
introduct
preval
obes
within
end
stage
renal
diseas
esrd
patient
await
renal
transplant
rtx
increas
obes
consid
rel
contraind
rtx
mani
institut
due
complic
univers
illinoi
hospit
health
scienc
system
perform
rtx
obes
patient
bmi
cutoff
emerg
depart
ed
visit
hospit
manifest
complic
research
question
hypothesi
obes
impact
ed
visit
hospit
within
first
month
studi
design
retrospect
studi
method
rtx
recipi
includ
patient
follow
month
date
rtx
obes
defin
bmi
demograph
complic
requir
ed
hospit
intervent
laboratori
valu
collect
comparison
result
rtx
recipi
includ
obes
rtx
ortx
rtx
nortx
patient
year
age
male
african
american
rtx
averag
bmi
ortx
receiv
robot
rtx
incid
ed
visit
nortx
vs
hospit
nortx
vs
similar
averag
number
ed
visit
hospit
differ
group
time
first
ed
visit
differ
nortx
day
vs
ortx
day
trend
toward
higher
reject
rate
ortx
nortx
vs
ortx
driven
empir
reject
treatment
higher
egfr
observ
nortx
compar
ortx
patient
month
p
egfr
similar
group
month
conclus
complic
requir
ed
hospit
intervent
obes
patient
similar
detail
analysi
healthcar
cost
comparison
perform
assess
differ
nich
popul
evalu
versu
valganciclovir
cytomegaloviru
diseas
prevent
liver
transplant
recipi
parth
parikh
pharmd
depart
pharmaci
servic
vcu
health
richmond
va
introduct
valganciclovir
mg
daili
current
drug
regimen
choic
prophylaxi
cytomegaloviru
cmv
diseas
solid
organ
transplant
recipi
howev
dose
associ
signific
bone
marrow
suppress
lower
dose
valganciclovir
mg
daili
shown
similar
efficaci
prevent
cmv
diseas
renal
transplant
recipi
howev
pauciti
literatur
substanti
efficaci
safeti
valganciclovir
cmv
diseas
prophylaxi
liver
transplant
recipi
ltr
research
question
hypothesi
daili
valganciclovir
effect
safe
cmv
diseas
prevent
liver
transplant
recipi
mg
daili
valganciclovir
studi
design
retrospect
chart
review
method
consecut
high
intermedi
cmv
risk
ltr
june
juli
assess
inclus
studi
primari
endpoint
incid
cmv
infect
andor
diseas
within
month
liver
transplant
secondari
outcom
includ
incid
breakthrough
cmv
infect
andor
diseas
biopsi
confirm
tissu
invas
diseas
prematur
valganciclovir
discontinu
incid
leukopenia
result
high
intermedi
risk
ltr
n
n
includ
cmv
infect
andor
diseas
occur
p
group
respect
patient
group
experienc
breakthrough
cmv
infect
andor
diseas
howev
statist
signific
differ
rate
biopsi
confirm
tissu
invas
diseas
prematur
valganciclovir
discontinu
leukopenia
two
group
patient
graft
surviv
outcom
also
similar
group
conclus
incid
rate
cmv
infect
valganciclovir
group
similar
suggest
valganciclovir
compar
valganciclovir
use
cmv
diseas
prophylaxi
high
intermedi
cmv
risk
ltr
rabbit
globulin
dose
strategi
renal
transplant
recipi
kent
botkin
claric
carthon
pharmd
timothi
horwedel
pharmd
jennif
hagopian
pharmd
april
pottebaum
andrew
malon
mb
pharmaci
hospit
saint
loui
mo
hospit
st
loui
mo
nephrolog
washington
univers
saint
loui
school
medicin
saint
loui
mo
introduct
rabbit
globulin
ratg
induct
commonli
use
renal
transplant
rtxp
howev
optim
dose
unknown
research
question
hypothesi
optim
dose
ratg
induct
base
reject
risk
studi
design
retrospect
compar
cohort
analysi
conduct
hospit
method
adult
rtxp
receiv
ratg
induct
evalu
exclud
patient
receiv
transplant
mainten
immunosuppress
tacrolimu
mycophenol
acid
prednison
dose
ratg
outsid
rang
experienc
graft
loss
death
within
hour
transplant
patient
met
follow
cpra
posit
flow
cdc
cross
match
year
old
black
dr
mismatch
prior
transplant
posit
dsa
defin
absenc
characterist
comparison
made
mgkg
mgkg
within
group
mgkg
mgkg
group
primari
outcom
six
month
composit
biopsi
proven
acut
reject
bpar
patient
surviv
graft
loss
addit
outcom
includ
reject
sever
cytomegaloviru
viremia
new
malign
result
rtxp
includ
analysi
baselin
demograph
clinic
differ
group
differ
primari
outcom
group
compar
mgkg
vs
mgkg
vs
group
show
signific
increas
primari
outcom
compar
mgkg
vs
mgkg
vs
driven
increas
bpar
mgkg
group
vs
secondari
outcom
similar
group
conclus
mgkg
dose
ratg
seem
provid
optim
composit
bpar
patient
surviv
graft
loss
regardless
defin
reject
risk
studi
warrant
oral
emerg
contracept
avail
comparison
chain
independ
retail
pharmaci
georgia
stella
hur
pharmd
candid
briell
scutt
pharmd
dennia
ernest
pharmd
salli
rafi
pharmd
rebecca
stone
pharmd
bcacp
pharmaci
univers
georgia
athen
ga
california
san
diego
skagg
school
pharmaci
pharmaceut
scienc
la
jolla
ca
clinic
administr
pharmaci
univers
georgia
colleg
pharmaci
athen
ga
introduct
emerg
contracept
ec
efficaci
highli
depend
time
administr
therefor
accur
pharmaci
stock
inform
import
ensur
time
access
research
question
hypothesi
compar
chain
c
independ
retail
pharmaci
georgia
differ
pharmacist
report
oral
ec
stock
avail
stock
discrep
studi
design
prospect
random
survey
method
list
georgia
retail
pharmaci
obtain
randomli
select
stratifi
across
nch
code
pharmaci
call
assess
pharmacist
report
stock
statu
levonorgestrel
lng
uliprist
acet
upa
ec
research
call
mysteri
patient
subsequ
call
day
later
research
analysi
util
descript
statist
chi
squar
result
randomli
select
pharmaci
c
vs
particip
call
pharmaci
report
lng
ec
stock
report
upa
ec
stock
chain
pharmaci
like
lng
ec
c
vs
p
differ
upa
ec
c
vs
stock
discrep
discord
avail
report
mysteri
patient
vs
research
identifi
pharmaci
chain
pharmaci
higher
incid
report
stock
discrep
c
vs
conclus
women
georgia
face
barrier
access
time
sensit
oral
ec
medic
pharmaci
oral
ec
stock
report
stock
discrep
caller
independ
pharmaci
less
like
stock
oral
ec
like
provid
accur
stock
inform
pharmacokinet
coadministr
bremelanotid
metformin
phase
random
trial
luana
pesco
koplowitz
md
barri
koplowitz
robert
jordan
johna
luca
md
flat
pharma
elbridg
ny
technolog
inc
cranburi
nj
introduct
bremelanotid
agonist
investig
treatment
hypoact
sexual
desir
disord
hsdd
premenopaus
women
diabet
mellitu
frequent
treat
metformin
occur
women
hsdd
shifren
et
al
research
question
hypothesi
purpos
studi
evalu
safeti
toler
pharmacokinet
pk
pharmacodynam
bremelanotid
administ
concomitantli
metformin
studi
design
phase
random
crossov
interact
studi
conduct
healthi
subject
age
year
metformin
bid
alon
oral
administ
phase
singl
subcutan
inject
bremelanotid
placebo
coadminist
metformin
phase
method
metformin
pk
paramet
includ
tmax
cmax
coadministr
bremelanotid
placebo
bremelanotid
pk
paramet
includ
tmax
cmax
mean
chang
blood
glucos
concentr
cgavg
measur
metformin
coadministr
advers
event
ae
also
monitor
result
seventeen
femal
male
complet
studi
concomit
administr
bremelanotid
decreas
metformin
cmax
approxim
respect
decreas
cmax
statist
signific
howev
differ
mean
chang
baselin
cgavg
bremelanotid
placebo
group
statist
signific
median
metformin
tmax
hour
treatment
median
bremelanotid
cmax
ngml
ng
hml
respect
median
bremelanotid
tmax
occur
hour
coadministr
metformin
among
subject
receiv
bremelanotid
experienc
ae
vs
receiv
placebo
common
ae
nausea
flush
headach
consist
known
safeti
profil
bremelanotid
conclus
clinic
signific
pk
interact
metformin
bremelanotid
concomit
administr
appear
affect
safeti
profil
either
drug
pharmacokinet
coadministr
bremelanotid
norethindroneethinyl
estradiol
oral
contracept
phase
random
trial
luana
pesco
koplowitz
md
barri
koplowitz
susan
kornstein
robert
jordan
johna
luca
md
flat
pharma
elbridg
ny
commonwealth
univers
school
medicin
richmond
va
technolog
inc
cranburi
nj
introduct
agonist
bremelanotid
investig
treatment
hypoact
sexual
desir
disord
premenopaus
women
popul
use
oral
contracept
oc
extens
research
question
hypothesi
purpos
studi
evalu
safeti
toler
pharmacokinet
pk
interact
bremelanotid
norethindroneethinyl
estradiol
neee
studi
design
phase
random
crossov
interact
studi
conduct
healthi
premenopaus
women
year
age
oc
month
prior
studi
combin
ne
ee
oral
administ
phase
bremelanotid
placebo
subcutan
coadminist
neee
phase
method
neee
pk
assess
includ
tmax
cmax
coadministr
bremelanotid
placebo
bremelanotid
pk
assess
includ
tmax
cmax
coadminist
neee
advers
event
ae
also
monitor
result
women
complet
studi
protocol
median
ne
tmax
hour
coadminist
bremelanotid
placebo
median
ee
tmax
approxim
hour
later
bremelanotid
placebo
statist
comparison
cmax
neee
bremelanotid
placebo
show
ne
ee
mean
decreas
approxim
mean
cmax
decreas
approxim
statist
signific
median
bremelanotid
tmax
approxim
hour
dose
median
cmax
ngml
ng
hml
respect
incid
ae
neee
coadminist
bremelanotid
vs
neee
alon
common
ae
associ
coadministr
bmt
neee
nausea
flush
vs
somnol
neee
alon
ae
mild
sever
conclus
statist
signific
pk
interact
neee
bremelanotid
concomit
administr
neee
bremelanotid
gener
well
toler
captur
treatment
high
blood
pressur
pregnanc
clinic
practic
chrystian
r
pereira
pharmd
bcp
sarah
westberg
jean
moon
pharmd
annett
becki
rosdahl
tanya
melnik
jill
bowman
peterson
pharmaceut
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
minnesota
minneapoli
mn
prevent
medicin
univers
minnesota
minneapoli
mn
introduct
acog
guidelin
set
blood
pressur
goal
pregnanc
list
methyldopa
nifedipin
labetalol
prefer
agent
studi
canada
show
disconnect
practic
physician
guidelin
chip
studi
demonstr
benefit
tighter
bp
control
reduc
sever
matern
hypertens
research
question
hypothesi
adher
clinic
guidelin
treatment
high
bp
pregnanc
studi
design
retrospect
chart
review
method
sampl
chart
collect
two
clinic
period
month
criteria
inclus
femal
patient
receiv
care
full
pregnanc
least
one
elev
bp
pregnanc
consent
use
chart
data
research
patient
meet
criteria
exclud
patient
chart
review
data
gestat
age
blood
pressur
read
document
blood
pressur
goal
pharmacolog
intervent
manag
hypertens
well
matern
fetalneonat
data
collect
result
total
chart
review
exclud
due
meet
inclus
criteria
patient
elev
bp
time
around
deliveri
singl
isol
high
bp
read
fourteen
remain
document
goal
bp
rang
sixteen
alreadi
bp
treatment
continu
origin
therapi
includ
dose
adjust
three
switch
labetalol
three
discontinu
hctz
six
patient
newli
start
treatment
newli
start
start
labetalol
nifedipin
conclus
major
patient
document
goal
bp
state
bp
goal
variabl
goal
consist
acog
guidelin
pregnant
women
elev
blood
pressur
treat
antihypertens
medic
mani
isol
elev
bp
evalu
prescrib
pattern
treatment
bipolar
disord
pregnanc
nalino
kernizan
alicia
forinash
fccp
bcp
abigail
yancey
pharmd
fccp
loui
colleg
pharmaci
st
loui
mo
pharmaci
practic
st
loui
colleg
pharmaci
st
loui
mo
introduct
uncontrol
bipolar
disord
pregnanc
associ
poor
prenat
care
decreas
fetal
growth
increas
risk
postnat
complic
psychosi
mood
stabil
first
line
therapi
control
patient
howev
pregnanc
data
lack
often
antidepress
initi
base
physician
comfort
safeti
data
may
increas
mania
risk
studi
aim
evalu
prescrib
pattern
bipolar
disord
obstetr
patient
research
question
hypothesi
psychiatr
medic
prescrib
pregnant
patient
bipolar
disord
studi
design
retrospect
chart
review
patient
refer
matern
fetal
care
center
method
pregnant
patient
bipolar
disord
two
document
visit
januari
ssm
deliveri
octob
includ
primari
outcom
describ
bipolar
treatment
regimen
first
visit
throughout
pregnanc
deliveri
result
overal
pregnanc
analyz
compar
first
visit
overal
psychiatr
medic
use
vs
mood
stabil
regimen
vs
antidepress
monotherapi
vs
increas
antepartum
patient
initi
mood
stabil
commonli
lurasidon
lamotrigin
half
mood
stabil
initi
recommend
clinic
pharmacist
fifti
patient
initi
antidepress
patient
buspiron
antepartum
deliveri
patient
report
adher
psychiatr
medic
includ
mood
stabil
antidepress
without
mood
stabil
conclus
physician
prescrib
patient
adher
mood
stabil
pregnanc
low
patient
antidepress
base
regimen
often
need
continu
therapi
optim
alcohol
consumpt
like
increas
clopidogrel
antiplatelet
activ
steven
laizur
pharmd
hui
phd
robert
parker
pharmd
depart
clinic
pharmaci
univers
tennesse
health
scienc
center
memphi
tn
introduct
clopidogrel
intermedi
metabolit
hydrolyz
human
hepat
inact
metabolit
enzym
primari
determin
activ
metabolit
format
subsequ
antiplatelet
activ
alcohol
known
inhibitor
enzym
human
could
potenti
alter
clopidogrel
activ
metabolit
disposit
research
question
hypothesi
studi
test
hypothesi
alcohol
inhibit
metabol
clopidogrel
inact
metabolit
caus
increas
format
activ
metabolit
studi
design
estim
extent
interact
determin
inhibitor
concentr
alcohol
concentr
ki
inhibitori
rate
constant
method
ki
determin
incub
clopidogrel
increas
concentr
alcohol
human
recombin
enzym
inhibitor
concentr
obtain
previou
human
alcohol
studi
publish
literatur
clopidogrel
metabolit
concentr
determin
result
dose
alcohol
human
studi
rang
gkg
correspond
alcohol
maximum
concentr
mm
ki
valu
clopidogrel
mm
respect
ki
valu
clopidogrel
respect
conclus
estim
ki
ratio
exceed
indic
convers
clopidogrel
inact
metabolit
reduc
consumpt
alcohol
inhibit
metabol
clopidogrel
moder
alcohol
consumpt
may
increas
activ
metabolit
format
antiplatelet
activ
human
effect
propofol
extracorpor
membran
oxygen
oxygen
exchang
kelsey
browder
pharmd
ayesha
ather
pharmd
bcp
komal
pandya
pharmd
bcccp
univers
kentucki
healthcar
lexington
ky
introduct
concern
propofol
administr
patient
extracorpor
membran
oxygen
ecmo
origin
propofol
use
cardiopulmonari
bypass
cpb
potenti
propofol
alter
diffus
oxygen
across
membran
perceiv
potenti
oxygen
issu
caus
benzodiazepin
use
increas
sed
choic
ecmo
popul
research
question
hypothesi
object
studi
determin
propofol
administr
ecmo
patient
institut
would
result
oxygen
exchang
often
patient
receiv
propofol
studi
design
singl
center
retrospect
studi
conduct
cardiothorac
intens
care
unit
includ
patient
older
venoven
ecmo
support
januari
januari
patient
exclud
requir
ecmo
support
less
hour
greater
day
method
patient
demograph
collect
includ
benzodiazepin
use
cumul
opioid
dose
ecmo
intens
care
unit
icu
hospit
length
stay
durat
ecmo
hospit
mortal
patient
receiv
propofol
compar
patient
receiv
propofol
outcom
includ
durat
ecmo
oxygen
exchang
per
ecmo
day
result
patient
analyz
five
patient
propofol
arm
requir
oxygen
exchang
patient
control
arm
total
number
oxygen
exchang
per
ecmo
day
differ
group
exchang
per
day
vs
exchang
per
day
requir
oxygen
exchang
differ
cumul
dose
propofol
receiv
per
ecmo
hour
mgkghr
vs
mgkghr
conclus
propofol
use
patient
ecmo
seem
increas
number
oxygen
exchang
idarucizumab
drug
administr
surveil
program
result
john
faniko
rph
mba
debra
murwin
bs
fredrik
gruenenfeld
igor
tartakovski
lionel
riou
franca
paul
reilli
deirdr
lane
ken
butcher
md
women
hospit
wakefield
ingelheim
pharmaceut
columbu
oh
ingelheim
pharma
gmbh
co
kg
ingelheim
rhein
germani
ingelheim
intern
gmbh
ingelheim
germani
ingelheim
ridgefield
ct
birmingham
institut
cardiovascular
scienc
birmingham
unit
kingdom
alberta
edmonton
ab
canada
introduct
idarucizumab
indic
emerg
surgeryurg
procedur
uncontrol
bleed
patient
treat
dabigatran
requir
rapid
revers
anticoagul
effect
present
data
global
surveil
program
idarucizumab
use
adult
patient
research
question
hypothesi
object
evalu
idarucizumab
usag
pattern
hospit
pharmaci
set
studi
design
intern
studi
base
medic
record
review
method
patient
year
age
treat
idarucizumab
dispens
hospit
pharmaci
hospit
clinic
unit
particip
dabigatran
idarucizumab
clinic
trial
elig
anonym
data
collect
hospit
pharmaci
characterist
patient
characterist
idarucizumab
util
result
patient
year
age
countri
across
asia
pacif
europ
north
america
particip
major
hospit
public
central
pharmaci
previou
anticoagul
treatment
dabigatran
bid
mg
mg
mg
mg
qd
mg
mg
mg
unknown
dose
rivaroxaban
apixaban
unknown
indic
idarucizumab
use
bleed
emerg
surgeryprocedur
plan
surgeryprocedur
patient
receiv
g
vial
g
vial
dose
six
patient
receiv
second
dose
g
rebleedingcoagul
test
increas
urgent
intervent
bleed
frequent
gastrointestin
intracrani
bleed
type
spontan
traumat
report
common
surgeri
type
gastrointestin
orthoped
vascular
thorac
includ
cardiac
conclus
surveil
show
new
inform
pattern
use
pharmaci
characterist
frequenc
low
consist
registr
trial
ad
trend
statin
use
among
patient
year
atherosclerot
cardiovascular
diseas
secondari
prevent
michel
wood
pharmd
thoma
delat
phd
sheila
stadler
pharmd
cardiolog
cl
ann
denham
pharmd
lesli
rupp
pharmd
cardiolog
roseann
hornak
pharmd
kari
l
olson
bsc
pharmd
bcp
pharmaci
cardiac
risk
servic
kaiser
permanent
colorado
aurora
co
clinic
pharmaci
kaiser
permanent
colorado
aurora
co
introduct
atherosclerot
cardiovascular
diseas
ascvd
remain
lead
caus
death
unit
state
high
intens
statin
therapi
hist
recommend
decreas
risk
recurr
ascvd
clinic
debat
benefit
hist
older
patient
preval
hist
use
popul
unknown
research
question
hypothesi
proport
patient
year
age
ascvd
receiv
hist
patient
characterist
associ
hist
use
studi
design
studi
conduct
within
integr
healthcar
deliveri
system
method
administr
databas
queri
use
collect
data
januari
decemb
patient
year
valid
ascvd
myocardi
infarct
cardiac
stent
percutan
coronari
intervent
coronari
arteri
bypass
graft
januari
index
date
year
patient
could
includ
multipl
year
met
criteria
statin
intens
determin
use
type
dose
statin
sold
within
day
index
date
patient
hist
year
categor
hist
group
logist
regress
model
util
determin
characterist
associ
hist
use
result
patient
includ
averag
age
year
male
receiv
hist
point
studi
period
percentag
patient
receiv
hist
steadili
increas
januari
juli
p
trend
factor
associ
hist
use
includ
younger
age
male
sex
lower
burden
chronic
diseas
well
antiplatelet
aspirin
use
conclus
use
hist
increas
substanti
patient
year
ascvd
studi
period
futur
studi
evalu
cardiovascular
outcom
hist
use
popul
comparison
sodium
acet
buffer
capac
critic
ill
patient
without
cirrhosi
brittani
bissel
pharmd
bcccp
alexand
flanneri
pharmd
bcccp
komal
pandya
melissa
thompson
bastin
pharmd
pharmaci
servic
univers
kentucki
healthcar
lexington
ky
kentucki
medic
center
lexington
ky
introduct
sodium
acet
nac
buffer
agent
substitut
sodium
bicarbon
variou
indic
intens
care
unit
icu
patient
acet
convert
bicarbon
citric
acid
cycl
mainli
liver
skelet
muscl
patient
liver
diseas
like
cirrhosi
may
convert
nac
time
drug
shortag
nac
recommend
altern
howev
littl
data
exist
regard
efficaci
nac
buffer
agent
cirrhosi
research
question
hypothesi
sought
evalu
serum
bicarbon
respons
defin
increas
valu
concomit
ph
increas
valu
nac
cirrhosi
versu
without
studi
design
retrospect
cohort
studi
adult
patient
without
cirrhosi
admit
medic
icu
month
period
shortag
receiv
nac
method
electron
medic
record
util
collect
nac
util
demograph
laboratori
valu
clinic
outcom
respons
nac
compar
patient
without
cirrhosi
result
order
sodium
acet
found
administ
patient
cirrhosi
differ
group
baselin
ph
despit
cirrhot
receiv
higher
averag
nac
dose
vs
meq
patient
either
group
met
criteria
respons
patient
cirrhosi
increas
compar
without
ph
increas
demonstr
cirrhot
versu
differ
seen
length
stay
mortal
conclus
nac
limit
buffer
capac
without
cirrhosi
cohort
howev
sampl
size
limit
discret
exercis
use
icu
patient
given
limit
evid
efficaci
safeti
obes
neg
impact
propofol
usag
icu
sedat
daniel
tompkin
sean
kane
scott
benken
pharmd
cardiolog
illinoi
chicago
chicago
il
franklin
colleg
pharmaci
north
chicago
il
introduct
intern
guidelin
sedat
ventil
patient
recommend
use
sed
other
studi
evalu
use
propofol
continu
icu
sedat
obes
bmi
vs
patient
research
question
hypothesi
total
bodi
weight
tbw
dose
propofol
higher
rate
oversed
side
effect
obes
patient
compar
patient
studi
design
retrospect
cohort
studi
method
patient
receiv
cumul
durat
propofol
least
hour
evalu
inclus
data
obtain
mimic
iii
databas
research
databas
result
nine
hundr
nineti
eight
patient
identifi
complet
data
median
age
iqr
vs
vs
male
vs
caucasian
median
bmi
vs
p
respect
obes
patient
higher
median
cumul
dose
propofol
mg
vs
p
rate
oversed
similar
two
group
vs
similar
median
deviat
goal
rass
target
vs
time
ventil
icu
length
stay
mortal
differ
group
significantli
obes
patent
hypertriglyceridemia
vs
numer
bradycardia
vs
though
reach
signific
class
obes
patient
compar
longer
propofol
durat
higher
total
propofol
exposur
p
higher
triglycerid
cox
proport
model
demonstr
longer
time
liber
mechan
ventil
class
obes
patient
vs
conclus
obes
associ
higher
cumul
exposur
propofol
continu
sedat
mechan
ventil
especi
class
obes
patient
may
impact
durat
mechan
ventil
safeti
paramet
futur
studi
warrant
effect
receptor
simul
neurogenesi
marker
rat
brain
follow
stroke
divya
khandekar
bpharm
ms
amaresh
ranjan
seema
briyal
rhea
dhingra
rahul
mehta
anil
gulati
md
colleg
pharmaci
midwestern
univers
downer
grove
il
pharmaceut
scienc
midwestern
univers
downer
grove
il
introduct
receptor
brain
neurogen
capac
stimul
receptor
agonist
improv
neurolog
function
follow
cerebr
ischemia
studi
evalu
effect
neurogenesi
research
question
hypothesi
hypothes
would
increas
express
neurogenesi
marker
studi
design
vivo
experi
consist
ischemia
ischemiavehicl
group
vitro
experi
hypoxiavehicl
group
method
perman
middl
cerebr
arteri
occlus
mcao
use
induc
cerebr
ischemia
male
rat
follow
mcao
anim
receiv
three
intraven
inject
salin
vehicl
hour
hour
studi
inject
day
day
studi
anim
sacrif
brain
process
evalu
express
neurogenesi
marker
doublecortin
huchud
stem
cell
marker
cerebr
hemispher
use
immunoblot
techniqu
primari
cultur
adult
rat
brain
cell
expos
hour
vehiclehypoxia
hypoxia
process
immunofluoresc
result
treatment
produc
signific
p
improv
neurolog
deficit
compar
vehicl
hour
day
respect
post
mcao
western
blot
analysi
hour
show
increas
express
huchud
doublecortin
group
compar
vehicl
right
infarct
hemispher
chang
observ
day
produc
chang
express
immunofluoresc
analysi
cultur
cell
confirm
find
elev
express
along
increas
neun
neural
marker
matur
neuron
hypox
cell
compar
vehicl
conclus
stimul
receptor
enhanc
express
neurogen
marker
lead
function
recoveri
think
evalu
preceptor
develop
program
incorpor
pharmacist
patient
care
process
experienti
teach
keri
hager
allyson
schlicht
pharmd
mba
caitlin
k
frail
pharmd
ms
bcacp
pharmaci
practic
pharmaceut
scienc
univers
minnesota
colleg
pharmaci
duluth
mn
health
servic
minneapoli
mn
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
introduct
effort
ongo
creat
consist
use
comprehens
medic
manag
cmm
pharmacist
patient
care
process
ppcp
practic
educ
research
expos
student
effect
ppcp
experienti
rotat
critic
ensur
consist
among
futur
practition
requir
activ
explicit
incorpor
ppcp
precept
research
question
hypothesi
preceptor
develop
continu
educ
ce
program
incorpor
ppcp
influenc
preceptor
percept
incorpor
ppcp
experienti
teach
confid
abil
articul
ppcp
team
member
student
studi
design
survey
design
use
question
method
onlin
preceptor
develop
ce
program
creat
address
compon
ppcp
applic
experienti
learn
survey
question
develop
assess
percept
whether
preceptor
incorpor
ppcp
teach
confid
articul
ppcp
team
member
student
data
assess
use
wilcoxon
sign
rank
test
result
total
preceptor
enrol
program
usabl
post
survey
complet
preceptor
percept
whether
incorpor
ppcp
ipp
student
chang
significantli
complet
program
v
howev
app
preceptor
less
like
strongli
agre
incorpor
ppcp
precept
vs
preceptor
felt
increas
confid
abil
articul
ppcp
team
member
vs
student
vs
follow
complet
program
conclus
onlin
preceptor
develop
ce
effect
increas
confid
preceptor
abil
articul
ppcp
team
member
student
effort
focus
preceptor
develop
area
potenti
treatment
nationwid
propens
score
match
cohort
studi
yoojin
noh
doctor
pharmaci
expect
jeon
sooyoung
shin
colleg
pharmaci
health
scienc
worcest
pharmaci
ajou
univers
suwon
korea
republ
south
introduct
preclin
data
suggest
dipeptidyl
inhibitor
may
promot
metastat
progress
preexist
cancer
via
nuclear
factor
erythroid
relat
factor
activ
research
question
hypothesi
aim
investig
associ
differ
glucos
lower
treatment
includ
inhibitor
metformin
potenti
modul
effect
metastat
cancer
among
type
diabet
patient
comorbid
incid
cancer
studi
design
cohort
studi
includ
diabet
patient
newli
diagnos
primari
cancer
korea
method
patient
categor
five
studi
cohort
accord
treatment
modal
end
drug
metformin
inhibitor
inhibitor
insulin
treatment
follow
propens
score
ps
match
ratio
group
patient
metformin
inhibitor
inhibitor
patient
insulin
group
identifi
cohort
entri
analyz
correspond
number
patient
comparison
pair
result
metastat
risk
lower
metformin
plu
minu
inhibitor
hr
ci
respect
significantli
associ
inhibitor
except
thyroid
cancer
higher
insulin
therapi
compar
use
cancer
combin
conclus
conclus
inhibitor
therapi
associ
signific
risk
cancer
metastasi
rel
therapi
irrespect
patient
age
sex
except
thyroid
cancer
metastat
risk
decreas
metformin
treatment
among
type
diabet
patient
preexist
cancer
inflammatori
bowel
diseas
patient
similar
varicella
zoster
immun
older
group
herp
zoster
immun
recommend
kate
berlin
bs
sue
mccrone
freddi
caldera
mari
hayney
pharmd
school
pharmaci
madison
wi
school
medicin
public
health
madison
wi
introduct
patient
inflammatori
bowel
diseas
ibd
inher
increas
risk
herp
zoster
hz
compar
healthi
counterpart
hz
subunit
vaccin
recent
approv
safe
administ
patient
ibd
without
concurr
immunosuppress
medic
reactiv
varicella
zoster
viru
vzv
result
hz
strong
immun
prevent
reactiv
hz
research
question
hypothesi
young
patient
ibd
age
similar
immun
varicella
zoster
viru
healthi
individu
age
year
zoster
vaccin
current
recommend
studi
design
prospect
studi
method
serum
sampl
obtain
elispot
assay
assess
immun
varicella
zoster
viru
patient
divid
healthi
control
age
year
patient
ibd
age
year
receiv
therapi
aminosalicyl
monotherapi
prior
histori
vzv
manifest
chicken
pox
elispot
plate
result
quantifi
aid
elispot
reader
system
result
per
studi
design
healthi
patient
older
patient
ibd
median
year
iqr
vs
year
iqr
p
mann
whitney
u
median
durat
ibd
month
iqr
healthi
patient
demonstr
similar
vzv
elispot
result
median
spot
iqr
compar
patient
ibd
receiv
therapi
aminosalicyl
monotherapi
median
spot
iqr
mann
whitney
u
elispot
result
describ
robust
immun
respons
vzv
conclus
young
patient
ibd
receiv
therapi
aminosalicyl
monotherapi
similar
immun
vzv
healthi
fifti
year
old
group
hz
immun
indic
given
low
immun
vzv
demonstr
ibd
patient
studi
hz
immun
age
younger
year
may
benefici
ibd
patient
increas
risk
hz
score
predict
optim
anticoagul
predominantli
minor
popul
liber
cutoff
indic
atrial
fibril
kunkun
wang
pharmd
candid
luci
yun
lu
pharmd
ms
mengistu
simegn
richard
asing
minnesota
minneapoli
mn
counti
medic
center
minneapoli
mn
introduct
decis
make
tool
predict
optim
anticoagul
may
guid
manag
score
sex
femal
age
year
medic
histori
comorbid
treatment
interact
drug
tobacco
use
doubl
point
race
doubl
point
wide
use
tool
deriv
valid
affirm
trial
popul
predict
qualiti
anticoagul
patient
atrial
fibril
nvaf
research
question
hypothesi
score
deriv
trial
cohort
minor
applic
predomin
minor
popul
indic
nvaf
studi
design
singl
center
retrospect
review
method
total
patient
median
age
year
male
long
term
vitamin
k
antagonist
vka
regular
follow
least
month
februari
april
identifi
hennepin
counti
medic
center
anticoagul
clinic
registri
patient
score
time
therapeut
rang
ttr
comput
logist
regress
use
assess
correl
group
score
ttr
receiv
oper
characterist
curv
use
identifi
best
cutoff
predict
desir
ttr
comput
accuraci
posit
likelihood
ratio
result
total
patient
indic
vka
nvaf
venou
thromboembol
diseas
prosthet
heart
valv
other
statist
signific
neg
correl
ttr
p
x
less
equal
identifi
best
threshold
predict
ttr
accuraci
posit
likelihood
ratio
respect
conclus
score
predict
optim
anticoagul
liber
cutoff
previous
thought
predomin
minor
inner
citi
patient
popul
nvaf
indic
vka
valid
argatroban
dose
protocol
academ
medic
center
paig
waugh
shaun
keegan
christoph
droeg
eric
mueller
neil
ernst
univers
mylan
colleg
pharmaci
pittsburgh
pa
cincinnati
medic
center
cincinnati
oh
introduct
argatroban
indic
treatment
thrombocytopenia
optim
start
dose
titrat
differ
ci
patient
nci
patient
higher
sever
ill
shown
requir
lower
dose
research
question
hypothesi
studi
evalu
efficaci
safeti
institut
argatroban
dose
protocol
look
identifi
independ
variabl
associ
failur
achiev
therapeut
activ
partial
thromboplastin
time
aptt
within
hour
initi
therapeut
dose
requir
mcgkgmin
studi
design
singl
retrospect
chart
review
method
cohort
studi
evalu
adult
patient
receiv
argatroban
infus
least
hour
multivari
logist
regress
analys
perform
identifi
predictor
aptt
therapeut
dose
requir
mcgkgmin
patient
divid
defin
start
dose
titrat
follow
institut
protocol
defin
differ
start
dose
titrat
follow
institut
protocol
group
protocol
start
argatroban
dose
ci
nci
patient
mcgkgmin
respect
aptt
goal
second
result
nineti
patient
ci
ci
includ
patient
achiev
therapeut
aptt
within
hour
differ
observ
group
mean
time
therapeut
aptt
similar
group
one
major
bleed
minor
bleed
clot
extens
occur
predictor
aptt
identifi
total
sofa
sequenti
organ
failur
assess
score
ci
argatroban
initi
independ
predictor
therapeut
dose
mcgkgmin
conclus
institut
argatroban
protocol
safe
effect
achiev
therapeut
aptt
within
hour
ci
nci
patient
occur
similar
timefram
group
differ
advers
event
sofa
score
may
effect
identifi
dose
reduct
evalu
risk
factor
empir
antimicrobi
regimen
acinetobact
baumannii
bacteremia
impact
patient
outcom
taylor
morrisett
chelsea
mitchel
tate
cutshal
jennif
twilla
pharmd
pharmaci
univers
colorado
hospit
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
pharmaci
froedtert
hospit
milwauke
wi
pharmaci
univers
alabama
birmingham
hospit
birmingham
al
pharmaci
methodist
univers
hospit
memphi
tn
introduct
acinetobact
baumannii
ab
coccobacillu
emerg
promin
nosocomi
pathogen
frequent
caus
bacteremia
prior
studi
identifi
risk
factor
rf
associ
ab
bacteremia
abb
develop
includ
antimicrobi
util
presenc
indwel
devic
recent
invas
procedur
prolong
intens
care
unit
stay
howev
report
evalu
rf
conjunct
empir
antimicrobi
regimen
ear
associ
patient
outcom
research
question
hypothesi
choic
ear
presenc
rf
abb
impact
patient
outcom
studi
design
retrospect
cohort
adult
patient
rf
posit
blood
cultur
bc
ab
method
patient
categor
two
group
base
ear
chosen
prior
bc
posit
group
one
patient
initi
meropenem
group
two
patient
initi
ear
polymicrobi
bacteremia
blood
cultur
bc
acinetobact
spp
ab
exclud
primari
endpoint
time
neg
bc
secondari
endpoint
includ
hospit
length
stay
lo
mortal
readmiss
recurr
bacteremia
result
patient
screen
met
inclus
criteria
meropenem
group
patient
ear
group
patient
statist
signific
differ
note
baselin
characterist
rf
abb
infect
sourc
group
statist
signific
meropenem
group
faster
time
bc
clearanc
day
vs
day
decreas
hospit
lo
day
vs
day
mortal
observ
frequent
patient
receiv
meropenem
vs
differ
readmiss
recurr
bacteremia
conclus
patient
suspect
infect
rf
abb
guid
choic
ear
meropenem
may
lead
faster
time
bc
clearanc
prospect
trial
need
valid
optim
choic
ear
patient
risk
abb
effect
renal
function
efficaci
eravacyclin
pool
analysi
allyson
font
pharmd
kenneth
lawrenc
pharmd
sergey
izmailyan
bs
steven
kolkin
pharmd
ms
medic
affair
tetraphas
pharmaceut
watertown
introduct
treatment
failur
risk
increas
certain
complic
infect
ciai
subgroup
eravacyclin
erv
novel
fluorocyclin
antibiot
evalu
two
phase
random
control
trial
rct
assess
efficaci
safeti
vs
carbapenem
adult
ciai
rct
met
primari
endpoint
clinic
respons
research
question
hypothesi
sought
explor
baselin
creatinin
clearanc
clcr
affect
clinic
efficaci
erv
studi
design
random
phase
trial
method
adult
patient
hospit
ciai
random
erv
vs
ertapenem
meropenem
respect
clinic
outcom
treat
popul
test
cure
visit
toc
day
random
primari
efficaci
endpoint
subject
classifi
renal
function
categori
base
baselin
clcr
calcul
equat
result
popul
consist
patient
grew
least
one
pathogen
consist
ciai
baselin
cultur
clinic
outcom
analyz
categori
baselin
renal
function
popul
toc
ctcompar
therapi
nnumber
subject
clinic
cure
nnumber
subject
within
specif
categori
renal
diseas
nenot
evalu
conclus
erv
maintain
efficaci
treat
patient
across
broad
rang
alter
renal
function
erv
provid
altern
carbapenem
inhibitor
empir
treatment
ciai
efficaci
eravacyclin
obes
patient
pool
analysi
allyson
font
pharmd
kenneth
lawrenc
pharmd
sergey
izmailyan
bs
steven
kolkin
pharmd
ms
medic
affair
tetraphas
pharmaceut
watertown
introduct
treatment
failur
risk
increas
certain
complic
infect
ciai
subgroup
eravacyclin
erv
novel
fluorocyclin
antibiot
evalu
two
phase
random
control
trial
rct
assess
efficaci
safeti
vs
carbapenem
adult
ciai
rct
met
primari
endpoint
clinic
respons
research
question
hypothesi
sought
explor
clinic
outcom
obes
patient
treat
erv
ciai
studi
design
random
phase
trial
method
adult
patient
hospit
ciai
random
dose
erv
mgkg
iv
vs
ertapenem
meropenem
respect
clinic
outcom
treat
popul
toc
visit
day
random
primari
efficaci
endpoint
subject
classifi
categori
base
bodi
mass
index
bmi
result
popul
consist
patient
grew
least
one
pathogen
consist
ciai
baselin
cultur
clinic
outcom
analyz
bmi
popul
toc
ctcompar
therapi
nnumber
subject
clinic
cure
nnumber
subject
within
specif
categori
nenot
evalu
conclus
erv
effect
treat
patient
regardless
bmi
erv
provid
altern
carbapenem
inhibitor
empir
treatment
ciai
evalu
outcom
follow
treatment
elizabeth
hirsch
delaney
hart
ashley
pich
ashley
cubillo
kirthana
beaulac
aiman
bandali
janet
raddatz
kimberli
boeser
brandon
dionn
pharmd
id
aahivp
laura
puzniak
monica
v
mahoney
pharmd
elizabeth
gancher
minnesota
colleg
pharmaci
minneapoli
mn
minnesota
medic
center
minneapoli
mn
medic
center
boston
univers
hospit
philadelphia
pa
co
inc
kenilworth
nj
women
hospit
boston
pharmaci
beth
israel
deaco
medic
center
boston
univers
colleg
medicin
philadelphia
pa
introduct
ct
novel
cephalosporin
combin
inhibitor
approv
treatment
complic
urinari
tract
infect
complic
infect
current
studi
ventil
nosocomi
pneumonia
ct
demonstr
vitro
activ
mdr
pseudomona
aeruginosa
enterobacteriacea
howev
patient
outcom
infrequ
report
research
question
hypothesi
clinic
outcom
follow
treatment
ct
studi
design
retrospect
cohort
studi
method
adult
inpati
treat
ct
hour
includ
clinic
microbiolog
data
extract
electron
record
primari
outcom
clinic
cure
assess
patient
receiv
hour
ct
therapi
defin
escal
addit
therapi
hospit
discharg
indic
clinic
stabil
secondari
outcom
includ
mortal
length
stay
lo
isol
character
mdr
resist
categori
antipseudomon
agent
resist
xdr
resist
categori
result
patient
includ
mean
patient
age
year
male
major
receiv
care
index
event
frequent
comorbid
chronic
pulmonari
diseas
renal
diseas
diabet
prior
hospit
within
day
patient
posit
cultur
frequent
isol
site
respiratori
blood
p
aeruginosa
common
organ
consid
mdr
addit
consid
xdr
clinic
cure
achiev
evalu
patient
mortal
median
interquartil
rang
lo
day
conclus
among
patient
treat
ct
primarili
mdrxdr
p
aeruginosa
infect
clinic
cure
ct
repres
promis
agent
treatment
p
aeruginosa
resist
tradit
antipseudomon
agent
acut
care
visit
among
adolesc
receiv
treatment
kim
walker
andrea
e
bonni
erin
r
mcknight
md
milap
c
nahata
pharmd
pharmaci
ohio
state
univers
columbu
oh
pediatr
nationwid
children
hospit
columbu
oh
introduct
rate
disord
oud
adolesc
young
adult
us
doubl
american
academi
pediatr
strongli
recommend
increas
access
medic
assist
treatment
mat
oud
popul
acknowledg
rigor
research
support
mat
adolesc
young
adult
exist
research
question
hypothesi
purpos
studi
evalu
effect
mat
present
adolesc
emerg
depart
ed
urgent
care
uc
inpati
admiss
due
acut
complaint
includ
overdos
withdraw
intox
hypothesi
mat
would
reduc
number
present
facil
acut
complaint
time
period
studi
design
retrospect
cohort
method
adolesc
age
year
present
acut
complaint
refer
outpati
mat
clinic
hospit
primari
outcom
assess
differ
number
proport
frequenc
visit
acut
complaint
mat
cohort
secondari
analysi
assess
chang
acut
visit
within
mat
cohort
mat
util
result
patient
met
inclus
criteria
util
mat
time
period
primari
endpoint
composit
acut
visit
ed
uc
inpati
admiss
complaint
occur
visit
frequenc
mat
cohort
versu
visit
frequenc
ci
p
ci
p
conclus
visit
ed
uc
inpati
facil
acut
complaint
reduc
adolesc
receiv
mat
outcom
staphylococcu
aureu
infect
critic
ill
children
vancomycin
trough
concentr
matter
nichola
fusco
pharmd
bcp
bcpp
staci
yi
pharmd
candid
calvin
meaney
pharmd
bcp
depart
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
introduct
although
data
lack
children
vancomycin
trough
concentr
vtc
mcgml
often
empir
target
treat
staphylococcu
aureu
infect
recent
pharmacokinet
model
data
children
suggest
suffici
vancomycin
exposur
occur
vtc
mcgml
addit
vtc
mcgml
associ
acut
kidney
injuri
aki
children
therefor
import
determin
initi
vtc
impact
clinic
outcom
children
research
question
hypothesi
initi
vtc
impact
clinic
outcom
critic
ill
children
infect
staphylococcu
aureu
studi
design
retrospect
cohort
studi
method
children
month
age
infect
staphylococcu
aureu
admit
pediatr
intens
care
unit
divid
initi
vtc
mcgml
mcgml
mcgml
primari
composit
outcom
includ
mortal
fever
last
hour
vancomycin
initi
posit
blood
cultur
hour
vancomycin
initi
secondarili
aki
defin
increas
serum
creatinin
baselin
within
hour
descript
statist
use
character
data
appropri
hypothesi
test
perform
vtc
group
analysi
complet
use
sa
result
total
children
includ
initi
vtc
mcgml
mcgml
mcgml
differ
primari
composit
outcom
children
vtc
mcgml
mcgml
mcgml
differ
rate
aki
children
vtc
mcgml
mcgml
mcgml
conclus
small
retrospect
studi
initi
vtc
impact
clinic
outcom
critic
ill
children
infect
staphylococcu
aureu
pharmacogenet
associ
clinic
methylphenid
outcom
pilot
studi
jacob
brown
pharmd
ms
ida
aka
thierri
chekouo
sara
van
driest
md
practic
pharmaceut
scienc
univers
minnesota
colleg
pharmaci
duluth
mn
univers
medic
center
nashvil
tn
statist
univers
calgari
calgari
ab
canada
medicin
vanderbilt
univers
nashvil
tn
introduct
methylphenid
commonli
prescrib
medic
adhd
nearli
children
prescrib
methylphenid
respond
treatment
nearli
half
discontinu
methylphenid
within
one
year
treatment
failur
ostens
caus
prevent
advers
effect
delay
desir
clinic
outcom
pharmacogenet
associ
valid
test
variat
impact
methylphenid
disposit
may
assist
improv
efficaci
research
question
hypothesi
determin
feasibl
retrospect
studi
test
hypothesi
variant
comt
associ
clinic
outcom
children
treat
methylphenid
studi
design
pilot
retrospect
pharmacogenet
associ
studi
method
studi
use
biovu
vanderbilt
electron
health
dna
repositori
inclus
criteria
age
year
start
methylphenid
treatment
adhd
demograph
clinic
outcom
variabl
determin
manual
review
primari
outcom
advers
effect
attribut
methylphenid
secondari
outcom
chang
dose
therapeut
cours
dna
sequenc
use
kailo
next
gener
assay
univari
multivari
analysi
test
associ
genotyp
outcom
firth
logist
model
use
reduc
varianc
odd
ratio
estim
result
total
individu
includ
although
pharmacogenet
variant
associ
advers
effect
race
identifi
signific
predictor
aor
caucasian
vs
individu
univari
analysi
variant
comt
trend
toward
signific
chang
dose
multivari
analys
heterozygot
ct
time
less
like
requir
dose
chang
cc
homozygot
adjust
demograph
variabl
snp
exclud
model
signific
conclus
pharmacogenet
variat
drug
disposit
gene
may
contribut
individu
variat
clinic
outcom
methylphenid
function
character
role
hepatotox
houda
alachkar
pharmd
sharon
wu
navin
rana
pharmaci
univers
southern
california
school
pharmaci
usc
lo
angel
ca
lo
angel
ca
introduct
overal
surviv
adult
acut
lymphoblast
leukemia
less
high
rate
toxic
particularli
hepatotox
limit
widespread
use
adult
hold
asparaginas
treatment
grade
hepatotox
develop
occur
patient
may
compromis
antileukemia
effect
clinic
outcom
recent
pharmacogenet
studi
demonstr
genet
variant
key
mitochondri
enzym
protect
cell
reactiv
oxygen
speci
ro
associ
hepatotox
adult
function
studi
role
need
valid
clinic
util
develop
therapeut
approach
mitig
toxic
research
question
hypothesi
function
snp
contribut
hepatotox
studi
design
preclin
function
studi
method
panel
liver
cell
line
genotyp
transduc
plasmid
carri
c
assess
ro
engin
naiv
cell
base
level
also
assess
ro
level
human
lymphoblastoid
cell
line
accord
genotyp
result
genotyp
analysi
liver
cell
line
result
identif
two
cc
five
tt
one
ct
genotyp
total
ro
level
significantli
higher
compar
tt
carri
cell
base
level
fold
p
respect
also
found
higher
increas
ro
level
base
level
cell
ectop
express
compar
ectop
express
allel
consist
lower
enzymat
activ
observ
cell
ectop
express
c
vs
respect
p
initi
analysi
total
ro
level
lcl
show
signific
differ
cc
tt
genotyp
conclus
associ
lower
enzymat
activ
higher
ro
level
concord
dehydrogenas
genotyp
phenotyp
pediatr
patient
hematolog
malign
katherin
robinson
bs
wenjian
yang
cyrin
e
haidar
jane
hankin
md
denni
jay
nanci
kornegay
jeffrey
rubnitz
md
ulrich
broeckel
cheng
cheng
pui
sima
jeha
mari
v
rell
pharmaceut
scienc
st
jude
children
research
hospit
memphi
tn
hematolog
st
jude
children
research
hospit
memphi
tn
clinic
chemistri
laboratori
informat
st
jude
children
research
hospit
memphi
tn
oncolog
st
jude
children
research
hospit
memphi
tn
pediatr
medic
colleg
wisconsin
milwauke
wi
biostatist
st
jude
children
research
hospit
memphi
tn
introduct
although
dehydrogenas
defici
long
recogn
pharmacogenet
trait
phenotyp
rather
genotyp
test
remain
gold
standard
diagnos
statu
defici
caus
methemoglobinemia
research
question
hypothesi
investig
util
genotyp
predict
defici
children
hematolog
malign
associ
genotyp
methemoglobinemia
studi
design
retrospect
analysi
patient
hematolog
malign
treat
st
jude
children
research
hospit
method
activ
erythrocyt
measur
use
spectrophotometr
assay
genotyp
data
avail
patient
three
genotyp
platform
statu
genotyp
classifi
defici
variabl
normal
base
clinic
pharmacogenet
implement
consortium
guidelin
medic
record
patient
methemoglobin
measur
review
rasburicas
administr
result
observ
male
class
genotyp
defici
activ
result
posit
predict
valu
male
two
male
class
allel
normal
activ
phenotyp
receiv
red
cell
transfus
prior
activ
assay
genotyp
sensit
predict
defici
male
femal
homozyg
class
allel
thu
none
predict
defici
base
genotyp
two
heterozyg
femal
defici
activ
methemoglobinemia
occur
patient
least
one
class
allel
despit
two
normal
activ
conclus
genotyp
indic
defici
phenotyp
patient
without
transfus
wherea
appar
wildtyp
genotyp
necessarili
impli
normal
phenotyp
although
genotyp
limit
use
confirm
statu
possibl
identifi
patient
risk
methemoglobinemia
rasburicas
includ
heterozyg
femal
effect
atyp
antipsychot
skelet
muscl
lipidom
bipolar
disord
kyle
burghardt
kristen
ward
berhan
seyoum
md
renu
kowluru
zhengp
yi
applebaum
colleg
pharmaci
health
scienc
depart
pharmaci
practic
wayn
state
univers
detroit
mi
pharmaci
depart
colleg
pharmaci
univers
michigan
ann
arbor
mi
medicin
wayn
state
univers
detroit
mi
applebaum
colleg
pharmaci
health
scienc
depart
pharmaceut
scienc
wayn
state
univers
detroit
mi
introduct
molecular
mechan
atyp
antipsychot
caus
insulin
resist
remain
poorli
understood
howev
lipid
metabol
thought
play
critic
role
current
research
focus
tissu
involv
develop
insulin
resist
skelet
muscl
research
question
hypothesi
atyp
antipsychot
caus
lipid
within
skelet
muscl
chang
correl
insulin
resist
studi
design
method
subject
bipolar
disord
current
atyp
antipsychot
mood
stabil
month
without
famili
histori
diabet
underw
fast
oral
glucos
toler
test
calcul
insulin
sensit
muscl
biopsi
analyz
total
fatti
acid
phosphatidylcholin
ceramid
comparison
individu
lipid
made
base
treatment
correl
analys
perform
insulin
sensit
fals
discov
rate
fdr
correct
consid
statist
signific
result
thirti
subject
includ
averag
age
subject
femal
caucasian
atyp
antipsychot
total
skelet
muscl
lipid
analyz
total
fatti
acid
phosphatidylcholin
ceramid
subject
atyp
antipsychot
lower
level
total
fatti
acid
phosphatidylcholin
higher
level
ceramid
q
compar
subject
mood
stabil
addit
subject
atyp
antipsychot
total
fatti
acid
phosphatidylcholin
tend
decreas
insulin
resist
ceramid
increas
insulin
resist
conclus
work
suggest
atyp
antipsychot
may
influenc
skelet
muscl
lipidom
may
correl
chang
insulin
sensit
caus
medic
confirmatori
work
could
lead
futur
approach
therapeut
design
avoid
deleteri
effect
drug
metabol
tissu
skelet
muscl
comprehens
medic
manag
provid
clinic
pharmacist
famili
medicin
clinic
jar
prudencio
michel
kim
practic
daniel
k
inouy
colleg
pharmaci
univers
hawaii
hilo
hilo
hi
practic
daniel
k
inouy
colleg
pharmaci
univers
hawaii
hilo
w
kawili
st
hi
servic
program
comprehens
medic
manag
cmm
provid
two
pharmacist
famili
medicin
resid
clinic
patient
refer
pharmacist
physician
schedul
appoint
visit
pharmacist
provid
complet
medic
reconcili
patient
educ
optim
medic
regimen
collabor
practic
agreement
allow
order
medic
laboratori
test
justificationdocument
base
retrospect
review
document
pharmacist
visit
total
patient
provid
cmm
visit
autonom
pharmacist
visit
visit
includ
nurs
practition
medic
discrep
found
cmm
visit
total
discrep
found
patient
diabet
pharmacist
address
patient
entir
regimen
standard
cmm
practic
averag
chang
systol
blood
pressur
chang
mmhg
medic
adjust
lab
order
visit
immeasur
duti
servic
includ
consult
provid
clinic
warfarin
manag
assist
medic
access
adapt
pharmacist
hold
faculti
posit
colleg
pharmaci
servic
allow
pharmacist
work
directli
clinic
valuabl
part
interprofession
patient
care
team
ambulatori
care
pharmacist
would
abl
implement
servic
similar
famili
medicin
clinic
signific
add
evid
cmm
servic
integr
famili
medicin
clinic
improv
patient
outcom
progress
pharmaci
servic
integr
medic
resid
resid
grow
accustom
cmm
may
desir
continu
work
ambulatori
care
pharmacist
futur
practic
primari
care
initi
pci
collabor
chronic
diseas
manag
visit
daniel
wilk
pharmd
juli
bartel
pharmd
pharmacotherapi
clinic
monro
wi
servic
program
clinic
rural
healthcar
system
locat
southern
wisconsin
implement
primari
care
initi
pci
improv
patient
access
primari
care
physician
pcp
transfer
appoint
chronic
diseas
manag
physician
pharmacotherapist
patient
diabet
hypertens
hyperlipidemia
thyroid
disord
uncompl
depressionanxieti
elig
pharmacotherapist
util
collabor
practic
agreement
cpa
adjust
medic
order
lab
patient
appropri
justificationdocument
robert
graham
center
project
pcp
demand
higher
wisconsin
compar
rest
midwest
correl
shortag
fte
servic
mitig
pcp
shortag
exacerb
rural
commun
like
green
counti
wisconsin
success
measur
chang
appoint
enrol
pcp
chang
emerg
depart
util
primari
care
issu
improv
patient
outcom
patient
provid
satisfact
chang
revenu
adapt
initi
implement
organ
pharmacist
use
cpa
initi
servic
develop
phase
follow
servic
implement
phase
extrapol
ambulatori
care
practic
shortag
pcp
concern
nationwid
thu
initi
restrict
rural
commun
signific
chronic
diseas
manag
within
primari
care
nich
pharmacist
add
signific
valu
healthcar
team
pharmacist
practic
top
licens
benefit
physician
patient
commun
organ
implement
phase
initi
start
januari
current
ten
pcp
enrol
program
financi
model
show
initi
expand
pharmacotherapist
accommod
pci
patient
per
week
result
addit
revenu
annual
profit
data
health
outcom
access
outcom
financi
outcom
collect
quarterli
begin
march
updat
initi
accp
ambulatori
care
practic
research
network
prn
focu
member
bill
reimburs
clinic
pharmaci
servic
jame
c
lee
pharmd
bcacp
sweta
patel
pharmd
ginel
bryant
pharmd
kelli
lempicki
pharmd
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
practic
mercer
univers
colleg
pharmaci
atlanta
ga
univers
colleg
pharmaci
health
scienc
de
moin
ia
pharmaci
practic
midwestern
univers
chicago
colleg
pharmaci
downer
grove
il
servic
program
accp
ambulatori
care
prn
activ
bodi
clinic
pharmacist
contribut
accp
prn
leadership
committe
involv
also
serv
ambulatori
care
pharmaci
member
regularli
queri
assess
impact
clinic
practic
administr
issu
may
significantli
affect
ambulatori
care
clinic
pharmaci
servic
justificationdocument
evalu
ambulatori
care
prn
practition
knowledg
confid
util
bill
reimburs
mechan
clinic
servic
electron
survey
develop
character
progress
prn
practition
contribut
toward
establish
financi
sustain
clinic
pharmaci
servic
adapt
data
obtain
survey
commun
compar
previou
year
signific
ambulatori
care
prn
consist
approxim
member
grow
number
prn
practition
member
provid
clinic
servic
increas
mix
practic
set
respond
report
actual
bill
servic
provid
frequent
bill
mechan
util
direct
patient
care
includ
bill
use
evaluationmanag
servic
code
facil
fee
medic
therapi
manag
code
convers
percentag
reimburs
clinic
servic
bill
major
payment
sourc
medicar
commerci
insur
frequent
report
bill
mechan
prn
practition
continu
face
numer
barrier
relat
bill
clinic
servic
includ
limit
lack
need
andor
incent
gener
revenu
lack
support
legisl
andor
health
system
focu
cost
save
lack
bill
reimburs
knowledg
effort
reduc
barrier
ambulatori
care
prn
continu
develop
program
relat
bill
reimburs
practic
ambulatori
care
pharmaci
includ
develop
implement
sustain
ideal
model
well
promot
legisl
advoc
role
pharmacist
clinic
provid
updat
accomplish
initi
accp
ambulatori
care
practic
research
network
prn
jame
c
lee
pharmd
bcacp
kelli
lempicki
pharmd
ginel
bryant
pharmd
sweta
patel
pharmd
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
practic
midwestern
univers
chicago
colleg
pharmaci
downer
grove
il
univers
colleg
pharmaci
health
scienc
de
moin
ia
pharmaci
gradi
health
system
atlanta
ga
servic
program
ambulatori
care
prn
activ
bodi
clinic
pharmacist
contribut
accp
prn
leadership
committe
involv
also
serv
ambulatori
care
pharmaci
member
current
queri
biannual
regard
individu
profession
accomplish
promot
award
fund
scholarli
activ
justificationdocument
evalu
initi
achiev
accp
ambulatori
care
prn
membership
electron
survey
updat
dissemin
character
progress
member
contribut
clinic
practic
servic
teach
research
adapt
data
obtain
survey
commun
compar
previou
year
record
contribut
accomplish
continu
document
report
via
accp
prn
report
signific
ambulatori
care
prn
consist
approxim
member
practic
set
servic
provid
prn
membership
continu
diversifi
prn
committe
continu
promot
initi
relat
advocaci
practic
support
prn
membership
outreach
network
advocaci
effort
includ
letter
write
campaign
develop
advocaci
toolkit
support
member
particip
profession
scholarli
clinic
develop
continu
increas
grant
fund
initi
aim
expand
prn
collabor
knowledg
advanc
develop
prn
subgroup
member
similar
practic
area
area
interest
initi
resid
journal
club
expand
use
social
media
technolog
platform
coordin
network
event
major
pharmaci
organ
meet
ambulatori
care
prn
continu
show
posit
growth
membership
depth
committe
contribut
membership
support
opportun
provid
accomplish
achiev
prn
remain
high
valu
prn
colleg
prn
continu
strive
provid
wide
rang
advocaci
educ
innov
opportun
object
advanc
pharmacist
develop
ambulatori
care
clinic
practic
patient
care
provis
impact
clinic
pharmacist
part
interdisciplinari
team
approach
control
substanc
prescrib
primari
care
set
brooklyn
nelson
jennif
trotter
elicia
white
emili
russel
center
medic
home
mountain
state
medic
group
johnson
citi
tn
center
medic
home
mountain
state
medic
group
abingdon
va
center
medic
home
mountain
state
medic
group
kingsport
tn
pharmaci
practic
east
tennesse
state
univers
bill
gatton
colleg
pharmaci
johnson
citi
tn
servic
program
three
clinic
pharmacist
current
embed
physician
offic
northeast
tennesse
southwest
virginia
activ
particip
closer
monitor
safer
prescrib
control
substanc
sinc
januari
current
provid
recommend
urin
drug
screen
monitor
evalu
prescript
monitor
databas
naloxon
prescrib
counsel
taper
protocol
recommend
medic
chronic
pain
justificationdocument
per
depart
health
tennesse
second
highest
per
capita
prescript
rate
opioid
unit
state
increas
unintent
overdos
death
sinc
increasingli
patient
seek
advic
primari
care
provid
treatment
chronic
pain
reason
interdisciplinari
approach
primari
care
may
benefici
reduc
unnecessari
opioid
prescript
provid
necessari
provid
patient
educ
regard
risk
control
substanc
provid
guidanc
interpret
urin
drug
screen
taper
protocol
naloxon
administr
medic
adapt
pilot
program
consist
three
ambulatori
care
clinic
pharmacist
along
pharmaci
student
complet
advanc
pharmaci
practic
experi
rotat
five
primari
care
offic
current
serv
three
clinic
pharmacist
import
note
pharmacist
role
still
focus
comprehens
primari
care
manag
safer
pain
manag
intervent
compris
part
role
therefor
one
clinic
pharmacist
work
exclus
initi
could
potenti
serv
three
four
practic
signific
preliminari
estim
opioid
reduct
includ
elimin
equival
hydrocodoneacetaminophen
mg
tablet
written
prescript
follow
year
addit
urin
drug
screen
adher
improv
patient
receiv
morphin
miliequival
per
day
naloxon
prescript
counsel
also
increas
dramat
sinc
initi
pilot
outcom
primari
care
comprehens
medic
manag
cmm
implement
project
academ
health
system
lesson
learn
involv
nation
learn
collabor
mari
kuzel
kyle
turner
kelse
wride
jenni
buu
golden
berrett
primari
care
servic
univers
utah
health
midval
ut
pharmacotherapi
univers
utah
colleg
pharmaci
salt
lake
citi
ut
primari
care
servic
univers
utah
health
south
jordan
ut
primari
care
servic
univers
utah
health
salt
lake
citi
ut
present
american
societi
pharmacist
summer
meet
ambulatori
care
confer
denver
co
june
ambulatori
transit
care
manag
anticoagul
therapi
util
nurs
model
donald
brown
pharmd
bcacp
steve
sytsma
pharmd
bcp
candac
minter
pharmd
bcacp
mari
morin
rn
msn
bsn
sentara
healthcar
system
sentara
medic
group
norfolk
va
servic
program
sentara
anticoagul
servic
clinic
sasc
comprehens
standard
anticoagul
manag
servic
within
larg
integr
healthcar
system
southeast
unit
state
develop
clinic
model
form
collabor
clinic
pharmaci
specialist
cp
refer
provid
regist
nurs
rn
order
improv
qualiti
anticoagul
therapi
stewardship
ambulatori
patient
justificationdocument
sasc
anticoagul
manag
clinic
grown
sinc
incept
first
conceiv
sasc
patient
encount
manag
clinic
rn
satellit
clinic
two
fte
cp
consult
patient
consult
rate
initi
period
overal
time
therapeut
rang
ttr
clinic
number
clinic
expand
locat
throughout
virginia
northeast
north
carolina
telephonicvirtu
rn
clinic
servic
ad
clinic
rn
patient
encount
fte
cp
consult
time
consult
rate
current
ttr
improv
patient
encount
adapt
model
util
telephon
rn
assess
patient
central
locat
cp
function
consult
patient
protocol
appli
sasc
anticoagul
manag
model
could
adapt
larg
healthcar
system
wish
reach
larg
number
patient
larg
geograph
area
group
develop
transit
care
model
identifi
review
patient
discharg
hospit
warfarin
order
improv
medic
safeti
signific
uniqu
aspect
sasc
includ
central
telephonicvirtu
pharmacist
growth
model
adapt
larg
geograph
area
allow
pharmacist
rn
practic
top
respect
licens
develop
justif
collabor
hypertens
manag
servic
primari
care
clinic
erin
carson
pharmd
univers
colleg
pharmaci
rockford
il
servic
program
primari
care
clinic
associ
health
system
rockford
il
without
previou
clinic
pharmaci
servic
collabor
practic
agreement
cpa
develop
primari
care
provid
pcp
pharmacist
provid
comprehens
servic
patient
uncontrol
hypertens
addit
provid
comprehens
educ
close
cpa
allow
pharmacist
physician
referr
independ
initi
discontinu
titrat
antihypertens
medic
clinic
blood
pressur
read
home
monitor
valid
machin
use
adjust
medic
patient
follow
monthli
adequ
control
achiev
peripher
thereaft
servic
reinstat
elev
blood
pressur
subsequ
identifi
justificationdocument
american
hypertens
uncontrol
hypertens
servic
includ
pharmacist
shown
improv
blood
pressur
control
compar
tradit
hypertens
manag
access
integr
pharmacist
primari
care
clinic
allow
close
patient
collabor
primari
care
team
goal
servic
describ
maintain
percentag
patient
control
hypertens
healthcar
effect
data
inform
set
hedi
percentil
adapt
hypertens
servic
implement
primari
care
clinic
long
written
cpa
develop
agre
upon
involv
parti
signific
manag
care
metric
compel
way
justifi
new
servic
nine
month
percentag
patient
receiv
comprehens
hypertens
servic
control
hypertens
hedi
percentil
current
improv
baselin
healthcar
system
goal
improv
manag
care
metric
allow
develop
clinic
pharmaci
servic
facil
previous
without
pharmaci
presenc
new
servic
demonstr
pharmacist
access
collabor
primari
care
team
advanc
clinic
pharmaci
practic
captain
jame
lovel
feder
health
care
center
clinic
pharmacist
specialist
new
patient
intak
clinic
megan
grischeau
pharmd
bcacp
ann
livorsi
pharmd
jessica
johnson
pharmd
captan
jame
lovel
feder
health
care
center
north
chicago
il
pharmaci
captain
jame
lovel
feder
health
care
center
north
chicago
il
captain
jame
lovel
feder
health
care
center
north
chicago
il
servic
program
captain
jame
lovel
feder
health
care
center
fhcc
first
joint
veteran
health
administr
vha
depart
defens
ventur
prior
project
implement
patient
new
primari
care
provid
pcp
design
team
staff
ie
lpn
rn
respons
complet
medic
reconcili
verifi
allergi
past
medic
histori
order
medic
lab
initi
visit
new
patient
intak
npi
clinic
purpos
increas
time
pc
staff
address
pertin
issu
part
npi
process
upon
patient
registr
schedul
make
appoint
clinic
pharmaci
specialist
cp
prior
initi
visit
appoint
patient
introduc
fhcc
prescript
process
vha
formulari
clinic
recommend
made
pcp
regard
formulari
convers
full
medic
reconcili
perform
justificationdocument
vha
pilot
site
found
npi
process
consum
minut
pcp
allot
time
initi
visit
npi
clinic
standard
streamlin
process
enhanc
overal
patient
experi
furthermor
lab
order
result
prior
appoint
addit
time
requir
contact
patient
visit
save
adapt
cboc
women
health
cp
first
implement
project
afterward
npi
project
implement
within
fhcc
patient
align
care
team
pact
process
also
serv
mode
patient
diseas
manag
signific
time
studi
estim
npi
appoint
translat
minut
save
pc
clinic
staff
first
seven
month
project
estim
hour
save
contact
patient
four
pilot
site
ongo
reflect
occur
ensur
intend
goal
npi
clinic
met
implement
cdc
diabet
prevent
program
primari
care
clinic
holli
gurgl
pharmd
bcacp
cde
christoph
khong
bs
pharmd
candid
class
alisyn
may
pharmd
bcacp
cde
depart
pharmacotherapi
univers
utah
colleg
pharmaci
salt
lake
citi
ut
servic
program
among
us
adult
obes
without
intervent
mani
develop
diabet
cardiovascular
diseas
great
cost
employ
health
payer
cdc
nation
diabet
prevent
program
dpp
lifestyl
chang
program
aim
support
particip
reduc
risk
diabet
lose
bodi
weight
januari
arup
laboratori
employ
implement
dpp
program
coordin
clinic
pharmacist
collabor
effort
includ
dietitian
well
coach
medic
assist
student
justificationdocument
use
health
risk
assess
employe
depend
bmi
previous
diagnos
diabet
identifi
invit
particip
group
session
held
individu
elect
particip
averag
particip
attend
session
record
minut
per
week
physic
activ
lost
bodi
weight
year
compar
baselin
one
year
particip
also
reduc
averag
systol
blood
pressur
vs
mmhg
vs
vs
p
particip
indic
high
level
satisfact
dpp
report
would
recommend
program
friend
famili
member
adapt
clinic
pharmacist
ambulatori
manag
care
set
uniqu
posit
identifi
elig
individu
implement
dpp
cdc
provid
dpp
curriculum
support
organ
cost
includ
onlin
cost
effect
calcul
fund
may
avail
local
health
depart
support
implement
signific
increasingli
medicar
medicaid
plan
offer
dpp
cover
benefit
implement
dpp
gener
revenu
reduc
health
cost
improv
patient
outcom
develop
implement
clinic
ambulatori
blood
pressur
monitor
servic
primari
care
medic
home
abbi
frye
pharmd
provid
medic
group
portland
servic
program
clinic
ambulatori
blood
pressur
monitor
abpm
servic
allow
primari
care
provid
easili
access
abpm
without
potenti
costli
referr
specialist
patient
could
benefit
abpm
identifi
primari
care
provid
pcp
schedul
clinic
pharmacist
patient
return
monitor
clinic
pharmacist
evalu
report
provid
relat
recommend
pcp
abpm
servic
initi
assist
grant
portland
interhospit
physician
associationjustificationdocument
abpm
support
wealth
evid
recommend
sever
nation
intern
guidelin
howev
prior
implement
abpm
servic
pcp
found
difficult
access
valuabl
tool
within
first
month
implement
patient
complet
abpm
session
reason
referr
includ
evalu
potenti
white
coat
effect
evalu
report
hypotens
clarif
confirm
new
diagnosi
allow
better
complet
assess
patient
current
blood
pressur
control
major
clinic
pharmacist
recommend
implement
pcp
major
patient
whose
abpm
result
consist
sustain
mask
hypertens
goaladapt
clinic
abpm
servic
could
implement
primari
care
clinic
throughout
countri
requir
addit
certif
credenti
requir
collabor
practic
agreement
howev
profici
hypertens
necessari
nurs
medic
assist
could
perform
associ
task
clinic
pharmacist
provid
ad
valu
base
expertis
abil
make
recommend
signific
abpm
opportun
clinic
pharmacist
provid
valuabl
servic
improv
patient
access
also
optim
hypertens
control
high
risk
patient
role
ambulatori
care
clinic
pharmacist
manag
refuge
patient
popul
univers
virginia
intern
famili
medicin
clinic
kristi
higgin
jeffrey
tingen
pharmd
mba
bcp
bcacp
pharmaci
univers
virginia
health
system
charlottesvil
va
famili
medicin
univers
virginia
health
system
charlottesvil
va
present
north
american
refuge
health
confer
portland
june
electron
pharmacotherapi
consult
servic
improv
provid
access
clinic
pharmacist
practition
primari
care
set
evalu
impact
servic
provid
patient
care
nanci
j
lee
pharmd
bcp
cde
kyann
wiss
pharmd
amanda
guild
pharmd
elizabeth
marn
pharmd
cyndi
clegg
bs
pharm
mha
medic
group
issaquah
wa
medic
group
seattl
wa
medic
center
edmond
wa
servic
program
swedish
medic
group
incorpor
clinic
pharmacist
practition
cpp
primari
care
clinic
valu
cpp
embed
clinic
evid
first
year
improv
chronic
diseas
outcom
physician
clinic
without
embed
cpp
request
cpp
financi
constraint
made
challeng
hire
addit
practition
order
meet
need
access
cpp
electron
pharmacotherapi
consult
servic
develop
implement
use
electron
medic
record
system
emr
name
epic
cpp
team
creat
pool
start
juli
primari
care
provid
send
question
regard
drug
therapi
late
earli
input
physician
champion
region
medic
director
pool
chang
platform
new
platform
allow
cpp
recommend
part
patient
chart
cpp
answer
question
per
week
manag
home
clinic
patient
care
activ
justificationdocument
juli
may
receiv
drug
therapi
question
clinic
without
embed
cpp
presenc
provid
accept
implement
recommend
consid
high
impact
patient
care
averag
minut
spent
research
answer
question
top
categori
question
receiv
chronic
diseas
med
review
side
effect
interact
adapt
servic
could
adopt
cpp
program
emr
improv
provid
access
cpp
primari
care
set
signific
servic
provid
cpp
view
drug
inform
servic
shown
type
question
receiv
high
util
clinic
without
embed
cpp
accept
recommend
time
save
provid
could
also
use
toward
increas
panel
size
optim
drug
therapi
reduc
harm
implement
integr
clinic
pharmaci
psychiatr
servic
primari
care
clinic
nikola
kovacich
pharmd
candid
emili
kosirog
pharmd
benjamin
chavez
pharmd
depart
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
servic
program
clinic
pharmaci
servic
alreadi
exist
multipl
chronic
diseas
state
feder
qualifi
health
center
fqhc
expand
chronic
diseas
servic
meet
grow
need
collabor
practic
agreement
develop
allow
pharmacist
initi
chang
discontinu
medic
depress
anxieti
bipolar
disord
pharmacist
also
avail
primari
care
provid
pcp
psychologist
psychiatr
medic
consult
servic
run
two
clinic
pharmacist
two
ambulatori
care
resid
pharmaci
student
justificationdocument
although
clinic
mani
psychologist
patient
difficult
time
access
psychiatr
medic
manag
servic
prior
servic
patient
refer
outsid
psychiatrist
process
often
took
month
pharmaci
servic
increas
access
allow
patient
receiv
psychiatr
care
medic
care
set
data
time
period
collect
pharmacist
complet
consult
visit
breakdown
intervent
made
consult
visit
provid
survey
pcp
reveal
respond
felt
clinic
pharmacist
help
feel
comfort
prescrib
psychotrop
medic
strongli
agre
agre
adapt
servic
place
year
well
receiv
member
healthcar
team
evidenc
provid
satisfact
survey
result
larg
volum
referr
consult
model
implement
outpati
clinic
clinic
pharmacist
provid
pharmaceut
care
need
increas
access
psychiatr
medic
manag
signific
replic
innov
servic
aim
improv
access
care
patient
seek
psychiatr
treatment
primari
care
fqhc
set
advanc
role
pharmacist
pharmaci
resid
student
provid
comprehens
care
primari
care
set
expand
clinic
servic
anticoagul
pharmacist
diabet
medic
manag
ashley
van
allen
leanna
davi
jay
wirawan
multicar
auburn
wa
educ
multicar
puyallup
wa
multicar
tacoma
wa
servic
program
multicar
health
system
oper
four
outpati
anticoagul
clinic
ac
washington
state
pharmacist
previous
work
collabor
practic
agreement
cpa
focus
sole
warfarin
manag
recogn
exist
multipl
chronic
diseas
state
anticoagul
patient
diabet
medic
manag
servic
ad
pharmacist
work
close
patient
design
medic
regimen
improv
glycem
control
frequent
increas
access
patient
justificationdocument
due
complex
diabet
medic
manag
prompt
discuss
expand
clinic
servic
ac
addit
healthcar
unit
state
us
evolv
valu
base
payment
healthcar
effect
data
inform
set
hedi
one
wide
use
set
healthcar
perform
measur
us
multipl
diabet
relat
measur
promin
focu
diabet
manag
hedi
compel
factor
choos
expand
diseas
state
due
ac
pharmacist
excel
clinic
safeti
data
warfarin
felt
could
extrapol
achiev
hedi
diabet
measur
adapt
expand
pharmacist
abil
provid
diabet
manag
consist
creat
new
cpa
addit
train
train
involv
didact
session
shadow
pharmacist
certifi
diabet
educ
cde
train
focus
clinic
compet
well
workflow
document
signific
ac
pharmacist
provid
diabet
manag
improv
patient
access
diabet
care
achiev
hedi
measur
pharmacist
manag
diabet
patient
patient
initi
refer
pharmacist
recent
last
appoint
refer
back
provid
impact
pharmacist
intervent
patient
meet
target
statin
dose
clinic
ascvd
amanda
guild
pharmd
bcacp
virginia
skipper
pharmd
elizabeth
marn
pharmd
nanci
j
lee
pharmd
bcp
kyann
wiss
pharmd
cyndi
clegg
bs
pharm
mha
medic
group
seattl
wa
wa
medic
group
issaquah
wa
medic
center
edmond
wa
servic
program
swedish
medic
group
clinic
pharmacist
practition
cpp
work
meet
system
goal
ensur
patient
clinic
atherosclerot
cardiovascular
diseas
ascvd
intens
statin
therapi
achiev
goal
pharmacist
review
report
may
octob
detail
patient
ascvd
appropri
statin
dose
work
provid
patient
ensur
proper
therapi
attain
justificationdocument
appropri
statin
therapi
clinic
ascvd
reduct
measur
nation
committe
qualiti
assur
ncqa
healthcar
effect
data
inform
set
hedi
import
cardiovascular
diseas
lead
caus
death
unit
state
swedish
medic
group
adapt
hedi
measur
ensur
patient
clinic
ascvd
target
therapi
dose
measur
success
initi
see
improv
percent
patient
meet
metric
two
clinic
pharmacist
saw
larger
improv
metric
percentag
initi
vs
one
clinic
without
pharmacist
improv
vs
improv
respect
adapt
workflow
initi
adapt
primari
care
clinic
support
cpp
collabor
drug
therapi
agreement
cdta
goal
improv
hedi
outcom
specif
secondari
ascvd
prevent
electron
health
record
abil
run
specif
report
would
necessari
signific
intens
statin
dose
patient
clinic
ascvd
import
uncommon
therapi
initi
kept
dose
patient
claim
intoler
without
trial
multipl
statin
variou
dose
strategi
ambulatori
pharmacist
therapeut
knowledg
educ
ensur
patient
receiv
appropri
statin
therapi
improv
outcom
provid
statu
reimburs
clinic
pharmacist
servic
primari
care
pilot
studi
elizabeth
marn
pharmd
bcacp
amanda
guild
pharmd
nanci
j
lee
pharmd
bcp
kyann
wiss
pharmd
cyndi
clegg
bs
pharm
mha
medic
group
seattl
wa
medic
group
issaquah
wa
medic
center
edmond
wa
servic
program
respons
recent
washington
state
legisl
sb
requir
commerci
insur
plan
recogn
pharmacist
provid
swedish
medic
group
develop
pilot
project
assess
impact
bill
pharmaci
servic
primari
care
clinic
bill
requir
feder
insur
medicaremedicaidtricar
recogn
pharmacist
provid
therefor
bill
matrix
develop
provid
guidanc
bill
commerci
feder
insur
patient
patient
visit
clinic
pharmacist
bill
insur
either
visit
refer
provid
name
current
procedur
terminolog
cpt
code
govern
payer
pharmacist
provid
visit
cpt
code
commerci
payer
metric
assess
pilot
includ
reimburs
receiv
well
patient
satisfact
justificationdocument
addit
expand
pharmacist
role
patient
care
bill
clinic
servic
allow
opportun
revenu
gener
today
financi
vulner
healthcar
environ
pilot
offic
visit
complet
visit
commerci
insur
patient
state
feder
fund
initi
reimburs
data
visit
reveal
fulli
adjud
reimburs
rate
gener
revenu
patient
satisfact
survey
demonstr
high
patient
satisfact
averag
rate
five
point
likert
scale
adapt
bill
model
could
appli
ambulatori
care
pharmacist
work
clinic
set
revenu
gener
opportun
would
greater
state
recogn
pharmacist
provid
structur
bill
model
could
appli
ambulatori
care
practic
set
signific
pharmacist
provid
statu
becom
commonplac
individu
state
eventu
feder
level
bill
pilot
demonstr
abil
gener
revenu
clinic
servic
primari
care
set
medic
refil
author
pilot
support
primari
care
clinic
commun
health
system
cindi
brasher
pharmd
ms
bcp
jerod
braschler
pharmd
lorna
doucett
pharmaci
mission
hospit
ashevil
nc
care
pharmaci
depart
mission
hospit
ashevil
nc
mission
hospit
ashevil
nc
servic
program
medic
refil
author
pilot
began
potenti
solut
root
caus
analysi
problem
primari
care
provid
burnout
due
part
number
medic
refil
request
come
electron
medic
record
emr
inbox
collabor
team
physician
nurs
practic
clinic
manag
informaticist
pharmacist
came
togeth
develop
central
remot
servic
funnel
medic
refil
request
away
provid
protocol
manag
pharmacist
two
pharmaci
technician
scope
includ
substanc
medic
request
refil
involv
two
primari
care
clinic
mission
health
system
justificationdocument
autom
decis
support
tool
use
develop
action
plan
well
commun
provid
emr
tool
act
place
smart
form
use
crosswalk
medic
diseas
state
along
laboratori
valu
visit
date
creat
complex
algorithm
design
remov
memori
step
allow
clinic
decis
make
result
day
includ
refil
team
take
care
follow
medic
refil
request
patient
clinic
visit
schedul
laboratori
order
gener
signific
clinic
intervent
identifi
adapt
concept
led
refil
servic
rel
new
healthcar
arena
hand
health
system
countri
establish
servic
signific
day
oper
servic
two
primari
care
clinic
pilot
evalu
result
develop
busi
plan
perman
servic
implement
benefit
refil
pilot
clinic
financi
success
enough
creat
perman
refil
team
pharmacist
technician
develop
implement
clinic
pharmaci
intervent
improv
qualiti
rate
osteoporosi
manag
women
fractur
kyann
wiss
pharmd
bcacp
nanci
j
lee
pharmd
bcp
amanda
guild
pharmd
elizabeth
marn
pharmd
cyndi
clegg
bs
pharm
mha
medic
group
seattl
wa
medic
group
issaquah
wa
medic
center
edmond
wa
servic
program
center
medicar
medicaid
servic
cm
use
qualiti
rate
rank
medicar
advantag
plan
higher
rate
correspond
higher
qualiti
one
evalu
measur
look
women
suffer
fractur
requir
absorptiometri
dexa
medic
treat
osteoporosi
within
six
month
event
swedish
medic
group
smg
leadership
request
clinic
pharmaci
team
develop
protocol
improv
measur
current
within
smg
clinic
pharmaci
practition
cpp
five
independ
clinic
servic
addit
network
clinic
electron
consult
servic
servic
would
provid
clinic
within
smg
cpp
review
current
procedur
develop
new
workflow
central
popul
manag
team
member
identifi
patient
fractur
intern
diagnosi
code
insur
claim
provid
report
cpp
cpp
review
chart
appropri
dexa
versu
osteoporosi
pharmacotherapi
recommend
made
primari
care
provid
patient
electron
medic
record
emr
justificationdocument
prior
cpp
involv
smg
rate
osteoporosi
manag
subsequ
involv
cpp
quarter
four
smg
reach
rate
patient
meet
measur
smg
remain
rate
patient
meet
measur
adapt
servic
could
adapt
institut
access
popul
health
level
data
electron
medic
record
emr
cpp
provid
popul
health
servic
smg
clinic
regardless
cpp
locat
recommend
provid
document
justif
recommend
obtain
emr
signific
clinic
pharmaci
involv
rate
within
institut
increas
reimburs
potenti
healthcar
plan
well
improv
qualiti
care
patient
reduc
risk
futur
fractur
implement
comprehens
medic
manag
servic
primari
care
clinic
urban
hospit
nicol
amadon
pharmd
bcgp
depart
pharmaci
lincoln
medic
mental
health
center
bronx
ny
servic
program
comprehens
medic
manag
cmm
servic
develop
integr
account
care
organ
aco
outpati
servic
hospit
new
york
citi
one
clinic
pharmacist
ad
one
physician
team
primari
care
clinic
popul
focu
initi
rollout
includ
senior
age
year
older
hemoglobin
greater
initi
cmm
visit
includ
medic
reconcili
evalu
medic
safeti
efficaci
adher
assess
medic
diseas
state
educ
recommend
prescrib
medic
optim
cmm
visit
focu
medic
optim
side
effect
mitig
adher
counsel
progress
educ
justificationdocument
cmm
servic
provid
collabor
support
pharmaci
busi
primari
care
clinic
never
pharmacist
assist
direct
patient
care
servic
target
senior
risk
polypharmaci
complic
therein
focus
uncontrol
diabet
help
aco
achiev
top
medic
adher
hedi
core
measur
initi
pharmacist
success
measur
number
problem
mrp
identifi
pharmacist
intervent
accept
rate
first
month
activ
clinic
pharmacist
identifi
mrp
averag
per
patient
recommend
accept
rate
longitudin
clinic
outcom
includ
chang
blood
pressur
ldl
hedi
measur
adapt
cmm
model
appli
primari
care
practic
model
also
adapt
focu
outcom
patient
popul
given
broad
scope
potenti
pharmacist
intervent
signific
aco
model
expand
grow
govern
polici
opportun
clinic
pharmacist
integr
primari
care
clinic
pharmacist
uniqu
posit
perform
cmm
servic
improv
patient
adher
impact
qualiti
measur
care
model
implement
fractur
liaison
servic
larg
academ
medic
center
sarah
j
billup
alexandra
marcu
mari
anderson
wallac
micol
rothman
lisa
schill
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
perform
univers
colorado
anschutz
medic
campu
aurora
co
medicin
univers
colorado
school
medicin
aurora
co
endocrinolog
univers
colorado
school
medicin
aurora
co
servic
program
interprofession
team
develop
implement
fractur
liaison
servic
fl
univers
colorado
health
system
juli
decemb
improv
care
patient
experienc
fractur
team
includ
physician
popul
health
outreach
coordin
clinic
pharmacist
analyst
fl
team
meet
monthli
review
process
outcom
adapt
workflow
need
workflow
analyst
gener
weekli
list
patient
age
seen
one
ten
primari
care
practic
discharg
hospit
ed
bill
diagnosi
hip
spine
wrist
fractur
popul
outreach
team
contact
patient
discharg
provid
educ
order
bmd
laboratori
test
indic
schedul
primari
care
appoint
osteoporosi
evalu
need
clinic
pharmacist
assess
pharmacotherapi
need
provid
telephon
educ
patient
initi
therapi
pharmacotherapi
indic
initi
pharmacist
send
therapeut
recommend
provid
justificationdocument
osteoporosi
undertr
even
patient
recent
year
fl
implement
elig
patient
complet
clinic
visit
within
day
without
recent
bmd
one
perform
within
six
month
patient
therapi
initi
treatment
interim
analys
perform
januari
show
differ
complet
visit
bmd
test
medic
initi
went
respect
adapt
servic
adapt
healthcar
system
abl
identifi
patient
discharg
fragil
fractur
commun
primari
care
provid
could
conduct
central
clinic
level
signific
fl
potenti
significantli
improv
outcom
decreas
healthcar
cost
util
transit
care
servic
percept
evalu
student
pharmacist
andrea
bejjani
bachelor
scienc
sharon
connor
pharmaci
univers
pittsburgh
pittsburgh
pa
pittsburgh
school
pharmaci
pittsburgh
pa
servic
program
describ
transit
care
toc
program
urban
commun
health
center
hc
util
innov
transit
care
tool
itoc
systemat
process
review
patient
hospit
discharg
pharmaci
student
use
itoc
form
target
patient
risk
problem
drp
patient
case
present
clinic
pharmacist
manag
interprofession
team
hc
underserv
area
provid
comprehens
primari
care
predominantli
patient
justificationdocument
toc
often
manag
inpati
set
limit
commun
outpati
care
team
model
student
pharmacist
review
patient
profil
month
drp
discrep
identifi
drp
compar
drp
student
accur
identifi
drp
vs
requir
intervent
mix
assess
evalu
student
confid
percept
servic
qualit
assess
reveal
although
initi
challeng
student
found
support
standard
polici
procedur
program
evalu
survey
reveal
student
score
confid
perform
process
likert
scale
indic
strong
agreement
statement
adapt
similar
program
potenti
success
pharmacist
supervis
student
describ
servic
initi
challeng
month
comfort
identifi
drp
present
case
pharmacist
student
indic
would
comfort
process
signific
almost
patient
experi
medic
regimen
alter
hospit
discharg
patient
receiv
care
set
may
higher
risk
program
led
accur
identif
drp
lead
pharmacist
correct
program
assess
reveal
increas
student
confid
time
process
identifi
drp
may
effici
aid
student
pharmacist
implement
direct
oral
anticoagul
servic
anticoagul
clinic
bianca
korki
alison
lobkovich
insaf
mohammad
pharmd
candic
l
garwood
pharmd
fccp
pharmaci
practic
eugen
applebaum
colleg
pharmaci
health
scienc
wayn
state
univers
detroit
mi
pharmaci
harper
univers
hospit
detroit
medic
center
detroit
mi
servic
program
novemb
direct
oral
anticoagul
doac
servic
integr
tradit
anticoagul
clinic
acc
affili
urban
academ
medic
center
model
pharmacist
contact
patient
follow
referr
address
urgent
need
arrang
first
visit
pharmacist
role
includ
assess
appropri
doac
therapi
decid
choic
anticoagul
therapi
laboratori
monitor
promot
adher
resolv
drug
access
issu
ongo
patient
provid
tailor
frequenc
mode
visit
justificationdocument
sever
challeng
exist
doac
warrant
regular
assess
includ
doac
prescrib
nuanc
poor
adher
high
cost
date
patient
refer
servic
outcom
data
collect
patient
total
variou
pharmacist
intervent
document
safeti
efficaci
outcom
eg
bleed
thromboembol
event
rate
medic
adher
measur
determin
success
servic
humanist
outcom
provid
patient
satisfact
also
measur
adapt
doac
servic
success
integr
exist
acc
without
need
addit
staff
space
fund
two
pharmacist
manag
servic
patient
visit
complet
averag
minut
use
protocol
laboratori
monitor
well
mechan
patient
referr
servic
could
implement
privat
acc
signific
pharmacist
equip
skill
ensur
appropri
doac
therapi
promot
adher
resolv
access
issu
poor
adher
doac
associ
increas
risk
stroke
mortal
doac
care
shown
improv
adher
compar
usual
care
anticip
servic
demonstr
improv
safeti
efficaci
outcom
medic
adher
provid
patient
satisfact
pharmacist
assist
share
decis
make
drug
therapi
select
patient
depress
daniel
larson
pharmd
jame
hoehn
pharmd
bcp
fccp
univers
iowa
colleg
pharmaci
northeast
iowa
famili
practic
center
waterloo
ia
servic
program
depress
common
costli
diseas
current
evid
suggest
minim
differ
efficaci
among
antidepress
patient
prefer
conjunct
distinct
toxic
burden
cost
may
use
differenti
antidepress
primari
object
prospect
qualiti
improv
studi
evalu
impact
share
sdm
tool
initi
medic
select
among
patient
depress
elig
particip
adult
patient
year
seen
clinic
novemb
diagnosi
depress
plan
initi
pharmacotherapi
depress
patient
currentrec
antidepress
use
suicid
ideat
pregnancybreastfeed
resid
care
facil
andor
patient
major
barrier
particip
sdm
exclud
pharmacist
met
patient
clinic
appoint
discuss
antidepress
medic
use
sdm
tool
develop
mayo
clinic
discuss
patient
identifi
prefer
antidepress
review
pharmacist
appropri
pharmacist
commun
inform
physician
disclos
initi
plan
antidepress
made
final
determin
antidepress
prescrib
justificationdocument
date
patient
particip
project
patient
complet
sdm
discuss
pharmacist
physician
prescrib
patient
prefer
medic
instanc
initi
discord
patientphysician
prefer
interim
result
show
antidepress
physician
plan
antidepress
match
time
overal
patient
report
increas
satisfact
medic
care
particip
sdm
process
adapt
project
applic
ambulatori
clinic
care
patient
depress
sdm
tool
includ
depress
medic
tool
avail
free
onlin
signific
pharmacist
use
sdm
tool
improv
patient
satisfact
strongli
influenc
initi
antidepress
select
best
knowledg
first
evalu
sdm
affect
initi
drug
select
depress
great
plain
hcv
echo
build
capac
fill
clinic
gap
cure
hepat
c
paulina
deme
bradley
moran
neelam
gazarian
jonathan
owen
david
stephen
bsn
jessica
leston
pharmaci
depart
pharmaci
practic
administr
scienc
univers
new
mexico
health
scienc
center
albuquerqu
nm
peck
servic
unit
indian
health
servic
ih
poplar
mt
public
health
servic
quentin
n
burdick
memori
hospit
belcourt
nd
portland
area
indian
health
board
portland
servic
program
project
echo
extens
commun
healthcar
outcom
develop
univers
new
mexico
health
scienc
center
unmhsc
improv
access
hepat
c
viru
hcv
treatment
best
practic
hcv
care
echo
leverag
videoconferenc
technolog
enabl
commun
primari
care
clinician
pcc
present
patient
case
team
specialist
regular
virtual
clinic
unlik
teleecho
clinic
great
plain
hcv
echo
gear
toward
pharmacist
faculti
specialist
provid
clinic
recommend
pharmacist
expertis
hcv
care
justificationdocument
american
indian
alaska
nativ
aian
peopl
highest
mortal
rate
hcv
race
ethnic
treatment
rate
among
aian
popul
low
despit
avail
highli
effect
hcv
treatment
indian
health
servicetribalurban
indian
itu
primari
care
clinic
develop
capac
provid
hcv
cure
mitig
challeng
lack
specialist
provid
specialti
care
rural
area
great
plain
hcv
echo
launch
januari
clinic
site
uniqu
clinic
particip
join
monthli
teleecho
session
date
patient
present
recommend
managementtreat
adapt
echo
model
train
pcc
provid
specialti
care
complex
condit
hcv
eventu
particip
project
echo
creat
cascad
treatment
beyond
number
case
present
teleecho
clinic
allow
pcc
gain
experi
knowledg
confid
treat
complex
condit
signific
mani
itu
clinic
remot
area
patient
experi
barrier
healthcar
pharmacist
emerg
import
compon
clinic
leadership
pharmacist
identifi
clinic
care
gap
provid
clinic
expertis
activ
particip
address
health
care
dispar
hcv
care
aian
patient
echo
model
provid
process
guid
transform
chang
hcv
treatment
patient
system
chang
itu
clinic
identifi
best
practic
document
comprehens
medic
manag
caitlin
k
frail
pharmd
ms
bcacp
carri
blanchard
pharmd
kyle
funk
pharmd
mari
roth
mcclurg
pharmd
todd
sorensen
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
medic
optim
unc
eshelman
school
pharmaci
chapel
hill
nc
eshelman
school
pharmaci
chapel
hill
nc
servic
program
standard
approach
document
critic
commun
pharmacist
patient
care
process
ppcp
healthcar
provid
payer
comprehens
medic
manag
cmm
effect
implement
studi
develop
rubric
evalu
fidel
cmm
ppcp
document
review
due
high
variabl
document
across
health
system
unabl
valid
rubric
team
three
research
review
note
repres
health
system
identifi
strength
weak
document
approach
six
best
practic
identifi
consist
categor
medic
therapi
problem
mtp
use
indic
effect
safeti
adher
iesa
framework
assess
structur
approach
medic
reconcili
clear
document
medic
experi
uniform
organ
note
inclus
explicit
plan
plan
implement
follow
justificationdocument
recent
effort
made
standard
ppcp
practic
educ
document
discuss
detail
part
standard
work
critic
compon
accp
standard
practic
clinic
pharmacist
adapt
best
practic
identifi
lead
standard
templat
document
practic
use
qualiti
assur
cmm
servic
evalu
pharmaci
student
resid
educ
signific
lack
consist
pharmacist
document
lead
ineffici
ineffect
commun
healthcar
provid
standard
approach
document
ppcp
creat
effici
commun
care
team
member
increas
provid
understand
confid
servic
enhanc
abil
extract
data
qualiti
measur
provid
assur
payer
payment
provid
expect
level
servic
best
practic
identifi
work
valuabl
resourc
help
teach
commun
consist
cmm
ppcp
transit
care
indig
popul
jeanna
sewel
pharmd
bcacp
depart
pharmaci
practic
auburn
univers
harrison
school
pharmaci
auburn
al
servic
program
transit
servic
implement
june
commun
hospit
indig
clinic
care
coordin
call
pharmacist
prior
uninsur
patient
discharg
schedul
visit
within
day
initi
visit
pharmacist
assess
diseas
control
medic
access
problem
need
patient
seen
provid
patient
establish
care
receiv
refil
physic
assess
pharmacist
follow
patient
via
phone
determin
diseas
state
control
readmiss
statu
justificationdocument
nonelderli
alabama
resid
lack
health
insur
uninsur
patient
frequent
land
hospit
typic
return
hospit
futur
problem
aris
due
limit
access
care
cost
associ
hospit
care
indig
patient
signific
therefor
resourc
suppli
patient
outpati
care
necessari
purpos
studi
determin
effect
transit
care
program
indig
popul
limit
access
primari
care
adapt
servic
could
implement
ambulatori
care
clinic
area
serv
patient
limit
access
medic
care
particularli
uninsur
signific
month
patient
refer
pharmacist
establish
primari
care
patient
attend
initi
visit
pharmacist
attend
initi
visit
patient
subsequ
admiss
ed
visit
within
day
day
discharg
respect
attend
patient
subsequ
admiss
ed
visit
day
respect
visit
patient
high
risk
hospit
readmiss
abl
establish
care
provid
implement
system
pharmaci
practic
operation
effect
comprehens
medic
manag
deliveri
primari
care
melani
livet
carri
blanchard
pharmd
todd
sorensen
mari
roth
mcclurg
pharmd
eshelman
school
pharmaci
chapel
hill
nc
medic
optim
unc
eshelman
school
pharmaci
chapel
hill
nc
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
servic
program
implement
system
describ
project
customiz
blueprint
deliveri
comprehens
medic
manag
cmm
medic
optim
servic
system
result
merg
implement
scienc
expertis
lesson
learn
parent
studi
cmm
primari
care
grant
system
compris
number
element
includ
implement
step
activ
practic
resourc
assess
inform
materi
learn
support
compon
integr
implement
effort
project
describ
uniqu
operation
deliveri
cmm
primari
care
context
applic
system
describ
exampl
justificationdocument
evalu
medic
optim
intervent
produc
consist
result
lack
consist
attribut
part
implement
variabl
reduc
variabl
requir
use
approach
focus
optim
implement
integr
implement
scienc
within
pharmaci
practic
recent
emerg
potenti
solut
howev
effect
implement
strategi
need
custom
medic
optim
intervent
healthcar
set
project
describ
effort
operation
implement
process
cmm
primari
care
set
adapt
system
use
pharmacist
health
profession
seek
implement
improv
implement
cmm
operation
specif
cmm
system
generaliz
medic
optim
intervent
addit
tailor
signific
implement
system
first
blueprint
facilit
implement
cmm
prospect
ground
implement
scienc
theori
retrospect
refin
base
lesson
learn
applic
larg
studi
ensur
medic
optim
intervent
like
cmm
implement
intend
effect
requir
creation
implement
system
serv
roadmap
interest
deliv
intervent
impact
novel
medic
educ
method
nurs
cv
surgeri
stepdown
unit
lauren
czosnowski
jessica
heinowski
practic
butler
univers
indianapoli
univers
indianapoli
servic
program
pharmacist
cv
surgeri
step
unit
bulletin
board
staff
bathroom
provid
educ
nurs
regard
medic
pharmacist
sit
qualiti
safeti
committe
unit
leadership
identifi
medic
relat
issu
medic
staff
could
benefit
educ
monthli
pharmaci
student
rotat
creat
educ
place
board
month
justificationdocument
nurs
unit
request
educ
medic
knowledg
better
educ
patient
concurr
initi
across
hospit
encourag
nurs
educ
patient
administ
medic
period
educ
board
establish
trivia
question
regard
current
topic
post
nurs
invit
particip
assess
efficaci
educ
deliveri
nurs
particip
answer
question
correctli
period
nurs
survey
regard
educ
board
nurs
referenc
board
least
month
felt
comfort
medic
inform
adapt
project
easili
adapt
requir
dedic
space
good
commun
elicit
feedback
team
member
regard
educ
need
educ
topic
could
easili
adapt
fit
target
popul
traine
easili
involv
guidanc
practition
signific
better
educ
nurs
medic
issu
potenti
improv
patient
care
ensur
confid
administ
med
help
nurs
better
educ
patient
encourag
dialogu
unit
pharmacist
nurs
move
new
practic
set
may
familiar
common
medic
util
set
util
traine
creat
educ
materi
also
improv
skill
creat
educ
materi
identifi
pertin
inform
includ
materi
develop
system
pharmaci
therapeut
committe
lead
qualiti
outcom
harmind
sikand
pharmd
fcshp
fashp
melissa
flaherti
pharmaci
scripp
merci
hospit
san
diego
ca
health
san
diego
ca
servic
program
scripp
health
hospit
acut
care
system
commun
teach
hospit
hospit
pharmaci
therapeut
p
committe
site
base
formulari
manag
process
report
describ
deliber
journey
standard
organ
system
p
formulari
manag
process
justificationdocument
site
base
p
committe
uniformli
effect
formulari
manag
volum
review
implement
restrict
lead
inconsist
decis
make
standard
p
focus
leverag
purchas
power
fiscal
stewardship
creat
cultur
share
decis
make
account
membership
p
council
ptc
includ
site
p
chair
physician
member
clinic
pharmaci
leader
nurs
repres
financi
analyst
corpor
pharmaci
leader
execut
sponsor
standard
work
creat
establish
charter
govern
formulari
review
cycl
approv
appeal
process
commun
cascad
develop
engag
stake
holder
site
p
committe
system
chief
medic
director
social
concept
site
base
medic
execut
committe
endors
ptc
thu
establish
sole
formulari
decis
make
bodi
system
adapt
systemat
process
appli
within
health
system
month
budget
neutral
concept
tool
use
translat
across
commun
academ
institut
standard
work
tool
process
flow
map
creat
signific
prior
ptc
annual
approxim
formulari
review
conduct
system
sinc
implement
review
perform
formulari
util
conduct
evalu
adher
restrict
save
million
dollar
achiev
initi
today
ptc
recogn
power
decis
make
platform
usp
assess
risk
conduct
commun
health
system
cindi
brasher
pharmd
ms
bcp
inpati
pharmaci
mission
hospit
ashevil
nc
servic
program
prepar
usp
enforc
multidisciplinari
group
mission
health
system
evalu
list
hazard
medic
administ
throughout
organ
complet
assess
risk
determin
practic
align
deviat
strict
recommend
niosh
guidelin
justificationdocument
medic
administ
acut
care
hospit
mission
health
system
evalu
base
follow
criteria
inclus
respect
niosh
tabl
dosag
form
volum
origin
dose
autom
dispens
cabinet
vs
pharmaci
medic
clinic
review
base
upon
indic
inclus
niosh
tabl
adapt
mission
health
system
identifi
area
niosh
tabl
biohazard
tabl
reproduct
risk
medic
practic
provid
increas
level
protect
current
state
long
term
exposur
would
still
deviat
strict
recommend
niosh
use
close
system
transfer
devic
limit
niosh
tabl
medic
antineoplast
medic
compound
administr
person
protect
equip
engin
control
stratifi
base
impact
exposur
altern
medic
dosag
form
identifi
use
limit
exposur
handl
signific
complianc
usp
requir
decemb
health
care
system
pharmaci
choos
strict
adher
niosh
recommend
handl
hazard
medic
conduct
assess
risk
identifi
altern
practic
provid
exposur
protect
employe
review
process
conduct
assess
risk
outlin
element
evalu
conclus
identifi
guid
practic
handl
hazard
medic
mission
experienti
research
intern
train
merit
program
develop
pharmaci
student
internship
program
commun
teach
hospit
cindi
brasher
pharmd
ms
bcp
inpati
pharmaci
mission
hospit
ashevil
nc
servic
program
mission
experienti
research
intern
train
merit
program
develop
mission
hospit
respons
need
provid
opportun
pharmaci
student
experi
oper
qualiti
improv
process
hospit
set
prepar
pharmaci
resid
justificationdocument
merit
intern
program
incorpor
key
area
throughout
pharmaci
school
experi
staf
pharmaci
technician
role
shadow
area
interest
clinic
research
process
improv
project
involv
clinic
knowledg
develop
pharmaci
student
opportun
train
gener
area
special
area
medic
histori
collect
emerg
depart
pediatr
chemotherapi
compound
etc
student
also
particip
researchqu
improv
project
encourag
depart
present
state
pharmaci
meet
quarterli
meet
includ
clinic
pearl
diseas
state
discuss
addit
program
busi
adapt
program
allow
pharmaci
student
learn
oper
aspect
inpati
pharmaci
staf
experi
clinic
aspect
research
project
develop
pharmaci
depart
benefit
internship
experi
highli
train
workforc
need
posit
complet
research
improv
patient
care
qualiti
signific
pharmaci
depart
benefit
extend
pharmaci
internship
program
includ
staf
clinic
develop
research
activ
pharmaci
student
type
program
mutual
benefici
pharmaci
student
prepar
pharmaci
resid
understand
role
workflow
pharmaci
technician
conduct
research
improv
process
outcom
understand
inpati
pharmaci
distribut
challeng
earli
implement
pennsylvania
pharmacist
care
network
initi
payor
contract
kim
c
coley
joni
carrol
melinda
kozminski
brandon
antinopoulo
nichola
leon
pharmd
bcp
david
pope
pat
eppl
luca
berenbrok
melissa
mcgivney
pittsburgh
school
pharmaci
pittsburgh
pa
colleg
pharmaci
penn
center
primari
care
penn
presbyterian
medic
center
philadelphia
pa
pharmacist
evan
ga
pharmacist
associ
harrisburg
pa
pharmaci
univers
pittsburgh
pittsburgh
pa
servic
program
implement
initi
payor
contract
provis
comprehens
medic
manag
cmm
within
pennsylvania
pharmacist
care
network
ppcn
pharmaci
began
septemb
commun
pharmaci
particip
ppcn
pharmaci
elig
particip
base
geograph
locat
payor
network
third
month
elig
pharmaci
sign
agreement
provid
cmm
servic
three
major
implement
stage
explor
instal
initi
implement
occur
far
major
task
within
phase
implement
includ
network
leadership
team
structur
format
stakehold
engag
feedback
pharmacist
engag
train
solidifi
key
partnership
patient
care
implement
continu
qualiti
improv
justificationdocument
ppcn
establish
viabl
network
medicaid
payor
contract
enabl
care
patient
age
one
chronic
medic
ppcn
pharmaci
locat
decemb
contract
pharmaci
complet
initi
patient
encount
encount
document
servic
standard
across
singl
platform
allow
bill
servic
patient
outcom
analys
adapt
seri
key
inform
interview
conduct
pharmaci
learn
success
challeng
implement
payor
contract
date
pharmaci
share
initi
experi
initi
result
demonstr
immedi
impact
individu
patient
age
abil
reach
patient
lost
care
includ
high
risk
patient
patient
suboxon
pediatr
patient
signific
implement
payor
contract
provid
cmm
medicaid
patient
practic
network
launch
pennsylvania
initi
implement
demonstr
immedi
impact
individu
patient
serv
share
learn
may
guid
implement
reimburs
patient
care
servic
network
futur
implement
academ
detail
program
larg
integr
health
system
whitney
mortensen
pharmd
mba
bcp
sabrina
cole
pharmd
bcp
cphim
jefferi
l
olson
pharmd
mba
bcp
bcacp
pharmaci
servic
intermountain
healthcar
taylorsvil
ut
servic
program
feasibl
use
educ
method
evalu
within
larg
integr
health
system
aim
effect
implement
maintain
academ
detail
program
mede
educ
prescrib
medic
mede
began
focu
outpati
clinic
includ
brief
bimonthli
group
discuss
led
ambulatori
care
commun
pharmacist
short
monthli
electron
newslett
mede
redesign
current
form
durabl
program
includ
brief
devic
demonstr
video
present
ambulatori
care
commun
pharmacist
webinar
led
ambulatori
care
commun
pharmacist
access
biweekli
edit
medic
letter
exclud
medic
letter
mede
content
develop
intern
drug
inform
specialist
justificationdocument
mani
prescrib
reli
pharmaceut
sale
repres
medic
inform
robust
academ
detail
program
also
meet
educ
need
addit
academ
detail
promot
safe
use
medic
primari
goal
provid
patient
care
adapt
either
initi
design
current
design
mede
could
replic
health
system
base
avail
resourc
program
scope
initi
design
reason
effect
approach
option
neither
feasibl
sustain
mani
health
system
current
design
mede
allow
access
includ
prescrib
rural
area
without
need
signific
addit
resourc
make
practic
approach
organ
signific
effect
educ
prescrib
health
system
differ
size
complex
pose
varieti
logist
challeng
academ
detail
program
fill
educ
gap
prescrib
promot
relationship
increas
visibl
pharmaci
depart
improv
patient
care
throughout
health
system
civilian
pharmaci
involv
depart
defens
innov
readi
train
abigail
hamlin
pharmd
misha
ann
misher
pharmd
bcacp
cde
pharmaci
univers
georgia
savannah
ga
georgia
savannah
ga
josephscandl
health
system
savannah
ga
servic
program
depart
defens
chose
savannah
georgia
innov
readi
train
irt
troop
everi
branch
along
healthcar
volunt
provid
medic
dental
pharmaceut
vision
veterinari
servic
four
locat
civilian
pharmacist
univers
georgia
uga
organ
pharmaci
servic
supplement
provid
militari
two
uga
faculti
attend
meet
coordin
volunt
clinic
pharmacist
resid
fourth
year
pharmaci
student
volunt
dischargedispens
area
two
four
site
volunt
assist
diseas
state
medic
educ
addit
clinic
pharmacist
provid
educ
member
militari
justificationdocument
irt
intend
help
us
militari
readi
train
provid
healthcar
cost
local
commun
civilian
pharmaci
servic
provid
irt
help
provid
addit
care
patient
collabor
militari
personnel
civilian
pharmacist
built
civilmilitari
relat
medic
educ
provid
primarili
antibiot
nonsteroid
drug
acetaminophen
steroid
antihistamin
patient
counsel
diabet
hypertens
smoke
cessat
nutrit
stress
manag
exercis
irt
provid
healthcar
patient
two
locat
cover
civilian
pharmaci
servic
patient
serv
approxim
minut
volunt
time
spent
counsel
educ
provid
militari
personnel
adapt
irt
collabor
program
conduct
throughout
unit
state
program
util
militari
civilian
resourc
servic
provid
savannah
ga
exampl
civilian
involv
make
impact
train
offer
equival
servic
could
provid
local
pharmacist
irt
conduct
signific
addit
healthcar
servic
provid
patient
pharmaci
volunt
provid
opportun
interprofession
collabor
militari
medic
personnel
civilian
pharmacist
made
impact
irt
oper
provid
recommend
improv
train
procedur
concomit
expans
geriatr
pharmacotherapi
servic
resid
train
experi
priya
shah
rebecca
chow
luigi
brunetti
pharmd
mph
bcp
bcgp
joan
perron
nanci
doherti
rph
pharmaci
robert
wood
johnson
univers
hospit
somerset
somervil
nj
pharmaci
practic
administr
rutger
state
univers
new
jersey
piscataway
nj
servic
program
set
program
inpati
geriatr
care
unit
locat
commun
teach
medic
center
goal
new
servic
expand
exposur
pharmacist
decentr
geriatr
patient
care
unit
creat
addit
resid
train
experi
servic
provid
includ
order
verif
particip
patient
care
round
medic
reconcili
intraven
oral
adjust
clinician
educ
justificationdocument
prior
implement
decentr
servic
geriatr
unit
pharmacist
involv
geriatr
care
limit
tradit
order
process
develop
program
allow
pharmacist
particip
direct
patient
care
optim
pharmacotherapi
program
initi
trial
pharmaci
resid
decentr
pharmacist
follow
trial
period
central
pharmacist
train
work
decentr
pharmacist
second
pharmaci
resid
complet
geriatr
rotat
five
month
later
program
becam
establish
metric
assess
impact
servic
includ
increas
advers
event
report
medic
intervent
beyond
captur
tradit
order
process
clinician
percept
increas
pharmacist
involv
resid
feedback
experi
increas
number
patient
counsel
session
trial
period
second
resid
experi
adapt
base
feedback
resid
clinician
servic
continu
evolv
rotat
becom
requir
learn
experi
expos
futur
resid
role
decentr
pharmacist
next
step
includ
analyz
effect
patient
satisfact
survey
score
interprofession
percept
pharmaci
servic
signific
servic
allow
pharmacist
engag
direct
patient
care
geriatr
unit
improv
qualiti
pharmacotherapi
provid
resid
rotat
experi
combin
resid
experi
expand
clinic
servic
allow
resid
improv
knowledg
base
learn
strategi
justifi
expand
pharmaci
program
develop
inpati
intern
medicin
critic
care
pharmaci
faculti
share
servic
model
meredith
howard
jessica
schillig
marian
gaviola
pharmacotherapi
univers
north
texa
system
colleg
pharmaci
fort
worth
tx
pharmaci
medic
citi
fort
worth
fort
worth
tx
servic
program
two
faculti
pharmacist
special
intern
medicin
critic
care
practic
commun
teach
hospit
histor
faculti
maintain
practic
simultan
four
weekli
throughout
year
share
servic
model
ssm
implement
last
year
allow
faculti
altern
month
cover
multipl
patient
care
unit
full
shift
faculti
pursu
research
teach
activ
justificationdocument
faculti
particip
ssm
gain
popular
particularli
ambulatori
care
howev
less
common
among
inpati
faculti
especi
involv
differ
specialti
benefit
ssm
may
includ
improv
effici
continu
patient
care
adapt
implement
ssm
faculti
two
differ
specialti
feasibl
may
enhanc
patient
care
optim
effici
approach
implement
sever
way
faculti
may
cover
unit
one
specialti
unit
serv
primari
focu
time
faculti
pharmacist
cover
respect
specialti
unit
servic
month
swap
patient
care
unit
coverag
need
former
model
may
best
hospit
assign
clinic
pharmacist
latter
may
prefer
decentr
clinic
pharmacist
rotat
unit
assign
key
factor
success
includ
excel
commun
flexibl
among
engag
stakehold
signific
model
faculti
safe
care
patient
spend
time
precept
survey
pharmaci
staff
reveal
ssm
highli
prefer
compar
histor
model
cite
improv
continu
care
student
learn
healthcar
provid
satisfact
repres
uniqu
approach
despit
differ
specialti
faculti
success
built
share
servic
benefit
patient
student
practic
site
colleg
given
demand
place
clinic
faculti
uniqu
innov
method
improv
effici
maintain
excel
clinic
servic
teach
scholarship
essenti
success
develop
implement
resid
equival
certif
program
kamaria
brown
susan
bear
caleb
littl
lydia
wang
shay
phillip
nick
wilkin
paig
carson
fern
tyler
greenwood
greenwood
katherin
rector
health
charlott
nc
health
concord
nc
servic
program
accp
commentari
resid
equival
publish
util
basi
develop
resid
equival
certif
atrium
health
individu
complet
certif
must
fulfil
requir
line
ashp
resid
standard
must
submit
portfolio
evid
profici
applic
pair
pharmacist
mentor
overse
guid
journey
begin
complet
particip
voluntari
certif
grant
pharmacist
appli
demonstr
excel
respect
practic
profess
justificationdocument
valu
need
resid
train
often
realiz
earli
career
year
atrium
health
pharmacist
practic
set
limit
clinic
role
repeatedli
request
opportun
growth
develop
addit
establish
career
ladder
resid
equival
certif
provid
addit
pathway
train
equival
resid
well
pathway
exist
clinic
practition
show
complet
requir
possess
skillset
equal
resid
adapt
atrium
health
employ
wide
array
pharmacist
vari
background
opportun
open
pharmacist
good
stand
demonstr
necessari
skill
profici
perform
direct
patient
care
activ
well
level
commit
necessari
success
candid
complet
certif
complet
portfolio
use
demonstr
profici
within
atrium
health
potenti
beyond
signific
goal
atrium
health
divis
pharmaci
pharmacist
direct
patient
care
role
train
accord
resid
standard
certif
help
bridg
gap
clinic
practic
resid
train
implement
interprofession
diabet
assess
homeless
individu
emili
knezevich
pharmd
bcp
cde
cynthia
hadenfeldt
edd
conni
liang
pharmd
kasey
rubin
pharmd
constanc
atkinson
pharmd
kateri
petto
pharmd
pharmaci
practic
creighton
univers
school
pharmaci
health
profess
omaha
ne
univers
school
nurs
omaha
ne
univers
school
pharmaci
health
profess
omaha
ne
servic
program
project
homeless
connect
omaha
phco
event
held
creighton
univers
day
homeless
come
servic
advanc
live
year
creighton
school
pharmaci
nurs
medicin
offer
diabet
assess
allow
interprofession
assess
individu
complianc
medic
standard
manag
diabet
faculti
member
develop
tool
student
util
assess
manag
addit
hemoglobin
test
obtain
grant
fund
complet
diabet
educ
provid
interview
patient
identifi
poor
control
new
diagnosi
refer
physician
day
provid
futur
appoint
commun
health
center
justificationdocument
prior
phco
event
provid
random
glucos
test
littl
diabet
educ
contrast
particip
event
screen
risk
develop
diabet
high
risk
demonstr
diabet
demonstr
poor
control
individu
newli
identifi
diabet
adapt
incid
diabet
homeless
popul
grow
pair
event
univers
servic
base
mission
recommend
identifi
volunt
desir
provid
care
underserv
addit
collabor
organ
larg
stakehold
commun
offer
mani
resourc
client
outsid
health
servic
signific
diabet
assess
servic
provid
interprofession
team
larg
success
meet
need
popul
mani
patient
identifi
risk
develop
diabet
poor
control
previous
diagnos
condit
like
new
diagnosi
diabet
servic
gave
individu
opportun
discuss
health
profession
may
access
otherwis
pharmacist
led
continu
glucos
monitor
share
medic
appoint
diana
isaac
pharmd
cleveland
clinic
diabet
center
cleveland
oh
servic
program
profession
continu
glucos
monitor
cgm
own
clinic
loan
patient
cover
medicar
privat
insur
plan
peopl
diabet
pharmacist
pair
diabet
educ
start
cgm
share
medic
appoint
sma
first
appoint
sensor
insert
one
week
later
patient
attend
sma
cgm
download
pharmacist
make
medic
adjust
need
collabor
practic
agreement
diabet
educ
recommend
lifestyl
chang
conclus
sensor
remov
patient
receiv
copi
cgm
report
along
individu
recommend
share
provid
visit
usual
includ
patient
pharmacist
diabet
educ
justificationdocument
reimburs
cgm
rang
per
insert
per
interpret
patient
cost
sensor
approxim
therefor
class
patient
yield
profit
adapt
cgm
technolog
continu
improv
becom
afford
pharmacist
skill
analyz
cgm
data
make
medic
chang
profession
cgm
also
billabl
procedur
pharmacist
util
within
variou
commun
ambulatori
care
set
gener
revenu
improv
health
outcom
signific
pharmacist
yet
provid
statu
howev
cgm
offer
innov
way
pharmacist
work
top
licens
improv
patient
outcom
gener
revenu
sinc
procedur
reimburs
insur
latent
tuberculosi
servic
famili
medicin
resid
program
ann
philbrick
pharmd
bcp
bcacp
ila
harri
pharmd
bcp
jame
van
vooren
pharmaceut
care
health
system
univers
minnesota
colleg
pharmaci
minneapoli
mn
famili
medicin
commun
health
univers
minnesota
medic
school
minneapoli
mn
servic
program
clinic
pharmacist
cp
famili
medicin
resid
program
develop
protocol
manag
patient
latent
tuberculosi
ltbi
patient
diagnos
clinic
physician
refer
cp
electron
medic
form
form
review
care
coordin
cc
medic
obtain
free
charg
local
health
depart
medic
arriv
cc
schedul
patient
initi
visit
cp
visit
cp
educ
patient
diseas
medic
potenti
advers
effect
import
adher
cp
see
patient
monthli
assess
activ
diseas
advers
effect
adher
pill
count
need
laboratori
monitor
patient
receiv
suppli
medic
visit
justificationdocument
overal
preval
ltbi
unit
state
increas
person
approxim
person
ltbi
convert
activ
diseas
difficult
treat
addit
complet
rate
low
half
peopl
complet
treatment
therefor
import
ltbi
treatment
monitor
close
healthcar
profession
adapt
program
adapt
ambulatori
care
set
benefici
add
team
member
process
order
allevi
administr
burden
signific
first
six
month
program
patient
refer
program
except
one
patient
immigr
southeast
asia
somalia
mani
patient
straightforward
requir
littl
pharmacist
intervent
uniqu
scenario
requir
intens
monitor
includ
exposur
resist
tuberculosi
hepatotox
drug
interact
complet
rate
therapi
collect
improv
medic
safeti
among
elderli
patient
ambulatori
set
alyssa
berri
rebecca
burgett
erin
day
aron
hrubetz
jame
hoehn
pharmd
bcp
fccp
pharmaci
practic
scienc
univers
iowa
colleg
pharmaci
iowa
citi
ia
iowa
colleg
pharmaci
northeast
iowa
famili
practic
center
waterloo
ia
servic
program
inappropri
medic
use
elderli
result
signific
patient
morbid
primari
object
prospect
qualiti
improv
studi
evalu
student
pharmacist
recommend
could
decreas
use
potenti
inappropri
medic
pim
use
elderli
patient
second
year
student
pharmacist
review
medic
profil
patient
northeast
iowa
famili
practic
center
elig
patient
year
age
identifi
pprnet
clinic
qualiti
report
novemb
indic
current
prescript
pim
base
upon
american
geriatr
societi
beer
criteria
student
review
medic
record
contact
prescrib
physician
within
electron
health
record
ehr
patient
attempt
via
telephon
improv
medic
use
justificationdocument
patient
initi
identifi
receiv
pim
patient
exclud
analysi
deceas
hospic
care
take
pim
result
elig
patient
mean
age
year
anticholinerg
antihistamin
common
pim
patient
take
pim
long
durat
mean
month
often
prescrib
regularli
schedul
basi
result
student
pharmacist
intervent
includ
patient
longer
take
pim
unabl
reach
via
telephon
recommend
refus
patient
physician
respect
six
pim
discontinu
adapt
student
driven
project
applic
ambulatori
clinic
care
elderli
patient
student
locat
offsit
commun
physician
patient
remot
signific
previou
effort
patient
provid
focus
improv
medic
use
elderli
produc
mix
result
primari
obstacl
includ
contact
patient
physician
patient
refus
recommend
project
util
student
earlier
train
minim
use
pim
elderli
like
requir
multifacet
approach
impact
integr
standard
protocol
deep
vein
thrombosi
prophylaxi
order
set
patient
undergo
total
joint
arthroplasti
kathryn
mundi
pharmd
daniel
tompkin
pharmd
juli
jun
pharmd
bcp
margaret
choy
pharmd
bcp
nina
huynh
pharmd
bcp
depart
pharmaci
practic
univers
illinoi
colleg
pharmaci
chicago
il
servic
program
venou
thromboembol
vte
common
postop
complic
follow
major
orthoped
surgeri
effort
improv
rate
vte
among
total
joint
arthroplasti
tja
patient
univers
illinoi
hospit
health
scienc
system
ui
health
standard
protocol
deep
vein
thrombosi
dvt
prophylaxi
develop
use
multidisciplinari
team
includ
clinic
pharmacist
protocol
subsequ
integr
order
set
implement
march
order
set
provid
physician
decision
support
appropri
dvt
prophylaxi
includ
earli
ambul
chemoprophylaxi
mechan
prophylaxi
justificationdocument
evalu
impact
order
set
clinic
outcom
measur
includ
demograph
ambul
chemoprophylaxi
mechan
prophylaxi
vte
bleed
event
evalu
may
compar
data
collect
prior
order
set
implement
may
implement
order
set
associ
time
initi
chemoprophylaxi
earli
ambul
encourag
group
signific
improv
observ
mechan
prophylaxi
vs
p
vte
rate
decreas
sinc
implement
order
set
vs
p
shift
chemoprophylaxi
pattern
note
aspirin
replac
warfarin
commonli
use
chemoprophylaxi
bleed
rate
statist
lower
sinc
implement
order
set
vs
p
adapt
order
set
design
provid
physician
decision
support
appropri
dvt
prophylaxi
patient
undergo
tja
use
order
set
adapt
patient
popul
andor
institut
signific
use
order
set
encourag
multidisciplinari
team
approach
improv
patient
care
clinic
pharmacist
play
vital
role
provid
decision
support
multidisciplinari
team
monitor
newer
anticoagul
justif
signific
anticoagul
toolkit
john
gum
beth
vanderheyden
david
p
reed
pharmacotherapi
translat
research
colleg
pharmaci
univers
florida
gainesvil
fl
global
medic
tallahasse
fl
global
medic
dunedin
fl
servic
program
although
doac
requir
laboratori
monitor
frequent
dose
adjust
consider
includ
renal
function
weight
age
concomit
medic
adher
requir
special
knowledg
select
appropri
drugdos
minim
risk
bleed
complic
optim
patient
manag
unbrand
anticoagul
toolkit
creat
toolkit
resourc
manag
repositori
compris
comprehens
compon
base
literatur
toolkit
includ
health
inform
technolog
resourc
clinician
digit
referr
stream
protocol
clinic
algorithm
toolkit
dynam
evolv
time
innov
approach
enhanc
patient
engag
improv
doac
adher
increas
monitor
doac
justificationdocument
rate
atrial
fibril
af
us
increas
project
million
pinnacl
registri
doac
use
increas
warfarin
use
decreas
first
year
doac
approv
tradit
af
patient
us
receiv
warfarin
therapi
follow
longitudin
anticoagul
manag
servic
am
util
publish
guidelin
institut
approv
protocol
comparison
comprehens
resourc
avail
assist
am
safe
effect
manag
doac
patient
adapt
wide
variabl
structur
function
servic
provid
am
mandat
compon
applic
practic
level
environ
toolkit
design
customiz
resourc
individu
compon
use
clinician
practic
set
patient
signific
anticoagul
toolkit
first
comprehens
updat
resourc
provid
am
clinician
tool
lead
safe
effect
manag
doac
patient
doac
use
increas
across
expand
indic
toolkit
provid
signific
advanc
care
doac
patient
impact
educ
prospect
audit
feedback
reduc
ciprofloxacin
util
small
commun
academ
hospit
alyssa
thompson
jason
newland
helen
newland
jennif
feldmann
msn
stephen
liang
md
west
counti
hospit
creve
coeur
mo
univers
school
medicin
st
loui
mo
center
clinic
excel
st
loui
mopres
idweek
san
francisco
ca
octob
pharmacist
direct
empir
vancomycin
pneumonia
mrsa
nasal
swab
kirstin
kooda
pharmd
bcp
bcccp
bradley
peter
pharmd
bcp
patrick
wieruszewski
gabriel
anderson
gabriel
golfu
lynn
est
pharmaci
servic
mayo
clinic
hospit
rochest
rochest
mn
pharmaci
mayo
clinic
rochest
mn
clinic
rochest
mn
servic
program
establish
neg
mrsa
nasal
colon
comport
neg
predict
valu
presenc
mrsa
pneumonia
octob
implement
protocol
allow
pharmacist
order
mrsa
nasal
swab
patient
vancomycin
start
pneumonia
swab
result
neg
autom
remind
messag
flag
pharmacist
lead
discuss
medic
team
favor
vancomycin
purpos
program
decreas
durat
empir
vancomycin
use
mrsa
swab
guid
protocol
enact
everi
inpati
set
includ
emerg
depart
intens
care
unit
gener
hospit
ward
justificationdocument
standard
empir
practic
institut
pneumonia
hcap
hap
vap
respect
includ
vancomycin
despit
low
rate
staphylococcu
aureu
mrsa
pneumonia
assess
patient
novemb
patient
novemb
median
durat
vancomycin
pneumonia
control
period
hour
protocol
implement
durat
vancomycin
pneumonia
reduc
median
hour
adapt
demonstr
feasibl
vancomycin
protocol
util
mrsa
swab
believ
extens
institut
microbiolog
capabl
may
done
rel
eas
pursu
incorpor
automat
mrsa
swab
order
electron
pneumonia
care
order
set
institut
signific
import
pharmacist
antimicrobi
steward
area
well
establish
pharmacist
multidisciplinari
team
possess
uniqu
vantag
point
util
medicin
minim
excess
use
antimicrobi
demonstr
eas
efficaci
pharmacist
driven
protocol
rapid
vancomycin
hcap
hap
vap
area
inpati
care
develop
implement
vancomycin
dose
protocol
inpati
set
peirung
huang
pharmd
candid
kevin
purcel
md
pharmd
mha
khiet
nguyen
pharmd
bcp
lauren
hernandez
pharmd
bcccp
depart
pharmaci
st
luke
baptist
hospit
san
antonio
tx
servic
program
vancomycin
consult
servic
provid
hospit
order
standard
determin
initi
mainten
regimen
pharmacist
involv
vancomycin
dose
protocol
base
nomogram
develop
patient
age
year
abw
kg
crcl
mlmin
receiv
renal
replac
therapi
rrt
exclud
justificationdocument
vancomycin
dose
protocol
develop
improv
percentag
time
initi
trough
level
within
target
rang
without
increas
rate
acut
kidney
injuri
aki
protocol
defin
vancomycin
trough
goal
base
indic
target
either
mcgml
mcgml
aki
defin
increas
serum
creatinin
mgdl
within
hour
protocol
implement
evalu
complet
measur
success
patient
inappropri
drawn
trough
level
andor
miss
dose
exclud
patient
includ
group
number
initi
therapeut
trough
level
group
compar
group
patient
group
subtherapeut
trough
compar
group
evid
aki
seen
patient
group
respect
adapt
vancomycin
dose
protocol
use
hospit
provid
vancomycin
consult
servic
mani
pharmacist
particip
next
step
continu
use
facil
collect
data
larger
patient
popul
support
effect
safeti
ultim
goal
expand
system
wide
signific
protocol
employ
vancomycin
dose
nomogram
provid
guidanc
standard
pharmacist
perform
vancomycin
consult
adult
patient
without
exclus
criteria
mild
improv
initi
target
trough
attain
without
increas
rate
aki
accomplish
implement
penicillin
allergi
skin
test
commun
hospit
result
chang
scope
practic
pharmacist
nathon
parker
pharmd
bcp
hoo
feng
choo
mandana
ghodrat
region
medic
center
cheyenn
wy
e
street
cheyenn
wy
servic
program
penicillin
pcn
allergi
skin
test
program
inpati
implement
bed
commun
hospit
servic
novel
cheyenn
region
medic
center
crmc
two
main
reason
pharmacist
administrationinterpret
test
instead
physician
nurs
scope
practic
allow
administr
intraderm
inject
pharmacist
wyom
state
board
pharmaci
wybop
grant
condit
approv
crmc
order
collect
data
present
wybop
fall
possibl
result
perman
chang
pharmacist
scope
practic
justificationdocument
primari
outcom
measur
includ
patient
neg
pcn
allergi
patient
antimicrobi
regimen
chang
number
day
length
stay
lo
decreas
associ
cost
save
far
patient
test
neg
antimicrobi
regimen
chang
chang
also
result
day
decreas
lo
cost
save
around
adapt
model
implement
variou
hospit
set
could
easili
modifi
also
serv
variou
outpati
set
pharmacist
train
other
help
process
signific
accord
cdc
pcn
allergi
true
consequ
correct
allergi
patient
medic
record
lead
signific
benefit
patient
commun
includ
decreas
unnecessari
antibiot
healthcar
cost
save
improv
patient
outcom
decreas
resist
bacteria
also
benefici
profess
pharmaci
extend
scope
practic
includ
administr
intraderm
inject
pharmacist
may
assist
addit
role
patient
care
discharg
autom
call
program
identifi
resolv
issu
care
transit
rafael
felippi
pharmd
janic
finder
rn
theresa
pinn
ashlyn
prosk
project
analyst
pharmaci
servic
houston
methodist
hospit
houston
methodist
physician
allianc
qualiti
houston
tx
methodist
physician
allianc
qualiti
houston
methodist
hospit
houston
tx
servic
program
nearli
patient
discharg
hospit
home
set
experi
advers
event
safeguard
autom
call
program
implement
houston
methodist
hm
hospit
system
discharg
patient
effort
reduc
readmiss
improv
patient
satisfact
reason
cost
telephon
questionnair
assess
patient
health
sinc
leav
facil
identifi
patient
question
regard
discharg
care
instruct
medic
appoint
dissatisfi
care
receiv
call
trigger
care
navig
nurs
pharmacist
patient
liaison
andor
coordin
provid
time
proactiv
intervent
justificationdocument
patient
contact
decemb
august
patient
complet
telephon
questionnair
trigger
alert
driver
alert
relat
instruct
medic
care
servic
health
statu
contact
request
patient
reach
program
lower
readmiss
rate
vs
patient
satisfact
hcahp
score
improv
point
adapt
alert
address
clinic
pharmacist
author
agent
hm
physician
two
pharmacist
pharmaci
intern
resid
rotat
monthli
address
discrep
facilit
insur
prior
author
request
educ
patient
collabor
physician
retail
pharmaci
insur
compani
commun
done
telephon
signific
implement
program
patient
hospit
abl
reach
patient
would
otherwis
overlook
select
base
risk
criteria
diagnosi
reduct
hospit
readmiss
increas
patient
satisfact
provid
hospit
financi
qualiti
interest
program
also
streamlin
workflow
sinc
alert
specifi
patient
question
concern
prior
call
develop
interprofession
team
manag
patient
combin
opioid
benzodiazepin
therapi
michael
conley
pharmd
bcacp
thoma
fant
hillari
green
jessica
andrad
phylli
baer
univers
boston
health
servic
inc
mattapan
servic
program
januari
interprofession
team
consist
clinic
pharmacist
addict
nurs
site
medic
director
began
manag
patient
chronic
concomit
opioid
benzodiazepin
bdz
feder
qualifi
health
center
boston
focu
project
taper
replac
combin
safe
efficaci
therapi
design
weekli
clinic
schedul
develop
team
could
review
discuss
patient
visit
visit
team
discuss
patient
risk
take
medic
combin
develop
appropri
patient
specif
treatment
justificationdocument
critic
need
address
overprescrib
opioid
especi
combin
bdz
identifi
patient
combin
past
year
schedul
meet
team
interplay
three
disciplin
exam
room
fundament
pharmacist
provid
clinic
decis
make
addict
nurs
provid
modal
psychosoci
support
option
need
medic
director
mandat
move
toward
safer
therapi
success
measur
dose
reduct
medic
discontinu
maintain
improv
symptom
control
adapt
interprofession
team
implement
health
center
clinic
pharmaci
support
medic
leadership
essenti
patient
includ
share
decis
make
even
mandat
dose
reduct
patient
involv
decis
medic
decreas
altern
employ
time
frame
chang
made
signific
clinic
pharmacist
expertis
perspect
medic
manag
allow
enhanc
team
base
care
clinic
pharmacist
ensur
intervent
lead
toward
evid
base
first
line
treatment
therebi
reduc
potenti
life
threaten
complic
associ
medic
literatur
review
show
limit
use
interprofession
team
deprescrib
combin
improv
transit
care
patient
medic
error
andrew
j
crannag
pharmd
bcp
erin
k
hennessey
pharmd
laura
challen
pharmd
mba
bcp
alison
steven
pharmd
tricia
berri
pharmd
loui
colleg
pharmaci
merci
hospit
st
loui
st
loui
mo
loui
colleg
pharmaci
st
loui
mo
servic
program
telephon
counsel
posit
affect
patient
outcom
howev
approach
often
limit
unsuccess
telephon
contact
due
unverifi
telephon
number
uncertain
patient
avail
discharg
clinic
pharmacist
merci
hospit
st
loui
design
discharg
educ
servic
patient
defin
receiv
greater
medic
reduc
error
made
transit
care
home
accomplish
part
increas
success
telephon
contact
inpati
pharmacist
provid
comprehens
medic
educ
schedul
appoint
time
telephon
call
outpati
clinic
pharmacist
justificationdocument
percent
patient
success
contact
within
two
day
discharg
increas
prior
servic
implement
telephon
call
patient
take
averag
medic
medic
form
discrep
requir
intervent
compar
discharg
summari
ask
understood
medic
prescrib
patient
strongli
agre
agre
none
disagre
addit
ask
found
program
benefici
strongli
agre
agre
neither
agre
disagre
adapt
patient
popul
well
match
gener
popul
mani
patient
meet
criterion
discharg
mean
time
complet
inpati
educ
telephon
appoint
schedul
telephon
call
minut
pharmacist
assum
role
appli
numer
set
patient
discharg
home
signific
american
colleg
clinic
pharmaci
standard
practic
clinic
pharmacist
document
guid
principl
care
one
compon
evalu
medic
monitor
employ
pharmacist
uniqu
skill
posit
impact
patient
outcom
transit
across
healthcar
set
servic
demonstr
concept
implement
practic
posit
pharmacist
traine
interact
popul
optim
care
hospit
system
respons
outbreak
brodifacoum
contamin
synthet
cannabinoid
rene
petzel
gimbar
michael
koronkowski
margaret
choy
pharmd
christina
mcknight
jason
devgun
arkadi
rasin
timothi
meehan
md
trevonn
thompson
jenni
jarrett
pharmd
bcp
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
practic
univers
illinoi
chicago
chicago
il
pharmaci
practic
univers
illinoi
colleg
pharmaci
chicago
il
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
consortium
chicago
il
medicin
univers
illinoi
chicago
colleg
medicin
chicago
il
pharmaci
depart
pharmaci
practic
univers
illinoi
chicago
chicago
il
servic
program
comprehens
coordin
medic
manag
program
devis
care
patient
amid
outbreak
present
contamin
synthet
cannabinoid
coagulopathi
patient
requir
phytonidion
manag
initi
patient
identifi
emerg
depart
medic
toxicolog
servic
coagulopathi
exposur
contamin
synthet
cannabinoid
toxicolog
clinic
pharmacist
tcp
coordin
inpati
care
medic
team
clinic
pharmacist
focus
care
transit
medic
manag
due
limit
includ
insur
coverag
medic
cost
drug
shortag
medic
assist
program
pharmacist
facilit
procur
medic
discharg
ongo
dispens
outpati
institut
pharmaci
tcp
provid
telephon
outpati
medic
manag
titrat
justificationdocument
marchapril
outbreak
contamin
synthet
cannabinoid
identifi
illinoi
synthet
cannabinoid
contamin
rodenticid
brodifacoum
substanc
vitamin
k
antagonist
result
long
term
coagulopathi
current
four
document
death
relat
contamin
synthet
cannabinoid
coagulopathi
occur
patient
popul
signific
social
barrier
altern
lifestyl
choic
unstabl
hous
limit
health
insur
coverag
make
patient
care
challeng
servic
necessari
provid
access
medic
sinc
care
target
program
patient
maintain
inr
report
bleed
complic
adapt
clinic
pharmacist
train
manag
medic
relat
inr
lab
valu
exposur
rodenticid
contamin
substanc
uniqu
could
occur
urban
rural
area
telephon
manag
plan
program
easili
adapt
mani
set
signific
coordin
care
transit
effort
clinic
pharmacist
ensur
continu
treatment
patient
coagulopathi
coordin
effort
highlight
clinic
pharmacist
leader
care
manag
futur
toxicolog
outbreak
requir
medic
oral
chemotherapi
program
commun
hospit
lien
pharmd
kevin
hiroo
pharmd
jane
white
pharmd
depart
pharmaci
valley
medic
center
renton
wa
servic
program
initi
oral
chemotherapi
program
assess
impact
patient
care
medic
safeti
oncolog
clinic
commun
hospit
justificationdocument
estim
chemotherapi
pipelin
formul
oral
agent
oral
chemotherapi
becom
forefront
cancer
treatment
mani
challeng
come
oral
chemotherapi
includ
shift
mani
respons
manag
treatment
regimen
monitor
toxic
oncolog
team
patient
oncolog
pharmacist
help
bridg
gap
howev
collabor
agreement
establish
oncolog
pharmacist
oncologist
wherebi
oncolog
pharmacist
review
oral
chemotherapi
prescript
prior
rout
pharmaci
counsel
patient
start
oral
chemotherapi
facilit
coordin
care
pharmaci
patient
prevent
delay
drug
procur
monitor
patient
close
side
effect
adher
follow
patient
one
week
therapi
initi
monthli
thereaft
period
program
incept
oncolog
pharmacist
review
oral
chemotherapi
prescript
monitor
patient
document
clinic
signific
intervent
survey
result
patient
show
oncolog
pharmacist
involv
help
patient
gain
better
understand
treatment
patient
knew
handl
oral
chemotherapi
manag
side
effect
survey
result
oncologist
oncolog
clinic
staff
show
oncolog
pharmacist
involv
increas
clinic
workflow
effici
regard
oral
chemotherapi
clinic
staff
felt
confid
patient
take
oral
chemotherapi
prescrib
adapt
agreement
oncologist
program
easili
adapt
oncolog
clinic
signific
implement
oral
chemotherapi
program
improv
medic
safeti
minim
delay
chemotherapi
initi
reduc
time
provid
spent
oral
issu
opioid
plan
educ
reduc
opioid
use
follow
hospit
surgic
discharg
jeremiah
saunder
laura
myhr
pharmd
nanci
chen
kimberli
karwoski
pharmd
eze
elechi
pharmd
juli
l
cunningham
pharmaci
mayo
clinic
hospit
rochest
mn
hospit
pharmaci
servic
colleg
medicin
mayo
clinic
mayo
clinic
rochest
mn
servic
program
nation
call
action
relat
opioid
prescrib
led
develop
new
opioid
prescript
guidelin
patient
hospit
discharg
larg
academ
medic
center
multidisciplinari
team
partner
implement
guidelin
recommend
significantli
reduc
opioid
quantiti
base
surgic
procedur
howev
gap
patient
knowledg
educ
regard
pain
manag
opioid
patient
identifi
four
week
pharmacist
pilot
approv
initi
opioid
educ
plan
orthoped
surgeri
patient
hospit
discharg
pharmacist
role
includ
assess
appropri
opioid
quantiti
prescrib
discharg
creat
individu
worksheet
base
expect
durat
opioid
use
interview
patient
discuss
goal
pain
manag
includ
util
mechan
safe
dispos
justificationdocument
patient
could
list
opioid
take
last
hour
awar
appropri
opioid
dispos
knew
risk
take
opioid
encouragingli
patient
activ
engag
discuss
claim
improv
understand
opioid
educ
adapt
individu
pharmacist
educ
patient
dismiss
opioid
sustain
practic
larg
medic
institut
extens
surgic
practic
howev
standard
handout
educ
feasibl
altern
complet
initi
pilot
opioid
worksheet
adapt
standard
handout
nurs
administ
signific
standard
opioid
pain
medic
reduct
educ
develop
meet
gap
patient
knowledg
well
new
joint
commiss
practic
standard
base
direct
interview
pharmacist
involv
throughout
develop
target
inpati
opioid
educ
imper
given
natur
opioid
medic
potenti
misus
curb
enthusiasm
stewardship
drug
periop
set
sara
jordan
pharmd
bcp
brian
kramer
adam
trimbl
medic
center
ohiohealth
columbu
oh
servic
grant
medic
center
ohiohealth
columbu
oh
servic
program
grant
medic
center
gmc
commun
teach
hospit
level
trauma
center
columbu
ohio
perform
surgeri
annual
periop
clinic
pharmaci
team
gmc
consist
individu
rotat
oper
roomorthoped
servic
posit
staf
everi
weekday
accord
accp
standard
practic
team
advanc
clinic
pharmacist
role
periop
set
optim
patient
institut
outcom
success
stewardship
effort
invalu
byproduct
practic
advanc
justificationdocument
institut
p
committe
increasingli
challeng
consid
cost
care
complic
extern
factor
includ
opioid
epidem
nationwid
drug
shortag
three
medic
particular
sugammadex
intraven
acetaminophen
liposom
bupivacain
forefront
hospit
p
challeng
result
team
success
driven
stewardship
effort
agent
evidenc
reduc
util
inform
medicin
dramat
cost
save
compar
similar
institut
lack
neg
effect
relat
clinic
qualiti
metric
describ
clinic
strategi
yield
measur
result
includ
medic
protocol
develop
implement
data
analysi
present
target
interprofession
collabor
prospect
research
adapt
demonstr
vital
import
develop
dedic
clinic
periop
pharmacist
institut
perform
surgeri
order
improv
patient
care
drive
initi
describ
specif
compet
strategi
develop
facilit
posit
clinic
pharmacist
leader
arena
includ
cost
justif
stewardship
medic
signific
posit
clinic
pharmacist
drive
success
medic
stewardship
effort
leverag
interdisciplinari
relationship
clinic
expertis
increasingli
vital
practic
area
proven
strategi
optim
qualiti
cost
care
becom
critic
surgic
specialti
move
bundl
payment
system
implement
hemophilia
manag
program
improv
clinic
outcom
gile
slocum
gari
peksa
thoma
webb
ishaq
lat
pharmd
fccm
pharmaci
rush
univers
medic
center
chicago
il
pharmaci
emerg
medicin
rush
univers
medic
center
chicago
il
resourc
manag
rush
univers
medic
center
chicago
il
servic
program
hemophilia
manag
program
hmp
develop
improv
care
reduc
spend
treatment
hemophilia
patient
hmp
promot
interdisciplinari
educ
clinic
manag
continu
care
one
lead
pharmacist
addit
pharmacist
train
support
role
prior
hmp
depart
pharmaci
assist
drug
acquisit
dispens
hmp
expand
clinic
pharmaci
servic
inclus
part
comprehens
care
team
hemophilia
patient
medic
center
justificationdocument
clot
factor
concentr
cfc
costli
hemophilia
patient
often
requir
multipl
dose
maintain
hemostasi
depart
pharmaci
drug
expens
cfc
million
drug
budget
busi
propos
hmp
outlin
return
invest
roi
cost
save
base
dedic
pharmaci
servic
stewardship
treatment
guidanc
formulari
manag
cfc
expenditur
addit
quantit
measur
includ
length
stay
lo
rate
blood
transfus
adapt
report
attest
clinic
care
pharmacist
train
hmp
potenti
program
like
transfer
center
treat
hemophilia
patient
therebi
expand
scope
pharmaci
practic
signific
total
hmp
result
net
save
million
factor
expens
cost
save
base
cfc
expens
result
roi
far
exceed
project
averag
lo
per
patient
stay
consist
prior
year
need
blood
transfus
per
patient
reduc
design
implement
hmp
result
signific
cost
save
improv
effici
enhanc
clinic
servic
patient
hemophilia
expans
pharmaci
servic
becom
first
program
countri
reduc
cost
also
improv
clinic
outcom
implement
pharmacogenet
consult
clinic
primari
care
set
meghan
j
arwood
eric
dietrich
benjamin
q
duong
max
smith
iii
eric
rosenberg
md
msph
katherin
n
huber
ying
nagoshi
md
ashleigh
wright
jeffrey
budd
amanda
r
elsey
larisa
h
cavallari
kristin
w
weitzel
juli
johnson
john
gum
pharmacotherapi
translat
research
center
pharmacogenom
colleg
pharmaci
univers
florida
gainesvil
fl
pharmacotherapi
translat
research
colleg
pharmaci
univers
florida
gainesvil
fl
gener
intern
medicin
depart
medicin
colleg
medicin
univers
florida
gainesvil
fl
gener
intern
medicin
depart
medicin
colleg
medicin
uf
health
intern
hill
univers
florida
gainesvil
fl
servic
program
person
medicin
program
pmp
multidisciplinari
practic
provid
pharmacogenet
pgx
recommend
guid
drugdos
select
sinc
continu
growth
pmp
refin
infrastructur
along
collabor
physician
pharmacist
informatician
led
develop
outpati
pgx
consult
clinic
pmp
launch
clinic
intern
hill
imth
provid
refer
patient
consult
pharmacist
pharmacist
role
confirm
need
order
pgx
test
deliv
drugdos
recommend
provid
educ
patient
provid
pgx
result
justificationdocument
imth
chosen
pgx
clinic
sinc
patient
take
target
medic
inform
test
iecertain
opioid
ssri
ppi
inappropri
dosingsect
medic
lead
delay
therapeut
benefit
andor
advers
effect
includ
death
mani
patient
pgx
result
make
normal
dose
unfavor
increas
risk
event
provid
correctli
identifi
patient
base
genotyp
accept
recommend
adapt
base
upon
current
success
pmp
plan
expand
pgx
clinic
primari
care
clinic
similar
medic
util
rate
provid
target
popul
signific
higher
proport
extrem
metabol
argu
provid
educ
refer
success
get
patient
genotyp
earlier
reduc
prescrib
also
high
recommend
accept
rate
reveal
trust
highlight
optim
patient
care
pgx
result
clinic
patient
vs
popul
clinic
pharmaci
intervent
improv
laboratori
monitor
patient
prescrib
antipsychot
primari
care
clinic
julianna
rivich
pharmd
benjamin
chavez
pharmd
depart
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
servic
program
servic
clinic
pharmacist
aim
improv
metabol
monitor
patient
prescrib
antipsychot
sga
feder
qualifi
health
center
primari
care
clinic
patient
receiv
prescript
sga
review
patient
due
routin
fast
blood
glucos
lipid
test
baselin
month
annual
messag
sent
primari
care
provid
pcp
via
electron
medic
record
clinic
pharmacist
order
applic
lab
inform
patient
drawn
lab
complet
pharmacist
call
patient
result
recommend
repeat
test
addit
therapi
made
clinic
pharmacist
pcp
justificationdocument
servic
met
previous
identifi
need
clinic
found
annual
monitor
glucos
lipid
complet
medicaid
patient
respect
clinic
system
intervent
sampl
patient
one
clinic
found
annual
monitor
glucos
lipid
complet
patient
respect
increas
pharmacist
intervent
respect
adapt
servic
would
valuabl
pharmacist
replic
outpati
set
recommend
consensu
statement
american
diabet
associ
american
psycholog
associ
serv
outlin
guid
recommend
monitor
patient
prescrib
sga
signific
servic
success
implement
ambulatori
care
pharmaci
resid
work
medic
underserv
clinic
impact
may
signific
primari
care
clinic
routin
metabol
monitor
sga
suboptim
improv
monitor
practic
patient
prescrib
sga
help
reduc
risk
prevent
progress
metabol
complic
implement
evalu
benzodiazepin
taper
servic
san
francisco
veteran
affair
health
care
system
tessa
rife
pharmd
bcgp
cacp
jennif
corapi
pharmaci
school
pharmaci
san
francisco
veteran
affair
health
care
system
univers
california
san
francisco
san
francisco
ca
pharmaci
san
francisco
veteran
affair
health
care
system
san
francisco
ca
servic
program
implement
benzodiazepin
educ
taper
servic
san
francisco
veteran
affair
health
care
system
veteran
refer
video
telephon
andor
electron
consult
evalu
histori
benzodiazepin
usealtern
withdraw
overdos
suicid
currentpast
substanc
use
provid
educ
advers
event
risk
safer
altern
discuss
concernstreat
prefer
partner
veteran
medic
provid
individu
taper
care
plan
justificationdocument
benzodiazepin
commonli
prescrib
medic
yet
increas
evid
demonstr
concern
risk
respiratori
depress
overdos
opioidsoth
central
nervou
system
depress
addit
risk
demonstr
older
adult
medic
comorbid
includ
cognit
impair
traumat
brain
injuri
posttraumat
stress
disord
suicid
historyrisk
substanc
use
disord
historyact
use
fall
historyrisk
chronic
pain
new
innov
strategi
urgent
need
reduc
benzodiazepin
use
popul
adapt
benzodiazepin
educ
taper
describ
varieti
settingsstrategi
patient
educ
lettereduc
mail
campaign
interdisciplinari
initi
behavior
taper
servic
use
combin
strategi
focus
reduc
use
veteran
signific
total
consult
benzodiazepin
educationtap
receiv
uniqu
outpati
februari
april
veteran
primarili
evalu
via
combin
visit
type
veteran
data
avail
mean
diazepam
equival
daili
dose
dedd
reduc
veteran
receiv
visit
type
combin
visit
data
avail
mean
dedd
reduc
consult
complet
therapi
benzodiazepin
engag
care
benzodiazepin
taper
servic
success
reduc
benzodiazepin
use
veteran
adult
attent
deficit
hyperact
disord
adhd
clinic
collabor
psychiatri
primari
care
pharmaci
improv
access
care
experi
afford
corinn
johnson
pharmd
mba
clinic
pharmaci
servic
kaiser
northwest
portland
servic
program
kaiser
permanent
northwest
kpnw
implement
collabor
adult
adhd
servic
psychiatri
develop
criteria
triag
uncompl
patient
select
appoint
slot
evalu
screen
workflow
clinic
interview
document
standard
pharmaci
develop
adult
adhd
practic
resourc
provid
care
guidanc
cdtm
protocol
pharmacist
provid
medic
manag
stabl
transit
care
primari
care
primari
care
leadership
approv
servic
model
includ
patient
remain
primari
care
manag
ad
psychiatrist
case
load
justificationdocument
psychiatri
depart
set
goal
improv
patient
access
high
number
referr
uncompl
adult
adhd
mani
primari
care
clinician
sought
assist
diagnosi
medic
manag
pharmaci
note
increas
number
adult
treat
adhd
well
opportun
improv
care
treatment
afford
servic
metric
includ
number
patient
manag
week
stabl
number
pharmacist
touch
minut
spent
psychiatrist
time
save
particip
satisfact
medic
util
cost
adapt
collabor
psychiatri
primari
care
pharmaci
could
replic
within
integr
care
organ
adapt
care
deliveri
system
tool
develop
could
share
eg
practic
resourc
servic
criteria
protocol
document
prescrib
criteria
etc
signific
servic
improv
access
psychiatri
satisfact
psychiatri
primari
care
care
deliveri
process
transit
care
addit
improv
care
experi
share
decis
make
care
standard
coordin
servic
help
lower
treatment
cost
due
use
prefer
medic
regimen
optim
subsequ
pharmaci
initi
aros
servic
includ
dose
consolid
regimen
optim
prescrib
criteria
develop
medic
applic
achiev
pharmaci
cost
save
approxim
million
substanc
use
intervent
team
pharmacist
tran
tran
pharmd
bcp
kathryn
perticon
henri
swoboda
elisabeth
ramsey
emili
mckernan
kristin
hill
colleg
pharmaci
midwestern
univers
downer
grove
il
rush
univers
medic
center
chicago
il
univers
medic
center
chicago
il
univers
medic
center
chciago
il
servic
program
substanc
use
intervent
team
suit
consult
servic
consist
physician
advanc
practic
nurs
social
worker
pharmacist
work
togeth
screen
treat
patient
risk
opioid
substanc
justificationdocument
suit
creat
hospit
initi
address
substanc
use
disord
sud
anticip
target
futur
cm
guidelin
program
built
inpati
sud
screen
identifi
patient
would
benefit
brief
intervent
medic
assist
therapi
mat
program
success
screen
inpati
admiss
suit
enabl
updat
made
institut
polici
procedur
hospit
formulari
effect
manag
patient
revis
assess
medic
protocol
suit
oversaw
revis
clinic
opioid
withdraw
scale
cow
protocol
medic
order
set
formulari
expand
increas
access
form
mat
hospit
outpati
pharmaci
inventori
tailor
includ
medic
formul
prefer
insur
afford
patient
suit
also
run
addict
clinic
monitor
treatment
mainten
collect
accomplish
help
expand
buprenorphin
servic
offer
institut
adapt
mat
cornerston
success
treatment
sud
medic
expert
pharmacist
ideal
posit
interpret
uniqu
econom
regulatori
pharmacokinet
issu
specif
mat
program
fte
fund
feder
grant
establish
faculti
pharmacist
key
member
suit
signific
pharmacist
knowledg
harm
reduct
motiv
interview
mat
contribut
provis
care
patient
sud
role
improv
comprehens
servic
offer
institut
pharmaci
profess
absenc
train
employ
pharmacist
addict
medicin
support
need
literatur
describ
pharmacist
role
implement
medicin
chang
counsel
pharmaci
mccp
servic
improv
drug
adher
therapeut
outcom
chronic
diseas
patient
chang
regimen
specialist
clinic
sopc
hong
kong
alfr
ka
chun
lok
mpharm
clin
pharm
cheung
hei
choi
mbchb
mrcp
fhkcp
fhkam
medicin
wilson
yun
shing
leung
bpharm
phd
lai
fun
lau
tsz
ming
ng
bpharm
clin
pharm
alan
worsley
bsc
msc
phd
cert
ed
pharmaci
queen
elizabeth
hospit
hong
kong
hong
kong
medicin
queen
elizabeth
hospit
hong
kong
hong
kong
pharmacolog
pharmaci
univers
hong
kong
hong
kong
hong
kong
servic
program
mccp
servic
implement
sopc
pharmaci
gener
acut
hospit
hk
sinc
june
patient
regimen
chang
refer
doctor
clinic
pharmacist
provid
initi
counsel
emphasi
regimen
chang
make
phone
call
assess
patient
adher
provid
advic
patient
fulli
adher
new
regimen
justificationdocument
due
busi
environ
limit
manpow
sopc
pharmaci
prescriptionsday
manag
pharmacist
pharmaci
technician
possibl
provid
detail
educationcounsel
everi
patient
servic
pilot
approach
priorit
medic
counsel
patient
recent
regimen
chang
inadequ
understand
regimen
chang
may
compromis
patient
drug
adher
diseas
control
retrospect
studi
conduct
assess
program
outcom
primari
endpoint
patient
adher
hisher
new
regimen
servic
secondari
endpoint
chang
subgroup
patient
recent
chang
metformin
dosag
receiv
servic
compar
histor
control
metformin
chosen
dosag
chang
commonest
metformin
amongst
chronic
drug
clinic
outcom
could
assess
object
use
tertiari
endpoint
patient
satisfact
adapt
patient
receiv
servic
within
studi
period
regimen
chang
taken
prescrib
averag
complianc
score
secondari
analysi
mccp
associ
trend
reduct
compar
histor
control
vs
overal
patient
rate
satisfi
servic
similar
servic
could
reproducedextend
set
high
patient
volum
limit
manpow
hk
signific
servic
target
patient
high
risk
result
high
level
patient
adher
new
regimen
potenti
improv
patient
clinic
outcom
led
peer
deliveri
program
servic
chronic
medic
patient
live
diseas
rural
western
kenya
immacul
kerubo
sara
fletcher
pharmd
edith
tonui
jame
kamadi
rakhi
karwa
merci
maina
bpharm
imran
manji
bpharm
monica
miller
pharmd
benson
njuguna
ellen
schellhas
dan
tran
sonak
pastakia
pharmd
mph
model
provid
access
healthcar
ampath
eldoret
kenya
pharmaci
practic
purdu
univers
colleg
pharmaci
purdu
kenya
partnership
eldoret
kenya
teach
referr
hospit
eldoret
kenya
pharmaci
practic
purdu
univers
colleg
pharmaci
west
lafayett
servic
program
led
peer
deliveri
program
provid
servic
includ
blood
pressur
bp
blood
glucos
bg
measur
chronic
medic
patient
live
diseas
ncd
diabet
hypertens
program
oper
two
commun
rural
western
kenya
milo
turbo
popul
respect
use
clinic
protocol
health
worker
chw
train
clinic
pharmacist
clinic
deliv
servic
base
patient
request
justificationdocument
document
unavail
medicin
distanc
clinic
long
queue
barrier
access
ncd
care
popul
patient
often
travel
great
distanc
get
clinic
thirti
minut
sever
hour
foot
motorbik
program
remedi
barrier
util
suppli
chain
system
revolv
fund
pharmaci
ensur
avail
medicin
train
chw
peer
use
basic
clinic
protocol
appropri
triag
deliv
manag
servic
bp
bg
measur
chronic
medic
patient
need
deliveri
model
develop
commun
need
assess
approxim
felt
peer
deliveri
program
would
address
care
gap
adapt
adapt
program
larg
due
simplic
necessari
compon
includ
patient
interest
appropri
train
chw
reliabl
suppli
chain
contextu
clinic
protocol
addit
chw
known
trust
commun
member
qualifi
provid
basic
medic
task
medic
deliveri
appropri
train
signific
program
demonstr
pharmacist
effect
implement
care
program
provid
critic
ncd
servic
commun
outsid
health
facil
set
goal
program
enhanc
adher
medic
improv
clinic
outcom
set
use
center
approach
commun
allerg
rhiniti
manag
servic
singapor
joann
sh
yap
bsc
pharm
hon
colin
tang
bsc
pharm
hon
boon
ka
chong
msc
comm
pharm
kai
zhen
yap
pharmaci
nation
univers
singapor
singapor
singapor
pharmaci
watson
person
care
store
pte
ltd
singapor
singapor
servic
program
start
watson
person
care
store
pte
ltd
singapor
april
pharmacist
intervent
includ
patient
assess
individu
care
plan
phone
optimis
allerg
rhiniti
ar
base
watson
ar
manag
protocol
refer
aria
guidelin
tailor
use
commun
pharmaci
set
train
pharmacist
involv
onlin
read
interact
workshop
academ
detail
ar
therapeut
servic
protocol
justificationdocument
singapor
ar
preval
high
recent
reclassif
intranas
corticosteroid
inc
enhanc
public
access
treatment
commun
pharmaci
without
requir
prescript
yet
suboptim
due
underus
inc
prescrib
henc
imper
optimis
ar
commun
feasibl
demonstr
process
evalu
studi
use
medic
research
council
pharmacist
enrol
custom
nine
month
provid
least
one
custom
success
exit
custom
respond
satisfact
survey
deem
pharmacist
profession
knowledg
provid
clear
detail
inform
ar
howev
lack
protect
time
barrier
servic
provis
adapt
better
resourc
manag
may
improv
pharmacist
particip
servic
provis
studi
outcom
requir
signific
nevertheless
demonstr
potenti
implement
pharmaci
chain
benefit
ar
patient
similar
program
improv
minor
ailment
treat
commun
pharmaci
may
also
ensu
refer
sj
fong
et
al
intranas
corticosteroid
use
preval
adher
allerg
rhiniti
studi
commun
pharmaci
singapor
pharmacotherapi
gf
et
al
process
evalu
complex
intervent
medic
research
council
guidanc
bmj
proton
pump
inhibitor
initi
conduct
commun
pharmaci
frank
hack
bsc
phm
msc
ahalya
mehta
bsc
pharm
yu
jin
lee
bsc
pharm
pharmaci
univers
torontoshopp
drug
mart
toronto
canada
drug
mart
toronto
canada
yr
faculti
pharmaci
doctor
pharmaci
candid
univers
toronto
toronto
canada
servic
program
proton
pump
inhibitor
ppi
initi
conduct
commun
pharmaci
toronto
canada
program
perform
period
juli
august
patient
dispens
ppi
includ
program
pharmacist
contact
patient
determin
elig
use
evid
base
clinic
practic
guidelin
elig
patient
inform
rational
includ
potenti
harm
use
ppi
without
ongo
indic
week
patient
began
trial
altern
day
therapi
ppi
regimen
contact
day
assess
feasibl
stop
ppi
therapi
collabor
prescrib
physician
justificationdocument
canada
ppi
ware
rank
overal
drug
util
cost
per
health
canada
million
prescript
ppi
dispens
common
indic
ppi
gastroesophag
reflux
diseas
symptom
resolv
approxim
patient
week
ppi
usag
usual
well
toler
howev
potenti
side
effect
includ
increas
risk
fractur
pneumonia
c
difficil
infect
patient
prescrib
ppi
candid
consent
particip
receiv
approv
physician
attempt
trial
patient
success
stop
ppi
therapi
adapt
ppi
intervent
conduct
hospit
care
home
primari
care
clinic
commun
pharmaci
ideal
posit
carri
similar
initi
signific
initi
demonstr
feasibl
conduct
pharmacist
initi
program
commun
pharmaci
set
similar
program
pharmaci
potenti
improv
overal
health
outcom
significantli
reduc
cost
public
privat
healthcar
system
mydispens
intern
collabor
advanc
commun
pharmaci
practic
simul
clark
kebodeaux
pharmd
bcacp
vivann
mak
bpharm
hon
phd
tina
brock
bspharm
lisa
holl
pharmd
jill
fitzgerald
marcu
ferron
jennif
marriott
bpharm
phd
keith
sewel
keenan
beaumont
marian
costello
pharmaci
practic
scienc
univers
kentucki
colleg
pharmaci
lexington
ky
pharmaci
pharmaceut
scienc
monash
univers
melbourn
australia
pharmaci
practic
univers
connecticut
school
pharmaci
storr
ct
pharmaci
univers
california
san
francisco
san
francisco
ca
servic
program
mydispens
freeli
avail
intern
commun
pharmaci
simul
design
develop
monash
univers
provid
opportun
teach
practic
assess
medic
use
process
virtual
pharmaci
set
mydispens
develop
respons
educ
need
australia
effect
global
collabor
use
student
pharmacist
multipl
countri
contribut
growth
pharmaci
simul
commun
justificationdocument
mydispens
expand
focu
technic
process
dispens
regard
prescript
otc
medic
verif
activ
priorit
scenario
common
commun
practic
instanc
mydispens
tailor
countri
region
enabl
pharmaci
faculti
design
unit
tutori
exercis
span
continuum
medic
use
process
product
patient
support
student
work
realist
clinic
virtual
situat
adapt
mydispens
use
school
colleg
pharmaci
across
globe
includ
contin
countri
import
export
exercis
domest
intern
intern
virtual
patient
virtual
prescrib
nearli
medic
includ
databas
effort
result
student
pharmacist
complet
exercis
sinc
initi
implement
signific
respons
interest
global
commun
second
intern
mydispens
symposium
held
prato
itali
juli
institut
countri
repres
particip
offici
releas
latest
softwar
version
mydispens
version
combin
prescript
verif
exercis
scenario
requir
clinic
time
manag
skill
improv
care
patient
commun
pharmaci
mydispens
commun
also
expand
includ
repres
pharmaci
technician
train
program
innov
medic
educ
pharmaci
bedsid
enhanc
care
complex
medic
ill
patient
central
taiwan
chang
pharmd
ms
huang
phd
depart
pharmaci
china
medic
univers
hospit
taichung
citi
taiwan
servic
program
multidisciplinari
discharg
servic
adopt
medic
counsel
provid
knowledg
skill
patient
caregiv
ensur
drug
complianc
case
manag
nurs
coordin
multidisciplinari
discharg
servic
base
counsel
score
model
medic
counsel
request
patient
score
equal
greater
point
meanwhil
pharmaci
launch
uniqu
computer
system
integr
drug
inform
databas
compris
medic
educ
handout
upon
receiv
counsel
pharmacist
would
assess
therapeut
regimen
arrang
bedsid
counsel
appoint
demonstr
drug
efficaci
safeti
distribut
medic
educ
handout
patient
caregiv
medic
complianc
evalu
week
justificationdocument
pivot
studi
perform
exam
case
receiv
medic
counsel
march
april
top
highli
demand
point
care
identifi
pulmonolog
neurosurgeri
neurolog
hematolog
oncolog
cardiovascular
medicin
despit
patient
caregiv
lost
person
health
problem
remain
present
medic
complianc
medic
complianc
reveal
caregiv
primarili
age
around
year
secondli
age
year
caregiv
mainli
patient
children
spous
caregiv
achiev
senior
high
school
undergradu
degre
adapt
medic
ill
patient
primari
caregiv
understand
drug
inform
pertain
current
therapi
learn
skill
maneuv
issu
pharmacist
play
vital
role
care
ensur
drug
complianc
signific
preliminari
evalu
provid
scope
hospit
discharg
servic
patient
requir
extend
health
care
outcom
medic
counsel
provid
guid
enhanc
point
care
implement
divers
custom
clinic
pharmaci
train
program
intern
pharmacist
student
marina
pharmd
kri
marcu
jeff
fortner
madelin
fri
judi
flynn
nicola
carter
sigrid
robert
pharmaci
pacif
univers
hillsboro
physician
assist
studi
pacif
univers
hillsboro
servic
program
clinic
pharmaci
train
program
implement
unit
state
us
academ
institut
partner
pharmaci
clinic
healthcar
system
provid
divers
exposur
us
pharmaci
practic
intern
pharmacist
scholar
student
program
identifi
gap
visit
profession
knowledg
custom
train
address
need
visit
particip
recruit
intern
organ
well
person
request
abroad
program
initi
particip
home
countri
conduct
detail
commun
offic
global
pharmaci
educ
research
particip
come
train
us
upon
return
countri
complet
reflect
help
implement
profession
goal
provid
feedback
program
improv
justificationdocument
prior
program
initi
clinic
train
intern
visitor
limit
primarili
academ
environ
diversif
train
toward
clinic
pharmaci
desir
base
particip
program
initi
train
request
receiv
austria
india
indonesia
algeria
egypt
januari
recent
train
includ
clinic
shadow
commun
institut
ambulatori
care
set
includ
primari
specialti
care
addit
shadow
provid
physician
assist
adapt
help
screen
potenti
particip
commit
match
interest
expertis
program
offer
student
found
interest
variou
aspect
clinic
pharmaci
wherea
practition
focus
interest
identifi
challeng
includ
pharmacistfaculti
time
avail
expertis
paperwork
coordin
signific
program
implement
particip
demograph
train
consider
diversifi
program
aim
promot
clinic
pharmaci
tailor
need
particip
countri
develop
exchang
program
clinic
pharmaci
train
japanes
us
pharmaci
student
marina
pharmd
naomi
nagai
yukari
ogawa
tetsuro
yumoto
junzo
kamei
ian
c
doyl
pharmd
reza
karimi
rph
pharmaci
pacif
univers
hillsboro
pharmaceut
scienc
musashino
univers
tokyo
japan
univers
tokyo
japan
univers
oregon
school
pharmaci
hillsboro
pharmaci
pacif
univers
oregon
hillsboro
servic
program
exchang
program
clinic
pharmaci
train
epcpt
develop
joint
effort
academ
institut
unit
state
us
two
univers
japan
promot
clinic
pharmaci
train
us
japanes
student
student
institut
particip
structur
epcpt
prior
visit
countri
train
student
complet
preparatori
learn
modul
provid
host
preceptor
learn
activ
includ
engag
classroom
activ
local
student
shadow
uniqu
practic
set
topic
discuss
incorpor
epcpt
yield
concept
understand
justificationdocument
program
develop
meet
student
interest
need
increas
cultur
awar
healthcar
exampl
learn
item
identifi
us
student
advantag
disadvantag
univers
healthcar
care
grow
elderli
popul
practic
incorpor
herbaltradit
medicin
focu
item
japanes
student
oral
written
commun
skill
patient
care
use
medic
english
divers
clinic
pharmaci
practic
us
implement
collabor
care
medic
team
interprofession
educ
uniqu
medic
use
respect
countri
identifi
summar
part
epcpt
assign
adapt
uniqu
countri
practic
learn
point
need
identifi
discuss
develop
meaning
program
learn
opportun
clinic
site
host
countri
need
coordin
advanc
languag
differ
barrier
also
opportun
japanes
student
learn
medic
english
identifi
necessari
area
improv
signific
epcpt
aim
broaden
student
perspect
improv
clinic
skill
provid
educ
opportun
japan
us
student
learn
uniqu
countri
healthcar
system
compar
advantag
challeng
activ
classroom
clinic
set
collabor
intern
pharmd
program
bridg
clinic
educ
practic
across
world
jennif
pham
pharmd
bcp
bcpp
lilian
azzopardi
bpharm
hon
mphil
phd
mrpharm
alan
lau
jenni
jarrett
pharmd
bcp
pharmaci
depart
pharmaci
practic
univers
illinoi
chicago
chicago
il
pharmaci
univers
malta
msida
malta
servic
program
univers
malta
um
univers
illinoi
chicago
uic
develop
collabor
pharmd
program
intern
pharmacist
program
consist
didact
clinic
experi
research
didact
cours
taught
uic
um
faculti
pharmacotherapeut
drug
informationstatist
pharmacoeconom
us
europ
lectur
pair
recit
taught
either
via
videoconferenc
clinic
experi
acquir
pharmaci
practic
set
malta
includ
hospit
commun
pharmacovigil
research
compon
mentor
um
uic
faculti
focus
appli
practic
research
justificationdocument
survey
perform
evalu
student
motiv
particip
satisfact
program
util
current
curriculum
respond
respons
rate
major
student
malta
practic
pharmaci
year
averag
prior
pharmd
enrol
student
note
improv
knowledg
skill
increas
job
opportun
main
motiv
enrol
student
found
pharmacotherapeut
cours
difficult
satisfi
likert
scale
felt
prepar
clinic
rotat
adapt
um
recogn
chang
healthcar
landscap
excel
europ
clinic
pharmaci
educ
research
took
lead
contribut
intern
uic
develop
profession
doctor
wide
rang
expertis
uic
faculti
hybrid
teach
model
provid
broad
perspect
clinic
special
merg
european
us
intern
collabor
colleg
pharmaci
possibl
technolog
equip
pharmacist
clinic
practic
advanc
signific
educ
model
use
advanc
clinic
pharmaci
practic
research
educ
around
world
particularli
countri
limit
access
clinic
pharmaci
faculti
expertis
smart
pharmaci
program
chang
practic
chang
educ
michael
rous
bpharm
hon
arijana
drsc
servic
program
accredit
council
pharmaci
educ
chicago
il
zagreb
croatia
servic
program
smart
pharmaci
program
learn
today
appli
tomorrow
design
sustain
initi
base
cpd
model
object
enhanc
practition
compet
expand
scope
practic
improv
qualiti
clinic
servic
posit
impact
patient
popul
outcom
beyond
build
knowledg
skill
program
address
motiv
commit
chang
stakehold
invit
initi
workshop
includ
swot
analysi
nation
tool
framework
developedadapt
trainer
train
pharmacist
train
cpd
key
principl
concept
clinic
modul
quickli
easili
demonstr
measur
patient
outcom
pharmacist
compet
qualiti
servic
appli
learn
care
patient
measur
result
standard
way
document
everyth
portfolio
justificationdocument
get
measur
get
done
turkish
pharmacist
requir
ce
maintain
licens
meaning
particip
ce
minim
mani
countri
pharmacist
requir
ce
may
well
noth
beyond
particip
program
design
make
learn
meaning
impact
practic
viabl
adapt
although
base
global
adopt
framework
principl
program
design
implement
flexibl
adapt
accord
nation
context
societ
need
differ
entiti
includ
nation
profession
associ
regul
hospit
ministri
health
led
program
support
acp
pharmaexpert
signific
program
posit
impact
individu
pharmacist
nation
organ
patient
sinc
launch
turkey
turkish
pharmacist
train
asthma
diabet
program
implement
six
addit
countri
two
launch
sever
countri
anticip
implement
program
soon
establish
collabor
intern
pharmaci
practic
experi
vellor
india
alyssa
christensen
pharmd
depart
pharmaci
practic
univers
illinoi
colleg
pharmaci
rockford
il
servic
program
report
develop
collabor
intern
pharmaci
student
rotat
univers
illinoi
chicago
uic
colleg
pharmaci
intern
advanc
pharmaci
practic
elect
experi
offer
year
uic
student
christian
medic
colleg
cmc
vellor
india
develop
collabor
key
stakehold
cmc
cmc
bed
academ
medic
center
pharmaci
depart
employe
pharmd
faculti
grow
clinic
pharmaci
servic
justificationdocument
student
activ
includ
medic
intens
care
unit
round
pharmd
perform
medic
counsel
investig
evalu
advers
drug
event
answer
drug
inform
question
particip
research
aim
evalu
impact
pharmaci
servic
cmc
uic
faculti
assist
growth
pharmaci
servic
aid
pharmaci
practic
research
design
implement
provid
preceptor
develop
educ
offer
mentorship
pharmaci
faculti
cmc
success
program
measur
expans
clinic
pharmaci
servic
cmc
adapt
uic
faculti
accompani
precept
uic
student
site
uic
faculti
work
cmc
pharmd
orient
train
act
preceptor
uic
faculti
absent
clinic
pharmaci
servic
grow
uic
student
offer
addit
rotat
opportun
includ
plan
geriatr
medic
servic
team
uic
faculti
collabor
cmc
faculti
research
effort
grow
pharmaci
servic
enhanc
student
experi
signific
pharmaci
student
faculti
gain
valuabl
experi
work
alongsid
patient
healthcar
provid
divers
background
exposur
medic
diseas
state
commonli
encount
us
experi
provid
student
faculti
person
profession
develop
well
improv
cultur
awar
sensit
return
uic
provid
guidanc
strategi
enhanc
clinic
pharmaci
servic
cmc
intern
advanc
pharmaci
practic
experi
app
southern
africa
focu
sustain
pharmaceut
care
public
health
intervent
ashley
crumiti
miranda
law
imbi
drame
shelter
muship
henri
fomundam
univers
colleg
pharmaci
washington
dc
univers
global
initi
south
africa
hugisa
hatfield
pretoria
south
africa
servic
program
howard
univers
colleg
pharmaci
hucop
develop
framework
intern
advanc
pharmaci
practic
experi
app
southern
africa
allow
student
pharmacist
contribut
sustain
public
health
activ
posit
impact
local
popul
student
develop
howard
univers
global
initi
south
africa
hugisa
hu
region
offic
establish
pretoria
south
africa
carri
health
intervent
project
southern
east
african
countri
carri
disproportion
high
preval
hivaid
infecti
supervis
howard
univers
preceptor
base
region
offic
hucop
student
pharmacist
receiv
uniqu
intens
concentr
reward
intern
app
experi
justificationdocument
constant
presenc
intern
base
pharmacist
allow
rapid
integr
student
pharmacist
public
health
initi
student
work
project
fund
major
us
agenc
cdc
pepfar
play
role
advanc
pharmaceut
care
develop
clinic
tool
hivaidstb
carri
oper
research
give
variou
topic
project
manag
hu
region
offic
adapt
stabl
presenc
pharmacist
allow
better
understand
global
health
care
need
especi
health
care
challeng
region
creat
opportun
pharmaci
intervent
meet
public
health
need
context
develop
countri
signific
program
allow
student
exposur
pharmaceut
care
global
challeng
provid
opportun
student
make
vital
contribut
sustain
public
health
solut
experi
student
popul
serv
learn
valu
pharmacist
advanc
health
care
global
interprofession
educ
global
health
experi
donna
beall
jennif
bell
darin
bell
jacquelin
brown
school
pharmaci
univers
montana
missoula
mt
physic
therapi
rehabilit
scienc
univers
montana
missoula
mt
famili
medicin
resid
western
montana
univers
montana
missoula
mt
psycholog
univers
montana
missoula
mt
servic
program
profess
requir
interprofession
educ
ipe
train
team
faculti
pharmaci
famili
medicin
physic
therapi
psycholog
form
identifi
global
opportun
ipe
object
creat
interprofession
experi
learner
increas
experi
differ
health
profess
creat
global
health
experi
gondar
ethiopia
learner
gain
better
understand
differ
cultur
expos
learner
train
health
care
system
serv
environ
develop
countri
justificationdocument
univers
montana
establish
relationship
univers
gondar
u
g
faculti
exchang
colleg
educ
human
psycholog
set
framework
u
g
interest
expand
relationship
health
profess
interprofession
team
faculti
learner
pharmaci
famili
medicin
physic
therapi
psycholog
form
visit
gondar
collabor
learner
faculti
classroom
clinichospit
adapt
mani
program
util
interprofession
educ
global
health
set
result
demonstr
despit
differ
train
program
differ
level
train
overal
learner
readi
interprofession
learn
prior
trip
learner
satisfi
experi
report
would
recommend
other
signific
learner
spent
three
week
gondar
ethiopia
work
learn
well
interprofession
set
faculti
abl
collabor
develop
formal
mentor
program
institut
integr
drug
inform
introductori
principl
research
cours
kingston
jamaica
tyler
mullen
maxin
bsc
mphil
cameil
pharmd
gene
mors
gina
prescott
pharmd
integr
global
biomed
scienc
center
excel
bioinformat
life
scienc
univers
buffalo
univers
buffalo
buffalo
ny
basic
medic
scienc
univers
west
indi
mona
campu
kingston
jamaica
pharmacolog
core
center
excel
bioinformat
life
scienc
school
pharmaci
univers
buffalo
buffalo
ny
pharmaci
pharmaceut
scienc
univers
buffalo
buffalo
ny
servic
program
drug
inform
scientif
literatur
review
cours
design
implement
univers
west
indi
uwi
mona
campu
doctor
pharmaci
pharmd
student
cours
design
provid
skill
need
advanc
pharmaci
practic
advanc
health
scienc
research
skill
compli
acp
certif
global
health
implement
fellow
develop
coordin
instruct
cours
cours
model
univers
buffalo
ub
pharmaci
cours
includ
journal
club
present
ethic
debat
written
drug
inform
respons
midterm
exam
justificationdocument
one
goal
health
research
task
forc
catalyz
develop
novel
educ
program
increas
capac
advanc
healthcar
jamaica
uwi
newli
develop
pharmd
program
follow
unmet
need
pharmd
train
faculti
acp
certif
research
prioriti
nine
student
enrol
success
complet
cours
topic
success
complet
includ
citi
train
mean
midterm
journal
club
b
debat
written
consultationrespons
b
student
need
mentor
scientif
write
skill
adapt
uwi
region
univers
throughout
caribbean
program
provid
uwi
campus
low
countri
util
distanc
learn
short
term
person
instruct
approach
facilit
train
pharmd
student
advanc
introductori
research
skill
maxim
util
qualifi
instructor
videoconfer
concern
avail
cost
drug
inform
resourc
remain
signific
jamaican
ministri
health
pharmaci
council
jamaica
state
expand
role
clinic
pharmacist
integr
continu
growth
qualiti
patient
care
caribbean
train
student
pharmacist
drug
inform
skill
essenti
certif
optim
patient
care
develop
research
practition
learn
across
border
develop
continu
profession
develop
program
baylor
colleg
medicin
intern
pediatr
aid
initi
pharmaci
network
dian
nguyen
pharmd
bcp
alexa
vyain
rustin
crutchley
ami
cheng
michael
mizwa
bs
pediatr
baylor
colleg
medicin
houston
tx
pharmaci
practic
translat
research
univers
houston
houston
pa
pharmaci
washington
state
univers
yakima
wa
pharmaci
practic
templ
univers
school
pharmaci
philadelphi
pa
baylor
colleg
medicin
houston
tx
servic
program
lead
provid
pediatr
hiv
care
treatment
world
bipai
oper
eight
center
excel
coe
five
satellit
coe
botswana
lesotho
eswatini
malawi
uganda
mbeya
mwanza
tanzania
learn
commun
enabl
pharmacist
technician
engag
opportun
build
capac
improv
oper
clinic
pharmaci
practic
share
best
pharmaci
practic
identifi
peer
point
contact
support
guidanc
resolv
problem
collabor
network
develop
continu
profession
develop
cpd
program
pharmaci
profession
learn
collabor
creat
connect
across
organiz
geograph
boundari
justificationdocument
conduct
develop
pilot
curriculum
focus
three
core
compon
suppli
chain
manag
clinic
pharmaci
practic
pharmaci
manag
polici
curriculum
consist
learn
modul
correspond
live
session
design
promot
exchang
inform
develop
practic
skill
eg
facilit
discuss
case
studi
journal
club
five
elect
modul
quantit
outcom
includ
curriculum
activ
track
eg
number
particip
modul
live
learn
compon
particip
score
curriculum
complet
rate
qualit
outcom
measur
survey
particip
individu
learn
modul
interact
compon
also
overal
profession
develop
adapt
curriculum
primarili
develop
pharmacist
special
hiv
global
health
pediatr
input
coe
pharmaci
profession
curriculum
ran
novemb
april
curriculum
materi
maintain
onlin
learn
platform
moodl
onlin
videoconfer
tool
zoom
use
connect
across
countri
signific
cpd
program
serv
basi
growth
enhanc
knowledg
skill
pharmaci
profession
coe
continu
serv
children
famili
develop
escap
room
learn
activ
therapeut
cours
seri
michael
j
gonyeau
bspharm
pharmd
med
bcp
fccp
school
pharmaci
northeastern
univers
boston
servic
program
escap
room
ludic
game
team
play
whose
object
escap
room
encourag
student
think
creativ
critic
pauciti
data
regard
escap
room
design
health
educ
object
util
iter
process
creat
immers
experi
stimul
deepen
knowledg
skill
attitud
promot
collabor
live
simul
set
therapeut
seminar
cours
justificationdocument
escap
room
develop
five
puzzl
integr
hyperlipidemia
pharmacolog
pathophysiolog
therapeut
half
seminar
section
experienc
activ
other
util
previous
creat
materi
act
control
group
escap
student
must
construct
appropri
prescript
base
patient
includ
opinion
base
knowledg
base
item
administ
exam
perform
evalu
detect
differ
potenti
attribut
activ
pair
perform
student
engag
applic
classroom
knowledg
collabor
attitud
toward
use
educ
game
singl
use
determin
curricular
fisher
exact
use
knowledg
base
question
student
complet
student
intervent
group
complet
signific
differ
observ
vs
respons
relat
work
group
effect
educ
game
exam
score
analysi
reveal
mean
increas
hyperlipidemia
content
score
intervent
group
adapt
pharmaci
program
could
adopt
method
develop
escap
room
activ
number
pharmaci
cours
offer
signific
construct
escap
room
help
develop
skill
team
work
creativ
problem
solv
critic
think
inher
mechan
increas
likelihood
student
engag
activ
enhanc
student
attitud
regard
collaborationteamwork
appli
knowledg
confid
institut
approach
intern
workshop
intend
promot
curricular
chang
janet
engl
joseph
dipiro
john
ressler
michael
rous
bpharm
hon
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
commonwealth
univers
richmond
va
associ
colleg
pharmaci
alexandria
va
servic
program
accredit
council
pharmaci
educ
chicago
il
servic
program
school
pharmaci
around
world
embark
curricular
chang
ensur
graduat
knowledg
skill
provid
clinic
pharmaci
servic
requir
curricula
prepar
graduat
possess
compet
suitabl
chang
role
health
care
program
develop
help
team
pharmaci
faculti
member
administr
univers
work
togeth
identifi
opportun
curricular
chang
expert
faculti
lead
particip
team
exercis
identifi
gap
current
didact
experienti
coursework
construct
object
new
educ
experi
design
new
model
teach
learn
assess
team
return
institut
plan
implement
curricular
chang
meet
local
need
health
care
system
topic
workshop
includ
curriculum
design
deliveri
assess
experienti
learn
justificationdocument
need
assess
school
variou
region
world
determin
programmat
need
enhanc
qualiti
pharmaci
educ
result
inform
develop
topic
offer
particip
work
team
institut
plan
base
local
need
adapt
program
util
institut
model
team
school
work
togeth
develop
plan
curricular
chang
meet
local
context
need
program
adapt
anyplac
world
program
offer
multipl
time
middl
east
europ
offer
plan
part
world
signific
date
faculti
repres
school
countri
particip
particip
survey
result
posit
particip
indic
concept
work
team
institut
confer
enrich
experi
enabl
go
back
institut
concret
plan
implement
curricular
chang
develop
valid
applic
inhal
techniqu
compet
assess
framework
pharmaci
technician
local
acut
hospit
hong
kong
gordon
h
miu
bpharm
mclinpharm
vicki
w
k
ling
doctor
wilson
leung
bpharm
phd
esther
wy
chan
bpharm
hon
mclinpharm
phd
pharmaci
queen
elizabeth
hospit
hong
kong
hong
kong
pharmaci
univers
hong
kong
hong
kong
hong
kong
servic
program
inhal
techniqu
compet
assess
framework
develop
valid
bp
certifi
pharmacist
queen
elizabeth
hospit
academ
pharmacist
univers
hong
kong
workshop
inhal
techniqu
establish
base
framework
pharmaci
technician
recruit
compet
train
assess
differ
time
point
use
framework
compet
technician
defin
obtain
total
score
qualifi
educ
patient
outpati
pharmaci
justificationdocument
demand
inhal
educ
patient
local
hospit
howev
variat
inhal
techniqu
report
literatur
suboptim
techniqu
observ
among
local
technician
therefor
establish
compet
import
twelv
technician
recruit
fail
baselin
assess
mdi
mdiaerochamb
accuhal
turbuhal
handihal
soft
mist
inhal
breezhal
ellipta
inhal
train
inhal
techniqu
significantli
improv
mdi
mdiaerochamb
accuhal
turbuhal
handihal
soft
mist
inhal
breezhal
ellipta
inhal
p
pair
technician
subsequ
reassess
determin
optim
interv
revalid
compet
maintain
year
given
technician
practis
work
mark
adapt
healthcar
profession
frequent
report
incompet
inhal
techniqu
use
framework
requir
specialist
skill
thu
wide
adopt
train
technician
pharmacist
nurs
physician
need
educ
patient
inhal
techniqu
commun
hospit
set
signific
inhal
techniqu
assess
framework
establish
improv
qualiti
care
also
enhanc
profession
develop
pharmaci
technician
spare
pharmacist
provis
advanc
clinic
servic
train
assess
model
establish
extend
medic
specif
handl
techniqu
bridg
intern
local
global
health
baylor
colleg
medicin
intern
pediatr
aid
initi
pharmaci
network
confer
dian
nguyen
pharmd
bcp
elizabeth
flatley
katherin
wang
ami
cheng
pharmd
bcacp
kemi
osundina
yen
phan
pediatr
baylor
colleg
medicin
houston
tx
children
hospit
houston
tx
pharmaci
practic
templ
univers
school
pharmaci
philadelphia
pa
state
univers
new
jersey
lawrencevil
nj
servic
program
lead
provid
pediatr
hiv
care
treatment
bipai
oper
eight
center
excel
coe
five
satellit
coe
botswana
lesotho
eswatini
malawi
uganda
mbeya
mwanza
tanzania
learn
commun
enabl
pharmacist
technician
engag
opportun
build
capac
improv
oper
clinic
pharmaci
practic
share
best
practic
identifi
peer
point
contact
support
guidanc
resolv
problem
collabor
host
first
global
pharmaci
confer
johannesburg
south
africa
novemb
object
justificationdocument
seventeen
pharmacist
across
texa
children
hospit
us
colleg
pharmaci
particip
program
includ
didact
session
workshop
focus
suppli
chain
manag
clinic
pharmaci
practic
pharmaci
manag
leadership
best
practic
share
network
impact
session
knowledg
measur
administ
qualiti
session
assess
particip
evalu
extent
relationship
establish
measur
use
liserserv
social
media
commun
applic
whatsapp
group
collabor
individu
site
adapt
confer
leverag
experi
pharmacist
pharmacist
creat
activ
learn
process
among
work
underserv
commun
local
intern
pharmacist
primarili
drove
process
prepar
facilit
confer
activ
howev
pair
coe
pharmacist
dialogu
ensur
appropri
adapt
content
set
facilit
joint
session
signific
confer
design
increas
pharmacist
technic
knowledg
skill
clinic
pharmaci
practic
strengthen
foster
qualiti
improv
project
coe
us
pharmacist
enhanc
pharmaci
oper
develop
clinic
role
coe
pharmacist
promot
pharmacist
integr
medic
team
intern
scholar
program
advanc
clinic
pharmaci
practic
educ
global
roger
lander
bspharm
pharmd
fccp
fashp
bcacp
michael
hogu
pharmd
fapha
michael
thoma
pharmd
bcp
practic
depart
mcwhorter
school
pharmaci
samford
univers
birmingham
al
pharmaceut
social
administr
scienc
mcwhorter
school
pharmaci
colleg
health
scienc
birmingham
al
pharmaci
practic
mcwhorter
school
pharmaci
colleg
health
scienc
birmingham
al
servic
program
provid
program
day
durat
pharmacist
pharmaci
student
differ
countri
come
us
learn
clinic
practic
educ
us
well
learn
share
experi
program
consist
patient
care
develop
clinic
practic
clinic
educ
method
simul
experi
justificationdocument
school
host
approxim
student
pharmacist
observ
studi
program
particip
time
experi
rang
observ
week
immers
type
experi
month
durat
particip
mainli
asia
includ
japan
korea
china
indonesia
malaysia
vietnam
singapor
desir
expand
offer
wider
geograph
region
increas
difficulti
place
scholar
practic
site
decid
design
program
would
provid
introduct
train
clinic
practic
educ
way
maintain
origin
goal
yet
achiev
grow
restrict
clinic
practic
placement
begin
continu
summer
offer
newli
format
program
particip
ten
differ
countri
five
previou
affili
adapt
program
includ
introduct
us
pharmaci
educ
system
care
process
util
clinic
simul
center
patient
interact
scholar
visit
commun
pharmaci
site
particip
number
cultur
enrich
activ
citi
school
could
easili
adapt
program
use
signific
receiv
posit
feedback
particip
date
complet
confer
well
mani
comment
util
informationskil
learn
return
home
countri
plan
continu
annual
program
evolut
experienti
focus
pharmaci
educ
program
within
eldoret
kenya
monica
l
miller
pharmd
rakhi
karwa
ellen
schellhas
sonak
pastakia
pharmd
mph
beatric
jakait
victor
kipyegon
maina
gabriel
kigen
bpharm
imran
manji
bpharm
susi
crow
pharmd
bcp
dan
tran
pharmaci
practic
purdu
univers
colleg
pharmaci
west
lafayett
pharmacolog
moi
univers
eldoret
kenya
pharmaci
practic
purdu
univers
colleg
pharmaci
purdu
kenya
partnership
eldoret
kenya
eldoret
kenya
teach
referr
hospit
eldoret
kenya
moi
univers
eldoret
kenya
pharmaci
academ
model
provid
access
healthcar
ampath
eldoret
kenya
tennesse
state
univers
johnson
citi
tn
servic
program
purdu
univers
colleg
pharmaci
pucop
member
ampath
consortium
includ
moi
teach
referr
hospit
mtrh
moi
univers
sinc
pucop
coupl
bilater
partnership
advanc
patient
care
educ
research
initi
educ
program
focus
experienti
train
pucop
student
kenyan
train
pharmaci
intern
provid
care
adult
medicin
ward
intern
interprofession
team
demonstr
success
kenyan
pharmacist
intern
abil
appli
knowledg
impact
care
led
pucop
team
expand
advanc
experienti
focus
train
opportun
within
kenya
effort
experienti
base
resid
diploma
program
pgd
master
clinic
pharmaci
ms
program
develop
partnership
local
partner
justificationdocument
although
posit
impact
clinic
pharmacist
patient
outcom
well
document
countri
data
lack
low
countri
lmic
like
due
challeng
includ
poor
essenti
medicin
avail
healthcar
worker
shortag
educ
program
mention
aim
train
pharmacist
address
challeng
improv
patient
care
intern
pgd
graduat
current
enrol
ms
student
pucop
student
train
within
individu
educ
program
seven
retain
clinic
pharmacist
develop
maintain
nine
new
patient
care
servic
directli
impact
patient
yearli
hous
program
mtrh
establish
first
clinic
pharmaci
unit
hospit
within
kenya
adapt
program
recogn
kenyan
pharmaci
poison
board
moi
univers
allow
replic
throughout
kenya
lmic
countri
look
advanc
patient
care
opportun
signific
educ
model
significantli
advanc
clinic
pharmaci
practic
within
kenya
impact
experienti
train
program
build
learner
variou
stage
career
creation
novel
interprofession
global
health
certif
emili
flore
megan
quinn
susi
crow
meira
yasin
jackson
william
pharmaci
practic
east
tennesse
state
univers
bill
gatton
colleg
pharmaci
johnson
citi
tn
tennesse
state
univers
colleg
public
health
johnson
citi
tn
tennesse
state
univers
bill
gatton
colleg
pharmaci
johnson
citi
tn
tennesse
state
univers
colleg
nurs
johnson
citi
tn
tennesse
state
univers
jame
quillen
colleg
medicin
johnson
citi
tn
servic
program
global
health
opportun
east
tennesse
state
univers
grown
collabor
academ
health
scienc
center
interprofession
faculti
result
new
didact
experienti
cours
global
health
certif
develop
clinic
research
partnership
develop
global
health
collabor
faculti
seek
interprofession
sustain
interprofession
global
health
certif
develop
provid
strong
educ
foundat
global
health
interest
student
etsu
provid
opportun
expand
collabor
abroad
justificationdocument
global
health
certif
requir
includ
foundat
didact
cours
field
placement
preparatori
cours
seminar
cours
interprofession
addit
cours
field
placement
allow
educ
develop
individu
interest
cours
certif
asynchron
onlin
blend
seat
travel
cours
incorpor
signific
activ
learn
cultur
immers
activ
develop
collabor
mbarara
uganda
priorit
field
placement
develop
collabor
seek
advanc
clinic
pharmacist
educ
practic
mbarara
uganda
effort
usa
ugandan
pharmaci
student
intern
faculti
clinic
pharmacist
adapt
similar
certif
could
implement
interprofession
offer
interest
univers
work
global
health
interest
faculti
advoc
collabor
qualiti
global
health
field
experi
administr
support
cours
approv
fund
challeng
curricular
coordin
faculti
time
coordin
effort
signific
global
health
train
pharmacist
signific
need
develop
clinic
pharmacist
workforc
worldwid
priorit
global
health
certif
provid
packag
train
futur
pharmacist
interprofession
global
health
certif
provid
addit
insight
success
team
member
develop
interprofession
compet
rolesrespons
teamsteamwork
valueseth
interprofession
commun
joint
intern
cours
pharmaci
student
taiwan
us
chelsea
pekni
elizabeth
chang
pharmd
lin
ms
pharmaci
ohio
state
univers
columbu
oh
pharmaci
colleg
pharmaci
taipei
medic
univers
taipei
citi
taiwan
pharmaci
graduat
institut
china
medic
univers
taichung
taiwan
servic
program
joint
intern
cours
pharmaci
student
taiwan
us
justificationdocument
focu
activ
learn
model
student
interest
global
experi
increas
opportun
exist
collabor
intern
partner
provid
interact
cours
student
pharmacist
sinc
one
us
two
taiwan
institut
partner
deliv
elect
cours
center
live
videoconfer
among
institut
cours
focus
pharmaci
practic
similar
differ
care
deliveri
us
taiwan
year
cours
theme
select
past
exampl
includ
smoke
cessat
drug
abus
geriatr
medic
use
recent
compon
regular
virtual
interact
ad
student
onlin
discuss
throughout
cours
pharmaci
educ
health
care
system
cours
theme
year
model
provid
uniqu
opportun
intern
engag
first
provid
regular
interact
student
case
interact
limit
fund
time
constraint
second
provid
date
inform
specif
pharmaci
practic
topic
pharmaci
student
vari
level
final
provid
opportun
student
institut
collabor
creation
present
util
teach
partner
institut
particip
question
answer
session
interact
videoconfer
date
student
us
student
taiwan
particip
videoconfer
well
faculti
administr
institut
adapt
facilit
cours
technolog
util
includ
onlin
access
discuss
board
equip
videoconferenc
capabl
signific
videoconfer
experi
give
profession
pharmaci
student
abil
interact
peer
around
world
discuss
time
pharmaci
practic
topic
sustain
access
fashion
first
step
build
larger
collabor
need
assess
preceptor
profession
develop
studi
sara
mahmoud
pharmd
bcccp
rasha
al
anani
wessam
elkassem
bsc
mba
moza
alhail
bsc
pharm
jodi
malhotra
medicin
surgeri
hamad
medic
corpor
doha
qatar
medic
corpor
doha
qatar
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
aurora
co
servic
program
resid
program
ashp
accredit
hamad
medic
corpor
qatar
justificationdocument
ensur
excel
experienti
program
import
invest
preceptor
profession
develop
per
current
evid
nt
enough
data
guid
aid
profession
develop
resid
preceptor
survey
conduct
measur
compet
pharmaci
resid
preceptor
hamad
medic
corpor
qatar
ashp
accredit
adapt
comprehens
literatur
review
conduct
translat
preceptor
develop
assess
rubric
rubric
depict
form
survey
measur
confid
profici
preceptor
survey
consist
question
focus
pharmaci
role
model
teach
skill
model
commun
profession
research
other
signific
preceptor
show
high
confid
pharmaci
role
model
abl
motiv
resid
howev
defici
abl
transit
differ
teach
model
coach
facilit
preceptor
also
report
requir
improv
teach
manag
skill
time
manag
critic
convers
global
level
found
preceptor
develop
requir
signific
improv
especi
pharmaci
resid
program
hmc
multipl
area
improv
teach
strategi
write
feedback
present
skill
establish
pharmaceut
servic
within
emerg
depart
graziella
portelli
lilian
azzopardi
bpharm
hon
mphil
phd
mrpharm
ffip
louis
grech
bpharm
hon
mphil
phd
dei
hopsit
msida
malta
pharmaci
univers
malta
msida
malta
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
servic
program
establish
pharmaceut
servic
tailor
need
adult
emerg
depart
ed
mater
dei
hospit
mdh
servic
provid
one
pharmacist
cover
weekday
justificationdocument
servic
absent
mdh
main
hospit
level
one
trauma
centr
malta
innov
prioritis
servic
provid
set
medic
nurs
team
request
pharmaceut
support
divers
multipl
aspect
adapt
ed
dynam
medic
use
process
observ
week
gap
analysi
concurr
familiaris
ed
physician
nurs
respect
valid
questionnair
dissemin
determin
perspect
expect
pharmacist
ed
depart
thegap
analysi
questionnair
find
respons
rate
physician
nurs
support
intern
guidelin
serv
blueprint
establish
ed
pharmaceut
servic
categoris
oper
clinic
other
follow
valid
key
manag
peopl
mdh
ed
pharmaci
servic
start
march
signific
oper
servic
primarili
set
ed
medic
stock
manag
centralis
pharmaci
model
new
drug
ad
floor
stock
chang
implement
formulari
list
reorganis
medic
cabinet
carri
high
alert
drug
identifi
letter
label
identif
light
sensit
drug
implement
antidot
hazard
vulner
exercis
carri
determin
offici
antidot
list
clinic
servic
start
novemb
month
period
clinic
pharmaci
intervent
document
ed
pharmacist
particip
resuscit
case
nation
major
event
four
department
polici
relat
medic
use
written
pharmacolog
lectur
nurs
staff
deliv
implement
transit
care
servic
acut
gener
hospit
denis
borg
bsc
pharm
sci
hon
louis
grech
bpharm
hon
mphil
phd
lilian
azzopardi
bpharm
hon
mphil
phd
mrpharm
ffip
pharmaci
faculti
medicin
surgeri
univers
malta
msida
malta
pharmaci
univers
malta
msida
malta
servic
program
innov
pharmaceut
servic
devis
patient
transit
acut
gener
hospit
clinic
set
holist
tailor
intervent
deliv
hospit
pharmacist
mater
dei
hospit
malta
follow
observ
phase
intervent
centr
around
customis
patient
counsel
valid
discharg
inform
provid
clinic
check
medic
reconcili
suppli
medic
discharg
justificationdocument
target
pharmaceut
intervent
allow
identif
potenti
medic
error
promot
interdisciplinari
approach
toward
ensur
continu
care
servic
target
previous
unexplor
nich
clinic
pharmacist
malta
focus
patient
transit
phase
hospit
discharg
adapt
servic
incept
alloc
pharmacist
perform
transit
care
role
pager
system
devis
enabl
healthcar
profession
flag
patient
pharmacist
perform
advanc
pharmaceut
intervent
model
task
alloc
facilit
enact
multidisciplinari
standardis
oper
procedur
govern
process
discharg
servic
model
replic
institut
global
engag
pharmacist
perform
transit
care
initi
promot
patient
safeti
signific
success
implement
discharg
servic
highlight
leadership
role
clinic
pharmacist
embark
transit
care
innov
servic
consist
bundl
pharmaceut
intervent
throughout
period
servic
incept
discharg
patient
benefit
intervent
correspond
approxim
patient
discharg
studi
set
pilot
medic
reconcili
servic
perform
discharg
patient
gaug
expans
servic
provis
patient
perspect
medic
rural
kenya
survey
erika
kim
pharmd
candid
vicki
ellingrod
pharmd
peter
ndege
mb
chb
mmed
intern
med
michigan
colleg
pharmaci
ann
arbor
mi
pharmaci
depart
colleg
pharmaci
univers
michigan
ann
arbor
mi
commun
medic
consult
clinic
meru
kenya
servic
program
michigan
institut
clinic
health
research
global
summer
clinic
research
program
kenya
methodist
univers
provid
opportun
pharmaci
student
conduct
intern
medic
use
studi
chronic
ill
patient
meru
kenya
prospect
commun
survey
held
local
kithoka
dispensari
govern
oper
meru
level
hospit
justificationdocument
medic
manag
crucial
growth
hiv
tuberculosi
noncommunic
diseas
result
doubl
burden
diseas
east
african
commun
studi
medic
use
focu
urban
nairobi
western
kenya
lead
lack
knowledg
rural
region
make
popul
june
juli
chronic
ill
patient
rural
meru
counti
complet
measur
drug
scale
med
survey
score
defin
adequ
drug
averag
med
score
show
inadequ
medic
signific
differ
across
age
gender
minor
side
effect
idea
take
medicin
disrupt
life
highli
associ
poor
medic
r
forget
poor
medic
highest
correl
r
agre
hard
time
pay
medicin
adapt
question
med
survey
statist
signific
correl
medic
survey
complet
english
offici
languag
kenya
implement
rural
east
african
commun
determin
baselin
rate
identifi
barrier
adequ
medic
signific
patient
rural
kenyan
popul
adequ
medic
med
questionnair
practic
tool
identifi
barrier
medic
rural
popul
may
indic
area
pharmacist
develop
educ
resourc
global
outreach
clinic
servic
educ
program
rural
commun
vietnam
truong
pharmd
mph
yen
dang
pharmd
school
pharmaci
health
profess
univers
maryland
eastern
shore
ume
princess
ann
md
servic
program
partnership
clinic
educ
program
aim
provid
primari
care
servic
reduc
cardiopulmonari
morbiditymort
vietnam
rural
commun
approach
implement
approach
includ
provid
primari
care
patient
train
clinic
staff
educ
commun
educ
train
consist
lectur
activ
focus
risk
symptom
treatment
prevent
strategi
clinic
servic
includ
assess
treatment
cardiopulmonari
diseas
dispens
medic
justificationdocument
team
includ
healthcar
profession
student
medicin
nurs
pharmaci
public
health
unit
state
vietnam
volunt
collabor
provid
primari
care
medic
health
educ
focu
stroke
chronic
obstruct
pulmonari
diseas
copd
smoke
cessat
lead
caus
death
vietnam
team
provid
primari
care
medic
patient
averag
year
age
medic
condit
per
patient
educ
patient
particip
survey
program
complet
agre
improv
lifestyl
factor
decreas
risk
cardiovascular
diseas
copd
respect
adapt
provid
global
health
servic
interprofession
intern
rural
commun
clinic
enabl
volunt
educ
care
divers
popul
gain
experi
learn
lesson
futur
mission
train
clinic
staff
would
respons
continu
clinic
educ
servic
mission
program
enhanc
clinic
pharmaci
servic
rural
set
could
replic
similar
global
set
signific
global
health
servic
includ
provis
health
educ
medic
mission
improv
health
equiti
peopl
worldwid
implement
program
first
kind
rural
set
util
interprofession
team
approach
led
clinic
pharmacist
train
clinic
staff
sustain
manag
chronic
diseas
enhanc
medic
knowledg
pharmacist
goa
india
golden
peter
pharmd
bcp
saint
loui
colleg
pharmaci
saint
loui
mo
servic
program
partnership
form
goa
colleg
pharmaci
gcp
st
loui
colleg
pharmaci
stlcop
develop
partnership
focus
implement
otc
medic
educ
program
member
goa
pharmacist
associ
gpa
gpa
meetingsworkshop
local
pharmacist
otc
medic
present
expand
knowledg
member
pre
assess
attende
knowledg
justificationdocument
otc
medic
india
readili
avail
otc
product
typic
store
behind
counter
usual
requir
prescript
prior
dispens
india
pharmaci
leader
make
progress
otc
product
move
product
behind
counter
shift
requir
pharmacist
goa
india
becom
knowledg
confid
provid
recommend
patient
adapt
project
led
pharmaci
leader
within
local
commun
guidanc
allow
stlcop
faculti
build
otc
list
otc
medic
seek
india
priorit
local
pharmaci
leader
servic
could
easili
adopt
pharmaci
organ
within
india
intern
locat
increas
local
pharmacist
otc
product
relev
pharmaci
topic
vital
ingredi
success
key
stakehold
within
local
commun
take
ownership
project
invest
time
assum
leadership
role
within
project
signific
project
fill
signific
educ
gap
within
commun
current
otc
medic
content
within
gcp
curriculum
plan
within
goa
throughout
india
mani
product
otc
medic
would
allow
patient
receiv
product
without
prescript
project
aim
fill
knowledg
gap
current
exist
pharmacist
india
regard
recommend
pharmacist
contribut
medic
brigad
rural
hondura
olivia
caron
bs
daniel
hess
bs
benjamin
van
tassel
pharmd
school
pharmaci
virginia
commonwealth
univers
richmond
va
servic
program
care
essenti
compon
global
health
effort
herein
describ
pharmaci
contribut
medic
brigad
hondura
justificationdocument
brigad
travel
rural
commun
near
olanchito
yoro
hondura
brigad
set
clinic
adult
pediatr
patient
day
central
villag
la
hicaca
day
remot
villag
lomita
cours
day
team
see
approxim
patient
adapt
team
consist
attend
pharmacist
student
pharmacist
attend
pediatr
physician
attend
intern
medicineinfecti
diseas
physician
pediatr
resid
physician
intern
medicin
resid
epidemiologist
laboratori
technician
medic
student
nurs
practition
nurs
upon
arriv
patient
regist
clinic
receiv
individu
flow
sheet
patient
rotat
station
focus
differ
organ
system
commonli
use
medic
packag
sandwich
bag
distribut
correspond
station
see
tabl
addit
medic
prescrib
need
patient
flow
sheet
dispens
pharmaci
station
amoxicillin
chewabl
tabletcapsulesuspens
atenolol
bacitracin
cefixim
cephalexin
ciprofloxacin
clindamycin
clotrimazol
topic
doxycyclin
enalapril
fluconazol
metformin
metronidazol
prednisoneprednisolon
tripl
antibiot
cream
signific
brigad
provid
practic
model
multidisciplinari
care
rural
medic
brigad
intern
masterclass
catalyst
expand
interprofession
learn
ipl
interprofession
practic
ipp
ireland
mckenzi
calhoun
pharmd
brian
cross
pharmd
debbi
byrd
pharmd
larri
calhoun
pharmd
etsu
bill
gatton
colleg
pharmaci
johnson
citi
tn
servic
program
intern
masterclass
catalyst
expand
interprofession
learn
ipl
interprofession
practic
ipp
ireland
justificationdocument
masterclass
symposium
titl
journey
healthcar
jointli
host
royal
colleg
surgeon
ireland
rcsi
irish
institut
pharmaci
east
tennesse
state
univers
etsu
design
attend
irish
healthcar
profession
polici
maker
academician
ultim
goal
determin
futur
direct
implement
iplipp
ireland
masterclass
provid
overview
ipl
ipp
process
etsu
present
faculti
pharmaci
medicin
nurs
engag
includ
etsu
deleg
meet
accredit
licens
oversight
organ
particip
nation
podcast
ignit
convers
toward
advanc
ambulatori
clinic
pharmaci
practic
ireland
adapt
iplipp
masterclass
symposium
approach
subsequ
implement
aberdeen
scotland
partnership
robert
gordon
univers
etsu
goal
determin
futur
direct
iplipp
scotland
would
benefici
develop
countri
signific
secondari
relationship
forg
rcsi
etsu
masterclass
symposium
process
fulbright
scholarship
applic
submit
fund
faculti
repres
etsu
spend
month
ireland
involv
further
iplipp
process
countri
experi
includ
involv
creation
ipl
experi
assess
involv
research
assess
use
pharmacist
within
primari
care
practic
area
engag
licens
organ
help
develop
standard
requir
assess
qualiti
care
pharmacist
provid
primari
care
practic
set
opportun
alreadi
realiz
futur
work
plan
progress
demonstr
valu
creat
set
intern
masterclass
serv
catalyst
iplipp
advanc
addit
quit
win
program
intens
smoke
cessat
therapi
kirk
evoy
kentya
ford
drph
amber
taylor
sabina
nduaguba
phd
univers
texa
austin
colleg
pharmaci
univers
texa
health
san
antonio
long
school
medicin
san
antonio
tx
outcom
pharmaci
practic
univers
texa
austin
colleg
pharmaci
austin
tx
texa
austin
colleg
pharmaci
austin
tx
introduct
quit
win
program
util
potenti
reward
eg
money
vacat
incentiv
smoke
cessat
program
shown
improv
cessat
rate
howev
studi
combin
quit
win
program
intens
smoke
cessat
program
includ
behavior
counsel
pharmacotherapi
research
question
hypothesi
ad
financi
incent
quit
win
contest
behavior
counsel
pharmacotherapi
intervent
improv
smoke
cessat
rate
versu
behavior
counsel
pharmacotherapi
alon
control
studi
design
prospect
control
clinic
studi
method
activ
recruit
current
smoker
receiv
behavior
counsel
cessat
counsel
encourag
attend
session
smoke
cessat
pharmacotherapi
medic
obtain
prescript
provid
free
patient
could
declin
pharmacotherapi
addit
patient
success
quit
verifi
exhal
carbon
monoxid
receiv
entri
draw
singl
cash
reward
month
follow
activ
phase
control
group
receiv
smoke
cessat
servic
without
opportun
win
result
total
enrol
patient
treatment
control
group
respect
percent
use
cigarett
cigar
cigarett
cigar
use
tobacco
unit
per
day
quit
rate
month
respect
treatment
group
time
point
control
group
howev
statist
signific
femal
gender
odd
ratio
confid
interv
ci
score
signific
predictor
quit
rate
conclus
quit
win
program
increas
clinic
referr
ie
increas
number
patient
tri
quit
numer
improv
cessat
rate
though
unexpectedli
high
studi
attrit
prevent
observ
statist
signific
differ
effect
statin
combin
therapi
prevent
cardiovascular
diseas
diabet
patient
meredith
sigler
pharmd
courtney
duval
pharmd
bcacp
trang
nguyen
carlo
alvarez
pharmd
msc
lisa
chastain
pharmd
practic
ttuhsc
sop
dalla
tx
tech
univers
school
pharmaci
dalla
tx
north
texa
healthcar
system
dalla
tx
pharmaci
texa
tech
univers
health
scienc
center
dalla
tx
practic
ambulatori
care
divis
texa
tech
univers
health
scienc
center
dalla
tx
introduct
diabet
dyslipidemia
highli
atherogen
lead
high
risk
cardiovascular
diseas
cvd
studi
evalu
addit
therapi
compar
statin
monotherapi
prevent
cvd
howev
studi
compar
statin
fibrat
statin
therapi
bile
acid
sequestr
ezetimib
niacin
fatti
acid
research
question
hypothesi
statin
plu
fibrat
combin
provid
protect
major
advers
cardiovascular
event
mace
statin
plu
therapi
high
risk
diabet
patient
studi
design
incid
retrospect
cohort
studi
va
north
texa
healthcar
system
method
veteran
year
age
triglycerid
low
hdl
male
femal
type
diabet
diagnosi
prescrib
statin
cholesterol
lower
drug
august
august
includ
patient
follow
year
initi
primari
outcom
comparison
time
first
occurr
mace
receiv
fibrat
versu
receiv
therapi
within
year
addit
cholesterol
medic
current
statin
therapi
cox
proport
hazard
model
use
time
event
analysi
control
sex
age
patient
censor
date
compet
risk
end
studi
period
mace
occur
result
cohort
includ
patient
averag
age
year
patient
male
receiv
statin
risk
mace
outcom
higher
receiv
statin
plu
compar
receiv
statin
plu
fibrat
hr
ci
year
period
conclus
combin
statin
fibrat
may
help
reduc
risk
cardiovascular
event
diabet
patient
therapi
dose
strategi
digoxin
acut
decompens
heart
failur
requir
inotrop
support
courtney
montepara
molli
e
wheeler
pharmd
simon
w
lam
pharmd
fccm
bcp
kathleen
faulkenberg
pharmd
j
bradley
william
pharmd
univers
school
pharmaci
pittsburgh
pa
pharmaci
cleveland
clinic
cleveland
oh
introduct
current
guidelin
recommend
use
digoxin
standard
therapi
reduc
symptom
associ
heart
failur
digoxin
narrow
therapeut
index
popul
benefit
therapi
remain
controversi
furthermor
guidelin
suggest
util
load
digoxin
heart
failur
howev
practic
still
perform
patient
acut
decompens
heart
failur
adhf
requir
inotrop
support
impact
differ
dose
strategi
digoxin
durat
concomit
intraven
inotrop
therapi
assess
research
question
hypothesi
adult
patient
adhf
initi
mainten
dose
digoxin
load
digoxin
regard
durat
concurr
inotrop
therapi
studi
design
retrospect
cohort
studi
method
adult
patient
admit
heart
failur
icu
cleveland
clinic
includ
newli
initi
digoxin
receiv
intraven
inotrop
therapi
adhf
patient
divid
two
cohort
receiv
mainten
dose
alon
receiv
load
dose
initi
primari
outcom
durat
intraven
inotrop
therapi
follow
digoxin
initi
margin
set
hour
result
load
dose
digoxin
without
subsequ
mainten
dose
given
patient
mainten
dose
given
patient
median
differ
durat
intraven
inotrop
therapi
follow
digoxin
initi
load
load
hour
hour
vs
hour
ci
hour
exceed
prespecifi
margin
conclus
durat
concurr
inotrop
therapi
subject
treat
mainten
digoxin
dose
subject
receiv
load
digoxin
dose
margin
employ
signific
numer
differ
observ
may
clinic
relev
futur
studi
larger
sampl
size
need
provid
evid
optimum
digoxin
dose
adhf
patient
popul
use
medic
regimen
complex
score
tool
predict
readmiss
transit
care
ann
misher
pharmd
bcacp
cde
kaitlyn
ray
pharmd
candid
nelli
ayen
pharmd
candid
joseph
campanelli
ba
pharmd
joseph
crosbi
phd
andrea
sikora
newsom
pharmd
bcp
clinic
administr
pharmaci
univers
georgia
colleg
pharmaci
savannah
ga
georgia
colleg
pharmaci
savannah
ga
univers
school
pharmaci
savannah
ga
medicin
candler
hospit
st
josephscandl
health
system
savannah
ga
health
scienc
kinesiolog
georgia
southern
univers
savannah
ga
pharmaci
uga
colleg
pharmaci
augusta
ga
introduct
medic
regimen
complex
correl
intens
care
unit
icu
length
stay
mortal
patient
acuiti
novel
use
tool
could
predict
readmiss
howev
associ
establish
sjch
hospit
readmiss
patient
discharg
icu
outpati
set
st
josephscandl
health
system
intern
tool
sjch
tool
assess
readmiss
risk
howev
resourc
allow
pharmacist
involv
patient
associ
establish
tool
may
identifi
patient
benefit
pharmaci
servic
research
question
hypothesi
andor
sjch
tool
predictor
readmiss
studi
design
retrospect
observ
analysi
icu
patient
method
patient
includ
least
year
old
discharg
icu
septemb
march
patient
exclud
expir
hospit
incomplet
data
bivari
correl
studi
variabl
includ
score
admiss
score
discharg
sjch
tool
score
readmiss
result
within
studi
period
patient
met
inclus
criteria
analyz
accord
sjch
tool
patient
low
risk
moder
risk
high
risk
readmiss
correl
coeffici
readmiss
sjch
tool
admiss
discharg
respect
coeffici
determin
sjch
tool
admiss
discharg
respect
conclus
result
indic
sjch
score
weak
associ
readmiss
risk
explain
varianc
associ
readmiss
patient
popul
score
predict
readmiss
risk
thu
patient
medic
regimen
complex
critic
ill
acuiti
inpati
hospit
may
effect
predictor
transit
care
need
narr
case
studi
effect
tool
develop
empathi
pharmaci
student
ryan
gibbard
charli
bodreau
amber
buhler
pharmaci
pacif
univers
oregon
hillsboro
pharmaci
provid
portland
medic
center
portland
introduct
although
accredit
standard
pharmaci
educ
exist
regard
graduat
abil
provid
care
limit
research
regard
effect
way
develop
attitud
belief
form
foundat
care
abil
effect
empath
patient
research
question
hypothesi
narr
patient
case
studi
effect
tool
develop
empathi
pharmaci
student
studi
design
methodolog
triangul
method
use
random
parallel
group
design
student
ask
read
two
version
patient
case
tradit
case
narr
case
respond
four
statement
two
assess
empathi
two
assess
efficaci
eas
use
case
format
order
case
revers
second
group
level
agreement
statement
measur
likert
scale
final
question
includ
qualit
result
analyz
team
use
themat
code
methodolog
triangul
studi
util
interpret
result
result
student
particip
studi
student
indic
significantli
greater
abil
empath
patient
read
narr
case
compar
clinic
case
group
vs
p
group
b
vs
p
regardless
case
order
theme
emerg
qualit
analysi
includ
greater
effici
tradit
case
increas
empathi
narr
case
mani
student
also
express
desir
integr
format
futur
practic
conclus
narr
case
studi
appear
effect
tool
develop
empathi
pharmaci
student
could
potenti
use
achiev
standard
pharmaci
educ
assess
curricula
pharmaci
educ
degre
inclus
topic
relat
combat
opioid
epidem
amanda
korenoski
pharmd
mha
lauren
albert
pharmd
pamela
l
smithburg
pharmd
ms
bcccp
pharmaci
therapeut
univers
pittsburgh
school
pharmaci
pittsburgh
pa
pittsburgh
school
pharmaci
pittsburgh
pa
introduct
individu
die
daili
overdos
increas
sinc
pharmacist
capac
interven
practic
opioid
prescrib
andor
dispens
prior
licensur
one
state
requir
educ
within
pharmd
program
specif
combat
opioid
misus
abus
accredit
standard
curricula
research
question
hypothesi
current
practic
surround
opioid
educ
addict
us
school
pharmaci
sop
practic
chang
consid
opioid
epidem
studi
design
survey
method
anonym
survey
regard
pain
manag
addict
opioid
dispens
distribut
one
faculti
member
sop
expertis
sop
curriculatoxicolog
question
consist
multipl
choic
text
numer
respons
describ
current
practic
curriculum
chang
made
within
year
data
analyz
use
descript
statist
result
survey
complet
sop
three
sop
state
addict
andor
opioid
dispens
specif
address
school
discuss
pain
manag
addict
opioid
dispens
either
individu
combin
time
spent
topic
chang
almost
half
sop
averag
total
requir
coursework
hour
pain
manag
addict
opioid
dispens
commonli
identifi
barrier
develop
addit
educ
time
faculti
resourc
conclus
base
small
sampl
sop
topic
pain
manag
addict
opioid
dispens
increas
respons
opioid
epidem
low
respons
rate
may
due
lack
focu
area
consider
made
sop
identifi
topic
surround
opioid
useabus
addict
miss
curriculum
address
implement
barrier
arm
graduat
best
care
patient
may
substanc
use
disord
mock
compound
steril
prepar
review
experienti
site
toral
patel
ami
go
ganesh
chandran
heather
anderson
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
pharmaci
univers
colorado
hospit
aurora
co
clinic
pharmaci
univers
colorado
denver
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
review
compound
steril
prepar
csp
pharmacist
respons
hospit
new
graduat
often
express
anxieti
assum
respons
pharmaci
student
receiv
vari
educ
compound
within
didact
curricula
process
prepar
final
csp
review
nt
often
actual
student
experienti
rotat
beyond
hospit
challeng
offer
opportun
prepar
actual
csp
rotat
research
question
hypothesi
practic
review
csp
rotat
increas
student
confid
studi
design
comparison
student
confid
review
csp
method
app
student
univers
colorado
hospit
uch
offer
educ
activ
review
csp
student
ask
complet
onlin
survey
examin
confid
follow
area
use
likert
scale
confid
somewhat
confid
somewhat
unconfid
unconfid
review
csp
identifi
necessari
miss
inform
determin
stabil
determin
concentr
determin
diluent
survey
provid
student
question
compar
use
wilcoxon
sign
rank
test
assess
chang
student
confid
statist
signific
set
result
student
complet
activ
march
august
twenti
student
complet
educ
activ
student
confid
increas
area
review
csp
identifi
necessari
miss
inform
determin
stabil
determin
concentr
determin
diluent
mean
increas
respect
student
prior
steril
compound
work
experi
increas
significantli
area
analyz
independ
conclus
incorpor
practic
review
csp
experienti
rotat
increas
student
perform
respons
student
prior
work
experi
prepar
csp
manag
dipeptidyl
angioedema
type
diabet
patient
systemat
review
raghda
elsay
pharmd
anthoni
walker
pharmd
clinic
scienc
univers
louisiana
monro
monro
la
background
inhibitor
appeal
patient
seek
oral
option
due
neglig
hypoglycemia
minim
side
effect
sinc
patient
take
angiotensin
convert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
increas
risk
bradykinin
angioedema
anticip
particularli
combin
two
inhibitor
bradykinin
catabol
acei
arb
plu
studi
aim
investig
angioedema
manag
practic
associ
symptom
resolut
patient
popul
method
systemat
pubm
databas
search
perform
use
keyword
sitagliptin
saxagliptin
linagliptin
alogliptin
dipeptidyl
dpp
coupl
advers
term
angioedema
use
boolean
oper
english
languag
public
involv
patient
includ
furthermor
review
articl
anim
studi
report
approv
exclud
find
report
use
descript
statist
result
seven
case
report
associ
angioedema
patient
select
inclus
patient
use
acei
arb
report
incid
improv
symptom
observ
steroid
antihistamin
epinephrin
administ
four
patient
present
emerg
depart
resolut
symptom
observ
bradykinin
inhibitor
icatib
tranexam
acid
prothrombin
complex
concentr
combin
therapeut
option
furthermor
withhold
acei
associ
recurr
worsen
angioedema
lead
nearli
therapi
resist
angioedema
intub
one
case
discuss
knowledg
first
systemat
review
studi
manag
practic
associ
angioedema
patient
discern
conclus
effect
util
specif
medic
associ
angioedema
difficult
time
due
limit
number
studi
thu
investig
need
author
report
conflict
fund
support
applic
prospero
registr
submit
id
effect
ezetimib
ad
statin
therapi
patient
hypercholesterolemia
hua
ling
pharmd
bcp
jiehyun
lee
pharmd
bcacp
cacp
michael
cooley
pharmaci
student
ricki
pharmaci
student
jame
hernandez
pharmaci
student
school
pharmaci
philadelphia
colleg
osteopath
medicin
suwane
ga
present
american
heart
associ
qcor
scientif
session
arlington
va
april
effect
high
dose
ranolazin
hemoglobin
level
patient
diabet
mellitu
systemat
review
hua
ling
pharmd
david
ombengi
pharmd
mba
mph
thuymi
nguyen
pharmaci
pharmaci
philadelphia
colleg
osteopath
medicin
suwane
ga
clinic
scienc
medic
colleg
wisconsin
school
pharmaci
milwauke
wi
background
antihyperglycem
effect
antiangin
drug
ranolazin
recent
report
object
systemat
review
summar
evid
publish
literatur
detail
impact
high
dose
ranolazin
mg
twice
daili
hemoglobin
level
patient
diabet
mellitu
dm
method
systemat
literatur
search
perform
feb
use
pubm
embas
cochran
databas
follow
key
term
ranolazin
glucos
diabet
glycem
review
restrict
random
control
trial
publish
english
diabet
patient
chang
report
studi
endpoint
studi
use
low
dose
ranolazin
mg
twice
daili
exclud
cochran
risk
bia
tool
use
assess
bia
risk
result
initi
citat
seven
random
control
trial
involv
patient
includ
review
four
seven
trial
conduct
show
ad
ranolazin
standard
antidiabet
therapi
significantli
reduc
level
ci
p
compar
placebo
heterogen
p
similar
result
report
anoth
studi
ranolazin
monotherapi
patient
uncontrol
dm
manag
lifestyl
alon
reduc
level
ci
p
two
studi
investig
relationship
effect
ranolazin
baselin
greater
reduct
observ
patient
poorer
glycem
control
result
consist
carisa
trial
higher
reduct
note
patient
take
insulin
discuss
high
dose
ranolazin
shown
posit
antihyperglycem
effect
patient
dm
ranolazin
adjunct
therapi
sever
chronic
angina
may
provid
addit
benefit
patient
comorbid
dm
chronic
stabl
angina
author
disclosur
midodrin
patient
resolv
shock
systemat
review
melani
smith
pharmd
bcp
gari
peksa
bryan
menich
jasshan
mehrotra
robert
balk
drayton
hammond
pharmd
mba
bcp
pharmaci
medic
univers
south
carolina
charleston
sc
pharmaci
emerg
medicin
rush
univers
medic
center
chicago
il
pharmaci
rush
univers
medic
center
chicago
il
pulmonari
critic
care
rush
univers
medic
center
chicago
il
background
midodrin
may
assist
transit
patient
resolv
shock
intraven
iv
vasopressor
facilit
intens
care
unit
icu
transfer
systemat
review
describ
effect
midodrin
adult
resolv
shock
outcom
evalu
icu
hospit
length
stay
lo
durat
iv
vasopressor
mortal
advers
event
patient
receiv
midodrin
versu
usual
care
method
medlin
embas
scopu
search
april
english
languag
control
trial
observ
studi
use
midodrin
liber
wean
hypotens
adult
continu
variabl
use
method
measur
mean
differ
dichotom
variabl
use
method
measur
odd
ratio
heterogen
assess
use
statist
pool
data
analyz
model
risk
bia
assess
use
nation
heart
lung
blood
institut
tool
result
five
studi
total
medic
surgic
icu
patient
includ
differ
midodrin
group
icu
day
ci
hospit
lo
day
ci
three
studi
mortal
similar
group
vs
ci
two
studi
patient
receiv
midodrin
longer
vasopressor
durat
day
ci
bradycardia
common
advers
event
occur
midodrin
patient
three
studi
good
qualiti
two
fair
discuss
although
midodrin
use
facilit
liber
patient
iv
vasopressor
found
patient
expos
midodrin
longer
vasopressor
durat
observ
studi
avail
signific
heterogen
exist
studi
need
defin
midodrin
benefit
vasopressor
titrat
trial
regist
prospero
conflict
interest
fund
glucagon
treatment
acut
esophag
foreign
bodi
food
impact
systemat
review
gari
peksa
joshua
demott
pharmd
gile
slocum
jaxson
burkin
michael
gottlieb
pharmaci
emerg
medicin
rush
univers
medic
center
chicago
il
pharmaci
rush
univers
medic
center
chicago
il
emerg
medicin
rush
univers
medic
center
chicago
il
background
glucagon
frequent
trial
relief
esophag
impact
systemat
review
perform
evalu
efficaci
safeti
glucagon
acut
esophag
foreign
bodi
food
impact
primari
outcom
treatment
success
secondari
outcom
includ
rate
advers
event
vomit
method
pubm
cinahl
lilac
scopu
cochran
databas
systemat
review
cochran
central
regist
control
trial
search
incept
march
without
languag
age
restrict
retrospect
observ
random
control
trial
assess
glucagon
relief
acut
esophag
foreign
bodi
food
impact
includ
studi
must
compar
eg
control
placebo
qualiti
analysi
perform
use
cochran
risk
bia
tool
result
five
studi
patient
identifi
treatment
success
occur
patient
glucagon
group
patient
control
group
odd
ratio
ci
advers
event
identifi
patient
glucagon
group
patient
placebo
group
ci
vomit
event
occur
frequent
glucagon
group
vs
ci
studi
overal
low
risk
bia
discuss
glucagon
associ
differ
treatment
success
higher
rate
advers
event
studi
support
use
glucagon
treatment
esophag
foreign
bodi
food
impact
protocol
regist
prospero
fund
receiv
author
declar
conflict
interest
use
melatonin
melatonin
receptor
agonist
treatment
insomnia
older
adult
systemat
review
srujitha
marupuru
pharmd
mira
patel
ms
ashley
campbel
pharmd
bcp
jeanni
k
lee
pharmd
bcp
bcgp
fashp
depart
pharmaci
practic
scienc
univers
arizona
tucson
az
background
insomnia
preval
sleep
condit
affect
older
adult
high
rate
melatonin
common
treatment
use
treat
condit
gener
popul
purpos
studi
investig
efficaci
melatonin
melatonin
receptor
agonist
mra
compar
placebo
among
studi
report
sleep
outcom
older
adult
chronic
insomnia
method
comprehens
search
conduct
nine
databas
includ
pubm
embas
psycinfo
use
combin
keyword
insomnia
melatonin
sleep
qualiti
sleep
durat
timefram
search
januari
march
studi
publish
english
languag
report
sleep
outcom
individu
age
year
older
take
melatonin
mra
includ
primari
outcom
includ
sleep
latenc
sleep
effici
sleep
qualiti
two
review
independ
screen
studi
elig
data
extract
met
consensu
inclus
studi
includ
studi
evalu
use
cochran
risk
bia
assess
heterogen
assess
random
effect
model
use
result
seventeen
studi
includ
systemat
review
suffici
data
includ
melatoninmra
demonstr
signific
efficaci
reduc
sleep
latenc
weight
mean
differ
wmd
minut
ci
z
p
increas
sleep
effici
wmd
ci
z
p
trial
use
lower
dose
longer
durat
demonstr
increas
effect
sleep
effici
sleep
qualiti
significantli
improv
subject
take
treatment
compar
placebo
discuss
melatonin
mra
show
posit
sleep
outcom
among
older
adult
chronic
insomnia
improv
seen
lower
dose
prolong
use
sourc
fund
none
conflict
interest
none
registr
number
none
systemat
review
data
evalu
adher
factor
xa
inhibitor
compar
oral
anticoagul
atrial
fibril
jaini
patel
pharmd
bcacp
regina
arellano
pharmd
practic
midwestern
univers
chicago
colleg
pharmaci
downer
grove
il
pharmaci
practic
midwestern
univers
chicago
colleg
pharmaci
downer
grove
il
background
oral
anticoagul
oac
therapi
atrial
fibril
nvaf
increas
risk
stroke
use
factor
xa
inhibitor
xaban
nvaf
rise
thu
import
evalu
xaban
provid
advantag
improv
adher
review
summar
compar
adher
literatur
xaban
oac
method
literatur
search
use
pubm
medlin
cinahl
databas
complet
peer
review
english
journal
publish
april
may
use
term
adher
persist
discontinu
combin
rivaroxaban
apixaban
edoxaban
oral
anticoagul
warfarin
dabigatran
atrial
fibril
inclus
criteria
oac
prescrib
nvaf
adher
persist
discontinu
rate
evalu
compar
fashion
includ
least
one
xaban
agent
investig
repeat
search
process
minim
select
bia
result
review
compris
studi
includ
retrospect
prospect
observ
trial
conduct
usa
uk
franc
germani
spain
itali
denmark
australia
sweden
canada
retrospect
trial
use
pharmaci
refil
record
insur
claim
medic
record
measur
adher
via
medic
possess
ratio
proport
day
cover
studi
compar
adher
rivaroxaban
apixaban
dabigatran
warfarin
overal
xaban
higher
adher
rate
compar
warfarin
dabigatran
discuss
base
review
xaban
provid
advantag
improv
adher
compar
oac
select
nvaf
manag
although
limit
studi
result
countri
ca
nt
extrapol
us
popul
due
sever
variabl
also
provid
extern
valid
find
review
facilit
select
one
xaban
anoth
data
compar
adher
rate
warrant
fund
none
conflict
interest
none
systemat
literatur
review
network
betrixaban
venou
thromboembol
prophylaxi
vicki
laskier
holli
guy
mark
fisher
w
richey
neuman
md
iwona
bucior
alexand
cohen
mbb
msc
md
shiji
ren
ltd
st
alban
unit
kingdom
pharmaceut
inc
south
san
francisco
ca
st
thoma
nh
foundat
trust
london
unit
kingdom
univers
sheffield
sheffield
unit
kingdom
background
risk
venou
thromboembol
vte
continu
hospit
nonsurg
acut
medic
ill
patient
object
determin
rel
clinic
effect
safeti
betrixaban
compar
altern
anticoagul
vte
prophylaxi
method
systemat
literatur
review
conduct
embas
medlin
cochran
decemb
identifi
random
control
trial
rct
vte
prophylaxi
hospit
nonsurg
acut
medic
ill
patient
risk
vte
studi
report
vte
event
includ
death
major
bleed
prophylaxi
initi
day
thereaft
retriev
extract
bia
heterogen
assess
use
pharmaceut
benefit
advisori
committe
guidelin
bayesian
fix
effect
network
use
estim
compar
efficaci
safeti
result
seven
rct
includ
betrixaban
low
molecular
weight
heparin
lmwh
unfraction
heparin
ufh
fondaparinux
sodium
fs
placebo
compar
odd
vte
significantli
higher
lmwh
median
odd
ratio
credibl
interv
ufh
placebo
compar
betrixaban
significantli
higher
odd
death
placebo
compar
betrixaban
numer
higher
odd
vte
fs
death
lmwh
fs
compar
betrixaban
although
odd
major
bleed
significantli
differ
betrixaban
rel
vte
prophylaxi
discuss
analysi
vte
prophylaxi
betrixaban
shown
effect
regimen
evid
posit
could
contribut
reduc
persist
burden
vte
hospit
nonsurg
patient
acut
medic
ill
need
vte
prophylaxi
fiecon
ltd
commiss
portola
pharmaceut
inc
perform
analysi
systemat
review
barrier
integr
complementari
health
approach
convent
care
unit
state
timothi
hutcherson
nicol
pharmd
ashley
gluszek
bs
pharmd
wei
xin
li
pharmd
mudit
singhal
pharmaci
dyouvil
colleg
buffalo
ny
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
background
approxim
american
util
complementari
health
approach
cha
although
convent
care
cc
practition
may
reluct
recommend
cha
systemat
review
character
perceiv
barrier
integr
cha
cc
report
unit
state
us
cc
practition
method
systemat
search
medlin
ovid
embas
intern
pharmaceut
abstract
perform
june
seek
primari
literatur
cc
practition
percept
cha
keyword
synonym
permut
thereof
includ
cha
convent
medicin
associ
practition
integr
opinion
search
limit
human
english
languag
duplic
remov
prior
screen
manual
bibliograph
review
conduct
verifi
rigor
search
screen
tool
identifi
articl
meet
predefin
inclus
criteria
cc
practition
report
barrier
cha
integr
articl
exclud
articl
screen
data
extract
least
two
investig
analysi
appli
includ
studi
result
search
yield
result
articl
studi
respond
met
inclus
criteria
studi
survey
interview
span
respond
includ
physician
medic
resid
student
nurs
pharmacist
clinician
barrier
integr
cha
cc
practic
includ
limit
cha
train
studi
limit
evid
support
cha
commun
limit
time
practic
cha
provid
belief
cha
lack
institut
infrastructur
lack
reimburs
liabil
interprofession
commun
discuss
sever
barrier
cha
integr
exist
per
cc
practition
develop
strategi
address
necessari
although
comprehens
systemat
natur
inclus
us
practition
may
limit
generaliz
review
author
conflict
interest
disclos
studi
neither
fund
regist
glecaprevirpibrentasvir
treatment
hepat
c
systemat
review
elia
chahin
pharmd
fccp
bcp
thica
tran
pharmd
candid
rita
chamoun
bs
pharmd
candid
annemari
blake
pharmd
candid
lloyd
l
gregori
school
pharmaci
palm
beach
atlant
univers
west
palm
beach
fl
background
antivir
daa
repres
breakthrough
treatment
hepat
c
viru
hcv
infect
object
report
review
efficaci
glecaprevirpibrentasvir
patient
hcv
infect
method
literatur
search
conduct
novemb
util
medlin
follow
search
term
glecaprevir
pibrentasvir
addit
relev
abstract
liver
meet
also
review
risk
bia
assess
use
cochran
risk
bia
tool
result
six
phase
six
phase
ii
twelv
phase
iii
trial
retriev
primari
endpoint
sustain
virolog
respons
svr
rate
week
end
treatment
enrol
patient
hcv
genotyp
without
cirrhosi
demonstr
arm
base
svr
rate
ci
ci
respect
enrol
patient
hcv
genotyp
without
cirrhosi
glecaprevirpibrentasvir
yield
svr
rate
ci
enrol
patient
hcv
genotyp
without
cirrhosi
svr
rate
ci
glecaprevirpibrentasvir
arm
ci
glecaprevirpibrentasvir
arm
ci
sofosbuvirdaclatasvir
arm
demonstr
glecaprevirpibrentasvir
arm
glecaprevirpibrentasvir
arm
sofosbubirdaclatasvir
arm
enrol
patient
hcv
genotyp
compens
cirrhosi
receiv
glecaprevirpibrentasvir
week
svr
rate
ci
glecaprevirpibrentasvir
well
toler
discuss
glecaprevirpibrentasvir
repres
pangenotyp
regimen
treatment
hcv
infect
high
svr
rate
patient
without
compens
cirrhosi
durat
therapi
rang
week
na
clinic
failur
cours
azithromycin
versu
long
cours
macrolid
adult
pneumonia
systemat
review
khalid
eljaali
pharmd
ms
samah
alshehri
pharmd
ms
bcp
arizona
tucson
az
pharmaci
depart
king
abdulaziz
univers
jeddah
saudi
arabia
background
azithromycin
day
recommend
treatment
pneumonia
cap
longer
cours
macrolid
option
clinician
concern
possibl
wors
outcom
shorter
durat
therapi
aim
studi
compar
clinic
failur
cap
adult
treat
cours
azithromycin
versu
long
cours
macrolid
method
two
investig
independ
search
pubm
embas
cochran
librari
databas
feb
trial
rct
compar
clinic
failur
therapi
azithromycin
cours
versu
longer
cours
day
macrolid
adult
cap
includ
studi
miss
one
criteria
exclud
estim
absolut
risk
differ
confid
interv
ci
use
model
evalu
heterogen
risk
bia
assess
cochran
risk
bia
tool
rct
result
five
rct
total
patient
includ
four
studi
use
day
macrolid
clarithromycin
one
studi
use
day
macrolid
roxithromycin
three
studi
includ
inpati
outpati
one
includ
inpati
one
includ
outpati
significantli
lower
clinic
failur
found
cours
azithromycin
compar
macrolid
rd
ci
discuss
main
strength
includ
rct
minim
risk
bia
confound
factor
hand
main
limit
probabl
includ
inpati
outpati
howev
decid
risk
includ
enough
studi
adequ
power
first
time
shown
cours
azithromycin
associ
lower
clinic
failur
versu
long
cours
macrolid
adult
cap
fund
conflict
interest
registr
applic
studi
systemat
review
antimicrobi
stewardship
care
facil
opportun
intervent
kristi
shaeer
pharmd
mph
jonathan
cho
pharmd
monika
zmarlicka
maryle
worley
joseph
hong
lauren
tesh
pharmacotherapeut
clinic
research
univers
south
florida
colleg
pharmaci
tampa
fl
pharmaci
univers
texa
tyler
tyler
tx
pharmaci
maricopa
medic
center
phoenix
az
practic
nova
southeastern
univers
colleg
pharmaci
fort
lauderdal
fl
pine
veteran
affair
heathcar
system
st
petersburg
fl
drug
administr
silver
spring
md
background
antimicrobi
stewardship
program
asp
care
facil
ltcf
need
prevent
develop
resist
advers
effect
associ
inappropri
use
ltcf
serv
reservoir
transmiss
multidrug
resist
organ
mdro
center
medicar
medicaid
servic
releas
rule
mandat
implement
infect
control
measur
ltcf
includ
asp
minim
mdro
transmiss
studi
conduct
provid
systemat
review
success
practic
ltcf
method
pubm
ebsco
embas
databas
search
august
public
english
describ
intervent
outcom
asp
ltcf
search
term
includ
nurs
home
antimicrobi
stewardship
care
facil
antibiot
use
resist
includ
articl
quantit
assess
impact
intervent
design
improv
antimicrobi
use
survey
current
practic
ltcf
nurs
home
skill
nurs
facil
result
studi
met
inclus
vari
studi
design
questionnair
random
control
trial
eighteen
studi
describ
intervent
impact
prescrib
practic
five
survey
provid
determin
current
practic
five
studi
assess
impact
prescrib
urinari
tract
infect
three
pneumonia
intervent
reli
heavili
provid
educ
involv
multidisciplinari
team
mani
studi
demonstr
posit
impact
recept
toward
implement
asp
discuss
avail
data
describ
asp
ltcf
variabl
difficult
make
direct
comparison
research
need
establish
best
practic
ltcf
asp
crucial
order
protect
health
resid
staff
healthcar
provid
ltcf
turn
protect
health
public
decreas
develop
mdro
optim
antimicrobi
use
select
bia
minim
clearli
defin
inclus
criteria
acut
care
hospit
exclud
due
vast
differ
practic
set
resourc
systemat
review
clinic
util
staphylococcu
aureu
mrsa
nasal
screen
mrsa
pneumonia
melani
smith
pharmd
bcp
ami
brotherton
katherin
lusardi
carri
tan
drayton
hammond
pharmd
mba
bcp
pharmaci
medic
univers
south
carolina
charleston
sc
pharmaci
miriam
hospit
provid
ri
arkansa
medic
scienc
littl
rock
ar
pharmaci
rush
univers
medic
center
chicago
il
background
staphylococcu
aureu
mrsa
nasal
screen
frequent
use
infect
control
purpos
use
antimicrobi
stewardship
program
asp
increas
object
systemat
review
describ
diagnost
perform
mrsa
nasal
screen
pneumonia
outcom
describ
util
mrsa
nasal
screen
includ
neg
predict
valu
npv
method
medlin
scopu
search
februari
english
languag
control
trial
observ
studi
use
mrsa
screen
surveil
nare
nasal
pneumonia
adult
studi
measur
correl
mrsa
nasal
screen
clinic
cultur
pneumonia
includ
risk
bia
assess
use
nation
heart
lung
blood
institut
tool
result
twenti
studi
includ
patient
includ
fifteen
critic
ill
acut
ill
specifi
nasal
screen
mrsa
high
npv
across
type
pneumonia
screen
site
nare
throattrachea
superior
npv
vs
four
studi
report
use
test
asp
time
screen
cultur
vari
day
base
studi
day
seem
appropri
asp
use
studi
found
implement
stewardship
initi
includ
test
led
day
reduct
vancomycin
p
cost
avoid
two
year
six
studi
good
qualiti
fair
poor
discuss
mrsa
nasal
screen
high
npv
mrsa
involv
pneumonia
util
test
asp
provid
tool
reduc
antibiot
provid
addit
cost
benefit
observ
studi
avail
signific
heterogen
exist
prospect
studi
need
defin
asp
use
test
potenti
clinic
cost
implic
trial
regist
prospero
conflict
interest
fund
systemat
review
impact
antifung
stewardship
intervent
unit
state
emili
hart
pharmd
student
melani
nguyen
pharmd
student
david
jacob
pharmd
phd
depart
pharmaci
practic
univers
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
background
antimicrobi
resist
wide
recogn
public
health
threat
stewardship
intervent
combat
problem
well
describ
less
known
antifung
stewardship
af
initi
influenc
program
within
unit
state
purpos
studi
evalu
evid
impact
af
intervent
clinic
perform
measur
method
systemat
review
english
languag
studi
use
pubm
embas
perform
novemb
review
conduct
accord
prisma
search
term
includ
antifung
stewardship
antimicrobi
stewardship
candida
candidemia
candiduria
invas
fungal
diseas
elig
studi
describ
af
program
intervent
occur
us
evalu
clinic
perform
measur
result
articl
identifi
includ
five
studi
evalu
af
intervent
report
clinic
outcom
mortal
length
stay
stewardship
measur
appropri
antifung
choic
time
therapi
remain
eight
studi
evalu
gener
stewardship
intervent
report
data
antifung
consumpt
studi
singl
center
vari
intervent
across
studi
af
program
impact
mortal
studi
rate
intervent
group
group
length
stay
also
similar
group
rang
vs
time
antifung
therapi
improv
studi
appropri
choic
antifung
increas
studi
antifung
consumpt
significantli
blunt
reduc
follow
stewardship
initi
although
direct
comparison
studi
possibl
due
lack
common
unit
discuss
avail
evid
suggest
af
intervent
improv
stewardship
measur
decreas
antifung
consumpt
although
review
detect
improv
clinic
outcom
signific
advers
outcom
report
fund
conflict
registr
effect
antiretrovir
therapi
high
central
nervou
system
penetr
cognit
impair
systemat
review
andrew
webb
pharmd
candid
ashley
buchanan
drph
ms
colleg
pharmaci
univers
rhode
island
kingston
ri
background
chronic
complic
concern
patient
live
hiv
infect
neurocognit
diseas
hand
preval
among
patient
hiv
medic
penetr
central
nervou
system
cn
may
effect
slow
hand
progress
studi
aim
evalu
higher
cn
penetr
effect
cpe
regimen
defin
cpe
delay
neurocognit
declin
adult
patient
hiv
method
use
pubm
embas
incept
novemb
primari
literatur
evalu
cognit
outcom
base
cpe
score
cart
regimen
assembl
two
aggreg
score
util
outcom
aggreg
four
common
neurocognit
test
global
deficit
score
gd
aggreg
twelv
common
neurocognit
test
result
combin
use
fix
random
effect
model
risk
bia
assess
use
heterogen
random
control
trial
cohort
studi
includ
studi
popul
defin
adult
age
without
cognit
impair
unrel
hiv
studi
need
run
least
month
includ
result
eight
studi
n
includ
systemat
review
four
studi
n
includ
quantit
analysi
three
eight
studi
report
posit
associ
cpe
score
gd
one
studi
report
neg
associ
cpe
found
hiv
regimen
higher
cpe
score
influenc
gd
standard
mean
differ
smd
ci
score
discuss
hiv
art
regimen
high
cpe
score
signific
effect
slow
cognit
impair
patient
hiv
studi
sever
limit
includ
pauciti
random
control
trial
avail
varieti
art
regimen
use
studi
author
conflict
interest
receiv
fund
registr
assess
evid
behind
inhibitor
classif
systemat
review
emili
j
cicali
pharmd
max
smith
iii
pharmd
benjamin
q
duong
pharmd
luka
kovar
pharmacist
candid
larisa
h
cavallari
pharmd
juli
johnson
pharmd
depart
pharmacotherapi
translat
research
center
pharmacogenom
colleg
pharmaci
univers
florida
gainesvil
fl
background
respons
metabol
medic
inhibitor
commonli
prescrib
food
drug
administr
fda
classifi
drug
strong
moder
weak
inhibitor
clinic
relev
clear
strong
inhibitor
moder
weak
inhibitor
object
examin
literatur
effect
inhibitor
area
curv
auc
substrat
human
identifi
fda
classif
support
publicli
avail
primari
literatur
method
systemat
review
conduct
use
fda
label
pubm
incept
decemb
search
term
moder
weak
inhibitor
sensit
substrat
human
pharmacokinet
drug
interact
individu
drug
name
insert
per
fda
classif
two
author
independ
review
result
disagr
resolv
third
studi
qualiti
apprais
meet
follow
criteria
conduct
human
report
substrat
auc
inhibitor
case
report
exclud
calcul
auc
compar
auc
threshold
moder
weak
inhibitor
respect
result
review
articl
includ
result
pair
inhibitor
match
research
design
clinic
criteria
ie
inhibitor
steadi
state
clinic
relev
dose
pair
affect
one
enzym
appli
inclus
criteria
pair
match
improv
desvenlafaxin
exhibit
inhibitori
effect
clinic
relev
dose
data
indic
cimetidin
fluvoxamin
moder
inhibitor
reclassifi
weak
inhibitor
discuss
addit
criteria
improv
consist
fda
classif
publish
literatur
inhibitor
previou
data
indic
auc
chang
found
weak
inhibitor
unlik
result
clinic
relev
effect
drug
lack
narrow
therapeut
index
na
efficaci
safeti
revefenacin
muscarin
antagonist
nebul
phase
trial
patient
moder
sever
chronic
obstruct
pulmonari
diseas
gari
ferguson
chri
barn
srikanth
pendyala
glenn
crater
candic
clay
research
institut
southeast
michigan
farmington
hill
mi
biopharma
us
inc
south
san
francisco
ca
background
revefenacin
muscarin
receptor
antagonist
shown
produc
signific
bronchodil
patient
chronic
obstruct
pulmonari
diseas
copd
phase
trial
report
efficaci
safeti
data
three
phase
random
trial
method
safeti
efficaci
evalu
patient
moder
sever
copd
ident
studi
studi
studi
safeti
trial
studi
revefenacin
compar
placebo
studi
tiotropium
studi
endpoint
bronchodil
effect
trough
peak
chang
baselin
day
overal
treatment
effect
ote
assess
safeti
toler
lab
electrocardiogram
ecg
advers
event
ae
collect
result
studi
revefenacin
significantli
increas
trough
ote
compar
placebo
p
valu
studi
signific
increas
baselin
trough
demonstr
revefenacin
group
tiotropium
treatment
period
signific
find
lab
ecg
observ
studi
ae
seriou
ae
instanc
major
advers
cardiac
event
compar
among
treatment
group
studi
low
incid
antimuscarin
ae
studi
numer
fewer
copd
exacerb
n
patient
observ
revefenacin
tiotropium
discuss
revefenacin
administ
daili
via
standard
jet
nebul
dose
clinic
statist
significantli
produc
sustain
bronchodil
limit
system
ae
revefenacin
well
toler
favor
profil
use
nebul
treatment
copd
case
report
enzalutamid
induc
liver
enzym
elev
metastat
prostat
cancer
patient
lu
bachelor
degre
fang
cheng
master
degre
tsai
master
degre
depart
pharmaci
chang
gung
memori
hospit
linkou
branch
taiwan
introduct
enzalutamid
androgen
receptor
inhibitor
approv
treatment
metastat
prostat
cancer
advers
effect
enzalutamid
musculoskelet
pain
fall
seizur
report
enzalutamid
induc
liver
enzym
elev
past
case
rare
might
first
one
report
case
patient
old
male
newli
diagnosi
metastat
prostat
cancer
stage
start
enzalutamid
daili
sinc
concomit
medic
includ
tamsulosin
degarelix
patient
deni
hepat
histori
herbal
medicin
use
alcohol
consumpt
acupunctur
patient
grade
alanin
aminotransferas
alt
aspart
aminotransferas
ast
increas
enzalutamid
dose
reduc
daili
patient
grade
astalt
elev
fatigu
mild
malais
withheld
use
enzalutamid
gastroenterologist
diagnos
acut
hepat
prescrib
silymarin
three
time
day
patient
fatigu
malais
improv
astalt
decreas
hepat
b
viru
surfac
antigen
hbsag
b
core
hbc
immunoglobulin
igm
nonreact
posit
discuss
sever
event
naranjo
score
possibl
advers
event
caus
enzalutamid
patient
grade
astalt
elev
receiv
enzalutamid
week
liver
function
becam
normal
discontinu
enzalutamid
interact
enzalutamid
degarelix
concurr
use
enzalutamid
induc
tamsulosin
substrat
affect
enzalutamid
concentr
unlik
abirateron
bicalutamid
may
caus
hepat
liver
enzym
elev
enzalutamid
hepat
advers
event
report
conclus
causal
hepat
advers
event
enzalutamid
case
report
remind
clinician
use
enzalutamid
probabl
thrombocytopenia
case
report
rachel
britt
jeffrey
c
pearson
monica
v
mahoney
pharmd
alexa
carlson
pharmd
bcp
pharmaci
beth
israel
deaco
medic
center
boston
pharmaci
health
system
scienc
colleg
health
pharmaci
northeastern
univers
boston
introduct
report
describ
probabl
case
thrombocytopenia
result
ceftarolin
therapi
case
woman
admit
staphylococcu
aureu
mrsa
endocard
receiv
six
week
daptomycin
three
day
treatment
complet
dyspnea
fever
encephalopathi
found
recurr
mrsa
bacteremia
veget
right
ventricular
pacemak
lead
initi
treat
vancomycin
transit
ceftarolin
due
persist
bacteremia
vancomycin
minimum
inhibitori
concentr
mic
eight
day
ceftarolin
therapi
develop
thrombocytopenia
platelet
nadir
prepar
discharg
transit
daptomycin
thrombocytopenia
resolv
next
week
subsequ
transit
back
ceftarolin
due
develop
rash
transamin
eosinophilia
daptomycin
develop
thrombocytopenia
three
day
therapi
platelet
nadir
naranjo
scale
six
reveal
probabl
associ
ceftarolin
administr
thrombocytopenia
consid
patient
complet
four
week
appropri
therapi
recent
isol
vancomycin
mic
vancomycin
restart
platelet
increas
discharg
six
day
ceftarolin
discontinu
patient
experi
advers
clinic
effect
transient
thrombocytopenia
discuss
current
evid
describ
caus
associ
ceftarolin
thrombocytopenia
limit
phase
iii
trial
ceftarolin
report
low
incid
thrombocytopenia
sever
small
retrospect
studi
also
show
similar
incid
rate
knowledg
first
case
report
describ
probabl
ceftarolin
advers
drug
reaction
detail
conclus
describ
first
probabl
naranjo
scale
ceftarolin
induc
thrombocytopenia
case
revers
upon
drug
discontinu
studi
need
establish
caus
associ
ceftarolin
thrombocytopenia
rare
carbamazepin
deinduct
phenomenon
caus
delay
viral
clearanc
hepat
c
treatment
jennif
e
stark
pharmd
bcp
jennif
cole
pharmd
bcp
bcccp
depart
pharmaci
veteran
health
care
system
ozark
fayettevil
ar
introduct
rapid
virolog
respons
expect
newest
direct
act
antivir
daa
treatment
hepat
c
viru
hcv
undetect
viral
load
week
typic
delay
viral
respons
daa
treatment
may
indic
noncompli
decreas
efficaci
result
need
prolong
treatment
carbamazepin
known
interact
ddi
induc
howev
ddi
prolong
well
past
drug
elimin
due
slow
rebound
enzym
product
deinduct
report
illustr
impact
uniqu
deinduct
ddi
daa
therapi
case
treatment
ledipasvirsofosbuvir
plu
ribavirin
plan
patient
chronic
hcv
infect
baselin
hcv
resist
identifi
prior
start
hcv
treatment
signific
ddi
identifi
patient
concomit
carbamazepin
result
decreas
level
ledipasvir
sofosbuvir
patient
agre
stop
carbamazepin
start
divalproex
wait
day
start
hcv
treatment
hcv
viral
load
baselin
log
treatment
week
log
treatment
week
log
patient
confirm
adher
serum
drug
level
confirm
carbamazepin
therapeut
valproic
acid
level
undetect
hcv
viral
load
occur
treatment
week
hcv
treatment
extend
due
slow
treatment
respons
discuss
term
deinduct
refer
time
cours
enzym
drug
transport
return
normal
activ
delay
beyond
time
requir
drug
clearanc
one
paper
report
deinduct
process
complet
within
week
carbamazepin
discontinu
like
contribut
slow
viral
clearanc
result
prolong
hcv
treatment
conclus
case
illustr
clinic
signific
consequ
carbamazepin
deinduct
occur
drug
discontinu
clinician
must
consid
impact
enzym
deinduct
concomit
medic
even
expect
clearanc
drug
acut
pancreat
episod
dose
increas
dulaglutid
patient
remot
histori
pancreat
case
report
heather
folz
pharmd
depart
pharmaci
john
hopkin
bayview
intern
medicin
baltimor
md
introduct
data
suggest
peptid
receptor
agonist
ra
may
increas
risk
pancreat
result
mix
analysi
dulaglutid
pancreat
safeti
show
incid
rate
similar
placebo
howev
patient
histori
pancreat
exclud
due
limit
data
dulaglutid
packag
insert
advis
consider
antidiabet
therapi
patient
histori
pancreat
case
report
describ
episod
acut
pancreat
patient
treat
dulaglutid
remot
histori
pancreat
case
femal
present
emerg
depart
complaint
histori
burn
abdomin
pain
report
similar
idiopath
episod
pancreat
eight
year
ago
histori
includ
type
diabet
diagnos
five
year
ago
prescrib
dulaglutid
week
prior
present
elev
lipas
ul
admiss
result
comput
tomographi
led
diagnosi
acut
uncompl
pancreat
common
caus
exclud
potenti
etiolog
note
dulaglutid
increas
mgweek
four
week
prior
dulaglutid
stop
admiss
discharg
six
day
normal
lipas
follow
discuss
research
show
percent
patient
experienc
pancreat
develop
prediabet
andor
diabet
make
signific
popul
contrast
safeti
result
larg
ra
timelin
event
suggest
patient
pancreat
may
trigger
increas
dulaglutid
dose
patient
histori
pancreat
may
suscept
risk
exclud
studi
conclus
known
safeti
ra
therapi
patient
histori
pancreat
altern
therapi
consid
popul
initi
patient
monitor
close
sign
symptom
pancreat
alter
mental
statu
sacubitrilvalsartan
case
report
elizabeth
cook
pharmd
bcacp
cde
jessica
wooster
pharmd
denver
shipman
pharmd
depart
clinic
scienc
univers
texa
tyler
ben
mayte
fisch
colleg
pharmaci
tyler
tx
introduct
sacubitrilvalsartan
angiotensin
inhibitor
anri
compos
neprilysin
inhibitor
sacubitril
angiotensin
ii
receptor
blocker
valsartan
neprilysin
degrad
bradykinin
natriuret
peptid
adrenomedullin
protein
latter
associ
develop
dementia
anri
proven
benefici
heart
failur
reduc
eject
fraction
hfref
concern
aris
sacubitrilvalsartan
may
caus
affili
cognit
declin
case
african
american
femal
hfref
admit
histori
confabul
paranoia
delus
audiovisu
tactil
hallucin
insomnia
nighttim
wander
patient
document
psychiatr
diagnos
stabil
sacubitrilvalsartan
mg
twice
daili
two
month
prior
symptom
present
seven
day
follow
titrat
mg
twice
daili
symptom
remit
follow
sacubitrilvalsartan
return
one
day
resum
therapi
recommend
primari
care
physician
symptom
escal
patient
admit
inpati
treatment
upon
admiss
vital
sign
laboratori
test
unremark
rule
infecti
process
illicit
substanc
use
diagnost
procedur
unremark
except
cranial
ct
scan
depict
intracrani
volum
loss
abnorm
age
commensur
mild
ventricular
enlarg
sacubitrilvalsartan
discontinu
inpati
symptom
resolv
intoler
document
medic
record
discuss
associ
sacubitrilvalsartan
am
categor
probabl
per
naranjo
scale
literatur
surround
sacubitrilvalsartan
lack
document
event
relat
am
limit
report
may
due
lack
systemat
cognit
assess
sacubitrilvalsartan
approv
process
result
ongo
perspect
trial
investig
chang
cognit
intracrani
imag
patient
hfref
random
either
sacubitrilvalsartan
valsartan
alon
still
pend
may
provid
insight
conclus
due
tempor
relationship
symptom
escal
sacubitrilvalsartan
dose
recommend
monitor
cognit
function
initi
titrat
therapi
drug
interact
amiodaron
rivaroxaban
result
elev
prothrombin
time
case
report
erika
l
hellenbart
pharmd
bcp
jaclynn
r
metay
pharmd
vicki
l
groo
pharmd
colleg
pharmaci
depart
pharmaci
practic
univers
illinoi
chicago
chicago
il
introduct
drug
interact
low
dose
amiodaron
rivaroxaban
well
document
howev
littl
evid
exist
regard
effect
higher
dose
amiodaron
rivaroxaban
pt
level
case
report
case
male
cardiomyopathi
atrial
fibril
ventricular
tachycardia
vt
hepat
c
cirrhosi
rivaroxaban
daili
start
amiodaron
daili
recurr
vt
episod
present
icd
test
four
day
later
five
hour
amiodaron
rivaroxaban
dose
admiss
ptinr
increas
rivaroxaban
held
pt
return
baselin
warfarin
start
ptinr
follow
discontinu
rivaroxaban
success
resum
amiodaron
dose
reduc
daili
pt
valu
similar
rivaroxaban
alon
result
drug
interact
probabl
scale
dip
score
indic
causal
relationship
stollberg
et
al
previous
describ
case
prolong
use
result
fatal
cerebr
bleed
pt
admiss
discuss
case
add
literatur
effect
amiodaron
use
rivaroxaban
pt
level
patient
experi
bleed
therapi
interrupt
chang
interrupt
increas
risk
bleed
stroke
effect
patient
liver
diseas
interact
unknown
although
child
pugh
document
significantli
impact
metabol
rivaroxaban
compar
pt
chromogen
xa
level
may
use
futur
case
interact
conclus
may
discern
interact
rivaroxaban
amiodaron
greater
increas
pt
level
higher
produc
low
dose
amiodaron
clinician
use
caution
use
agent
concomitantli
monitor
sign
symptom
bleed
use
purg
solut
percutan
ventricular
assist
devic
shannon
lawson
bs
pharmaceut
scienc
pharmd
candid
margaret
loweri
bs
pharmaceut
scienc
pharmd
candid
rickey
evan
pharmd
jenna
cox
pharmd
bcp
carolina
colleg
pharmaci
columbia
sc
south
carolina
colleg
pharmaci
columbia
sc
pharmaceut
servic
palmetto
health
richland
columbia
sc
introduct
impella
cathet
percutan
ventricular
assist
devic
pvad
indic
mechan
circulatori
support
impella
cathet
requir
purg
solut
flow
cathet
blood
pump
prevent
blood
enter
motor
devic
thrombosi
purg
solut
typic
compos
dextros
solut
heparin
patient
may
requir
addit
system
anticoagul
reach
target
coagul
paramet
reduc
risk
thrombot
complic
expos
patient
risk
thrombocytopenia
hit
manufactur
recommend
advis
ad
anticoagul
purg
solut
use
purg
solut
describ
case
report
three
patient
case
nine
patient
receiv
purg
solut
impella
support
includ
demograph
inform
indic
pvad
presenc
addit
anticoagulantsantithrombot
hit
test
coagul
test
advers
event
collect
case
suspicion
hit
prompt
switch
purg
solut
patient
receiv
argatroban
system
purg
solut
eight
patient
test
hit
two
posit
result
expir
two
six
patient
neg
hit
test
expir
hit
statu
one
patient
indetermin
due
elev
bilirubin
platelet
nadir
prior
argatroban
initi
averag
averag
durat
purg
solut
day
three
patient
experienc
advers
event
includ
deep
vein
thrombosi
hematuria
gastrointestin
bleed
discuss
major
institut
develop
strategi
manag
patient
receiv
impella
support
context
hit
data
support
use
direct
thrombin
inhibitor
eg
argatroban
purg
solut
limit
largest
case
seri
evalu
use
purg
solut
date
conclus
studi
need
substanti
efficaci
safeti
purg
solut
patient
receiv
impella
support
remain
option
case
report
elev
inr
set
increas
coagulopathi
hayley
tatro
lesli
hamilton
pharmd
bcp
bcccp
fccp
j
russel
langdon
shaun
row
pharmd
bcp
bcccp
fnc
pharmaci
univers
tennesse
medic
center
knoxvil
tn
clinic
pharmaci
univers
tennesse
health
scienc
center
colleg
pharmaci
knoxvil
tn
tennesse
medic
center
knoxvil
tn
introduct
thromboelastographi
teg
test
allow
evalu
complet
coagul
system
unlik
tradit
coagul
test
eg
prothrombin
time
activ
partial
thromboplastin
time
platelet
function
etc
teg
allow
clinician
apprais
whole
coagul
process
singl
test
teg
util
guid
manag
coagulopathi
trauma
patient
orthopt
liver
transplant
obstetr
diseas
state
case
describ
use
teg
manag
patient
liver
failur
elev
inr
thrombosi
case
male
histori
atrial
fibril
cardiomyopathi
diagnos
septemb
right
ica
stroke
receiv
mechan
thrombectomi
discharg
warfarin
day
discharg
present
emerg
depart
found
left
ica
stroke
receiv
mechan
thrombectomi
hospit
cours
patient
develop
lower
limb
ischemia
acut
liver
failur
inr
teg
perform
determin
platelet
function
coagul
patient
found
hypercoagul
despit
elev
inr
heparin
drip
initi
patient
ultim
discharg
home
warfarin
three
month
admiss
discuss
although
mani
patient
liver
failur
prolong
ptinr
necessarili
reliabl
marker
coagul
statu
patient
past
medic
histori
signific
atrial
fibril
cardiomyopathi
multipl
embol
event
teg
determin
patient
hypercoagul
despit
elev
inr
conclus
elev
inr
patient
acut
liver
failur
may
predict
coagulopathi
teg
evalu
whole
coagul
system
util
determin
whether
patient
risk
bleed
clot
event
guanfacin
agit
two
critic
ill
medic
patient
case
seri
allison
oswalt
kimberli
mean
pharmaci
univers
arkansa
medic
scienc
littl
rock
ar
pharmaci
servic
virginia
commonwealth
univers
health
system
richmond
va
introduct
guanfacin
central
act
receptor
agonist
indic
hypertens
attent
deficit
hyperact
disord
use
one
case
report
thu
far
sedat
critic
ill
patient
refractori
anxieti
agit
cardiac
surgeri
mani
patient
especi
prolong
hospit
cours
difficulti
wean
sedat
lead
increas
length
stay
intens
care
unit
case
two
patient
refractori
agit
success
treat
enter
guanfacin
first
patient
present
respiratori
failur
set
pneumonia
cours
complic
use
benzodiazepin
opioid
difficulti
wean
agent
secondari
agit
second
patient
present
statu
epilepticu
due
receptor
enceph
difficulti
wean
sedat
persist
agit
patient
treat
enter
guanfacin
result
substanti
reduct
sed
dose
neither
patient
experienc
advers
effect
associ
guanfacin
administr
withdraw
discuss
first
report
regard
success
use
enter
guanfacin
refractori
agit
critic
ill
medic
patient
clonidin
anoth
central
agonist
use
facilit
wean
continu
infus
sed
howev
guanfacin
offer
sever
advantag
clonidin
includ
increas
select
subunit
receptor
select
lessen
likelihood
hemodynam
instabl
potenti
central
nervou
system
effect
includ
sedat
anxiolyt
properti
furthermor
guanfacin
longer
clonidin
may
reduc
elimin
rebound
side
effect
follow
discontinu
avail
multipl
tablet
size
formul
includ
extend
immedi
releas
prepar
allow
eas
administr
conclus
guanfacin
may
consid
refractori
agit
critic
ill
medic
patient
studi
done
assess
efficaci
safeti
therapeut
intervent
propofol
treatment
refractori
migrain
headach
emerg
depart
case
report
henri
leder
pharmd
bcp
yelena
figuerado
pharmd
adrienn
kercsak
pharmd
bcp
depart
pharmaci
scripp
merci
hospit
san
diego
ca
introduct
propofol
sed
hypnot
propos
treatment
option
migrain
headach
refractori
standard
therapi
studi
describ
efficaci
treatment
pauciti
data
optim
dose
util
parenter
agent
report
case
refractori
migrain
headach
success
treat
propofol
use
lower
total
dose
describ
previou
studi
case
year
old
femal
histori
migrain
headach
present
emerg
depart
chief
complaint
headach
photophobia
nausea
vomit
treatment
sumatriptan
naproxen
home
within
hour
present
unsuccess
describ
pain
worsen
head
movement
lay
supin
posit
physic
exam
find
benign
lab
within
normal
limit
propofol
intraven
administ
everi
minut
pain
score
zero
achiev
total
four
dose
bodi
weight
patient
report
pain
score
zero
abl
return
baselin
function
discharg
home
within
two
hour
treatment
initi
discuss
compar
parenter
agent
migrain
headach
propofol
offer
advantag
fast
onset
may
requir
addit
monitor
supervis
due
sed
respiratori
hemodynam
effect
prior
studi
case
report
use
propofol
refractori
migrain
headach
describ
correl
total
dose
patient
disposit
case
demonstr
efficaci
lower
total
dose
may
reduc
util
healthcar
resourc
treatment
expedit
patient
discharg
compar
pharmacolog
option
conclus
treatment
refractori
migrain
headach
emerg
depart
propofol
may
viabl
parenter
treatment
option
two
bleed
mani
use
idarucizumab
two
instanc
bleed
one
patient
kimberli
friend
pharmd
nadia
awad
pharmd
bcp
depart
pharmaci
robert
wood
johnson
univers
hospit
new
brunswick
nj
introduct
idarucizumab
use
clinic
practic
revers
threaten
bleed
anticoagul
revers
effect
measur
via
direct
thrombin
time
dtt
ecarin
clot
time
ect
sensit
low
concentr
dabigatran
case
femal
dabigatran
outpati
therapi
present
emerg
depart
sever
epistaxi
follow
traumat
fall
initi
vital
sign
blood
pressur
mmhg
heart
rate
beat
per
minut
satur
room
air
multipl
attempt
made
control
bleed
unsuccess
warrant
endotrach
intub
decis
made
administ
idarucizumab
result
thrombin
time
yield
prolong
clot
format
follow
administr
idarucizumab
thrombin
time
reflect
surrog
correct
second
normal
rang
second
comput
tomographi
head
reveal
subdur
hemorrhag
patient
repeat
episod
epistaxi
hematemesi
throughout
hospit
stay
success
discharg
home
six
month
later
patient
present
emerg
depart
gastrointestin
bleed
discov
still
maintain
dabigatran
outpati
therapi
therebi
requir
repeat
administr
idarucizumab
discuss
absenc
laboratori
paramet
clinic
set
hemorrhag
patient
document
outpati
dabigatran
therapi
may
reason
consid
administr
antidot
acut
set
although
contraind
outlin
idarucizumab
prescrib
inform
monoclon
antibodi
administr
carri
risk
immunogen
reaction
case
patient
inadvert
maintain
dabigatran
despit
histori
bleed
secondari
drug
warrant
repeat
administr
idarucizumab
conclus
first
document
case
report
use
idarucizumab
two
separ
instanc
bleed
patient
case
report
sustain
low
effici
hemodialysi
treatment
sever
lactic
acidosi
substanti
metformin
overdos
ruchita
amin
rachel
wilkinson
pharmd
brian
hawkin
nathan
wild
konrad
stepniakowski
jaclyn
stoffel
pharmaci
methodist
univers
hospit
memphi
tn
pharmaci
methodist
univers
hosptial
memphi
tn
emerg
medicin
methodist
univers
hospit
memphi
tn
critic
care
methodist
univers
hospit
memphi
tn
nephrolog
methodist
univers
hospit
memphi
tn
introduct
metformin
associ
lactic
acidosi
mala
concentr
base
toxic
metformin
distribut
peripher
tissu
lead
redistribut
phenomenon
util
hemodialysi
mala
treatment
previou
case
report
highlight
use
continu
renal
replac
therapi
mala
treatment
howev
pauciti
literatur
discuss
correspond
metformin
level
potenti
rebound
effect
case
report
describ
util
sustain
low
effici
hemodialysi
sled
evalu
serum
metformin
level
treatment
massiv
metformin
overdos
case
old
male
type
diabet
mellitu
schizophrenia
present
abdomin
pain
initi
disclos
acut
ingest
later
admit
consum
gram
metformin
initi
vital
sign
stabl
except
hypothermia
howev
later
becam
hypotens
requir
norepinephrin
drip
initi
lab
reveal
anion
gap
metabol
acidosi
elev
lactic
acid
concern
mala
treatment
bicarbon
infus
insuffici
lead
emerg
sled
initi
follow
hour
sled
metabol
acidosi
correct
serial
serum
metformin
level
consist
declin
mcgml
hour
rebound
metformin
level
detect
day
patient
regain
renal
function
discharg
full
recoveri
discuss
current
mala
treatment
encompass
acidosi
correct
bicarbon
escal
hemodialysi
need
still
spars
literatur
surround
util
sled
correspond
metformin
level
case
mala
treat
hour
sled
result
full
recoveri
acidosi
rebound
increas
metformin
level
patient
retain
renal
function
discharg
day
thu
earli
initi
extend
durat
sled
efficaci
mala
treatment
conclus
sustain
hemodialysi
efficaci
treatment
sever
mala
secondari
acut
ingest
without
rebound
serum
metformin
level
resurrect
pioglitazon
case
report
pioglitazon
type
diabet
kam
capoccia
pharmd
depart
pharmaci
practic
western
new
england
univers
colleg
pharmcay
health
scienc
springfield
introduct
thiazolidinedion
commonli
use
treatment
type
diabet
due
advers
effect
weight
gain
fluid
retent
edema
guidelin
recommend
insulin
sensit
therapi
four
clinic
trial
describ
util
pioglitazon
statist
signific
reduct
without
signific
advers
effect
three
case
report
highlight
addit
low
dose
pioglitazon
viabl
option
armamentarium
case
three
patient
elev
blood
glucos
valu
despit
multipl
antihyperglycem
agent
struggl
achiev
appropri
goal
safe
patient
initi
pioglitazon
either
fourth
fifth
antihyperglycem
agent
basal
insulin
maximum
dose
metformin
antihyperglycem
agent
use
bolu
insulin
glimepirid
agonist
baselin
american
diabet
associ
goal
month
decreas
month
decreas
insulin
dose
subsequ
decreas
avoid
hypoglycem
event
advers
event
report
discuss
case
demonstr
pioglitazon
effect
patient
lower
blood
glucos
safe
without
common
advers
effect
weight
gain
fluid
retent
edema
pioglitazon
gener
inexpens
avail
oral
make
viabl
treatment
option
pioglitazon
use
nyha
class
iii
iv
heart
failur
increas
risk
fractur
limit
includ
factor
could
influenc
chang
patient
report
chang
lifestyl
modif
conclus
pioglitazon
significantli
lower
peopl
without
expect
side
effect
weight
gain
fluid
retent
edema
pioglitazon
resurrect
viabl
treatment
option
appropri
candid
third
fourth
line
antihyperglycem
agent
need
pegyl
carboxyhemoglobin
bovin
emerg
tissu
oxygen
anem
jehovah
wit
patient
case
seri
sean
mcconachi
pharmd
bcp
sheila
wilhelm
pharmd
fccp
krista
wahbi
pharmd
zinah
almadrahi
applebaum
colleg
pharmaci
health
scienc
wayn
state
univers
detroit
mi
pharmaci
practic
wayn
state
univers
eugen
applebaum
colleg
pharmaci
health
scienc
detroit
mi
univers
hospit
detroit
medic
center
detroit
mi
introduct
pharmacolog
manag
anem
jehovah
wit
jw
patient
refus
transfus
limit
stimul
hematopoiesi
iron
erythropoietin
supplement
characterist
delay
oxygen
carrier
hboc
repres
pharmacolog
modal
capabl
acut
increas
patient
oxygen
carri
capac
howev
current
hboc
avail
unit
state
herein
report
three
case
anem
jw
patient
experiment
hboc
pegyl
carboxyhemoglobin
bovin
sanguin
request
emerg
circumst
case
three
sever
anem
hemoglobin
gdl
jw
patient
present
hemorrhag
cardiovascular
surgeri
bleed
patient
receiv
concomit
iron
erythropoietin
supplement
oxygen
two
patient
receiv
hboc
infus
patient
expir
prior
receiv
medic
one
patient
receiv
pegyl
carboxyhemoglobin
bovin
expir
secondari
multisystem
organ
failur
unit
medic
patient
hemoglobin
recov
receiv
unit
discharg
stabl
condit
discuss
limit
treatment
option
avail
anem
jw
patient
may
lead
relianc
experiment
hboc
therapi
therapi
link
past
advers
cardiovascular
event
mortal
littl
publish
data
agent
use
jw
popul
howev
repres
potenti
treatment
option
set
sever
anemia
patient
experienc
advers
effect
medic
howev
two
patient
expir
case
demonstr
need
earli
medic
team
pharmacist
ensur
medic
promptli
deliv
safe
administ
conclus
pegyl
carboxyhemoglobin
bovin
may
repres
potenti
benefici
therapi
critic
anem
jw
popul
seri
demonstr
complex
natur
anem
jw
patient
critic
need
research
hboc
therapi
serotonin
releas
assay
sra
hit
newli
recogn
entiti
implic
diagnosi
manag
eric
johnson
pharmd
bcccp
komal
pandya
pharmd
georg
davi
pharmd
anand
padmanabhan
md
phd
pharmaci
uk
healthcar
lexington
ky
wisconsin
milwauke
wi
introduct
thrombocytopenia
hit
threaten
complic
heparin
therapi
serotonin
releas
assay
sra
consid
confirmatori
laboratori
test
part
clinicopatholog
diagnosi
hit
neg
result
suggest
hit
extrem
unlik
clinic
sensitivityspecif
howev
recent
find
suggest
pathogen
hit
antibodi
recogn
platelet
factor
use
platelet
reveal
antibodi
detect
standard
sra
case
present
two
separ
patient
high
probabl
hit
base
pretest
case
elisa
note
posit
optic
densiti
od
respect
case
sra
neg
given
high
clinic
suspicion
novel
assay
call
express
assay
pea
use
analyz
sampl
hit
antibodi
detect
pea
case
posit
result
indic
discuss
sra
consid
gold
confirmatori
standard
test
diagnosi
hit
howev
recent
studi
diagnost
sensit
sra
brought
question
two
patient
clinic
present
strong
elisa
result
rapid
recoveri
platelet
count
upon
heparin
cessat
suggest
hit
confound
sra
result
conclus
case
highlight
limit
current
gold
standard
confirmatori
laboratori
test
hit
alert
clinician
exist
hit
recognit
entiti
critic
ensur
patient
receiv
time
therapeut
intervent
anticoagul
result
alway
correl
clinic
find
manag
complic
patient
requir
anticoagul
case
report
nicol
pharmd
bcp
timothi
hutcherson
alyssa
cizdziel
allison
englert
elizabeth
riegl
karen
mlodozeniec
bs
pharm
buffalo
school
pharmaci
pharmaceut
scienc
buffalo
ny
pharmaci
dyouvil
colleg
buffalo
ny
introduct
pharmacist
valuabl
role
manag
complic
patient
requir
anticoagul
case
describ
manag
unusu
complex
hypercoagul
patient
case
caucasian
male
recent
past
medic
histori
deep
vein
thrombosi
dvt
admit
hospit
develop
thrombu
extens
manag
rivaroxaban
social
histori
posit
opioid
use
abus
concurr
develop
gastrointestin
bleed
like
due
excess
nsaid
consumpt
pain
set
anticoagul
use
thrombolysi
although
initi
recommend
upon
vascular
consult
contraind
follow
gastrointestin
bleed
warfarin
initi
heparin
infus
bridg
anticoagul
manag
dvt
light
possibl
rivaroxaban
failur
hypercoagul
test
report
posit
antibodi
patient
subsequ
develop
laboratori
confirm
od
sra
posit
thrombocytopenia
hit
initi
argatroban
bridg
anticoagul
addit
warfarin
platelet
recoveri
patient
transit
fondaparinux
warfarin
due
inr
prolong
follow
second
consecut
therapeut
inr
fondaparinux
appropri
discontinu
howev
second
dvt
discov
differenti
diagnos
includ
warfarin
failur
hit
thrombosi
hitt
patient
discharg
fondaparinux
counsel
reinforc
adher
due
social
histori
discuss
knowledg
first
case
patient
risk
possibl
direct
oral
anticoagul
failur
antiphospholipid
antibodi
syndrom
gastrointestin
bleed
hit
possibl
warfarin
failur
requir
resourc
stepwis
anticoagul
manag
propos
develop
tool
facilit
practition
determin
feasibl
therapi
option
complex
patient
requir
anticoagul
conclus
difficult
recommend
appropri
pharmacotherapi
patient
multipl
factor
complic
anticoagul
manag
literatur
guidelin
review
requir
provid
strong
recommend
could
aid
algorithm
tool
four
factor
prothrombin
complex
concentr
intracrani
hemorrhag
initi
inr
case
seri
kaitlin
ferguson
pharmd
natalija
farrel
pharmd
bcp
dabat
lindsay
arnold
pharmd
bcp
depart
pharmaci
boston
medic
center
boston
introduct
four
factor
prothrombin
complex
concentr
use
establish
efficaci
urgent
revers
vitamin
k
antagonist
inr
therapi
set
intracrani
hemorrhag
ich
current
literatur
limit
case
seri
suggest
use
ich
inr
may
benefici
reduc
inr
progress
bleed
variou
dose
strategi
employ
studi
includ
protocol
present
case
seri
use
unitskg
maximum
unit
patient
ich
initi
inr
case
eleven
patient
receiv
baselin
inr
purpos
inr
revers
set
ich
may
june
patient
demograph
inr
valu
vitamin
k
use
vte
event
admiss
collect
eleven
warfarin
patient
receiv
total
twelv
administr
administr
patient
repeat
inr
median
time
hour
intraven
phytonadion
given
nine
twelv
administr
eleven
total
patient
one
experienc
vte
event
discuss
case
seri
suggest
use
dose
unitskg
effect
revers
inr
may
correl
higher
vte
rate
previou
literatur
report
vte
rate
note
may
due
low
number
patient
warrant
consider
dose
reduct
indic
assess
elucid
implic
vte
rate
conclus
administr
unitskg
ich
initi
inr
success
revers
inr
may
lead
unexpect
vte
event
case
report
possibl
hypersensit
reaction
neg
patient
spencer
durham
pharmd
bcp
depart
pharmaci
practic
auburn
univers
harrison
school
pharmaci
auburn
al
introduct
sever
hypersensit
reaction
abacavir
phenomenon
patient
posit
allel
symptom
appear
within
first
six
week
gradual
worsen
drug
discontinu
test
allel
recommend
prior
initi
abacavir
howev
risk
abacavir
hypersensit
patient
neg
case
caucasian
male
elvitegravircobicistatemtricitabinetenofovir
disoproxil
renal
function
progress
worsen
requir
regimen
chang
previous
test
neg
chang
dolutegravirabacavirlamivudin
three
week
therapi
began
develop
sore
throat
prurit
rash
myalgia
fever
symptom
worsen
sever
day
clinic
present
immedi
concern
hypersensit
reaction
medic
immedi
discontinu
repeat
test
order
also
return
neg
symptom
resolv
sever
week
regimen
chang
elvitegravircobicistatemtricitabinetenofovir
alafenamid
discuss
literatur
report
hypersensit
patient
neg
lack
three
report
could
identifi
patient
naranjo
advers
drug
reaction
probabl
scale
demonstr
score
indic
probabl
associ
dolutegravirabacavirlamivudin
unlik
reaction
caus
lamivudin
patient
previous
treat
upon
initi
hiv
diagnosi
although
reaction
dolutegravir
exclud
also
unlik
patient
experienc
reaction
relat
drug
elvitegravir
hypersensit
dolutegravir
appear
extrem
rate
base
literatur
report
addit
patient
classic
present
hypersensit
reaction
base
symptom
time
conclus
hypersensit
reaction
patient
neg
extrem
rare
possibl
therefor
clinician
monitor
hypersensit
reaction
patient
receiv
abacavir
edwardsiella
tarda
bacteremia
untreat
hepat
c
fatal
case
report
taylor
morrisett
hannah
hewgley
pharmaci
univers
colorado
hospit
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
pharmaci
methodist
univers
hospit
memphi
tn
introduct
edwardsiella
tarda
bacillu
rare
caus
bacteremia
howev
e
tarda
bacteremia
etb
highli
fatal
recent
review
conclud
liver
cirrhosi
etb
found
associ
mortal
knowledg
present
first
case
unit
state
us
fatal
etb
patient
untreat
hepat
c
case
african
american
male
medic
histori
hepat
c
alcohol
abus
present
emerg
depart
ed
left
hand
swell
due
suspect
catfish
sting
ed
patient
found
lactic
acid
mmoll
white
blood
cell
count
cellsl
ast
unitsl
alt
unitsl
posit
hepat
c
antibodi
viral
level
iuml
patient
admit
intens
care
unit
diagnosi
septic
shock
empir
antibiot
includ
meropenem
ciprofloxacin
linezolid
final
blood
sampl
identifi
e
tarda
howev
patient
remain
meropenem
linezolid
due
sever
ill
lack
improv
repeat
blood
cultur
drawn
hospit
day
four
neg
hospit
day
six
patient
made
dnr
plan
palli
extub
howev
patient
pass
shortli
thereaft
discuss
patient
hepatobiliari
diseas
document
etb
popul
recent
literatur
review
conclud
liver
cirrhosi
independ
risk
factor
associ
mortal
untreat
hepat
c
known
lead
hepat
complic
patient
untreat
hepat
c
possibl
risk
factor
develop
fatal
etb
earli
identif
initi
antimicrobi
therapi
potenti
improv
surviv
etb
conclus
knowledg
first
fatal
case
etb
patient
untreat
hepat
c
report
us
case
report
mycobacterium
conceptionens
pneumon
patient
sarah
michienzi
rodrigo
burgo
richard
novak
pharmaci
practic
section
infecti
diseas
pharmacotherapi
univers
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
practic
section
infecti
diseas
pharmacotherapi
univers
illinoi
chicago
colleg
pharmaci
chicago
il
medicin
colleg
medicin
univers
illinoi
chicago
chicago
il
introduct
number
mycobacterium
conceptionens
case
report
literatur
howev
outsid
us
optim
treatment
remain
uncertain
report
clinic
cours
manag
conceptionens
pneumon
human
immunodefici
viru
hiv
patient
case
patient
black
male
hiv
diagnos
untreat
present
emerg
depart
institut
complaint
includ
cough
short
breath
diarrhea
iv
ceftriaxon
azithromycin
initi
ct
show
bilater
interstiti
groundglass
opac
nodul
day
four
ceftriaxon
azithromycin
discontinu
induc
sputum
cultur
day
return
acid
fast
bacilli
afb
posit
patient
symptom
improv
admiss
day
discharg
oral
prophylact
azithromycin
day
patient
follow
clinic
time
cours
complet
addit
sputum
day
return
azithromycin
switch
daili
day
pneumon
clinic
resolv
conceptionens
diagnosi
confirm
sputum
cultur
doxycyclin
ad
repeat
ct
afb
cultur
neg
patient
remain
profoundli
immunosuppress
due
antiretrovir
nonadher
plan
continu
oral
azithromycin
doxycyclin
immun
reconstitut
discuss
similar
report
case
patient
start
antibiot
tailor
receiv
diagnosi
nontubercul
mycobacteria
macrolid
fluoroquinolon
doxycyclin
commonli
report
target
treatment
conceptionens
given
report
us
case
import
addit
literatur
conclus
case
demonstr
clinic
microbiolog
cure
conceptionens
pulmonari
infect
azithromycin
doxycyclin
staphylococcu
pseudintermediu
infect
case
report
man
best
friend
scott
hall
pharmd
vanthida
huang
pharmd
bsphm
fccp
john
c
lincoln
medic
center
phoenix
az
pharmaci
practic
midwestern
univers
colleg
glendal
az
introduct
staphylococcu
pseudintermediu
mrsp
zoonot
organ
part
natur
skin
flora
dog
cat
domest
wild
anim
implement
laser
flight
clinic
microbiolog
lab
increas
identif
organ
previous
unrecogn
misidentifi
aureu
staphylococcu
cn
howev
case
report
infect
unit
state
limit
present
case
pseudintermediu
treat
effect
linezolid
case
male
sustain
burn
left
middl
finger
boil
water
present
one
month
debrid
evolv
wound
necrosi
necessit
amput
past
medic
histori
includ
renal
transplant
depress
anxieti
treat
escitalopram
trazodon
cultur
obtain
intraop
infecti
diseas
consult
obtain
patient
empir
place
daptomycin
note
despit
normal
white
blood
cell
count
patient
immunosuppress
addit
patient
dog
owner
display
small
scratch
right
hand
attribut
said
dog
hospit
day
pseudintermediu
isol
wound
resist
methicillin
suscept
vancomycinlinezolid
sever
option
complet
antibiot
therapi
discharg
consid
given
limit
suscept
potenti
drug
interact
patient
request
immedi
discharg
prescript
given
six
day
linezolid
mg
oral
twice
daili
instruct
hold
escitalopram
trazodon
complet
antibiot
discuss
mrsp
shown
suscept
typic
antistaphylococc
agent
howev
increas
preval
resist
document
treatment
newer
agent
oritavancin
dalbavancin
tedizolid
delafloxacin
consid
conclus
pseudintermediu
effect
treat
avail
antistaphylococc
agent
studi
newer
agent
warrant
util
mathemat
model
middl
east
respiratori
syndrom
nosocomi
outbreak
determin
effect
paramet
control
yasar
tasnif
tamer
orabi
mustafa
ayesha
araya
pharmd
hanan
balkhi
health
affair
cooper
pharmaci
program
univers
texa
rio
grand
valley
edinburg
tx
mathemat
statist
scienc
univers
texa
rio
grand
valley
edinburg
tx
commun
environment
health
colleg
public
health
health
informat
king
saud
bin
abdulaziz
univers
health
scienc
riyadh
saudi
arabia
introduct
middl
east
respiratori
high
fatal
rate
global
collabor
saudi
arabia
usa
canada
model
construct
depict
nosocomi
outbreak
king
abdul
aziz
medic
center
riyadh
saudi
arabia
model
use
estim
paramet
relat
outbreak
test
effect
infecti
diseas
control
plan
hospit
prevent
commun
case
hypothesi
rapid
diagnosi
would
effect
halt
spread
diseas
studi
design
model
spread
diseas
construct
depict
three
type
agent
hospit
unit
er
hospit
ward
etc
calibr
data
outbreak
number
patient
infect
patient
worker
etc
method
transit
rate
unit
estim
via
standard
independ
compet
risk
model
fulli
observ
data
seir
model
use
calcul
rate
impact
transmiss
basic
reproduct
number
averag
number
secondari
infect
due
introduct
infecti
individu
calcul
next
gener
matrix
determin
potenti
epidem
epidem
die
potenti
exist
epidem
simul
uncertainti
quantif
model
calibr
paramet
estim
sensit
analysi
latin
sampl
n
uniform
random
point
perform
valid
analyz
model
discuss
found
differ
degre
influenc
made
paramet
potenti
epidem
spread
rapid
diagnosi
diseas
decreas
mani
diseas
paramet
conclus
rapid
diagnost
method
confirm
may
lead
earli
quarantin
therapeut
intervent
potenti
halt
epidem
model
may
assist
inform
updat
infect
control
polici
prolong
use
novel
enterobacteriacea
case
report
kathi
choi
pharmd
candid
bs
truong
pharmd
candid
scott
hall
pharmd
lesli
b
robinson
vanthida
huang
pharmd
bsphm
pharmaci
practic
midwestern
univers
colleg
glendal
az
john
c
lincoln
medic
center
phoenix
az
introduct
treatment
option
limit
klebsiella
pneumonia
kp
preval
among
enterobacteriacea
cre
mv
novel
carbapenem
inhibitor
combin
target
cre
infect
although
meropenem
show
poor
penetr
central
nervou
system
cn
potenti
use
mv
cn
cre
kp
infect
remain
unknown
thu
describ
patient
case
success
treat
prolong
mv
mdr
kp
ventricul
case
male
past
medic
histori
traumat
brain
injuri
statu
post
motor
vehicl
accid
present
alter
mental
statu
admit
sutur
site
drainag
recent
cranioplasti
blood
cultur
bc
posit
cre
kp
suscept
gentamicin
tigecyclin
receiv
intraven
iv
gentamicin
tigecyclin
empir
day
suscept
result
resist
test
unavail
secondari
test
product
shortag
switch
mv
iv
everi
hour
plu
intrathec
gentamicin
mg
daili
ventricul
mv
schedul
total
durat
week
receiv
total
day
patient
develop
leukopenia
day
mv
treatment
chest
rash
unknown
origin
day
also
underw
multipl
procedur
includ
ventriculostomi
hospit
day
ventriculoperiton
shunt
vp
surgeri
due
hydrocephalu
hospit
day
patient
discharg
neg
cerebrospin
fluid
cultur
clinic
resolut
ventricul
due
vp
infect
day
hospit
discuss
case
reveal
mv
potenti
treatment
clearanc
cre
kp
especi
cn
infect
ventricul
mv
may
promis
addit
limit
arsen
cn
infect
due
cre
kp
conclus
era
rise
mdr
organ
mv
great
addit
armamentarium
treatment
cn
infect
lactobacillu
bacteremia
follow
singl
dose
probiot
contain
lactobacillu
rhamnosu
gg
case
report
gari
burdg
steven
smoke
pharmd
bcp
maria
devivo
pharmd
mpa
bcp
rwjbarnaba
health
behavior
health
center
tom
river
nj
jersey
citi
medic
center
jersey
citi
nj
introduct
use
probiot
contain
lactobacillu
speci
link
bacteremia
risk
factor
includ
presenc
central
venou
cathet
cvc
immunosuppress
prior
surgic
intervent
prolong
hospit
case
detail
surgic
patient
develop
lactobacillu
bacteremia
singl
dose
probiot
contain
lactobacillu
rhamnosu
gg
case
old
guyanes
woman
admit
chief
complaint
chest
pain
diagnos
nstemi
underw
coronari
arteri
bypass
graft
develop
acut
respiratori
failur
receiv
two
cours
antibiot
possibl
pneumonia
sever
fail
extub
underw
tracheostomi
day
day
patient
start
lactobacillu
rhamnosu
gg
administ
percutan
endoscop
gastrostomi
tube
time
cvc
sever
hour
later
placement
peripher
insert
central
cathet
patient
becam
hypotens
requir
vasopressor
develop
leukocytosi
blood
cultur
collect
maintain
current
antibiot
therapi
time
meropenem
blood
cultur
result
eventu
reveal
lactobacillu
speci
grow
cultur
probiot
promptli
discontinu
patient
receiv
meropenem
vancomycin
durat
hospit
discharg
day
extend
care
facil
complet
total
day
therapi
discuss
unlik
previous
publish
case
patient
develop
bacteremia
singl
dose
probiot
speciat
lactobacillu
grew
avail
therefor
causat
directli
link
probiot
specul
probiot
capsul
may
open
administr
presenc
cvc
may
contribut
subsequ
bacteremia
conclus
clinician
awar
risk
bacteremia
probiot
use
caution
exercis
open
probiot
capsul
administr
particularli
patient
cvc
brucella
bacteremia
misidentifi
ochrobactrum
anthropi
infect
kyle
c
molina
lesli
b
robinson
vanthida
huang
pharmd
bsphm
john
c
lincoln
medic
center
phoenix
az
pharmaci
practic
midwestern
univers
colleg
glendal
az
introduct
brucellosi
due
brucella
speci
facult
intracellular
coccobacilli
associ
case
human
annual
us
brucella
transmit
anim
human
ingest
contamin
food
product
direct
contact
infect
anim
inhal
aerosol
ochrobactrum
spp
genotyp
similar
brucella
therefor
misidentifi
mani
diagnost
system
herein
describ
case
brucella
bacteremia
misidentifi
ochrobactrum
anthropi
case
femal
present
ed
complaint
intermitt
feverfatigu
report
recent
travel
saudi
arabiaafrica
initi
blood
cultur
bc
reveal
rod
initi
everi
hour
two
day
initi
result
ochrobactrumn
anthropi
identifi
cultur
show
persist
bacteremia
five
set
posit
bc
day
day
elev
brucella
igm
detect
outsid
laboratori
exhaust
histori
reveal
consum
raw
camel
milk
africa
brucella
spp
confirm
state
arizona
initi
ciprofloxacin
mg
iv
everi
hour
patient
discharg
ciprofloxacin
mg
po
bid
doxycyclin
mg
po
bid
rifampin
mg
po
bid
microbiolog
cure
hospit
day
discuss
brucellosi
rare
howev
differenti
diagnos
includ
brucella
spp
patient
recent
travel
endem
area
includ
kenyaindiasaudi
arabia
consum
camel
milk
case
reinforc
need
thorough
patient
histori
understand
pathogen
like
misidentifi
pathogen
misidentif
consid
posit
ochrobactrum
anthropi
use
rapid
diagnost
brucella
serolog
trigger
identif
ochrobactrum
spp
conclus
brucellosi
rare
us
proper
algorithm
need
prevent
misidentif
treatment
delay
case
demonstr
difficulti
initi
identif
brucella
spp
ensu
delay
appropri
therapi
symptomat
intracerebr
hemorrhag
thrombolysi
tpa
minor
stroke
case
report
ahm
zaki
pharmd
candid
jessica
l
johnson
pharmd
pharmaci
xavier
univers
lousiana
new
orlean
la
carey
univers
school
pharmaci
biloxi
ms
present
ashp
la
vega
nv
decemb
persist
akathisia
case
report
eric
tobin
pharmd
candid
catherin
derington
pharmd
benjamin
chavez
pharmd
depart
clinic
pharmaci
univers
colorado
skagg
school
pharmaci
pharmaceut
scienc
aurora
co
introduct
aripiprazol
asenapin
lurasidon
known
higher
risk
akathisia
compar
antipsychot
sga
rel
aripiprazol
high
incid
akathisia
treat
ill
durat
persist
akathisia
symptom
case
white
femal
medic
histori
brain
injuri
migrain
major
depress
disord
mdd
present
ongo
depress
symptom
includ
lack
motiv
energi
start
aripiprazol
daili
augment
escitalopram
bupropion
xl
five
week
initi
patient
report
improv
depress
symptom
experienc
akathisia
consequ
dose
decreas
mg
daili
one
week
later
aripiprazol
discontinu
due
persist
akathisia
symptom
time
medic
diet
lifestyl
chang
made
two
week
discontinu
patient
report
less
sever
persist
akathisia
extend
beyond
expect
period
day
base
elimin
symptom
accompani
worsen
depress
symptom
propranolol
x
day
temporarili
reliev
akathisia
week
akathisia
continu
improv
discuss
pubm
search
akathisia
symptom
specif
aripiprazol
yield
inform
tempor
relationship
akathisia
durat
persist
discontinu
naranjo
advers
event
probabl
scale
classifi
event
probabl
given
variabl
receptor
type
affin
sga
research
need
character
incid
sever
durat
extrapyramid
symptom
ep
aripiprazol
versu
antipsychot
conclus
summari
case
describ
ep
persist
week
discontinu
aripiprazol
research
need
antipsychot
use
mdd
fulli
evalu
incid
sever
durat
ep
research
caus
character
ep
may
warrant
transit
oral
selexipag
parenter
prostacyclin
patient
eisenmeng
syndrom
case
report
ranran
xia
ashrith
guha
md
mph
kevin
donahu
pharmaci
houston
methodist
hospit
houston
tx
methodist
debakey
heart
vascular
center
houston
methodist
hospit
houston
tx
introduct
selexipag
oral
prostacyclin
analog
select
prostacyclin
receptor
agonist
stabil
long
combin
oral
administr
make
appeal
agent
treatment
pulmonari
arteri
hypertens
pah
howev
evid
limit
transit
selexipag
intraven
iv
prostacyclin
analog
pah
diseas
progress
case
year
old
femal
right
left
shunt
secondari
larg
unrepair
atrial
septal
defect
eisenmeng
physiolog
sever
pah
present
short
breath
lower
extrem
edema
right
heart
cather
reveal
elev
pap
oxygen
satur
despit
increas
support
pah
regimen
admiss
includ
macitentan
selexipag
riociguat
due
continu
hemodynam
deterior
transit
iv
epoprostenol
use
conserv
cross
titrat
regimen
epoprostenol
start
increas
rate
per
day
selexipag
titrat
mcg
per
day
discontinu
day
patient
experi
signific
side
effect
hemodynam
instabl
cross
titrat
process
oxygen
satur
improv
discuss
knowledg
first
case
describ
succes
transit
selexipag
parenter
prostacyclin
eisenmeng
syndrom
patient
intraven
epoprostenol
rapidli
toler
theoret
maximum
dose
usual
selexipag
mcg
twice
daili
weekli
interv
yet
recommend
exist
taper
selexipag
post
hoc
analysi
evalu
consequ
selexipag
treatment
interrupt
low
rate
advers
event
report
acut
deterior
occur
within
day
like
due
longer
selexipag
activ
metabolit
compar
parenter
prostacyclin
conclus
selexipag
could
potenti
discontinu
earli
cross
titrat
minimum
complic
loperamid
associ
opioid
use
disord
treatment
buprenorphin
taper
stephani
nichol
pharmd
bcp
bcpp
lee
wolfrum
chri
racin
aime
nordmey
pharmaci
husson
univers
bangor
medic
center
portland
introduct
report
describ
case
patient
opioid
use
disord
develop
cardiac
toxic
secondari
use
loperamid
replac
illicit
opioid
sinc
loperamid
substrat
high
dose
loperamid
caus
cn
opioid
agon
wherea
low
dose
loperamid
remain
peripher
use
treat
diarrhea
complic
loperamid
use
document
includ
cardiotox
death
particularli
import
light
ongo
opioid
epidem
case
subsequ
cessat
prescrib
oxycodon
daili
patient
began
take
oxycodon
heroin
ultim
oral
loperamid
daili
present
ed
qtc
normal
electrolyt
thu
admit
telemetri
unit
close
monitor
abrupt
cessat
high
dose
loperamid
therapi
result
opioid
withdraw
symptom
success
treat
buprenorphin
taper
discuss
methadon
dose
daili
associ
qtc
prolong
buprenorphin
select
avoid
administ
qtc
prolong
medic
methadon
buprenorphin
legal
permit
inpati
administr
sinc
patient
admit
medic
reason
qtc
prolong
given
signific
risk
cardiac
toxic
current
eas
otc
acquisit
consider
given
place
loperamid
behind
pharmaci
counter
restrict
sale
licens
pharmacist
manner
similar
current
pseudoephedrin
law
conclus
result
mark
life
threaten
toxic
use
loperamid
requir
increas
recognit
entir
healthcar
commun
includ
physician
pharmacist
opioid
use
disord
withdraw
success
safe
treat
buprenorphin
smell
rat
coagulopathi
exposur
brodifacoum
contamin
synthet
cannabinoid
rene
petzel
gimbar
margaret
choy
pharmd
michael
koronkowski
christina
mcknight
jason
devgun
arkadi
rasin
timothi
meehan
md
trevonn
thompson
jenni
jarrett
pharmd
bcp
mmede
pharmaci
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
pharmaci
practic
univers
illinoi
colleg
pharmaci
chicago
il
practic
univers
illinoi
chicago
chicago
il
practic
univers
illinoi
chicago
colleg
pharmaci
chicago
il
consortium
chicago
il
medicin
univers
illinoi
chicago
colleg
medicin
chicago
il
pharmaci
depart
pharmaci
practic
univers
illinoi
chicago
chicago
il
introduct
synthet
cannabinoid
illicit
substanc
psychoact
effect
contamin
brodifacoum
addit
danger
anticoagul
effect
recent
outbreak
contamin
synthet
cannabinoid
occur
metropolitan
chicago
area
marchapril
case
three
case
present
univers
illinoi
hospit
emerg
depart
complain
bleed
smoke
synthet
cannabinoid
multipl
time
daili
first
old
hispan
male
present
hematuria
blood
rectum
lab
includ
hemoglobin
hgb
gdl
drop
gdl
hour
unmeasur
inr
patient
receiv
phytonidion
cryoprecipit
unit
fresh
frozen
plasma
ffp
unit
intraven
iv
titrat
phytonidion
mouth
po
three
time
daili
tid
daili
outpati
titrat
daili
next
old
black
femal
present
excess
bleed
mouth
heavi
menstruat
lab
demonstr
hgb
gdl
drop
gdl
hour
unmeasur
inr
receiv
phytonidion
iv
ffp
unit
iv
start
phytonidion
po
tid
titrat
twice
daili
bid
discharg
outpati
titrat
daili
final
old
black
male
present
hematuria
initi
hgb
gdl
inr
unmeasur
receiv
phytonidion
iv
start
phytonidion
po
tid
titrat
bid
discharg
outpati
titrat
bid
outpati
inr
howev
patient
lost
day
discuss
contamin
synthet
cannabinoid
use
occur
across
multipl
state
lead
multipl
patient
death
clinic
pharmacist
involv
critic
initi
ongo
treatment
manag
high
dose
phytonidion
conclus
treatment
coagulopathi
associ
contamin
synthet
cannabinoid
use
individu
consist
high
dose
oral
phytonidion
allergi
polyethylen
glycol
intraven
phytonadion
liver
transplant
candid
timothi
horwedel
pharmd
bcp
jennif
hagopian
pharmd
bcp
claric
carthon
pharmd
bcp
hospit
st
loui
mo
introduct
polyethylen
glycol
peg
commonli
util
pharmaceut
agent
includ
use
lax
peg
reaction
agent
rare
commonli
report
reaction
iv
phytonadion
present
patient
allerg
reaction
phytonadion
peg
spur
reactiv
backbon
polym
case
patient
hispan
femal
histori
primari
scleros
cholang
evalu
liver
transplant
report
medic
allergi
part
evalu
colonoscopi
schedul
prepar
order
patient
present
emerg
room
minut
administr
hypotens
erythema
resolv
discontinu
methylprednisolon
diphenhydramin
note
elev
inr
phytonadion
iv
mg
given
within
minut
patient
develop
anaphylactoid
reaction
requir
treatment
transplant
pharmacist
consult
investig
two
uncommon
seemingli
unrel
reaction
interest
patient
discharg
experienc
similar
reaction
drink
contain
acacia
gum
discuss
allergi
iv
phytonadion
document
although
low
frequenc
case
per
dose
incid
peg
allergi
poorli
understood
howev
appear
mechanist
link
phytonadion
contain
polyoxyethyl
fatti
acid
known
caus
anaphylactoid
igg
igm
mediat
reaction
research
note
igg
igm
antibodi
target
backbon
react
polym
commonli
use
drug
food
three
product
elicit
respons
patient
emulsifi
agent
backbon
conclus
allergi
phytonadion
peg
like
driven
antibodi
backbon
polym
use
pharmacolog
product
understand
drug
pharmacist
may
prevent
substanti
harm
patient
